Clinical trial NCT04224688
Conditions: Primary Immune Thrombocytopenia
Keywords: ITP UCB7665 Rozanolixizumab Primary Immune Thrombocytopenia
Sponsor: UCB Biopharma SRL
Start date: 2020-06-03; Completion date: 2022-05-05
Enrollment: 30 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
The purpose of this study is to demonstrate the clinical efficacy of rozanolixizumab in maintenance treatment and assess safety and tolerability of rozanolixizumab in adult study participants with primary immune thrombocytopenia (ITP).

Detailed description:

Arms: arm 1: Study participants randomized to this arm will receive fixed-unit doses of rozanolixizumab across body weight tiers at pre-specified time points during the Treatment Period. Doses will be adjusted based on platelet count values or medical needs. arm 2: Study participants randomized to this arm receive placebo at pre-specified time points during the Treatment Period.
Interventions: intervention 1: Rozanolixizumab intervention 2: Placebo
Intervention descriptions: intervention 1: Study participants receive rozanolixizumab by subcutaneous infusion at pre-specified time points. intervention 2: Study participants receive placebo by subcutaneous infusion at pre-specified time points.

Protocol documents:
Prot_000.pdf: 
UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 1 of 202
A PHASE 3 MULTICENTER, DOUBLE-BLIND, RANDOMIZED, 
PLACEBO-CONTROLLED STUDY TO EVALUATE THE
EFFICACY, SAFETY, AND TOLERABILITY OF 
ROZANOLIXIZUMAB IN ADULT STUDY PARTICIPANTS WITH 
PERSISTENT OR CHRONIC PRIMARY IMMUNE 
THROMBOCYTOPENIA (ITP)
PROTOCOL TP0006 AMENDMENT 3
PHASE 3
Short title:
A Phase 3 study evaluating the efficacy, safety, and tolerability of rozanolixizumab in adult 
study participants with ITP
Sponsor:
UCB Biopharma SRL
Allée de la Recherche 60
1070 Brussels
BELGIUM
Regulatory agency identifying number:
EudraCT Number:
2019-003451-11
IND Number
143499
NCT Number
NCT04224688
Confidential Material
Confidential
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.
PUBLIC COPY
d tolerab
PY 
d tolerab
Spon
C C
Spon
UCB Bi
BLIC
UCB Bi
Allée
UB
Allée
This document cannot be used to support any marketing authorization 
lity of roz
any
lity of roz
or:
p
or:
opharma S
sup
opharma S
de la Rec
to s
de la Rec
1070 
d t
1070 
B
agency i
t ca
agency i
application and any extensions or variations thereof.
zanolixizu
riat
zanolixizu
SRL
ns
SRL
herche 60
sio
herche 60
Brussels
ens
Brussels
BELGIU
exte
BELGIU
identifyi
ion 
identifyi
Eu
ti
Eu
titio
ati
a


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 2 of 202
PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE
Document History
Document
Date
Type of amendment
Protocol Amendment 3
06 Dec 2021
Substantial
Protocol Amendment 2.1 
(China)
14 Dec 2020
Substantial
Protocol Amendment 2
08 Dec 2020
Substantial
Protocol Amendment 1a
29 Sep 2020
Substantial
Protocol Amendment 0.2 
(France)
27 Apr 2020
Substantial
Protocol Amendment 0.1 
(US and Canada)
21 Feb 2020
Substantial
Original Protocol
21 Nov 2019
Not applicable
a Protocol amendment 1 was an internally approved document, which was not submitted to the regulatory 
authorities or implemented at the study sites. Details of the changes between protocol amendment 1 and 
protocol amendment 2 are provided in Section 10.26.
Amendment 3 (06 Dec 2021)
Overall Rationale for the Amendment
The primary reason for this protocol amendment is the recommendation of the external 
Independent Data Monitoring Committee (IDMC) to modify the dosing regimen of the study.
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union.
Section # and Name
Description of Change
Brief Rationale
Global 
IMP dosing every 2 weeks was updated to 
weekly dosing.
Updated based on the 
feedback from the IDMC 
recommending the option 
to increase the frequency in 
dosing, to reduce the 
potential risks associated 
with low platelet counts.
1.1 Synopsis, Objectives 
and endpoints
3 Objectives and endpoints
A secondary efficacy endpoint for the ITP-
PAQ was updated to delete “including all 
intermediate timepoints”.
Intermediate timepoints 
were removed based on 
FDA feedback. 
1.1 Synopsis, Objectives 
and endpoints
3 Objectives and endpoints
The other safety endpoint “Change from 
Baseline in concentrations of total protein, 
and albumin, α globulin, and β globulin 
was updated to “ Change from Baseline in 
The endpoint was removed 
to decrease study 
complexity, as scientific 
value is limited.
The endpoint was removed 
UBLIC COPY
cument,
PY 
cument,
of the ch
OPY
of the ch
26
O
26.
O
.
t
L
t
ol amend
UBL
ol amend
PU
ommitte
PUB
ommitte
o be
P
o be
o support any marketing authorization 
h
ut
tial
n
tial
g a
ubstantia
rke
ubstantia
et
Not a
y m
Not a
ma
y
hich was no
ny 
hich was no
nges betwe
any
nges betwe
ment is th
o su
ment is th
ment cannot be used to
e (IDMC)
to 
e (IDMC)
substantia
ed 
substantia
pean Parl
use
pean Parl
Descriptio
be u
Descriptio
us
IMP d
t b
IMP d
wee
ot 
wee
be
ot
s docume
Synopsis, O
ume
Synopsis, O
nd endpoin
cum
nd endpoin
3 Obj
do
3 Obj
This d
me
s d
s 
1
s d
s d
s
sions or variations thereof.
o
eo
alal
he
applicable
tion
applicable
ns
tio
ot submitted
iati
ot submitted
en protoco
aria
en protoco
he recomm
ion
he recomm
cation and any extens
) to modif
nsio
) to modif
al based o
ten
al based o
liament an
exte
liament an
on of Cha
ny e
on of Cha
e
dosing ever
d an
dosing ever
ekly dosin
nd a
ekly dosin
ny
on
applica
Objectives
plic
Objectives
nts
p
nts
s an
a
s an
ca


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 3 of 202
Section # and Name
Description of Change
Brief Rationale
concentrations of total protein and 
albumin.
The other safety endpoint “Change from 
Baseline in cytokines during the study (for 
study participants experiencing infusion 
reactions or hypersensitivity reactions)” 
was deleted.
as the analysis of cytokines 
is not required in the ITP 
protocols as samples have 
been collected in other 
rozanolixizumab studies 
and no additional 
information is expected 
from the ITP population.
1.1 Synopsis, Objectives 
and endpoints
3 Objectives and endpoints
The exploratory PD endpoints were 
updated as follows: 
“Minimum value in total serum IgG and 
maximum decrease from Baseline in total 
serum IgG concentration” was deleted.
“Change from Baseline in serum IgG and 
in serum IgG subclass concentration” was 
updated to “Total serum IgG (absolute 
value) and change from Baseline (absolute 
value and percentage) in serum IgG and in 
serum IgG subclass concentration at each 
scheduled assessment”.
“Change from Baseline in serum 
immunoglobulin concentrations (IgA, IgE, 
IgM)” was updated to “Absolute values 
and change from Baseline (absolute value 
and percentage) in serum immunoglobulin 
concentrations (IgA, IgE, IgM) at each 
scheduled assessment”.
“Change from Baseline in ITP-specific 
autoantibodies in serum” was deleted.
Deleted as this variable 
will be followed at every 
scheduled visit rather than 
only reporting the lowest 
value across the duration of 
the study
Endpoint was amended to 
provide further details of 
the endpoint and to add 
clarity.
Endpoint was amended to 
provide further details of 
the endpoint and to add 
clarity.
The endpoint was deleted 
as the results of the 
analysis will not be part of 
the CSR of this study and 
will be described in a 
separate report.
1.1 Synopsis, Objectives 
and endpoints
3 Objectives and endpoints
The objective “To evaluate the effects of 
rozanolixizumab on exploratory 
biomarkers” and its associated endpoints 
were removed. 
Objective and endpoint 
were removed as the 
exploratory biomarker 
samples are taken for 
future analysis, with no 
predefined analysis 
objective and endpoints.
1.1 Synopsis, Objectives 
and endpoints
The following exploratory objective and 
endpoint were added:
New objective and 
endpoint are needed for the 
collection of information 
PUBLIC COPY
n serum
PY 
n serum
concentr
OPY
concentr
erum IgG
COP
erum IgG
ge from B
C CO
ge from B
centage) 
C C
centage) 
subclass
LIC
subclass
d assess
BL
d assess
ange from
PUB
ange from
munogl
PU
munogl
)” w
P
)” w
thorization 
d 
o
d 
ation.
ho
ation.
za
marketing autho
 this varia
g a
 this varia
followed 
ting
followed 
duled visi
etin
duled visi
nly report
rket
nly report
value ac
ark
value ac
the s
ma
the st
ot be used to support any m
gG and 
ny
gG and 
ation” was 
t any
ation” was 
(absolute
rt a
(absolute
aseline (ab
port
aseline (ab
n serum Ig
ppo
n serum Ig
con
u
concentrat
upp
centrat
ment”
su
ment”.
su
.
Baseline i
to s
Baseline i
bulin conc
d to
bulin conc
as updated
ed 
as updated
hange from
use
hange from
d percenta
e us
d percenta
concentrat
be 
concentrat
schedu
t be
schedu
“Ch
ot 
“Ch
o
ent cannot
tho
ot
m
s docume
ynopsis, O
me
ynopsis, O
d endpoin
cum
d endpoin
3 Obje
do
3 Obje
This d
e
s d
variations thereof.
able
eo
able
at every 
ereo
at every 
t rather th
her
t rather th
ting the low
the
ting the low
ross the d
s t
ross the d
tudy
on
tudy
Endpoint
iati
Endpoint
provid
aria
provid
the 
ar
the 
on and any extensions or variations thereof
bsolute 
or v
bsolute 
gG and in
s or
gG and in
ion at each
ns o
ion at each
in serum 
sio
in serum 
centration
ens
centration
d to “Abso
xten
d to “Abso
m Baseline
ext
m Baseline
age) in seru
y ex
age) in seru
ations (IgA
ny 
ations (IgA
led assess
any
led assess
hange from
nd a
hange from
autoantibo
and
autoantibo
cation
on
va
applica
Objectives
plica
Objectives
nts
p
nts
es an
a
es an
ca


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 4 of 202
Section # and Name
Description of Change
Brief Rationale
3 Objectives and endpoints
Objective: To assess the effect of 
rozanolixizumab on response to 
vaccination in study participants who 
received COVID-19 vaccine
Endpoint: Change in biomarkers of 
COVID-19 vaccine response over time
on post-vaccination 
biomarkers for participants 
who have received the 
COVID-19 vaccination.
1.1 Synopsis, Overall 
design
4.1 Overall design
The vaccination requirements for 
splenectomized participants were updated. 
The requirement for vaccination titers 
assessment for eligibility purposes was 
removed.
Updated for consistency 
with the changes done in 
Section 8.2.6. 
1.1 Synopsis, Overall 
design
4.1 Overall design
The sentence regarding home visits was 
updated to state that home visits including 
home dosing and assessments as per 
Section 1.3 can be conducted once all pre-
requisites for a home dosing visit are 
fulfilled. 
Updated for consistency.  
1.1 Synopsis, Overall 
design
4.1 Overall design
The one-time fixed unit starting dose of 
rozanolixizumab equivalent to 
 or 
placebo was removed. 
Deleted because of the new 
dose regimen of 
 
equivalent once a week. A 
 equivalent QW 
dose regimen is anticipated 
to achieve similar level of 
receptor occupancy (RO)% 
to a 
 equivalent-
dose, with a range on RO% 
from peak to trough of 99 
to 50% during the 7 days 
dosing interval.
1.1 Synopsis, Overall 
design
4.1 Overall design
Week 13 was updated to Week 12.
Updated to correct an error.
1.1 Synopsis, Overall 
design
4.1 Overall design
Platelet count of “≥50×109/L to 
200×109/L” was updated to “≥50×109/L to 
≤150×109/L”.
For consistency to other 
changes in the protocol. 
1.1 Synopsis, Overall 
design, Table 1-1 Dose 
adjustments of IMP 
following initial dose, 
Figure 1-1 TP0003 dose 
adjustments of IMP
4.1 Overall design
The following text was added or updated:
Platelet count of <10×109/L, rescue therapy 
is highly recommended. 
Platelet count of ≥10×109/L to <30×109/L 
(on at least two consecutive visits), rescue 
therapy is recommended. 
Updated to provide further 
guidance on when rescue 
medication is highly 
recommended or 
recommended
PUBLIC COPY 
it starting
OPY
it starting
quivalent 
COP
quivalent 
oved.
C CO
oved.
PY
t any marketing authorization 
za
ncy 
ho
ncy 
done in
tho
done in
riz
ated for co
eting
ated for co
ng
m
dose of 
t an
dose of 
t any
cument cannot be used to support
o o 
gn
c
gn
Week 
ot b
Week 
be
ot
s, Overall
nt c
s, Overall
Overall d
cum
Overall d
ca
s docu
1.1 Syno
doc
1.1 Syno
design
do
design
adj
d
adj
This d cu
s d
ort a
pplication and any extensions or variations thereof.
onsistency
here
onsistency
re
or 
v
or 
Delete
aria
Delete
do
a
do
ia
va
k 13 was up
d an
k 13 was up
ny
n
design
ppli
design
Pl
n
Pl
n 
on
app
psis, Ove
app
sis, Ove
ble 1
a
ble 1
pp


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 5 of 202
Section # and Name
Description of Change
Brief Rationale
Platelet count of <50×109/L was updated to 
≥30×109/L to <50×109/L, Dose adjustment 
instructions were updated to "dose level 
can be increased unless the study 
participant is on a maintenance dose of 
Platelet count of ≥50×109/L to ≤200×109/L 
was updated to ≥50×109/L to ≤150×109/L. 
Platelet count of >200×109/L to 
<400×109/L was updated to ≥150×109/L to 
<400×109/L
For platelet counts of ≥400×109/L, 
instructions were updated to “Stop IMP 
treatment. Once the platelet count is 
≤150×109/L reinitiate treatment decreased 
by one dose level”.
The text regarding interindividual variable
platelet response was moved as table 
footnote b.
Updated to permit 
reduction in dose earlier in 
the event of a platelet 
increase given the change 
to a weekly dosing 
regimen
Updated in order to clarify 
that all study participants 
with platelet counts 
≤150×109/L should 
reinitiate treatment with a 
dose decreased with one 
level.
Updated to provide clarity 
that the text belongs to 
Table 1-1.
1.1 Synopsis, Overall 
design
4.1 Overall design
The visit window upon rollover from 
TP0003 or TP0006 into TP0004 has been 
updated from 1 week to 3 days. 
The requirement for a SFU visit in between 
the rollover, and the requirement for or 
platelet count measurement in case of a late 
rollover have both been removed. 
Day 211 was updated to Day 218.
Updated for consistency 
with the weekly dosing 
regimen and for 
consistency throughout the 
protocol.
1.1 Synopsis, Overall 
design
4.1 Overall design
The following paragraph was added:
Based on feedback from the IDMC, weekly 
dosing was implemented in protocol 
amendment 3. Study participants being 
treated with the bi-weekly dosing regimen 
will switch to the weekly dosing regimen 
once protocol amendment 3 is approved at 
the respective study site.
To clarify the dosing for 
existing study participants 
receiving bi-weekly dosing.
1.1 Synopsis, Number of 
study participants
4.1 Overall design
The two-stage statistical design and interim 
analysis were deleted. 
The target number of study participants 
was updated to 90, at least 60 of which will 
Updated for consistency 
with the change in dosing 
regimen and to reflect 
current statistical analysis 
plans.
PUBLIC COPY
cou
Y
cou
atment d
PY 
atment d
arding
LIC
arding in
C 
in
esponse w
BLIC
esponse w
e b.
UB
e b.
e visit w
PU
e visit w
0003
P
0003
UB
This document cannot be used to support any marketing authorization 
creased 
any
creased 
rindividu
pp
rindividu
as moved 
sup
as moved 
ted in orde
ting
ted in orde
at all study
keti
at all study
wi
r
with plate
rke
th plate
≤150×
mar
≤150×
rein
ma
rein
d
m
d
m
za
ndow upon
d to
ndow upon
r TP0006
ed 
r TP0006
ed from 1 w
se
ed from 1 w
e requirem
e us
e requirem
the rollove
be 
the rollove
platelet
t be
platelet
rollo
ot 
rollo
D
o
D
to
ot
verall
can
verall
erall desig
men
erall desig
n
s d
s 
1
s d
s d
s
on and any extensions or variations thereof.
al variable
s o
al variable
as table 
ons
as table 
er to clarif
here
er to clarif
y participa
the
y participa
elet counts
s th
elet counts
10
n
109
n
9/L shou
ns 
/L shou
itiate treat
ion
itiate treat
ose decre
atio
ose decre
level.
riat
level.
va
n rollover
ens
n rollover
into TP00
ten
into TP00
week to 3 
exte
week to 3 
ment for a 
y ex
ment for a 
ver, and the
ny 
ver, and the
t count me
any
t count me
over have 
d a
over have 
Day 211 w
and
Day 211 w
sio
The fo
n a
The fo
Ba
n
Ba
an
application
gn
li
gn
on


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 6 of 202
Section # and Name
Description of Change
Brief Rationale
be randomized to weekly IMP 
administration.
1.1 Synopsis, Treatment 
groups and duration
4.1 Overall design
The total maximum study duration per 
study participants was updated to 35 
weeks. 
Updated as the final dose 
will be administered at 
Week 24 instead of Week 
23 and therefore the final 
visit (8 weeks after the 
final dose) was moved to 
Week 32.
1.1 Synopsis, Treatment 
groups and duration
4.1 Overall design
The Prolonged Screening Period for 
splenectomized participants was updated 
from 14 weeks to 20 weeks.
Updated for improving 
study participants' 
experience in the study by 
decreasing the time 
pressure on the vaccination 
schedule.
1.1 Synopsis, Treatment 
groups and duration, Table 
1-2 TP0006 dose levels 
and weight tiers of IMP
The table title was updated from “TP0003 
dose levels and weight tiers of 
rozanolixizumab” to “TP0003 dose levels 
and weight tiers of IMP”.
The one-time fixed unit starting dose of 
rozanolixizumab equivalent to 
or 
placebo was removed. 
Reference to “maintenance dose” was 
removed in the table headers. 
Platelet count of >200x109/L was updated 
to >150×109/L in the table footnote.
Table title was corrected.
Deleted as the 
 
equivalent starting dose is 
no longer required with the 
new dosing regimen of 
 once a week.
Updated for consistency 
with the changes in Table 
1-1.
1.2 Schema, Figure 1-2 
TP0006 study schematic
IMP dosing every 2 weeks was updated to 
weekly dosing. 
The one-time fixed unit starting dose of 
rozanolixizumab equivalent to 
or 
placebo was removed. 
The dose adjustment period was corrected 
to Week 1 to 12. 
The total maximum study duration per 
study participants was updated to 35 
weeks. 
The Safety Follow-up Period was updated 
Updated upon request from 
the IDMC 
Updated as the 
 
equivalent starting dose is 
no longer needed with the 
new dose regimen of 
equivalent once a 
week.
Updated for clarity
Updated for consistency 
with the weekly dosing 
regimen
Updated for consistency 
PUBLIC COPY 
ro
Y
ro
rs of 
PY
rs of 
P0003 d
OPY
P0003 d
MP”.
COP
MP”.
ed unit st
CO
ed unit st
ab equiv
C C
ab equiv
s remove
LIC
s remove
ce to “ma
BL
ce to “ma
ved in th
UB
ved in th
elet
P
elet
used to support any marketing authorization 
l
he
ho
he
oved to 
tho
oved to 
za
r improvin
g au
r improvin
rticipants'
ng 
rticipants'
rience in th
ting
rience in th
creasing th
keti
creasing th
pressure o
arke
pressure o
schedu
mar
schedu
au
m
003
y
003
se levels
any
se levels
rting dose
ort
rting dose
lent to 
ppo
lent to 
d.d.
ntenance 
sup
ntenance 
table head
to s
table head
count of >
ed 
count of >
50×10
use
50×109
se
9/L i
e
/L i
Ta
m
Ta
ma
m
ot be us
MP dosing
be u
MP dosing
weekly d
be
weekly d
This document cannot
Th
ot
Th
us
s d
ot
po
extensions or variations thereof.
ng
o
ng
he study b
here
he study b
he time
the
he time
on the vac
s th
on the vac
ule.
n
ule.
f
e of 
r
e of 
or 
or 
or 
dose” was
ons
dose” was
ders.
sio
ders.
200x10
ten
200x109
n
9/L
n
/L
in the tabl
ext
in the tabl
able title
tion
able title w
n
w
Del
ar
Del
on
va
nd any e
g e
ny
g every 2 w
ny e
very 2 w
dosing.
any
dosing.
application an
e one
nd
e one-
d
-tim
d 
tim
rozanolix
and
rozanolix
placeb
n a
placeb
ex
on
or


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 7 of 202
Section # and Name
Description of Change
Brief Rationale
to 7 weeks after Week 25 leading to the 
visit moving to Week 32.
Figure footnote relating to the Prolonged 
Screening Period for splenectomized 
participants was updated from 14 weeks to 
20 weeks. 
with the weekly dosing and 
final dosing being Week 
24. 
Updated for consistency 
with the changes in 
Sections 1.1 and 4.1.
Table 1-3 Schedule of 
activities (Prolonged 
Screening only for 
splenectomized study 
participants)
Prolonged Screening was extended to 20 
weeks.
Vaccination titers prior to vaccination and 
post vaccination titers during the Prolonged 
Screening Period and associated footnotes 
were removed. 
An additional footnote was added to state 
that Inclusion criterion #8 is not applicable 
for the Prolonged Screening Period. Study 
participants may take ITP concomitant 
medication as per Table 6-2.
Updated for consistency 
with the changes in Section 
1.1 and Section 4.1.
Updated for consistency 
with the changes done in 
Section 8.2.6.
Updated to clarify that the 
splenectomized study 
participants needing 
vaccination do not need to 
have low platelet counts 
throughout the Prolonged 
Screening Period.
Table 1-4 Schedule of 
activities
IMP dosing every 2 weeks was updated to 
weekly dosing. Call to IRT for treatment 
kit number was updated accordingly.
Day 5 (Week 1, Visit 4) was deleted. 
Subsequent visit numbering was updated 
accordingly. 
Concomitant medical procedures, vital 
signs and recording of AEs were added to
each visit following Baseline. 
The EOS Visit was amended from W31, 
Day 211 to W32, Day 218.
Column related to home visits have been 
grayed out.
Notes were added to clarify white columns 
are site visits and gray column refers to 
optional home visits. Additional text was 
added to state “Home IMP administration 
and assessments are optional and can be 
conducted (if approved by regulatory 
agencies) at the sites as deemed necessary 
by site personnel and/or the study 
participant.”
Updated to harmonize the 
assessments and visits with 
the change in dosing 
regimen and to provide 
consistency with other 
changes made to the 
protocol that are outlined in 
this section of the 
protocol.
UBLIC COPY
dd
Y
dd
8 is not 
PY 
8 is not 
ening Pe
OPY
ening Pe
ke ITP co
COP
ke ITP co
r Table 6
C CO
r Table 6
PUB
P dosing
PU
P dosing
ekly d
P
ekly d
UB
o support any marketing authorization 
.
h
.
za
ate
y
ate
plicable
ny
plicable
iod. Study
t any
iod. Study
ncomitant
rt a
ncomitant
2.
p
2.
nsistency 
auth
nsistency 
anges in Se
au
anges in Se
ection 4.1
g a
ection 4.1
pdated for 
keti
pdated for 
with the c
rke
with the c
Section
mar
Section
th
m
ot be used to 
every 2 we
d to
every 2 we
osing. Call
ed t
osing. Call
mber was u
sed
mber was u
y 5 (Week 
us
y 5 (Week 
Subsequen
be u
Subsequen
accordin
t be
accordin
Con
ot 
Con
sisi
This document cannot
o s
s d
ot
ions or variations thereof.
y
ection 
of
ection 
.
consistenc
the
consistenc
changes
s th
changes do
h
do
n 8.2.6.
ns
n 8.2.6.
Updated
riat
Updated
splen
ari
splen
pa
a
pa
va
on and any extensio
eeks was
nsi
eeks was
l to IRT fo
ten
l to IRT fo
updated ac
xte
updated ac
k 1, Visit 4
y ex
k 1, Visit 4
nt visit num
ny e
nt visit num
ngly.
an
ngly.
ncomitant m
d a
ncomitant m
igns and r
and
igns and r
each vis
an
each vis
The 
n 
The 
D
n
D
application
sio
on


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 8 of 202
Section # and Name
Description of Change
Brief Rationale
Footnote “a” regarding home visits, was 
deleted.
A new footnote “a” was added: The 
allowed time window for assessments is 
±5 mins for assessments <30 mins and 
±15 mins for assessments >30 mins.
Footnote d was updated to: The visit 
windows are relative to the Dosing Visit 1 
date. At Day 3 a visit window of +2 days is 
allowed. For all remaining visits a visit 
window of +/-2 days is allowed. However 
there should be a minimum interval of 
5 days and a maximum interval of 9 days 
between two doses of IMP. 
Footnote g: was updated to state that the 
last available platelet count can be 
considered rather than the last two 
available platelet counts. 
A new footnote “h” was added to state that 
platelet counts can be taken at home visits; 
home visits are allowed if the previous 4 
platelet counts were stable between 50 to 
150×109/L and there was no dose change. 
If criteria are met, the visit may be 
conducted at home, administering the same 
dose of IMP as for the previous visit. 
Footnote h, now i: was updated with vital 
signs assessment timepoints. 
Footnote i, now j: was updated to remove 
triplicate and three ECGs.
Footnote j now k: was updated to delete the 
vaccination titer sample at the Screening 
visit and W13 and a sample at Baseline 
was added. 
Footnote k was moved from Screening to 
the assessment name. 
Footnote l relating to vaccination titers 
against tetanus was deleted. 
Footnotes m, n and o relating to the IGRA 
test and TB chest x-ray were deleted. 
COVID-19 biomarkers sampling and 
associated footnotes (footnote “m” and 
“n”) were added. 
Footnote r relating to the starting dose 
equivalent to 
was deleted. 
PUBLIC COPY 
st 
Y
st 
as added
OPY
as added
be taken
CO
be taken
allowed i
C CO
allowed i
ts were 
IC C
ts were st
C
st
L and ther
BLIC
L and ther
ia are me
UBL
ia are me
ducted at 
PUB
ducted at 
se of IM
PU
se of IM
no
P
no
This document cannot be used to support any marketing authorization 
o state tha
t an
o state tha
at home vi
ort a
at home vi
the previo
por
the previo
ble betwe
ppo
ble betwe
e was no d
supp
e was no d
, the visit 
su
, the visit 
home, adm
to s
home, adm
P as for the
d to
P as for the
e h, now i:
sed
e h, now i:
assessmen
use
assessmen
oo
e
ootnote i, 
e u
tnote i, 
triplicate
be
triplicate
Footn
ot b
Footn
va
ot
va
s d
ot
m
za
application and any extensions or variations thereof.
atat
isits;
v
isits;
ous 4
or
ous 4
en 50 to
s o
en 50 to
dose chang
ns 
dose chang
may be 
ion
may be 
ministering 
sio
ministering 
e previous
ens
e previous
: was upda
xte
: was upda
ent timepoi
ext
ent timepoi
now j: wa
y e
now j: wa
e and three
any
e and three
note j now
d a
note j now
accination 
nd 
accination 
visit and 
an
visit and 
was ad
n a
was ad
Fo
n
Fo
on
va


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 9 of 202
Section # and Name
Description of Change
Brief Rationale
Footnote s relating to the IMP equivalent to 
was deleted.
Footnote q now p: was updated with more 
details on post-dose observation.
Footnote u now r: was updated to reflect 
the PK and ADA sampling times. 
Footnote v now s and footnote y now u: 
were updated to include sample collection 
at Baseline (Day 1) and W25 for all study 
participants.
Footnote w regarding serum and plasma 
complements and cytokines at W23 4 
hours postdose was deleted. 
A new footnote “v” was added to state “If 
total IgG levels are <1g/L, ad hoc 
assessments (eg, additional IgG samples) 
may be performed to monitor recovery of 
IgG levels. See Section 10.25”
Footnote ‘y’ (formerly footnote ‘aa’) was 
updated to state that the assessment can 
also be done remotely eg, via phone 
interview. 
The IGRA TB test and chest x-ray were 
deleted. 
Samples for cytokines were removed. 
2.2 Background 
IMP dosing every 2 weeks was updated to 
weekly dosing. 
The one-time fixed unit starting dose of 
rozanolixizumab equivalent to 
or 
placebo was removed.
CIDP04, MG0004 and MG0007 were 
added as ongoing studies. CIDP01 was 
added to the list of completed studies.
A summary of the safety data from 
CIDP01 was added.
Brief details about CIDP04 were added. 
Updated for consistency 
with the change in dosing 
regimen, and with relevant 
completed or ongoing 
study information.
2.3 Benefit/risk assessment The Benefit/risk assessment was updated to 
include recommendations regarding 
COVID-19 vaccinations and to remove 
“important potential risks” such as effects 
on the kidney, and reductions in albumin 
and plasma proteins. 
Updated to be consistent 
across the Phase 3 
rozanolixizumab clinical 
program.
4.1 Overall design 
The text regarding post-dose observation 
time following the end of infusion was 
updated. 
Updated to be consistent 
across the Phase 3 
PUBLIC COPY 
or re
Y
or re
0.25”
PY
0.25”
y footno
OP
y footno
at the ass
CO
at the ass
motely eg
C C
motely eg
A TB tes
BLIC
A TB tes
d.
U
d.
mples fo
PU
mples fo
P
do
P
do
P
d to support any marketing authorization 
) ) 
y of 
y
y of 
e ‘aa’) was
t a
e ‘aa’) was
essment ca
ort 
essment ca
, via phone
por
, via phone
and chest 
sup
and chest 
cytokines
d to
cytokines
m
za
ot be used 
sing every 
sed
sing every 
kly dosing.
use
kly dosing.
he one
e u
he one-
u
-tim
u
tim
rozanolix
be 
rozanolix
This document cannot
placeb
ot b
placeb
CI
ot
CI
d
ot
3 Benefit/r
cum
3 Benefit/r
m
s d
ensions or variations thereof.
s
v
s
an 
r
an 
e
x
o
x-ray we
ons
ray we
s were rem
ns
s were rem
va
any exten
y 2 weeks w
xte
y 2 weeks w
me fixed un
y e
me fixed un
xizumab e
any
xizumab e
application and a
bo was rem
d an
bo was rem
IDP04, MG
nd 
IDP04, MG
added as 
an
added as 
added 
n a
added 
A 
n
A 
en
on
risk assess
ppl
risk assess
lic


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 10 of 202
Section # and Name
Description of Change
Brief Rationale
Day 211 was updated to Day 218.
The text on rozanolixizumab infusion was 
updated.
rozanolixizumab clinical 
program.
4.2 Scientific rationale for 
study design 
IMP dosing every 2 weeks until Week 23 
was updated to weekly dosing until Week 
24.
Details of the number of study participants 
from CIDP01 and CIDP04 treated 
 
with 
rozanolixizumab were 
added.
Updated for consistency 
with the change in dosing 
regimen and to provide 
additional data in support 
of the 
dosing regimen
4.3 Justification for dose 
A more frequent dosing regimen of 
equivalent 
 is 
introduced in TP0003,TP0006 and the  
OLE TP0004 study. 
The 
 equivalent starting dose is 
removed from the protocol.
The change follows the 
advice of the external 
IDMC on a more frequent 
dosing regimen, following 
the review of the platelet 
data from TP0004 where 
platelets are not sustained 
at the desired level within 
the 
4.4 End of study definition 
6.6 Treatment after the end 
of the study
The visit window of 1 week for rollover 
into TP0004 was updated to 3 days. 
Visit numbers were updated according to
updated schedule of activities. 
The SFU Visit to be conducted in between 
rollover was deleted. 
The text “In case of late rollover, platelet 
counts will need to be remeasured” was 
deleted. 
Updated for consistency 
with the 
 dosing 
regimen and for 
consistency throughout the 
protocol.
5.1 Inclusion criteria 
Inclusion criterion 4a, now 4b, was 
updated to clarify ITP treatments and to 
add splenectomy. 
Updated for clarity.
5.1 Inclusion criteria 
Inclusion criterion #12, now 12a, was 
updated to correct “or” to “and”
“as confirmed by a negative pregnancy test 
and not planning to get pregnant”.
The sentence was 
corrected. 
5.2 Exclusion criteria
Exclusion criterion 2, now 2a, updated to 
clarify ‘current’ anticoagulant treatment. 
Cross-reference to Table 5-1 was added. 
Exclusion criterion 7a, now 7b was 
updated to clarify a clear association with 
other medical conditions. 
Updated to provide 
additional clarity to certain 
exclusion criteria, remove 
redundancies and ensure 
consistency throughout the 
protocol.
LIC COPY 
t starting
OPY
t starting
otocol.
OP
otocol.
PUBLIC
t window
BL
t window
TP0004 w
UB
TP0004 w
sit numb
PU
sit numb
ated
P
ated
LIC
authorization 
za
ncy 
ho
ncy 
dosing
tho
dosing
provide
uth
provide
ata in supp
au
ata in supp
iz
upport any marketing
regimen
ting
regimen
dose is 
any
dose is 
The chan
arke
The chan
advice
mar
advice
IDM
m
IDM
d
m
d
ke
m
ot be used to sup
of 1 week
sup
of 1 week
as updated
to s
as updated
ers were u
d to
ers were u
schedule o
ed
schedule o
SFU Visit 
use
SFU Visit 
llover was
e u
llover was
The text 
be
The text 
count
ot b
count
del
ot
del
document cannot
up
ot
ria
a
ria
n
usion crite
en
usion crite
nt
This do
d
5.2 E
d
5.2 E
do
s d
g a
ns or variations thereof.
port
of
port
nge follow
s th
nge follow
e of the ex
ns
e of the ex
MC on a m
tion
MC on a m
dosing reg
iatio
dosing reg
the revi
aria
the revi
data
ar
data
p
a
p
th
va
nd any extensions
for rollov
ons
for rollov
d to 3 days
sio
d to 3 days
updated ac
ens
updated ac
of activitie
xten
of activitie
to be con
ext
to be con
s deleted.
y e
s deleted.
t “In case o
any
t “In case o
s will nee
d an
s will nee
leted.
nd
leted.
application and
ns
Inclusio
an
Inclusio
updat
n a
updat
ad
n
ad
nd
on
ria
c
ria
tio
a
o
n
a
eo


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 11 of 202
Section # and Name
Description of Change
Brief Rationale
Exclusion criterion 15 regarding Karnofsky 
Performance Status was removed. 
Exclusion criterion 20, now 20a was 
updated to remove the requirement for
S. pneumoniae, N. meningitidis and H. 
influenzae vaccine titers during the 
Prolonged Screening Period.
Exclusion criteria 22, 23a, and 29 were 
removed. 
In Table 5-1, the cross-reference to 
Exclusion criterion 23a was removed and 
corresponding exclusionary requirements 
were added to Table 5-1.
Exclusion criterion 33a, now 33b, was 
amended to remove the following bullet 
point: ALT, AST, or ALP results up to 
25% above the exclusion limit may be 
repeated once for confirmation, including 
rescreening. 
Exclusion criterion 42 was removed. 
The Karnofsky score is 
generally used for 
predicting the length of 
survival in terminally ill 
patients. This score was 
considered as not suited for 
the target patient 
population for the study 
and removed.
Updated to provide 
additional clarity to certain 
exclusion criteria, remove 
redundancies and ensure 
consistency throughout the 
protocol.
5.4 Screen failures 
References to IGRA TB tests and tests that 
result in ALT, AST, or ALP up to 25% the 
exclusion limit have been removed. 
Updated for consistency of 
the respective changes 
throughout the protocol.
5.4 Screen failures
The wording about vaccination for 
splenectomized participants was updated. 
Updated for consistency 
with the changes done in 
Section 8.2.6.
6 Study Treatments, Table 
6-1 Treatments 
administered 
IMP dosing every 2 weeks was updated to 
weekly dosing. 
The one-time fixed unit starting dose of 
rozanolixizumab equivalent to 
 
was removed.
Updated for consistency 
with the change in dosing 
regimen.
6 Study Treatments, Table 
6-1 Treatments 
administered
References to vial fill volumes were 
removed. 
Updated to reflect the 
foreseeable change in vial 
fill volumes
PUBLIC COPY 
reference
OPY
reference
3a was r
OP
3a was r
clusionar
CO
clusionar
Table 5
C C
Table 5
criterion 
LIC
criterion 
d to remo
BLI
d to remo
: ALT, A
UB
: ALT, A
% above
PU
% above
eated
P
eated
nt cannot be used to support any marketing authorization 
to 
a
to 
mov
rt a
moved an
t a
ed an
y requirem
ort
y requirem
3a, now 3
upp
3a, now 3
ve the follo
sup
ve the follo
ST, or ALP
to s
ST, or ALP
the exclusi
d to
the exclusi
once for co
ed 
once for co
ening. 
sed
ening. 
clusion cri
us
clusion cri
d for 
riz
d for 
e study 
utho
e study 
to provid
ng 
to provid
onal clarit
ting
onal clarit
clusion cri
keti
clusion cri
redundanc
rke
redundanc
consi
mar
consistst
prot
ma
prot
m
za
Referenc
be
Referenc
result
ot b
result
exc
ot
exc
e
ot
This document cann
Treatment
men
Treatment
reatments
me
reatments
ministered
cum
ministered
nt
s d
s
nd any extensions or variations thereof.
d 
v
d 
ments 
r v
ments 
3b, was
ns o
3b, was
owing bul
ons
owing bul
P results u
sio
P results u
ion limit m
ns
ion limit m
onfirmatio
ten
onfirmatio
iterion 42 
y ex
iterion 42 
de
r
de
ty to certa
here
ty to certa
iteria, rem
the
iteria, rem
cies and en
s th
cies and en
tency throu
ns 
tency throu
tocol.
ion
tocol.
va
ces to IGR
any
ces to IGR
t in ALT, A
d an
t in ALT, A
clusion lim
nd 
clusion lim
y
cation and
The wor
an
The wor
splen
n a
splen
applica
nd
on
nts, Table
cat
nts, Table
d 
p
d 
tio


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 12 of 202
Section # and Name
Description of Change
Brief Rationale
6 Study Treatments, Table 
6-1 Treatments 
administered
Dosing instructions were updated. 
To align with the latest 
dosing instructions. 
6.2.1.1 Maintenance of 
study treatment blind
Bullet point #2 was updated to delete “on 
request”.
To align with the current 
procedure.
6.2.1.1 Maintenance of 
study treatment blind
The text was updated to state the procedure 
in case the serum IgG level decreases to 
<1g/L. A cross reference to Appendix 25 
was added.
Updated to ensure 
consistency with the 
changes in Section 10.25.
6.3 Treatment compliance
The text was updated to add “study 
participant’s home”. 
Updated as optional home 
dosing visits have been 
included in the schedule. 
6.4.1 Permitted 
concomitant treatments 
(medications and 
therapies)
The text was updated to clarify that the 
following concomitant medications are 
permitted during the study and if possible, 
kept stable for the duration of the study.
Updated for clarity.
6.4.1 Permitted 
concomitant treatments 
(medications and 
therapies)
Table 6-2 Permitted 
concomitant treatments 
(medications and 
therapies)
Permitted oral corticosteroids dose was 
increased to ≤20mg/day.
A dose of "≤4mg/kg/day for modified" was 
added for cyclosporin.
Allowed dose of oral 
corticosteroids was 
increased to a maximum of 
20 mg/day for more 
flexibility in managing the 
concomitant ITP treatment. 
Updated to clarify 
permitted concomitant 
medications.
6.4.3 Rescue therapy 
The conditions to commence IMP 
treatment following rescue therapy with 
high dose corticosteroids were updated.
Permitted oral corticosteroids dose was 
updated to 20mg/day.  
Updated for consistency 
with the new dosing 
regimen and other allowed 
rescue medication (platelet 
count is considered the 
more clinically relevant 
trigger for IMP initiation 
compared with a strict time 
interval of 4 weeks). 
6.4.3 Rescue therapy
Text was updated to state that details of the 
rescue therapy administered must be 
recorded in the eCRF. 
Updated for clarity. 
6.5 Dose modification 
Text pertaining to dose modification was 
modified to clarify that dose modifications 
of the IMP were permitted in order to 
maintain the platelet counts between 
≥50x109/L and ≤150x109/L. References to 
up and down titration of the IMP was 
deleted. Additional text was added to state 
Updated to reflect that 
platelet counts should be 
maintained between 
≥50x109/L and 
≤150x109/L. 
Added to provide clarity 
PUBLIC COPY 
n of the
Y
n of the
teroids d
OPY
teroids d
/day.
CO
/day.
ose o
P
ose o
PY
This document cannot be used to support any marketing authorization 
za
he 
th
he 
on 10.25.
uth
on 10.25.
iza
za
as optiona
ng a
as optiona
g visits hav
ting
g visits hav
uded in th
keti
uded in th
a
ble,
ble,
udy.
ny
udy.
Updated 
ark
Updated 
ke
m
se was 
an
se was 
f "≤4mg/k
ed 
f "≤4mg/k
for cyclos
se
for cyclos
ny
he conditi
e u
he conditi
treatmen
be
treatmen
high d
ot b
high d
Pe
o
Pe
us
ot
3 Rescue 
um
3 Rescue 
me
d
s do
6.5 
d
6.5 
do
s d
application and any extensions or variations thereof.
al home
eof
al home
ve been
ere
ve been
he schedul
her
he schedul
of.
for clarity
s th
for clarity
th
kg/day for 
ten
kg/day for 
sporin.
exte
sporin.
Allow
aria
Allow
cor
a
cor
ia
va
ions to com
y e
ions to com
nt followin
any
nt followin
dose corti
d an
dose corti
ermitted o
nd 
ermitted o
updated 
an
updated 
e
on
therapy
plic
therapy
ic
a


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 13 of 202
Section # and Name
Description of Change
Brief Rationale
“Dose modifications or temporary IMP 
treatment discontinuation are permitted if 
serum IgG value is <1g/L (Section 10.26).”
that dose modifications 
based on IgG values are 
permitted.
6.5 Dose modification
An additional bullet point regarding 
moderate to severe toxicities was added. 
Updated to remain 
consistent with the 
rozanolixizumab program.
7.1.2 QTc stopping criteria
“Average of triplicate” ECG was removed. 
Updated to reflect the 
changes in Section 8.1.3.
7.1.3 Discontinuation of 
IMP due to other adverse 
events or medical 
condition
The text was updated to: Study participant 
has a significant infective episode 
including but not limited to: bacteremia or 
sepsis, infectious meningitis, osteomyelitis, 
septic arthritis, complicated pneumonia or 
visceral abscess which may or may not 
result in hospitalization. This list is not 
intended to be all inclusive, and the 
investigator is expected to apply his/her 
judgment on continuing IMP based on the 
clinical situation at hand.
Updated for consistency 
within the rozanolixizumab 
clinical program.
7.1.3 Discontinuation of 
IMP due to other adverse 
events or medical 
condition
The text was updated as follows: Study 
participant has a serious AE of headache or 
GI disturbance that is considered related to
the IMP in the opinion of the investigator; 
or recurrent severe AE of headache (see 
Appendix 22, Section 10.22) or GI 
disturbance that is considered related to the 
IMP in the opinion of the investigator (See 
Appendix 23, Section 10.23).
Updated to remain 
consistent with Phase 3 ITP 
clinical program.
7.1.3 Discontinuation of 
IMP due to other adverse 
events or medical 
condition
Reference to TB test was removed. 
Updated for consistency 
with changes in Section 
8.2.5.
7.1.4 Temporary IMP 
discontinuation
Instructions for temporary IMP 
discontinuation were updated to remove 
individual requirements for splenectomized 
and non-splenectomized participants. 
Updated to ensure 
consistency with the 
changes in Section 10.25.
7.1.4 Temporary IMP 
discontinuation
Instructions in relation to restarting IMP 
following COVID-19 infection/exposure 
were updated.
Updated for providing 
additional clarity on the 
temporary IMP 
discontinuation due to 
COVID-19 infection/ 
exposure.
7.1.4 Temporary IMP 
discontinuation
Text was added/updated as follows: 
Updated to ensure 
consistency with the 
COPY
an
Y
an
 apply 
PY 
 apply 
g IMP ba
OPY
g IMP ba
and.
COP
and.
PUBLIC CO
dated as 
C C
dated as 
as a serio
IC 
as a serio
ance that
LIC
ance that
P in the o
UBL
P in the o
ecurrent s
PUB
ecurrent s
pendix 
PU
pendix 
rb
P
rb
CO
rt any marketing authorization 
m.
ri
m.
za
he 
h
he 
on 8.1.3.
utho
on 8.1.3.
riz
/her 
ny
/her 
ed on the
any
ed on the
consist
au
consisten
u
en
rozanolix
g a
rozanolix
l program.
ting
l program.
ut
m
e used to support
ollows: St
por
ollows: St
us AE of h
pp
us AE of h
s consider
up
s consider
pinion of th
o su
pinion of th
evere AE o
to 
evere AE o
22, Section
d to
22, Section
nce that is 
ed
nce that is 
in the opin
use
in the opin
ppendix 2
e us
ppendix 23
s
3
annot be 
ort
Referenc
be
Referenc
e
ot
ment can
ry IMP
ca
ry IMP
on
nt
on
an
s docum
1.4 Tempo
cum
1.4 Tempo
discontin
ocu
discontin
This d
m
s d
variations thereof.
cy 
of
cy 
xizumab
eof
xizumab
e
va
y extensions or v
tudy 
or
tudy 
headache o
s o
headache o
red related
ns 
red related
he investig
ion
he investig
of headach
nsio
of headach
n
e
n 10.22) or
ens
10.22) or
considere
xten
considere
nion of the
ext
nion of the
, Section
y ex
, Section
lication and any 
v
ce to TB t
any
ce to TB t
y
Inst
n a
Instru
a
ru
di
n
di
a
on
applic
orary IMP
ppl
orary IMP
uation
app
uation
lic


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 14 of 202
Section # and Name
Description of Change
Brief Rationale
Study participant MAY temporarily 
discontinue IMP if any of the following 
events occur:
1.
A severe AE of headache that is 
considered related to the IMP in 
the opinion of the investigator 
(Section 10.22)
2.
A splenectomised study participant 
develops a (persistent or re-
occurring) nonserious infection, as 
per investigator’s decision 
(Section 10.25)
3.
Total serum IgG value is <1g/L as 
per investigator’s decision. As IMP 
treatment is administered weekly, 
the decision to temporarily hold 
the treatment should be determined 
based on the most recently 
available total IgG value. As the 
IgG, IgG subtypes, albumin and 
total protein levels will be blinded 
to both the study site personnel and 
the clinical team at the sponsor and 
CRO, unblinded Medical Monitors 
will be monitoring the IgG levels 
and will alert the investigator in 
case of decreases <1g/L. 
Additionally, guidance for 
investigators on management of 
infections can be found in 
Appendix 25, Section 10.25.
changes in Section 10.22 
and Section 10.25.
7.2 Participant 
discontinuation/withdrawal 
from the study
#3 was added as follows: 3. Study 
participant meets the mandatory IMP 
discontinuation criteria as per Section 
7.1.1, Section 7.1.2 or Section 7.1.3 .
Added for consistency 
throughout the protocol. 
8 Study assessments and 
procedures 
Additional text was added regarding home-
nursing visits. 
Text added to provide 
additional details on the 
optional home-nursing 
visits and the conditions 
that need to be met prior to 
the conduct of home-
nursing visits.
PUBLIC COPY
stere
Y
stere
emporari
PY 
emporari
should b
OP
should b
the most 
CO
the most 
ble total I
C C
ble total I
G, IgG su
LIC
G, IgG su
total prot
BLI
total prot
to bot
UB
to bot
the
U
the
cument cannot be used to support any marketing authorization 
MP
m
MP
ekly, 
y
ekly, 
y hold 
any
y hold 
e determin
t a
e determin
ecently 
ort
ecently 
gG value. A
ppo
gG value. A
types, albu
upp
types, albu
ein levels w
sup
ein levels w
h the study
to s
h the study
clinical te
d to
clinical te
CRO, unbl
ed 
CRO, unbl
will be 
use
will be 
and 
us
and 
c
ot
m
za
pant 
nt
pant 
nuation/wi
en
nuation/wi
the study
me
the study
t c
s docu
8 Study 
doc
8 Study 
proce
do
proce
This d cu
s d
pplication and any extensions or variations thereof.
ned 
va
ned 
As the
or
As the
umin and 
ns o
umin and 
will be blin
ons
will be blin
y site perso
sio
y site perso
eam at the 
ens
eam at the 
linded Me
xten
linded Me
monitorin
ext
monitorin
will alert 
y e
will alert 
case of dec
any
case of dec
Additio
d an
Additio
inve
d 
inve
inin
on
va
ithdrawal 
cat
ithdrawal 
#
on
on
on
on
app
ssessmen
ap
ssessmen
pp


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 15 of 202
Section # and Name
Description of Change
Brief Rationale
8.1.1 Platelet counts
The first endpoint was updated to clarify 
that the last 12 weeks refer to Weeks 13 to 
25.
Updated for consistency 
with the Objectives section 
and to provide further 
clarity on the endpoint 
assessment timepoint.
8.2.2 Vital signs
Vital signs measurement time points for all 
visits were updated and clarified.
Updated for consistency 
with the change in dosing 
regimen and to provide 
consistency across the 
studies in the 
rozanolixizumab 
development program.
8.2.3 Electrocardiograms
Text was updated to remove references to 
triplicate ECGs :“Triplicate 12 lead ECG” 
ECG was replaced with “A 12-lead ECG”.
No identification of cardio-
toxicity from non-clinical 
data, supported by lack of 
signal of cardiac events in 
the rozanolixizumab-
program. Updated in order 
to decrease the burden to 
the sites and study 
participants.
8.2.5 Assessment and 
management of TB and TB 
risk factors
The text was updated to clarify that 
assessment and management of TB and TB 
risk factors should follow local or national 
guidelines. 
Patients with known 
tuberculosis (TB) infection, 
at high risk of acquiring 
TB infection, or latent 
tuberculosis infection 
(LTBI), or current/history 
of nontuberculous 
mycobacterial infection 
(NTMBI) are already 
excluded from 
TP0003/TP0006, therefore 
the sites are expected to 
follow national / local 
guidelines for the 
management of TB, in case 
needed.
In addition, the mechanism 
of action of 
rozanolixizumab is 
expected to have little or 
not impact on the immune 
response against 
intracellular organisms 
which is involved in 
controlling the infection 
PUBLIC COPY 
as update
LIC
as update
ent and m
BL
ent and m
actors sh
UB
actors sh
idelines.
PU
idelines.
C
ting authorization 
za
y y 
osing
hori
osing
ovide
tho
ovide
ross the
auth
ross the
e e 
izumab
g a
izumab
opment 
ting
opment pr
g
pr
za
za
marketi
o identific
ket
o identific
toxicity f
arke
toxicity f
data, s
mar
data, s
sign
m
sign
m
pport any m
ti
m
ot be used to supp
d to clarify
upp
d to clarify
anagemen
sup
anagemen
uld follow
to s
uld follow
This document cannot
pp
s d
ot
hereof.
ogram.
ere
ogram.
variations the
ation of c
the
ation of c
from non
s th
from non
supported 
ons
supported 
nal of card
tion
nal of card
the rozano
atio
the rozano
program
aria
program
to de
ar
to de
th
a
th
or va
her
va
on and any extensions o
y that 
ns
y that 
nt of TB an
ions
nt of TB an
w local or 
sio
w local or 
application
o
on


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 16 of 202
Section # and Name
Description of Change
Brief Rationale
with Mycobacterium 
tuberculosis.
8.2.5.1 Tuberculosis 
assessment 
Sections on physical examination for TB, 
TB assessment by IGRA, and TB 
assessment by chest x-ray were removed. 
Updated to ensure
consistency with Section 
8.2.5.
8.2.5.2 Tuberculosis 
management
Text on test conversion for IGRA was 
removed.
Updated to ensure 
consistency with Section 
8.2.5.
8.1.5.2 Tuberculosis 
management
The definition for LTBI was updated. 
The definitions for active TB and NTMBI 
were added. 
LTBI definition updated as 
per WHO and CDC 
guidelines. Active TB and 
NTMBI definitions as per 
WHO and CDC guidelines 
were added for 
consistency. 
8.2.5.2 Tuberculosis 
management
Text pertaining to AE reporting for Latent 
TB was removed. 
Updated for consistency in 
reporting any TB related 
AEs as per Section 8.2.5.1.
8.2.6 Splenectomized 
study participants 
The vaccination requirements for 
splenectomized participants were updated.
The requirement for vaccination titers 
collection during Screening was moved to 
Baseline. Vaccination titers at W13 were 
removed. 
Due to the lack of 
evidence-based best 
practice in the area, 
updated to align with the 
general clinical practice 
standards.
8.3 Adverse events 
A note was added that in order to protect 
the blind, the events of 
hypogammaglobulinemia should not be 
captured as an AE in the eCRF.
The blinded study teams at 
the Sponsor, CRO and site 
must remain blinded in 
case an event of 
hypogammaglobulinemia 
occurs. Only the unblinded 
Medical Monitors and the 
investigator will have 
access to this information. 
The respective AEs will be 
reconciled based on the 
IgG values at the end of the 
study, after data base lock 
will take place and the data 
will be unblinded.
8.3.8 Adverse events of 
special monitoring
Text was added to state that the headache 
questionnaire should also be completed in 
case of moderate headache although 
moderate headache is not considered an 
AESM.
Updated to ensure 
consistency with the 
changes in Section 10.22.
PUBLIC COPY 
rting 
Y
rting 
requirem
CO
requirem
d particip
C C
d particip
ment for
LIC
ment for
n during 
BLI
n during 
ne. Vacc
UB
ne. Vacc
moved.
PU
moved.
CO
te
P
te
P
This document cannot be used to support any marketing authorization 
za
ction 
ho
ction 
za
za
ion update
au
ion update
and CDC
g a
and CDC
nes. Activ
ting
nes. Activ
MBI defin
ketin
MBI defin
WHO and C
rke
WHO and C
were add
ark
were add
consi
ma
consi
ut
m
Latent 
ny
Latent 
U
m
U
m
nts for 
ort
nts for 
ants were u
ppo
ants were u
vaccination
upp
vaccination
Screening w
sup
Screening w
nation tite
o s
nation tite
rt
was added 
sed
was added 
ind, the ev
use
ind, the ev
pogammag
e us
pogammag
captured a
be 
captured a
d t
d
ot
s do
8.3.
d
8.3.
do
s d
application and any extensions or variations thereof.
ed as 
of
ed as 
ve TB and 
ereo
ve TB and 
nitions as p
her
nitions as p
CDC guid
the
CDC guid
ded for 
s t
ded for 
istency. 
ons
istency. 
Updated fo
atio
Updated fo
reportin
riat
reportin
AEs 
ari
AEs 
ion
va
updated.
or
updated.
n titers
ns o
n titers
was move
ons
was move
rs at W13
sio
rs at W13
D
va
va
va
va
that in ord
xten
that in ord
vents of 
ext
vents of 
aglobulinem
y e
aglobulinem
as an AE i
ny 
as an AE i
en
on
a


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 17 of 202
Section # and Name
Description of Change
Brief Rationale
8.3.10 COVID-19 
vaccination
A new subsection has been included to 
ensure AEs considered related to COVID-
19 vaccination are captured. 
Implemented to ensure 
study participant safety in 
response to the COVID-19 
pandemic.
8.7 Pharmacodynamics 
A sentence was added to state that results 
of the ITP-specific autoantibodies analyses 
will not be outlined in the Clinical Study 
Report for this study.
Analysis of the ITP-
specific autoantibodies is a 
lengthy method and 
therefore the results will be 
provided in a separate 
report.
8.8.2 Immunology 
Serum cytokines were deleted.
Week 23 was updated to Week 25. 
Removed as the scientific 
value of the serum 
cytokines is limited.
Updated to reflect the 
change in the study design 
due to weekly dosing.
8.9 Exploratory 
biomarkers
α- and β-globulins were removed. 
Removed as the scientific 
value of these exploratory 
biomarkers is limited.
9.3.1 Analysis of the 
primary efficacy/primary 
endpoint 
The two-stage statistical design was 
removed. 
Additional wording to clarify that platelet 
count from Week 14 to Week 25 will be 
used to assess durable clinically 
meaningful platelet count was included.
To reflect inclusion of 
weekly sc infusion 
treatment as the primary 
efficacy assessment and the 
requirement to randomize a 
fixed number of 
participants on weekly 
dosing.
Table 9-1 Estimands for 
the primary endpoint 
The RS population was updated to those 
who were randomized to weekly dosing 
compared to placebo. 
Geographical region was removed as a 
stratification factor from the CMH model. 
Updated to reflect that the 
primary objective is to 
assess the rozanolixizumab 
treatment effect for weekly 
sc infusions.
Geographical region 
removed from the model to 
add convergence of the 
statistical model. Region 
will be explored through 
subgroup analyses detailed 
in the SAP.
Table 9-2 Estimands for 
secondary endpoints
The RS population was updated to those 
who were randomized to weekly dosing 
compared to placebo. 
Geographical region 
removed from the analysis 
models to mirror the 
C COPY 
re remov
OPY
re remov
PY
PUBLIC C
ge statist
LIC 
ge statist
ional wo
UBL
ional wo
nt from 
PU
nt from 
d to a
P
d to a
C C
port any marketing authorization 
is a 
ri
is a 
ts will be 
tho
ts will be 
eparate
auth
eparate
za
d as the s
ng 
d as the s
 of the ser
eting
 of the ser
ytokines is
ket
ytokines is
Updat
mar
Updat
cha
m
cha
d
m
d
g a
m
d.
t
d.
ny
be used to suppo
cal design 
upp
cal design 
ding to cla
to s
ding to cla
Week 14 to
d to
Week 14 to
sess durab
ed t
sess durab
ngful plate
sed
ngful plate
po
ot be 
The RS
t be
The RS
who 
ot b
who 
co
o
co
This document cannot be
s d
ot
or variations thereof.
cientific
reo
cientific
rum 
he
rum 
s limited.
the
s limited.
ted to refle
ons
ted to refle
ange in the
tion
ange in the
due t
ati
due to we
atio
o we
of
Remo
aria
Remo
val
a
val
ia
va
ny extensions or
was 
s
was 
arify that p
sion
arify that p
o Week 25
nsi
o Week 25
ble clinical
ten
ble clinical
elet count w
xte
elet count w
or
on and any
S populatio
any
S populatio
were rand
d a
were rand
ompared to
nd 
ompared to
Geograp
an
Geograp
strati
n a
strati
application
ny
on


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 18 of 202
Section # and Name
Description of Change
Brief Rationale
Geographical region was removed as a 
stratification factor from the statistical 
models.
Statistical tests were updated.
analysis of the primary 
endpoint.
Statistical tests updated to 
reflect proposed analyses in 
the SAP.
9.3.3.1 Analysis of 
pharmacokinetic endpoint 
The text was updated as follows: “A 
statistical summary of rozanolixizumab 
plasma concentrations will be reported by 
scheduled time point overall and by body 
weight tier, stratified by dose regimen. 
Further details on summaries for dose 
modifications will be provided in the 
corresponding SAP.”
To reflect the change to 
weekly sc infusion 
treatment by summarising 
the data by bi-weekly and 
weekly treatment
9.3.3.3 Analysis of 
pharmacodynamic 
endpoints
The total IgG endpoint wording was 
updated. 
Updated to reflect that IgG 
will measured and analyzed 
at every scheduled visit 
rather than only reporting 
the lowest value across the 
duration of the study.
9.4.1 Safety analyses 
Text was added to state that data will be 
further presented by randomized dosing 
regimen. 
To reflect the change to 
weekly sc infusions.
9.6 Handling of dropouts 
or missing data 
Text was added to state that if individual 
platelet visit data is missing it will be set to 
zero; participants who are lost to follow-up 
will be imputed as nonresponders.
To clarify how missing 
platelet count data will be 
handled in the statistical 
analyses. 
9.7 Data monitoring
The 2-stage design and interim analysis 
was removed. 
To reflect the requirement 
to randomize a fixed 
number of participants on 
weekly sc infusions and 
removal of option to 
increase sample size based 
on an interim analysis.
9.7.1 Early stopping for 
efficacy 
9.7.2 Early stopping for 
futility 
Sections are no longer applicable. 
To reflect the requirement 
to randomize a fixed 
number of participants on 
weekly sc infusions and 
removal of option to 
increase sample size based 
on an interim analysis.
9.8 Determination of 
sample size
The same size calculation was updated. 
To reflect the requirement 
to randomize a fixed 
number of participants on 
PUBLIC COPY 
dded to s
LIC
dded to s
presented
BL
presented
men.
UB
men.
C
PU
xt was 
PU
xt was 
PU
to support any marketing authorization 
s in 
iz
s in 
za
nge to
tho
nge to
sion 
aut
sion 
y summari
au
y summari
by bi
ng
by bi-
g
-week
g a
week
y treatmen
ting
y treatmen
hor
m
Up
m
Up
ma
m
ate that da
upp
ate that da
by random
sup
by random
pp
be used to
dded to st
d t
dded to st
visit data 
sed
visit data 
 participan
use
 participan
ill be impu
e u
ill be impu
ent cannot be 
to
The 2
t be
The 2-s
e
s
was r
ot b
was r
be
ot
s documen
Early stop
me
Early stop
icacy 
cum
icacy 
9.7.2 Earl
ocu
9.7.2 Earl
futility
do
futility
This d
en
s d
nsions or variations thereof.
ising 
of
ising 
kly and 
eof
kly and 
nt
e
nt
pdated to re
tion
pdated to re
will measu
iatio
will measu
at every
aria
at every
rathe
ar
rathe
th
a
th
ns
va
ta will be 
ns 
ta will be 
mized dosi
ions
mized dosi
o
ny extens
ate that if 
ens
ate that if 
is missing
xte
is missing
nts who ar
ext
nts who ar
uted as no
y e
uted as no
ation and any
ns
stage desig
any
stage desig
removed
d a
removed
ny
on
applica
pping for 
lica
pping for 
ly stoppin
app
y stoppin
ca


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 19 of 202
Section # and Name
Description of Change
Brief Rationale
Table 9-3 Expected sample 
size for TP0006
weekly sc infusions and 
removal of option to 
increase sample size based 
on an interim analysis.
10.2 Appendix 2:
Table 10-1 Protocol-
required safety laboratory 
assessments
Platelet reticulocytes and glycosylated 
hemoglobin were removed. Associated 
footnotes were removed. 
Updated to reflect that the 
analysis will not be 
performed.
10.2 Appendix 2
Table 10-1 Protocol-
required safety laboratory 
assessments
Footnote a was updated from “sponsor” to 
“study participant”. 
Updated to correct an error.
10.4 Appendix 4:
Table 10-2 Highly 
effective contraceptive 
methods
Footnote c has been removed from Table 
10-2.
To remain consistent with 
the Phase 3 
rozanolixizumab clinical 
program.
10.6 Appendix 6: Liver 
safety – suggested actions 
and follow-up assessments
The cross-reference to the liver chemistry 
stopping criteria was corrected in Table 10-
4. 
Corrected to reference the 
appropriate section of the 
protocol.
10.8 Appendix 8: Country-
specific requirements
Poland 
Visit 29 was updated to Visit 28.
Updated to align with the 
updated Visit numbering.
10.9 Appendix 9: 
Abbreviations and 
trademarks
The definitions for the following 
abbreviations were added: COVID-19, 
LTBI, OPSI, QW, Q2W and RO. 
General update. 
10.11 Appendix 11: 
Karnofsky Performance 
Status Scale 
The Karnofsky Performance Status Scale 
was removed. 
Updated to ensure 
consistency with the 
removal of Exclusion 
Criterion 15.
10.22 Appendix 22: 
Management of Headaches 
The text was updated to clarify the 
management of IMP administration 
including dose adjustment following an AE 
of headache.
Updated to reflect the 
current general program 
guidance for the 
management of headaches
10.24 Appendix 24: 
Management of infusion 
reactions or 
hypersensitivity reactions
Additional text was added: “Fully trained 
healthcare professionals administering the 
IMP at home should follow their own 
management guidelines, which should be 
reviewed and endorsed by the investigator 
prior to first home administration.”
Updated for consistency.
10.24 Appendix 24: 
Management of infusion 
reactions or 
hypersensitivity reactions
Serum cytokines were removed 
Blood cytokine sampling 
was removed as analysis of 
cytokines is not required in 
the ITP protocols as 
PUBLIC COPY 
the liver 
OPY
the liver 
s correcte
COP
s correcte
Y
updated 
IC 
updated 
C C
e definit
PU
e definit
revia
P
revia
UB
ent cannot be used to support any marketing authorization 
za
orrect an e
aut
orrect an e
uth
To remain
rke
To remain
the Pha
mar
the Pha
roza
ma
roza
p
m
p
ke
m
hemistry 
any
hemistry 
d in Table 
rt a
d in Table 
ny
o Visit 28.
pp
o Visit 28.
po
ons for the
d to
ons for the
ions were 
ed 
ions were 
OPSI, QW
se
OPSI, QW
to
he Karnofs
e u
he Karnofs
was remo
be 
was remo
us
ot
2:
a
2:
f Headache
can
f Headache
o
no
s documen
Appendix
me
Appendix
anagement
cum
anagement
reactions o
ocu
reactions o
hyperse
doc
hyperse
This d
en
s d
nd any extensions or variations thereof.
error.
f
error.
n consisten
s th
n consisten
ase 3 
ns
ase 3 
anolixizum
ion
anolixizum
program.
atio
program.
the
10
v
10-
va
-
Correc
aria
Correc
app
ar
app
iat
va
or
e followin
ens
e followin
added: CO
ten
added: CO
W, Q2W a
exte
W, Q2W a
sio
fsky Perfor
y e
fsky Perfor
oved.
ny
oved.
ex
ation and
es
es
The text 
an
The text 
manag
n a
manag
inc
n
inc
nd
on
applica
x 24:
lic
x 24:
t of infusio
ppli
t of infusio
or 
a
or 
itivity 
ap
itivity 
ca


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 20 of 202
Section # and Name
Description of Change
Brief Rationale
samples have been 
collected in other 
rozanolixizumab studies 
and no additional 
information is expected 
from the ITP population.
10.25 Appendix 25: 
Management of infections 
and 
hypogammaglobulinemia
The text was updated to clarify the 
management of IMP administration 
including dose adjustment following 
episodes of infections and 
hypogammaglobulinemia.
The total serum IgG cut-off 
value for informing the 
investigators has been 
aligned for all study 
participants based on the 
lack of conclusive literature 
supporting the previous 
approach. 
The investigators are given 
total flexibility in deciding 
if and how to continue the 
IMP treatment in cases of 
total IgG values <1g/L, 
based on a holistic 
approach of the study 
participant's status 
(platelets response, signs 
and symptoms of non-
serious/serious infection, 
potential risk of acquiring a 
non-serious/serious 
infection).
10.26 Appendix 26: 
Protocol Amendment 
History 
Protocol amendment 2 (global amendment) 
has been added. 
General update.
Throughout
Minor editorial and formatting changes 
have been made.
Minor, therefore have not 
been summarized.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
za
cut
ho
cut-
o
-off 
oriz
off 
g the 
tho
g the 
as been 
uth
as been 
ll study 
au
ll study 
nts based o
g a
nts based o
conclusiv
ing
conclusiv
porting the
etin
porting the
pproach. 
rket
pproach. 
The inv
ark
The inv
total 
ma
total 
if
m
if
iz
m
z
otocol
e u
otocol am
u
am
has been 
be 
has been 
us
ot
M
o
M
ot
ot
ot
ca
ot
application and any extensions or variations thereof.
on the
eof
on the
e literatur
reo
e literatur
e previous
her
e previous
vestigators
ns t
vestigators
 flexibility
ons
 flexibility
and how t
tio
and how t
IMP trea
iat
IMP trea
total I
aria
total I
bas
a
bas
va
mendment 2
y e
mendment 2
added.
ny
added.
ex
Minor edito
nd 
Minor edito
have bee
an
have bee
d a
on
on
on
on


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 21 of 202
SERIOUS ADVERSE EVENT REPORTING
Serious adverse event reporting (24h)
All serious adverse events (SAEs) will be reported and transmitted to Patient 
Safety through the electronic Case Report Form (eCRF) system. The numbers 
below are to be used to send ancillary documentation only (eg, discharge 
summaries, death certificates) or in the event that the eCRF is not available.
Fax
Europe and Rest of the World: +32 2 386 24 21
US: +1 800 880 6949 or +1 866 890 3175
Email
Global (for interventional clinical studies): DS_ICT@ucb.com
PUBLIC COPY 
eting authorization 
ho
ho
ho
ho
ucb.com
ting
ucb.com
g
This document cannot be used to support any market
et
hereof.
eo
eo
eo
application and any extensions or variations the
he eo


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 22 of 202
TABLE OF CONTENTS
PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE......................................2
SERIOUS ADVERSE EVENT REPORTING........................................................................21
1
PROTOCOL SUMMARY...............................................................................................27
1.1 Synopsis ...........................................................................................................................27
1.2 Schema.............................................................................................................................37
1.3 Schedule of activities .......................................................................................................38
2
INTRODUCTION ...........................................................................................................47
2.1 Study rationale .................................................................................................................47
2.2 Background......................................................................................................................49
2.3 Benefit/risk assessment....................................................................................................51
3
OBJECTIVES AND ENDPOINTS .................................................................................53
4
STUDY DESIGN.............................................................................................................57
4.1 Overall design ..................................................................................................................57
4.2 Scientific rationale for study design.................................................................................59
4.3 Justification for dose........................................................................................................60
4.4 End of study definition.....................................................................................................61
5
STUDY POPULATION ..................................................................................................62
5.1 Inclusion criteria ..............................................................................................................62
5.2 Exclusion criteria .............................................................................................................63
5.3 Lifestyle restrictions.........................................................................................................67
5.4 Screen failures..................................................................................................................68
6
STUDY TREATMENTS.................................................................................................69
6.1 Preparation, handling, storage, and accountability requirements ....................................69
6.1.1
Drug accountability .............................................................................................70
6.2 Measures to minimize bias: randomization and blinding ................................................70
6.2.1
Procedures for maintaining and breaking the treatment blind.............................71
6.2.1.1
Maintenance of study treatment blind.......................................................71
6.2.1.2
Breaking the treatment blind in an emergency situation...........................72
6.3 Treatment compliance......................................................................................................72
6.4 Concomitant medication(s)/treatment(s)..........................................................................73
6.4.1
Permitted concomitant treatments (medications and therapies) ..........................73
6.4.2
Prohibited concomitant treatments (medications and therapies) .........................73
6.4.3
Rescue therapy.....................................................................................................74
6.5 Dose modification............................................................................................................75
6.6 Treatment after the end of the study ................................................................................75
7
DISCONTINUATION OF IMP AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL........................................................................76
UBLIC COPY 
.........
PY 
.........
..........
OP
..........
....
C
..........
CO
......
.........
C C
.........
......
LIC
..........
LIC
....
PUB
.........
UB
.........
..........
PU
..........
.
P
.
support any marketing authorization 
7
r
7
..
h
..38
hor
38
........
uth
........47
h
47
............
a
............
............
ng
............
............
tin
............
...........
ke
...........
............
a
............
............
m
............
............
ny
............
............
t a
............
...........
ort
...........
............
p
............
............
up
............
nt cannot be used to s
............
o s
............
........
d to
............
to
....
....
ed
...........
ed
.......
............
us
............
orage, and
be u
orage, and
ability
t be
ability ....
mize bias
not 
mize bias
dures for m
nno
dures for m
Maint
can
Maint
2
n
2
This docume
Br
c
Br
atment co
men
atment co
Conc
m
Concomit
me
omit
6.4.1
cu
6.4.1
6.4.2
doc
6.4.2
6
d
6
6
s
6
ions or variations thereof.
47
of
47
.....
e
.....49
eo
49
.......
her
...........
er
....51
e
51
...........
th
...........
.........
ns
............
s
...
..........
tio
..............
............
iat
............
............
ar
............
.......
r v
...........
v
....
............
o
............
..........
ns
..........
on and any extensio
....
............
io
............
............
ns
............
...........
te
...........
............
ex
............
d account
ny e
d account
............
an
............
s: random
d a
s: random
maintaini
and
maintaini
tenance o
n a
tenance o
applicatio
reaking th
tion
reaking th
ompliance
cat
ompliance
tant medi
plic
tant medi
Permitt
app
Permitt
Proh
ap
Proh


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 23 of 202
7.1 Discontinuation of IMP....................................................................................................76
7.1.1
Liver chemistry stopping criteria.........................................................................76
7.1.2
QTc stopping criteria ...........................................................................................77
7.1.3
Discontinuation of IMP due to other adverse events or medical condition.........78
7.1.4
Temporary IMP discontinuation..........................................................................78
7.2 Participant discontinuation/withdrawal from the study ...................................................79
7.3 Lost to follow up..............................................................................................................80
8
STUDY ASSESSMENTS AND PROCEDURES...........................................................80
8.1 Efficacy assessments........................................................................................................82
8.1.1
Platelet counts......................................................................................................82
8.1.2
ITP bleeding score ...............................................................................................83
8.1.3
Patient Reported Outcomes .................................................................................84
8.1.3.1
ITP-PAQ....................................................................................................84
8.1.3.2
SF-36 .........................................................................................................84
8.1.3.3
FATIGUE-PRO Physical Fatigue Scale....................................................84
8.1.3.4
EQ-5D-5L..................................................................................................84
8.1.3.5
PGI-S.........................................................................................................85
8.1.3.6
PGI-C.........................................................................................................85
8.2 Safety assessments...........................................................................................................85
8.2.1
Physical examination...........................................................................................85
8.2.2
Vital signs ............................................................................................................86
8.2.3
Electrocardiograms..............................................................................................86
8.2.4
Clinical safety laboratory assessments ................................................................86
8.2.5
Assessment and management of TB and TB risk factors....................................87
8.2.5.1
Tuberculosis assessment............................................................................87
8.2.5.2
Tuberculosis management.........................................................................87
8.2.6
Splenectomized study participants ......................................................................89
8.3 Adverse events.................................................................................................................89
8.3.1
Time period and frequency for collecting AE and SAE information..................90
8.3.2
Method of detecting AEs and SAEs ....................................................................90
8.3.3
Follow-up of AEs and SAEs................................................................................90
8.3.4
Regulatory reporting requirements for SAEs ......................................................90
8.3.5
Pregnancy ............................................................................................................91
8.3.6
Anticipated serious adverse events......................................................................91
8.3.7
Adverse events of special interest........................................................................91
8.3.8
Adverse events of special monitoring..................................................................91
8.3.9
Treatment-emergent adverse events ....................................................................92
8.3.10
COVID-19 vaccination........................................................................................92
PUBLIC COPY 
Scale
Y
Scale
.........
OPY
.........
..........
CO
..........
...
C
.........
C C
......
.......
LIC
.........
C
..
..........
BL
..........
.........
PU
.........
s
P
s.....
P
.....
This document cannot be used to support any marketing authorization 
.80
or
80
......
th
......80
ho
80
....
a
............
au
........8
...........
g
...........
............
tin
............
............
ke
............
............
ar
............
............
m
............
...........
y
...........
............
an
............
............
rt
............
............
po
............
............
upp
............
...........
su
...........
...
t
............
to
.........
............
d 
............
tory asses
sed
tory asses
manageme
e us
manageme
losis asse
be 
losis asse
erculosis m
ot b
erculosis m
tomized s
nno
tomized s
nts
a
nts.......
an
.......
Time perio
t ca
Time perio
Metho
ent
Metho
3
Fol
e
Fol
8.
c
8.3.4
cu
3.4
8.3.5
doc
8.3.5
8.3
d
8.3
application and any extensions or variations thereof.
2
f
2
...
e
...82
eof
82
.........
ere
.........83
e
83
............
th
............
............
s
............
............
on
............
...........
ati
...........
...
a
............
ari
.........
..............
va
..........
.......
or
............
r
.....
...........
s
............
...........
on
...........
............
si
............
.........
ten
............
n
...
ssments
exte
ssments
ent of TB 
y ex
ent of TB 
ssment
ny
ssment
managem
d a
managem
study par
and
study par
............
n a
............
iod and fr
tion
iod and fr
od of dete
atio
od of dete
llow
lic
llow-
ic
-up o
ca
up o
Regulato
ppl
Regulato
Pregn
ap
Pregn
A


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 24 of 202
8.4 Safety signal detection .....................................................................................................92
8.5 Treatment of overdose .....................................................................................................93
8.6 Pharmacokinetics and antidrug antibodies.......................................................................93
8.7 Pharmacodynamics ..........................................................................................................94
8.8 Genetics............................................................................................................................94
8.8.1
Pharmacogenomics..............................................................................................94
8.8.2
Immunology.........................................................................................................94
8.9 Exploratory biomarkers ...................................................................................................95
8.10 Medical resource utilization and health economics .........................................................95
9
STATISTICAL CONSIDERATIONS.............................................................................96
9.1 Definition of analysis sets................................................................................................96
9.2 General statistical considerations.....................................................................................96
9.3 Planned efficacy/outcome analyses .................................................................................97
9.3.1
Analysis of the primary efficacy/primary endpoint.............................................97
9.3.2
Analysis of the secondary efficacy endpoints ...................................................101
9.3.3
Other efficacy/other outcome analyses..............................................................107
9.3.3.1
Analysis of pharmacokinetic endpoint ....................................................107
9.3.3.2
Antidrug antibodies analyses...................................................................107
9.3.3.3
Analysis of pharmacodynamic endpoints................................................107
9.4 Planned safety and other analyses..................................................................................108
9.4.1
Safety analyses...................................................................................................108
9.5 Handling of protocol deviations.....................................................................................108
9.6 Handling of dropouts or missing data............................................................................108
9.7 Data monitoring .............................................................................................................108
9.7.1
Early stopping for efficacy ................................................................................109
9.7.2
Early stopping for futility ..................................................................................109
9.8 Determination of sample size.........................................................................................109
10
SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS.110
10.1 Appendix 1: Regulatory, ethical, and study oversight considerations...........................110
10.1.1
Regulatory and ethical considerations...............................................................110
10.1.2
Financial disclosure ...........................................................................................111
10.1.3
Informed consent process ..................................................................................111
10.1.4
Data protection...................................................................................................112
10.1.5
Committees structure.........................................................................................112
10.1.6
Data quality assurance .......................................................................................112
10.1.6.1
Electronic Case Report Form completion ...............................................113
10.1.6.2
Apps.........................................................................................................113
10.1.7
Source documents..............................................................................................113
PUBLIC COPY 
oints
Y
oints
s
O
s........
OPY
........
ic endpo
COP
ic endpo
lyses
C C
lyses..
C
..
codynam
LIC 
codynam
ses
B
ses......
BL
......
.........
PU
.........
ations
PU
ations
This document cannot be used to support any marketing authorization 
.94
or
94
...
th
......
th
...95
ho
95
............
au
............9
....
g
...........
g
.......
............
tin
............
........
ke
............
e
....
............
ar
............
............
m
............
...........
y
...........
............
an
............
ntnt .........
rt
.........
............
po
............
c endpoin
upp
c endpoin
...........
su
...........
..........
to
..............
............
d 
............
ing data
sed
ing data
............
u
............
for effica
be 
for effica
ing for fu
ot b
ing for fu
of sample
nno
of sample
NG DOC
an
NG DOC
ix 1: Regu
t ca
ix 1: Regu
Regula
ent
Regula
.2
m
.2
Fin
e
Fin
10.1
cu
10.1.3
cum
.3
10.1.4
doc
10.1.4
10
d
10
plication and any extensions or variations thereof.
5
f
5
...
e
...96
eof
96
.........
ere
.........96
e
96
............
th
............
...
s
............
s
.........
............
on
............
..........
ati
...........
.....
ari
............
ari
.......
............
va
............
...........
or
............
nts
s
nts........
s
........
.......
on
...........
n
....
............
si
............
............
ten
............
............
xt
............
...
y
............
y e
.........
acy
an
acy ......
ny
......
utility
d a
utility ...
a
...
e size
and
e size....
nd
....
UMENT
n a
UMENT
ulatory, e
tion
ulatory, e
atory and
atio
atory and
nancial di
lica
nancial di
app
Informed
ppl
Informed
Data 
ap
Data 
C


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 25 of 202
10.1.8
Study and site closure ........................................................................................114
10.1.9
Publication policy..............................................................................................114
10.2 Appendix 2: Clinical laboratory tests ............................................................................115
10.3 Appendix 3: Adverse events – definitions and procedures for recording, evaluating, 
follow up, and reporting.................................................................................................117
10.3.1
Definition of AE ................................................................................................117
10.3.2
Definition of SAE..............................................................................................118
10.3.3
Recording and Follow up of AE and/or SAE ....................................................120
10.3.4
Reporting of SAEs.............................................................................................122
10.4 Appendix 4: Contraceptive guidance and collection of pregnancy information ...........123
10.5 Appendix 5: Genetics.....................................................................................................126
10.6 Appendix 6: Liver safety – suggested actions and follow-up assessments ...................127
10.7 Appendix 7: Medical device incidents – definition and procedures for recording, 
evaluating, follow up, and reporting..............................................................................131
10.8 Appendix 8: Country-specific requirements..................................................................132
10.9 Appendix 9: Abbreviations and trademarks ..................................................................133
10.10
Appendix 10: Rapid alert procedures ..................................................................136
10.11
Appendix 11: Karnofsky Performance Status Scale............................................137
10.12
Appendix 12: ITP-BAT .......................................................................................138
10.13
Appendix 13: ITP-PAQ .......................................................................................146
10.14
Appendix 14: SF-36 Form ...................................................................................157
10.15
Appendix 15: FATIGUE-PRO Physical Fatigue Scale .......................................162
10.16
Appendix 16: EQ-5D-5L .....................................................................................163
10.17
Appendix 17: PGI-S.............................................................................................165
10.18
Appendix 18: PGI-C ............................................................................................166
10.19
Appendix 19: Tuberculosis assessment ...............................................................167
10.20
Appendix 20: Headache questionnaire ................................................................168
10.21
Appendix 21: Sampson Criteria Questionnaire ...................................................172
10.22
Appendix 22: Management of headaches............................................................173
10.23
Appendix 23: Management of diarrhea ...............................................................175
10.24
Appendix 24: Management of infusion reactions or hypersensitivity reactions..176
10.25
Appendix 25: Management of infections and hypogammaglobulinemia............178
Dose adjustments/mock infusions .....................................................................................179
Splenectomized study participants.....................................................................................179
10.26
Appendix 26: Protocol Amendment History .......................................................181
11
REFERENCES ..............................................................................................................200
SPONSOR DECLARATION................................................................................................202
C COPY 
..
Y
..
.........
PY
.........
.........
OP
.........
mance St
CO
mance St
PUBLIC
.........
C 
.........
..........
BL
..........
or
U
orm
UB
m ...
UB
...
GUE
PU
GUE-
U
-P
U
P
5
P
5
support any marketing authorization 
18
or
18
...
th
...120
tho
120
.........
au
.........122
th
122
on
g
on ........
g a
........
............
ting
............
ents
ket
ents .....
et
.....
s for reco
arke
s for reco
............
ma
............
.......
y m
...........
m
....
............
any
............
............
t a
............
atus Scale
port
atus Scale
used to su
.........
pp
............
p
...
...........
su
...........
............
o
............
RO Physic
d to
RO Physic
L
s
L ...........
se
...........
t cannot be us
............
us
............
GI
b
GI-
b
-C
be
C ......
e
......
Tubercul
t b
Tubercul
20: Head
not
20: Head
dix 21: Sa
ann
dix 21: Sa
pendix 22
t ca
pendix 22
cumen
Appendix
nt 
Appendix
Appen
men
Appen
5
Ap
m
Ap
This docu
Dose ad
ocu
Dose ad
Sple
do
Sple
10.
s 
10.
or variations thereof.
2
f
2
123
of
123
......
re
.....126
reo
126
............
the
............1
ording, 
s th
ording, 
........
ns
............
ns
....
...........
tio
...........
............
ria
............
.....
va
............
va
.......
o
............
r v
............
extensions o
............
s o
............
...........
ns
...........
..........
sio
............
o
..
ical Fatigu
ens
ical Fatigu
............
xte
............
tion and any e
............
e
............
...........
ny
...........
losis asse
d any
losis asse
dache que
nd 
dache que
ampson C
an
ampson C
2: Manage
on 
2: Manage
pplicat
x 23: Man
atio
x 23: Man
endix 24: M
ica
endix 24: M
Appendix 2
pplic
Appendix 2
ap
djustment
app
djustment
omiz
a
omiz


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 26 of 202
LIST OF TABLES
Table 1-1:
Dose adjustments of IMP following initial dose..............................................33
Table 1-2:
TP0006 dose levels and weight tiers of IMP ...................................................36
Table 1-3:
Schedule of activities (Prolonged Screening only for splenectomized 
study participants)............................................................................................38
Table 1-4:
Schedule of activities.......................................................................................39
Table 3-1:
Study objectives and endpoints........................................................................53
Table 5-1:
Treatment-free periods for immunosuppressants, biologics, other 
therapies, and antiplatelet/anticoagulant agents...............................................65
Table 6-1:
Treatments administered..................................................................................69
Table 6-2:
Permitted concomitant treatments (medications and therapies) ......................73
Table 8-1:
Anticipated serious adverse events for ITP population ...................................91
Table 9-1:
Estimands for the primary endpoint.................................................................98
Table 9-2:
Estimands for secondary endpoints ...............................................................102
Table 9-3:
Expected sample size for TP0006..................................................................110
Table 10-1:
Protocol-required safety laboratory assessments...........................................115
Table 10-2:
Highly effective contraceptive methods ........................................................124
Table 10-3:
Phase 3-4 liver chemistry stopping criteria and follow-up assessments........128
Table 10-4:
Phase 3-4 liver chemistry increased monitoring criteria with continued 
IMP ................................................................................................................130
Table 10-5:
ITP-Bleeding Assessment Tool .....................................................................138
Table 10-6:
Headache Questionnaire ................................................................................168
Table 10-7:
Suggested management guidelines at the study site for infusion reactions...176
Table 10-8:
Management of infections and hypogammaglobulinemia.............................179
LIST OF FIGURES
Figure 1-1:
TP0006 dose adjustments of IMP....................................................................34
Figure 1-2:
TP0006 study schematic ..................................................................................37
Figure 7-1:
Liver chemistry stopping criteria and increased monitoring algorithm...........76
Figure 7-2:
Liver chemistry increased monitoring algorithm with continued study 
intervention for participants with ALT ≥3xULN but <8xULN.......................77
PUBLIC COPY 
..
Y
..
..........
PY
..........
06
CO
06......
CO
......
boratory
C C
boratory
aceptive 
BLIC
aceptive 
emistry s
UB
emistry s
chemis
PU
chemis
used to support any marketing authorization 
39
or
39
......
th
......53
ho
53
..
g
............
g
..........
......
tin
............
tin
......
apies)
rket
apies) ...
e
...
n
m
n ..........
ma
..........
...........
y m
............
m
.
...........
an
...........
............
rt 
............
assessmen
ppo
assessmen
methods
supp
methods
topping cr
to s
topping cr
ry increas
d to
ry increas
......
se
...........
e
.....
This document cannot be u
ssessment
us
ssessment
uestionna
be
uestionna
ed manag
ot 
ed manag
nagement
ann
nagement
1
m
1-
m
-1:
me
1:
igure
ocu
igure 1
cu
1-
u
-2:
u
2:
Figure
do
Figure
Fig
s 
Fig
d any extensions or variations thereof.
...
e
...65
eof
65
..........
er
..........69
e
69
............
th
............
............
ns
............
............
tio
............
....
r
............
ria
........
.......
va
............
va
.....
ents
o
ents.......
o
.......
............
ns
............
riteria and
sio
riteria and
sed monit
tens
sed monit
............
xte
............
application and
nt Tool
y ex
nt Tool ..
e
..
aire
an
aire ......
ny
......
gement gu
d a
gement gu
t of infect
and
t of infect
TP0006 d
plica
TP0006 d
TP00
pp
TP00
L


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 27 of 202
1
PROTOCOL SUMMARY
1.1
Synopsis
Protocol title
A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the 
Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants with 
Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
Short title
A Phase 3 study evaluating the efficacy, safety, and tolerability of rozanolixizumab in adult 
study participants with ITP
Rationale
Immune thrombocytopenia is a clinical disorder in which thrombocytopenia manifests as a 
bleeding tendency, purpura, or petechiae. Autoantibodies against platelet antigens are considered 
to be a hallmark of ITP. Production of pathogenic immunoglobulin (Ig) G autoantibodies by 
plasma cells is accepted as the central underlying pathophysiological mechanism in a number of 
IgG-mediated autoimmune diseases, which includes ITP. In some patients, antibodies recognize 
antigens derived from a single glycoprotein; whereas in others, antibodies recognize multiple 
glycoproteins. The spleen is the key organ in the pathophysiology of ITP, not only because 
platelet autoantibodies are formed in the white pulp, but also because mononuclear macrophages 
in the red pulp destroy immunoglobulin-coated platelets.
Treatments aimed at reducing the quantity of circulating IgG autoantibodies are being used for 
primary and secondary therapy of autoimmune diseases including ITP, particularly where 
corticosteroid-based immune suppression is not or no longer effective. The therapeutic approach 
of these treatments is based on lowering levels of pathogenic autoantibodies, which represents 
rational and effective treatment modalities of autoimmune diseases. The primary goal for 
treatment of ITP is to achieve a platelet count that prevents major bleeding, rather than correcting 
the platelet count to normal levels.
Rozanolixizumab is a humanized IgG4P monoclonal antibody that is being developed as an 
inhibitor of the activity of neonatal Fc receptor (FcRn). The FcRn receptor recycles IgG and 
albumin and transports it bidirectionally across epithelial barriers. Recent studies have shown 
that FcRn rescues both IgG and albumin from intracellular lysosomal degradation by recycling it 
from the sorting endosome to the cell surface (Anderson et al, 2006). Rozanolixizumab has been 
specifically designed to block IgG binding to FcRn without blocking the binding and recycling 
of albumin. By blocking the activity of FcRn, rozanolixizumab accelerates the catabolism of IgG 
antibodies, including IgG autoantibodies. This Phase 3 study, TP0006, will be one of 2 studies 
that will provide the required data to establish the efficacy and safety of rozanolixizumab over 
placebo in study participants with persistent or chronic primary ITP who have failed or were 
intolerant to two or more prior ITP therapy and who require an increase and sustained effect in 
their platelet counts.
PUBLIC COPY
p
Y
p
ITP. I
PY 
ITP. I
reas in o
OPY
reas in o
he patho
COP
he patho
hite pulp
C CO
hite pulp
coated p
IC C
coated p
antity of
BLI
antity of
f autoimm
UB
f autoimm
uppressi
PU
uppressi
owe
P
owe
nt cannot be used to support any marketing authorization 
in adult
auth
in adult
nia manif
ket
nia manif
elet antige
arke
elet antige
(Ig)
ma
(Ig) G
ar
G au
r
au
gical mec
y m
gical mec
ome patie
ny 
ome patie
hers, antib
any
hers, antib
physiology
rt a
physiology
but also b
por
but also b
atelets.
ppo
atelets.
circulatin
sup
circulatin
mune disea
to s
mune disea
on is not o
d to
on is not o
ring levels
ed 
ring levels
odalities 
use
odalities 
a platelet 
e us
a platelet 
levels.
be
levels.
umanized
ot b
umanized
ity of neo
nno
ity of neo
ports it bi
ann
ports it bi
ues both I
ca
ues both I
rting endo
nt c
rting endo
This docume
lly design
ent
lly design
umin. By 
me
umin. By 
ibodies, in
cum
ibodies, in
that will p
docu
that will p
placebo
do
placebo
into
s d
into
th
s
th
ation and any extensions or variations thereof.
fests as a 
the
fests as a 
ens are co
s th
ens are co
utoantibo
ons
utoantibo
chanism i
tion
chanism i
ents, antib
iati
ents, antib
ibodies re
aria
ibodies re
gy of ITP,
va
gy of ITP,
because m
or v
because m
ng IgG au
ons
ng IgG au
eases inclu
sio
eases inclu
or no long
ens
or no long
ls of patho
xten
ls of patho
of autoim
exte
of autoim
count tha
y ex
count tha
d IgG4P m
d a
d IgG4P m
onatal Fc r
nd 
onatal Fc r
idirection
an
idirection
IgG and a
on a
IgG and a
osome to 
tion
osome to 
applica
ned to blo
cati
ned to blo
y blocking
lica
y blocking
including 
ppli
including 
provide th
app
rovide th
study
a
study


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 28 of 202
Objectives and endpoints
Objectives
Endpoints
Primary
•
To demonstrate the clinical efficacy of 
rozanolixizumab in maintenance treatment 
in study participants with primary ITP
The primary efficacy endpoint is:
•
Durable Clinically Meaningful Platelet 
Response of ≥50x109/L, for at least 8 out 
of 12 weeks during the last 12 weeks 
(Week 13 to 25)
The secondary efficacy endpoints are:
•
Cumulative number of weeks with 
Clinically Meaningful Platelet Response 
of ≥50x109/L over the 24-week treatment 
period
•
Time to first Clinically Meaningful 
Platelet Response of ≥50x109/L: time 
from starting treatment to achievement of 
first response of ≥50x109/L 
•
Clinically Meaningful Platelet Response 
of ≥50x109/L by Day 8
•
Response defined as platelet count 
≥30x109/L and at least a 2-fold increase of 
the Baseline count confirmed on at least 
2 separate occasions at two adjacent 
nominal visits at least 7 days apart, and 
absence of bleeding by visit a,b
•
Time to first rescue therapy
•
Change from Baseline to Week 25 in ITP 
Patient Assessment Questionnaire 
(ITP-PAQ) Symptoms Score
The other efficacy endpoints are:
•
Duration of first Clinically Meaningful 
Platelet Response of ≥50x109/L: measured 
from achievement of first Response to 
loss of first Response (loss of Response 
defined as platelet count <50x109/L)
•
Time to first Response: time from starting 
treatment to achievement of Response 
•
Usage of rescue therapy by visit
COPY
Pla
Y
Pla
from
PY 
from
firs
PY
firs
•
CO
•
PUBLIC CO
CO
support any marketing authorization 
out 
ri
out 
ks
h
ks
s are:
au
s are:
eeks with
ng a
eeks with
Platelet R
ting
Platelet R
h
k
he 24
keti
e 24-
et
-we
ti
we
Clinically
ma
Clinically
esponse o
y m
esponse o
arting tre
ny 
arting tre
response
t an
response
Clinically
ort 
Clinically
of ≥50x
po
of ≥50x
•
u
•
Res
pp
Res
This document cannot be used to s
s d
s
za
xtensions or variations thereof.
Response
ere
Response
eek treatm
the
eek treatm
y Meanin
ons
y Meanin
of ≥50x10
tio
of ≥50x10
eatment to
riat
eatment to
e of ≥50x
aria
e of ≥50x
y Meaning
r va
y Meaning
x10
o
x109
or
9/L by
or 
/L by
esponse de
ns o
esponse de
≥30x10
ions
≥30x109
s
9/
s
/
the Ba
sio
the Ba
2
ns
2 se
s
se
application and any exte
xte


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 29 of 202
•
Complete Response defined as platelet 
count ≥100x109/L confirmed on at least 
2 separate occasions at two adjacent 
nominal visits at least 7 days apart, and 
absence of bleeding by visit a,b
•
Cumulative number of weeks over the 
planned 24-week treatment period with 
platelet count of ≥100x109/L.
•
Cumulative number of weeks over the 
planned 24-week treatment period with 
platelet counts ≥30×109/L and at least 
doubling from Baseline.
•
Mean change from Baseline in platelet 
count by visit.
•
Clinically Meaningful Platelet Response 
of ≥50x109/L, for at least 4 out of 6 weeks 
during the last 6 weeks (Week 19 to 25).
•
Clinically Meaningful Platelet Response 
of ≥50x109/L, for at least 6 out of 8 weeks 
during the last 8 weeks (Week 17 to 25).
Secondary
•
To assess the safety and tolerability of 
rozanolixizumab
The safety endpoints are:
•
Occurrence of treatment-emergent adverse 
events (TEAEs)
•
Occurrence of TEAEs leading to 
withdrawal of investigational medicinal 
product (IMP) (ie, study discontinuation)
The other safety endpoints are:
•
Occurrence of serious TEAEs
•
Occurrence of treatment related TEAEs
•
Occurrence of adverse events of special 
monitoring (AESM)
•
Vital signs change from Baseline (blood 
pressure [BP], pulse rate, body 
temperature) at each scheduled 
assessment during Treatment and Safety 
Follow-up (SFU) Periods
PUBLIC COPY 
of ≥5
Y
of ≥5
durin
PY
durin
•
CO
•
CO
LI
olerabilit
PU
olerabilit
UB
This document cannot be used to support any marketing authorization 
h
ver the
uth
ver the
period wit
au
period wit
and at le
g a
and at le
e.
t
e.
m Baseline
rket
m Baseline
Meaningfu
ma
Meaningfu
10
n
109
y
9/L, for
ny m
/L, for
g the last 
any
g the last 
Clinically 
ort 
Clinically 
of ≥50x
por
of ≥50x
durin
pp
durin
za
up
y of 
d t
y of 
o
s d
xtensions or variations thereof.
th
of
th
east 
eo
east 
e in platel
the
e in platel
ful Platele
tion
ful Platele
r at least 4
iatio
r at least 4
t 6 weeks 
aria
t 6 weeks 
y Meaning
r va
y Meaning
x10
o
x109
or
9/L, fo
or v
/L, fo
ing the las
s o
ing the las
ns
The safe
nsi
The safe
•
te
•
O
n
O
sio
application and any exte
xte


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 30 of 202
•
12-lead electrocardiogram (ECG) change 
from Baseline at each scheduled ECG 
visit 
•
Laboratory change from Baseline 
(hematology including coagulation 
parameters, clinical chemistry, and 
urinalysis) at each scheduled assessment 
during Treatment and SFU Periods
•
Change from Baseline in concentrations 
of total protein and albumin 
•
Change from Baseline in serum 
complement levels (C3 and C4) and 
plasma complement levels (C3a and C5a) 
at each scheduled assessment during the 
study (for study participants experiencing 
infusion reactions or hypersensitivity 
reactions)
Exploratory
•
To evaluate the clinical efficacy as 
measured by the ITP bleeding score
•
ITP-specific Bleeding Assessment Tool 
(ITP-BAT) bleeding events and severity 
by visit
•
To assess the effect of rozanolixizumab 
on health-related quality of life (HRQoL)
•
Change from Baseline in European 
Quality of Life (EuroQol) -5 dimension 
5 Levels (EQ-5D-5L) item responses
•
Change from Baseline in Short form 
36-item (SF-36) domain and composite 
scores
•
Change from Baseline in the ITP-PAQ 
domain scores
•
To assess hospitalizations due to ITP
•
Number and length of hospitalizations
•
To assess the effect of rozanolixizumab 
on patient reported outcomes (PROs)
•
Change from Baseline in FATIGUE-PRO 
Physical Fatigue Score
•
Change from Baseline in Patient Global 
Impression of Severity (PGI-S)
•
Patient Global Impression of Change 
(PGI-C) at all available post-baseline 
assessments
•
To assess the pharmacokinetics of 
rozanolixizumab administered by 
subcutaneous (sc) infusion
•
Plasma concentration of rozanolixizumab 
OPY 
react
Y
react
PY
COP
•
CO
•
LIC COP
CO
PUBLI
ixizuma
UBL
ixizuma
f life (HR
PUB
f life (HR
LI
t any marketing authorization 
nt 
r
nt 
trations 
utho
trations 
serum 
g a
serum 
and C4) 
ting
and C4) 
levels (C
ketin
levels (C
d assessme
rke
d assessme
dy particip
mar
dy particip
actions or 
ma
actions or 
s)
n
s)
za
ny
support a
TP
o
TP-
ort
-speci
ort 
speci
(ITP
ppo
(ITP-
o
-B
by v
pp
by v
nnot be used to s
t a
b
o
b
RQoL)
d to
RQoL)
sup
•
s
•
cann
sup
s
hospitaliza
can
hospitaliza
nn
s document c
ess the ef
nt c
ess the ef
patient rep
men
patient rep
ca
This d
s d
variations thereof.
and 
ere
and 
C3a and C
ther
C3a and C
ment durin
s th
ment durin
pants exp
ns 
pants exp
r hypersen
tion
r hypersen
ia
ns or va
ific Bleed
r va
ific Bleed
BAT) 
or
BAT) blee
or 
blee
visit
ns
visit
va
xtensions
Change 
sion
Change 
Quali
nsio
Quali
5
n
5 L
•
t
•
on and any exte
ns
xte
zations du
n a
zations du
an
application
ffect of ro
tio
ffect of ro
ported ou
cat
ported ou
on


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 31 of 202
•
To evaluate the incidence and emergence 
of antidrug antibodies (ADAs) of 
rozanolixizumab
•
ADAs at each scheduled assessment 
•
To assess the pharmacodynamic (PD) 
effects of rozanolixizumab
The exploratory PD endpoints are:
•
Total serum IgG (absolute value) and 
change from Baseline (absolute value and 
percentage) in serum IgG and in serum 
IgG subclass concentration at each 
scheduled assessment 
•
Absolute values and change from 
Baseline (absolute value and percentage)
in serum immunoglobulin concentrations 
(IgA, IgE, IgM) at each scheduled 
assessment
•
To assess the influence of 
rozanolixizumab treatment on vaccination 
titers
•
Percent change from Baseline in 
vaccination titers against Streptococcus 
pneumoniae, Neisseria meningitidis, and 
Haemophilus influenzae in 
splenectomized study participants
•
Percent change from Baseline in 
vaccination titers against tetanus in all 
study participants
•
To assess the effect of rozanolixizumab 
on response to vaccination in study 
participants who received coronavirus 
disease 2019 (COVID-19) vaccine
•
Change in biomarkers of COVID-19 
vaccine response over time
a Absence of bleeding indicated by Grade 0 for all domains of the skin, mucosae, and organs (SMOG), or a Skin 
Grade of 0 or 1.
b Nominal visits are on-site visits where ITP bleeding scale assessment is performed.
Overall design
This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study with 
rozanolixizumab in study participants with persistent or chronic primary ITP defined as more 
than 3 months, or more than 12 months of duration respectively, since diagnosis.
The study participants will be male and female adults with persistent or chronic primary ITP, 
history of prior ITP treatment, a platelet count measurement at Screening (Visit 1) and at 
Baseline with an average of the two <30x109/L (no single count may be >35x109/L) and a 
documented history of low platelet count (<30x109/L) any time prior to Screening.
Participants should previously have received two or more ITP therapies and should have initially 
responded to such therapy and have a current or history of a blood smear consistent with primary 
ITP.
PUBLIC COPY 
vacc
Y
vacc
pneu
PY
pneu
H
P
H
CO
anolix
PU
anolix
PU
be used to support any marketing authorization 
nd 
i
nd 
m
o
m
t
e from
g au
e from
and perce
ng 
and perce
ulin conc
eting
ulin conc
each sche
ket
each sche
za
ange from
ma
ange from
ion t
ny
ion titers 
y m
iters 
moniae, N
any
moniae, N
aemophilu
rt a
aemophilu
splenecto
port
splenecto
•
Perc
pp
Perc
va
p
va
ar
s
zumab
d t
zumab
study 
sed
study 
coronaviru
us
coronaviru
9) vaccin
be u
9) vaccin
to
ent cannot be
ted by Grad
t b
ted by Grad
site visits 
nno
site visits 
be
gn
c
gn
hase 3, mu
nt 
hase 3, mu
This docume
xizumab 
men
xizumab 
3 months,
ume
3 months,
The study 
ocu
The study 
history 
do
history 
Base
s d
Base
do
s
do
ny extensions or variations thereof.
entage)
reo
entage)
centration
here
centration
eduled 
the
eduled 
m Baseline
tion
m Baseline
s against
iatio
s against S
o
S
Neisseria 
aria
Neisseria 
lus influen
var
lus influen
omized st
or v
omized st
cent chang
s o
cent chang
vaccinatio
ons
vaccinatio
study p
sion
study p
ns
us
us
ne
n
ne
•
ten
•
C
n
C
ns
xte
ation and any
de 0 for all
any
de 0 for all
where ITP
and
where ITP
ny
multicenter
atio
multicenter
applica
in study p
icat
in study p
s, or more
plic
s, or more
y participa
app
participa
prior I
ap
prior I


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 32 of 202
Study participants who have previously undergone a splenectomy will be included in the study 
provided they do not meet the protocol defined exclusion criteria (Section 5.2) in order to 
optimize protection against overwhelming post-splenectomy infection (OPSI). Splenectomized 
study participants should be vaccinated against the encapsulated organisms, such as 
Streptococcus pneumoniae (S. pneumoniae), Neisseria meningitidis (N. meningitidis), and 
Haemophilus influenzae (H. influenzae) (as per local/or national guidance, as applicable) as 
evidenced from immunization records or during the Prolonged Screening Period. Study 
participants, who are due to receive a booster, can be screened after they received the required 
booster. 
Splenectomized study participants will be required to attend a Prolonged Screening Period prior 
to the Screening Visit to receive, if applicable, the required vaccinations (see Table 1-3)
The study will assess whether multiple sc infusions of rozanolixizumab will result in a durable 
Clinically Meaningful Platelet Count of ≥50x109/L, for at least 8 out of 12 weeks during the last 
12 weeks of the Treatment Period (Weeks 13 to 25). Starting at Week 2, platelet counts will be 
measured every week at a local laboratory. Home visits including home dosing and assessments 
as per Section 1.3 can be conducted once all prerequisites for a home dosing visit are fulfilled. 
Once eligibility is confirmed on Day 1 (Baseline Visit), study participants will enter the 
Treatment Period (24 weeks) and will be randomized 2:1 to receive a fixed-unit dose of 
rozanolixizumab equivalent to 
 or placebo once a week (QW) with randomization 
stratified by the degree of thrombocytopenia (platelet count < or ≥15x109/L) and history of 
splenectomy (yes or no). The last assessment of the Treatment Period will take place at Week 25.
During the first 12 weeks in the study (Week 1 until Week 12) IMP dose adaptations, depending 
on the observed levels of platelets as detailed in Table 1-1, will be allowed. The Dose Adaptation 
Period aims at achieving an IMP dose regimen that sustains a platelet count ≥50x109/L to 
≤150x109/L until the beginning of Week 13. Following the initial dose equivalent to 
 
subsequent QW doses can be adapted to dose equivalents to 
 QW or 
(corresponding to an average 
 in a participant weighing 70kg) QW based on the 
platelet count. Following this Dose Adaptation Period, study participants will enter the 
Maintenance Period starting at Week 13 until Week 25. The dose regimen that achieves platelet 
stabilization in the adaptation period will be continued throughout the Maintenance Period. 
During the Maintenance Period the dose regimen should remain stable and further dose 
adaptations should be avoided if possible. However, adjustments for safety and efficacy reasons 
will still be allowed as outlined in Table 1-1 and Figure 1-1, which presents the dose titration for 
IMP based on the platelet count. 
PUBLIC COPY
sit), stu
PY 
sit), stu
ized 2:1
OPY
ized 2:1
cebo
CO
cebo on
OP
on
a (platel
C CO
a (platel
ment of 
IC 
ment of 
dy (Week
BLI
dy (Week
s as deta
UB
s as deta
P
P dose 
PU
P dose 
of W
P
of W
to support any marketing authorization 
red 
or
red 
Period pr
aut
Period pr
le
g
le 1
g a
1-
a
-3
au
3)
au
)
result in a
ting
result in a
2 w
ke
2 weeks d
ketin
eeks d
2, platelet
rke
2, platelet
ome dosin
mar
ome dosin
ome dosin
ma
ome dosin
y participa
ny 
y participa
to receive
t any
to receive
e a week
rt a
e a week
et count <
por
et count <
he Treatm
pp
he Treatm
1 until W
sup
1 until W
le
t
led in
to s
d in Tab
s
Tab
used 
regimen th
d to
regimen th
Week 13. F
ed 
Week 13. F
pted to do
use
pted to do
This document cannot be 
is Dose A
be 
is Dose A
ting at We
ot b
ting at We
aptation p
not
aptation p
nance Per
ann
nance Per
uld be avo
can
uld be avo
llowed as
t ca
llowed as
d on the p
ent 
d on the p
e u
nsions or variations thereof.
rior
f
rior
a durable
ereo
a durable
during the
ther
during the
t counts w
s th
t counts w
ng and as
ns 
ng and as
ng visit ar
tion
ng visit ar
pants will 
iati
pants will 
e a fixed
aria
e a fixed
a
(QW) wi
va
(QW) wi
< or ≥15x
or v
< or ≥15x
ment Perio
s o
ment Perio
Week 12) 
ons
Week 12) 
ble
si
ble
y exten
1
sio
1-
io
-1
o
1, w
o
, w
hat sustai
ens
hat sustai
Following
xten
Following
ose equiv
ext
ose equiv
in a p
y e
in a p
application and any
Adaptation
any
Adaptation
Week 13 un
d an
Week 13 un
period wil
nd 
period wil
riod the d
and
riod the d
oided if p
n a
oided if p
s outlined
ion
s outlined
platelet co
atio
platelet co
y


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 33 of 202
Table 1-1:
Dose adjustments of IMP following initial dose
Platelet count resulta
Dose adjustment (based on weekly platelet counts)
<10x109/L 
Rescue therapy is highly recommended as per Section 6.4.3
≥10x109/L to <30x109/L (on at least two 
consecutive visits)
Rescue therapy is recommended as per Section 6.4.3
≥30x109/L to <50x109/L
(on at least two consecutive visits)
Increase by one dose level, unless study participant is on 
maintenance dose of 
≥50x109/L to ≤150x109/Lb
Continue with current dose level
>150x109/L to <400 x109/L (on at least 
two consecutive visits)
Decrease by one dose level, unless study participant is on 
maintenance dose of 
≥400x109/L
Stop IMP treatment.
Once the platelet count is ≤150x109/L, reinitiate treatment 
decreased by one dose level 
a All analyses of platelet counts will be based on local laboratory results.
b Due to the interindividual variable platelet response, in some study participants platelet count may abruptly fall 
below 50×109/L after dose reduction or treatment discontinuation. In these cases, if clinically appropriate, higher 
cut-off levels of platelet count for dose reduction (>150×109/L) may be considered according to medical 
judgment, but should not exceed 250×109/L.
For the dose adjustments where a decrease is required, study participants receiving 
 
should continue at this dose level, as dose reductions below 
 are not applicable. If a study 
participant is in the lowest body weight tier (below 50kg) and is on the lowest dose level with a 
platelet count between >150×109/L and <400×109/L, the investigator might decide to temporarily 
stop treatment according to medical judgment based on the observation of platelet variability. If 
the platelet count increases to above 400×109/L, then IMP must be stopped.
IC COPY
e study 
PY 
e study 
nuation. I
OPY
nuation. I
0×10
CO
0×109
OP
9/L) 
OP
/L) 
PUBLI
ease is r
LIC
ease is r
as dose r
UBL
as dose r
weight t
PUB
weight t
0
P
09
P
9/L an
PU
/L an
P
marketing authorization 
za
n n 
za
za
ho
rticipant is
g au
rticipant is
u
10
rk
109
k
9/L
ke
/L,
ke
, rein
ke
rein
ing
pport any ma
ticipants pl
ny 
ticipants pl
these case
any
these case
may be cons
rt a
may be cons
ed to sup
ma
quired, st
upp
quired, st
ductions b
su
ductions b
er (below
to s
er (below
d <400×1
d to
d <400×1
This document cannot be use
l judgmen
sed
l judgmen
ove 400×
use
ove 400×
ns thereof.
s on 
of
s on 
f
itiate treat
th
itiate treat
re
s or variations
latelet coun
iati
latelet coun
s, if clinica
aria
s, if clinica
sidered acc
va
sidered acc
tensions
ns
tudy parti
ns 
tudy parti
below 
ion
below 
w 50kg)
nsio
w 50kg) an
o
an
0
e
0
application and any ext
9/L, the 
ens
/L, the 
nt based o
xte
nt based o
10
e
109
e
9/L, th
ext
/L, th
n


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 34 of 202
Figure 1-1:
TP0006 dose adjustments of IMP
eqv=equivalent; QW=once a week
Dose adaptations may start as early as Week 2
* eqv: fixed-unit dose with body weight tiers equivalent to the mg/kg dose in terms of IgG reductions and safety 
profile
If treatment as per Table 1-1 and Figure 1-1 does not lead to an increase in platelet count 
≥30x109/L, the study participant can be treated with rescue therapy, if deemed needed by the 
investigator. If platelet count is ≥10x109/L to <30x109/L or active bleeding, rescue therapy is 
recommended (eg, commercially available medication, such as intravenous immunoglobulin 
[IVIg], high dose corticosteroids and pulse steroids, platelet transfusions, or any other 
medication listed in Section 6.4.3). If platelet count is <10x109/L, rescue therapy is highly 
recommended as per Section 6.4.3. If a study participant has been down-titrated to a fixed-unit 
dose equivalent to 
 or the 
 (corresponding to an average 
 in 
C COPY 
BLI
PUBLI
BLIC 
This document cannot be used to support any marketing authorization 
QW=once 
t ca
QW=once 
ons may sta
nt c
ons may sta
d-unit dose
en
unit dose
treatment 
cum
treatment 
≥30x10
doc
≥30x109
u
9/
investi
do
investi
reco
s d
reco
[
s
[
annot be used to support any marketing authoriz
s
application and any extensions or variations thereof
a week
on
a week
art as early
tio
art as early
with body
cati
with body
t as per 
ppl
t as per Ta
pl
Ta
L, the stu
app
L, the stu
r. If
a
r If
and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 35 of 202
a participant weighing 70kg), and platelet count decreases to less than 50x109/L, then up-titration 
to a fixed-unit dose equivalent to 
 QW or 
QW, respectively, would be allowed.
Study participants should be monitored for signs of arterial or venous thrombotic and 
thromboembolic events. If such events occur, the investigator should undertake the appropriate 
management per medical judgment and local guidance, and contact the Medical Monitor. 
Thrombotic or embolic events are considered AESM, as described in Section 8.3.8, and the 
reporting rules can be found in Appendix 3, Section 10.3.
All study participants completing the Treatment Period (regardless of whether they received 
rescue therapy or not) and fulfilling the open-label extension (OLE) study (TP0004) eligibility 
criteria will be allowed to enroll into the 1-year OLE treatment study TP0004. The enrollment 
into the TP0004 study should be conducted on the same day as Visit 27 (Week 25) of the feeder 
study. In case the enrollment into TP0004 is not conducted at Week 25 (Visit 27), a visit window 
of +3 days will be granted; therefore, rollover needs to be completed 3 days after Week 25 at the 
latest.
Participants that will not be enrolling into the OLE study will be followed for up for 8 weeks 
after the last administration of IMP. The End of Study (EOS) Visit will be performed after the
SFU Period.
An external Independent Data Monitoring Committee (IDMC) will be established to review the 
safety data at predefined intervals and ad hoc as needed should emerging safety concerns arise 
during the study. The first IDMC meeting for the review of safety data is planned to occur after 
approximately 15 participants have received 3 doses of IMP in TP0006. The study will to be put 
on hold if any of the following occurs: 
•
The IDMC judges it necessary for medical or safety reasons and
•
The sponsor or its designee judges it necessary for medical, safety, regulatory, or any other 
reasons consistent with applicable laws, regulations and Good Clinical Practice.
•
Three study participants experience any serious adverse advent (SAE) of the same type 
within the first 15 study participants who have received 3 doses of IMP across TP0003 and 
TP0006, unless the SAE is clearly unrelated to the study drug.
−
For US and Canada only: Three study participants experience any SAE within the first 
15 study participants who have received at least one dose of IMP across TP0003 and 
TP0006, unless the SAE is clearly unrelated to the study drug.
It is intended to have one IDMC for both of the pivotal studies (TP0003 and TP0006), where the 
safety data will be initially presented unpooled, ie, data from each study will be reviewed 
separately. Key safety data may be pooled at the discretion of the IDMC for protection of all 
study participants if warranted. 
Based on feedback from the IDMC, weekly dosing was implemented in protocol amendment 3. 
Study participants being treated with the bi-weekly dosing regimen will switch to the weekly 
dosing regimen once protocol amendment 3 is approved at the respective study site. 
Additionally, the sponsor's Safety Signal Detection Team will perform aggregated safety data 
reviews at predefined intervals across all rozanolixizumab programs.
PUBLIC COPY 
(E
Y
(E
mittee (I
OP
mittee (I
c as need
CO
c as need
for the r
C C
for the r
eived 3
LIC
eived 3 d
r
B
rs
B
s:
B
:
ary for m
PUB
ary for m
udg
P
udg
nt cannot be used to support any marketing authorization 
ved 
tho
ved 
eligibility 
uth
eligibility 
enrollme
au
enrollme
25) of the
g a
25) of the
t 27)
tin
t 27),
ng
, a vi
ng
a vi
ys after W
ketin
ys after W
ollowed fo
ma
ollowed fo
isit will b
y m
isit will b
DMC)
rt a
DMC) wil
a
wil
ed should 
ort 
ed should 
eview o
ppo
eview of s
o
f s
oses of IM
upp
oses of IM
edical or s
d to 
edical or s
es it neces
ed 
es it neces
able laws
use
able laws
experience
be u
experience
y particip
t be
y particip
SAE is cl
ot b
SAE is cl
d Canada
nno
d Canada
participa
can
participa
06, unless
t ca
06, unless
This docume
nded to ha
ent
nded to ha
data will 
me
data will 
arately. K
cum
arately. K
study part
docu
study part
Based
s do
Based
Stu
s 
Stu
ation and any extensions or variations thereof.
ent 
of
ent 
e feeder 
eof
e feeder 
sit windo
ereo
sit windo
Week 25 a
ther
Week 25 a
or up for 
ons
or up for 
be perform
tion
be perform
ll be
va
ll be estab
ar
estab
d emerging
r va
d emerging
safety dat
or 
safety dat
MP in TP
s o
MP in TP
safety rea
nsio
safety rea
essary for 
xten
essary for 
s, regulati
ext
s, regulati
ce any seri
ny e
ce any seri
pants who
any
pants who
learly unr
d a
learly unr
a only
and
a only: Th
nd
: Th
ants who h
n a
ants who h
s the SAE
tion
s the SAE
applica
ave one ID
cati
ave one ID
l be initial
plica
l be initial
Key safety
ppli
Key safety
icipants 
app
icipants 
edb
a
db


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 36 of 202
Number of participants
Study participants will be randomly assigned to IMP in a 2:1 ratio to either rozanolixizumab or 
placebo, respectively. The total sample size will be approximately 90 study participants, at least 
60 of which will be randomized to weekly IMP administration (for determination of sample size,
see Section 9.8).
Treatment groups and duration
The total maximum study duration per study participant is up to 35 weeks, consisting of a 
Screening Period (up to 4 weeks), a Dose Adaptation Period (12 weeks), a Maintenance Period 
(12 weeks) and a SFU Period (8 weeks after final dose administered). The eligibility of study 
participants to participate in the study will be determined during the Screening Period (Day -28 
to Day -1). Splenectomized participants will be required to attend a Prolonged Screening Period 
prior to the Screening Visit to assess and receive, if applicable, the required vaccinations, which 
will extend the total study duration by up to 20 weeks.
Fixed-unit doses across body weight tiers and treatment arms will be employed in this study 
according to the following scheme, as presented in Table 1-2.
Table 1-2:
TP0006 dose levels and weight tiers of IMP
Dose* eqv
Bodyweight
>35 to <50kg
No weight adjustment  
≥50 to <70kg
≥70 to <100kg
≥100kg
eqv=equivalent; IMP=investigational medicinal product
If a study participant is in the lowest body weight tier (below 50kg) and is on the lowest dose level with 
a platelet count between >150×109/L and <400×109/L, the investigator might decide to temporarily stop 
treatment according to medical judgment based on the observation of platelet variability. If the platelet 
count increases above 400×109/L then treatment must be stopped anyway.
The placebo arm will use 0.9% sodium chloride aqueous solution (physiological saline, 
preservative free) for sc administration, matching the volumes of the rozanolixizumab arm.
PY
tiers 
PY 
tiers 
PY
PUBLIC COPY
any marketing authorization 
e Period 
tho
e Period 
of study 
auth
of study 
riod (Day
g au
riod (Day
Screeni
ng 
Screening
ng
vaccinati
eting
vaccinati
e employe
mark
e employe
IMP
ny
IMP
an
t cannot be u
igational m
be 
igational m
n the lowes
ot b
n the lowes
en >150×1
not
en >150×1
g to medica
nn
g to medica
bove 400×
can
bove 400×
This document
e u
o arm will
nt c
o arm will
tive free) 
men
tive free) 
e used to support an
variations thereof.
y
f
y
y y -
of
-28 
of
28 
ng Period 
reo
ng Period 
tions, whi
here
tions, whi
ed in this 
ns t
ed in this 
ria
ion and any 
medicinal 
any
medicinal 
st body we
d an
st body we
10
n
109
d
9/L and <
nd 
/L and <
al judgme
and
al judgme
×10
n
×109
a
9/L the
n a
/L the
applicati
y e
l use 0.9%
tion
l use 0.9%
for sc adm
cat
for sc adm
y e
y extensions or vari


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 37 of 202
1.2
Schema
A schematic diagram of the study is presented in Figure 1-2.
Figure 1-2:
TP0006 study schematic
QW=once a week; SFU=safety follow-up
Platelet counts will be measured weekly at local laboratories.
Splenectomized participants would need to attend a Prolonged Screening Period for up to 20 weeks prior to the 
Screening Visit.
PUBLIC CO
boratorie
C C
boratorie
nd a Prolo
LIC 
nd a Prolo
OPY 
This document cannot be used to support any marketing authorization 
nged Screen
upp
nged Screen
t any marketing authoriz
application and any extensions or variations thereof
ning Period
s o
ning Period
variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 38 of 202
1.3
Schedule of activities
The Schedule of Activities for TP0006 is presented in Table 1-3 (specific for splenectomized 
study participants) and Table 1-4 (for all study participants).
Table 1-3:
Schedule of activities (Prolonged Screening only for 
splenectomized study participants) 
Assessments
Prolonged Screening 
Visit Part 1a
Prolonged Screening 
Visit Part 2
Visit
1.1
Additional visits may be 
required depending on the 
vaccine and on the vaccination 
history 
1.2
Week
-20
-20 to -8
-4 to -1
Day
-140
-140 to -56
-28 to -1
Visit 
Window
±14d
±14d
Written informed consent and written 
pharmacogenomics substudy informed 
consent (for participating study participants)
X
All remaining 
assessments of Visit 1 
as outlined in 
Table 1-4, including 
the Platelet counts 
(using site's local 
laboratory)
General medical/procedures history
X
Vaccinationb, c
X
X
ITP=primary immune thrombocytopenia
a Inclusion criterion #8 is not applicable to the Prolonged Screening Period (Visit Part 1). Study participants may 
take ITP concomitant medication as per Table 6-2.
b Administer vaccines to splenectomized participants without previous vaccination history for S. pneumoniae, H. 
influenzae, and N. meningitidis.
c Administer vaccines to splenectomized participants who require a booster protection against S. pneumoniae, H. 
influenzae, and N. meningitidis.
BLIC COPY 
OP
CO
X
C C
X
PUBLIC C
LIC C
o the Prol
UBL
o the Prol
er 
P
er Table
PUB
Table 6
B
6
P
zed par
PU
zed par
ort any marketing authorization 
ning 
riz
ning 
2
o
2
za
za
2
ho
-
g
-4 t
g
4 t
g
tin
ke
ke
ke
ke
ke
m
t a
d to suppor
up
nged Scree
o s
nged Scree
2.
This document cannot be used 
cipants wit
d t
cipants wit
d participan
use
d participan
r variations thereof.
to
to -
r
-1
re
1
eo
-
h
-28 to
the
28 to -
e
-1
e
1
er
th
o
a
on
tio
a
nsions or 
X
o
X
r v
ns
ening Perio
sion
ening Perio
application and any exten
thout previ
ens
thout previ
nts who req
ext
nts who req


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 39 of 202
Table 1-4:
Schedule of activities
Screening 
Period
Dose
Treatment Period
SFU Period
Visit(s)
1
BL/
2
3
4
5
6
7
8, 10, 
12,14, 16, 
18, 20, 22, 
24
9, 13, 17, 
21, 25
11, 15, 19, 
23
26
27
28
29
EW
EOS
b, c
Week
-4 to -1
1
1
2
3
4
5
6, 8, 10, 
12, 14, 
16, 18, 
20, 22
7, 11, 15, 
19, 23
9, 13, 17, 
21
24
25
28
32
Day
-28 to -1
1
3
8
15
22
29
36, 50, 
64, 78, 
92, 106, 
120, 134, 
148
43, 71, 
99, 127, 
155
57, 85, 
113, 141
162
169
190
218
Assessmentsa
Visit 
Windowc
+2d
d
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
Written informed consent 
and written 
pharmacogenomics substudy 
informed consent (for 
participating study 
participants)
X
Xe
Verification of 
inclusion/exclusion criteria
X
X
Demographic data
X
General medical/procedures 
history
X
ITP history
X
Prior and concomitant 
medication
X
X
X
X
X
X
X
X
X
X
X
X
X
X
PUBLIC COPY
29
PY
29
Y 
Y
C CO Y
±2d
LI
±2dd
LIC
d
IC
IC
IC
UB IC
UB
UB
UB
UB
UB
not be used to support any marketing authorization 
06 
n 
06
a
or
15, 19,
au
15, 19,
23
g
23
au
au
au
au
et
y m
y
2
y
2
11, 15, 
rke
11, 15, 
19, 23
ark
19, 23
9
e
9
ket
et
et
y m
et
port any
any
6, 50, 
any
6, 50, 
t any
64, 78, 
t an
64, 78, 
rt a
92, 106
rt a
92, 106
ort
120,
ort
120,
o
y
po
y
d
s
dd
±2d
up
±2dd
pp
d
pp
su p
o s
b
us
 t
be
ment cannot
no b
no
no
no
a no
an
ca
X
en
X
nt
This docume
a
T
al
T
l
X
me
ocum
d any extensions or variations thereof.
26
of
26
f
e
, 13, 17, 
th
, 13, 17, 
21
s t
21
he
o
e
r v
6, 
6, 
or v
134, 
or
134, 
s or
148
o
148
43, 71,
riat
43, 71,
99, 127
ari
99, 127
15
a
15
ati
v
ons
ons o
±2d
ns
±2dd
s o
o
sio
y e te
o
any
ication and a
d a
nd
a d
a
io
a
tioioio
applicat
ic
i
X
c
X
icicica
app
applic


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 40 of 202
Screening 
Period
Dose
Treatment Period
SFU Period
Visit(s)
1
BL/
2
3
4
5
6
7
8, 10, 
12,14, 16, 
18, 20, 22, 
24
9, 13, 17, 
21, 25
11, 15, 19, 
23
26
27
28
29
EW
EOS
b, c
Week
-4 to -1
1
1
2
3
4
5
6, 8, 10, 
12, 14, 
16, 18, 
20, 22
7, 11, 15, 
19, 23
9, 13, 17, 
21
24
25
28
32
Day
-28 to -1
1
3
8
15
22
29
36, 50, 
64, 78, 
92, 106, 
120, 134, 
148
43, 71, 
99, 127, 
155
57, 85, 
113, 141
162
169
190
218
Assessmentsa
Visit 
Windowc
+2d
d
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
Concomitant medical 
procedures
X
X
X
X
X
X
X
X
X
X
X
X
X
Serum pregnancy test
X
Urine pregnancy test
X
X
X
Xf
X
Platelet counts (using site's 
local laboratory)
X
Xg
X
Xg
X
X
X
Xh
X
X
X
X
X
X
Randomization
X
Withdrawal criteriac
X
X
X
X
X
X
X
X
X
X
X
X
Vital signsi
X
X
X
X
X
X
X
X
X
X
X
X
X
Body weight
X
X
Height
X
Recording of AEs
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Full physical examination
X
X
X
PUBLIC COPY 
CO Y
±2d
C C
±2dd
C
d
CO
CO
CO
IC CO
X
BL
X
LIC
IC
IC
IC
IC
UB IC
U
P
sed to support any marketing authorization 
06 
n 
06
a
za
,
u
,
26
th
26
ho
ut
ut
aut
,
23
k
23
9, 13, 1
ting
9, 13, 1
2
ng
et
ort any m
y
78, 
y
78, 
any
2, 106, 
any
2, 106, 
t any
120, 134, 
t an
120, 134, 
ort a
148
t a
148
43, 7
ma
43, 7
99,
m
99,
ma
o
y m
±2d
p
±2dd
p
d
por
or
ort
u po
X
s
X
X
up
X
up
t
su
to
t
d
ent cannot be used 
s
 
Xg
u
g
X
s
X
se
b
us
be
o b
X
n
X
X
ot
X
ot
no
X
an
X
nn
ca n
ca
ca
This document ca
a
T
al
T
l
ca
ca
X
en
X
nt
X
e
X
e
um
on
c
on
um
um
um
ocum
extensions or variations thereof.f
17, 
e
17, 
1
h
1
24
re
24
eo
e
v
1,
ti
1,
, 127,
atio
, 127,
155
riat
155
57, 
n
57, 
1
o
1
ns
v
o
s or v
or v
±2d
o
±2dd
o
d
r v
ons
ons
X
s
X
ns
o
si
e
ten
X
tion and any ex en
e te
X
X
ex
X
ex
y e
ny
d a y
X
nd
X
d a
d a
d a
a d a
X
X
an
X
an
a
application 
n
io
tioioio
c
io
X
c
X
ca
plic
X
p
X
plplplpl
ap
appl


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 41 of 202
Screening 
Period
Dose
Treatment Period
SFU Period
Visit(s)
1
BL/
2
3
4
5
6
7
8, 10, 
12,14, 16, 
18, 20, 22, 
24
9, 13, 17, 
21, 25
11, 15, 19, 
23
26
27
28
29
EW
EOS
b, c
Week
-4 to -1
1
1
2
3
4
5
6, 8, 10, 
12, 14, 
16, 18, 
20, 22
7, 11, 15, 
19, 23
9, 13, 17, 
21
24
25
28
32
Day
-28 to -1
1
3
8
15
22
29
36, 50, 
64, 78, 
92, 106, 
120, 134, 
148
43, 71, 
99, 127, 
155
57, 85, 
113, 141
162
169
190
218
Assessmentsa
Visit 
Windowc
+2d
d
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
Short physical examination
X
X
X
X
X
12-lead ECGj
X
X
X
Laboratory parameters 
(hematology, clinical 
chemistry, and urinalysis)
X
X
X
X
X
X
X
X
Serology test for HIV, 
hepatitis B, and hepatitis C
X
Vaccination titers
(in splenectomized 
participants)k
X
X
X
X
Tetanus titerl
X
X
X
X
COVID-19 biomarkers 
sampling (in participants 
vaccinated prior to entry into 
TP0006)m
X
X
X
PUBLIC COPY 
CO Y
±2d
C C
±2dd
C
d
CO
CO
CO
IC CO
X
BL
X
LIC
IC
IC
IC
IC
B IC
X
B
X
B
UB
X
P
X
PU
used to support any marketing authorization 
06 
n 
06
a
za
,
u
,
26
th
26
ho
ut
ut
aut
,
23
k
23
9, 13, 1
ting
9, 13, 1
2
ng
et
ort any m
y
78, 
y
78, 
any
2, 106, 
any
2, 106, 
t any
120, 134, 
t an
120, 134, 
ort a
148
t a
148
43, 7
ma
43, 7
99,
m
99,
ma
o
y m
±2d
p
±2dd
p
d
por
or
ort
u po
X
up
X
up
su
s
t
s
X
ed
X
d to
This document cannot be use
a
T
al
T
l
us
 t
u
b
u
t b
a no b
X
a
X
a
ca
o
u
o
t c
cum
u
extensions or variations thereof.f
17, 
e
17, 
1
h
1
24
re
24
eo
e
v
1,
ti
1,
, 127,
atio
, 127,
155
riat
155
57, 
n
57, 
1
o
1
ns
v
o
s or v
or v
±2d
o
±2dd
o
d
r v
on
ons
ns
oio
X
n
X
ns
ion and any ex
e te
e
a y e
X
a
X
a
a d a
n a
plication a
io
a
X
ati
X
tioioio
applic
pplic
io


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 42 of 202
Screening 
Period
Dose
Treatment Period
SFU Period
Visit(s)
1
BL/
2
3
4
5
6
7
8, 10, 
12,14, 16, 
18, 20, 22, 
24
9, 13, 17, 
21, 25
11, 15, 19, 
23
26
27
28
29
EW
EOS
b, c
Week
-4 to -1
1
1
2
3
4
5
6, 8, 10, 
12, 14, 
16, 18, 
20, 22
7, 11, 15, 
19, 23
9, 13, 17, 
21
24
25
28
32
Day
-28 to -1
1
3
8
15
22
29
36, 50, 
64, 78, 
92, 106, 
120, 134, 
148
43, 71, 
99, 127, 
155
57, 85, 
113, 141
162
169
190
218
Assessmentsa
Visit 
Windowc
+2d
d
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
COVID-19 biomarkers 
sampling (in participants 
vaccinated during TP0006)
Xn
X
TB signs and symptoms 
questionnaireo
X
X
X 
W13 only
X
X
Call to IRT for treatment kit 
number
X
X
X
X
X
X
X
X
X
Administration of IMPp
X
X
X
X
X
X
X
X
X
Blood sampling for plasma 
concentration of 
rozanolixizumabq
X
X
X
X
Xr
all predose 
and 1 to 5 
days 
postdose 
after W13 
only
Xr
predos
e and 1 
to 5 
days 
postdos
e
PUBLIC COPY 
CO Y
±2d
C C
±2dd
C
d
CO
CO
CO
IC CO
LIC
IC
IC
PU
cannot be used to support any marketing authorization 
06 
n 
06
a
za
,
u
,
26
th
26
ho
ut
ut
aut
,
23
k
23
9, 13, 1
ting
9, 13, 1
2
ng
et
ort any m
y
78, 
y
78, 
any
2, 106, 
any
2, 106, 
t any
120, 134, 
t an
120, 134, 
ort a
148
t a
148
43, 7
ma
43, 7
99,
m
99,
ma
o
y m
±2d
p
±2dd
p
d
por
or
ort
u po
up
d t
us
 t
X
e u
X
us
us
us
b
us
X
b
o b
X
nn
X
X
o
X
ot
This document ca
a
T
al
T
l
me
ca no
and any extensions or variations thereof.f
17, 
e
17, 
1
h
1
24
re
24
eo
e
v
1,
ti
1,
, 127,
atio
, 127,
155
riat
155
57, 
n
57, 
1
o
1
ns
v
o
s or v
or v
±2d
o
±2dd
o
d
r v
X
ons
Xn
ns
n
ns
n
e te
X
y
X
X
e
X
ex
a y e
X
d
X
X
a
X
any
d a
d
application a
icicicica io
a d


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 43 of 202
Screening 
Period
Dose
Treatment Period
SFU Period
Visit(s)
1
BL/
2
3
4
5
6
7
8, 10, 
12,14, 16, 
18, 20, 22, 
24
9, 13, 17, 
21, 25
11, 15, 19, 
23
26
27
28
29
EW
EOS
b, c
Week
-4 to -1
1
1
2
3
4
5
6, 8, 10, 
12, 14, 
16, 18, 
20, 22
7, 11, 15, 
19, 23
9, 13, 17, 
21
24
25
28
32
Day
-28 to -1
1
3
8
15
22
29
36, 50, 
64, 78, 
92, 106, 
120, 134, 
148
43, 71, 
99, 127, 
155
57, 85, 
113, 141
162
169
190
218
Assessmentsa
Visit 
Windowc
+2d
d
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
Anti-rozanolixizumab 
antibodiesq
X
X
X
X
Xr
all predose 
and 1 to 5 
days 
postdose 
after W13 
only
X
X
Serum complements (C3 and 
C4)s
X
X
Plasma complements (C3a 
and C5as
X
X
Whole blood collection for 
DNAt
X
X
Whole blood collection for 
RNAt
X
X
Blood collection for 
exploratory biomarkersu
X
X
PUBLIC COPY 
CO Y
±2d
C C
±2dd
C
d
CO
CO
CO
IC CO
X
BL
X
LIC
IC
IC
IC
IC
UB IC
ment cannot be used to support any marketing authorization 
06 
n 
06
a
za
,
u
,
26
th
26
ho
ut
ut
aut
,
23
k
23
9, 13, 1
ting
9, 13, 1
2
ng
et
ort any m
y
78, 
y
78, 
any
2, 106, 
any
2, 106, 
t any
120, 134, 
t an
120, 134, 
ort a
148
t a
148
43, 7
ma
43, 7
99,
m
99,
ma
o
y m
±2d
p
±2dd
p
d
por
or
ort
u po
X
up
X
up
us
 t
su
us
us
us
b
t b
no b
X
an
X
nn
ca n
t c
This docume
a
T
al
T
l
me
ocum
application and any extensions or variations thereof.f
17, 
e
17, 
1
h
1
24
re
24
eo
e
v
1,
ti
1,
, 127,
atio
, 127,
155
riat
155
57, 
n
57, 
1
o
1
ns
v
o
s or v
or v
±2d
o
±2dd
o
d
r v
ons
ons
ns
e te
o
ex
an
an
o
a
X
ati
X
on
ic
io
applic
X
c
X
icicic
applic


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 44 of 202
Screening 
Period
Dose
Treatment Period
SFU Period
Visit(s)
1
BL/
2
3
4
5
6
7
8, 10, 
12,14, 16, 
18, 20, 22, 
24
9, 13, 17, 
21, 25
11, 15, 19, 
23
26
27
28
29
EW
EOS
b, c
Week
-4 to -1
1
1
2
3
4
5
6, 8, 10, 
12, 14, 
16, 18, 
20, 22
7, 11, 15, 
19, 23
9, 13, 17, 
21
24
25
28
32
Day
-28 to -1
1
3
8
15
22
29
36, 50, 
64, 78, 
92, 106, 
120, 134, 
148
43, 71, 
99, 127, 
155
57, 85, 
113, 141
162
169
190
218
Assessmentsa
Visit 
Windowc
+2d
d
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
Immunoglobulins (total IgG, 
IgG subclasses) 
X
X
X
X
X
X
Xv
Xv
Xv
X
X
IgA, IgM, IgE
X
X
X
W13 only
X
X
ITP-specific autoantibodies
X
X 
W13 only 
X
ITP bleeding scale
X
X
X
X
X
X
X
X
X
X
X
X
SF-36w
X
X
X
X
ITP-PAQw
X
X
X
X
EQ-5D-5Lw
X
X
X
X
PGI-Cw
X
X
X
PGI-Sw
X
X
X
X
FATIGUE-PRO Physical 
Fatigue Scalew
X
X
X
X
PUBLIC COPY 
CO Y
±2d
C C
±2dd
C
d
CO
CO
CO
IC CO
X
BL
X
LIC
IC
IC
IC
IC
UB IC
U
be used to support any marketing authorization 
06 
n 
06
a
za
,
u
,
26
th
26
ho
ut
ut
aut
,
23
k
23
9, 13, 1
ting
9, 13, 1
2
ng
et
ort any m
y
78, 
y
78, 
any
2, 106, 
any
2, 106, 
t any
120, 134, 
t an
120, 134, 
ort a
148
t a
148
43, 7
ma
43, 7
99,
m
99,
ma
o
y m
±2d
p
±2dd
p
d
por
or
ort
u po
X
s
X
X
up
Xv
p
v
up
t
su
X
d
X
to
s
 t
se
ent cannot be u
b
us
X
t b
X
X
e
X
be 
b
t b
no b
X
nn
X
no
no
no
a no
X
a
X
an
ca
ment c
t c
en
ocume
m
This doc
a
T
al
T
l
ocum
y extensions or variations thereof.f
17, 
e
17, 
1
h
1
24
re
24
eo
e
v
1,
ti
1,
, 127,
atio
, 127,
155
riat
155
57, 
n
57, 
1
o
1
ns
v
o
s or v
or v
±2d
o
±2dd
o
d
r v
ons
ons
ns
o
si
te
on and any extxt
y e t
X
any
X
ny
a y
a
d a
nd
a d
a
lication 
o
a
on
io
X
ca
X
at
applicat
lic
lic
lic
plic
lic
ap
applic


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 45 of 202
Screening 
Period
Dose
Treatment Period
SFU Period
Visit(s)
1
BL/
2
3
4
5
6
7
8, 10, 
12,14, 16, 
18, 20, 22, 
24
9, 13, 17, 
21, 25
11, 15, 19, 
23
26
27
28
29
EW
EOS
b, c
Week
-4 to -1
1
1
2
3
4
5
6, 8, 10, 
12, 14, 
16, 18, 
20, 22
7, 11, 15, 
19, 23
9, 13, 17, 
21
24
25
28
32
Day
-28 to -1
1
3
8
15
22
29
36, 50, 
64, 78, 
92, 106, 
120, 134, 
148
43, 71, 
99, 127, 
155
57, 85, 
113, 141
162
169
190
218
Assessmentsa
Visit 
Windowc
+2d
d
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
±2dd
Headache questionnairex
X
Xy
ADA=antidrug antibodies; AE=adverse event; AESM=adverse event of special monitoring; BP=blood pressure; BL=Baseline; COVID-19=coronavirus disease 
2019; d=day(s); D=Day; DNA=deoxyribonucleic acid; ECG=electrocardiogram; EOS=End of Study; EQ-5D-5L=European Quality of Life Health Status 
Questionnaire-5 Dimensions, 5 Levels; EW=Early Withdrawal; GI=gastrointestinal; HIV=human immunodeficiency virus; ICF=Informed Consent Form; 
Ig=immunoglobulin; IMP=investigational medicinal product; IRT=interactive response technology; ITP=immune thrombocytopenia; ITP-PAQ=ITP Patient 
Assessment Questionnaire; PGI-C=Patient Global Impression of Change; PGI-S=Patient Global Impression of Severity; PK=pharmacokinetic; PRO=patient-
reported outcomes; RNA=ribonucleic acid; SF-36: Short-Form 36-Item Health Survey; SFU=Safety Follow-Up; TB=tuberculosis; W=Week
Site visit
Optional home visit: Home IMP administration and assessments are optional and can be conducted (if approved by regulatory agencies). Alternatively, these 
visits can be conducted at the sites, as deemed necessary by site personnel and/or the study participant.
a The allowed time window for assessments is ±5 mins for assessments <30 mins and ±15 mins for assessments >30 mins. 
b The EOS Visit is 8 weeks following the final dose.
c Study participants can withdraw at any time during the study, based on criteria in Section 7.
d A visit window of +3 days is allowed, however there should be a minimum interval of 5 days and a maximum interval of 9 days, as compared to the previous 
dose. The visit windows are relative to the Dosing Visit 1 date.
e The TP0004 ICF will be given to the study participants that are willing to enroll into TP0004.
f Will be used to check study participant’s eligibility for TP0004.
g If required, by site’s local procedure, the platelet count assessed by the local laboratory can be done -1 day for Baseline (Visit 2) and for W2 (Visit 4). For 
subsequent dosing visits, the last available platelet count can be considered.
IC COPY 
CO Y
±2d
C C
±2dd
C
d
PUBLIC CO
CO
CO
CO
IC CO
LIC
IC
IC
UB
e event of
PUB
e event of
CG=elect
PU
CG=elect
wal;
P
wal;
ort any marketing authorization 
06 
n 
06
a
za
,
u
,
26
th
26
ho
ut
ut
aut
,
23
k
23
9, 13, 1
ting
9, 13, 1
2
ng
et
ort any m
y
78, 
y
78, 
any
2, 106, 
any
2, 106, 
t any
120, 134, 
t an
120, 134, 
ort a
148
t a
148
43, 7
ma
43, 7
99,
m
99,
ma
o
y m
e used to suppo
±2d
p
±2dd
p
d
por
or
ort
u po
up
s
special mon
to s
special mon
ocardiogram
d to
ocardiogram
GI=gastroin
ed 
GI=gastroin
IRT=intera
sed
IRT=intera
on of Chan
us
on of Chan
cument cannot be u
Form 36
e u
Form 36 I
n and assess
ot b
n and assess
cessary b
not
cessary by
±5 mins f
nn
±5 mins f
final dose.
can
final dose.
y time duri
t ca
y time duri
wed, howev
nt c
wed, howev
ative to t
en
ative to the
n
he
en to the st
me
en to the st
dy particip
cum
dy particip
This doc
a
T
al
T
l
ocal proced
ocu
ocal proced
visits, the la
doc
visits, the la
variations thereof.f
17, 
e
17, 
1
h
1
24
re
24
eo
e
v
1,
ti
1,
, 127,
atio
, 127,
155
riat
155
57, 
n
57, 
1
o
1
ns
v
o
extensions or v
s or v
or v
±2d
o
±2dd
o
d
r v
ns
io
nitoring; B
sio
nitoring; B
m; EOS=En
ens
m; EOS=En
ntestinal; H
ten
ntestinal; H
active respo
exte
active respo
nge; PGI
ex
nge; PGI-
x
-S=
x
S=
pplication and any 
Item Health
y e
Item Health
sments are 
d an
sments are 
site person
nd 
site person
or assessm
and
or assessm
ing the stud
ion 
ing the stud
ver there sh
atio
ver there sh
e Dosing Vi
cat
e Dosing Vi
udy partici
lica
udy partici
ant’s eligib
ppli
ant’s eligib
ap
dure, the pla
app
ure, the pla
availabl
ap
availabl


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 46 of 202
h Platelet counts can be taken at home visits; home visits are allowed if the previous 4 platelet counts were stable between 50 to 150×109/L and there was no dose 
change. If criteria are met, the visit may be conducted at home, administering the same dose of IMP as at the previous visit.
i Vital signs will include BP, pulse rate, and body temperature. On dosing days, for the first 2 weeks (W1, W2), vital signs will be measured prior to IMP 
administration, at the end of the infusion, and 4 hours after the end of the infusion. For the next 3 visits (W3, W4 and W5), vital signs will be measured prior to 
IMP administration, at the end of the infusion, and 1 hour after the end of the infusion. From W6, vital signs will be measured prior to IMP administration, at 
the end of the infusion, and 15 minutes after the end of infusion. At nondosing visits, vital signs need only be taken once during the visit. In case of dose 
increase, vital signs will be measured prior to IMP administration, at the end of infusion, and 1 hour after the end of infusion for the next 2 infusions. In case of 
untoward event, additional vital signs (unscheduled assessment) should be taken at the discretion of the investigator and post-observation time can be extended. 
These recommendations are applicable for dosing at site and at home.
j The ECG should be performed prior to blood collection for assessment of laboratory parameters (central reading of ECGs). ECGs have to be recorded at W1, 
Day 1 (predose and 4 hours postdose), W3 (predose), and W25.
k Vaccination titers against S. pneumoniae, N. meningitidis, and H. influenzae (only in splenectomized participants) collected at W1 (Baseline), W3 (predose), 
EW Visit and EOS Visit.
l Vaccination titers against tetanus to be collected in all participants at Baseline (predose), W3 (predose), EW Visit, and EOS Visit.
m For study participants who received COVID-19 vaccine prior to entry into TP0006, biomarker samples should be taken at Baseline (predose), EW Visit, and 
EOS Visit.
n For study participants who received COVID-19 vaccine during enrollment in TP0006. The collection of COVID-19 biomarkers baseline samples should occur 
predose, 2 to 3 weeks after the participant has received his/her last COVID vaccination (ie, second dose of a 2-dose vaccine, including booster). A second 
sample should be collected 3 months after last vaccination. There should be a minimum window of 72 hours between COVID vaccination and IMP 
administration.
o TB signs and symptoms questionnaire has to be completed at Screening, W1, W13, W25, and EOS Visit.
p
On dosing days, for the first 2 weeks, a 4-hour post-dose observation will be in place. Assuming the first 2 doses were well tolerated, on dosing days at 
Week 3, 4, and 5, a 1-hour post dose observation will be in place. Assuming the first 5 doses were well tolerated, on subsequent weeks, a 15-minute post-dose 
observation will be in place. However, if the dose needs to be decreased due to a TEAE(s) or dose needs to be increased, post dose observation will be extended 
to 1 hour after the end of infusion for the next 2 infusions. The post-dose observation time frame may be extended at the discretion of the investigator. These 
recommendations are applicable for dosing at site and at home. Approval from the investigator and sponsor is required prior to the start of home dosing. 
q
PK and ADA blood samples are to be taken predose unless otherwise indicated.
r PK and ADA samples to be taken predose and one additional sample within 1 to 5 days postdose following administration at W13 (Days 86 to 89) for PK and 
ADA and one additional sample within 1 to 5 days postdose W24 (Days 163 to 166) for PK. 
s Serum complements (C3, C4) and plasma complements (C3a, C5a), should be taken predose at Baseline (Day 1) and W25 for all study participants. Additional 
samples should be collected 2 hours and 4 hours postevent or as soon as possible before the next IMP for study participants with infusion reaction or 
hypersensitivity reaction (see Section 8.3.8).
t Optional blood collection if study participant selects “yes” on the pharmacogenomics substudy ICF.
u Exploratory biomarker samples should be taken predose at Baseline (Day 1) and W25 for all study participants (see Section 8.9). Additional samples should be 
collected 4 hours postevent or as soon as possible before the next IMP for study participants with severe and/or serious headaches or severe and/or serious GI 
disorders (ie, abdominal pain, diarrhea, vomiting; see Section 8.3.8).
v If total IgG levels are <1g/L, ad hoc assessments (eg, additional IgG samples) may be performed to monitor recovery of IgG levels. See Section 10.25.
w PROs to be completed prior to dosing and prior to any other study procedures.
x This assessment is applicable only to study participants experiencing severe and/or serious headaches and will be performed daily until resolution (ie, if 
headache becomes moderate or mild, normal collection of AEs should apply). This assessment can also be done remotely eg, via phone interview. 
PUBLIC COPY 
ose), W
Y
ose), W
6, biomar
PY
6, biomar
n TP0006
CO
n TP0006
D vaccin
C CO
D vaccin
uld be a m
C C
uld be a m
reening, W
BLI
reening, W
observatio
UB
observatio
PU
place. As
PU
place. As
e decr
P
e decr
to support any marketing authorization 
06 
n 
06
a
0
r
09
i
9/L and th
iza
/L and th
be measure
tho
be measure
vital signs w
uth
vital signs w
sur
a
sured prior
aut
ed prior
nce during t
g a
nce during t
f infus
ng
f infusion f
g 
ion f
ator and po
ting
ator and po
eading of E
rke
eading of E
participant
ma
participant
predose), E
ny 
predose), E
ker samples
any
ker samples
The collec
ort 
The collec
tion (ie, sec
por
tion (ie, sec
nimum win
ppo
nimum win
W1, W13, W
sup
W1, W13, W
will be in 
to s
will be in 
annot be used t
uming the f
d to
uming the f
ased due to
ed 
ased due to
ost
s
ost-
se
-dose ob
sed
dose ob
e. Approva
use
e. Approva
nless otherw
e u
nless otherw
ditional sam
be 
ditional sam
postd
t b
postdose W
b
ose W
lements (C
not 
lements (C
urs posteve
nno
urs posteve
ment ca
)
a
).
a
.
cipant selec
can
cipant selec
uld be taken
nt c
uld be taken
soon as po
ent 
soon as po
diarrhea, v
men
diarrhea, v
This docum
a
T
al
T
l
, ad hoc as
ume
, ad hoc as
rior to dosi
cum
rior to dosi
plicable on
ocu
plicable on
moderate 
do
moderate 
sions or variations thereof.
r to IM
f
r to IM
the visit. I
of.
the visit. 
for the next
eo
for the next
ost
e
ost-
e
-observa
ere
observa
ECGs). ECG
th
ECGs). ECG
ts) collecte
ons
ts) collecte
W Visit, an
iatio
W Visit, an
s should be
ria
s should be
ction of 
r va
ction of CO
a
CO
cond dose o
or v
cond dose o
ndow of 72
or
ndow of 72
W25, and EO
ons
W25, and EO
place. Assu
sio
place. Assu
n and any exten
first 5 dose
ns
first 5 dose
o a TEAE(s
ten
o a TEAE(s
bservation t
xte
bservation t
al from the 
ex
al from the 
wise indica
y e
wise indica
mple within
any
mple within
W24 (Days
d an
W24 (Days
3a, C5a), s
d a
3a, C5a), s
ent or as so
and
ent or as so
lication
cts “yes” on
on a
cts “yes” on
n predose a
tion
n predose a
ssible befo
atio
ssible befo
vomiting; se
ica
vomiting; se
appli
sessments 
plic
sessments 
ing and prio
ppl
ing and prio
ly to study
app
y to study
mild, no
ap
mild, no


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 47 of 202
2
INTRODUCTION
Rozanolixizumab (UCB7665) is a humanized IgG 4P monoclonal antibody that is being 
developed as an inhibitor of the activity of the FcRn for IgG.
By blocking the activity of FcRn, rozanolixizumab accelerates the catabolism of IgG antibodies, 
including IgG autoantibodies. The aim is to reduce the concentration of pathogenic IgG in 
patients with autoimmune diseases mediated by the action of IgG autoantibodies.
The FcRn recycles IgG and albumin and transports it bidirectionally across epithelial barriers. 
Recent studies have shown that FcRn rescues both IgG and albumin from intracellular lysosomal 
degradation by recycling it from the sorting endosome to the cell surface (Roopenian and 
Akilesh, 2007). Neonatal Fc receptor may also mediate transcytosis of IgG to facilitate its 
distribution within tissues. Rozanolixizumab has been specifically designed to block IgG binding 
to FcRn without blocking the binding and recycling of albumin.
Rozanolixizumab binds with high affinity to FcRn at both neutral and acidic pH. 
Immunoglobulin G that is constitutively taken up by pinocytosis into cells fails to bind to FcRn, 
even at the acidic pH found in the endosome. It is therefore not recycled and is trafficked to the 
lysosomes for degradation.
Production of pathogenic IgG autoantibodies is the major pathophysiology leading to a number 
of autoimmune diseases, which include ITP, myasthenia gravis (MG), pemphigus vulgaris, 
Goodpasture’s syndrome, neuromyelitis optica, Guillain-Barré Syndrome, and chronic 
inflammatory demyelinating polyradiculoneuropathy (CIDP).
As individual disease entities, IgG autoantibody-mediated conditions are relatively rare. 
Treatment of these disorders remains a difficult clinical problem, requiring in many of these 
conditions the long-term use of corticosteroids alone or combined with other immunomodulatory 
agents. These therapeutic approaches are not effective in all patients and conditions and have 
broad immunosuppressive effects causing considerable toxicity and treatment-related morbidity.
Treatments aimed at reducing the quantity of circulating IgG autoantibodies, including 
plasmapheresis, immunoadsorption, or high dose IVIg, are being used for primary and secondary 
therapy of autoimmune diseases. The therapeutic approach of these treatments is thought in part 
to be based on lowering levels of pathogenic autoantibodies, which represents rational and 
effective treatment modalities of autoimmune diseases.
Therefore, specific and sustained removal of the IgG autoantibodies by FcRn blockade may 
provide an effective therapeutic option for IgG autoantibody-mediated autoimmune disorders.
More detailed information regarding the nonclinical and clinical development programs for 
rozanolixizumab, including all completed and ongoing studies, can be found in the Investigator’s 
Brochure (IB).
2.1
Study rationale
Immune thrombocytopenia, previously defined as immune thrombocytopenic purpura and 
idiopathic thrombocytopenic purpura (Rodeghiero et al, 2009), is a rare, orphan hematological 
autoimmune disease characterized by an isolated low platelet count (thrombocytopenia) caused 
by specific antibodies directed against platelets and the absence of other causes of 
PUBLIC COPY 
efo
Y
efo
the majo
OP
the majo
myasthe
CO
myasthe
ptica, G
C C
ptica, G
uloneuro
LIC
uloneuro
autoanti
UBL
autoanti
mains a d
PUB
mains a d
f cortic
PU
f cortic
annot be used to support any marketing authorization 
rriers.
thor
rriers.
r lysosom
uth
r lysosom
an and 
au
an and 
acilitate it
g a
acilitate it
to block I
ting
to block I
acidic pH
ark
acidic pH
nto cells fa
ma
nto cells fa
recycled a
y m
recycled a
r pathoph
rt a
r pathoph
nia gravis
ort 
nia gravis
uillain
ppo
uillain-
po
-Bar
po
Bar
pathy (CID
upp
pathy (CID
body
o s
body-
s
-med
su
med
ifficult cli
to 
ifficult cli
osteroids 
ed t
osteroids 
es are not
sed
es are not
ts causing
us
ts causing
ng the qua
be 
ng the qua
adsorption
ot b
adsorption
e diseases
not 
e diseases
ering leve
nno
ering leve
This document ca
nt modal
can
nt modal
pecific an
nt c
pecific an
an effectiv
ent
an effectiv
e detailed 
ume
e detailed 
zanolixizu
cum
zanolixizu
Brochure
doc
Brochure
2.1
s d
2.1
and any extensions or variations thereof.
ts 
e
ts 
IgG bindin
ere
IgG bindin
H. 
s
H. 
fails to bin
ons
fails to bin
and is tra
tion
and is tra
hysiology 
var
hysiology 
s (MG), p
r va
s (MG), p
arré Syndr
or 
arré Syndr
IDP).
ns
IDP).
diated con
ion
diated con
linical pro
nsio
linical pro
alone or 
tens
alone or 
t effective
xte
t effective
g consider
ex
g consider
antity of c
ny 
antity of c
on, or high
d an
on, or high
es. The the
nd a
es. The the
els of path
and
els of path
application 
ities of au
n a
ities of au
nd sustain
tion
nd sustain
ve therape
cati
ve therape
d informat
plic
d informat
zumab, inc
pp
zumab, inc
(IB).
ap
(IB).


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 48 of 202
thrombocytopenia. In a pathological disease state these platelets are coated with autoantibodies 
to platelet membrane antigens, resulting in splenic sequestration and phagocytosis by 
mononuclear macrophages. The resulting shortened life span of platelets in the circulation, 
together with platelet underproduction by autoantibody-mediated megakaryocytes inhibition 
results in a decreased platelet count (Arnold et al, 2015; McMillan et al, 2004).
The spleen is the key organ in the pathophysiology of ITP, as it is the site of autoantibody 
production (white pulp) and the site of phagocytosis of autoantibody-coated platelets (red pulp). 
The slow passage of platelets through splenic sinusoids with a high local concentration of 
antibodies, and Fc-gamma receptors on splenic macrophages supports the role of the spleen as a 
site of platelet destruction (Sandler, 2000).
Recently, new definitions for the phases of the disease were introduced (Rodeghiero et al, 2009). 
Based on the time from diagnosis, the first phase (up to 3 months) is the “newly-diagnosed ITP 
phase;” phase 2 (>3 months up to 12 months) is the “persistent phase;” and after 12 months, the 
“chronic phase” starts. These phases also reflect the line of treatment.
The major goal for treatment of ITP is to achieve a platelet count that prevents major bleeding, 
rather than correcting the platelet count to normal levels. The management of ITP should be 
tailored to the individual patient and it is rarely indicated in those with platelet counts >50x109/L 
in the absence of bleeding, trauma, surgery, or high-risk factors (eg, patients on anticoagulation 
therapy) (EMA/CHMP/153191/2013, 2014). However, there is general agreement that adults 
with a count of <30x109/L with bleeding at diagnosis require treatment.
The first line of treatment for newly-diagnosed ITP is generally agreed and is based on the use of 
corticosteroids and IVIg. Although corticosteroids are effective, their long-term use is not 
recommended due to concerns over their safety (eg, osteoporosis, hypertension, 
immunosuppression). Patients who fail to respond or who relapse face the options of treatment 
with second line drug therapy or splenectomy, but there is no clear evidence to support the best 
approach (Rodeghiero et al, 2009; Provan et al, 2010; Neunert, 2011). Splenectomy can provide 
long-term efficacy in approximately 60% of cases, and recent guidelines suggest considering a 
splenectomy after 12 months. Splenectomy is an invasive procedure associated with acute 
complications (due to thrombocytopenia-like bleeding events) and long-term complications from 
loss of splenic functions. Asplenic individuals are at an increased risk of life-threatening 
infections, although minimized with vaccination prophylaxis. Splenectomy may increase 
morbidity from venous thromboembolism or atherosclerosis (Ghanima et al, 2012). Second-line 
drug therapies include high dose dexamethasone or methylprednisolone; high dose IVIg or anti-
D Ig; vinca alkaloids; dapsone and danazol; the immunosuppressants cyclophosphamide, 
azathioprine, and cyclosporine; or mycophenolate mofetil and Helicobacter pylori eradication if 
applicable. The anti-CD20 monoclonal antibody rituximab, even if not licensed for the treatment 
of ITP, and the thrombopoietin-receptor agonists (eltrombopag, romiplostim [both approved in 
the US and Europe] and avatrombopag [approved in the US in 2019]) are considered as second 
line (Ghanima et al, 2018) as well as third line options. In 2018, in the US, fostamatinib, a 
SYK-inhibitor, has been approved for the treatment of chronic ITP. Each of these treatments 
discussed above has unique benefits, limitations, tolerability considerations, and risks. Taking 
the side-effect profile and long-term complications of existing treatments together, there remains 
a considerable unmet medical need for novel therapeutic options in the treatment of persistent 
and chronic ITP.
PUBLIC COPY
cated in
PY 
cated in
gh
OP
gh-
P
-risk f
OPY
risk f
However
COP
However
diagnos
C CO
diagnos
agnosed 
LIC 
agnosed 
orticoste
BLI
orticoste
er their s
UB
er their s
who fail
PU
who fail
r spl
P
r spl
This document cannot be used to support any marketing authorization 
lp).
riz
lp).
pleen as a 
tho
pleen as a 
hiero et al,
g a
hiero et al,
wly
tin
wly-
n
-diagno
ing
diagno
d after 12
ketin
d after 12
hat preven
mar
hat preven
anagemen
y m
anagemen
hose with 
ny 
hose with 
actors (eg,
any
actors (eg,
there is g
rt a
there is g
s require t
port
s require t
TP is gen
upp
TP is gen
roids are 
sup
roids are 
afety (eg, 
to s
afety (eg, 
to respon
d to
to respon
enectomy,
ed 
enectomy,
 Provan e
use
 Provan e
mately 60%
e us
mately 60%
s. Splenec
be 
s. Splenec
ombocyto
ot b
ombocyto
ns. Asplen
not 
ns. Asplen
h minimiz
nno
h minimiz
veno
ca
venous th
an
us th
s include 
t ca
s include 
a alkaloid
ent 
a alkaloid
prine, and
men
prine, and
icable. Th
um
icable. Th
f ITP, and
ocu
f ITP, and
the US a
doc
the US a
line (
s d
line (
SY
s 
SY
application and any extensions or variations thereof.
l, 2009).
eof.
l, 2009).
nosed ITP
ereo
nosed ITP
months, 
her
months, 
nts major 
ons
nts major 
nt of ITP 
tion
nt of ITP 
h platelet c
iati
h platelet c
, patients 
aria
, patients 
general ag
va
general ag
treatment
or v
treatment
nerally ag
s o
nerally ag
effective,
ons
effective,
, osteopor
sio
, osteopor
nd or who
ens
nd or who
y, but there
ten
y, but there
et al, 2010
exte
et al, 2010
% of case
y ex
% of case
ectomy is 
ny 
ectomy is 
open
d an
openia
an
ia-lik
n
lik
enic indiv
nd a
enic indiv
zed with v
and
zed with v
hromboem
n a
hromboem
high
tion
high dos
n
dos
ds; dapson
atio
ds; dapson
d cyclospo
lica
d cyclospo
he anti
plic
he anti-
i
-CD
c
CD
d the throm
app
d the throm
d Europ
ap
d Europ


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 49 of 202
By blocking the activity of FcRn, rozanolixizumab accelerates the catabolism of antibodies and 
reduces the concentration of pathogenic IgG in primary ITP patients, thus potentially offering a 
safe, effective, and convenient alternative to existing treatments. This Phase 3 study will provide 
the required data to establish the safety and efficacy of rozanolixizumab in study participants 
with persistent or chronic primary ITP who have failed or were intolerant to two or more prior 
therapy and who require an increase and sustained effect in their platelet counts.
2.2
Background
To date, rozanolixizumab has been administered to human study participants in 9 clinical studies: 
UP0018, UP0060, CIDP01, CIDP04, MG0002, MG0003, MG0004, and its replacement study 
MG0007, and TP0001. UP0018 is a completed first-in-human (FIH) study. MG0002 is a 
completed Phase 2a study in participants with generalized MG, TP0001 is a completed Phase 2 
study in study participants with primary ITP, and CIDP01 is a completed Phase 2a study in study 
participants with CIDP. UP0060 is a Phase 1 study in healthy volunteers, CIPD04 (OLE) is an 
ongoing Phase 2a study in study participants with CIDP, and MG0003 and MG0004 (OLE 
replaced by MG0007) are ongoing Phase 3 studies in study participants with generalized MG.
UP0018 was conducted in 49 healthy study participants. The study evaluated the safety, 
tolerability, pharmacokinetic (PK), and PD effect on total IgG levels of 
ascending doses of 
intravenous (iv) and sc rozanolixizumab. Doses of rozanolixizumab 
 and 
 were administered by both iv and sc routes in 3 cohorts, respectively, as 
There were no deaths or SAEs reported during UP0018, and no study participants discontinued 
the study due to TEAEs. Rozanolixizumab was tolerated with an acceptable safety profile after 
the 
administration of 
and 
 (both iv and sc) and 
sc doses. 
Four TEAEs with a maximum intensity of severe were reported in this study: headache 
(3 participants [50.0%]) and back pain (1 participant [16.7%]); all of which were reported in the 
rozanolixizumab 
 iv group. For sc administration of rozanolixizumab, the most frequently 
reported TEAEs were headache (5 participants [27.8%]), and back pain and diarrhea (each 
reported by 3 participants [16.7%]). No severe adverse events (AEs) were reported following sc 
administration. The peak and total exposure of rozanolixizumab showed nonlinear increases 
consistent with target-mediated drug disposition. Dose-dependent statistically significant 
reductions in levels of total IgG and dose-dependent reductions in levels of IgG subclasses 
(IgG 1 to 4) were observed after rozanolixizumab was administered by iv or sc routes.
UP0060 is a randomized, participant-blind, investigator-blind, placebo-controlled, single dose-
ascending, cohort design to compare the safety, tolerability, and PK of rozanolixizumab, and to 
explore the PD of rozanolixizumab administered by sc infusion in Japanese, Chinese, and 
Caucasian healthy study participants.
CIDP01 is a completed Phase 2a, multicenter, randomized, participant-blind, investigator-blind, 
placebo-controlled, parallel-group study with the primary objective of evaluating the clinical 
efficacy of rozanolixizumab as a treatment for study participants with CIDP. There were 
2 treatment arms in this study: 
PUBLIC COPY
s. 
Y
s. 
n total
PY
n total I
Y 
I
of rozano
OPY
of rozano
outes in 
CO
outes in 
d during 
LIC
d during 
zumab w
BLI
zumab w
and 
PUB
and 
intensit
PU
intensit
k p
P
k p
PUB
be used to support any marketing authorization 
l studi
hor
l studies
o
es
ent study 
uth
ent study 
02 is a
au
02 is a
mpleted P
ng a
mpleted P
ase 2a stu
ting
ase 2a stu
CIPD04 (
keti
CIPD04 (
and MG0
rke
and MG0
ants with 
mar
ants with 
udy evalu
y m
udy evalu
G levels o
ny 
G levels o
lixizumab
t an
lixizumab
o
cohorts,
ort a
cohorts,
UP0018, a
upp
UP0018, a
was tolerat
sup
was tolerat
 (bo
to s
 (bo
y of severe
d to
y of severe
ain (1
sed
ain (1 part
d
part
p. For sc a
use
p. For sc a
This document cannot b
he (5
e u
he (5 parti
us
parti
16.7%]). N
be 
16.7%]). N
k and total
ot b
k and total
mediated
not
mediated
s of total 
ann
s of total 
re observe
can
re observe
a randomi
nt c
a randomi
g, cohort 
men
g, cohort 
re the PD
ume
re the PD
ucasian h
cum
ucasian h
CIDP01
doc
CIDP01
place
s d
place
ef
s
ef
to s
riations thereof.
Phas
eo
Phase 2
eof
e 2
udy in stu
ere
udy in stu
(OLE) is 
the
(OLE) is 
0004 (OL
s th
0004 (OL
generaliz
ns 
generaliz
uated the s
tio
uated the s
of 
a
riat
of 
a
extensions or vari
b
, respectiv
va
, respectiv
and no stu
ns o
and no stu
ted with a
ions
ted with a
oth iv and
sio
oth iv and
re were re
ens
re were re
rticipant [
xten
rticipant [
administr
ext
administr
application and any 
icipants [2
y e
icipants [2
No sever
any
No sever
al exposur
d an
al exposur
d drug dis
nd 
d drug dis
IgG and 
an
IgG and 
ved after r
n a
ved after r
mized, part
atio
mized, part
t design to
cat
t design to
D of rozan
plica
D of rozan
healthy stu
ppl
healthy stu
s a com
ap
 a com
aria
riat


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 50 of 202
Overall, 
administration of rozanolixizumab at a dose level of 
 sc was generally 
and well tolerated, with an acceptable safety profile. No new safety concerns were 
identified. The incidence of TEAEs was similar between the rozanolixizumab and placebo 
groups, with the exception of the TEAE of injection/infusion site reactions which was reported at 
a higher frequency in study participants treated with rozanolixizumab. The majority of TEAEs 
were of mild to moderate intensity. The only severe TEAEs reported were in the context of 
underlying CIDP. During the Treatment Period, 10 (58.8%) study participants in the 
rozanolixizumab group and 5 (29.4%) in the placebo group experienced at least 1 drug-related 
TEAE. During the Observation Period, 1 (5.9%) study participant each in the rozanolixizumab 
and placebo groups experienced at least 1 drug-related TEAE. Two (11.8%) study participants in 
the rozanolixizumab group experienced serious TEAEs of CIDP relapse which were in the 
context of their underlying CIDP. No cases of severe headache, moderate or severe abdominal 
pain, moderate or severe vomiting, or severe diarrhea were reported. One (5.9%) study 
participant each in the rozanolixizumab and placebo groups experienced moderate diarrhea. No 
clinically meaningful trends were observed for clinical laboratory evaluations, vital signs 
measurements, or physical examinations. 
CIDP04 is an ongoing Phase 2a, multicenter, open-label extension study to investigate the long-
term safety, tolerability, and efficacy of rozanolixizumab in study participants with CIDP. The 
study includes 2 Treatment Periods with 
 in 2 parts of the study
MG0002 is a completed Phase 2a, multicenter, randomized, investigator- and participant-blind, 
placebo-controlled, treatment sequence study evaluating the safety, tolerability, and efficacy of 
rozanolixizumab in study participants with generalized MG. The study included 2 Dosing 
Periods with 
 of IMP at 
intervals each:
The primary efficacy variable was the change from Baseline in Quantitative MG score (a 
measure of muscular strength) to Day 29.
Overall, repeated administrations of rozanolixizumab at dose levels of 
and 
 sc 
were generally considered 
and well tolerated, with an acceptable safety profile. No new 
safety concerns were identified in MG0002. The TEAE profile was similar between 
rozanolixizumab and placebo except for headaches where increased frequency and severity was 
observed in the rozanolixizumab-treated patients.
MG0003 is an ongoing Phase 3 multicenter, randomized, double-blind, placebo-controlled, 
3-arm, repeat-dose study evaluating the efficacy and safety of 2 doses (equivalent to 
approximately
 and approximately
 of rozanolixizumab and matching placebo 
administered 
 over a period of 6 weeks 
 in study participants with 
generalized MG who experience moderate to severe symptoms and are being considered for 
treatment with IVIg or plasma exchange (PEX).
PY
el 
Y
el 
umab in
PY 
umab in
OP
OPY
PUBLIC CO
ticenter,
LIC
ticenter,
nce stud
BL
nce stud
pants wi
PUB
pants wi
PU
PU
CO
any marketing authorization 
ted 
or
ted 
zumab
tho
zumab
rticipants
uth
rticipants
re in the
au
re in the
vere abdo
ng a
vere abdo
9%) stud
ting
9%) stud
moderate 
keti
moderate 
uations, v
arke
uations, v
ion study 
y m
ion study 
study part
any 
study part
rt a
t an
d to suppor
randomiz
upp
randomiz
y evaluatin
sup
y evaluatin
h generali
to s
h generali
intervals 
d to
intervals 
ent cannot
y variable
nno
y variable
ular streng
ann
ular streng
ated admi
t ca
ated admi
rally cons
ent 
rally cons
This docume
concerns w
men
concerns w
nolixizum
um
nolixizum
bserved in
ocu
bserved in
MG00
do
MG00
3
s d
3-ar
d
ar
s
ot be used 
ort 
riations thereof.
ominal
eof
ominal
dy 
e
dy 
diarrhea.
the
diarrhea.
vital signs
s th
vital signs
y to inv
atio
y to invest
o
est
rticipants 
riat
rticipants 
va
vari
ensions or v
zed, inves
ns o
zed, inves
ing the sa
ions
ing the sa
lized MG
sio
lized MG
each:
ens
each:
cation and 
e was the 
and
e was the 
ngth) to D
n an
ngth) to D
ministration
tion
ministration
sidered 
atio
sidered 
applic
were iden
lica
were iden
mab and p
plic
mab and p
n the roza
app
n the roza
an o
a
an o
d any exten
o
r va


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 51 of 202
TP0001 is a completed, Phase 2, multicenter, open-label, multiple-arm study to evaluate the 
safety and tolerability of rozanolixizumab in study participants with primary persistent and 
chronic ITP. The following dose arms were used in the study:
•
Dose Arm 1 (15 participants): rozanolixizumab 4mg/kg sc (5 doses at 1-week intervals)
•
Dose Arm 2 (15 participants): rozanolixizumab 7mg/kg sc (3 doses at 1-week intervals)
•
Dose Arm 3 (12 participants): rozanolixizumab 10mg/kg sc (2 doses at 1-week intervals)
•
Dose Arm 4 (12 participants): rozanolixizumab 15mg/kg sc (1 dose)
•
Dose Arm 5 (12 participants): rozanolixizumab 20mg/kg sc (1 dose)
Data from study TP0001 indicate that rozanolixizumab was tolerated with an acceptable safety
profile after multiple (4mg/kg, 7mg/kg, and 10mg/kg) and single (15mg/kg and 20mg/kg) doses. 
The most frequent AE was headache (mild to moderate in intensity) and no severe headache was 
reported. There were no TEAEs leading to IMP discontinuation. Four serious TEAEs were 
reported overall (none were considered to be treatment-related by the investigator and were 
related to the underlying disease). A dose-dependent decrease in total IgG was observed: 43.6% 
(range 21.9% to 68.6%) for the 4mg/kg group (~Day 29), 49.9% (range 29.5% to 65.5%) for the 
7mg/kg group (~Day 22), 63.8% (range 38.4% to 75.0%) for the 10mg/kg group (~Day 15), and 
on Day 8, after a single dose, for the 15mg/kg and 20mg/kg groups 52.3% (range 30.1% to 
68.0%) and 60.2% (range 51.8% to 65.4%), respectively. Responders were classified as having a 
clinically relevant platelet response (≥50x109/L). Five (35.7%) participants in the 4mg/kg and 
7mg/kg groups, 5 (45.5%) of 11 participants in the 10mg/kg group, 8 (66.7%) of 12 participants 
in the single administration 15mg/kg dose group, and 6 (54.5%) of 12 participants in the single 
administration 20mg/kg group were clinically relevant responders.
Based on the above, UCB considers that TP0001 established supportive evidence of efficacy and 
safety and is proceeding with the development of rozanolixizumab for the treatment of adults 
with persistent or chronic primary ITP. UCB is proposing a clinical development Phase 3 
program in this orphan disease population comprised of two placebo-controlled, confirmatory 
maintenance treatment efficacy and safety studies, TP0003 and TP0006, and a one-year 
long-term safety, OLE study, TP0004.
The current study, TP0006, will assess the efficacy, safety, and tolerability of rozanolixizumab 
administered as a fixed-unit dose equivalent to 
 QW via sc infusion in adult study 
participants with persistent or chronic primary ITP.
2.3
Benefit/risk assessment
Although there were a number of treatment options approved for chronic ITP in the recent years, 
there is still an unmet medical need as for many of these medications the effect diminishes over 
time. The current available therapies like thrombopoietin-receptor agonists (TPO-RAs) have 
dietary exclusions, require liver function test monitoring or are increasing the risk of thrombosis 
or thromboembolic events. Corticosteroids are associated with significant long-term side effects. 
PUBLIC COPY
ntinu
Y
ntinu
ment
PY
ment-
PY
-rela
PY 
rela
ndent dec
OP
ndent dec
p (~Day
CO
p (~Day
8.4% to 
C C
8.4% to 
mg/kg a
LIC 
mg/kg a
65.4%
BLI
65.4%), 
LI
), 
se (≥50x
UB
se (≥50x
1
P
1 partic
PU
partic
g/k
P
g/k
t be used to support any marketing authorization 
ith an acc
rke
ith an acc
mg/kg an
ark
mg/kg an
ty) and no
ma
ty) and no
n. Four
y m
n. Four se
m
se
ted by the
any
ted by the
rease in to
t an
rease in to
29
o
29), 49.9%
ort 
), 49.9%
5.0%) for
ppo
5.0%) for
nd 20mg/k
upp
nd 20mg/k
espective
sup
espective
10
to
109
o
9/L). Fi
to s
/L). Fi
pants in th
d to
pants in th
g dose gro
ed 
g dose gro
ere clinica
use
ere clinica
nsiders th
be u
nsiders th
with the de
t be
with the de
ment cannot
ic primar
ot b
ic primar
an disease
nno
an disease
ment effic
ann
ment effic
ty, OLE s
t ca
ty, OLE s
nt study, T
ent 
nt study, T
tered as a
men
tered as a
This docum
cipants w
um
cipants w
2.3
o
2.3
Altho
s do
Altho
the
s 
the
eting a
any extensions or variations thereof.
ceptable s
the
ceptable s
nd 20mg/k
ns t
nd 20mg/k
o severe h
ions
o severe h
e
a
erious TE
atio
rious TE
e investig
riat
e investig
otal IgG w
vari
otal IgG w
% (range 
r va
% (range 
or the 10m
or 
or the 10m
/kg group
ns o
/kg group
ely. Respo
ons
ely. Respo
ive (35.7%
sio
ive (35.7%
the 10mg/
ens
the 10mg/
oup, and 6
xten
oup, and 6
ally releva
ext
ally releva
hat TP000
ny e
hat TP000
evelopme
any
evelopme
lication and 
ry ITP. UC
d a
ry ITP. UC
e populat
and
e populat
icacy and 
an
icacy and 
study, TP
on a
study, TP
TP0006, w
atio
TP0006, w
a fixed
icat
a fixed-
a
-un
at
un
appl
with persis
plic
with persis
Ben
pp
Ben
ere
a
hereof


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 52 of 202
Thus, there is an unmet medical need for new treatments that can reduce the complexity of the 
existing therapies.
The clinical efficacy data obtained in the Phase 2 study TP0001 indicate that rozanolixizumab 
has a rapid effect on lowering IgG and rapid onset of response in platelet count (increase in 
platelet count >50x109/L ) and an acceptable safety profile. The ability to administer via sc 
infusion results in low systemic fluid volumes with no impact on plasma viscosity, significant 
reduction in time for infusion, and reduced potential for infusion reactions. 
The clinical safety data to date indicate that rozanolixizumab is well tolerated, and the common 
side effects are generally mild to moderate in severity, can be monitored and are manageable.
The most common adverse drug reactions observed after use of rozanolixizumab across 
indications are headaches and gastrointestinal (GI) disturbances (diarrhea, nausea, vomiting). 
Potential risks are serious infusion/hypersensitivity reactions, serious infections, and effects on 
vaccination response. 
The risks of serious infusion/hypersensitivity and serious infections can be mitigated by careful 
monitoring, exclusion of at-risk study participants, and appropriate protocol withdrawal and 
stopping criteria. Additionally, protocol guidance for management of GI disturbances, severe 
and/or serious headaches, and infusions is also provided as well as expedited reporting 
requirements of AESM. 
Restrictions on use of live vaccines have been defined in the Exclusion Criterion #21a. If 
vaccination with nonlive vaccines (including COVID-19 vaccines) is considered necessary once 
a study participant has started therapy with IMP, the degree of protection afforded with a vaccine 
may be compromised while the participant is being treated with IMP.
Based on its mechanism of action, rozanolixizumab will reduce total IgG levels including 
vaccine specific IgG. However, it is unlikely that the immunogenicity of vaccine will be 
compromised by FcRn inhibition. Given the study population characteristics (eg, status of the 
underlying disease, concomitant immunosuppressive therapies, etc.), it is recommended to 
perform individualized benefit/risk assessment for vaccination and specifically vaccination 
against COVID-19 infection. If vaccination is planned, information regarding vaccine should be 
recorded (Section 6.4.1). Vaccination should be scheduled, if at all possible, to allow 
differentiation of safety profiles of IMP and vaccine (eg, a minimum window of 72 hours 
between COVID-19 vaccination and IMP administration). If any AEs were to occur, they should 
be handled as described in (Section 8.3.10) with causality assessment provided for both IMP and 
vaccine. Additionally, to further characterize the effect of rozanolixizumab on vaccination 
response, measurement of vaccine titers are being tested in our development programs.  
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of rozanolixizumab may be found in the current version of the IB.
PUBLIC COPY
man
Y
man
vided as
PY 
vided as
en defin
CO
en defin
ding CO
IC C
ding CO
with IM
BLIC
with IM
rticipant 
UBL
rticipant 
on, roza
PU
on, roza
it is
P
it is
ot be used to support any marketing authorization 
mmon
hor
mmon
ageable.
uth
ageable.
across
g au
across
sea, vomi
ng 
sea, vomi
ions, and 
eting
ions, and 
can be mi
mark
can be mi
te protoco
ma
te protoco
ment of GI
ny m
ment of GI
well as ex
any
well as ex
d in the E
port
d in the E
VID
pp
VID-
pp
-19 va
ppo
19 va
P, the deg
supp
P, the deg
s being tr
o su
s being tr
nolixizum
d to
nolixizum
unlikely t
ed 
nlikely t
Given th
use
Given th
nt immuno
e us
nt immuno
efit/risk as
be 
efit/risk as
tion. If va
ot b
tion. If va
nt canno
1
n
1). Vaccin
not 
). Vaccin
afety profi
nno
afety profi
-19 vacci
can
19 vacci
 described
t ca
 described
This documen
Additionall
ent 
Additionall
e, measur
men
e, measur
re detaile
cum
re detaile
expected A
ocu
expected A
d any extensions or variations thereof.
iting).
reo
iting).
d effects o
here
d effects o
itigated b
ns t
itigated b
ol withdra
ions
ol withdra
GI disturba
atio
GI disturba
xpedited
riat
xpedited
Exclusion
or v
Exclusion
vaccines) i
s or
vaccines) i
gree of pr
ns 
gree of pr
reated wit
ion
reated wit
mab will r
ens
mab will r
that the im
ten
that the im
he study p
exte
he study p
nosuppres
y ex
nosuppres
ssessmen
ny 
ssessmen
accination
d an
accination
tion and
ination sh
nd a
ination sh
files of IM
and
files of IM
cination an
n a
cination an
ed in (
tion
ed in (Sec
n
Sec
applicat
lly, to fur
atio
lly, to fur
rement of
lica
rement of
ed inform
ppli
ed inform
AEs of 
app
AEs of ro
p
ro


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 53 of 202
3
OBJECTIVES AND ENDPOINTS
The objectives and corresponding endpoints for this study are presented in Table 3-1.
Table 3-1:
Study objectives and endpoints
Objectives
Endpoints
Primary
•
To demonstrate the clinical efficacy of 
rozanolixizumab in maintenance treatment 
in study participants with primary ITP
The primary efficacy endpoint is:
•
Durable Clinically Meaningful Platelet 
Response of ≥50x109/L, for at least 8 out 
of 12 weeks during the last 12 weeks 
(Week 13 to 25)
The secondary efficacy endpoints are:
•
Cumulative number of weeks with 
Clinically Meaningful Platelet Response 
of ≥50x109/L over the 24-week treatment 
period
•
Time to first Clinically Meaningful 
Platelet Response of ≥50x109/L: time 
from starting treatment to achievement of 
first response of ≥50x109/L 
•
Clinically Meaningful Platelet Response 
of ≥50x109/L by Day 8
•
Response defined as platelet count 
≥30x109/L and at least a 2-fold increase of 
the Baseline count confirmed on at least 
2 separate occasions at two adjacent 
nominal visits at least 7 days apart, and 
absence of bleeding by visit a,b
•
Time to first rescue therapy
•
Change from Baseline to Week 25 in ITP 
Patient Assessment Questionnaire 
(ITP-PAQ) Symptoms Score
COPY
of ≥
Y
of ≥
perio
PY 
perio
•
O
•
T
P
T
PUBLIC CO
CO
support any marketing authorization 
a
za
za
Platelet 
auth
Platelet 
at least 8
g au
at least 8
ast 12 wee
ng 
ast 12 wee
y endpoin
ket
y endpoin
mber of w
ark
mber of w
Meaningfu
ma
Meaningfu
09
y
9/L over
y m
/L over
me to firs
rt a
me to firs
Platelet R
port
Platelet R
from s
ppo
from s
firs
pp
firs
•
s
•
This document cannot be used to s
ori
me
s
xtensions or variations thereof.
8 out 
of
8 out 
eks
re
eks
nts are:
the
nts are:
weeks wit
ns t
weeks wit
ul Platelet
ion
ul Platelet
r the 24
atio
r the 24-
o
-w
o
w
st Clinica
var
st Clinica
Response
or v
Response
starting tr
s or
starting tr
st respons
ns 
st respons
Clinical
sion
Clinical
of ≥5
nsio
of ≥5
•
ten
•
R
n
R
application and any exte
ica
xte


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 54 of 202
The other efficacy endpoints are:
•
Duration of first Clinically Meaningful 
Platelet Response of ≥50x109/L: measured 
from achievement of first Response to loss 
of first Response (loss of Response 
defined as platelet count <50x109/L)
•
Time to first Response: time from starting 
treatment to achievement of Response 
•
Time to first Complete Response: time 
from starting treatment to achievement of 
Complete Response
•
Usage of rescue therapy by visit
•
Complete Response defined as platelet 
count ≥100x109/L confirmed on at least 
2 separate occasions at two adjacent 
nominal visits at least 7 days apart, and 
absence of bleeding by visit a,b
•
Cumulative number of weeks over the 
planned 24-week treatment period with 
platelet counts of ≥100x109/L
•
Cumulative number of weeks over the 
planned 24-week treatment period with 
platelet counts ≥30×109/L and at least 
doubling from Baseline
•
Mean change from Baseline in platelet 
count by visit
•
Clinically Meaningful Platelet Response 
of ≥50x109/L, for at least 4 out of 6 weeks 
during the last 6 weeks (Week 19 to 25).
•
Clinically Meaningful Platelet Response 
of ≥50x109/L, for at least 6 out of 8 weeks 
during the last 8 weeks (Week 17 to 25).
Secondary
•
To assess the safety and tolerability of 
rozanolixizumab 
The safety endpoints are:
•
Occurrence of TEAEs
•
Occurrence of TEAEs leading to 
withdrawal of IMP (ie, study 
discontinuation)
COPY
se
Y
se
nomi
PY 
nomi
abs
PY
abs
•
CO
•
PUBLIC CO
CO
support any marketing authorization 
arting 
horiz
arting 
onse
tho
onse
nse: tim
aut
nse: time
achievem
g a
achievem
erapy by v
keti
erapy by v
onse defin
ark
onse defin
10
m
109
m
9/L con
ma
/L con
e occasion
y m
e occasion
al visits at
any 
al visits at
n
t
nce of bl
t an
ce of bl
Cumulati
ort
Cumulati
planne
ppo
planne
plat
pp
plat
•
s
•
cument cannot be used to s
za
econdary
cum
econdary
m
s doc
•
do
•
To
oc
To
oc
This d
s d
xtensions or variations thereof.
ment of 
eof
ment of 
visit
th
visit
ned as pla
ns t
ned as pla
nfirmed o
ons
nfirmed o
ns at two 
atio
ns at two 
at least 7 d
riat
at least 7 d
leeding by
aria
leeding by
ive numb
r v
ive numb
ed 24
or
ed 24-
o
-we
or
we
atelet coun
ns o
atelet coun
Cumula
ion
Cumula
plann
nsi
plann
pl
n
pl
application and any extensions or variations thereof
xte
y
lic
app
sess th
ap
sess th
app


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 55 of 202
The other safety endpoints are:
•
Occurrence of serious TEAEs
•
Occurrence of treatment related TEAEs
•
Occurrence of AESM
•
Vital signs change from Baseline (BP, 
pulse rate, body temperature) at each 
scheduled assessment during Treatment 
and SFU Periods
•
12-lead ECG change from Baseline at 
each scheduled ECG visit 
•
Laboratory change from Baseline 
(hematology including coagulation 
parameters, clinical chemistry, and 
urinalysis) at each scheduled assessment 
during Treatment and SFU Periods
•
Change from Baseline in concentrations 
of total protein and albumin
•
Change from Baseline in serum 
complement levels (C3 and C4) and 
plasma complement levels (C3a and C5a) 
at each scheduled assessment during the 
study (for study participants experiencing 
infusion reactions or hypersensitivity 
reactions)
Exploratory
•
To evaluate the clinical efficacy as 
measured by the ITP bleeding score
•
ITP-BAT bleeding events and severity by 
visit
•
To assess the effect of rozanolixizumab on 
health-related quality of life (HRQoL)
•
Change from Baseline in European 
Quality of Life (EuroQol) -5 dimension 
5 Levels (EQ-5D-5L) item responses
•
Change from Baseline in Short form 
36-item (SF-36) domain and composite 
scores
•
Change from Baseline in the ITP-PAQ 
domain scores
•
To assess hospitalizations due to ITP
•
Number and length of hospitalizations
PUBLIC COPY
u
Y
u
Chan
PY 
Chan
of 
PY
of 
•
CO
•
CO
This document cannot be used to support any marketing authorization 
ment 
ho
ment 
aseline at
au
aseline at
om Baselin
eting
om Baselin
ding coagu
ket
ding coagu
ical chem
arke
ical chem
each sche
mar
each sche
eatment an
y m
eatment an
e from Ba
any
e from Ba
otal prote
t an
otal prote
Change fr
ort 
Change fr
comple
ppo
comple
plas
pp
plas
p
s
za
se
l efficacy
be 
l efficacy
P bleeding
ot b
P bleeding
u
fect of ro
nno
fect of ro
d quality 
ann
d quality 
ot
d
•
d
s d
application and any extensions or variations thereof.
o
ine
he
ine
gulation
the
gulation
mistry, and
s th
mistry, and
eduled as
ons
eduled as
nd SFU P
tion
nd SFU P
aseline in
riat
aseline in
ein and alb
vari
ein and alb
from Base
r va
from Base
lement lev
or 
lement lev
sma comp
ns o
sma comp
at each sc
ions
at each sc
study (
sio
study (
infu
ns
infu
n
xte
xtxtxt
y as 
an
y as 
ng score
d an
ng score
y e
ozanolixiz
nd
ozanolixiz
of life (H
n an
of life (H
d


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 56 of 202
•
To assess the effect of rozanolixizumab 
on patient reported outcomes (PROs)
•
Change from Baseline in FATIGUE-PRO 
Physical Fatigue Score
•
Change from Baseline in Patient Global 
Impression of Severity (PGI-S)
•
Patient Global Impression of Change 
(PGI-C) at all available post-baseline 
assessments
•
To assess the pharmacokinetics of 
rozanolixizumab administered by 
subcutaneous (sc) infusion
•
Plasma concentration of rozanolixizumab 
•
To evaluate the incidence and emergence 
of antidrug antibodies (ADAs) of 
rozanolixizumab
•
ADAs at each scheduled assessment 
•
To assess the pharmacodynamic (PD) 
effects of rozanolixizumab
The exploratory PD endpoints are:
•
Total serum IgG (absolute value) and 
change from Baseline (absolute value and 
percentage) in serum IgG and in serum 
IgG subclass concentration at each 
scheduled assessment 
•
Absolute values and change from Baseline 
(absolute value and percentage) in serum 
immunoglobulin concentrations (IgA, IgE, 
IgM) at each scheduled assessment
•
To assess the influence of 
rozanolixizumab treatment on vaccination 
titers
•
Percent change from Baseline in 
vaccination titers against Streptococcus 
pneumoniae, Neisseria meningitidis, and 
Haemophilus influenzae in 
splenectomized study participants
•
Percent change from Baseline in 
vaccination titers against tetanus in all 
study participants
•
To assess the effect of rozanolixizumab 
on response to vaccination in study 
participants who received COVID-19 
vaccine
•
Change in biomarkers of COVID-19 
vaccine response over time
a Absence of bleeding indicated by Grade 0 for all domains of the SMOG, or a Skin Grade of 0 or 1
b Nominal visits are on-site visits where ITP bleeding scale assessment is performed
COPY
Tot
Y
Tot
chan
PY 
chan
per
PY
per
PUBLIC CO
CO
P
arketing authorization 
za
xizumab
tho
xizumab
or
d assessm
ting
d assessm
g
support any mar
PD endpo
ma
PD endpo
um IgG (a
y m
um IgG (a
e from Ba
any
e from Ba
centage) i
t an
centage) i
gG subcl
ort 
gG subcl
schedu
po
schedu
•
u
•
Abs
pp
Abs
(
p
(
ent cannot be used to s
ark
s
on vaccin
us
on vaccin
d
This documen
assess th
me
assess th
on respo
um
on respo
partic
ocu
partic
vac
oc
vac
en
d
a
d
a A
d
A
b
d
s thereof.
ment 
ere
ment 
eo
tensions or variations 
oints are:
ons
oints are:
absolute v
atio
absolute v
aseline (ab
riat
aseline (ab
in serum 
vari
in serum 
lass conce
r va
lass conce
led asses
or 
led asses
bsolute va
ns o
bsolute va
(absolute 
ions
(absolute 
i
si
immun
sio
mmun
IgM
ns
IgM
ation and any exten
s
te
nation
ex
nation
•
t
•
te
te
ten
xte
applicat
he effect 
lica
he effect 
onse to va
pplic
onse to va
cip
a
cipants wh
app
ants wh
ne
a
ne
at


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 57 of 202
4
STUDY DESIGN
4.1
Overall design
This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study with 
rozanolixizumab in study participants with persistent or chronic primary ITP defined as more 
than 3 months, or 12 months of duration, respectively, since diagnosis.
The study participants will be male and female adults with persistent or chronic primary ITP, a 
platelet count measurement at Screening and at Baseline with an average of the two <30x109/L 
(no single count may be >35x109/L) and a documented history of low platelet count prior to 
Screening.
The primary objective of TP0006 is to evaluate the clinical efficacy of rozanolixizumab as a 
maintenance treatment in participants with persistent or chronic primary ITP. 
The study design was selected to assess whether multiple sc infusions of rozanolixizumab will 
result in a durable Clinically Meaningful Platelet count increase of ≥50x109/L, for at least 8 out 
of 12 weeks during the last 12 weeks of the Treatment Period (Week 13 to 25). On Day 1 
(Baseline Visit), study participants will be randomized 2:1 to receive a fixed-unit dose of 
rozanolixizumab equivalent to 
or placebo QW until Week 24, with randomization 
stratified by the degree of thrombocytopenia (platelet count < or ≥15x109/L) and history of 
splenectomy (yes or no). The last assessments prior to the SFU Visit will be done at Week 25. 
Study participants will be observed during the 8-week SFU Period after the final administered 
dose. The TP0006 study schematic is presented in Figure 1-2.
The total maximum study duration per study participant is up to 35 weeks, including a Screening 
Period (up to 4 weeks), a Dose Adaptation Period (12 weeks), a Maintenance Period (12 weeks) 
and an SFU Period (8 weeks after final dose administered). Splenectomized participants will be 
required to attend a Prolonged Period prior to the Screening Visit in order to receive, if 
applicable, the required vaccinations, which will extend the total study duration by up to 
20 weeks.
The eligibility of study participants to participate in the study will be determined during the 
Screening Period. Once eligibility is confirmed, the study participants will come to the site on 
Day 1 (Baseline Visit) and receive a single fixed-unit dose of rozanolixizumab or placebo 
administered sc (based on randomization).
Rozanolixizumab or placebo will be administered as a sc infusion with an infusion pump at a 
constant flow rate of approximately 
 (based on the syringe driver used) for up to 
 (depending on the dose). A fixed-unit dose across different body weight tiers, as 
presented in Table 1-2 will be applied. 
If the participant is unable to tolerate a 
 a slower rate may be used at the discretion 
of the clinical personnel administering the infusion. 
Dosing will be followed by a series of postdose study assessments on Day 1 through Day 169, 
with a subsequent SFU Period through Day 218. On dosing days, for the first 2 weeks, a 4-hour 
post-dose observation will be in place. Assuming the first 2 doses were well tolerated, on dosing 
days in Week 3, 4, and 5, a 1-hour post dose observation will be in place. Assuming the first 5 
doses were well tolerated, on subsequent weeks, a 15-minute post-dose observation will be in 
PUBLIC COPY 
d 2:
Y
d 2:
o QW un
PY
o QW un
latelet co
COP
latelet co
ts prior t
CO
ts prior t
g the 8
C C
g the 8-
C
-w
C
w
resented
LIC
resented
per stud
UBL
per stud
Adaptati
PUB
Adaptati
fter fin
PU
fter fin
ed to support any marketing authorization 
P, a 
ori
P, a 
x10
tho
x109
ho
9/L
hor
/L
prior t
uth
prior to
th
o
lixizumab
ng 
lixizumab
P. 
et
P. 
f rozanol
rke
f rozanol
≥50x10
mark
≥50x109
rk
9/L
k
/L
eek 13 to 
ma
eek 13 to 
eceive a
y m
eceive a f
m
f
til Week 2
any
til Week 2
unt < or ≥
rt a
unt < or ≥
o the SFU
ort 
o the SFU
eek SFU 
ppo
eek SFU 
in
u
in Figure
upp
Figure
y particip
o su
y particip
on Period 
d to 
on Period 
al dose ad
ed t
al dose ad
This document cannot be use
od prior t
sed
od prior t
tions, whi
us
tions, whi
articipant
ot b
articipant
ce eligibil
not
ce eligibil
isit) and re
nn
isit) and re
(based on
can
(based on
umab or p
nt c
umab or p
flow rate 
en
flow rate 
(dep
me
(dep
sented in
cum
sented in
If the pa
doc
If the pa
of the
s do
of the
D
s
D
me
tensions or variations thereof.
b as a 
reo
b as a 
lixizumab
th
lixizumab
L, for at le
ns 
L, for at le
o 25). On 
tion
o 25). On 
fixed
atio
fixed-
ti
-uni
io
uni
24, with r
aria
24, with r
≥15x10
var
≥15x109
r
9/L
/L
U Visit wi
r va
U Visit wi
Period af
or 
Period af
1
n
1-
s
-2
ns
2.
s
.
pant is up 
ion
pant is up 
d (12 week
nsio
d (12 week
dministere
tens
dministere
application and any ex
to the Scr
xte
to the Scr
hich will e
ex
hich will e
t
d
ts to parti
d an
s to parti
lity is con
nd a
lity is con
receive a s
and
receive a s
n random
n a
n random
placebo w
tion
placebo w
 of approx
cati
 of approx
pending o
plica
pending o
Table
ppl
Table 1
icipant 
ap
icipant 
al
a
l


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 58 of 202
place. However, if the dose needs to be decreased due to a TEAE(s) or dose needs to be 
increased, post dose observation will be extended to 1 hour after the end of infusion for the next 
2 infusions. The post-dose observation time frame may be extended at the discretion of the 
investigator. These recommendations are applicable for dosing at site and at home. Approval 
from the investigator and sponsor is required prior to the start of home dosing. 
In exceptional circumstances (eg, pandemic, hurricanes, etc) where study-specific investigations 
may not be conducted according to study protocol, contingency measures will be in place (see 
Section 8).
Approximately 150 study participants will be screened at approximately 70 sites from North 
America, Europe and Asia to achieve the targeted number of approximately 60 evaluable study 
participants randomized to weekly dosing. 
All study participants completing the Treatment Period (with or without the need for rescue 
therapy) and fulfilling the OLE study (TP0004) eligibility criteria will be allowed to enroll into 
TP0004.
If study participants require rescue therapy during the Treatment Period (Week 1 to Week 25), 
they are allowed to receive commercially available rescue therapy (Section 6.4.3).
An external IDMC will be established to review the safety data at predefined intervals and ad 
hoc as needed, should emerging safety concerns arise during the study. The first IDMC meeting 
for the review of safety data is planned to occur after approximately 15 participants have 
received 3 doses of IMP in TP0003. The study will be put on hold if any of the following occurs:
•
The IDMC judges it necessary for medical or safety reasons and
•
The sponsor or its designee judges it necessary for medical, safety, regulatory, or any other 
reasons consistent with applicable laws, regulations and Good Clinical Practice.
•
Three study participants experience any SAE of same type within the first 15 study 
participants who have received 3 doses of IMP across TP0006 and TP0003, unless the SAE 
is clearly unrelated to the study drug. After protocol amendment 3, this rule no longer 
applies. 
−
For US and Canada only: Three study participants experience any SAE within the first 
15 study participants who have received at least one dose of IMP across TP0006 and 
TP0003, unless the SAE is clearly unrelated to the study drug.
The IDMC has the possibility to unblind the data. Details of the IDMC composition, processes, 
and responsibilities will be documented in the IDMC charter. It is intended to have one IDMC 
for both of the pivotal studies (TP0006 and TP0003), where the data will be presented unpooled, 
ie, data from each study will be reviewed separately. Key safety data may be pooled at the 
discretion of the IDMC for protection of all study participants if warranted. 
Based on feedback from the IDMC, weekly dosing was implemented in protocol amendment 3. 
Study participants being treated with the bi-weekly dosing regimen will switch to the weekly 
dosing regimen once protocol amendment 3 is approved at the respective study site. 
Additionally, a Safety Signal Detection Team will perform rozanolixizumab program-wide 
aggregated safety data reviews at predefined intervals.
PUBLIC COPY 
scue
Y
scue
he safety
OPY
he safety
ns arise d
COP
ns arise d
ccur afte
C CO
ccur afte
study w
IC C
study w
or medic
BLI
or medic
udges it
PUB
udges it
licable
PU
licable
t cannot be used to support any marketing authorization 
s
z
s
ee
r
ee
m North
uth
m North
aluable stu
au
aluable stu
 need for 
eting
 need for 
e allowed 
ket
e allowed 
Period (W
ma
Period (W
apy (Sect
ny m
apy (Sect
data at pr
any
data at pr
uring the 
rt a
uring the 
r approxim
port
r approxim
ll be put o
ppo
ll be put o
al or safety
sup
al or safety
necessary
to 
necessary
laws, reg
ed t
laws, reg
rience any
use
rience any
ived 3 dos
e us
ived 3 dos
e study dr
be 
e study dr
Canada o
nno
Canada o
articipant
ann
articipant
3, unless t
ca
3, unless t
This documen
C has the p
ent 
C has the p
ponsibiliti
men
ponsibiliti
oth of the
um
oth of the
, data from
ocu
, data from
discretio
doc
discretio
Base
s d
Base
S
s
S
tion and any extensions or variations thereof.
udy 
of
udy 
r rescue 
here
r rescue 
d to enroll 
the
d to enroll 
Week 1 to 
ions
Week 1 to 
tion
ati
tion 6.4.3
atio
6.4.3
predefined
aria
predefined
study. Th
va
study. Th
mately 15
or v
mately 15
on hold if
s or
on hold if
ty reasons
ons
ty reasons
y for med
nsio
y for med
gulations a
tens
gulations a
y SAE of 
exte
y SAE of 
ses of IM
y ex
ses of IM
drug. After
ny 
drug. After
only
nd
only: Thr
nd 
: Thr
ts who ha
an
ts who ha
the SAE i
on a
the SAE i
applicat
possibility
atio
possibility
ies will be
icat
ies will be
e pivotal s
plic
e pivotal s
m each st
app
m each st
of the I
ap
of the I


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 59 of 202
4.2
Scientific rationale for study design
Autoantibodies against platelet antigens are considered to be a hallmark of ITP. Production of 
pathogenic IgG autoantibodies by plasma cells is accepted as the central underlying 
pathophysiological mechanism in a number of IgG-mediated autoimmune diseases, which 
include ITP.
Treatments aimed at reducing the quantity of circulating IgG autoantibodies are being used for 
primary and secondary therapy of autoimmune diseases, particularly where corticosteroid-based 
immune suppression is not or no longer effective. The therapeutic approach of these treatments is 
based on lowering levels of pathogenic autoantibodies, which represents rational and effective 
treatment modalities of autoimmune diseases.
TP0006 is designed to evaluate the efficacy, safety, and tolerability of rozanolixizumab given as 
fixed-unit doses equivalent to 
or lower, weekly until Week 24 in adult study 
participants with primary ITP.
Historical clinical data have demonstrated that the likelihood of bleeding is reduced with platelet 
counts >50x109/L, including both spontaneous bleeding and bleeding during minor surgical 
interventions such as dental manipulations. Conversely, the likelihood of bleeding events 
increases with platelet counts <35x109/L, with bleeding risk increasing as platelet count 
decreases. Hence, the participant population to be enrolled into this study should have a 
diagnosis of primary ITP (persistent or chronic) and a platelet count of <30x109/L. Study 
participants with evidence of a secondary cause of ITP and study participants with chronic or 
latent infections or active infections are excluded.
Safety and tolerability of rozanolixizumab up to 
sc and iv doses have been evaluated in 
healthy study participants in study UP0018. In the subsequent Phase 2 study TP0001, in study 
participants with primary persistent and chronic ITP, different dosing regimens were tested, and 
a dose up to 15mg/kg as a single sc infusion was well tolerated and showed a 67% clinically 
meaningful responder rate, defined as platelet count increases to ≥50×109/L. In CIDP01, 34 
study participants randomized to IMP (1:1 placebo:rozanolixizumab) followed 
of 
administrations. Of the 34 study participants, 21 study participants rolled over into 
the ongoing 52-week OLE study CIDP04. At least 6 participants have been treated with a 
 sc infusion for 1 year. Rozanolixizumab was well tolerated to date and the 
results of these two studies support the dosing regimen of 
 equivalent 
 for 24 weeks 
in this study. 
A 24-week Treatment Period to initiate and maintain a platelet increase and a subsequent 8-week 
SFU Period is considered sufficiently long to evaluate a difference between rozanolixizumab 
treatment and placebo.
It is generally recognized that a double-blind, randomized, parallel, placebo-controlled study is 
the most robust means of assessing the efficacy of a new treatment. The EMA guideline on the 
clinical development of medicinal products intended for the treatment of chronic ITP (effective 
as of Sep 2014) proposes a double-blind, placebo-controlled design. The placebo arm is justified, 
as rescue therapy and background treatment for ITP is allowed, provided the medication has 
been taken on a stable dose for a certain period of time and below a maximum dose as specified 
in Table 6-2.
PUBLIC COPY 
ly, th
Y
ly, th
eding ris
PY
eding ris
be enrol
COP
be enrol
nic) and 
CO
nic) and 
cause of
C C
cause of
exclud
LIC
exclud
xizumab 
UBL
xizumab 
dy UP00
PUB
dy UP00
P
stent a
PU
stent a
d to support any marketing authorization 
i
ased 
oriz
ased 
atments is
thor
atments is
effective
uth
effective
ixizumab
ng 
ixizumab
adult study
eting
adult study
ding is re
mark
ding is re
ding durin
ma
ding durin
kelihood o
ny m
kelihood o
k increasin
any
k increasin
ed into thi
rt a
ed into thi
platelet c
ort 
platelet c
ITP and s
ppo
ITP and s
d.
u
d.
up to 
o su
up to 
18.
d t
18.
nt cannot be used
In the
to 
In the
nd chronic
ed t
nd chronic
c infusion 
sed
c infusion 
ned as pla
us
ned as pla
d to IMP 
be u
d to IMP 
ns. Of the 
t be
ns. Of the 
OLE study
ot 
OLE study
infusion f
nno
infusion f
wo studies
ann
wo studies
This documen
k Treatme
ent 
k Treatme
eriod is co
men
eriod is co
ment and
um
ment and
It is gener
docu
It is gener
the mo
do
the mo
clin
s d
clin
a
s
a
su
sions or variations thereof.
b given as
reo
b given as
dy 
h
dy 
educed wi
ns 
educed wi
ng minor 
tion
ng minor 
of bleedin
atio
of bleedin
ng as plat
aria
ng as plat
his study s
var
his study s
count of <
r va
count of <
study par
or 
study par
sc an
ion
sc an
tion and any extens
e subsequ
nsio
e subsequ
ic ITP, dif
tens
ic ITP, dif
n was wel
xte
n was wel
atelet coun
ex
atelet coun
(1:1 plac
ny e
(1:1 plac
e 34 study
any
e 34 study
y CIDP04
d a
y CIDP04
for 1 year
and
for 1 year
s support 
n an
s support 
applicat
ent Period
atio
ent Period
onsidered
lica
onsidered
d placebo.
plic
d placebo.
rally reco
app
ally reco
bust
a
bust
sio


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 60 of 202
4.3
Justification for dose
Initially, a fixed-unit dosing regimen across body weight tiers equivalent to 
 (starting 
dose) followed by
 (maintenance doses) every 2 weeks (Q2W) was proposed for use in 
the confirmatory TP0003 study, based upon response rate (>50×109/L), time to onset of the 
platelet count increase, and safety profile observed in the Phase 2 study, TP0001. Data from 
TP0001 showed that a single dose of 
 reached a 52% decrease in IgG from Baseline by 
Day 8, and a clinical response was observed for most study participants in the cohort before the 
IgG nadir on Day 8. The study also showed that the median (and range) duration of platelet 
response (platelet count >50×109/L) following a dose of 
 QW and a single dose of 
 was 12 (6 to 19) days and 11.96 (6 to 20) days, respectively. Hence, a starting dose of 
 equivalent followed by 
equivalent Q2W was expected to sustain IgG levels 
reduced from its Baseline level by >50% and expected to be sufficient to translate into a relevant 
platelet response. Dose adjustments to 
 or approximately 
 were allowed if 
medically indicated, eg, for thrombocytosis. The proposed dose regimens were stratified by 
weight tiers as presented in Table 1-2.
Following the IDMC data review and the available OLE TP0004 data with the initially proposed 
dose regimen of
 the IgG reductions appear to be in concordance with the anticipated 
reductions of ~50%, however the observed platelet count data are not sustained in TP0004 
during the
 dosing interval. Protocol Amendment 3 follows the advice from the 
external IDMC to increase the frequency of dosing, as in the OLE study TP0004 platelets are not 
sustained over a 
 (observed platelet levels <50×109/L). Following the 
advice, the dose regimen for study TP0003 and OLE TP0004 will be changed to 
 
equivalent
 This dose regimen is anticipated to be
 and more likely to sustain the 
platelets  across the dosing interval reducing the risks associated with low platelet counts. A dose 
of 
equivalent 
 is predicted to sustain IgG levels with mean percentage change from 
Baseline reduction of 70% and maintain FcRn receptor occupancy (RO%) levels above 50% 
throughout the dosing interval as opposed to the 
 that only sustained it above this level 
during the first week following each dose and not for the entire 
 between doses. 
A 
equivalent QW dose regimen is anticipated to achieve similar level of RO% to a 
equivalent-dose, with a range on RO% from peak to trough of 99 to 50% during the 
7 days dosing interval. A minimal difference in IgG reduction between 
 and 
 
during the first 7 days was already observed in TP0001. Based on the minimal advantage from a 
RO% and IgG reduction perspective that a 
 starting dose will provide, the starting dose 
of 
equivalent is therefore no longer required with the 
 QW dose regimen. The 
 equivalent QW dose is predicted to achieve mean concentrations at steady state (Cmax,ss) 
of ~30ug/mL (2 days post dose) and Ctrough of 0.31ug/mL. 
In terms of safety, 
 weekly doses have been tested in TP0001 and showed a good 
safety and tolerability profile. In addition, this dose regimen of 
 has been studied in 
other indications like CIDP01, where 34 study participants (1:1 placebo:rozanolixizumab) 
followed 
 of 
administrations. Of the 34 study participants, 21 study 
participants rolled over into the ongoing 52-week OLE study CIDP04. At least 6 participants 
have been treated with a
 sc infusion for 1 year. The 
 doses were 
generally 
 and well tolerated, with an acceptable safety profile and no new safety concerns 
were identified. 
PUBLIC COPY 
be in c
Y
be in c
t count d
OPY
t count d
Amendm
COP
Amendm
dosing, 
CO
dosing, 
observed
C C
observed
0003 and
LIC
0003 and
is anticip
UBL
is anticip
val reduc
PUB
val reduc
predicte
PU
predicte
ai
P
ai
not be used to support any marketing authorization 
y
z
y
the
ri
the
et 
h
et 
dose of 
utho
dose of 
ting d
aut
ting dose 
ut
ose 
ain IgG le
g a
ain IgG le
slate into 
ing 
slate into 
ere allow
etin
ere allow
ns were str
rket
ns were str
data with
ma
data with
cordance 
ny m
cordance 
ata are no
any
ata are no
ent 3 follo
rt a
ent 3 follo
s in the O
port
s in the O
plate
ppo
platelet l
po
let l
OLE TP0
upp
OLE TP0
ated to be
su
ated to be
in
t
ing the ris
to s
g the ris
d to susta
d to
d to susta
ntain FcR
sed
ntain FcR
opposed 
use
opposed 
g each do
be u
g each do
W dose re
t be
W dose re
ose, with a
not 
ose, with a
This document cann
val. A min
nno
val. A min
days was
an
days was
reduction
t ca
reduction
equivale
nt c
equivale
equivale
men
equivale
0ug/mL (2
ume
0ug/mL (2
n terms of
ocu
n terms of
safety an
doc
safety an
other
s d
other
fo
s 
fo
m
nd any extensions or variations thereof.
of 
f
of 
evels
of
evels
a relevan
reo
a relevan
wed if 
her
wed if 
tratified b
the
tratified b
h the initi
tion
h the initi
with the 
iatio
with the 
ot su
aria
ot sustaine
ria
staine
lows the a
var
lows the a
OLE study
or v
OLE study
evels <50
or
evels <50
0004 will
ns o
0004 will
e
 and
ions
e
 and
sks assoc
nsio
sks assoc
ain IgG le
ens
ain IgG le
Rn recepto
xte
Rn recepto
d to the 
ext
d to the 
ose and no
y e
ose and no
egimen is 
any
egimen is 
a range on
d a
a range on
application an
nimal diff
and
nimal diff
s already o
n an
s already o
n perspec
on 
n perspec
ent is ther
atio
ent is ther
ent QW d
cat
ent QW d
(2 days po
plic
(2 days po
f safety, 
app
f safety, 
d tolerab
ap
tolerab
i
ion
x
p


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 61 of 202
In addition, in order to avoid platelet count increases to ≥150×109/L, down-titration of the IMP 
dose level as described in Table 1-1 will be allowed. Weekly platelet assessments will be 
performed during the study, to support the dosing strategy with the aim to increase platelet 
counts ≥50×109/L and to minimize platelet counts ≥150×109/L in the study participants. Up 
titration to fixed-unit doses of 
 rozanolixizumab equivalent QW will also be allowed to 
maintain stable platelet counts of ≥50×109/L over the Treatment Period if a previous down 
titration has occurred and subsequently platelet counts dropped again to below 50×109/L.
In summary, the new proposed dose regimen for Phase 3 is a 
 equivalent QW dose as 
starting and maintenance dose, allowing to down-titrate to 
 and 
total dose based 
on the efficacy and safety profile. This regimen is supported by the observed data in the program 
thus far.
4.4
End of study definition
A study participant is considered to have completed the study if he/she has completed all phases 
of the study including the SFU Period, or has successfully been enrolled into TP0004 at Week 25 
(Visit 27). Study participants not rolling over into TP0004 will have an EOS Visit performed 
8 weeks after the final dose of IMP, or upon discontinuation of the study.
The enrollment into the TP0004 study should be conducted on the same day as Visit 27 
(Week 25) of the feeder study. In case the enrollment into TP0004 is not conducted at Week 
25 (Visit 27), a visit window of +3 days will be granted; therefore, rollover needs to be 
completed 3 days after Week 25 at the latest. 
The EOS is defined as the date of the last visit of the last participant in the study.
LIC COPY
ua
Y
ua
onducted
PY 
onducted
lment in
OP
lment in
be grant
CO
be grant
PUBL
est.
C
est.
last visit
BLIC
last visit
pport any marketing authorization 
se as
hor
se as
e based 
tho
e based 
the progr
auth
the progr
as comple
ket
as comple
ed into TP
arke
ed into TP
ve an EOS
mar
ve an EOS
the study.
y m
the study.
on the sam
any
on the sam
o TP0004
t an
o TP0004
ed; therefo
ort 
ed; therefo
This document cannot be used to su
of the las
supp
of the las
s or variations thereof.
ram
f
ram
leted all p
the
leted all p
TP0004 at 
s th
TP0004 at 
S Visit pe
ons
S Visit pe
ame day a
riat
ame day a
4 is not co
var
4 is not co
fore, rollov
r va
fore, rollov
application and any extensions
st particip
ns 
st particip


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 62 of 202
5
STUDY POPULATION
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.
5.1
Inclusion criteria
Study participants are eligible to be included in the study only if all of the following criteria 
apply:
Age
1. Study participant must be ≥18 years of age at the time of the Screening Visit.
Type of participant and disease characteristics
2. Study participant is considered reliable and capable of adhering to the protocol, visit 
schedule, or medication intake according to the judgment of the investigator.
3. Study participant has a diagnosis of persistent (>3 months duration) or chronic (>12 months 
duration) primary ITP at the Screening Visit.
4b. Study participant has a documented intolerance or insufficient response to two or more 
appropriate standard of care ITP treatments (including but not limited to corticosteroids, 
immunoglobulins, TPO-RAs, azathioprine, danazol, cyclophosphamide, and/or rituximab or 
other immunosuppressants, splenectomy) prior to Screening. Two or more appropriate ITP 
treatments are defined as either at least two prior treatments if the participant is not taking 
concurrent ITP medications, or if the participant is on a concurrent ITP treatment at the study 
start (Screening), has received at least one prior ITP treatment.
5. Study participants must have prior history of a response to a previous ITP therapy. 
6a. If taking allowed drugs (see Table 6-2), study participant must be on stable doses during 
defined time periods prior to Baseline (Day 1).
7. Study participant has a documented history of low platelet count (<30x109/L) prior to 
Screening.
8. Study participant has a platelet count measurement at Screening and at Baseline (Day 1) with 
an average of the two <30x109/L and no single count may be >35x109/L (using local 
laboratories).
9. Study participant has a current or history of a peripheral blood smear consistent with ITP.
10. Study participant at Screening has an IgG level of:
a.
>5.5g/L for non-splenectomized participants
b. ≥6.5g/L for splenectomized participants
Weight
11. Body weight >35kg at Screening.
PUBLIC COPY
or insu
PY 
or insu
includin
OPY
includin
e, danazo
CO
e, danazo
my) prior
C C
my) prior
ast two p
LIC 
ast two p
f the part
BLIC
f the part
at least 
UBL
at least 
ve prior
PU
ve prior
ment cannot be used to support any marketing authorization 
protocol, 
etin
protocol, 
estigator.
rke
estigator.
ion) or ch
mar
ion) or ch
ficient resp
any
ficient resp
g but not l
t an
g but not l
l, cycloph
ort 
l, cycloph
to Screeni
por
to Screeni
rior treatm
upp
rior treatm
cipant is 
sup
cipant is 
one prior 
to s
one prior 
history of
d to
history of
ble
s
ble 6
sed
6-
e
-2
ed
2), 
d
), 
o Baseline
us
o Baseline
document
be 
document
t has a pla
nno
t has a pla
the two <
ann
the two <
s).
t
s).
participan
ent 
participan
This docum
udy partic
me
udy partic
a.
c
a.
>5.5
u
>5.5
b.
o
b.
W
s
W
cation and any extensions or variations thereof.
visit 
he
visit 
hronic (>1
ons 
hronic (>1
sponse to 
riat
sponse to 
limited to
vari
limited to
hosphami
r va
hosphami
ning. Two
or v
ning. Two
ments if t
s o
ments if t
on a conc
ons
on a conc
ITP treatm
sion
ITP treatm
f a respon
ens
f a respon
 study par
exte
 study par
e (Day 1)
y ex
e (Day 1)
nted histor
any
nted histor
atelet cou
and
atelet cou
<30x10
n an
<30x109
n
9/L
n
/L
nt has a cu
atio
nt has a cu
applic
cipant at S
plica
cipant at S
5g/L for n
app
5g/L for n
5g/L 
ap
5g/L 


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 63 of 202
Sex
12a.
Study participants may be male or female:
−
A male participant must agree to use contraception as detailed in Appendix 4, 
Section 10.4 during the Treatment Period and for at least 3 months after the final dose of 
study treatment and refrain from donating sperm during this period.
−
A female participant is eligible to participate if she is not pregnant (see Appendix 4, 
Section 10.4) as confirmed by a negative serum pregnancy test and not planning to get 
pregnant during the participation in the study, not breastfeeding, and at least one of the 
following conditions applies:
◦
Not a woman of childbearing potential (WOCBP) as defined in Appendix 4, 
Section 10.4.
OR
A WOCBP who agrees to follow the contraceptive guidance in Appendix 4, 
Section 10.4 during the Treatment Period and for at least 3 months after the dose of 
study treatment.
Informed consent
13. Study participant must be capable of giving signed informed consent as described in 
Appendix 1, Section 10.1.3 which includes compliance with the requirements and restrictions 
listed in the Informed Consent Form (ICF) and in this protocol.
5.2
Exclusion criteria
Participants are excluded from the study if any of the following criteria apply:
Medical conditions
1. Study participant has any medical or psychiatric condition that, in the opinion of the 
investigator, could jeopardize or would compromise the study participant’s ability to 
participate in this study.
2a. Participant has a history of arterial or venous thromboembolism (eg, stroke, transient 
ischemic attack, myocardial infarction, deep vein thrombosis or pulmonary embolism) within 
the 6 months prior to randomization or requires current anticoagulant treatment (Table 5-1).
3. Study participant has clinically significant bleeding that warrants immediate platelet 
adjustment (eg, menorrhagia with significant drop in hemoglobin).
4. Study participant has a history of alcohol use or other substance use disorder within the 
previous 12 months of the Screening Visit.
5a. Study participant has a known hypersensitivity to any components of the study medication or 
any other anti-FcRn medications.
6. Study participant has a known history of hyperprolinemia, 
7b. Study participant has evidence of a secondary cause of immune thrombocytopenia (clear 
association with other medical conditions eg, untreated H. pylori infection, leukemia, 
PUBLIC COPY 
g signed 
COP
g signed 
des comp
C CO
des comp
(ICF) an
IC C
(ICF) an
a
B
a
the stud
PU
the stud
annot be used to support any marketing authorization 
o get 
hor
o get 
e of the
tho
e of the
endix
g a
endix 4,
g a
4,
e in Appen
rke
e in Appen
3 months
ark
3 months
nformed 
rt a
nformed 
liance wi
port
liance wi
d in this p
ppo
d in this p
y if any of
d to
y if any of
edical or p
us
edical or p
rdize or w
be u
rdize or w
y.
t
y.
history of 
not
history of 
k, myocard
ann
k, myocard
This document ca
s prior to 
can
s prior to 
articipant 
nt c
articipant 
tment (eg
en
tment (eg
Study part
um
Study part
previou
ocu
previou
5a.
do
5a. Stu
o
Stu
and any extensions or variations thereof.
endix
s th
endix 4,
th
4,
s after the
ns 
after the
consent a
var
consent a
ith the req
or v
ith the req
protocol.
s or
protocol.
f the follo
nsi
f the follo
psychiatr
ex
psychiatr
would com
ny e
would com
f arterial o
nd 
f arterial o
rdial infar
and
rdial infar
application 
randomiz
n a
randomiz
t has clini
tion
t has clini
g, menorr
cat
g, menorr
ticipant h
plic
ticipant h
us 12
app
us 12 mon
pp
mon
partic
ap
partic


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 64 of 202
lymphoma, common variable immunodeficiency, systemic lupus erythematosus, autoimmune 
thyroid disease or is drug induced), participant has a multiple immune cytopenia (eg, Evan’s 
syndrome) etc.
8a. Study participant has a clinically relevant active infection (eg, sepsis, pneumonia, or abscess) 
in the opinion of the investigator, or had a serious infection (resulting in hospitalization or 
requiring parenteral antibiotic treatment) within 6 weeks prior to the first dose of IMP.
9. Study participant with a known tuberculosis (TB) infection, at high risk of acquiring TB 
infection, or latent tuberculosis infection (LTBI), or current/history of nontuberculous 
mycobacterial infection (NTMBI).
10. Study participant has a history of a major organ transplant or hematopoietic stem cell/marrow 
transplant.
11a. Study participant has any of the following active GI disorders: inflammatory bowel disease, 
GI ulceration or diverticulitis.
12. Study participant has experienced a clinically symptomatic GI bleed (positive hemoccult 
tests without any signs and symptoms of GI bleeding will not be considered as “clinically 
symptomatic”) in the last 6 months prior to the Screening Visit and/or has current gastritis or 
esophagitis and/or has a known risk for clinically relevant GI bleeding beyond ITP.
13. Study participant has experienced intracranial bleed in the last 6 months prior to the 
Screening Visit.
14. Study participant has a history of coagulopathy disorders other than ITP.
15. Criterion removed.
16. Splenectomized participant with past medical history of OPSI.
17. Study participant with current or medical history of IgA deficiency, or a measurement of IgA 
<50mg/dL at the Screening Visit.
Prior/Concomitant therapy/procedures
18. Study participant who has received any blood or blood products within 2 weeks prior to the 
Baseline Visit.
19. Study participant has undergone a splenectomy in the 2 years prior to the Baseline Visit.
20a.Splenectomized participant without adequate vaccination against S. pneumoniae, 
N. meningitidis, and H. influenzae as evidenced by: 
-
a lack of documented vaccination records per local guidance, OR
-
have not completed required vaccinations (S. pneumoniae, H. influenzae, and 
N. meningitidis) per Section 8.2.6 during the Prolonged Screening Period
Note: For splenectomized participants without any prior vaccination against one or all of the 
above-mentioned bacteria please refer to Section 8.2.6 of the protocol.
21a.Study participant has received a live vaccination within 8 weeks prior to Day 1 (Baseline 
Visit); or intends to have a live vaccination during the course of the study or within 7 weeks 
following the final dose of IMP.
PUBLIC COPY
g
Y
g
creeni
PY 
creeni
ally rele
OPY
ally rele
nial ble
CO
nial ble
coagulop
LIC
coagulop
with p
PU
with p
This document cannot be used to support any marketing authorization 
o
us 
th
us 
tem cell/m
g au
tem cell/m
mmatory bo
ketin
mmatory bo
bleed (pos
mar
bleed (pos
ot be consi
y m
ot be consi
Visit and
ny 
Visit and
vant GI ble
any
vant GI ble
d in the la
ort 
d in the la
athy disor
supp
athy disor
ast medica
d to
ast medica
or medica
sed
or medica
Visit.
us
Visit.
rapy/pro
t be
rapy/pro
who has re
not 
who has re
cipant has
ca
cipant has
ctomized
ent 
ctomized
meningitid
men
meningitid
-
m
-
application and any extensions or variations thereof.
marrow
of.
marrow
bowel dise
her
bowel dise
sitive hem
ons
sitive hem
sidered as
tion
sidered as
d/or has cu
iati
d/or has cu
leeding be
aria
leeding be
ast 6
r v
ast 6 mon
va
mon
rders othe
ns 
rders othe
al history
ens
al history
al history 
exte
al history 
ocedure
any
ocedure
received a
nd a
received a
s undergo
on a
s undergo
d participa
atio
d participa
dis,
ic
dis, and 
cat
and H
t
H
a lack o
pli
a lack o
-
a
-
hav
pp
hav


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 65 of 202
22. Criterion removed.
23a. Criterion removed.
24a. Study participant has been treated with prohibited immunosuppressants, biologics and other 
therapies within a timeframe shorter than detailed in Table 5-1. Medications as presented in 
Table 5-1 are prohibited during the study, unless required as rescue therapy (specified in 
Section 6.4.3) during the study.
Table 5-1:
Treatment-free periods for immunosuppressants, biologics, 
other therapies, and antiplatelet/anticoagulant agents
Generic name (commercial/trade name)
Period relative to Baseline Visit 
(regardless of route of administration)
Immunosuppressants
Cyclophosphamide
6 months
Pimecrolimus (Elidel®)
4 weeks
Vinca alkaloids (vincristine, vinblastine)
12 weeks
Biologics (monoclonal antibodies and fusion proteins)
Abatacept (CTLA 4-Ig) (Orencia®)
6 months
Belimumab (Benlysta™)
6 months
Golimumab (Simponi™)
6 months
Natalizumab (Tysabri®)
6 months
Ofatumumab (Arzerra®)
6 months
Rituximab (Rituxan®) and ocrelizumab
6 months or if more than 6 months and 
B cells have not returned to normal
TACI-Ig (Atacicept®)
10 months
Veltuzumab
6 months
Other biologics
3 months or within 5 half-lives prior to the 
Baseline Visit (whichever is longer)
Inebulizumab
6 months and B-cell counts are within 
normal range
Other
Intravenous immunoglobulin
4 weeks
Plasma exchange (PEX)
4 weeks
Anti-D
4 weeks
Romiplostim (Nplate®)
4 weeks
Antiplatelets and Anticoagulants (eg, thrombin inhibitors, Vitamin K antagonists, factor 
inhibitors)a
Warfarin
2 weeks
PUBLIC COPY 
Y
ns)
P
ns)
Y
OP
CO
C
LI
UB
m
P
m
P
ot be used to support any marketing authorization 
Visit
au
Visit
administr
g a
administr
ut
ng
eti
rk
ks
y
ks
ma
y
6 months
rt a
6 months
an
o
6 mo
por
6 mo
ort
po
pp
up
o
b
s
b
d
us
be
This document cannot 
ot
an
nt
ravenous im
um
ravenous im
me
Plasma e
doc
Plasma e
cu
d
Anti
d
Anti
do
s d
R
s
d any extensions or variations thereof.
ration)
eof
ration)
eo
he
s t
on
ati
s
ari
onths
or
onths
v
6 months
s o
6 months
o
6 mo
on
6 mo
ns
io
6
sioioioio
en
e
ny
application and a
d a
a
ati
immunoglo
pplic
immunoglo
lic
xchange (
app
change (
pp
a


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 66 of 202
Table 5-1:
Treatment-free periods for immunosuppressants, biologics, 
other therapies, and antiplatelet/anticoagulant agents
Generic name (commercial/trade name)
Period relative to Baseline Visit 
(regardless of route of administration)
Phenprocoumon
2 weeks
Acenocoumarol
2 weeks
Heparin
1 week
Clopidogrel
1 week
Salicylates (Aspirin)
1 week (enteric coated aspirin up to 
150mg daily allowed)
Dipyridamole
1 week
Prasugrel
1 week
Ticagrelor
1 week
Tirofiban
1 week
Abciximab
1 week
a This is not a complete list. The treatment free period relative to Baseline should be at least 5 half-lives from last 
dose, but a minimum of 1 week, whichever is longer.
Prior/Concurrent clinical study experience
25. Study participant has previously received rozanolixizumab in another clinical study.
26. Study participant has participated in another study of an investigational IMP (and/or an 
investigational device) within the previous 30 days prior to the Screening Visit or within 
5 half-lives prior to Baseline (whichever is longer) or is currently participating in another 
study of an investigational IMP (and/or an investigational device).
27. Criterion removed.
Diagnostic assessments
28a. Study participant has absolute neutrophil count <1500 cells/mm3 at the Screening Visit.
29. Criterion removed.
30. Study participant has a partial thromboplastin time ≥1.5x upper limit of normal (ULN) or 
International Normalized Ratio (INR) ≥1.5 at the Screening Visit.
31a. Study participant has 12-lead ECG with changes considered to be clinically significant upon 
medical review at Baseline.
32. Study participant has renal impairment, defined as:
−
Glomerular filtration rate (GFR) less than 45ml/min/1.73 m2 at the Screening Visit. 
BLIC COPY 
Y
OPY
elative
COP
elative to
OP
to
er.
C C
er.
xperien
LIC
xperien
PUB
ly receiv
UBL
ly receiv
ipated i
PU
ipated i
n th
P
n th
support any marketing authorization 
a
za
riz
tho
pirin up to
g au
pirin up to
au
ing
ket
ar
k
m
week
an
week
ny
t a
Baseline sh
rt a
Baseline sh
ce
u
ce
ment cannot be used to 
ed rozano
o su
ed rozano
n another 
d to
n another 
e previou
ed 
e previou
(whicheve
use
(whicheve
IMP (and
e us
IMP (and
sments
nno
sments
cipant 
can
cipant has
n
has
removed
t c
removed
y particip
men
y particip
This docum
nternation
ume
nternation
1a. Study
ocu
1a. Study
med
oc
med
32.
s d
32.
ons or variations thereof.f
re
the
s
ion
iat
ar
ould be at 
va
ould be at 
ication and any extensio
olixizumab
sion
olixizumab
study of 
ens
study of 
us 30
xte
us 30 days
en
days
ver is long
ext
ver is long
d/or an in
y e
d/or an in
s absolute
n a
s absolute
d.
t
d.
pant
ica
pant has a
cat
has a
appl
nal Norma
plic
nal Norma
y participa
app
y participa
al revie
ap
al revie


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 67 of 202
33b. Study participant has 3.0xULN of any of the following: alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), or alkaline phosphatase (ALP) at the Screening Visit.
−
If participant has >ULN for ALT, AST, or ALP that does not meet the exclusion limit at 
Screening, repeat the tests, if possible, prior to dosing to ensure there is no further 
ongoing clinically relevant increase. In case of a clinically relevant increase, inclusion of 
the participant must be discussed with the Medical Monitor.
−
For participants with a Baseline result >ULN for ALT, AST, ALP, or total bilirubin, a 
Baseline diagnosis and/or the cause of any clinically meaningful elevation must be 
recorded in the eCRF.
34a. Study participant has bilirubin >1.5xULN (unless confirmed Gilbert’s syndrome). If 
participant has elevations only in total bilirubin, fractionate bilirubin to identify possible 
undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%) at the Screening Visit.
35. Current unstable liver or biliary disease per investigator assessment defined by the presence 
of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, 
persistent jaundice, or cirrhosis. NOTE: with exception of stable hepatobiliary conditions 
(including Gilbert’s syndrome, asymptomatic gallstones).
36. Presence of hepatitis B surface antigen (HBsAg) at the Screening Visit.
37. Positive hepatitis C antibody test result at Screening or within 3 months prior to the IMP 
dose. NOTE: Study participant with a positive hepatitis C antibody due to prior resolved 
disease can be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained.
38. Study participant tests positive for HIV at the Screening Visit.
39a. Study participant has a current or medical history of primary immunodeficiency.
40. Study participant has active neoplastic disease or history of neoplastic disease within 5 years 
of the Screening Visit (except for basal or squamous cell carcinoma of the skin or carcinoma 
in situ of the uterine cervix which has been definitively treated with standard of care 
approaches).
41a. Study participant has corrected QT interval for heart rate using Fridericia's formula (QTcF) 
>450msec (for male participants) or QTcF >470msec (for female participants) or QTcF 
>480msec in participants with bundle branch block at the Baseline Visit.
Other exclusions
42. Criterion removed.
43a. Study participant has planned major elective surgical procedure for the duration of their 
participation in the study.
5.3
Lifestyle restrictions
There are no lifestyle restrictions during the study unless deemed to interfere with compliance 
with the protocol as deemed by the investigator.
PUBLIC COPY 
lstone
Y
lstone
Ag) at th
OPY
Ag) at th
t Screeni
CO
t Screeni
positive
C C
positive
nfirmato
LIC 
nfirmato
for HIV
UBL
for HIV
rrent or 
PU
rrent or 
P
t cannot be used to support any marketing authorization 
n, a 
o
n, a 
be
th
be
ome). If 
g au
ome). If 
ent
in
entify pos
ing 
ify pos
ening Visi
eting
ening Visi
t defined b
rke
t defined b
m
phageal o
mark
phageal o
ble hepato
ma
ble hepato
e Screenin
t any
e Screenin
ng or with
ort 
ng or with
hepatitis C
ppo
hepatitis C
ry negativ
upp
ry negativ
at the Scr
o su
at the Scr
medical hi
d to
medical hi
plastic di
sed
plastic di
t for basa
use
t for basa
x which h
be u
x which h
has correc
not 
has correc
male parti
nno
male parti
participan
can
participan
This document
usions
nt c
usions
erion rem
men
erion rem
a. Study
cum
a. Study p
m
p
partic
ocu
partic
5.3
s d
5.3
plication and any extensions or variations thereof.
ssible
reo
ssible
it.
h
it.
by the pre
s th
by the pre
or gastric
ns 
or gastric
tobiliary c
tion
tobiliary c
ng Visit.
aria
ng Visit.
hin 3 mon
r va
hin 3 mon
C antibod
or 
C antibod
ve Hepati
ns o
ve Hepati
reening V
ion
reening V
istory of p
nsi
istory of p
isease or h
xte
isease or h
al or squa
ext
al or squa
has been d
ny e
has been d
ected QT i
d a
ected QT i
icipants) o
and
icipants) o
ants with b
n a
ants with b
app
moved.
ica
moved.
participan
ppl
participan
ipation in
app
pation in


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 68 of 202
5.4
Screen failures
Screen failures are defined as study participants who consent to participate in the clinical study 
but are not subsequently randomly assigned to study treatment. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participants to meet the 
Consolidated Standards of Reporting Trials publishing requirements and to respond to queries 
from regulatory authorities. Minimal information includes demography, screen failure details, 
eligibility criteria, and any SAE.
Individuals who do not meet the platelet count criteria for participation in this study (screen 
failure) may be rescreened. Individuals who do not meet other criteria for participation in this 
study may be rescreened once. Additional rescreening of these individuals following upfront 
discussion with the Medical Monitor or Study Physician might be allowed. Rescreened study 
participants should be assigned a new participant number for rescreening.
If a study participant has isolated test results (specifically those mentioned in the inclusion or 
exclusion criteria) that are outside of the specific range but are clinically nonsignificant, the 
abnormal value may be rechecked at the discretion of the investigator, following discussion with 
the Medical Monitor or Study Physician.
Rescreening of study participants is separate from the repeating of individual tests.
Adequate vaccination for all splenectomized participants within 4 years prior to enrollment is 
preferred. However, non-vaccinated splenectomized study participants can receive vaccination 
during the Prolonged Screening Period. If a booster is due during the study, to avoid treatment 
interruption, the booster can be given ahead of the 5-year schedule if needed, also as part of the 
Prolonged Screening Period. Splenectomized participants who received vaccination during the 
Prolonged Screening Period, including those who received vaccination booster, can be 
randomized at a minimum 4 weeks after the last vaccination provided all other eligibility criteria 
are met. 
LIC COPY 
the repe
PY
the repe
articipan
COP
articipan
ctomized
C CO
ctomized
If a boos
IC C
If a boos
PUBL
ahead o
BLIC
ahead o
nectomiz
UBL
nectomiz
cluding t
PUB
cluding t
P
eeks a
PU
eeks a
support any marketing authorization 
een
tho
een
n in this
uth
n in this
ng upfron
au
ng upfron
creened st
ng a
creened st
ed in the i
ket
ed in the i
ally nonsig
ark
ally nonsig
ator, follow
ma
ator, follow
ating of in
any
ating of in
ts within 
ort a
ts within 
study par
por
study par
er is due 
ppo
er is due 
d to s
f the 5
sup
f the 5-
up
-yea
p
yea
ed particip
o su
ed particip
hose who 
d to 
hose who 
This document cannot be used
er the las
d t
er the las
s or variations thereof.
nt 
of
nt 
study 
eof
study 
inclusion
the
inclusion
ignificant,
s t
ignificant,
owi
o
owing disc
ons
ng disc
ndividual 
aria
ndividual 
4 years p
va
4 years p
articipants
or v
articipants
during th
s o
during th
nsion
ar schedu
ns 
ar schedu
pants who
ion
pants who
received 
nsio
received 
application and any exten
st vaccina
tens
st vaccina


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 69 of 202
6
STUDY TREATMENTS
Table 6-1:
Treatments administered
Study Treatment Name:
Rozanolixizumab
Placebo
Dosage formulation
Solution for infusion
Aqueous solution
Unit dose strength(s)/Dosage level(s):
 QW
 QW
 QW
0.9% sodium chloride 
aqueous solution 
(physiological saline, 
preservative free)
Volume matching the 
rozanolixizumab volume for 
the weight tier; QW
Route of administration
Subcutaneous infusion
Dosing instructions:
Study treatment will be administered as a sc infusion with an 
infusion pump at a constant
 (based on the syringe driver used) 
 
 (depending on the dose). A fixed-unit dose across 
different body weight tiers, as presented in Table 1-2 will be 
applied. The study participant’s body weight at the Screening 
Visit will be used for the dose assignation. In the case of any 
blockage of the infusion, a suitable flush 
is allowed.
If the participant is unable to tolerate a 
, a slower 
rate may be used at the discretion of the clinical site 
personnel administering the infusion.
Packaging and labeling:
Rozanolixizumab will be 
provided in glass vials, will 
be labeled as required per 
country requirement.
US/Canada: 10mL vial, 
 
 aqueous 
solution
All countries except 
US/Canada: 10mL ampoule, 
aqueous solution
hr=hour; QW=every week; sc=subcutaneous; w/v=weight/volume
Details on the rate of infusion and storage conditions are provided in the IMP Handling Manual.
6.1
Preparation, handling, storage, and accountability requirements
The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study treatment received and that any discrepancies were 
reported and resolved before the use of the study treatment.
Only participants enrolled in the study may receive study treatment, and only authorized site 
staff may supply or administer study treatment. All study treatments must be stored in a secure, 
IC COPY
ment wil
PY 
ment wil
pump at a
OPY
pump at a
(based
COP
(based
(dep
CO
(dep
iffere
C C
ifferent 
C C
nt 
PUBLIC
applied
LIC
applied
Vis
BL
Vis
b
B
b
Y
BL C C
y marketing authorization 
a
h
ing the 
aut
ing the 
mab volu
g a
mab volu
ht tier; QW
ing
ht tier; QW
a
m
za
aneous inf
m
aneous inf
ma
support any 
be adminis
any
be adminis
constant
t an
constant
on the syr
ort a
on the syr
ending on 
por
ending on 
ody weigh
ppo
ody weigh
to s
. T
u
. The study
upp
he study
will be us
su
will be us
ockage of 
to s
ockage of 
y
n
ent cannot be used t
If the
ed
If the
rat
e
rat
se
e
en
This docum
QW=ever
me
QW=ever
etails on t
ocu
etails on t
6.1
do
6.1
Th
s 
Th
d to
tions thereof.
me for 
of
me for 
W
fusion
tion
fusion
ns
riatio
stered as a 
riat
stered as a 
tio
s or va
ringe drive
va
ringe drive
the dose).
or v
the dose).
ht tiers, as 
s or
ht tiers, as 
cation and any extensions
y participa
ns 
y participa
sed for the
ons
sed for the
f the infusi
sio
f the infusi
is allowe
ns
is allowe
e participan
xten
e participan
te may be 
ext
te may be 
personnel
y e
personnel
Roza
ny
Roza
pr
n
pr
y
ca
applic
an
y week; sc
lica
y week; sc
the rate o
app
the rate o
P
p
P
ari
e


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 70 of 202
environmentally controlled, and monitored (manual or automated) area in accordance with the 
labeled storage conditions with access limited to the unblinded authorized site staff or pharmacy 
staff.
The investigator or designee is responsible for study treatment accountability, reconciliation, and 
record maintenance (ie, receipt, reconciliation, and final disposition records).
In case an out-of-range temperature is noted, it must be immediately reported as per instructions 
contained in the IMP Handling Manual.
Further guidance and information for the final disposition of unused study treatment are provided 
in the IMP Handling Manual.
6.1.1
Drug accountability
A Drug Accountability form will be used to record IMP dispensing and return information on a 
by-participant basis and will serve as source documentation during the course of the study. 
Details of any IMP lost, damaged (due to breakage or wastage), not used, partially used, 
disposed of at the study site, or returned to the sponsor or designee must also be recorded on the 
appropriate forms. All supplies and pharmacy documentation must be made available throughout 
the study for UCB (or designee) to review.
UCB is responsible for retaining all used, unused, and partially used containers of IMP until 
returned or destroyed.
The investigator may assign some of the investigator’s duties for drug accountability at the study 
site to an appropriate qualified person and/or pharmacist/designee.
The investigator must ensure that the IMP is used only in accordance with the protocol.
Periodically, and/or after completion of the clinical phase of the study, all used (including empty 
containers)/partially used, unused, damaged, and/or expired IMP must be reconciled and either 
destroyed at the site according to local laws and regulations considering UCB standard operating 
procedures (SOPs) or returned to UCB (or designee). IMP intended for the study cannot be used 
for any other purpose than that described in this protocol.
6.2
Measures to minimize bias: randomization and blinding
An interactive response technology (IRT) will be used for assigning eligible study participants to 
a treatment regimen (as applicable) based on a predetermined production randomization and/or 
packaging schedule provided by UCB (or designee). The randomization schedule will be 
produced by the IRT vendor. The IRT will generate individual assignments for kits of IMP, as 
appropriate, according to the visit schedule.
To enroll a study participant (Screening Visit), the investigator or designee will contact the IRT 
and provide brief details about the participant to be enrolled. Each participant will receive a 
5-digit number assigned at Screening that serves as the participant identifier throughout the 
study. The participant number will be required in all communication between the investigator or 
designee and the IRT regarding a particular study participant. Participant numbers and kit 
numbers will be tracked via the IRT.
To randomize a study participant, the investigator or designee will contact the IRT and provide 
brief details about the participant to be randomized. The IRT will automatically inform the 
PUBLIC COPY 
Y
d, and pa
OPY
d, and pa
investiga
C C
investiga
and/or p
LIC
and/or p
the IMP
UBL
the IMP
letion o
PU
letion o
d
P
d
This document cannot be used to support any marketing authorization 
ns
iz
ns
e provided
tho
e provided
rn inform
ting
rn inform
ourse of th
keti
ourse of th
sed, partia
arke
sed, partia
must also
mar
must also
ust be ma
y m
ust be ma
rtially use
t an
rtially use
tor’s dutie
ppo
tor’s dutie
harmacist
upp
harmacist
is used on
o s
is used on
f the clini
d to
f the clini
damaged, 
sed
damaged, 
local law
use
local law
d to UCB 
e u
d to UCB 
that descr
be 
that descr
ures to m
not 
ures to m
ponse tech
ann
ponse tech
men (as a
can
men (as a
hedule pr
nt c
hedule pr
by the IR
ent
by the IR
riate, acco
me
riate, acco
enroll a s
cum
enroll a s
and provi
doc
and provi
5
d
5-
d
-digit
do
digit
stud
s d
stud
d
s
d
application and any extensions or variations thereof.
mation on 
here
mation on 
he study.
the
he study.
ally used,
s th
ally used,
o be recor
ons
o be recor
ade avai
tion
ade availa
n
la
ed contain
vari
ed contain
ies for dru
s or
ies for dru
t/designee
ns 
t/designee
nly in acc
sion
nly in acc
ical phase
ens
ical phase
and/or ex
xten
and/or ex
ws and reg
ext
ws and reg
(or desi
y e
(or desig
ribed in th
any
ribed in th
minimiz
d a
minimiz
hnology (
an
hnology (
applicable
n a
applicable
rovided b
tion
rovided b
RT
a
RT vendor
atio
vendor
cording to
lica
cording to
study part
ppl
study part
de brief d
app
de brief d
ber
a
ber


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 71 of 202
investigator or designee of the participant’s randomization. The IRT will allocate kit numbers to 
the participant based on the participant number during the course of the study. The 
randomization number will be incorporated from the IRT into the eCRF by automatic data 
transfer.
The randomization will be stratified by the following:
•
Degree of thrombocytopenia (platelet count < or ≥15x109/L)
•
Splenectomy: yes/no
6.2.1
Procedures for maintaining and breaking the treatment blind
6.2.1.1
Maintenance of study treatment blind
All study participant treatment details, rozanolixizumab treatment arm, planned dose, or placebo,
will be allocated and maintained by the IRT system.
Study site pharmacists or other suitably qualified site personnel who are responsible for 
preparations of the IMP will be unblinded as they have access to treatment allocations for 
individual participants via the IRT. The unblinded pharmacy monitors from the contract research 
organization (CRO), the Clinical Supply Manager, and the unblinded Clinical Project Manager 
(CPM) (or designee) will also have access to the treatment allocations and to the drug 
accountability records, if applicable.
The following individuals may, as necessary, have access to the treatment allocations for 
individual participants via the IRT:
•
Sponsor Patient Safety (PS) staff as needed for reporting SAEs to regulatory authorities.
•
Members of the IDMC who participate in unblinded sessions will be given information about 
the IMP allocation for those participants for whom data are provided at these sessions.
•
Sponsor and/or CRO staff supporting preparation of the data outputs for the IDMC review 
and/or any interim analyses.
•
A Quantitative Clinical Pharmacologist/Modeling and Simulation Scientist may have access 
to the randomization code if PK data are requested for review by the IDMC.
•
The bioanalytical scientific manager (or designee)
An independent Quantitative Clinical Pharmacologist/Modeling and Simulation Scientist may 
have access to the randomization code to review unblinded PK, platelet and serum IgG data. 
All study participant treatment details will be allocated and maintained by the IRT system.
For safety reasons, the blinded investigator (or designee) has to receive and review the platelet 
counts from the local laboratory, which will be documented by the blinded site personnel in the 
eCRF. An increase in platelet count during the Treatment Period is not considered as an 
unblinding. As such, an increase in platelet count is expected for approximately 60% of the study 
participants, and up to 10% of placebo-treated study participants may experience an increase in 
platelet count. Platelet counts may be shared with study participants as this is deemed necessary 
information for participants when engaging in activities of daily living.
PUBLIC COPY
rm
Y
rm
and the
PY 
and the
treatme
OPY
treatme
ary, hav
C C
ary, hav
aff as ne
UBL
aff as ne
o partic
PU
o partic
pa
P
pa
This document cannot be used to support any marketing authorization 
nd
u
nd
ned dose,
ting
ned dose,
are respon
ark
are respon
reatment a
ma
reatment a
onitors fr
y m
onitors fr
nblinded 
any
nblinded 
nt allocatio
t an
nt allocatio
e access to
ppo
e access to
eded for re
o s
eded for re
pate in un
d to
pate in un
ticipants f
sed
ticipants f
upporting
us
upporting
ses.
be
ses.
cal Pharm
ot b
cal Pharm
ion code i
not
ion code i
tical scien
an
tical scien
dent Quan
nt c
dent Quan
ess to the 
en
ess to the 
study par
cum
study par
For safet
doc
For safet
count
s do
count
eC
s 
eC
application and any extensions or variations thereof.
, or placeb
ere
, or placeb
onsible for
ns t
onsible for
allocation
ons
allocation
rom the
atio
rom the co
co
Clinical 
riat
Clinical 
ions and t
vari
ions and t
o the
s o
o the trea
or
trea
reporting 
sion
reporting 
nblinded s
ens
nblinded s
for whom
xte
for whom
g preparat
y ex
g preparat
macologis
d an
macologis
if PK dat
nd 
if PK dat
ntific man
n an
ntific man
antitative C
atio
antitative C
rand
cat
randomi
at
omi
rticipant t
ppli
rticipant t
y reason
ap
reason
th
a
th


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 72 of 202
Unintentional formal unblinding occurs when the unblinded study site pharmacists or other 
suitably qualified site personnel responsible for IMP preparation share the treatment allocations 
for individual participants (or equivalent information) with the blinded site personnel 
accidentally. The same applies to the blinded sponsor and/or CRO staff.
Unintentional informal unblinding of the blinded investigator (or designee) and the blinded site 
personnel is only applicable if IgG levels are shared by the central laboratory in error. Given the 
pharmacological property of the IMP, a change of IgG level may be suggestive of a treatment 
effect however, does not disclose the treatment allocation.
To maintain the study integrity, study personnel, the UCB and CRO study teams will remain 
blinded to IgG levels. However, to ensure study participants’ safety, serum IgG level will be 
monitored by unblinded Medical Monitors external to UCB. In case the serum IgG level 
decreases <1g/L, the unblinded Medical Monitors will inform the investigator as described in
Section 10.25. Potential actions to be taken may include maintaining the dose, reducing the dose 
or initiation of mock infusions. Temporary treatment discontinuation due to low IgG levels may 
informally unblind the treatment assignment to the participant. Therefore, infusions will be 
continued but given as mock infusions with only placebo irrespective of IMP designation. 
Allocation of mock kit numbers will be handled via the IRT. Refer to Appendix 25, 
Section 10.25 for further information.
Further details are provided in the study manual and site blinding plan.
6.2.1.2
Breaking the treatment blind in an emergency situation
In the event of an emergency, it will be possible to determine to which treatment arm and dose 
the study participant has been allocated by contacting the IRT. At the start of the study, all sites 
will be provided with details of how to contact the system for code breaking. The Medical 
Monitor or equivalent should be consulted prior to unblinding, whenever possible.
The CPM will be informed immediately via the IRT when a code is broken but will remain 
blinded to specific treatment information. Any unblinding of the IMP performed by the 
investigator must be recorded in the source documents and on the Study Termination eCRF page.
6.3
Treatment compliance
During the Treatment Period, IMP will be administered at the clinical site or study participant’s 
home as a sc infusion by a qualified designee. Drug accountability must be recorded on the Drug 
Accountability form (see Section 6.1.1)
PUBLIC COPY 
he IR
Y
he IR
al and si
COP
al and si
t blind i
C C
t blind i
e possib
BLIC
e possib
cated by 
UBL
cated by 
how to c
PUB
how to c
e cons
PU
e cons
annot be used to support any marketing authorization 
nt 
nt 
remain
uth
remain
vel will be
au
vel will be
gG level 
g a
gG level 
or as descr
ting
or as descr
dose, redu
ketin
dose, redu
ue to low 
rke
ue to low 
efore, infu
mar
efore, infu
ctive of IM
ma
ctive of IM
Refer to A
ny m
Refer to A
te blinding
ort a
te blinding
n an eme
ppo
n an eme
e to deter
supp
e to deter
contacting
o su
contacting
ontact the
to 
ontact the
ulted prior
ed t
ulted prior
diately via
use
diately via
nformation
e us
nformation
ed in the s
be 
ed in the s
ment com
ot b
ment com
ent Period
nno
ent Period
This document ca
usion by a
can
usion by a
y form (se
t ca
y form (se
and any extensions or variations thereof.
e
o
e
ribed in
ereo
ribed in
ucing the 
ther
ucing the 
w IgG leve
s th
w IgG leve
fusions w
ns 
fusions w
MP design
tion
MP design
Appendix 
atio
Appendix 
ng plan.
va
ng plan.
ergency
or 
ergency
rmine to w
ns 
rmine to w
g the IRT
ion
g the IRT
e sys
nsi
e system f
sio
tem f
or to unbli
tens
or to unbli
a the IRT
exte
a the IRT
n. Any un
y ex
n. Any un
source do
ny 
source do
mplianc
d a
mplianc
d, IMP wi
and
d, IMP wi
application 
a qualifie
n a
a qualifie
see Sectio
ion 
see Sectio


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 73 of 202
6.4
Concomitant medication(s)/treatment(s)
6.4.1
Permitted concomitant treatments (medications and therapies)
The following concomitant medications are permitted during the study and if possible, kept
stable for the duration of the study (Table 6-2):
Table 6-2:
Permitted concomitant treatments (medications and therapies)
Permitted Medications
Dose
Commenta
Oral corticosteroids
≤20mg/day
(prednisone equivalent dose)
Stable dose 
 prior to 
Baseline
Mycophenolate mofetil
≤3g/day
Stable dose 
 prior to 
Baseline
Cyclosporin
≤5mg/kg/day for unmodified
≤4mg/kg/day for modified
Stable dose 
 prior to 
Baseline
Azathioprine
≤3mg/kg/day
Stable dose 
 prior to 
Baseline
Danazol
≤15mg/kg/day
Stable dose 
 prior to 
Baseline
Dapsone
100mg/day
Stable dose 
 prior to 
Baseline
Eltrombopag, 
Avatrombopag
Any dose
Stable dose 
 prior to 
Baseline
Fostamatinib
Any dose
Stable dose 
 prior to 
Baseline
a Stable dose is defined as either the same dose and frequency of the respective medication taken for the period of 
time defined in Table 6-2, or no dose of the respective medication taken for the period of time as defined in 
Table 6-2.
The use of medicinal cannabidiols and medicinal marijuana (prescribed by a physician) is also 
permitted. When applicable, the study participant must be on a stable dose of cannabidiols and/or 
medicinal marijuana 
 prior to Screening and remain stable for the duration of the 
study.
6.4.2
Prohibited concomitant treatments (medications and therapies)
The following concomitant medications are prohibited during the study:
•
IVIg (unless given as a rescue therapy)
•
All biologics including rituximab
•
Cyclophosphamide
•
Pimecrolimus
•
PEX 
LIC COPY 
PY
CO
PUBLIC
se
B
se
LIC
ny dose
PU
ny dose
PU
keting authorization 
riz
r to
ut
r to
ho
prior 
ng 
prior 
a
eti
upport any mark
e dose 
m
e dose 
seline
y m
seline
ma
Stable d
any
Stable d
Basel
rt a
Basel
ny
ort
S
ort
ort
ort
or
ment cannot be used to sup
up
to
se
ame dose an
us
ame dose an
ose of the r
e u
ose of the r
annabidio
ot b
annabidio
plicable, t
nno
plicable, t
ana 
ann
ana 
This docum
Pro
nt
Pro
following 
ume
following 
IVIg (
ocu
IVIg (
•
d
•
A
o
A
•
s
•
ng
rke
m
ann
ons thereof.
r to
re
r to
of
prior to
the
prior to
he
ns
nsions or variatio
ose 
ar
ose 
line
v
line
ia
Stable dos
or 
Stable dos
Baselin
s o
Baselin
r v
n
ation and any extensions
Sta
ns
Sta
B
ns
on
ns
xt
nd frequenc
ex
nd frequenc
respective m
y e
respective m
ols and me
d a
ols and me
the study 
and
the study 
 pr
n an
 pr
applica
ohibited
cati
ohibited
g concomi
plic
g concomi
unless gi
app
unless gi
ogi
a
i
t
tion
aria
n an


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 74 of 202
•
Immunoadsorption 
•
Anti-D
•
Any systemically administered corticosteroids above the allowed background dose (unless 
required as a rescue therapy)
•
Romiplostim
•
Vinca alkaloids (vincristine, vinblastine)
•
Anticoagulants and antiplatelets (warfarin, heparin, clopidogrel, aspirin [enteric coated up to 
150mg daily allowed], salicylics, dipyridamole, prasugrel, ticagrelor, tirofiban, and 
abciximab).
For study participants who require a medical or surgical procedure that requires the use of 
general anesthesia, discussion must occur prior to the procedure with the Medical Monitor or 
study physician, such that a decision on the participant's continued participation in the study can 
be made. In an emergency situation, discussion should occur as soon as possible after the 
procedure.
The use of prohibited concomitant treatment will lead to permanent discontinuation from IMP. 
Study participants should then complete the assessments outlined for the Early Withdrawal (EW) 
Visit and enter the SFU Period.
6.4.3
Rescue therapy
Rescue treatment will be given as per standard of care and at the discretion of the investigator as 
described below. If such rescue therapy is given, the participant is allowed to continue IMP 
treatment (as per guidance below), and should continue to complete all remaining scheduled 
visits in the Treatment Period, as per the Schedule of Activities (Section 1.3). The following 
rescue therapies may be used:
•
Any increase in concomitant ITP therapies above Baseline dose
•
Any additional ITP medication/therapies including but not limited to:
−
Platelet transfusion (only in cases of severe bleeding)
−
Commercially available IVIg
−
Any systemically administered corticosteroids (above the background doses, ie, pulse, 
oral and iv steroids). Any systemic corticosteroids used for the management of infusion 
reactions or other medical conditions are also considered rescue therapy.
−
Immunosuppressants (except for those listed in Section 6.4.2).
Although the use of rescue therapy is allowable at any time during the study, the use of rescue 
therapy should be delayed, if possible, for at least 2 days following the administration of study 
treatment. 
If IVIg, high dose corticosteroids, or platelet transfusion are given as rescue therapy, IMP 
treatment can commence at the same dose as previously when platelet counts are <50x109/L. 
Dose can be up-titrated at a later timepoint, if needed, depending on platelet level.
PUBLIC COPY
ad to pe
PY 
ad to pe
ssments 
OPY
ssments 
standard
BLIC
standard
rapy is g
UBL
rapy is g
w), and s
PUB
w), and s
P
as per 
PU
as per 
d to support any marketing authorization 
ated up to
tho
ated up to
and 
au
and 
res the us
ting
res the us
Medical M
ketin
Medical M
icipation 
rke
icipation 
n as po
mar
n as possi
r
ssi
manent di
ny 
manent di
outlined fo
t any
outlined fo
of care an
supp
of care an
iven, the p
o su
iven, the p
hould con
to 
hould con
cannot be used
he Schedu
ed t
he Schedu
nt ITP the
e us
nt ITP the
edication
t be
edication/
usion (onl
not 
usion (onl
ally avail
ann
ally avail
ocument c
ystemical
t ca
ystemical
l and iv st
ent 
l and iv st
reactions 
men
reactions 
−
Immu
um
Immu
This do
Although
doc
Although
therap
s do
therap
tre
s 
tre
nsions or variations thereof.
se of 
ere
se of 
Monitor o
ther
Monitor o
n in the stu
s th
n in the stu
ble after 
ns 
ble after 
iscontinua
iati
iscontinua
for the Ear
aria
for the Ear
and at the 
ns 
and at the 
participan
ion
participan
ntinue t
nsio
ntinue t
n and any exte
o c
o
o c
dule of Ac
tens
dule of Ac
erapies ab
y ex
erapies ab
therapies 
any
therapies 
ly in case
nd a
ly in case
lable IVIg
an
lable IVIg
applicatio
lly admin
ion 
lly admin
steroids). A
atio
steroids). A
or other m
icat
or other m
unosuppr
ppli
unosuppr
a
the use 
ap
the use 
uld
a
ld


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 75 of 202
A high dose of corticosteroids is defined as any iv administration of corticosteroids given for any 
reason or doubling of an oral dose resulting in a dose more than 20mg/day prednisone equivalent 
dose.
In case of an increase of Baseline oral corticosteroids, not resulting in doubling of the oral dose 
more than 20mg/day prednisone equivalent dose, an increase in the concomitant ITP therapies 
above Baseline, or in case of administration of immunosuppressants as rescue therapy, IMP 
administration can continue as per Schedule of Activities (Section 1.3) at a dose adjusted 
depending on the platelet level.
The date and time of rescue therapy administration as well as the name and dosage regimen of 
the rescue therapy must be recorded in the eCRF.
6.5
Dose modification
Dose modifications of the IMP are permitted in order to maintain the platelet counts between 
≥50x109/L and ≤150x109/L (Table 1-1 and Figure 1-1). 
Dose modifications or temporary discontinuation of the IMP treatment are permitted if serum 
IgG value is <1g/L (Section 10.25).
In the event of treatment-related AEs, other than those that meet the IMP discontinuation criteria
(as defined in Section 7.1) a dose reduction is permitted. Treatment-related AEs due to which 
dose modifications are recommended may include, but are not limited to:
•
Moderate to severe headaches 
•
Severe vomiting and diarrhea 
•
Moderate to severe toxicities (Grade 2 and above, as defined by Common Terminology 
Criteria for Adverse Events version 5.0) for which rozanolixizumab cannot be excluded as a 
cause
6.6
Treatment after the end of the study
Study participants (regardless of whether they receive rescue therapy), upon completion of the 
Treatment Period and fulfilling the eligibility criteria, will be given the opportunity to enroll into 
the OLE study, TP0004.
In case the enrollment into TP0004 is not conducted at Week 25 (Visit 27), a visit window of 
+3 days will be granted; therefore, rollover into TP0004 needs to be completed 3 days after 
Week 25 at the latest.
For study participants not enrolling into the OLE study, there are no plans for continued 
provision of rozanolixizumab after the end of the study. The participant should discuss any 
alternative treatment options (if needed after the study) with their healthcare provider.
PUBLIC COPY
ose that
PY 
ose that
ermitted.
OPY
ermitted.
clude, bu
CO
clude, bu
s (Grade
PUB
s (Grade
 versio
PU
 versio
ment cannot be used to support any marketing authorization 
gimen of 
uth
gimen of 
elet counts
ketin
elet counts
ent 
ma
ent ar
ma
are p
ar
e p
meet the I
any
meet the I
Treatmen
t an
Treatmen
t are
ort
t are not l
rt 
not l
2 and abo
to 
2 and abo
n 5.0) for 
d to
n 5.0) for 
fter the e
e us
fter the e
ess of wh
be
ess of wh
ulfilling th
ot b
ulfilling th
04.
n
4.
lment into
can
lment into
be granted
t ca
be granted
the latest
nt 
the latest
dy partici
me
dy partici
This docu
vision of r
um
vision of r
lternative
ocu
lternative
lication and any extensions or variations thereof.
ts between
ther
ts between
permitted 
ons
permitted 
MP disco
riat
MP disco
ntnt-
a
-related 
ari
related 
imited to
r va
imited to
ove, as de
nsio
ove, as de
r which ro
ens
r which ro
end of t
y ex
end of t
hether they
any
hether they
he eligibil
d a
he eligibil
o TP0004
n an
o TP0004
d; therefor
ion 
d; therefor
t.
a
t.
ipants not
lica
ipants not
app
rozanolix
pplic
rozanolix
e treatmen
app
e treatmen


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 76 of 202
7
DISCONTINUATION OF IMP AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL
7.1
Discontinuation of IMP
7.1.1
Liver chemistry stopping criteria
Discontinuation of study treatment for abnormal liver function should be considered by the 
investigator when a study participant meets one of the conditions outlined in Figure 7-1 and 
Figure 7-2, or if the investigator believes that it is in the best interest of the participant.
Figure 7-1:
Liver chemistry stopping criteria and increased monitoring algorithm
ALT=alanine transaminase; AST=aspartate aminotransferase; INR=international normalized ratio; SAE=serious 
adverse event; ULN=upper limit of normal
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
d 
o
d 
g algorit
aut
g algorit
minase; AST
ann
minase; AST
N=upper li
ca
N=upper li
not be used to support any marketing a
application and any extensions or variations thereof.
thm
f
thm
T=aspartat
an
T=aspartat
imit of norm
on a
imit of norm
nd any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 77 of 202
Figure 7-2:
Liver chemistry increased monitoring algorithm with continued study 
intervention for participants with ALT ≥3xULN but <8xULN
ALT=alanine transaminase; AST=aspartate aminotransferase; bili=bilirubin; INR=international normalized ratio; 
SAE=serious adverse event; ULN=upper limit of normal
Specific assessments and follow-up actions for potential drug-induced liver injury (PDILI) are 
provided in Appendix 6, Section 10.6.
7.1.2
QTc stopping criteria
If a clinically significant finding is identified (including but not limited to: changes from 
Baseline in QT interval corrected using Fridericia’s formula) after enrollment, the investigator or 
qualified designee will determine if the study participant can continue in the study and if any 
change in participant management is needed. This review of the ECG printed at the time of 
collection must be documented. Any new clinically relevant finding should be reported as an AE.
A study participant who meets the bulleted criteria based on the ECG readings will discontinue 
IMP and move into the SFU Period. The study participant should be referred to a specialist (ie, 
cardiologist) and managed as per local guidance.
•
QTc >500 msec OR uncorrected QT >600 msec
•
Change from Baseline of QTc >60 msec
For study participants with underlying bundle branch block, follow the discontinuation criteria 
listed below:
PU
artate
P
artate
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
aminotransf
ed 
aminotransf
limit of nor
sed
limit of nor
w
e
w-up actio
e us
up actio
ction
be
ction 10.6
e 
10.6
opping c
ot b
opping c
ficant find
nno
ficant find
nterval co
can
nterval co
gnee will 
t ca
gnee will 
participan
ent 
participan
on must b
men
on must b
tudy parti
cum
tudy parti
MP and m
ocu
MP and m
cardi
do
cardiolo
o
olo
•
s 
•
to support any marketing authoriz
application and any extensions or variations thereof
ferase; bili=
ten
ferase; bili=
rmal
xt
rmal
ons for 
y ex
ons for po
x
po
6.
criteria
d a
criteria
ding is ide
and
ding is ide
orrected u
n a
orrected u
 determin
ion 
 determin
nt manage
atio
nt manage
be docume
icat
be docume
icipant wh
pplic
icipant wh
move into
app
move into
st) and
ap
st) and
nsions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 78 of 202
Baseline QTc with Bundle Branch Block
Discontinuation QTc Threshold with Bundle 
Branch Block
<450 msec
>500 msec
450 to 480 msec
≥530 msec
7.1.3
Discontinuation of IMP due to other adverse events or medical 
condition
Study participants MUST permanently discontinue IMP and move into the SFU Period if any 
of the following events occur:
−
Study participant has a significant infective episode including but not limited to: 
bacteremia or sepsis, infectious meningitis, osteomyelitis, septic arthritis, complicated 
pneumonia or visceral abscess which may or may not result in hospitalization. This list is 
not intended to be all inclusive, and the investigator is expected to apply his/her judgment 
on continuing IMP based on the clinical situation at hand (see Appendix 25, 
Section 10.25).
−
Study participant has new onset or recurrent neoplastic disease (except for superficial 
basal or squamous cell carcinoma of the skin not requiring targeted biological therapy, 
chemotherapy or radiation).
−
Study participant has an AE of severe or serious hypersensitivity, infusion related 
reaction (see Appendix 24, Section 10.24) or anaphylaxis requiring corticosteroid and/or 
epinephrine therapy (see Appendix 21, Section 10.21) (Sampson et al, 2006).
−
Study participant has a serious AE of headache or GI disturbance that is considered 
related to the IMP in the opinion of the investigator; or recurrent severe AE of headache 
(see Appendix 22, Section 10.22) or GI disturbance that is considered related to the IMP 
in the opinion of the investigator (See Appendix 23, Section 10.23).
−
Study participant has a life-threatening bleeding event.
−
Study participant has an AE of arterial or venous thromboembolic event (eg stroke, 
myocardial infarction, pulmonary embolism, deep vein thrombosis).
−
Study participant has evidence suggestive of potential TB infection (eg, exposure), and 
further examinations result in a diagnosis of active TB, LTBI, or NTMBI (see 
Section 8.2.5). 
−
If a NTMBI is identified during the study, the same withdrawal procedures as those used 
for an active TB infection identified during the study should be followed.
Study participants who permanently discontinue IMP during the Treatment Period and hence are 
withdrawn from the study should complete the assessments outlined for the Early Withdrawal 
(EW) Visit and enter the SFU Period.
7.1.4
Temporary IMP discontinuation
Study participant MUST temporarily discontinue IMP if any of the following events occur:
1. Thrombocytosis (platelet count of ≥400x109/L).
PUBLIC COPY 
neopla
Y
neopla
in not re
OPY
in not re
re or ser
C CO
re or ser
on
IC
on 10.24
IC 
10.24
endix 21
BLIC
endix 21
rious AE
PUB
rious AE
e opinio
PU
e opinio
n
P
n 1
P
1
ot be used to support any marketing authorization 
d if any 
thor
d if any 
ited to:
g au
ited to:
tis, compl
ng 
tis, compl
italization
eting
italization
o apply h
ket
o apply h
Appendix
ark
Appendix
 disease (
ny m
 disease (
quiring tar
any
quiring tar
ous
po
ous hyper
por
hyper
) or anaph
pp
) or anaph
Section
sup
Section 1
p
1
of heada
to s
of heada
n of the in
d to
n of the in
0.22
ed
0.22) or G
ed
) or G
stigator (S
use
stigator (S
a life
be u
a life
ent canno
-
e
-thre
u
thre
has
ot b
has an A
t b
an A
farction, p
not
farction, p
ticipant ha
ann
ticipant ha
examinat
t ca
examinat
ion
nt
ion 8.2.5
nt c
8.2.5
This docume
)
If a NTM
men
If a NTM
for an 
um
for an 
Study par
docu
Study par
withdr
do
withdr
(EW
s d
(EW
y extensions or variations thereof.
licated 
reo
licated 
n. This lis
here
n. This lis
his/her jud
the
his/her jud
ix 25,
s t
ix 25,
(except fo
atio
(except fo
argeted bio
aria
argeted bio
ersensitivi
or v
ersensitivi
hylaxis re
s o
hylaxis re
10.21
ns
10.21) (S
s 
) (S
ache or GI
sio
ache or GI
nvestigato
ens
nvestigato
GI disturb
xten
GI disturb
See Appe
ext
See Appe
cation and any
reatening 
ny e
reatening 
AE of arter
d an
AE of arter
pulmonar
nd 
pulmonar
has eviden
n an
has eviden
ations resu
on 
ations resu
applic
).
at
).
MBI is ide
lica
MBI is ide
activ
plic
active TB
plic
e TB
ticipants 
app
icipants 
from
a
from


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 79 of 202
2. For all participants: In the event of confirmed COVID-19 infection (eg, signs/symptoms 
such as fever, cough, shortness of breath), or known exposure sufficient to necessitate 
testing or self-imposed quarantine. The IMP may be restarted if:
a. COVID-19 test is negative, and signs and symptoms have resolved
b. If test is not available, resolution of signs and symptoms and 14 days have passed since 
initial presentation of the clinical signs/symptoms. 
c. If asymptomatic, 14 days have elapsed since known exposure. 
Study participant MAY temporarily discontinue IMP if any of the following events occur:
1. A severe AE of headache that is considered related to the IMP in the opinion of the 
investigator (Section 10.22)
2. A splenectomised study participant develops a (persistent or re-occurring) nonserious 
infection, as per investigator’s decision (Section 10.25)
3. Total serum IgG value is <1g/L as per investigator’s decision. As IMP treatment is 
administered weekly, the decision to temporarily hold the treatment should be determined 
based on the most recently available total IgG value. As the IgG, IgG subtypes, albumin 
and total protein levels will be blinded to both the study site personnel and the clinical 
team at the sponsor and CRO, unblinded Medical Monitors will be monitoring the IgG 
levels and will alert the investigator in case of decreases <1g/L. Additionally, guidance 
for investigators on management of infections can be found in Appendix 25, 
Section 10.25.
7.2
Participant discontinuation/withdrawal from the study
Study participants are free to withdraw from the study at any time, without prejudice to their 
continued care. Participants who withdraw from the study should complete the EOS Visit.
A study participant may also be withdrawn from the study at any time at the discretion of the 
investigator for safety, behavioral, compliance, or administrative reasons.
If the study participant withdraws consent for disclosure of future information, the sponsor may 
retain and continue to use any data collected before such a withdrawal of consent.
If a study participant withdraws from the study, he/she may request destruction of any samples 
taken and not tested, and the investigator must document this in the site study records.
See the Schedule of Activities (Section 1.3) for data to be collected at the time of study 
discontinuation and follow up and for any further evaluations that need to be completed.
Study participants must be withdrawn from the study and permanently discontinued from IMP if 
any of the following events occur:
1. Study participant withdraws his/her consent.
2. Study participant takes prohibited concomitant medications as defined in this protocol.
3. Study participant meets the mandatory IMP discontinuation criteria as per Section 7.1.1,
Section 7.1.2 or Section 7.1.3.
PUBLIC COPY 
G valu
Y
G valu
both the 
OPY
both the 
d Medic
COP
d Medic
in case o
CO
in case o
of infect
C C
of infect
scontin
PUB
scontin
ithdra
PU
ithdra
ocument cannot be used to support any marketing authorization 
occur:
utho
occur:
on of the
au
on of the
urring) no
etin
urring) no
n.
m
n. As IMP
mar
As IMP
e treatmen
ma
e treatmen
As the IgG
ny m
As the IgG
tudy site p
any
tudy site p
al Monitor
rt a
al Monitor
f decrease
port
f decrease
ons can b
ppo
ons can b
uation/w
to s
uation/w
w from th
ed t
w from th
withdraw f
sed
withdraw f
e withdra
e us
e withdra
avioral, co
be 
avioral, co
withdraw
ot b
withdraw
o use any
nno
o use any
pant with
can
pant with
tested, an
t ca
tested, an
chedule o
ent
chedule o
ntinuation 
me
ntinuation 
udy partic
cum
udy partic
This do
any of th
doc
any of th
1.
s d
1. S
application and any extensions or variations thereof.
onserious
here
onserious
P treatme
ns 
P treatme
nt should 
tion
nt should 
G, IgG sub
iatio
G, IgG sub
personne
aria
personne
rs will be
var
rs will be
es <1g/L. 
or v
es <1g/L. 
be found i
s or
be found i
/withdra
sio
/withdra
he study a
ten
he study a
from the s
exte
from the s
awn from
y e
awn from
ompliance
any
ompliance
ws consent
d a
ws consent
y data coll
and
y data coll
hdraws fro
n a
hdraws fro
and the inv
tion
and the inv
of Activit
cati
of Activit
n and follo
lica
n and follo
icipants
app
icipants m
p
m
a
 follow
ap
follow


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 80 of 202
4. There is confirmation of a pregnancy during the study, as evidenced by a positive pregnancy 
test. 
5. The Sponsor or a regulatory agency requests withdrawal of the study participant.
Study participants who withdraw from the study or permanently discontinue IMP during the 
Treatment Period should complete the assessments outlined for the EW Visit, enter the SFU 
Period and complete the EOS Visit. 
Investigators should contact the Medical Monitor, whenever possible, to discuss the withdrawal 
of a participant in advance. Study participants who are withdrawn will not be replaced.
7.3
Lost to follow up
A study participant will be considered lost to follow-up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site.
The following actions must be taken if a study participant fails to return to the clinic for a 
required study visit:
•
The site must attempt to contact the study participant and reschedule the missed visit as soon 
as possible and counsel the study participant on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the participant wishes to and/or should continue in 
the study.
•
Before a study participant is deemed lost to follow up, the investigator or designee must 
make every effort to regain contact with the participant (at least 1 phone call and 1 written 
message to the participant), and document his/her effort (date and summary of the phone call 
and copy of the written message) in the source documents.
Should the study participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study with a primary reason of lost to follow-up documented in the eCRF.
8
STUDY ASSESSMENTS AND PROCEDURES
Study procedures and their timing are summarized in the Schedule of Activities (Section 1.3).
Protocol waivers or exemptions are not allowed.
Immediate safety concerns should be discussed with the sponsor (or designee - Medical Monitor 
at CRO) immediately upon occurrence or awareness to determine if the participant should 
continue or discontinue study treatment.
Adherence to the study design requirements, including those specified in the Schedule of 
Activities (see Section 1.3), is essential and required for study conduct.
All Screening evaluations must be completed and reviewed to confirm that potential participants 
meet all eligibility criteria. Screening assessments can be performed on different days throughout 
the Screening Period, if required. The investigator will maintain a Screening log to record details 
of all participants screened and to confirm eligibility or record reasons for Screening failure, as 
applicable.
Procedures conducted as part of the participant’s routine clinical management (eg, blood count) 
and obtained before signing of the ICF may be utilized for Screening or Baseline purposes 
PUBLIC COPY
he imp
PY 
he imp
e particip
OPY
e particip
ost to fol
C C
ost to fol
with the
LIC 
with the
documen
BLI
documen
ge) in th
UB
ge) in th
ntinue
PU
ntinue
P
This document cannot be used to support any marketing authorization 
rawal 
horiz
rawal 
fails to re
ng 
fails to re
n to the cli
rke
n to the cli
schedule t
y m
schedule t
rtance of m
ny 
rtance of m
ant wishe
any
ant wishe
ow up, th
po
ow up, th
participan
upp
participan
t his/her e
sup
t his/her e
e source d
to s
e source d
to be unre
d to
to be unre
imary rea
sed
imary rea
ESSME
us
ESSME
r timing ar
t be
r timing ar
emptions
not 
emptions
concerns s
ann
concerns s
diately up
can
diately up
discontinu
nt c
discontinu
nce to the 
men
nce to the 
ities (see
ume
ities (see
All Screen
ocu
All Screen
meet all
doc
meet all
the S
s d
the S
of
s
of
application and any extensions or variations thereof.
eturn for 
reo
eturn for 
inic for a 
the
inic for a 
the misse
tion
the misse
maintaini
iatio
maintaini
es to and/o
aria
es to and/o
he investig
or 
he investig
nt 
n
nt (at leas
ns o
(at leas
eff
o
effort (dat
ons
ort (dat
fo
f
o
fo
f
document
sio
document
eachable, 
tens
eachable, 
ason of lo
xte
ason of lo
ENTS A
y ex
ENTS A
are summa
any
are summa
s are not a
nd a
s are not a
should be
an
should be
pon occurr
on a
pon occurr
ue study t
tion
ue study t
study des
icat
study des
Section
plic
Section
ning evalu
app
ning evalu
igibili
ap
igibili


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 81 of 202
provided the procedures met the protocol-specified criteria and were performed within the time 
frame defined in the Schedule of Activities (see Section 1.3).
An Unscheduled Visit can be conducted at the discretion of the investigator (eg, due to an AE).
During the Unscheduled Visit, the following assessments will be performed:
•
AE reporting
•
Concomitant medications 
•
Review of withdrawal criteria
•
Physical examination
•
Vital signs
•
Blood samples for PK, IgG, hematology, biochemistry, other testing such as for TB or 
C-reactive protein (CRP) as clinically indicated in the opinion of the investigator.
Other assessments may be performed at the discretion of the investigator.
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the 
samples.
Some study-specific investigations may not be conducted according to the study protocol during 
a pandemic or other exceptional circumstances (eg, hurricanes) due to the need to implement 
safety measures and guidance from regulatory authorities. In such a situation, which may be 
accompanied by local or global containment or other measures, sites may need to prohibit access 
to study participants and study-related personnel. Study participant visits to the study site may be 
replaced by contingency measures. These measures are primarily established to ensure the safety 
of study participants during the course of the study and to maintain the study participants 
treatment schedule, if the investigator considers it appropriate. These measures include but are 
not limited to virtual visits or home-nursing visits replacing site visits, eg, telemedicine contacts 
or home-nursing visits when treatment and/or blood sampling is scheduled. The contingency 
measures are described in a contingency plan which will be maintained by UCB for the 
respective study. The contingency measures are shared with the investigator and the respective 
study-related personnel as soon as there are indications that it is necessary to implement any of 
the measures.
The participant may have the option to have home-nursing visits as specified in Section 1.3.
Home-nursing visits will be conducted by 2 fully trained healthcare professionals (1 unblinded 
for IMP preparation and 1 blinded for the other assessments) visiting the participant at his/her 
home or other locations (eg, rehabilitation or day care centers, etc). Alternatively, these visits can 
be conducted at the site as deemed necessary by site personnel and/or participant, or when home-
nursing visits are not available. Where dosing is performed at home or at other locations, the
same safety monitoring schedule will be followed as in the clinic. These healthcare professionals 
will be present during the full duration of the visit. Home visits and visits at other locations can 
be conducted in case the following conditions are met:
•
The participant is willing to be dosed and monitored at home, or at an alternative location by 
healthcare professionals.
PUBLIC COPY 
ty re
Y
ty re
conduct
COP
conduct
ces (eg, 
CO
ces (eg, 
atory au
C C
atory au
nment o
LIC
nment o
ted perso
UBL
ted perso
es. Thes
PUB
es. Thes
cours
PU
cours
P
ment cannot be used to support any marketing authorization 
uch as for
ketin
uch as for
e investig
rke
e investig
igator.
mar
igator.
s or for te
y m
s or for te
ed accordi
rt a
ed accordi
hurricanes
port
hurricanes
horities. I
ppo
horities. I
other me
upp
other me
nnel. Stud
o su
nnel. Stud
e measure
to s
e measure
of the stu
d to
of the stu
or consid
sed
or consid
me
u
me-
us
-nursin
use
nursin
treatment 
be u
treatment 
a continge
t be
a continge
ontingency
ot b
ontingency
nel as soo
nno
nel as soo
nt may ha
t ca
nt may ha
sing visits
ent 
sing visits
preparati
men
preparati
This docum
e or other 
ume
e or other 
conducte
cum
conducte
nursing v
doc
nursing v
same 
s do
same 
wil
s 
wil
b
lication and any extensions or variations thereof.
r TB or 
her
r TB or 
gator.
s th
gator.
echnical is
atio
echnical is
ing to the
var
ing to the
s) due to t
or v
s) due to t
In such a 
s or
In such a 
easur
ns
easures, si
s 
es, si
udy partici
ion
udy partici
es are prim
nsio
es are prim
udy and to
ens
udy and to
ders it app
xte
ders it app
ng visits r
ex
ng visits r
t and/or bl
ny e
t and/or bl
ency plan
any
ency plan
cy measur
d a
cy measur
on as there
nd 
on as there
ave the op
ion 
ave the op
s will be c
atio
s will be c
ion and 1 
icat
ion and 1 
appl
locations
plic
locations
ed at the s
pp
ed at the s
isits are 
ap
sits are 
mo
a
mo


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 82 of 202
•
The participant has shown good acute tolerability to previous administrations of IMP 
(namely they must have had no moderate or severe infusion reactions, or other AEs which 
the investigator considers could increase the risk of home administration).
•
The participant does not require specific medical supervision based on their medical 
history/condition.
•
The team delivering the home dose must be trained in the identification and management of 
infusion reactions and hypersensitivity and must have access to immediate treatments (eg, an 
EpiPen or adequate alternative).
•
The participant’s home or alternative location allows rapid access to emergency treatment if 
required (ie, the participant must not live so remotely that a reasonable arrival time of an 
ambulance could not be predicted).
•
The investigator or site designee is contactable to support the healthcare provider if needed.
•
UCB has not requested to limit the possibility to perform home visits or visits at other 
locations (eg, based on IDMC recommendation).
The investigator will be asked to complete a checklist confirming all criteria have been fully
evaluated. This checklist will be shared with the UCB study physician or designee and reviewed
before the first home visit for IMP administration can take place.
8.1
Efficacy assessments
8.1.1
Platelet counts
For assessment of platelet counts, blood samples will be collected by qualified site personnel at 
the same time that samples are collected for standard clinical laboratory assessments. The time 
and date of the blood draws will be recorded in medical source data and the eCRF. Assessment 
will be performed according to the Schedule of Activities (Section 1.3).
Platelet counts will be determined by a local laboratory and the following endpoints will be 
derived for the purpose of analysis:
•
Durable Clinically Meaningful Platelet Response of ≥50x109/L, for at least 8 out of 12 weeks 
during the last 12 weeks (Week 13 to 25)
•
Cumulative number of weeks with Clinically Meaningful Platelet Response defined as: 
platelet count ≥50x109/L over the 24-week treatment period
•
Time to first Clinically Meaningful Platelet Response of ≥50x109/L defined as: time from 
starting treatment to achievement of first response of ≥50x109/L
•
Clinically Meaningful Response defined as ≥50x109/L by Day 8
•
Response defined as platelet count ≥30x109/L and at least a 2-fold increase of the Baseline 
count confirmed on at least 2 separate occasions at two adjacent nominal visits at least 7 days 
apart, and absence of bleeding by visit 
•
Time to first Response defined as: time from starting treatment to achievement of Response
PUBLIC COPY 
t con
Y
t con
CB stud
OPY
CB stud
on can ta
COP
on can ta
blood sam
UBL
blood sam
collected
PUB
collected
ll be re
PU
ll be re
This document cannot be used to support any marketing authorization 
of 
iz
of 
eg, an 
oriz
eg, an 
treatmen
aut
treatmen
l time of 
g a
l time of 
are
ke
are provid
keti
provid
isits or vis
ark
isits or vis
ing all cri
ny m
ing all cri
y physicia
any
y physicia
ke place.
rt a
ke place.
mples will
o su
mples will
for standa
to 
for standa
corded in 
d t
corded in 
Schedule
sed
Schedule
ned by a l
e us
ned by a l
nalysis:
be 
nalysis:
Meaningfu
ot b
Meaningfu
2 weeks (W
nno
2 weeks (W
number o
can
number o
ount ≥50x
t ca
ount ≥50x
to first C
ent
to first C
arting trea
me
arting trea
Clinical
ocu
Clinical
•
d
•
Res
o
Res
application and any extensions or variations thereof.
nt if 
f
nt if 
an
o
an
der if need
the
der if need
sits at oth
ns t
sits at oth
riteria hav
atio
riteria hav
an or desi
aria
an or desi
l be
io
l be collec
on
collec
ard clinic
nsio
ard clinic
medical 
ens
medical 
e of Activ
xte
e of Activ
local labo
y ex
local labo
ful Platele
d a
ful Platele
Week 13 
nd 
Week 13 
of weeks w
n a
of weeks w
x10
io
x109
on
9/L ov
on
/L ov
Clinically 
cati
Clinically 
atment to 
lica
atment to 
ally Meani
app
ally Meani
nse de
ap
nse de


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 83 of 202
•
Duration of first Clinically Meaningful Platelet Response of <50x109/L: measured from 
achievement of first Response to loss of first Response (loss of Response defined as platelet 
count <50x109/L) 
•
Complete Response defined as platelet count ≥100x109/L confirmed on at least 2 separate 
occasions at two adjacent nominal visits at least 7 days apart, and absence of bleeding by 
visit
•
Cumulative number of weeks over the planned 24-week treatment period with a platelet 
count of ≥100x109/L 
•
Cumulative number of weeks over the planned 24-week treatment period with platelet counts 
≥30×109/L and at least doubling from Baseline
•
Mean change from Baseline in platelet count by visit
•
Clinically Meaningful Platelet Response of ≥50x109/L, for at least 4 out of 6 weeks during 
the last 6 weeks (Week 19 to 25).
•
Clinically Meaningful Platelet Response of ≥50x109/L, for at least 6 out of 8 weeks during 
the last 8 weeks (Week 17 to 25).
The Response and Complete Response variables will be assessed only for visits for which both 
platelet counts and the ITP bleeding score are assessed (with the exception of the confirmatory 
platelet assessments which may be obtained at any visit (scheduled or unscheduled) provided 
that they meet the criteria below). In order to define a Response (platelet count ≥30x109/L), the 
platelet count must be confirmed on 2 separate occasions and in the absence of bleeding. The 
time to first Response will be taken as the time to the first platelet assessment (obtained at the 
same time as the corresponding ITP bleeding score assessment). If the second assessment does 
not fulfill the required criteria for a Clinical Response, the study participant will be considered as 
a nonresponder at the respective visits. Further details will be provided in the Statistical Analysis 
Plan (SAP). 
Refer to Section 9.3 for details of statistical analysis of these variables.
8.1.2
ITP bleeding score
The International Working Group on ITP proposes a consensus-based ITP-BAT, based on a 
precise definition of bleeding manifestations and on the grading of their severity (Rodeghiero et 
al, 2013). The ITP bleeding score will be assessed using the ITP-BAT tool Version 1.0. 
Assessment will be performed according to the Schedule of Activities (Section 1.3).
For the ITP-BAT, bleeding manifestations were grouped into 3 major domains: S, M, and O, 
with the skin, mucosae, organs with grading of severity (SMOG) system. Each bleeding 
manifestation is assessed at the time of examination. Severity is graded from 0 to 3 or 4, with 
Grade 5 for any fatal bleeding. Absence of bleeding will correspond to a Grade 0 or 1 for Skin 
and Grade 0 for Mucosae or Organ domains. Presence of bleeding is indicated by a Mucosae or 
Organs Grade ≥1, or Skin Grade ≥2. Bleeding reported by the participant without medical 
documentation is Graded 1. Within each domain, the same grade is assigned to bleeding 
manifestations of similar clinical impact. The “worst” bleeding manifestation since the last visit 
PUBLIC COPY 
s will be
OP
s will be
e assesse
CO
e assesse
ed at any
C C
ed at any
rder to d
LIC
rder to d
2
B
2 separ
BLI
separ
en as the
PUB
en as the
g ITP bl
PU
g ITP bl
r a
P
r a
nt cannot be used to support any marketing authorization 
t 
o
t 
latelet cou
aut
latelet cou
out of 6 w
ket
out of 6 w
least 6 ou
ma
least 6 ou
assessed 
rt a
assessed 
d (with th
ort 
d (with th
visit (sch
ppo
visit (sch
fine a Res
upp
fine a Res
te occasio
sup
te occasio
time to th
to s
time to th
eeding sco
d to
eeding sco
Clinical R
ed 
Clinical R
visits. Fur
use
visits. Fur
etails of st
t be
etails of st
eeding s
not 
eeding s
Working 
ann
Working 
on of blee
ca
on of blee
he ITP ble
nt c
he ITP ble
This docume
ent will be
ent
ent will be
he ITP
um
he ITP-
m
-BA
BA
ith the ski
cu
ith the ski
manifest
doc
manifest
Grade
s do
Grade
and
s 
and
ation and any extensions or variations thereof.
ount
f
ount
weeks du
the
weeks du
ut of 8 we
tion
ut of 8 we
only for v
var
only for v
he excepti
r va
he excepti
heduled o
or 
heduled o
esponse (p
ns o
esponse (p
ons and in
ions
ons and in
he f
si
he first pl
sio
irst pl
fif
si
fif
ore assess
ens
ore assess
Response,
xten
Response,
rther deta
ext
rther deta
tatistical a
any
tatistical a
score
nd a
score
 Group on
an
 Group on
eding ma
on a
eding ma
eeding sc
tion
eeding sc
applica
be perform
cati
be perform
BAT, bleed
plic
BAT, bleed
kin, mucos
app
kin, mucos
tion is a
ap
ion is a
an
a


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 84 of 202
is graded, and the highest grade within each domain is recorded. The SMOG system provides a 
consistent description of the bleeding phenotype in ITP.
A standardized data collection form will be used to facilitate collection of information and 
communication among physicians and investigators. The grading of bleeding symptoms at 
presentation and at each subsequent evaluation is presented in Appendix 12, Section 10.12.
8.1.3
Patient Reported Outcomes
Patient reported outcomes must be completed as per time points mentioned in the Schedule of 
Activities (Section 1.3). The PROs should be completed prior to any intrusive procedures in a 
quiet place. On dosing days, PROs will be completed prior to dosing.
The PROs should be completed in the following order: ITP-PAQ, SF-36, the FATIGUE-PRO 
Physical Fatigue Scale, EQ-5D-5L, PGI-S, and PGI-C.
8.1.3.1
ITP-PAQ
The ITP-PAQ is a 44-item disease-specific Health-Related Quality of Life (HRQoL) 
questionnaire developed for use in adults with chronic ITP. It includes 11 scales: Symptoms, 
Fatigue, Physical Health – Bother, Physical Health – Activity, Emotional Health –
Psychological, Emotional Health – Fear, Overall QoL, Social Activity, Women’s Reproductive 
Health – Fertility, Women’s Reproductive Health - Menstrual Symptoms, and Work. Each item 
is rated on a Likert-type scale containing 4 to 7 responses. All item scores are transformed to a 0 
to 100 continuum and are weighted equally to derive individual scale scores. Higher scores 
indicate better health status (Mathias et al, 2007; Mathias et al, 2009).
The ITP-PAQ Symptoms score was selected as secondary efficacy endpoint for the study to 
capture the benefits of rozanolixizumab in terms of patient-perceived symptoms. It covers 6 core 
symptoms of ITP: bruising/petechiae, wounds/scars (from blood tests, injections or IV needles), 
blood blisters in mouth, bleeding episodes, muscle aches, and cramps in legs.
The ITP-PAQ sample questionnaire is available in Appendix 13, Section 10.13.
8.1.3.2
SF-36
Study participants will complete the SF-36 questionnaire according to the Schedule of Activities 
(see Section 1.3). The SF-36 sample questionnaire is available in Appendix 14, Section 10.14.
8.1.3.3
FATIGUE-PRO Physical Fatigue Scale
The FATIGUE-PRO Physical Fatigue scale is one of the three scales of the broader 
FATIGUE-PRO instrument developed by UCB. It consists of 9 items rated on a 5-point 
frequency response scale ranging from "none of time" to "all of the time", with a 7-day recall 
period. The FATIGUE-PRO Physical Fatigue score ranges 0 to 100, with higher score meaning 
more physical fatigue.
The FATIGUE-PRO Physical Fatigue scale is available in Appendix 15, Section 10.15.
8.1.3.4
EQ-5D-5L
The EQ-5D-5L is designed to improve the instrument’s sensitivity and to reduce ceiling effects.
The EQ-5D-5L consists of 2 pages: the EQ-5D descriptive system and the EuroQol visual 
analogue scale (EQ VAS).
PUBLIC COPY
Acti
Y
Acti
oL, Soc
PY 
oL, Soc
h 
O
h -
O
- Men
OPY
Men
7
C
7 respon
CO
respon
y to deri
C C
y to deri
al,
LIC
al, 2007
LIC 
2007
s selecte
UBL
s selecte
izumab 
PUB
izumab 
echiae,
PU
echiae,
P
used to support any marketing authorization 
e of 
hor
e of 
res in a
tho
res in a
ATIGUE
g a
ATIGUE-
a
-P
f Life (HR
ark
f Life (HR
udes 11
ma
udes 11 sc
sc
Emotiona
y m
Emotiona
al Activity
any
al Activity
trual Sym
t an
trual Sym
ses. All it
ort 
ses. All it
ve individu
po
ve individu
Mathias 
upp
Mathias 
d as secon
su
d as secon
n terms of
to s
n terms of
wounds/s
d to
wounds/s
ment cannot be u
pisode
sed
pisodes, m
ed
s, m
naire is av
us
naire is av
complete
ot 
complete
he SF
nno
he SF-
no
-36 s
no
36 s
ATIGUE
can
ATIGUE
UE
nt
UE-
nt
-
This docum
PRO 
nt c
PRO 
E-
e
-PRO in
en
PRO in
ency respo
me
ency respo
iod. The F
cum
iod. The F
more phy
docu
more phy
The F
s do
The F
8
s
8
tensions or variations thereof.
PRO
eof
PRO
RQoL)
ns t
RQoL)
scales: Sym
ions
scales: Sym
al Health
atio
al Health
y, Women
riat
y, Women
mptoms, a
vari
mptoms, a
item score
r va
item score
dual scale 
or 
dual scale 
et al, 200
s o
et al, 200
ndary effic
ion
ndary effic
f patient
nsio
f patient
scars (from
ens
scars (from
on and any ext
muscle ach
xte
muscle ach
vailable in
y ex
vailable in
e the SF
d a
e the SF-
a
-3
sample qu
and
sample qu
E-
n
-PRO P
n a
PRO P
applicatio
O Physical
tion
O Physical
nstrumen
cati
nstrumen
onse scale
plica
onse scale
FATIGU
ppl
FATIGU
sical fatig
app
ical fatig
UE
UE


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 85 of 202
The descriptive system comprises 5 dimensions: mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight 
problems, moderate problems, severe problems, and extreme problems. The study participant is 
asked to indicate his/her health state by ticking the box next to the most appropriate statement in 
each of the 5 dimensions. This decision results in a 1-digit number that expresses the level 
selected for that dimension. The digits for the 5 dimensions can be combined into a 5-digit 
number that describes the study participant’s health state.
The EQ-VAS records the study participant’s self-rated health on a vertical visual analogue scale, 
where the endpoints are labelled ‘The best health you can imagine’ and ‘The worst health you 
can imagine’. The VAS can be used as a quantitative measure of health outcome that reflect the 
study participant’s own judgment.
Study participants will complete the EQ-5D-5L questionnaire according to the Schedule of 
Activities (see Section 1.3). The EQ-5D-5L sample questionnaire is available in Appendix 16, 
Section 10.16.
8.1.3.5
PGI-S
The PGI-S is a single-state, self-report measure that rates a study participant's severity of a 
specific condition. The PGI-S is a 5-point scale depicting a study participant's rating of overall 
symptoms (“none,” “mild,” “moderate,” “severe,” or “very severe”). 
The PGI-S sample questionnaire is available in Appendix 17, Section 10.17.
8.1.3.6
PGI-C
The PGI-C is a single-state, self-report measure that reflects a study participant's belief about the 
efficacy of treatment for a specific condition. The PGI-C is a 7-point scale depicting a study 
participant's rating of overall improvement (“very much improved,” “much improved,” 
“minimally improved,” “no change,” “minimally worse,” “much worse,” or “very much worse”).
The PGI-C sample questionnaire is available in Appendix 18, Section 10.18.
8.2
Safety assessments
Planned time points for all safety assessments are provided in the Schedule of Activities 
(Section 1.3).
8.2.1
Physical examination
A full physical examination will include, at a minimum, assessments of general appearance; 
ear, nose, and throat; eyes, hair, and skin; assessments of the cardiovascular, respiratory, GI, 
neurological, musculoskeletal, and hepatic systems; and mental status. 
A short physical examination will include, at a minimum, assessments of general appearance; 
ear, nose, and throat; skin, respiratory, GI, and neurological systems..
For full and short physical examinations, investigators should pay special attention to clinical 
signs related to previous serious illnesses as well as signs and symptoms of infections.
Clinically relevant findings or worsening of previous findings will be recorded as AEs.
PUBLIC COPY
ates 
Y
ates 
picting a
PY 
picting a
e,” or “v
OP
e,” or “v
e in App
C CO
e in App
port mea
UBL
port mea
fic condi
PUB
fic condi
mprove
PU
mprove
P
ment cannot be used to support any marketing authorization 
e scale,
hori
e scale,
alth you
tho
alth you
at reflect t
aut
at reflect t
he Sched
ting
he Schedu
g
u
able in Ap
ketin
able in Ap
dy partici
y m
dy partici
study par
any
study par
ry severe
t a
ry severe
endix 17, 
port
endix 17, 
ure that r
su
ure that r
ion. The P
to s
ion. The P
men
d
ment (“ve
d to
t (“ve
,” “minim
sed
,” “minim
re is avail
us
re is avail
sessme
be 
sessme
r all safety
not 
r all safety
Physical
can
Physical
ical exam
nt c
ical exam
nt
, and thro
men
, and thro
This docum
logical, m
me
logical, m
short ph
ocu
short ph
oc
ear, nose
doc
ear, nose
For 
s d
For 
s
s
s
ication and any extensions or variations thereof.
the
f
the
ule of 
ere
ule of 
ppendix 1
ther
ppendix 1
ipant's sev
atio
ipant's sev
rticipant's
riat
rticipant's
e”). 
va
e”). 
Section
or v
Section 1
reflects a 
ion
reflects a 
PGI
nsi
PGI-
si
-C is 
sio
C is 
ery much 
ens
ery much 
mally wor
xte
mally wor
lable in A
y ex
lable in A
ents
any
ents
ty assessm
d a
ty assessm
l examin
n a
l examin
mination
atio
mination
atio
oat; eyes, 
cat
oat; eyes, 
appli
musculosk
plica
musculosk
hysical ex
app
hysical ex
app
and thr
ap
and thr


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 86 of 202
8.2.2
Vital signs
Oral, tympanic, or axillary temperature, pulse rate, and BP will be assessed.
Blood pressure (systolic and diastolic) and pulse rate measurements should be preceded by at 
least 5 minutes of rest for the study participant in a quiet setting without distractions (eg, 
television, cell phones). All measurements will be assessed in a sitting position with a completely 
automated device. Manual techniques will be used only if an automated device is not available.
All vital signs should be taken before any blood sampling.
On dosing days, for the first 2 weeks, vital signs will be measured prior to IMP administration, at 
the end of the infusion, and 4 hours after the end of the infusion. For the next 3 visits, vital signs 
will be measured prior to IMP administration, at the end of infusion, and 1 hour after the end of 
infusion. From Week 6, vital signs will be measured prior to IMP administration, at the end of 
the infusion, and 15 minutes after the end of infusion. At nondosing visits, vital signs need only 
to be taken once during the visit. In case of dose increase, vital signs will be measured prior to 
IMP administration, at the end of infusion, and 1 hour after the end of infusion for the next 
2 infusions. In case of an untoward event, additional vital signs (unscheduled assessment) should 
be taken at the discretion of the investigator and post-observation time can be extended. These 
recommendations are applicable for dosing at site and at home.
8.2.3
Electrocardiograms
A 12-lead ECG will be obtained as outlined in the Schedule of Activities (see Section 1.3) using 
an ECG machine that automatically calculates the heart rate and measures pulse rate, QRS, QT, 
and QTc intervals.
Central reading of ECGs will be performed but for the assessment of the ECG during the visit, 
the assessment of the investigator or designee will be used to determine eligibility and 
continuation in the study.
All ECG recordings should be taken prior to blood collection for assessment of laboratory 
parameters, with the study participant resting in the supine position for at least 5 minutes before 
the recording.
8.2.4
Clinical safety laboratory assessments
See Appendix 2, Section 10.2 for the list of clinical laboratory tests to be performed and to the 
Schedule of Activities (Section 1.3) for the timing and frequency.
The investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the eCRF. The 
laboratory reports must be filed with the source documents. Clinically significant abnormal 
laboratory findings are those which are not associated with the underlying disease, unless judged 
by the investigator to be more severe than expected for the participant's condition.
All laboratory tests with values considered clinically significantly abnormal during participation 
in the study should be repeated until the values return to normal or Baseline or are no longer 
considered clinically significant by the investigator or Medical Monitor.
If such values do not return to normal/Baseline within a period of time judged reasonable by the 
investigator, the etiology should be identified, and the sponsor notified.
PUBLIC COPY
obs
Y
obs
and at ho
PY 
and at ho
d in the 
C C
d in the 
culates t
LIC 
culates t
perform
PUB
perform
tor or d
PU
tor or d
ment cannot be used to support any marketing authorization 
y
e.
i
e.
istration, 
utho
istration, 
ts, vital si
aut
ts, vital si
after the e
g a
after the e
tion, at the
ting
tion, at the
vital sign
ketin
vital sign
ill be mea
rke
ill be mea
of infusion
ark
of infusion
unschedul
ma
unschedul
on time c
y m
on time c
me.
an
me.
Schedule o
po
Schedule o
he heart ra
upp
he heart ra
ed but for
to s
ed but for
esignee w
d to
esignee w
taken prio
us
taken prio
articipant 
be u
articipant 
cal safety
not
cal safety
Section
ann
Section 1
n
1
ctivities (
t ca
ctivities (
tigator mu
ent 
tigator mu
ly relevan
men
ly relevan
This docu
ratory rep
um
ratory rep
aboratory 
ocu
aboratory 
by the in
doc
by the in
All 
s d
All 
i
s
i
lication and any extensions or variations thereof.
signs
f.
signs
end of 
eof
end of 
he end of 
ereo
he end of 
ns need o
her
ns need o
asured pri
th
asured pri
n for the n
ns t
n for the n
led assess
ions
led assess
can be ext
atio
can be ext
of Activit
or 
of Activit
ate and m
s o
ate and m
r the asses
nsio
r the asses
will be use
ens
will be use
or to bloo
y ex
or to bloo
t resting in
ny 
t resting in
ty labora
nd 
ty labora
0.2
a
0.2 for th
an
for th
(Section
on 
Section 1
ust review
atio
ust review
nt change
lica
nt change
app
ports mus
plic
ports mus
y findings 
app
findings 
estigat
ap
estigat


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 87 of 202
All protocol-required laboratory assessments, as defined in Appendix 2, Section 10.2, must be 
conducted in accordance with the laboratory manual and the Schedule of Activities.
If laboratory values from nonprotocol specified laboratory assessments performed at the 
institution’s local laboratory require a change in participant management or are considered 
clinically significant by the investigator (eg, SAE or AE or dose modification), then the results 
must be recorded in the eCRF.
8.2.5
Assessment and management of TB and TB risk factors
Precautions are being taken within this protocol to monitor the risk of TB infection in this study 
(see Section 5.2, Exclusion Criterion 9). Any presumptive diagnosis or the diagnosis of a TB 
infection is a reportable event. Assessment and management of TB and TB risk factors should 
follow local or national guidelines. 
8.2.5.1
Tuberculosis assessment
Monitoring for TB during the study
Study participants will be monitored for signs/symptoms of TB using routine pharmacovigilance 
measures for AEs. Study participants reporting AEs related to signs/symptoms of TB will be 
evaluated for LTB and active TB according to the local medical practice guidelines.
Confirmed LTB, active TB, and NTMBI must be reported to UCB immediately regardless of 
seriousness using the SAE Report Form. Additional information received by the investigator 
should be provided within 24 hours of awareness.
Once withdrawn from study treatment, study participants should return for the EW and complete 
all EOS assessments.
TB signs and symptoms questionnaire
Study participants will be evaluated both for signs and symptoms of latent or active TB infection 
and for risk factors for exposure to TB using the TB questionnaire (Appendix 19, Section 10.19) 
as indicated in the Schedule of Activities (Section 1.3).
The TB questionnaire should be completed accurately and filed as a critical source document. 
The questionnaire will assist with the identification of participants who may require therapy for 
TB.
A “Yes” response to any of the questions in the TB questionnaire during the study may trigger 
further assessments to determine if the participant has either LTB infection or active TB 
infection. As an example, a participant who answers “Yes” at Screening to the question 
 
 should not be allowed into the study 
pending further assessments (including TB specialist consult).
8.2.5.2
Tuberculosis management
In line with the World Health Organization (WHO) and the Centers for Disease Control and 
Prevention (CDC) guidelines, UCB has adopted the following definitions for latent TB, active 
TB and non-tuberculosis mycobacterium infection for the purposes of its clinical trials.
PUBLIC COPY
late
Y
late
ocal me
PY 
ocal me
be repor
COP
be repor
ditional 
CO
ditional 
areness
C C
areness
nt, study 
BLIC
nt, study 
uestio
PU
uestio
used to support any marketing authorization 
his study 
tho
his study 
s of a TB
auth
s of a TB
actors sho
g au
actors sho
ing routin
ma
ing routin
signs/sym
y m
signs/sym
ical pract
any
ical pract
ed to UCB
rt a
ed to UCB
nformatio
port
nformatio
participan
sup
participan
nnaire
d to
nnaire
d both for
sed
d both for
e to
u
e to
ment cannot be
TB us
us
TB us
of Activit
be u
of Activit
ould be co
ot b
ould be co
l assist wi
not
l assist wi
nse to any
t ca
nse to any
ssments to
nt c
ssments to
. As an ex
en
. As an ex
This docum
pending f
docu
pending f
8.2.5
s do
8.2.5
In
s
In
me
cum
extensions or variations thereof.
ould 
of
ould 
ne pharm
ons
ne pharm
mptoms of
atio
mptoms of
tice guide
riat
tice guide
B immed
var
B immed
on receive
or v
on receive
nts should
ons
nts should
r signs an
xte
r signs an
ication and any e
sing the T
ex
sing the T
ties (
ny
ties (Secti
y e
Secti
completed
d an
completed
with the id
nd a
with the id
y of the q
on a
y of the q
to determi
tion
to determi
xample, a
cati
xample, a
appli
urther as
app
urther as
plica
ppl


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 88 of 202
Latent TB
Latent TB infection is defined an infection by Mycobacterium tuberculosis with:
•
a positive IGRA test or 2 indeterminate IGRA tests AND
•
a chest x-ray [or other imaging]) negative for TB infection AND
•
the absence of signs, symptoms (eg, evidence of organ specific involvement, or physical 
findings) suggestive of TB infection.
Active TB and nontuberculous mycobacterium infection
A clinically verified case of TB meets the following criteria:
•
a positive Tuberculin Skin Test (TST) or positive IGRA for Mycobacterium tuberculosis
•
other signs and symptoms compatible with TB (eg, abnormal chest radiograph, abnormal 
chest computerized axial tomography scan or other chest imaging study, or other clinical 
evidence of active disease)
Nontuberculous mycobacterium infection (NTMBI) is defined as a clinical infection caused by 
mycobacterial species other than those belonging to the Mycobacterium tuberculosis complex. 
Study participants who develop active TB or NTMB infection during the study (conversion 
demonstrated by IGRA) must be withdrawn from the study. The participant must be permanently 
discontinued from IMP and the EW Visit must be scheduled as soon as possible, but no later than 
the next scheduled visit. Participants should be encouraged to enter the SFU period, attend 
Visit 29, and keep the EOS Visit as specified by the protocol. Treatment for active TB or NTMB 
should be started immediately based on local guidelines.
Confirmed active TB is always considered an SAE. UCB’s process requires that this must be 
captured on an SAE report form and provided to UCB in accordance with SAE reporting 
requirements. Follow-up reports should be completed as per protocol requirement until such time 
as the TB infection resolves (Appendix 3, Section 10.3).
LTB infection, active TB, or other NTMB identified during study
During TP0006, study participants who develop evidence of LTB infection, active TB, or NTMB 
infection will be referred to an appropriate TB specialist (pulmonologist or infectious disease 
specialist) for further evaluation. These study participants will not be permitted to enroll into 
TP0004. Study participants diagnosed with active TB or LTB infection should receive 
appropriate TB treatment or prophylaxis therapy. The study participant should be transferred to 
the care of their physician and managed according to the standard of care.
If infection with NTMB is identified during the study, the same procedure as for active TB 
acquired during the study and compliant TB treatment shall be followed.
Follow-up information of suspected and confirmed TB cases should be provided to UCB at least 
after 3, 9, and 12 months of the start date of anti-TB treatment, including hematological and 
biochemical safety parameters, chest x-ray evolution data, and TB diagnostic procedures used to 
follow up and confirm recovery of TB.
BLIC COPY
the 
PY
the My
Y 
My
MB infec
OPY
MB infec
om the s
COP
om the s
ust be sc
C CO
ust be sc
uld be en
IC C
uld be en
ecified b
BLIC
ecified b
PUB
d on loc
UBL
d on loc
conside
PU
conside
 and
P
 and
to support any marketing authorization 
m tubercu
ng a
m tubercu
iograph, a
ketin
iograph, a
tudy, or ot
rke
tudy, or ot
s a clinica
y m
s a clinica
bacterium
ny 
bacterium
tion durin
any
tion durin
udy. The p
rt a
udy. The p
heduled a
port
heduled a
couraged 
ppo
couraged 
y the prot
supp
y the prot
nnot be used t
al guid
o su
al guidelin
su
elin
red an SA
d to
red an SA
provided 
ed 
provided 
hould be c
use
hould be c
ppendix 3
e us
ppendix 3
B, or oth
be
B, or oth
participan
not 
participan
erred to a
nno
erred to a
This document ca
rther evalu
can
rther evalu
y particip
t ca
y particip
 TB treatm
nt c
 TB treatm
of their p
men
of their p
nfection w
um
nfection w
cquired d
ocu
cquired d
Follow
do
Follow
afte
s d
afte
b
s
b
sions or variations thereof.
ulosis
reo
ulosis
abnormal
her
abnormal
other clini
the
other clini
al infectio
tion
al infectio
m
i
m tubercu
iatio
tubercu
ng the stud
aria
ng the stud
participan
var
participan
as soon as
or v
as soon as
d to enter t
s or
d to enter t
tocol. Tre
ns 
tocol. Tre
and any exten
nes.
io
nes.
AE. UCB’
nsi
AE. UCB’
d to UCB i
ten
d to UCB i
complete
exte
complete
3, Section
y ex
3, Section
her NTM
any
her NTM
nts who d
d a
nts who d
an approp
and
an approp
application a
uation. Th
n an
uation. Th
pants diag
ion 
pants diag
tment or p
atio
tment or p
physician 
icat
physician 
with NTM
pplic
with NTM
during the
app
during the
nfo
a
nfo


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 89 of 202
8.2.6
Splenectomized study participants
Study participants who have previously undergone a splenectomy will be included in the study 
provided they do not meet the protocol defined exclusion criteria (Section 5.2) in order to 
optimize protection against OPSI. Adequate vaccination for all splenectomized participants 
within 4 years prior to enrollment is preferred. Splenectomized study participants should be 
vaccinated against the encapsulated organisms such as S. pneumoniae, N. meningitidis, and H. 
influenzae (as per local/or a national guidance, as applicable) as evidenced from personal 
immunization records. Study participants, who are due to receive a booster, can be screened after 
they have received the required booster. However, if the next booster is due during the study, to 
avoid the treatment interruption, it can be given ahead of the 5-year schedule if needed, and prior 
to enrollment.
Splenectomized study participants without any prior vaccination against one or all of the above-
mentioned bacteria and who are willing to participate in the study, will have to undergo a 
Prolonged Screening Period after the signing of ICF. During this period, splenectomized study 
participants will receive the required vaccinations against the above-mentioned bacteria (see 
Table 1-3). 
Splenectomized participants can be enrolled in the study if they have documentation of previous 
vaccination within the past 4 years for S. Pneumoniae, H. influenzae, and N. meningitidis (as per 
local /national guidance) or have completed the required vaccinations during the Prolonged 
Screening Period.
Additionally, for the whole duration of the study, splenectomized participants will be required to 
carry a card indicating they have undergone splenectomy and may be at increased risk of 
infection particularly with encapsulated organisms. Splenectomized study participants should 
have a prophylactic antibiotic available or take already an antibiotic as per local guidance.
Antibody titers against S. pneumoniae, N. meningitidis, and H. influenzae in splenectomized 
study participants will be collected predose at W1 (Baseline), W3, W25 (EW Visit), and at the 
EOS Visit.
Antibody titers against tetanus will be collected in all participants at W1 (Baseline), W3 
(predose), W25 (EW Visit), and EOS Visit.
8.3
Adverse events
The definitions of an AE or SAE can be found in Appendix 3, Section 10.3.
Adverse events will be reported by the study participant (or, when appropriate, by a caregiver, 
surrogate, or the participant's legally authorized representative).
The investigator and any designees are responsible for detecting, documenting, and recording 
events that meet the definition of an AE or SAE and remain responsible for following up AEs 
that are serious, considered related to the study treatment or study procedures, or that caused the 
participant to discontinue study treatment or TP0006 (see Section 7).
In order to protect the blind, the events of hypogammaglobulinemia should not be captured as an 
AE in the eCRF. 
PUBLIC COPY
tudy if
PY 
tudy if
oniae, H.
OPY
oniae, H.
he requir
COP
he requir
the stud
LIC
the stud
dergone 
BLI
dergone 
ulated o
UB
ulated o
availabl
PU
availabl
ument cannot be used to support any marketing authorization 
ed after 
hori
ed after 
study, to
tho
study, to
ded, and p
aut
ded, and p
or all of t
ting
or all of t
ve to und
ketin
ve to und
d, splenec
rke
d, splenec
mentione
mark
mentione
hey have d
ny 
hey have d
influenza
t any
influenza
d vaccina
ort a
d vaccina
y, splenec
upp
y, splenec
splenectom
sup
splenectom
rganisms. 
to s
rganisms. 
or take a
d to
or take a
iae
se
iae,
se
, N. me
sed
N. me
ted predos
use
ted predos
tanus 
ot b
tanus wil
b
wil
Visit), and
not 
Visit), and
verse e
ann
verse e
ns of an A
t ca
ns of an A
events wil
ent
events wil
ate, or the
me
ate, or the
This docu
he investig
cum
he investig
events th
doc
events th
that ar
s do
that ar
par
s 
par
plication and any extensions or variations thereof.
prio
f
prio
the above
ereo
the above
dergo a 
ther
dergo a 
ctomized 
s th
ctomized 
ed bacteri
ns 
ed bacteri
document
iati
document
ae, and N.
aria
ae, and N.
ations dur
va
ations dur
ctomized p
ns o
ctomized p
my and m
ons
my and m
 Splenect
sio
 Splenect
already an
ens
already an
meningitidi
xte
meningitidi
ose at W1 
ex
ose at W1 
ll be colle
d any
ll be colle
d EOS Vi
nd a
d EOS Vi
events
an
events
AE or SAE
ion 
AE or SAE
ill be repo
cati
ill be repo
e particip
lica
e particip
app
gator and
ppl
gator and
at meet t
ap
t meet t
ous
a
ous


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 90 of 202
8.3.1
Time period and frequency for collecting AE and SAE information
All SAEs and AEs will be collected from the time of signing the ICF until the EOS Visit at the 
time points specified in the Schedule of Activities (Section 1.3).
All SAEs will be recorded and reported to UCB or designee within 24 hours, as indicated in 
Appendix 3, Section 10.3. The investigator will submit any updated SAE data to UCB within 
24 hours of it being available.
The investigator is specifically requested to collect and report to UCB (or its representative) any 
SAEs (even if the investigator is certain that they are in no way associated with the IMP), up to 
30 days from the end of the study for each participant, and to also inform participants of the need 
to inform the investigator of any SAE within this period. Serious AEs that the investigator thinks 
may be associated with the IMP must be reported to UCB regardless of the time between the 
event and the end of the study.
The method of recording, evaluating, and assessing causality of AE and SAE and the procedures 
for completing and transmitting SAE reports are provided in Appendix 3, Section 10.3.
8.3.2
Method of detecting AEs and SAEs
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences.
8.3.3
Follow-up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts. All SAEs and nonserious AEs of special interest and AEs of special 
monitoring (AESM) (as defined in Sections 8.3.7 and Section 8.3.8, respectively), will be 
followed until resolution, stabilization, the investigator determines that it is no longer clinically 
significant, the event is otherwise explained, or the participant is lost to follow up (as defined in 
Section 7.3). Further information on follow-up procedures is provided in Appendix 3, 
Section 10.3.
8.3.4
Regulatory reporting requirements for SAEs
Prompt notification by the investigator to the sponsor of a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of study participants and the safety of a 
IMP under clinical investigation are met.
UCB has a legal responsibility to notify both the local regulatory authority and other regulatory 
agencies about the safety of a IMP under clinical investigation. UCB will comply with country-
specific regulatory requirements relating to safety reporting to the regulatory authority, 
Institutional Review Board (IRB)/Independent Ethics Committee (IEC), and investigators.
Investigator safety reports must be prepared for suspected unexpected serious adverse reactions 
according to local regulatory requirements and sponsor policy and forwarded to investigators as 
necessary.
An investigator who receives an investigator safety report describing a SAE or other specific 
safety information (eg, summary or listing of SAEs) from UCB will review and then file it along 
with the IB and will notify the IRB/IEC, if appropriate according to local requirements.
PUBLIC COPY
ting AE
PY 
ting AE
is the pr
OPY
is the pr
SAEs
C C
SAEs
nvestiga
BLIC
nvestiga
SAEs an
UBL
SAEs an
d in Sect
PU
d in Sect
izatio
P
izatio
t be used to support any marketing authorization 
e
h
e) any 
horiz
) any 
P), up to
tho
P), up to
s of the n
auth
s of the n
vestigator 
g au
vestigator 
me between
ng 
me between
d SAE and
rke
d SAE and
dix
ma
dix 3, Sec
ark
3, Sec
and/or SA
any
and/or SA
eferred me
t an
eferred me
or is requ
sup
or is requ
d nonserio
o s
d nonserio
ons
d t
ons 8.3.7
to
8.3.7
n, the inve
ed t
n, the inve
explained
sed
explained
on on follo
us
on on follo
This document cannot 
ory repo
ot b
ory repo
by the inv
nno
by the inv
thical resp
ann
thical resp
nical inve
t ca
nical inve
a legal res
ent 
a legal res
es about th
men
es about th
ific regula
um
ific regula
nstitutiona
ocu
nstitutiona
Investi
do
Investi
acco
s d
acco
n
any extensions or variations thereof.
nee
f
nee
thinks
of.
thinks
en the
reo
en the
d the proc
th
d the proc
ction
ns
ction 10.3
s t
10.3
AEs. Ope
riat
AEs. Ope
method to i
vari
method to i
uir
o
uired to pr
ons
ed to pr
ous AEs o
sion
ous AEs o
and Sect
nsi
and Sect
vestigator 
ten
vestigator 
d, or the p
exte
d, or the p
ow
y e
ow-
e
-
application and a
up pr
y ex
up pr
orting re
d an
orting re
vestigator
and
vestigator
p
n
ponsibilit
n an
onsibilit
estigation 
on 
estigation 
sponsibili
atio
sponsibili
he safety 
lica
he safety 
latory req
plic
latory req
al Review
app
al Review
r saf
a
r saf


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 91 of 202
8.3.5
Pregnancy
Details of all pregnancies in female participants and, if indicated, female partners of male 
participants will be collected after the start of study treatment and until 3 months after dosing.
If a pregnancy is reported, the investigator must immediately inform UCB within 24 hours of 
learning of the pregnancy and should follow the procedures outlined in Appendix 4, 
Section 10.4.
The study participant must be withdrawn from the study and permanently discontinued from 
IMP as soon as the pregnancy is known (by positive pregnancy test), and the following should be 
completed:
•
The study participant should return for the EW visit and complete the SFU Period.
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, or ectopic pregnancy) are considered SAEs.
In case of confirmed pregnancy in TP0006, the study participant cannot enroll into TP0004.
8.3.6
Anticipated serious adverse events
The following anticipated SAEs are anticipated to occur in the population studied in this protocol 
at some frequency that is independent of drug exposure (Table 8-1).
This list does not change the investigator’s obligation to report all SAEs (including anticipated 
SAEs) as detailed in Section 8.3.1 and Appendix 3, Section 10.3.
Table 8-1:
Anticipated serious adverse events for ITP population
Anemia
Hemorrhagic events
Fatigue
Thrombocytopenia
8.3.7
Adverse events of special interest
An AE of special interest is any AE that a regulatory authority has mandated be reported on an 
expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the 
administration of a UCB product/compound. 
Potential Hy’s Law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN total bilirubin in 
the absence of ≥2xULN ALP, with no alternative explanation for the biochemical abnormality, 
must ALWAYS be reported to UCB as an AE of special interest (ie, without waiting for any 
additional etiologic investigations to have been concluded). Follow-up information should then 
be reported if an alternative etiology is identified during investigation and monitoring of the 
participant.
See Appendix 6, Section 10.6 for further information on liver safety monitoring.
8.3.8
Adverse events of special monitoring
For rozanolixizumab, AESM that require immediate reporting (within 24 hours regardless of 
seriousness) to UCB are:
•
Severe headache
PUBLIC COPY
occur in
PY 
occur in
posure (
OPY
posure (
bligation
CO
bligation
ppendix 
C C
ppendix 
ious ad
BLIC
ious ad
BL
PU
ent cannot be used to support any marketing authorization 
om
ho
om
should be
tho
should be
Period.
g a
Period.
irth, cong
ting
irth, cong
not enroll
ark
not enroll
he popula
any 
he popula
Table
t a
Table 8
an
8-1
n
1)
n to report
ort
n to report
, Section
ppo
, Section
verse ev
sup
verse ev
Hemorr
to s
Hemorr
s
t
Thr
 t
Thr
to
ed t
d
ts of spe
us
ts of spe
s any AE t
be 
s any AE t
ess of the 
ot b
ess of the 
CB produ
not
CB produ
aw, defi
ann
aw, define
n
ne
f ≥2xULN
t ca
f ≥2xULN
AYS be r
nt c
AYS be r
This docume
al etiologi
men
al etiologi
ported if a
ume
ported if a
rticipant.
cum
rticipant.
See App
doc
See App
8.3
s d
8.3
ation and any extensions or variations thereof.
genital
here
genital
l into TP0
ns t
l into TP0
ation stud
riat
ation stud
).).
o
all
r
all SAEs
r v
SAEs
r
10.3
or
10.3.
o
.
vents for
ons 
vents for
rhagic even
sio
rhagic even
ion
rombocyto
ten
rombocyto
ns
te
ecial int
y ex
ecial int
that a reg
any
that a reg
seriousne
d an
seriousne
uct/compo
nd 
uct/compo
ed as ≥3x
n an
ed as ≥3x
N ALP, wi
on 
N ALP, wi
reported t
atio
reported t
applica
gic investi
cat
gic investi
an alterna
plic
an alterna
ndix 6,
ap
ndix 6,


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 92 of 202
•
Severe GI disorders (ie, diarrhea, abdominal pain, vomiting)
•
Opportunistic infection
•
Arterial and venous thrombotic and thromboembolic events
An AESM is not necessarily a serious adverse event unless one of the seriousness criteria 
defined in the Appendix 3 (Section 10.3) is met. All AESM will follow the SAE recording and 
reporting procedures as indicated in Appendix 3, Section 10.3.
In case of severe headache or serious headache (regardless of severity), the headache 
questionnaire (Appendix 20, Section 10.20) must be completed. The questionnaire should also be 
completed in case of moderate headache although moderate headache is not considered an 
AESM. Additional procedures for management of headaches are provided in Appendix 22, 
Section 10.22.
Procedures for the management of diarrhea are provided in Appendix 23, Section 10.23.
Although hypersensitivity reactions including infusion-related reactions and anaphylaxis are not 
classified as AESM, these AEs will be monitored by the investigators. If such an event is 
suspected it should be managed according the guidance provided in Appendix 24, Section 10.24. 
In case of suspected anaphylaxis, the Sampson’s Criteria (Sampson et al, 2006) (Appendix 21, 
Section 10.21) should be completed. All hypersensitivity reactions will be recorded and reported 
as per the AE reporting procedure outlined in Appendix 3, Section 10.3.
8.3.9
Treatment-emergent adverse events
Treatment-emergent AEs are defined as AEs starting after the time of first IMP administration up 
to and including 8 weeks after the final dose.
8.3.10
COVID-19 vaccination
Coronavirus disease 2019 vaccines will be recorded on the concomitant medication eCRF page 
(Section 6.4.1). In the AE eCRF page, there is the possibility to assess causality to the IMP and 
to any concomitant medication. If an AE is considered related to COVID-19 vaccine, causality
assessment should be entered on the AE eCRF. Note that in this case, the national
recommendation for reporting an AE related to COVID-19 vaccines should be followed. If an 
AE is the result of an interaction of a COVID-19 vaccine with the IMP in the clinical study then 
the causal association should be for both IMP and COVID-19 vaccine. In case of a seriousness 
criteria, the Suspected Unexpected Serious Adverse Reaction process will be followed.
8.4
Safety signal detection
Selected data from this study will be reviewed periodically to detect as early as possible any 
safety concern(s) related to the IMP so that investigators, clinical study participants, regulatory 
authorities, and IRBs/IECs will be informed appropriately and as early as possible.
In addition, an unblinded IDMC will periodically review and monitor safety data from this study 
and advise UCB. Details are provided in the IDMC Charter.
The Study Physician or medically qualified designee/equivalent will conduct an ongoing review 
of SAEs and perform ongoing SAE reconciliations in collaboration with the PS representative.
PUBLIC COPY
nce pro
PY 
nce pro
Criteria 
OPY
Criteria 
sensitivi
COP
sensitivi
in
C
in Appen
C CO
Appen
advers
LIC 
advers
ed as AE
UBL
ed as AE
he final d
PUB
he final d
cina
P
cina
nnot be used to support any marketing authorization 
i
hould also
auth
hould also
idered an 
g au
idered an 
Appendix 
ng 
Appendix 
3, Section
rke
3, Section
tions and 
mar
tions and 
gators. If s
y m
gators. If s
ded in Ap
ny 
ded in Ap
Sampson 
any
Sampson 
ty reaction
rt a
ty reaction
dix
po
dix 3, Sec
port
3, Sec
e events
upp
e events
s starting 
o su
s starting 
ose.
to
ose.
on
ed
on
es will be
use
es will be
RF page, t
e u
RF page, t
ion. If an
be 
ion. If an
tered on t
ot b
tered on t
reporting 
not
reporting 
cument can
an interac
nn
an interac
iation sho
can
iation sho
Suspected
nt c
Suspected
Sa
n
Sa
cted data 
um
cted data 
This doc
afety conc
ocu
afety conc
authorit
doc
authorit
In a
s d
In a
s
d any extensions or variations thereof.
o b
f
o b
22,
re
22,
n 10.23
th
10.23.
d anaphyla
ons
d anaphyla
such an e
tion
such an e
ppendix 2
iati
ppendix 2
n et al, 200
aria
n et al, 200
ns will be
va
ns will be
ction
or v
ction 10.3
v
10.3
s
after the 
ion
after the 
e recorded
ext
e recorded
there is 
y e
there is th
e
th
n AE is co
any
n AE is co
the AE eC
d an
the AE eC
nd 
a
n
a
pplication a
n AE re
nd 
n AE re
ction of a
an
ction of a
ould be fo
n a
ould be fo
d Unexpec
tion
d Unexpec
afety sig
icat
afety sig
a from this
pplic
a from this
ap
ncern(s) re
app
cern(s) re
s, and I
ap
s, and I


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 93 of 202
As appropriate for the stage of development and accumulated experience with the IMP, 
medically qualified personnel at UCB may identify additional safety measures (eg, AEs, vital 
signs, laboratory, or ECG results) for which data will be periodically reviewed during the course 
of the study.
8.5
Treatment of overdose
For this study, any dose increase of 10% or greater than the assigned dose for each administered 
dose of IMP will be considered an overdose, irrespective of the weight tier band. Overdose 
events are only considered AEs or SAEs if there are associated clinical signs and symptoms or if 
the act of taking the excess IMP itself is an AE or SAE (eg, suicide attempt).
UCB does not recommend specific treatment for an overdose.
In the event of an overdose, the investigator or treating physician should:
1. Contact the Medical Monitor immediately.
2. Closely monitor the participant for any AE/SAE and laboratory abnormalities for at least
5 days. 
3. Obtain a plasma sample for PK analysis within 3 days from the date of the final dose of 
study treatment if requested by the Medical Monitor (determined on a case-by-case 
basis).
4. Document the quantity of the excess dose as well as the duration of the overdose in the 
eCRF.
Decisions regarding dose interruptions or modifications will be made by the investigator in 
consultation with the Medical Monitor based on the clinical evaluation of the participant.
8.6
Pharmacokinetics and antidrug antibodies
Whole blood samples will be collected for measurement of plasma concentrations of 
rozanolixizumab and ADA as specified in the Schedule of Activities (Section 1.3). Blood 
samples may be collected at additional time points during the study if warranted and agreed upon 
between the investigator and the sponsor. Instructions for the collection and handling of 
biological samples will be provided in the laboratory manual for this study. The actual date and 
time (24-hour clock time) of each sample will be recorded.
Samples will be used to evaluate the PK of rozanolixizumab and ADA and may be used for 
establishing assay parameters (eg, ADA cut point setting and PK selectivity assessment). 
Samples collected for analyses of rozanolixizumab concentration may also be used to evaluate 
safety or efficacy aspects related to concerns arising during or after the study.
Participant confidentiality will be maintained. At visits during which only plasma samples for the 
determination of concentration of rozanolixizumab will be taken, 1 sample of sufficient volume 
can be used.
Drug concentration information that may unblind the study will not be reported to study sites or 
blinded personnel until the study has been unblinded.
Any changes in the timing or addition of time points for any planned study assessments must be 
documented and approved by the relevant study team member and then archived in the UCB and 
PUBLIC COPY
in 3
PY
in 3 da
Y 
da
al Monit
OPY
al Monit
ss dose a
C C
ss dose a
ons or m
UBL
ons or m
onitor b
PUB
onitor b
netic
P
netic
This document cannot be used to support any marketing authorization 
ed 
iz
ed 
oms or if 
thor
oms or if 
ory abnorm
ark
ory abnorm
from the 
ny 
from the 
or (determ
any
or (determ
s well as t
por
s well as t
odification
su
odification
sed on the
to s
sed on the
s and an
ed t
s and an
lected for
use
lected for
specified
e u
specified
at addition
be 
at addition
r and the s
ot b
r and the s
ill be prov
not
ill be prov
k time) o
ann
k time) o
be used to
t ca
be used to
g assay pa
nt c
g assay pa
collected
men
collected
y or e
um
y or effica
me
ffica
articipant
ocu
articipant
determi
doc
determi
can b
s d
can b
D
s
D
application and any extensions or variations thereof.
malities f
ns t
malities f
e date of t
iatio
e date of t
mined on a
aria
mined on a
the durati
or 
the durati
ons will be
ions
ons will be
he clinical
nsio
he clinical
ntidrug 
ten
ntidrug 
r measure
ext
r measure
d in the Sc
y e
d in the Sc
nal time p
any
nal time p
sponsor. I
d an
sponsor. I
vided in t
nd 
vided in t
of each sam
an
of each sam
o evaluate
on 
evaluate
arameters
atio
arameters
d for anal
cat
d for anal
acy aspect
plic
acy aspect
t confiden
app
t confiden
tion of
ap
tion of


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 94 of 202
site study files but will not constitute a protocol amendment. The IRB/IEC will be informed of 
any safety issues that require alteration of the safety monitoring scheme or amendment of the 
ICF.
8.7
Pharmacodynamics
Venous blood samples will be collected at time points specified in the Schedule of Activities 
(Section 1.3) for measurement of:
•
Serum IgG and IgG subclasses concentrations
•
Serum IgA, IgE, and IgM concentrations
•
Serum ITP-specific autoantibodies
For all PD assessments, blood samples will be collected predose at the Baseline Visit (Day 1). 
Instructions pertaining to sample collection, processing, storage, labeling, and shipping are 
provided in the laboratory manual for this study. Results of the ITP-specific autoantibodies 
analyses will not be outlined in the Clinical Study Report for this study.
8.8
Genetics
8.8.1
Pharmacogenomics
Blood sample for DNA and RNA biomarkers will be collected as specified in the Schedule of 
Activities (Section 1.3) from study participants who have consented to participate in the 
pharmacogenomics sub-study. This sampling is optional for study participants and requires a 
separate informed consent. A decision not to consent does not exclude the study participant from 
the study. 
If not used immediately, these samples will be stored at -80°C for up to 20 years for later 
exploratory analyses. Any exploratory biomarker or genomic analysis will only ever be related to 
the exploration of the cause, progression, and appropriate treatment of ITP.
The nature and format of these tentative additional analyses will be determined at a later time. 
Details on the collection, storage, preparation, and shipping of samples will be presented in the 
laboratory manual provided separately. Instructions pertaining to sample collection, processing, 
storage, labeling, and shipping are provided in the laboratory manual for this study. Detailed 
information on sample analyses will be provided in a bioanalytical report. Results of the DNA 
and RNA biomarker analyses will not be outlined in the Clinical Study Report for this study. 
8.8.2
Immunology
Blood samples for immunological testing are required and will be collected from all study 
participants in this study predose, as specified in the Schedule of Activities (Section 1.3) for 
measurement of:
•
Serum complements (C3, C4)
•
Plasma complements (C3a, C5a)
Serum complements (C3, C4) and plasma complements (C3a, C5a) should be taken predose at 
Baseline (Day 1) and 4 hours postdose at Week 25 for all study participants. In participants who 
experience an infusion reaction or hypersensitivity reaction at the site, samples should also be 
PUBLIC COPY 
will be c
COP
will be c
ants who
C CO
ants who
pling is o
IC C
pling is o
n not to c
BLIC
n not to c
samples
PU
samples
rato
P
rato
cument cannot be used to support any marketing authorization 
ine Visit (
ting
ine Visit (
and shipp
ketin
and shipp
ecific auto
rke
ecific auto
udy.
ma
udy.
ollected as
rt a
ollected as
have cons
port
have cons
ptional fo
ppo
ptional fo
onsent do
supp
onsent do
will be sto
d to
will be sto
ry biomark
ed 
ry biomark
ression, an
use
ression, an
e tentativ
be u
e tentativ
torage, pr
t be
torage, pr
ided separ
ot b
ided separ
d shipping
no
d shipping
mple anal
ann
mple anal
arker ana
ca
rker ana
Imm
nt 
Imm
samples f
me
samples f
icipants
cum
icipants inin
This doc
measurem
ocu
measurem
•
d
•
Se
o
Se
•
s
•
application and any extensions or variations thereof.
(Day
ere
(Day 1). 
eo
1). 
ping are
ther
ping are
oantibodie
s th
oantibodie
s specifie
va
s specifie
nsented to 
or v
nsented to 
or study p
s or
or study p
oes not ex
ns 
oes not ex
tored at 
ns
tored at -8
rker or ge
ten
rker or ge
and approp
exte
and approp
ve addition
ny e
ve addition
reparation
any
reparation
arately. In
d a
arately. In
g are prov
nd 
g are prov
lyses will
an
lyses will
alyses wil
on a
alyses wil
munology
atio
munology
for immun
lica
for immun
in this stu
pplic
in this stu
ent of:
app
ent of:
om
a
om


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 95 of 202
taken 2 hours postevent and 4 hours postevent or otherwise as soon as possible but prior to the 
next dosing, as specified in the Schedule of Activities (Section 1.3).
Instructions pertaining to sample collection, processing, storage, labeling, and shipping are 
provided in the laboratory manual for this study.
8.9
Exploratory biomarkers
Collection of samples for exploratory biomarker research is also part of this study. 
Blood samples for biomarker research are required and will be collected from all study 
participants in this study. Exploratory biomarker samples should be taken predose at Baseline 
(Day 1) for all study participants. In study participants who experience severe and/or serious
headaches or and/or severe GI disorders (ie, abdominal pain, diarrhea, vomiting), samples should 
also be taken 4 hours postevent, or otherwise as soon as possible but prior to the next dosing, as 
specified in the Schedule of Activities (Section 1.3).
Protein and metabolites biomarkers such as but not limited to albumin, B-cell activating factor, 
and Circulating Immune Complexes may be measured to assess the effect of rozanolixizumab on 
exploratory biomarkers, and explore the relationship between protein, and metabolite biomarkers 
and cause, progression, and appropriate treatment of ITP.
If not used immediately, these samples will be stored at -80°C for up to 20 years for later 
exploratory analyses. Any exploratory biomarker will only ever be related to the exploration of 
cause, progression, and appropriate treatment of ITP. They may also be used to develop 
tests/assays including diagnostic tests related to rozanolixizumab and/or FcRn inhibitor and ITP.
The nature and format of these tentative additional analyses will be determined at a later time. 
Details on the collection, storage, preparation, and shipping of samples will be presented in the 
laboratory manual provided separately. Detailed information on sample analyses will be 
provided in a bioanalytical report.
8.10
Medical resource utilization and health economics
Medical Resource Utilization and Health Economics parameters are not evaluated in this study.
PUBLIC COPY 
Y
f ITP.
PY
f ITP.
tored at 
OP
tored at 
rker wil
CO
rker wil
ent of IT
C C
ent of IT
elated to
LIC 
elated to
ative ad
UBL
ative ad
e, prepar
PUB
e, prepar
paratel
PU
paratel
This document cannot be used to support any marketing authorization 
Baseline
uth
Baseline
or serious
aut
or serious
), samples
g a
), samples
the next d
ting
the next d
n, B
ar
n, B-
rk
-cell a
arke
cell a
e effect of
mar
e effect of
otein, and
y m
otein, and
80°C for 
t an
80°C for 
only ever
ort 
only ever
P. They m
ppo
P. They m
rozanolix
upp
rozanolix
ditional an
o su
ditional an
atation, and
to 
ion, and
y. Detailed
d t
y. Detailed
urce ut
us
urce ut
on 
b
on and H
be
and H
application and any extensions or variations thereof.
s
es should 
eof
es should
dosing, 
ereo
dosing, a
activating
s th
activating
f rozanoli
ons
f rozanoli
d metabol
tion
d metabol
up to 20 
vari
up to 20 
r be relate
r va
r be relate
may also b
or 
may also b
xizumab a
ns o
xizumab a
nalyses w
ion
nalyses w
d shipping
nsio
d shipping
d informa
tens
d informa
tilization
y ex
tilization
Health Eco
any
Health Eco


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 96 of 202
9
STATISTICAL CONSIDERATIONS
A description of statistical methods follows and will be described in more detail in the SAP.
9.1
Definition of analysis sets
•
Enrolled Set: All study participants who have signed the informed consent.
•
Randomized Set (RS): All enrolled study participants who were randomized. This is 
equivalent to the Intent-to-Treat Set.
•
Safety Set (SS): All randomized study participants who received at least one dose of IMP 
(partial or full). Analysis of this set will be according to the treatment the participants 
actually received and will be used for the demographic and safety analyses.
The analysis of the PD (excluding total IgG, and IgG subclasses) and immunologic variables 
will be performed on the SS. Selected outputs may be repeated for the PD Per-Protocol Set 
(PD-PPS). Further details will be provided in the SAP.
•
Full Analysis Set (FAS): Consists of all study participants randomized who have received at 
least one complete sc infusion of IMP, have a valid Baseline, and at least 1 valid 
post-Baseline platelet count measurement during Weeks 13-25.
•
Pharmacodynamic Per-Protocol Set (PD-PPS): A subset of the SS, consisting of those study 
participants who had no important protocol deviations potentially affecting the serum 
concentration of total IgG, as confirmed during a pre-analysis review of the data prior to 
database lock. Protocol deviations may not necessarily lead to total exclusion of a participant 
from the PD-PPS but may lead to exclusion of specific data.
•
Pharmacokinetic Per-Protocol Set (PK-PPS): A subset of the SS, consisting of those study 
participants who received at least 1 dose, had at least 1 valid PK measurement, and no 
important protocol deviations affecting the PK variable, as confirmed during a pre-analysis 
review of the data prior to database lock.
The RS will be the primary analysis set for efficacy analyses.
The PD-PPS will be used for the analysis of the total IgG, and IgG subclasses.
9.2
General statistical considerations
All analyses will be performed using SAS® version 9.2 or later (SAS Institute, Cary, NC, USA). 
Continuous variables will be summarized by visit (where applicable) with the statistics including 
the number of participants (n), mean, standard deviation (SD), median, minimum, and maximum.
Data listings containing all documented data and all calculated data will be generated.
Baseline will be the last non-missing data collected prior to the dose of IMP, and measurement-
specific Baseline values will be defined in the SAP.
Data handling conventions for data affected by COVID-19 will be detailed fully in the SAP.
UBLIC COPY
d B
Y
d B
g Week
PY 
g Week
PS): A su
COP
PS): A su
col devia
CO
col devia
ed durin
C C
ed durin
may not
LIC
may not
to ex
BL
to exclus
BL
clus
PU
col Set (P
PUB
col Set (P
t leas
P
t leas
d to support any marketing authorization 
of IMP
utho
of IMP
ipants
aut
ipants
munologi
ting
munologi
 PD Per
keti
 PD Per-P
domized w
ma
domized w
e, and at l
y m
e, and at l
13
an
13-
n
-25
ny
25.
y
.
bset of the
rt a
bset of the
tio
o
tions pote
ort
ns pote
g a pre
ppo
g a pre-
po
-an
o
an
necessaril
upp
necessaril
ion of spe
su
ion of spe
nt cannot be used t
K
d t
K-
t
-PPS): 
d to 
PPS): 
1
e
1 dose, h
ed t
dose, h
affecting t
sed
affecting t
database lo
us
database lo
analysis 
be 
analysis 
ed for the
ot 
ed for the
neral st
nno
neral st
ill be perf
t ca
ill be perf
variables
nt c
variables
This docume
ber of part
men
ber of part
listings c
um
listings c
Baseline w
ocu
Baseline w
specific
do
specific
Da
s 
Da
sions or variations thereof.
ic variable
ere
ic variable
Protocol 
the
Protocol 
who have
ons
who have
least 1
tio
least 1 va
o
va
he SS, con
var
he SS, con
entially af
or v
entially af
nalysis rev
or
nalysis rev
ily lead to
ns o
ily lead to
ecific data
ions
ecific data
ation and any extens
A subset 
nsi
A subset 
had at leas
ten
had at leas
the PK va
exte
the PK va
ock.
y e
ock.
set for ef
any
set for ef
e analysis
d a
e analysis
atistica
and
atistica
rformed u
on 
rformed u
s will be s
tio
s will be s
applica
rticipants 
cat
rticipants 
containing
plic
containing
will be th
app
will be th
selin
a
selin


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 97 of 202
9.3
Planned efficacy/outcome analyses
9.3.1
Analysis of the primary efficacy/primary endpoint
The primary efficacy variable is the durable clinically meaningful platelet response ≥50x109/L, 
for at least 8 out of 12 weeks during the last 12 weeks (platelet count recorded at Week 14 to 
Week 25 corresponding to the response achieved following dosing at Week 13 to Week 24). 
Missing platelet count at any visit will be considered "worst case" and set to zero ("no platelet 
response") for that specific visit.
The primary and supportive analyses for the durable platelet count endpoint are detailed in 
Table 9-1. The main intercurrent events are rescue therapy prior to Week 26 and treatment 
discontinuation (withdrawal from study) due to TEAEs. 
Confirmatory testing of single hypotheses is based on a closed-testing procedure.
The primary analysis of the study will use a Stratified Cochran-Mantel-Haenszel test statistic.
PUBLIC COPY 
keting authorization 
et 
r
et 
ed in
uth
ed in
eatment 
aut
eatment 
This document cannot be used to support any marke
edure.
tin
edure.
Haenszel 
ke
Haenszel 
application and any extensions or variations thereof.
test stati
the
test stati


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 98 of 202
Table 9-1:
Estimands for the primary endpoint
Estimand
Objective 
Clinical 
Category
Statistical 
Category
Variable/ 
Endpoint
Population
IESa
PLSb (Analysis)
Primary Objective: To demonstrate clinical efficacy of rozanolixizumab as a maintenance treatment in participants with primary ITP
Platelet 
Count
Primary/MCP
Durable Clinically 
Meaningful 
Platelet Response 
of ≥50x109/L, for 
at least 8 out of 12 
weeks during the 
last 12 weeks 
(Week 13 to 
Week 25)
RS who 
were 
randomized 
to 
rozanolixiz
umab 
weekly 
dosing 
compared 
against 
those who 
received 
placebo.
A composite strategy will be used, 
in which participants who require 
rescue therapy, who experience 
any TEAEs leading to treatment 
discontinuation, discontinue prior 
to receiving IMP, or do not have a 
post-treatment assessment will be 
considered as nonresponders.
To test of the null hypothesis (H0) 
in participants who have achieved a 
durable platelet count that the true 
common odds ratio between 
treatment arms is 1 (odds ratio = 1) 
vs the alternative hypothesis (Ha) 
that the odds ratio is less than 1, a 
Cochran-Mantel-Haenszel model 
adjusted for the stratification 
factors, namely baseline degree of 
thrombocytopenia (platelet count 
< or ≥15x109/L), history of 
splenectomy (yes or no).
Platelet 
Count
Sensitivity
Durable Clinically 
Meaningful 
Platelet Response 
of ≥50x109/L, for 
at least 8 out of 12 
weeks during the 
last 12 weeks 
(Week 13 to 
Week 25)
RS who 
were 
randomized 
to 
rozanolixiz
umab 
weekly 
dosing 
compared 
against 
those who 
received 
placebo.
A composite strategy: participants 
who experience any TEAEs 
leading to treatment 
discontinuation will be considered 
as nonresponders.
All other cases included but not 
limited to participants who 
discontinue prior to receiving 
IMP, or do not have a 
post-treatment assessment or 
participants who require rescue 
therapy the response variable will 
be imputed using a fully 
conditional specification method.
To test of the null hypothesis (H0) 
in participants who have achieved a 
durable platelet count that the true 
common odds ratio between 
treatment arms is 1 (odds ratio = 1) 
vs the alternative hypothesis (Ha) 
that the odds ratio is less than 1, a 
Cochran-Mantel-Haenszel model 
adjusted for the stratification 
factors, namely baseline degree of 
thrombocytopenia (platelet count 
< or ≥15x109/L), history of 
splenectomy (yes or no).
C COPY
AEs l
Y
AEs l
ntinuatio
PY 
ntinuatio
receiving
OPY
receiving
post
CO
post-
CO
-trea
CO
trea
con
C C
consi
C
si
PUBLIC
d 
I
d 
st
BL
st
se who 
BL
se who 
received
PUB
received
placeb
PU
placeb
P
C
P
be used to support any marketing authorization 
06 D
on 
06 
a
or
(Analys
aut
(Analys
th
i
ment in part
etin
ment in part
ing
be used,
arke
be used,
ho require
mar
ho require
experience
ma
experience
g to treatm
y m
g to treatm
, discontin
any
, discontin
IMP, or do
t an
IMP, or do
ment asses
ort 
ment asses
ered as no
por
ered as no
ke
d to
o.
d
o.
to
e
who 
sed
who 
were
us
were
random
e u
random
to
be
to
r
b
r
ed
ment cannot be
or 
b
or 
of 12 
ot b
of 12 
ring the 
not
ring the 
weeks
nn
weeks
eek 13 to
can
eek 13 to
Week
t c
Week 25)
ca
25)
This docume
al
T
al
do
me
be
ons thereof.
sis)
f
sis)
rticipants w
her
rticipants w
re
To test of
s th
To test of
in part
ns 
in part
dura
n
dura
the
tensions or variation
e 
ti
e 
ment
ati
ment
nue prior 
riat
nue prior 
do not have
vari
do not have
ssment wi
va
ssment wi
onresponde
or v
onresponde
on
y exte
A comp
xte
A comp
who 
ex
who 
le
e
le
ten
and any e
mized 
y e
mized 
ozanolixiz
d an
ozanolixiz
umab
nd 
umab
week
and
week
do
a
do
application an
ap
an
y e


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 99 of 202
Estimand
Objective 
Clinical 
Category
Statistical 
Category
Variable/ 
Endpoint
Population
IESa
PLSb (Analysis)
Platelet 
Count
Supplemental
Durable Clinically 
Meaningful 
Platelet Response 
of ≥50x109/L, for 
at least 8 out of 12 
weeks during the 
last 12 weeks 
(Week 13 to 
Week 25)
RS who 
were 
randomized 
to 
rozanolixiz
umab 
weekly 
dosing 
compared 
against 
those who 
received 
placebo.
A composite strategy, in which 
participants who require rescue 
therapy, who experience any 
TEAEs leading to treatment 
discontinuation, discontinue prior 
to receiving IMP, or do not have a 
post-treatment assessment will be 
considered as nonresponders.
Difference in proportions of 
participants between treatment 
arms who achieved a durable 
platelet count, analyzed using 
Fisher’s Exact Test. 
Platelet 
Count
Sensitivity
Durable Clinically 
Meaningful 
Platelet Response 
of ≥50x109/L, for 
at least 8 out of 12 
weeks during the 
last 12 weeks 
(Week 13 to Week 
25)
FAS who 
were 
randomized 
to 
rozanolixiz
umab 
weekly 
dosing 
compared 
against 
those who 
received 
placebo.
Composite strategy as described 
above with the addition of 
excluding participants who have 
not received a sufficient sc 
infusion. Participants who are not 
part of the FAS population will 
not be included in the analysis.
To test of the null hypothesis (H0) 
in participants who have achieved a 
durable platelet count of ≥50x109/L 
for at least 8 weeks out of the last 
12 weeks (Week 13 to Week 25) 
that the true common odds ratio 
between treatment arms is 1 (odds 
ratio = 1) vs the alternative 
hypothesis (Ha) that the odds ratio 
is less than 1, a logistic regression 
model adjusted for the stratification 
factors, namely baseline degree of 
thrombocytopenia (platelet count 
< or ≥15x109/L), history of 
splenectomy (yes or no).
Platelet 
Count
Sensitivity
Durable Clinically 
Meaningful 
RS who 
were 
Composite strategy as described 
for the primary analysis
To test of the null hypothesis (H0) 
in participants who have achieved a 
BLIC COPY
bo.
BL
bo.
me
Y
me
dered as 
PY 
dered as 
C
PUBL
AS who 
UBL
AS who 
were
PU
were
rand
PU
rand
P BL
P
support any marketing authorization 
06 D
on 
06 
a
za
nalysis)
tho
nalysis)
or
t t 
inue prior 
mar
inue prior 
do not hav
ma
do not hav
ssment w
y m
ssment w
onrespond
any
onrespond
Differenc
ng 
Differenc
partic
ting
partic
arm
ti
arm
a
eti
be used to su
mized 
d t
mized 
rozanolixi
use
rozanolixi
umab
e u
umab
wee
be
wee
d
ment cannot be
Week 
ot b
Week 
docume
Compo
o s
Compo
abov
o 
abov
e
su
me
be
to
ivity
cu
ivity
This docum
al
T
al
um
do
m
ns or variations thereof.
ve a 
io
ve a 
ill b
ati
ill be
atio
e
ders.
ria
ders.
nce in prop
reo
nce in prop
cipants bet
ere
cipants bet
ms who ac
the
ms who ac
platelet co
s th
platelet co
Fisher’
ns 
Fisher’
of
on
and any extension
iziz
ekly 
an
ekly 
dosing
d an
dosing
compare
nd 
compare
again
and
again
tho
a
tho
plication an
osite strate
sion
osite strate
ve with th
nsi
ve with th
excluding
ten
excluding
not rece
xte
not rece
infus
ex
infus
pa
e
pa
on
an
y e
appl
Durable
pp
Durable
Mean
ap
Mean
pli
ap
a


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 100 of 202
Estimand
Objective 
Clinical 
Category
Statistical 
Category
Variable/ 
Endpoint
Population
IESa
PLSb (Analysis)
Platelet Response 
of ≥50x109/L for 
at least 8 out of 12 
weeks during the 
last 12 weeks 
(Week 13 to 
Week 25)
randomized 
to 
rozanolixiz
umab 
weekly 
dosing 
compared 
against 
those who 
received 
placebo.
durable platelet response of 
≥50x109/L count for at least 8 out 
of 12 weeks during the last 
12 weeks (Week 13 to Week 25) 
that the true common odds ratio 
between treatment arms is 1 (odds 
ratio = 1) vs the alternative 
hypothesis (Ha) that the odds ratio 
is less than 1, a logistic regression 
model adjusted for the stratification 
factors, namely baseline degree of 
thrombocytopenia (platelet count 
< or ≥15x109/L), history of 
splenectomy (yes or no).
H0=null hypothesis; Ha=alternative hypothesis; IES=Intercurrent event(s) strategy; IMP=investigational medicinal product; FAS=Full Analysis Set; 
MCP=Multiple comparisons procedure; PLS=Population-level summary; RS=Randomized Set; TEAE=treatment-emergent adverse event
MCP: FWER controlled for hypothesis testing of selected endpoints as specified.
a The potential impact of any temporary treatment discontinuations (as detailed in Section 7.1.4) on the estimand strategy will be explored and detailed in 
the Statistical Analysis Plan.
bAll estimand attributes explicitly identified for primary/secondary and selected key estimands only.
UBLIC COPY 
C
PUB
current ev
PUB
current ev
n
P
n-
P
-level s
PU
level s
d end
P
d end
UB
authorization 
06 D
on 
06 
a
za
nalysis)
tho
nalysis)
or
eting a
durable p
ng a
durable p
≥50x1
ting
≥50x1
of 1
tin
of 1
1
This document cannot be used to support any marketi
al
T
al
a
eti
nt(s) strate
to s
nt(s) strate
mmary; RS
d to
mmary; RS
points as sp
ed 
points as sp
uations (as 
sed
uations (as 
ry/secondar
e u
ry/secondar
o s
ons thereof.
platelet res
eof
platelet res
0
e
09/L coun
ere
/L coun
12 weeks d
ther
12 weeks d
2 weeks (
th
weeks (
that the
ns t
that the
betw
ns
betw
rara
ions or variation
of
on
application and any extensio
egy;
s
egy; IMP=i
sio
IMP=i
S=Random
ens
S=Random
pecified.
ten
pecified.
detailed in
exte
detailed in
ry and sele
y e
ry and sele
io


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 101 of 202
9.3.2
Analysis of the secondary efficacy endpoints
The analyses for secondary endpoints are detailed in Table 9-2. The main intercurrent events are 
the use of rescue therapy prior to Week 25 and treatment discontinuation (or withdrawal from 
study) due to treatment emergent AEs.
In addition, all continuous secondary efficacy variables will be listed and summarized 
descriptively by treatment group and week. Descriptive statistics will be generated for the 
observed values and the change from Baseline. For the binary variables, frequency counts and 
percentages will be produced.
A sequential hierarchical test procedure will be applied to protect the overall significance level 
for the multiplicity of endpoints. The predefined order of formal hypotheses testing for the 
secondary endpoints will be performed in the following sequence:
•
Cumulative number of weeks with Clinically Meaningful Platelet Response of ≥50x109/L 
over the 24-week treatment period
•
Time to first Clinically Meaningful Platelet Response of ≥50x109/L: time from starting 
treatment to achievement of first response of ≥50x109/L 
•
Clinically Meaningful Platelet Response of ≥50x109/L by Day 8
•
Response defined as platelet count ≥30x109/L and at least a 2-fold increase of the 
Baseline count confirmed on at least 2 separate occasions at two adjacent nominal visits 
at least 7 days apart, and absence of bleeding by visit
•
Time to first rescue therapy
•
Change from Baseline to Week 25 in ITP-PAQ Symptoms Score
OPY
≥50x10
PY 
≥50x10
10
O
109
O
9/L an
OPY
/L an
PUBLIC CO
2 separat
CO
2 separat
f bleedi
C C
f bleedi
C
Week 25 
UBL
Week 25 
rt any marketing authorization 
and 
or
and 
cance leve
auth
cance leve
ng for the
g au
ng for the
Response 
ketin
Response 
0x10
ma
0x109
ar
9/L: t
ar
/L: t
L by Day 
ny 
L by Day 
at least a
t an
at least a
This document cannot be used to suppor
e occasion
ort 
e occasion
g by visit
po
g by visit
n
o
n ITP
o s
ITP-
s
-PA
su
PA
variations thereof.
el 
f
el 
e of ≥50x1
her
e of ≥50x1
time from
ns 
time from
y 8
i
y 8
a 2
a
a 2
ons or v
-
a
-fold in
ari
fold in
ns at two 
r va
ns at two 
application and any extensio
AQ Sympt
sion
AQ Sympt


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 102 of 202
Table 9-2:
Estimands for secondary endpoints
Estimand
Objective 
Clinical 
Category
Statistical 
Category
Variable/Endpoint
Population
IESa
PLSb (Analysis)
Secondary Objective: To assess the safety and tolerability of rozanolixizumab
Platelet 
Count
Secondary/
MCP
Cumulative number 
of weeks with 
Clinically 
Meaningful Platelet 
Response of 
≥50x109/L over the 
24-week treatment 
period
RS who 
were 
randomized 
to 
rozanolixiz
umab 
weekly 
dosing 
compared 
against 
those who 
received
placebo.
A composite endpoint will be 
used where, in the case rescue 
therapy are taken, only the 
platelet data up to the start date 
of rescue therapy will be 
utilized for the statistical 
analysis. Participants who take 
rescue therapy or who are 
withdrawn owing to TEAEs 
are defined as having a loss of 
durable platelet response at the 
time of the event occurring.
Cumulative number of 
weeks with clinically 
meaningful platelet 
response will be analyzed 
using an analysis of 
covariance with fixed terms 
for treatment, splenectomy, 
degree of thrombocytopenia 
(platelet count < or 
≥15x109/L). Estimated 
means and 95% CI will be 
presented for each treatment 
group.
Platelet 
Count
Secondary/
MCP
Time to first 
Clinically 
Meaningful Platelet 
Response of 
≥50x109/L: time 
from starting 
treatment to 
achievement of first 
response of 
≥50x109/L
RS who 
were 
randomized 
to 
rozanolixiz
umab 
weekly 
dosing 
compared 
against 
those who 
received 
placebo.
A composite strategy will be 
used where, in the case rescue 
therapy are taken, only the
platelet data up to the start date 
of rescue therapy will be 
utilized for the statistical 
analysis. Participants who take 
rescue therapy or who are 
withdrawn due to TEAEs are 
defined as having a loss of 
clinically meaningful platelet 
response and will be censored 
at the time of the event.
Time to first Clinically 
Meaningful Response will 
be analyzed using a 
stratified Log Rank Test 
with fixed terms for 
treatment, splenectomy, 
degree of thrombocytopenia 
(platelet count < or ≥ 
15x109/L).
Estimated hazard ratios and 
95% CIs will be presented. 
The time to first Clinically 
Meaningful Response will 
PUBLIC COPY
kly 
C
kly 
osing
LIC
osing
compare
BLI
compare
again
UB
again
th
U
th
w
Y
w
erapy a
PY 
erapy a
platelet 
OPY
platelet 
of re
COP
of re
ut
CO
ut
PU
CO
nt cannot be used to support any marketing authorization 
06 D
on 
06 
a
th
PLS
g a
PLSb
g a
b (A
a
(A
au
tin
ke
d d 
st
t
st
se who 
d to
se who 
eceived
ed t
eceived
placebo
sed
placebo
point will b
ma
point will b
the case r
y m
the case r
taken, onl
ny 
taken, onl
data up to t
any
data up to t
cue therap
rt a
cue therap
ized for th
ort
ized for th
analysis. P
ppo
analysis. P
rescue t
upp
rescue t
with
sup
with
ar
s
ar
ar
u
su
ul Platelet
t be
ul Platelet
nse of 
not
nse of 
x10
nn
x109
n
9/L: tim
nno
/L: tim
o
a
om startin
ann
m startin
treatmen
ca
treatmen
achiev
t c
achiev
res
t
res
RS
us
RS
us
This document
al
T
al
do
do
do
do
nt
u
d any extensions or variations thereof.
Analysis)
eof
Analysis)
f.
the
o.
e
o.
be 
o
be 
rescue
tio
rescue
ly the
iati
ly the
the start d
aria
the start d
py will be
var
py will be
he statistic
r v
he statistic
Participant
or
Participant
therapy or
ns o
therapy or
drawn 
ons
drawn ow
s
ow
re defined
sio
re defined
durable p
nsi
durable p
time o
en
time o
Cum
ns
Cum
s
te
ns
who 
y e
who 
were
ny
were
random
any
random
to
a
to
ro
ro
ex
pplication and
me 
a
me 
ng 
ng 
nt to 
on
nt to 
vement of
tion
vement of
sponse of 
cati
sponse of 
≥50x10
lica
≥50x109
a
9/L
/L
app
app
d


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 103 of 202
Estimand
Objective 
Clinical 
Category
Statistical 
Category
Variable/Endpoint
Population
IESa
PLSb (Analysis)
be presented graphically 
using a Kaplan-Meier curve.
Platelet 
Count
Secondary/
MCP
Clinically 
Meaningful 
Response by Day 8, 
defined as platelet 
count ≥50x109/L.
RS who 
were 
randomized 
to 
rozanolixiz
umab 
weekly 
dosing 
compared 
against 
those who 
received 
placebo.
A composite strategy will be 
used for rescue therapy, ie, 
participants who require rescue 
therapy will be considered a 
non-responder. The same 
strategy will be used for 
TEAEs leading to treatment 
discontinuation, and 
participants who discontinue 
prior to receiving IMP, do not 
have a valid Baseline 
assessment or do not have a 
post-treatment assessment.
To test of the null 
hypothesis (H0) in 
participants who have 
achieved a Clinically 
Meaningful Response by 
Day 8, defined as: Platelet 
count ≥50x109/L that the 
true common odds ratio 
between treatment arms is 1 
(odds ratio = 1) vs the 
alternative hypothesis (Ha) 
that the odds ratio is less 
than 1, a 
Cochran-Mantel-Haenszel 
model adjusted for the 
stratification factors, namely 
baseline degree of 
thrombocytopenia (platelet 
count < or ≥15x109/L), 
history of splenectomy (yes 
or no).
COPY 
-
Y
-resp
Y
resp
strategy w
PY
strategy w
TEAE
OP
TEAE
dis
CO
dis
C
UBLIC CO
ared 
C C
ared 
ainst
LIC
ainst
hose wh
BLIC
hose wh
receiv
UBL
receiv
pla
UB
pla
PU
PU
CO
support any marketing authorization 
06 D
on 
06 
a
za
Analysis)
tho
Analysis)
or
be prese
ng a
be prese
using
ng
using
a
tin
ll be
ke
ll be
py, ie, 
ark
py, ie, 
equire resc
mar
equire resc
considered
m
considered
er. The sam
ny m
er. The sam
will be used
any
will be used
s leading to
t a
s leading to
ontinuatio
ort 
ontinuatio
articipants
po
articipants
prior to r
upp
prior to r
have a
sup
have a
ass
su
ass
ti
T
tin
tin
tin
used to su
d 
o
d 
ebo.
to
ebo.
This document cannot be u
al
T
al
nn
u
su
ti
ereof.
ented grap
eof
ented grap
g a Kaplan
ere
g a Kaplan
of
ns ther
To test of t
the
To test of t
hypothe
s th
hypothe
par
ns 
partic
tic
ac
n
ac
her
tensions or variations
cue 
on
cue 
d a
tio
d a
m
a
me
at
e
d for 
ria
d for 
o treatmen
var
o treatmen
on, and 
r va
on, and 
s who disc
or 
s who disc
receiving 
s o
receiving 
a valid Ba
ns
a valid Ba
sessment o
ion
sessment o
post
nsi
post-
si
-treat
sio
treat
application and any exte
and
te
ns


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 104 of 202
Estimand
Objective 
Clinical 
Category
Statistical 
Category
Variable/Endpoint
Population
IESa
PLSb (Analysis)
Platelet 
Count
Secondary/
MCP
Response defined 
as platelet count 
≥30x109/L and at 
least a 2-fold 
increase of the 
Baseline count 
confirmed on at 
least 2 separate 
occasions at two 
adjacent nominal 
visits at least 7 days 
apart, and absence 
of bleeding.
RS who 
were 
randomized 
to 
rozanolixiz
umab 
weekly 
dosing 
compared 
against 
those who 
received 
placebo.
A composite strategy as 
described for Clinically 
Meaningful Response by 
Day 8 will be used.
To test of the null 
hypothesis (H0) in 
participants who have 
achieved a Response, 
defined as: Platelet count 
≥30x109/L and at least a 
2-fold increase of the 
Baseline count, confirmed 
on at least 2 separate 
occasions at two nominal 
visits at least 7 days apart, 
and absence of bleeding, 
that the true common odds 
ratio between treatment 
arms is 1 (odds ratio = 1) vs 
the alternative hypothesis 
(Ha) that the odds ratio is 
less than 1, a 
Cochran-Mantel-Haenszel 
model adjusted for the 
stratification factors, namely 
baseline degree of 
thrombocytopenia (platelet 
count < or ≥15x109/L), 
history of splenectomy (yes 
or no).
UBLIC COPY 
who 
C C
who 
ived 
C
ived 
lacebo.
BLIC
lacebo.
PU
PU
CO
authorization 
06 D
on 
06 
a
za
Analysis)
tho
Analysis)
or
ting a
To test o
g a
To test o
hypo
ng
hypo
pa
n
pa
This document cannot be used to support any marketin
al
T
al
a
t c
u
su
tin
ns thereof.
of the null
eof
of the null
othesis (H
ere
othesis (H
articipants
ther
articipants
achieved
th
achieved
define
ns t
define
≥30
ns
≥30
application and any extensions or variations
of
tio
d
te
ns


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 105 of 202
Estimand
Objective 
Clinical 
Category
Statistical 
Category
Variable/Endpoint
Population
IESa
PLSb (Analysis)
Platelet 
Count
Sensitivity
Response defined 
as platelet count 
≥30x109/L and at 
least a 2-fold 
increase of the 
Baseline count 
confirmed on at 
least 2 separate 
occasions at two 
adjacent nominal 
visits at least 7 days 
apart, and absence 
of bleeding.
RS who 
were 
randomized 
to 
rozanolixiz
umab 
weekly 
dosing 
compared 
against 
those who 
received 
placebo.
A composite strategy as 
described for Clinically 
Meaningful Response by 
Day 8 will be used.
Difference in the proportion 
of participants between 
treatment arms who have 
achieved a durable platelet 
count analyzed using 
logistic regression model 
adjusting for the covariates 
treatment, splenectomy, and 
degree of thrombocytopenia 
(platelet count < or 
≥15x109/L).
Rescue 
therapy
Secondary
Time to first rescue 
therapy. 
RS who 
were 
randomized 
to 
rozanolixiz
umab 
weekly 
dosing 
compared 
against 
those who 
received 
placebo.
A composite strategy will be 
used where, in the case rescue 
therapy are taken, only the 
platelet data up to the start date 
of rescue therapy will be 
utilized for the statistical 
analysis. Participants who take 
rescue therapy or who are 
withdrawn due to TEAEs are 
defined as having a loss of 
clinically meaningful platelet 
response and will be censored 
at the time of the event. 
Time to first rescue therapy 
use will be analyzed using a 
stratified Log Rank Test 
model with fixed terms for 
treatment, splenectomy, 
degree of thrombocytopenia 
(platelet count < or ≥ 
15x109/L), and estimated 
hazard ratios and 95% CIs 
will be presented. The time 
to first rescue therapy use 
will be presented 
graphically using a Kaplan-
Meier curve.
BLIC COPY 
who 
C C
who 
ived 
C
ived 
lacebo.
BLIC
lacebo.
CO
UBL
RS w
UBL
RS w
w
U
w
BL
PU
PU
used to support any marketing authorization 
06 D
on 
06 
a
za
Analysis)
tho
Analysis)
or
Differe
ng 
Differe
of pa
ng
of pa
trtr
a
su
tin
o 
o
o 
e
andomized
d t
andomized
to 
se
to 
rozan
use
rozan
um
u
um
su
A 
s
A 
su
su
su
This document cannot be u
al
T
al
ment
u
su
ns or variations thereof.
ence in the
reo
ence in the
articipants
ere
articipants
eatment a
the
eatment a
achieved
s th
achieved
count
ns 
count
log
n
log
of
ns
tension
A composit
sion
A composit
used whe
nsi
used whe
therap
en
therap
pla
e
pla
on
d any exte
d 
t
d 
nolixiz
ex
nolixiz
mab
y
mab
weekly 
any
weekly 
dosing
an
dosing
com
 
com
application and
ica
d
te


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 106 of 202
Estimand
Objective 
Clinical 
Category
Statistical 
Category
Variable/Endpoint
Population
IESa
PLSb (Analysis)
PRO
Secondary/
MCP
Change from 
Baseline to 
Week 25 in 
ITP-PAQ Symptom 
score.
RS who 
were 
randomized 
to 
rozanolixiz
umab 
weekly 
dosing 
compared 
against 
those who 
received 
placebo.
A hypothetical strategy will be 
used for rescue therapy intake: 
ITP-PAQ Symptom scores 
after rescue medication will 
not be included in the 
estimation of the repeated 
measurement mixed model.
Change in ITP-PAQ from 
Baseline to Week 25 will be 
estimated from a 
generalized linear model 
including all available 
assessment of the ITP-PAQ 
between Baseline and 
Week 25. Treatment and 
visit will be included in the 
model, adjusting for the 
covariates splenectomy, 
degree of thrombocytopenia 
(platelet count < or 
≥15x109/L) and Baseline 
ITP-PAQ Symptoms score. 
The difference between 
treatment arms will be 
compared using 
model-based estimates of 
mean ITP-PAQ Symptom 
score in each arm at Week 
25.
CI=confidence interval; H0=null hypothesis; Ha=alternative hypothesis; IES=Intercurrent event(s) strategy; IMP=investigational 
medicinal product; ITP-PAQ=primary Immune Thrombocytopenia Patient Assessment Questionnaire; FWER=family-wise error-rate; 
MCP=Multiple comparisons procedure; PLS=Population-level summary; PRO=patient reported outcome; RS=Randomized Set;
TEAE=treatment emergent adverse event
MCP: FWER controlled for hypothesis testing of selected endpoints as specified (to be determined).
a The potential impact of any temporary treatment discontinuations (as detailed in Section 7.1.4) on the estimand strategy will be explored 
and detailed in the Statistical Analysis Plan.
bAll estimand attributes explicitly identified for primary/secondary and selected key estimands only.
PUBLIC COPY 
who 
C C
who 
ived 
C
ived 
lacebo.
BLIC
lacebo.
sur
Y
sur
PU
CO
not be used to support any marketing authorization 
06 D
on 
06 
a
za
Analysis)
tho
Analysis)
or
ke:
ti
ke:
es 
k
es 
n will 
rke
n will 
he 
he 
 repeated 
ma
 repeated 
mixed mo
y m
mixed mo
Change
ng 
Change
Base
ng
Base
es
es
a
u
su
tin
This document canno
al
T
al
ypothesis; 
nno
ypothesis; 
mary Immu
an
mary Immu
rocedure; P
ca
rocedure; P
adverse ev
nt c
adverse ev
for hypoth
ent 
for hypoth
t of any tem
men
t of any tem
he Statistica
ume
he Statistica
tributes exp
cum
tributes exp
no
application and any extensions or variations thereof.
odel.
ati
odel.
e in ITP
reo
e in ITP-
o
-P
eline to W
ere
eline to W
stimated f
the
stimated f
generali
s th
generali
includ
ns 
includ
ass
n
ass
of
d
te
ns
H
a
Ha
an
a=altern
and
=altern
une Throm
an
une Throm
PLS=Popul
on a
PLS=Popul
vent
tio
vent
hesis testing
atio
hesis testing
mporary tre
ica
mporary tre
al Analysis
plic
al Analysis
plicitly ide
ppl
plicitly ide
nd


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 107 of 202
9.3.3
Other efficacy/other outcome analyses
9.3.3.1
Analysis of pharmacokinetic endpoint
The PK-PPS dataset will be used. Rozanolixizumab plasma concentration data will be listed by 
study participant and actual time. A statistical summary of rozanolixizumab plasma 
concentrations will be reported by scheduled time point overall and by body weight tier, 
stratified by dose regimen. Further details on summaries for dose modifications will be provided 
in the corresponding SAP. Summaries by geographical region may be performed. The number of 
available observations, mean, median, SD, minimum, maximum, geometric mean (and 
associated 95% CI), and geometric coefficient of variation (assuming log normally distributed 
data) will be calculated. Values below the LLOQ will be reported as LLOQ/2 for calculation of 
descriptive statistics. Descriptive statistics of concentrations will be calculated if at least two-
thirds of the individual data points are quantifiable (≥LLOQ).
Individual concentrations of rozanolixizumab may also be displayed graphically as spaghetti 
plots stratified by body weight tier (ie, changing color of line and type of data points when dose 
regimen changes, if down-titration was performed). Summaries by geographical region may be 
performed. Similarly individual plots will be performed where the potential change in dose will 
be display graphically and ADA, PK, PD and/or platelets will be evaluated and displayed.
Further details will be provided in the SAP.
If data merit, PK data may be included in a population PK analysis, further details would be 
provided in a separate Data Analysis Plan and reported separately.
9.3.3.2
Antidrug antibodies analyses
A tiered ADA approach will be used for the study. Samples will first be evaluated in the 
screening assay using a false positivity rate of 5% (reported as negative screen or positive 
screen), followed by analysis of screened positive samples in the confirmatory assay (which is a 
drug depletion assay) to confirm the true positivity of the samples (reported as negative 
immunodepletion or positive immunodepletion). Samples that are confirmed as positive will be 
evaluated in a titration assay to quantify the ADA level and will be reported as titer (reciprocal 
dilution factor including MRD). For anti-rozanolixizumab antibody positive samples (or subset 
of), further characterization for neutralizing ADA potential in vitro will be performed, and 
results will be presented in a listing. Full details will be covered in the SAP.
The impact of ADA on PK, PD, and safety will be evaluated.
Further details will be provided in the SAP.
9.3.3.3
Analysis of pharmacodynamic endpoints
For total IgG, the absolute serum IgG and change from Baseline on serum IgG with time will be 
summarized by dose regimen in the Adaptation Period and the Maintenance Period.
Spaghetti plots of the % change from Baseline and absolute IgG levels will be displayed, 
stratification by body weight tiers may be done, as well as by dose regimen during the 
Adaptation and Maintenance Dose Period (ie, changing color of lines in graph by dose regimen 
administered). 
PUBLIC COPY
d 
Y
d 
telets w
PY 
telets w
populati
C CO
populati
n and rep
IC C
n and rep
es analy
BLIC
es analy
used for 
PUB
used for 
ositivit
PU
ositivit
P
ot be used to support any marketing authorization 
ed 
iz
ed 
ber of 
oriz
ber of 
stributed 
uth
stributed 
alculation
au
alculation
f at least t
g a
f at least t
phically a
ket
phically a
e of data p
arke
e of data p
geograph
mar
geograph
he potenti
y m
he potenti
l be evalu
ny 
l be evalu
on PK ana
port
on PK ana
orted sep
ppo
orted sep
ses
su
ses
he study. 
to s
he study. 
y rate of 5
d to
y rate of 5
eened pos
sed
eened pos
the true p
use
the true p
immunod
be u
immunod
ay to quan
t be
ay to quan
g MRD). F
ot b
g MRD). F
This document cann
ization fo
no
ization fo
sented i
ann
sented in 
n
n 
f ADA on
t ca
f ADA on
etails will
ent
etails will
3
or total Ig
ocu
or total Ig
summar
doc
summar
Spa
s d
Spa
s
d any extensions or variations thereof.
n of 
of
n of 
two
eo
two-
o
-
as spaghet
the
as spaghet
points wh
s th
points wh
hical regio
ons
hical regio
tial chang
tion
tial chang
uated 
iati
uated and
ati
and
alysis, fur
or v
alysis, fur
parately.
s or
parately.
. Samples
nsio
. Samples
5% (repor
ens
5% (repor
sitive sam
xte
sitive sam
positivity 
ext
positivity 
depletion)
y e
depletion)
ntify the A
any
ntify the A
For anti
d a
For anti-
application and
or neutrali
nd 
or neutrali
a listing. 
an
a listing. 
n PK, PD,
ion 
n PK, PD,
l be provi
catio
l be provi
Analysi
plica
Analysi
gG, the ab
app
gG, the ab
ed by d
ap
ed by d


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 108 of 202
If data merits, IgG data will be included in a population pharmacokinetic/pharmacodynamic 
analysis and link to the platelet outcome, further details would be provided in a separate data 
analysis plan (DAP) and reported separately.
9.4
Planned safety and other analyses
9.4.1
Safety analyses
The frequency and severity of all TEAEs will be presented for each treatment group separately 
by system organ class, high level term, and preferred term (Medical Dictionary for Regulatory 
Activities). Data will be further presented by randomized dosing regimen. The data will be 
displayed as number of participants experiencing the TEAE, percentage of participants, and 
number of TEAEs.
Laboratory evaluations and vital signs as well as ECG data will be analyzed over time. All safety 
analyses will be based on the SS, consisting of all participants who receive at least 1 dose of 
IMP.
9.5
Handling of protocol deviations
Important protocol deviations are identified as part of the data cleaning process in the Data 
Cleaning Plan (DCP). Ongoing data cleaning meetings will be held throughout the duration of 
the study. Objectives of these meetings include the review of important protocol deviations and 
update (if necessary) the important protocol deviation specification and discuss exclusion of 
participants from analysis populations. Furthermore, overall trends in protocol deviations will be 
discussed at the Data Evaluation Meetings. Through this ongoing data cleaning and evaluation 
process, all decisions regarding important protocol deviations and exclusions from analysis 
populations are made on an ongoing basis.
9.6
Handling of dropouts or missing data
All imputation of missing or partial dates for safety assessments, as well as handling missing 
efficacy data (where applicable), will be detailed in the SAP.
If individual platelet visit data is missing it will be set to zero; participants who are lost to 
follow-up will be imputed as nonresponders.
It is not anticipated that there will be missing data, due to the adoption of the responder endpoint 
definition, where study participants who have not met the threshold for clinically meaningful 
response will be imputed as nonresponders for the analysis.
9.7
Data monitoring
An external IDMC will be established to review the safety data at predefined intervals and ad 
hoc as needed, should emerging safety concerns arise during the study. The IDMC will have the 
possibility to unblind the data. Details of the IDMC composition, processes, and responsibilities 
will be documented in the IDMC charter. One IDMC is planned for both pivotal studies (TP0006 
and TP0003), where the safety data will be initially presented unpooled, ie, data from each study 
PUBLIC COPY
the 
Y
the 
ings wil
PY 
ings wil
the revie
OP
the revie
deviation
CO
deviation
rthermo
C C
rthermo
ngs. Thr
LIC
ngs. Thr
orta
BL
ortant pr
BLI
nt pr
ing basis
UB
ing basis
dropo
PU
dropo
ment cannot be used to support any marketing authorization 
ly 
ri
ly 
atory 
hori
atory 
l be 
th
l be 
nts, and 
auth
nts, and 
over time
ting
over time
e at least 1
ketin
e at least 1
cleaning p
y m
cleaning p
be held th
any
be held th
w of impo
t an
w of impo
specifica
ort 
specifica
e, overall 
ppo
e, overall 
ough this o
upp
ough this o
otocol dev
sup
otocol dev
t
outs or m
ed t
outs or m
al dates fo
use
al dates fo
e), will be
e us
e), will be
data is mis
t be
data is mis
ted as non
ot b
ted as non
that there
nno
that there
e study pa
can
e study pa
be impute
t ca
be impute
This docum
Dat
nt
Dat
xternal ID
ume
xternal ID
oc as need
cum
oc as need
possibili
doc
possibili
will b
s do
will b
and
s 
and
tion and any extensions or variations thereof.
e. All safe
ereo
e. All safe
1
th
1 dose of
her
dose of
process in
atio
process in
hroughou
riat
hroughou
ortant pro
var
ortant pro
ation a
r va
ation and 
va
nd 
l trends in
or 
l trends in
ongoing d
ns o
ongoing d
viations a
ons
viations a
missing
tens
missing
for safety 
exte
for safety 
e detailed 
y ex
e detailed 
issing it w
any
issing it w
nresponde
d a
nresponde
e will be m
and
e will be m
articipants
n a
articipants
ted as non
ion 
ted as non
applica
ata moni
cati
ata moni
DMC will
plic
DMC will
ded, shoul
pp
ded, shoul
y to unb
ap
y to unb
ume
a


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 109 of 202
will be reviewed separately. Key safety data may be pooled at the discretion of the IDMC for 
protection of all study participants if warranted.
The IDMC will consist of members independent from UCB. Study enrollment will not be halted 
during planned IDMC review of the safety and efficacy data. 
9.7.1
Early stopping for efficacy
Not applicable.
9.7.2
Early stopping for futility
Not applicable.
9.8
Determination of sample size
The observed response rates from Kuter et al (2008) in splenectomized participants were 38% 
(16/42) on active and 0% (0/21) on placebo. In non-splenectomized participants the rates were 
61% (25/41) and 5% (1/21), respectively.
Using the true response rate of 0.45 versus 0.05, a sample size of 60 participants randomized in a 
2:1 ratio (ie, n=40 on rozanolixizumab and n=20 on placebo) receiving weekly infusions will 
provide >90% power to detect a statistically significant difference between treatment groups 
using Fisher’s Exact Test at an alpha level of 0.025 (1-sided). By definition, participants who 
dropout of the study are determined as nonresponders and are incorporated in the overall 
response rate. If the number of dropouts is greater than anticipated by 10%, the impact on the 
rozanolixizumab response rate would mean that it would drop to a response rate of 0.4. In such 
cases, the study would still achieve >80% power if the overall response rate on placebo remains 
at 0.05.
If the response rate on placebo was 0.1 rather than the anticipated 0.05, the rozanolixizumab rate 
would need to be >0.45 to achieve 80% and >0.5 to achieve 90% power. Table 9-3 provides 
power estimates for a fixed study design of n=60 participants in a 2:1 randomization ratio.
The power of the study maybe increased by including the platelet count data from the 
participants who received bi-weekly placebo infusions in the assessment of the rozanolixizumab 
treatment effect. For instance, if 10 participants received bi-weekly infusions on the placebo arm, 
the overall sample size would increase to n=70 (ie, n=40 on rozanolixizumab and n=30 on 
placebo), and 90% power would be achieved for rozanolixizumab response rates of >0.35 and 
>0.45 if the true placebo response rate was 0.05 and 0.10 respectively.
PUBLIC COPY 
placeb
Y
placeb
ficant dif
OPY
ficant dif
025 (1
COP
025 (1
P
esponder
CO
esponder
s greater
C C
s greater
mean tha
LIC
mean tha
>80% p
UBL
>80% p
was 0
P
was 0
cannot be used to support any marketing authorization 
ticipants w
eting
ticipants w
icipants t
rket
icipants t
f 60 partic
ma
f 60 partic
rece
ny
receiving 
ny m
iving 
ference be
any
ference be
ided). By 
rt a
ided). By 
s and are i
ort
s and are i
than antic
ppo
than antic
t it would
upp
t it would
ower if the
su
ower if the
1 rather th
ed t
1 rather th
80% and
sed
80% and
dy design 
us
dy design 
ybe increa
be 
ybe increa
d bi
ot
d bi-
t b
-week
t b
week
nstance, i
not
nstance, i
s
a
size woul
ann
ize woul
0% power
can
0% power
This document 
rue placeb
nt c
rue placeb
on and any extensions or variations thereof.
were 38%
here
were 38%
the rates w
the
the rates w
cipants ran
tion
cipants ran
 weekly i
iatio
 weekly i
etween tr
aria
etween tr
y definition
var
y definition
incorpora
or v
incorpora
cipated by
or
cipated by
d drop to a
ns o
d drop to a
e overall 
ions
e overall 
than the a
ten
than the a
d >0.5 to a
exte
d >0.5 to a
of n=60 p
y ex
of n=60 p
ased by in
any
ased by in
kly placeb
d an
kly placeb
if 10 part
nd 
if 10 part
uld increas
an
uld increas
r would b
n a
r would b
applicatio
ebo respon
tion
ebo respon


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 110 of 202
Table 9-3:
Expected sample size for TP0006
Scenario
Placebo Response Rate of 0.05
Placebo Response Rate of 0.10
Rozimab
Placebo
Powera
Rozimab
Placebo
Powera
1
0.30
0.05
56%
0.30
0.10
32%
2
0.35
0.05
73%
0.35
0.10
48%
3
0.40
0.05
85%
0.40
0.10
63%
4
0.45
0.05
93%
0.45
0.10
77%
5
0.50
0.05
97%
0.50
0.10
87%
6
0.55
0.05
98%
0.55
0.10
93%
Rozimab= rozanolixizumab
a
Power for a parallel group design with n=60 in a 2:1 randomization test computed with Fisher’s exact 
test using nQuery Advisor 7.0.  
The power of the study maybe increased by including the platelet count data from the 
participants who received bi-weekly placebo infusions in the assessment of the rozanolixizumab 
treatment effect. For instance, if 10 participants received bi-weekly infusions on the placebo arm, 
the overall sample size would increase to n=70 (ie, n=40 on rozanolixizumab and n=30 on 
placebo), and 90% power would be achieved for rozanolixizumab response rates of >0.35 and 
>0.45 if the true placebo response rate was 0.05 and 0.10 respectively.
10
SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDERATIONS
10.1
Appendix 1: Regulatory, ethical, and study oversight 
considerations
10.1.1
Regulatory and ethical considerations
The study will be conducted under the auspices of an IRB/IEC, as defined in local regulations, 
International Council for Harmonisation-Good Clinical Practice (ICH-GCP), and in accordance 
with the ethical principles that have their origin in the Declaration of Helsinki.
The investigator/UCB will ensure that an appropriately constituted IRB/IEC that complies with 
the requirements of the current ICH-GCP version or applicable country-specific regulations will 
be responsible for the initial and continuing review and approval of the clinical study. Prior to 
initiation of the study, the investigator/UCB will forward copies of the protocol, ICF, IB, 
investigator’s curriculum vitae (if applicable), advertisement (if applicable), and all other 
participant-related documents to be used for the study to the IRB/IEC for its review and 
approval.
Before initiating a study, the investigator will have written and dated full approval from the 
responsible IRB/IEC for the protocol.
The investigator will also promptly report to the IRB/IEC all changes in the study, all 
unanticipated problems involving risks to participants or others, and any protocol deviations, to 
eliminate immediate hazards to participants.
PUBLIC COPY 
s in t
Y
s in t
ceived b
OPY
ceived b
(ie, n=4
COP
(ie, n=4
d for roz
CO
d for roz
as 0.05 a
C C
as 0.05 a
OCUM
BLIC
OCUM
TIONS
UB
TIONS
Regu
PU
Regu
not be used to support any marketing authorization 
a
za
3%
o
3%
iz
77%
utho
77%
ho
87
u
87
ut
g
0
g a
ting
omputed w
rke
omputed w
t count da
ma
t count da
assessmen
ny m
assessmen
weekly i
any
weekly i
0 on rozan
rt a
0 on rozan
anolixizum
port
anolixizum
nd 0.10 re
ppo
nd 0.10 re
ENTA
sup
ENTAT
p
T
latory, e
ed t
latory, e
nd ethic
e us
nd ethic
ed under t
t be
ed under t
r Harmon
ot b
r Harmon
ocument cann
ciples that
nno
ciples that
/UCB wil
can
/UCB wil
ents of the
t ca
ents of the
ible for th
ent 
ible for th
n of the s
men
n of the s
stigator’s 
um
stigator’s 
articipant
ocu
articipant
This do
approva
doc
approva
Befo
s d
Befo
re
s
re
d any extensions or variations thereof.
7%
of
7%
93%
reo
93%
of
ere
with Fisher
th
with Fisher
ata from t
tion
ata from t
nt of the r
atio
nt of the r
infusions
aria
infusions
nolixizum
var
nolixizum
mab respo
or v
mab respo
espectivel
s or
espectivel
TION A
ons
TION A
ethical,
tens
ethical,
cal consi
y e
cal consi
the auspic
any
the auspic
nisation
d a
nisation
application an
G
at have the
and
at have the
ll ensure 
n a
ll ensure 
e current 
tion
e current 
he initial 
atio
he initial 
study, the
ica
study, the
 curriculu
plic
 curriculu
a
related d
app
related d


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 111 of 202
The investigator will not make any changes in the study or study conduct without IRB/IEC 
approval, except where necessary to eliminate apparent immediate hazards to the participants. 
For minor changes to a previously approved protocol during the period covered by the original 
approval, it may be possible for the investigator to obtain an expedited review by the IRB/IEC as 
allowed.
As part of the IRB/IEC requirements for continuing review of approved studies, the investigator 
will be responsible for submitting periodic progress reports to the IRB/IEC (based on IRB/IEC 
requirements), at intervals appropriate to the degree of participant risk involved, but no less than 
once per year. The investigator should provide a final report to the IRB/IEC following study 
completion.
UCB (or its representative) will communicate safety information to the appropriate regulatory 
authorities and all active investigators in accordance with applicable regulatory requirements. 
The appropriate IRB/IEC will also be informed by the investigator or the sponsor, as specified by 
the applicable regulatory requirements in each concerned country. Where applicable, 
investigators are to provide the sponsor (or its representative) with evidence of such IRB/IEC 
notification.
10.1.2
Financial disclosure
Insurance coverage will be handled according to local requirements.
Finance and insurance are addressed in the investigator and/or CRO agreements, as applicable.
10.1.3
Informed consent process
Participant’s informed consent must be obtained and documented in accordance with local 
regulations, ICH-GCP requirements, and the ethical principles that have their origin in the 
principles of the Declaration of Helsinki.
Prior to obtaining informed consent, information should be given in a language and at a level of 
complexity understandable to the participant in both oral and written form by the investigator (or 
designee). Each participant will have the opportunity to discuss the study and its alternatives 
with the investigator.
Prior to participation in the study, the ICF should be signed and personally dated by the study 
participant, and by the person who conducted the informed consent discussion (investigator or 
designee) at the site. The study participant must receive a copy of the signed and dated ICF. As 
part of the consent process, each participant must consent to direct access to his/her medical 
records for study-related monitoring, auditing, IRB/IEC review, and regulatory inspection.
If the ICF is amended during the study, the investigator (or UCB, if applicable) must follow all 
applicable regulatory requirements pertaining to the approval of the amended ICF by the 
IRB/IEC and use of the amended form.
All studies conducted at centers in the United States must include the use of a Health Insurance 
Portability and Accountability Act Authorization form.
The participant may withdraw his/her consent to participate in the study at any time. A 
participant is considered as enrolled in the study when he/she has signed the ICF. An eCRF must 
not be started, nor may any study specific procedure be performed for a given participant, 
without having obtained his/her written consent to participate in the study.
PUBLIC COPY 
o local re
OP
o local re
investiga
C CO
investiga
ocess
LIC
ocess
t be obta
UBL
t be obta
ents, and
PUB
ents, and
f Helsin
PU
f Helsin
ment cannot be used to support any marketing authorization 
z
EC 
ri
EC 
ss than 
hori
ss than 
study 
tho
study 
iate regula
g a
iate regula
ory require
ting
ory require
sponsor, a
ketin
sponsor, a
ere applic
rke
ere applic
vidence o
mar
vidence o
quirement
t a
quirement
tor and/or
port
tor and/or
ined and d
su
ined and d
the ethica
to s
the ethica
ki.
d
ki.
nt, inform
sed
nt, inform
he particip
us
he particip
will have t
be u
will have t
in the stu
not
in the stu
y the perso
ann
y the perso
site. The
can
site. The
onsent pro
nt c
onsent pro
or study
ent
or study-rere
This docum
ICF is am
ume
ICF is am
plicable re
cum
plicable re
IRB/IEC 
doc
IRB/IEC 
All s
s d
All s
Po
s
Po
ication and any extensions or variations thereof.
latory 
eof
latory 
rements. 
ereo
rements. 
as specifi
ther
as specifi
cable, 
s th
cable, 
of such IR
ns 
of such IR
nts.
v
nts.
r CRO ag
or v
r CRO ag
documen
ion
documen
al princip
nsio
al princip
mation sho
exte
mation sho
pant in bo
y ex
pant in bo
the oppor
ny 
the oppor
udy, the IC
nd 
udy, the IC
on who co
an
on who co
e study pa
on a
e study pa
o
t
ocess, eac
tion
cess, eac
related mo
catio
related mo
appli
mended d
plic
mended d
regulatory
ppl
regulatory
and use 
app
and use 


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 112 of 202
10.1.4
Data protection
UCB staff (or designee) will affirm and uphold the participant’s confidentiality. Throughout this 
study, all data forwarded to UCB (or designee) will be identified only by the participant number 
assigned at Screening.
The investigator agrees that representatives of UCB, its designee, representatives of the relevant 
IRB/IEC, or representatives of regulatory authorities will be allowed to review that portion of the 
participant’s primary medical records that directly concerns this study (including, but not limited 
to, laboratory test result reports, ECG reports, admission/discharge summaries for hospital 
admissions occurring during a participant’s study participation, and autopsy reports for deaths 
occurring during the study).
The participant must be informed that his/her personal study-related data will be used by the 
sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the participant.
The participant must be informed that his/her medical records may be examined by Clinical 
Quality Assurance auditors or other authorized personnel appointed by the sponsor, by 
appropriate IRB/IEC members, and by inspectors from regulatory authorities.
10.1.5
Committees structure
An external IDMC will be established to mainly review the safety data at predefined intervals 
and ad hoc as needed, should emerging safety concerns arise during the study. The IDMC will 
have the possibility to unblind the data. Details of the IDMC composition, processes, and 
responsibilities will be documented in the IDMC charter.
10.1.6
Data quality assurance
All participant data relating to the study will be recorded in the eCRF. The investigator is 
responsible for verifying that data entries are accurate and correct by electronically signing the 
eCRF.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the eCRF.
The investigator must permit study-related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct access to source data documents.
The sponsor or designee is responsible for the data management of this study including quality 
checking of the data.
Study monitors will perform ongoing source data verification to confirm that data entered into 
the eCRF by authorized site personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study is 
being conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP, and all applicable regulatory requirements.
All essential documents are to be retained by the investigator until at least 2 years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region, or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the IMP. These documents should be retained 
PUBLIC COPY 
m reg
Y
m reg
nly revie
CO
nly revie
fety conc
C C
fety conc
Details 
LIC 
Details 
n the ID
BLI
n the ID
suranc
PUB
suranc
he stu
P
he stu
nt cannot be used to support any marketing authorization 
the
iz
the
mited 
oriz
mited 
al
th
al
or deaths
uth
or deaths
be used by
ng 
be used by
e must als
ting
e must als
e examin
mark
e examin
ed by the 
ma
ed by the 
ory autho
y m
ory autho
w the safe
ort 
w the safe
erns arise
po
erns arise
of the IDM
upp
of the IDM
MC charte
sup
MC charte
e
dy will be
ed t
dy will be
entries ar
sed
entries ar
ntain accur
be 
ntain accur
e eCRF.
ot b
e eCRF.
st permit 
nno
st permit 
ns and pro
ann
ns and pro
or designe
t ca
or designe
This document
of 
e
of the data
ent 
the data
monitors
me
monitors
eCRF by
cum
eCRF by
document
docu
document
being c
do
being c
agre
s d
agre
ication and any extensions or variations thereof.
by the
reo
by the
so be
ere
so be
ned by Cli
ns t
ned by Cli
e sponsor, 
ions
e sponsor, 
orities.
atio
orities.
ety data a
r va
ety data a
e during th
or 
e during th
MC comp
s o
MC comp
ter.
o
ter.
e recorde
ten
e recorde
re accurat
exte
re accurat
urate docu
any
urate docu
study
and
study-
d
-rel
d
rel
ovide dire
n an
ovide dire
nee is resp
tion
nee is resp
appli
a.
a
a.
s will perf
plica
s will perf
y authoriz
ppl
y authoriz
s; that th
app
s; that th
ucted
a
ucted


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 113 of 202
for a longer period, however, if required by the applicable regulatory requirement(s) or by an 
agreement with UCB (CPMP/ICH/135/95, 2002 [Section 4.9.5]). The investigator will contact 
UCB for authorization prior to the destruction of any study records or in the event of accidental 
loss or destruction of any study records. The investigator will also notify UCB should he/she 
relocate or move the study-related files to a location other than that specified in the sponsor’s 
trial master file.
Quality tolerance limits will be established for the study using parameters related to patient 
safety reporting and reliability of study results. The parameters will be monitored throughout the 
study to identify systematic issues. Parameters used, parameter values, important deviations from 
the quality tolerance limits, and actions taken will be summarized in the clinical study report.
10.1.6.1
Electronic Case Report Form completion
The investigator is responsible for prompt reporting of accurate, complete, and legible data in the 
eCRFs and in all required reports.
Any change or correction to the eCRF after saving must be accompanied by a reason for the 
change.
Corrections made after the investigator’s review and approval (by means of a 
password/electronic signature) will be reapproved by the investigator.
The investigator should maintain a list of personnel authorized to enter data into the eCRF.
Detailed instructions will be provided in the eCRF Completion Guidelines.
10.1.6.2
Apps
Not applicable.
10.1.7
Source documents
All source documents must be accurate, clear, unambiguous, permanent, and capable of being 
audited. They should be made using some permanent form of recording (ink, typing, printing, 
optical disc). They should not be obscured by correction fluid or have temporary attachments 
(such as removable self-stick notes). Photocopies and/or printouts of eCRFs are not considered 
acceptable source documents.
Source documents are original records in which raw data are first recorded. These may include 
hospital/clinic/general practitioner records, charts, diaries, x-rays, laboratory results, printouts, 
pharmacy records, care records, ECG or other printouts, completed scales, quality of life 
questionnaires, or video, for example. Source documents should be kept in a secure, limited 
access area.
The following data will be recorded directly in the eCRF and will not appear in a separate source 
document as defined above.
Source documents that are computer generated and stored electronically must be printed for 
review by the monitor (eg, ECG reports). Once printed, these copies should be signed and dated 
by the investigator and become a permanent part of the participant’s source documents. The 
investigator will facilitate the process for enabling the monitor to compare the content of the 
printout and the data stored in the computer to ensure all data are consistent.
PUBLIC COPY
appro
PY 
appro
d by the 
OPY
d by the 
sonnel au
CO
sonnel au
the eCR
C C
the eCR
ments
PU
ments
nnot be used to support any marketing authorization 
out the 
hori
out the 
ations from
tho
ations from
dy report.
aut
dy report.
and legibl
eting
and legibl
nied by a 
mark
nied by a 
l (by m
ny 
l (by mea
y
ea
nvestigato
any
nvestigato
uthorized t
ort 
uthorized t
F Complet
ppo
F Complet
curate, cle
use
curate, cle
using som
e us
using som
not be obs
be 
not be obs
stick note
ot b
stick note
uments.
not
uments.
ocument can
s are origi
ann
s are origi
general p
t ca
general p
ecords, ca
nt c
ecords, ca
naires, or 
en
naires, or 
area.
me
area.
he follow
ocu
he follow
This do
documen
doc
documen
Sour
s d
Sour
re
s
re
and any extensions or variations thereof.f
le data in 
here
le data in 
a reason fo
ns t
a reason fo
ns of a 
iati
ns of a 
or.
a
or.
to enter d
r va
to enter d
tion Guid
s or
tion Guid
ear, unam
ext
ear, unam
me perma
y e
me perma
scured 
any
scured by 
y 
by 
es). Photo
d an
es). Photo
application a
ginal recor
an
ginal recor
practitione
on a
practitione
are record
tion
are record
video, fo
cati
video, fo
wing data w
app
wing data w
a
as defi
ap
as defi


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 114 of 202
Electronic data records, such as Holter monitor records or electroencephalogram records, must 
be saved and stored as instructed by UCB (or designee).
10.1.8
Study and site closure
The UCB designee reserves the right to close the study site or terminate the study at any time for 
any reason at the sole discretion of the sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been collected and a study-site closure visit has been performed.
The investigator may initiate study-site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the early closure of a study site by the sponsor or investigator may include but are 
not limited to:
•
Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or 
local health authorities, the sponsor's procedures, or GCP guidelines.
•
Inadequate recruitment of participants by the investigator.
•
Discontinuation of further IMP development.
10.1.9
Publication policy
The results of this study may be published or presented at scientific meetings. If this is foreseen, 
the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission. 
This allows UCB to protect proprietary information and to provide comments.
UCB will comply with the requirements for publication of study results. In accordance with 
standard editorial and ethical practice, UCB will generally support publication of multicenter 
studies only in their entirety and not as individual site data. In this case, a coordinating 
investigator will be designated by mutual agreement.
Authorship will be determined by mutual agreement and in line with International Committee of 
Medical Journal Editors authorship requirements.
PUBLIC COPY 
or prese
C C
or prese
nuscripts
LIC 
nuscripts
ry inform
BLIC
ry inform
rements 
PUB
rements 
ractice,
PU
ractice,
no
P
no
sed to support any marketing authorization 
e cause 
tho
e cause 
nclude bu
g a
nclude bu
ents of the
ket
ents of the
es.
a
es.
nted at sci
por
nted at sci
or abstrac
upp
or abstrac
mation and
sup
mation and
or publica
to s
or publica
UCB will
d to
UCB will
as indivi
sed
as indivi
This document cannot be us
y mutual a
use
y mutual a
ed by mut
be u
ed by mut
uthorship
t be
uthorship
xtensions or variations thereof.
ut are 
eof
ut are 
e IRB/IEC
the
e IRB/IEC
ientific 
or v
ientific m
v
m
cts to the 
s o
cts to the 
d to provi
ons
d to provi
atio
si
ation of s
sio
n of s
l generall
ens
l generall
idual site 
xten
idual site 
application and any ex
agreemen
ext
agreemen
tual agree
ny e
tual agree
p requirem
any
p requirem


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 115 of 202
10.2
Appendix 2: Clinical laboratory tests
•
The tests detailed in Table 10-1 will be performed by the central laboratory, with the 
exception of platelet count assessments.
•
With the exception of platelet counts, local laboratory results are only required in the event 
that the central laboratory results are not available in time for either IMP administration 
and/or response evaluation. If a local sample is required, it is important that the sample for 
central analysis is obtained at the same time. Additionally, if the local laboratory results are 
used to make either a study treatment decision or response evaluation, the results must be 
entered into the eCRF.
•
Protocol-specific requirements for inclusion or exclusion of participants are detailed in 
Section 5.1 and Section 5.2 of the protocol, respectively.
•
Additional tests may be performed at any time during the study as determined necessary by 
the investigator or required by local regulations.
Table 10-1: Protocol-required safety laboratory assessments
Laboratory 
Assessments
Parameters
Hematology
Platelet Count 
(local laboratory)
a
Red blood cell (RBC) Indices:
Mean corpuscular volume (MCV)
Mean corpuscular hemoglobin 
(MCH)
White blood 
cell (WBC) 
Count with 
Differential:
Neutrophils
Lymphocytes
Monocytes
Eosinophils
Basophils
RBC Count
Hemoglobin
Hematocrit
Coagulation
International 
Normalized Ratio 
(INR)b
Activated partial thromboplastin 
time (aPTT)c
Fibrinogenc
Clinical Chemistryd
Blood Urea 
Nitrogen (BUN)
Potassium
Aspartate 
Aminotransferase 
(AST)/Serum 
Glutamic-Oxaloacetic 
Transaminase
(SGOT)
Total and direct 
bilirubin
Creatinine
Sodium
Alanine 
Aminotransferase
(ALT)/Serum 
Glutamic-Pyruvic 
Transaminase 
(SGPT)
Total Protein
PUBLIC COPY
OPY
PY 
Y
Red bloo
CO
Red bloo
C
Mean
C C
Mean
M
C
M
OP
IC
t
B
t
LIC
IC
IC
globin
PUB
globin
UB
ocrit
P
ocrit
PU
be used to support any marketing authorization 
s are
ori
s are
ust be
tho
ust be
etailed in
g a
etailed in
ermined n
keti
ermined n
sments
ma
sments
t an
any y
d cell (RBC
ort 
d cell (RBC
or
corpuscul
ppo
corpuscul
ean corpus
upp
ean corpus
(MCH)
su
(MCH)
t a
t
d t t
s document cannot be
Internation
t be
Internation
Normal
ot 
Normal
(INR
no
(INR
nn
be
n
try
c
tryd
a
d
nn
This d
s d
and any extensions or variations thereof.
n
necessary
the
necessary
varia
riatio
tio
C) Indices
r va
C) Indices
r v
lar volume
or
lar volume
scular hem
ns 
scular hem
va
y e
nal 
a
nal 
lized Rati
d a
lized Rati
R)
a
R)b
n
b
y
ny
tion an
Blood Ur
n a
Blood Ur
Nitrog
ion 
Nitrog
applicatio
an
tio


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 116 of 202
Laboratory 
Assessments
Parameters
Glucose (fasting 
state preferred)
Calcium
Alkaline phosphatase
C-reactive 
protein (CRP)
Immunoglobulinse
Albumin
Low-density 
lipoprotein (LDL)
High-density 
lipoprotein (HDL)
Total cholesterol
Triglycerides
Routine Urinalysis
•
Specific gravity
•
pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, 
leukocyte esterase by dipstick
•
Microscopic examination (if blood or protein is abnormal)
Other Screening Tests
•
Follicle-stimulating hormone and estradiol (as needed in women of 
non-childbearing potential only)
•
Serum or urine human chorionic gonadotropin (hCG) pregnancy test (as 
needed for women of childbearing potential)f
•
Serology (human immunodeficiency [HIV] antibody, hepatitis B surface 
antigen [HBsAg], and hepatitis C virus antibody)
•
All study-required laboratory assessments will be performed by a central 
laboratory except the platelet count which is done by local laboratory.
•
The results of each test must be entered into the electronic Case Report 
Form (eCRF).
a Platelet count testing will be performed by a local laboratory. Results will be unblinded to the investigator, site, 
and study participant (see Section 6.2.1.1).
b International Normalized Ratio (INR) to be done only at Screening (Visit 1) and for PDILI.
c Activated partial thromboplastin time (aPTT) and Fibrinogen will be done at all visits which require safety 
laboratory assessments.
d Details of liver chemistry stopping criteria and required actions and follow-up assessments after liver stopping 
or monitoring event are given in Section 7.1.1 and Appendix 6, Section 10.6. All events of ALT 3x upper limit 
of normal (ULN) and bilirubin 2xULN (>35% direct bilirubin) or ALT 3xULN and international normalized 
ratio (INR) >1.5, if INR measured, may indicate severe liver injury (possible Hy’s Law) and must be reported 
as a serious adverse event (SAE) (excluding studies of hepatic impairment or cirrhosis).
e Includes total IgG, IgG subclasses, IgA, IgM, and IgE. Results of the IgG testing including the vaccination 
specific titers will be blinded to the investigator, site, and sponsor for post baseline results.
f Local urine testing will be standard for the protocol unless serum testing is required by local regulation or 
Independent Review Board/Independent Ethics Committee.
Investigators must document their review of each laboratory safety report.
Laboratory/analyte results that could unblind the study will not be reported to study sites or other 
blinded personnel until the study has been unblinded.
PUBLIC COPY
ne 
Y
ne 
ial only)
PY 
ial only)
an chorio
OP
an chorio
n of chil
CO
n of chil
man imm
C C
man imm
HBsAg], a
LIC
HBsAg], a
udy
UB
udy-
B
-requ
BL
requ
oratory e
PUB
oratory e
he res
P
he res
used to support any marketing authorization 
za
obilinogen
etin
obilinogen
ein is abno
mar
ein is abno
a
radiol (as n
y m
radiol (as n
nic gonado
t an
nic gonado
bearing po
ort 
bearing po
unodeficie
ppo
unodeficie
nd hepatiti
upp
nd hepatiti
red laborat
o su
red laborat
xcept the p
to 
xcept the p
ts of each
ed t
ts of each
(eCRF).
sed
(eCRF).
ma
This document cannot be us
rmed by a l
us
rmed by a l
on
b
on 6.2.1.1
be u
6.2.1.1)
u
)
tio (INR) to
t be
tio (INR) to
plastin tim
ot b
plastin tim
mistry stopp
nn
mistry stopp
ent are give
can
ent are give
LN) and bil
t ca
LN) and bil
>1.5, if IN
nt c
>1.5, if IN
ous adverse
ent
ous adverse
des total Ig
me
des total Ig
ecific titers
um
ecific titers
Local urin
cu
Local urin
Indepen
doc
Indepen
us
Inve
s d
Inve
extensions or variations thereof.
n, nitrite,
her
n, nitrite,
ormal)
ns
ormal)
of
needed in 
tio
needed in 
otropin (hC
vari
otropin (hC
otential)
r va
otential)f
a
f
ency [HIV
or
ency [HIV
is C virus 
ns o
is C virus 
tory assess
ion
tory assess
platelet cou
nsio
platelet cou
h test must
ten
h test must
on
application and any ex
local labor
y ex
local labor
o be done o
any
o be done o
e (aPTT) a
d a
e (aPTT) a
ping criteri
and
ping criteri
en in Sectio
n a
en in Sectio
lirubin 
on
lirubin 
n
2x
 
2x
NR measure
tio
NR measure
e event (SA
cati
e event (SA
gG, IgG sub
lica
gG, IgG sub
s will be bli
plic
s will be bli
ne testing w
pp
ne testing w
dent Revie
ap
ent Revie
ex


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 117 of 202
10.3
Appendix 3: Adverse events – definitions and procedures for 
recording, evaluating, follow up, and reporting
10.3.1
Definition of AE
Adverse event (AE) Definition
•
An AE is any untoward medical occurrence in a patient or clinical study participant, 
temporally associated with the use of IMP, whether or not considered related to the IMP.
•
NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of IMP.
Events Meeting the AE Definition
•
Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from Baseline, considered clinically significant in the medical 
and scientific judgment of the investigator (ie, not related to progression of underlying 
disease).
•
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity of the condition.
•
New conditions detected or diagnosed after IMP administration even though it may have 
been present before the start of the study.
•
Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.
•
Signs, symptoms, or the clinical sequelae of a suspected overdose of either IMP or a 
concomitant medication. Overdose per se will not be reported as an AE/serious AE (SAE) 
unless it is an intentional overdose taken with possible suicidal/self-harming intent. Such 
overdoses should be reported regardless of sequelae.
•
"Lack of efficacy" or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments. 
However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will 
be reported as AE or SAE if they fulfil the definition of an AE or SAE.
PUBLIC COPY 
idere
Y
idere
, not rel
OPY
, not rel
nt pre
C CO
nt pre-
C
-ex
CO
ex
ty of the
IC C
ty of the
nosed af
BLIC
nosed af
of the stu
UBL
of the stu
linical s
PU
linical s
nic
P
nic
ting authorization 
P.
o
P.
ally 
ut
ally 
g a
za
rketitin
t cannot be used to support any mark
mistry, or 
mark
mistry, or 
signs mea
ma
signs mea
nically si
ny m
nically si
ted to pro
any
ted to pro
isting con
port
isting con
condition
ppo
condition
ter IMP ad
sup
ter IMP ad
dy.
o
dy.
equelae of
d to
equelae of
al sequela
sed
al sequela
verdose pe
use
verdose pe
overdose
e u
overdose
eported re
be
eported re
or "failur
ot b
or "failur
AE or SAE
nno
AE or SAE
e signs, sy
ann
e signs, sy
ed as AE o
t ca
ed as AE o
This document c
rk
t c
ereof.
of
ther
her
ion and any extensions or variations t
r urinalysi
ns 
r urinalysi
asuremen
tion
asuremen
ignificant
atio
ignificant
ogression 
aria
ogression 
ndition in
or v
ndition in
n.
s
n.
administra
ons
administra
f a suspec
ens
f a suspec
ae of a sus
xte
ae of a sus
er se will 
ext
er se will 
e taken wi
y e
e taken wi
egardless 
any
egardless 
ure of expe
d a
ure of expe
AE. Such i
and
AE. Such i
ymptoms
an
ymptoms
or SAE if
on 
or SAE if
applicatio
t
io


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 118 of 202
Events NOT Meeting the AE Definition
•
Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condition.
•
The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the study participant’s 
condition.
•
Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE.
•
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
•
Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.
10.3.2
Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met (eg, hospitalization for signs/symptoms of the disease under study, death due to 
progression of disease).
A SAE is defined as any untoward medical occurrence that, at any dose:
a.
Results in death
b.
Is life-threatening
The term “life-threatening” in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, which 
hypothetically might have caused death, if it were more severe.
c.
Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalization signifies that the participant has been detained (usually involving at 
least an overnight stay) at the hospital or emergency ward for observation and/or treatment that 
would not have been appropriate in the physician’s office or outpatient setting. Complications 
that occur during hospitalization are AEs. If a complication prolongs hospitalization or fulfills 
any other serious criteria, the event is serious. When in doubt as to whether “hospitalization” 
occurred or was necessary, the AE should be considered serious.
Hospitalization for elective treatment of a pre-existing condition that did not worsen from 
Baseline is not considered an AE.
d.
Results in persistent disability/incapacity
•
The term disability means a substantial disruption of a person’s ability to conduct normal 
life functions.
PUBLIC COPY
t canno
PY 
t canno
of the
OPY
of the dis
PY
dis
IC C
edical oc
C C
edical oc
C
IC
h
P
h
UB
be used to support any marketing authorization 
t’s
iz
t’s
leads to
tho
leads to
nd/or 
g a
nd/or 
dition(s) p
ketin
dition(s) p
ark
za
be an SAE
ny 
be an SAE
ease unde
t any
ease unde
ppo
currence 
ppo
currence 
o
pp
definition
sed
definition
at the tim
use
at the tim
aused deat
be u
aused deat
o s
document cannot be
nt hospita
ot b
nt hospita
lization si
nno
lization si
ht stay) at
ann
ht stay) at
ve been a
t ca
ve been a
during ho
nt c
during ho
er serious
men
er serious
urred or w
ume
urred or w
Hospitaliz
ocu
Hospitaliz
Baselin
doc
Baselin
This d
be
d
s d
d
d
s d
ny extensions or variations thereof.
present or
ther
present or
s
E even if 
riati
E even if 
er study, d
aria
er study, d
s or 
e that, at a
s or
e that, at a
r
s
n of “serio
xte
n of “serio
me of the e
ext
me of the e
ath, if it w
ny e
ath, if it w
io
application and any
alization 
d an
alization 
ignifies th
and
ignifies th
at the
n a
at the hosp
an
hosp
appropriat
on 
appropriat
ospitaliza
atio
ospitaliza
s criteria,
cat
s criteria,
was necess
plic
was necess
ization for
app
zation for
is not 
ap
is not 
ny


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 119 of 202
•
This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenzae, and 
accidental trauma (eg, sprained ankle) which may interfere with or prevent everyday life 
functions but do not constitute a substantial disruption.
e.
Is a congenital anomaly/birth defect
f.
Important medical events:
•
Medical or scientific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations such as important medical events that may not be 
immediately life-threatening or result in death or hospitalization but may jeopardize the 
participant or may require medical or surgical intervention to prevent one of the other 
outcomes listed in the above definition. These events should usually be considered serious.
Examples of such events include, but are not limited to potential Hy’s law, invasive or 
malignant cancers, intensive treatment in an emergency room or at home for allergic 
bronchospasm, blood dyscrasias or convulsions that do not result in hospitalization, or 
development of drug dependency or drug abuse.
PUBLIC COPY 
PY
ny marketing authorization 
za
rting is
tho
rting is
a
pardize th
g au
pardize th
of the oth
ng 
of the oth
e consider
eting
e consider
Hy’s law, i
rke
Hy’s law, i
r
m
r at home
mark
at home
esult in ho
ma
esult in ho
This document cannot be used to support any
za
ny
za
iations thereof.
he
o
he
her 
re
her 
ered seriou
here
ered seriou
invasive 
s th
invasive 
e for aller
ns 
e for aller
hospitaliza
ion
hospitaliza
application and any extensions or variations thereof
ia


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 120 of 202
10.3.3
Recording and Follow up of AE and/or SAE
AE and SAE Recording
•
When an AE/SAE occurs, it is the responsibility of the investigator to review all
documentation (eg, hospital progress notes, laboratory reports, and diagnostics reports) 
related to the event.
•
The investigator will then record all relevant AE/SAE information in the eCRF.
•
It is not acceptable for the investigator to send photocopies of the participant’s medical 
records to UCB in lieu of completion of the UCB AE/SAE eCRF page.
•
There may be instances when copies of medical records for certain cases are requested by 
UCB. In this case, all participant identifiers, with the exception of the participant number, 
will be redacted on the copies of the medical records before submission to UCB.
•
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study and assign it to 1 of the following categories:
•
Mild: An event that is easily tolerated by the participant, causing minimal discomfort and 
not interfering with everyday activities.
•
Moderate: An event that causes sufficient discomfort and interferes with normal everyday 
activities.
•
Severe: An event that prevents normal everyday activities. An AE that is assessed as 
severe should not be confused with a SAE. Severe is a category utilized for rating the 
intensity of an event; and both AEs and SAEs can be assessed as severe.
•
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe (eg, a severe AE may 
be either serious or not serious, depending on whether these criteria are also met).
The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-
CTCAE) should be used as a supportive standardization instrument to evaluate AEs and SAEs 
but the final intensity grading by the investigator must be mild, moderate, or severe.
Y
s t
Y
s t
OPY 
Y
PUBLIC COP
f intensit
CO
f intensit
ng categ
C C
ng categ
rated by 
BLIC
rated by 
activitie
UBL
activitie
auses su
PU
auses su
OP
y marketing authorization 
edical 
tho
edical 
re request
g a
re request
articipant 
ting
articipant 
on to UC
ketin
on to UC
t based on
ark
t based on
ble, the di
ma
ble, the di
/SAE.
y m
/SAE.
za
any
ny
ument cannot be used to support a
y for each
ort 
y for each
ories:
ppo
ories:
the partici
supp
the partici
o
fficient di
d to
fficient di
ents norma
use
ents norma
fused wit
be u
fused wit
and both 
t be
and both 
ed as “ser
not 
ed as “ser
he definiti
nno
he definiti
rious or n
can
rious or n
nal Cancer
nt c
nal Cancer
) should b
ent
) should b
he final in
me
he final in
This docum
t a
um
ations thereof.
ted by 
eof
ted by 
t number,
ereo
t number,
CB.
th
CB.
n signs,
s th
n signs,
iagnosis (
ons
iagnosis (
ariat
at
plication and any extensions or var
h AE and 
r va
h AE and 
ipant, cau
ns 
ipant, cau
scomfort
ns
scomfort
mal everyd
ex
mal everyd
th a SAE.
ny e
th a SAE.
AEs and 
any
AEs and 
rious” wh
nd a
rious” wh
ion of an 
and
ion of an 
not seriou
n a
not seriou
r Institute
tion
r Institute
be used a
cati
be used a
ntensity gr
lica
ntensity gr
appl
ar
pl


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 121 of 202
Assessment of Causality
•
The investigator is obligated to assess the relationship between IMP and each occurrence 
of each AE/SAE.
•
A "reasonable possibility" of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.
•
The investigator will use clinical judgment to determine the relationship.
•
Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to IMP administration will be 
considered and investigated.
•
The investigator will also consult the Investigator’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.
•
For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.
•
There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to UCB. However, it is very important that the 
investigator always makes an assessment of causality for every event before the initial 
transmission of the SAE data to UCB.
•
The investigator may change his/her opinion of causality in light of follow-up information 
and send a SAE follow-up report with the updated causality assessment.
•
The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.
Follow-up of AEs and SAEs
•
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by UCB to 
elucidate the nature and/or causality of the AE or SAE as fully as possible. This may 
include additional laboratory tests or investigations, histopathological examinations, or 
consultation with other health care professionals.
•
An AE should be followed until it has resolved, has a stable sequelae, the investigator 
determines that it is no longer clinically significant, the event is otherwise explained, or the 
participant is lost to follow up. This follow-up requirement applies to AEs, SAEs, and AEs 
of special interest.
•
If a participant dies during participation in the study or during a recognized Follow-up 
Period, the investigator will provide UCB with a copy of any post-mortem findings 
including histopathology.
•
New or updated information will be recorded in the originally completed eCRF.
•
The investigator will submit any updated SAE data to UCB within 24 hours of receipt of 
the information.
PUBLIC COPY
. H
Y
. H
causal
PY 
causal
nion of c
CO
nion of c
h the upd
C C
h the upd
f the crit
LIC
f the crit
UB
P
d to support any marketing authorization 
k 
h
k 
ll be
uth
ll be
roduct 
g a
roduct 
otes that h
keti
otes that h
ty.
a
ty.
e investig
ma
e investig
er,
y
er, it is ve
y m
it is ve
y for ever
ny 
y for ever
ausality 
ort 
ausality inin
ated causa
po
ated causa
eria used w
upp
eria used w
o s
za
sed 
d
s document cannot be us
ted to per
e us
ted to per
evaluation
be 
evaluation
and/or ca
ot b
and/or ca
l lab
not
l laborato
ot
orato
with other 
ann
with other 
ould be fo
can
ould be fo
ines that i
nt c
ines that i
cipant is 
ent
cipant is 
f special i
me
f special i
If a pa
cum
If a pa
Peri
c
Peri
i
•
This d
s
s d
ensions or variations thereof.
he/she has
the
he/she has
gator has 
ons
gator has 
ery impo
tion
ery impo
ry event b
riati
ry event b
n light of
r va
n light of
ality asse
or 
ality asse
when dete
ns o
when dete
io
exten
en
application and any ex
rform or a
y e
rform or a
ns as med
any
ns as med
ausality o
d an
ausality o
ory tests o
nd 
ory tests o
r health ca
and
r health ca
ollowed u
on a
ollowed u
it is no lon
tion
it is no lon
lost to fo
cati
lost to fo
interest.
lica
interest.
articipant 
ppl
articipant 
od,
a
od, the in
app
the in
ding
a
ding
ex


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 122 of 202
10.3.4
Reporting of SAEs
SAE Reporting to UCB via an Electronic Data Collection Tool
•
The primary mechanism for reporting an SAE to UCB will be the electronic data collection 
tool.
•
If the electronic system is unavailable for more than 24 hours, then the site will use the 
paper SAE data collection tool (see “SAE Reporting to UCB via Paper Case Report Form 
[CRF]” below).
•
The site will enter the SAE data into the electronic system as soon as it becomes available.
•
After the study is completed at a given site, the electronic data collection tool will be taken 
off-line to prevent the entry of new data or changes to existing data.
•
If a site receives a report of a new SAE from a study participant or receives updated data 
on a previously reported SAE after the electronic data collection tool has been taken off-
line, then the site can report this information on a paper SAE form (see “SAE Reporting to 
UCB via Paper CRF” below).
•
Contacts for SAE reporting can be found in SERIOUS ADVERSE EVENT REPORTING.
SAE Reporting to UCB via Paper CRF
•
Facsimile transmission of the SAE paper CRF is the preferred method to transmit this 
information to UCB; see SERIOUS ADVERSE EVENT REPORTING.
•
In rare circumstances and in the absence of facsimile equipment, notification by telephone 
is acceptable with a copy of the SAE data collection tool sent by overnight mail or courier 
service.
•
Initial notification via telephone does not replace the need for the investigator to complete 
and sign the SAE CRF pages within the designated reporting time frames.
•
Contacts for SAE reporting can be found in SERIOUS ADVERSE EVENT REPORTING.
OPY 
OU
Y
OU
Y
C CO
PUBLIC C
paper C
LIC 
paper C
US ADV
BLIC
US ADV
the abse
UB
the abse
of the SA
PU
of the SA
C C
t any marketing authorization 
m
ri
m
available.
utho
available.
will be ta
au
will be ta
eives upda
eting
eives upda
l has been
ket
l has been
m (see “SA
arke
m (see “SA
DVERSE E
y m
DVERSE E
ny
za
port a
t a
t be used to suppo
RF is the p
pp
RF is the p
VERSE EV
sup
VERSE EV
nce of fac
to s
nce of fac
AE data co
d to
AE data co
hone does
use
hone does
ages withi
e u
ages withi
orting can
t be
orting can
This document cannot b
po
t b
variations thereof.
aken 
of
aken 
dated data 
here
dated data 
n taken o
the
n taken o
SAE Repo
s th
SAE Repo
EVENT R
atio
EVENT R
at
or va
va
any extensions or 
preferred 
s o
preferred 
VENT RE
ons
VENT RE
csimile eq
sio
csimile eq
ollection 
ens
ollection 
s not repla
ext
s not repla
hin t
y
hin the des
y e
he des
n be foun
any
n be foun
application and a
or
a


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 123 of 202
10.4
Appendix 4: Contraceptive guidance and collection of 
pregnancy information
Definitions
Woman of childbearing potential (WOCBP)
A woman is considered fertile following menarche and until becoming post-menopausal unless 
permanently sterile (see below).
Women in the following categories are not considered WOCBP:
1. Premenarchal
2. Premenopausal female with 1 of the following:
−
Documented hysterectomy
−
Documented bilateral salpingectomy
−
Documented bilateral oophorectomy
Note: Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history interview.
3. Postmenopausal female 
−
A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. A high follicle stimulating hormone (FSH) level (>40mIU/mL) in the 
postmenopausal range may be used to confirm a postmenopausal state in women not 
using hormonal contraception or hormonal replacement therapy (HRT). However, in the 
absence of 12 months of amenorrhea, a single FSH measurement is insufficient.
−
Females on HRT and whose menopausal status is in doubt will be required to use one of 
the non-estrogen hormonal highly effective contraception methods if they wish to 
continue their HRT during the study. Otherwise, they must discontinue HRT to allow 
confirmation of postmenopausal status before study enrollment.
Contraception guidance
Male participants
Male participants with female partners of childbearing potential are eligible to participate if they 
agree to ONE of the following during the Treatment Period and for at least 3 months after the 
final dose of study treatment:
•
Are abstinent from penile-vaginal intercourse as their usual and preferred lifestyle (abstinent 
on a long term and persistent basis) and agree to remain abstinent.
•
Agree to use a male condom when having penile-vaginal intercourse with a woman of 
childbearing potential who is not currently pregnant.
In addition, male participants must refrain from donating sperm for the duration of the study and 
for 3 months after the final dose of study medication.
PUBLIC COPY
onn
Y
onn
ry interv
PY 
ry interv
s no me
C C
s no me
imulatin
LIC 
imulatin
e used to
BLIC
e used to
i
U
ion or h
UBL
on or h
f ameno
PU
f ameno
os
P
os
This document cannot be used to support any marketing authorization 
eview of t
y m
eview of t
ew.
an
ew.
nses for 1
por
nses for 1
g hormone
upp
g hormone
confirm a
sup
confirm a
ormonal re
to s
ormonal re
rhea, a sin
d to
rhea, a sin
menopau
sed
menopau
al highly 
use
al highly 
uring the s
e u
uring the s
stmenopau
be
stmenopau
dance
not
dance
nts
a
nts
ants with
t ca
ants with
NE of the
ent 
NE of the
ose of stud
men
ose of stud
Are absti
cum
Are absti
on a lo
ocu
on a lo
•
s d
•
A
application and any extensions or variations thereof.
the partici
atio
the partici
2 months
or v
2 months
ne (FSH) l
s o
ne (FSH) l
a postmen
ons
a postmen
eplaceme
sion
eplaceme
ingle FSH
nsi
ingle FSH
usal statu
xte
usal statu
effective 
ext
ffective 
study. Oth
y e
study. Oth
usal statu
any
usal statu
t
female p
tion
female p
e followin
atio
e followin
dy treatm
lica
dy treatm
tinent from
ppl
tinent from
ong term 
app
ong term 


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 124 of 202
Male participants with a pregnant or breastfeeding partner must agree to remain abstinent from 
penile-vaginal intercourse or use a male condom during each episode of penile penetration 
during the Treatment Period and for at least 3 months after the final dose of study treatment.
Female participants
Female participants of childbearing potential are eligible to participate if they agree to use a 
highly effective method of contraception consistently and correctly as described in Table 10-2.
Table 10-2: Highly effective contraceptive methods a
Highly Effective Contraceptive Methods That Are User Dependent b
Failure rate of <1% per year when used consistently and correctly.
Combined (estrogen- and progesterone-containing) hormonal contraception associated with 
inhibition of ovulation
• Oral
• Intravaginal
• Transdermal
Progesterone only hormonal contraception associated with inhibition of ovulation
• Oral
• Injectable
Highly Effective Methods That Are User Independent
Implantable progesterone only hormonal contraception associated with inhibition of ovulation
• Intrauterine device (IUD)
• Intrauterine hormone-releasing system (IUS)
• Bilateral tubal occlusion
Vasectomized partner
Vasectomy is a highly effective contraception method provided that the vasectomized partner is 
the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If 
not, an additional highly effective method of contraception should be used.
Sexual abstinence
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study medication. 
The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study 
and the preferred and usual lifestyle of the participant.
a In case of newly started contraception pills/IUDs, the primary investigator should consider the correct timing of 
starting/applying such methods in relation to the menstrual cycle and the manufacturing instruction as when these 
newly started methods would become effective.
b Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent 
with local regulations regarding the use of contraceptive methods for participants in clinical studies.
PUBLIC COPY 
ciated w
OPY
ciated w
PY
re User I
BLIC
re User I
IC
hormona
PUB
hormona
BL
cannot be used to support any marketing authorization 
th
n associat
eting
n associat
ng
th inhibiti
t any
th inhibiti
ny
ndepende
sup
ndepende
pp
contracep
to s
contracep
g system (
sed
g system (
su
y effective
ot 
y effective
al partner 
nno
al partner 
al highly e
ann
al highly e
e
document ca
nence
t ca
nence
bstinence
ent
bstinence
osexual in
me
osexual in
e reliabili
cum
e reliabili
and the p
ocu
and the p
ca
This do
a
d
a In case
do
In case
star
d
star
doc
n and any extensions or variations thereof.
ated with 
here
ated with 
eo
ion of ovu
aria
ion of ovu
ria
ent
on
ent
s o
ption asso
sio
ption asso
(IUS)
exte
(IUS)
on
e contrace
d a
e contrace
of the W
and
of the W
effective 
n an
effective 
y
application 
e is consid
catio
e is consid
ntercourse
lica
ntercourse
ity of sex
pplic
ity of sex
preferred a
app
referred a
n
ap
ewly 
a
ewly 
ap


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 125 of 202
Pregnancy testing
•
WOCBP should only be included after a confirmed menstrual period and a negative highly 
sensitive urine pregnancy test.
•
Additional urine pregnancy testing should be performed at time points specified in the 
Schedule of Activities (Section 1.3) and as required locally.
•
Pregnancy testing will be performed whenever a menstrual cycle is missed or when 
pregnancy is otherwise suspected.
•
Pregnancy testing with a sensitivity of 25mIU/mL will be performed. A serum pregnancy test 
will be performed to confirm a positive urine pregnancy test.
Male participants with partners who become pregnant
•
The investigator will attempt to collect pregnancy information on any male participant’s 
female partner who becomes pregnant while the male participant is in this study. This applies 
only to male participants who receive IMP.
•
After obtaining the necessary signed informed consent from the pregnant female partner 
directly, the investigator will record pregnancy information on the appropriate form and 
submit it to the sponsor within one working day of learning of the partner’s pregnancy. The 
female partner will also be followed to determine the outcome of the pregnancy. Information 
on the status of the mother and child will be forwarded to the sponsor. Generally, the follow-
up will be at least 12 months after the delivery date. Any termination of the pregnancy will 
be reported regardless of fetal status (presence or absence of anomalies) or indication for the 
procedure.
Female participants who become pregnant
•
Any female participant who becomes pregnant while participating in the study will be 
withdrawn from the study
•
The investigator will collect pregnancy information on any female participant who becomes 
pregnant while participating in this study. Information will be recorded on the appropriate 
form and submitted to the sponsor within one working day of learning of a participant's 
pregnancy. The participant will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow-up information on the participant and the neonate and the 
information will be forwarded to the sponsor. Generally, the follow-up will be at least 
12 months after the delivery date. Any termination of pregnancy will be reported, regardless 
of fetal status (presence or absence of anomalies) or indication for the procedure.
•
While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy will be reported as an AE or SAE. A spontaneous 
abortion is always considered to be an SAE and will be reported as such. Any post-study 
pregnancy-related SAE considered reasonably related to the IMP by the investigator will be 
reported to the sponsor as described in Section 8.3.5. While the investigator is not obligated 
to actively seek this information in former study participants, he or she may learn of an SAE 
through spontaneous reporting.
PUBLIC COPY
se
Y
se
nforma
PY 
nforma
ay of lea
OPY
ay of lea
ermine t
COP
ermine t
ll be for
C CO
ll be for
e deliver
IC C
e deliver
tus (pres
BLIC
tus (pres
becom
PU
becom
This document cannot be used to support any marketing authorization 
egnancy te
uth
egnancy te
male part
ketin
male part
in this stu
rke
in this stu
the pregn
y m
the pregn
on on the 
ny 
on on the 
rning of th
t any
rning of th
he outcom
ort a
he outcom
warded to 
por
warded to 
y date. An
ppo
y date. An
ence or ab
sup
ence or ab
e pregna
ed t
e pregna
ecomes pr
use
ecomes pr
ollect preg
t be
ollect preg
cipating i
ot b
cipating i
ted to the 
nno
ted to the 
he particip
ann
he particip
r will coll
ca
r will coll
ion will b
nt c
ion will b
onths afte
ent
onths afte
fetal statu
me
fetal statu
While p
ocu
While p
elect
oc
elect
ab
o
ab
application and any extensions or variations thereof.
ticipant’s
ther
ticipant’s
udy. This
s th
udy. This
nant fema
tion
nant fema
 appropri
iati
 appropri
the partne
aria
the partne
me of the p
va
me of the p
 the spon
or v
 the spon
n
s
ny termin
s o
y termin
bsence of 
ons 
bsence of 
ant
ten
ant
pregnant w
exte
pregnant w
egnancy in
any
egnancy in
in this stu
d a
in this stu
sponsor w
nd 
sponsor w
pant will b
an
pant will b
lect follow
on a
lect follow
be for
tion
be forwar
on
war
er the deli
cati
er the deli
us (presen
plica
us (presen
pregnanc
app
pregnanc
ve termi
ap
e termi
isi


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 126 of 202
10.5
Appendix 5: Genetics
Use and Analysis of DNA
•
Genetic variation may impact a participant’s response to IMP, susceptibility to, and severity 
and progression of disease. Variable response to IMP may be due to genetic determinants 
that impact drug absorption, distribution, metabolism, and excretion; mechanism of action of 
the drug; disease etiology; and/or molecular subtype of the disease being treated. Therefore, 
where local regulations and IRB/IEC allow, a blood sample will be collected for 
deoxyribonucleic acid (DNA) analysis from consenting participants. DNA samples will be 
used for research related to cause, progression, and appropriate treatment of ITP. They may 
also be used to develop tests/assays including diagnostic tests related to rozanolixizumab and 
ITP. Genetic research may consist of the analysis of 1 or more candidate genes or the 
analysis of genetic markers throughout the genome.
•
The samples may be analyzed as part of a multi-study assessment of genetic factors involved 
in the response to rozanolixizumab or IMPs of this class to understand ITP or related 
conditions.
•
The results of genetic analyses may be reported in the clinical study report or in a separate 
study summary.
•
The sponsor will store the DNA samples in a secure storage space with adequate measures to 
protect confidentiality.
•
The samples will be retained while research on rozanolixizumab continues, but no longer 
than 20 years or other period as per local requirements.
BLIC COPY
in the c
PY 
in the c
in a sec
CO
in a sec
e resear
BLIC
e resear
PUB
s per loc
UBL
s per loc
support any marketing authorization 
f 
z
f 
ore,
ri
ore,
will be
tho
will be
. They ma
auth
. They ma
nolixizum
g au
nolixizum
enes or th
ing 
enes or th
of genetic 
rke
of genetic 
rstand ITP
mar
rstand ITP
nical stud
ny 
nical stud
ure storage
ort 
ure storage
h on
su
h on roza
up
roza
This document cannot be used to 
al requirem
o su
al requirem
application and any extensions or variations thereof.
may 
f
may 
mab
of
mab and 
of.
and 
he 
r
he 
c factors in
s th
c factors in
TP or relat
ns 
TP or relat
dy report 
riati
dy report 
ge space w
r va
ge space w
anolixiz
ns
anolixizum
 
um
ments.
sion
ments.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 127 of 202
10.6
Appendix 6: Liver safety – suggested actions and follow-up 
assessments
Study treatment, including all concomitant medications and herbal supplements that are not 
medically necessary, should be discontinued immediately in study participants with suspected 
PDILI. These study participants must be assessed thoroughly and followed up closely during the 
Treatment Period for confirmation of PDILI. Because study participants in TP0006 will be 
provided the chance to enroll in the OLE study TP0004 upon completion of TP0006, if PDILI is 
confirmed, these study participants must not be enrolled in the OLE study TP0004.
Investigators should attempt to obtain information on study participants to complete the final 
evaluation.
Study participants with PDILI should not be withdrawn from the study until investigation and 
monitoring are complete. All results of these evaluations and observations, as well as the 
reason(s) for study participant withdrawal (if applicable, eg, withdrawal of consent), must be 
recorded in the source documents. The eCRF must document the primary reason for study 
withdrawal in such a case.
A specific monitoring plan must be agreed between the UCB study physician and the 
investigator for study participants who have ALT >5 ULN. The monitoring plan should include 
any necessary follow-up assessments (until resolution of the abnormal lab values).
Phase 3-4 liver chemistry stopping criteria are designed to assure participant safety and to 
evaluate liver event etiology (Table 10-3).
Phase 3-4 liver chemistry increased monitoring criteria with continued IMP are designed to 
assure participant safety and to evaluate liver event etiology (Table 10-4). 
PUBLIC COPY 
he UC
Y
he UC
>5 ULN
OPY
>5 ULN
olution o
COP
olution o
are desig
C CO
are desig
)
I
).
IC
.
monitor
BLI
monitor
valuate l
UB
valuate l
This document cannot be used to support any marketing authorization 
LI is 
riz
LI is 
the final
uth
the final
nvestigatio
ing 
nvestigatio
as well as
eting
as well as
of consen
ket
of consen
mary reaso
ark
mary reaso
study phy
ny m
study phy
The mon
any
The mon
f the abno
rt a
f the abno
ned to ass
por
ned to ass
ng criteria
sup
ng criteria
ver event 
to s
ver event 
application and any extensions or variations thereof.
ion and 
reo
ion and 
as the 
her
as the 
nt), must 
the
nt), must 
on for stu
ns t
on for stu
ysician an
atio
ysician an
nitoring pl
aria
nitoring pl
ormal lab 
var
ormal lab 
sure parti
or v
sure parti
a with con
ons
a with con
t etiology 
sio
t etiology 


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 128 of 202
Table 10-3: Phase 3-4 liver chemistry stopping criteria and follow-up 
assessments
Liver Chemistry Stopping Criteria
ALT-absolute
ALT 8xULN
ALT Increase
ALT 5xULN but <8xULN persists for 2 weeks
ALT 3xULN but <5xULN persists for 4 weeks
Bilirubin a b
ALT 3xULN and bilirubin 2xULN (>35% direct bilirubin) 
INR b
ALT 3xULN and international normalized ratio (INR) >1.5, if INR measured
Cannot 
Monitor
ALT 5xULN but <8xULN and cannot be monitored weekly for 2 weeks
ALT 3xULN but <5xULN and cannot be monitored weekly for 4 weeks
Symptomatic c
ALT 3xULN associated with symptoms (new or worsening) believed to be related 
to liver injury or hypersensitivity
Suggested Actions and Follow-Up Assessments
Actions
Follow-Up Assessments
•
Immediately discontinue IMP.
•
Report the event to UCB within
24 hours.
•
Complete the liver event electronic Case 
Report Form (eCRF), and complete a 
serious adverse event (SAE) data 
collection tool if the event also met the 
criteria for an SAE. b
•
Perform liver chemistry follow-up 
assessments. 
•
Monitor the participant until liver 
chemistry test abnormalities resolve, 
stabilize, or return to Baseline (see 
MONITORING).
•
Do not restart/rechallenge participant 
with IMP unless allowed per protocol 
and UCB approval is granted.
If restart/rechallenge not allowed per protocol 
or not granted, permanently discontinue IMP 
and continue participant in the study for any 
protocol specified follow up assessments. 
Consider the need for a toxicology screening.
MONITORING:
For bilirubin or INR criteria:
•
Viral hepatitis serology d
•
Obtain INR and recheck with each liver 
chemistry assessment until the 
transaminases values show downward 
trend
•
Only in those with underlying chronic 
hepatitis B at study entry (identified by 
positive hepatitis B surface antigen), 
quantitative hepatitis B deoxyribonucleic 
acid (DNA) and hepatitis delta antibody e
•
Obtain blood sample for pharmacokinetic 
(PK) analysis as soon as feasible after the 
most recent dose f
•
Serum creatine phosphokinase (CPK) and 
lactate dehydrogenase (LDH)
•
Fractionate bilirubin, if total bilirubin 
2xULN
•
Obtain complete blood count with 
differential to assess eosinophilia
•
Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on the adverse event (AE) 
report form
OPY 
w
Y
w-
Y
-
Y
PY 
CO
•
CO
•
O
PUBLIC C
tronic C
UBL
tronic C
complet
PU
complet
E) da
P
E) da
C
t any marketing authorization 
a
za
ho
R measure
au
R measure
ut
or 
i
or 
n
2 week
ng
2 week
ly for 
keti
ly for 
tin
4 w
n
4 w
g a
ening) bel
arke
ening) bel
ke
sessment
y m
sessment
m
Follow
any
Follow
ny
support a
Viral hepa
port
Viral hepa
Obtain
ppo
Obtain
che
p
che
t a
s document cannot be used to s
ase 
to
ase 
e a 
d
e a 
a
e
a
o met the
sed
o met the
y follow
be 
y follow
ticipant un
no
ticipant un
t abnorma
ann
t abnorma
or return t
can
or return t
TORING
nt c
TORING
not resta
men
not resta
with IMP 
ume
with IMP 
and UC
cum
and UC
If restart
doc
If restart
or no
do
or no
an
d
an
This d
s d
o s
variations thereof.
ed
o
ed
ks
r
ks
weeks
her
weeks
of
lieved to b
s th
lieved to b
th
ts
at
ts
on
Up Asse
aria
Up Asse
iat
xtensions or va
atitis sero
or v
atitis sero
n INR and
s or
n INR and
emistry as
ns 
emistry as
transamin
ion
transamin
trend
nsio
trend
•
te
•
On
n
On
va
application and any ext
e
e
e
up
an
up
until liver 
nd 
until liver 
malities res
an
malities res
to Baselin
on a
to Baselin
G
t
G).
ti
).
art/rechal
cat
art/rechal
unless al
plic
unless al
CB
p
CB approv
ppl
approv
rechallen
ap
echallen
nted
a
nted
xt


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 129 of 202
•
Repeat liver chemistry tests (include 
ALT, aspartate transaminase [AST], 
alkaline phosphatase, bilirubin) and 
perform liver event follow-up 
assessments within 24 hours.
•
Monitor participant twice weekly until 
liver chemistry test abnormalities 
resolve, stabilize, or return to Baseline.
•
A specialist or hepatology consultation is 
recommended.
For all other criteria
•
Repeat liver chemistry tests (include 
ALT, AST, alkaline phosphatase, 
bilirubin) and perform liver chemistry 
follow-up assessments within 24 to 72 
hours.
•
Monitor participants weekly until liver 
chemistry abnormalities resolve, 
stabilize, or return to Baseline.
•
Record use of concomitant medications 
(including acetaminophen, herbal 
remedies, and other over-the-counter 
medications) on the concomitant 
medications eCRF.
•
Record alcohol use on the liver event 
alcohol intake eCRF
•
Exclude pregnancy
For bilirubin or INR criteria:
•
Anti-nuclear antibody, anti-smooth muscle 
antibody, Type 1 anti-liver kidney 
microsomal antibodies, and quantitative 
total immunoglobulin G (IgG) or gamma 
globulins g
•
Serum acetaminophen concentration and 
serum acetaminophen adduct assay (where 
available) for assessing the potential 
acetaminophen contribution to liver injury 
•
Liver imaging (ultrasound, magnetic 
resonance, or computerized tomography) 
and/or liver biopsy to evaluate liver 
disease; complete Liver Imaging and/or 
Liver Biopsy eCRFs
a Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue IMP if ALT ≥3xULN and bilirubin ≥2xULN. Additionally, if serum 
bilirubin fractionation testing is unavailable, record the absence/presence of detectable urinary bilirubin on 
dipstick, which is indicative of direct bilirubin elevations suggesting liver injury.
b All events of ALT ≥3xULN and bilirubin ≥2xULN (>35% direct bilirubin) or ALT ≥3xULN and INR >1.5 
may indicate severe liver injury (possible ‘Hy’s Law’) and must be reported as an SAE (excluding studies 
of hepatic impairment or cirrhosis). The INR measurement is not required, and the stated threshold value will 
not apply to participants receiving anticoagulants.
c New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness, or jaundice) or hypersensitivity (such as fever, rash or eosinophilia).
d Includes: Hepatitis A immunoglobulin M (IgM) antibody; HBsAg and HBcAb; hepatitis C RNA; 
cytomegalovirus IgM antibody; Epstein-Barr viral capsid antigen IgM antibody (or if unavailable, heterophile 
antibody or monospot testing); and hepatitis E IgM antibody.
e If hepatitis delta antibody assay cannot be performed, it can be replaced with a polymerase chain reaction (PCR) 
of hepatitis D RNA virus (where needed) [Le Gal, 2005].
f Pharmacokinetic sample may not be required for participants known to be receiving placebo or non-comparator 
interventions. Record the date/time of the PK blood sample draw and the date/time of the final dose of IMP 
prior to the PK blood sample draw on the eCRF. If the date or time of the final dose is unclear, provide the 
participant’s best approximation. If the date/time of the final dose cannot be approximated OR a PK sample 
cannot be collected in the time period indicated above, do not obtain a PK sample. Instructions for sample 
handling and shipping are in the Pharmacy Manual.
g These tests should be obtained when IgG levels are approaching normal levels because IMP may interfere with 
IgG levels and interpretation.
PUBLIC COPY
ru
Y
ru
availa
PY 
availa
aceta
OPY
aceta
•
CO
•
L
O
L
C
PU
uld be pe
PU
uld be pe
IMP
P
IMP
PU
This document cannot be used to support any marketing authorization 
mooth mu
au
mooth mu
r kidney 
ng a
r kidney 
and quan
ting
and quan
n G (IgG)
keti
n G (IgG)
minophen
ma
minophen
aminophe
y m
aminophe
e) for asse
ny 
e) for asse
minophen
t an
minophen
iver imag
ort 
iver imag
resonan
po
resonan
and/o
pp
and/o
di
p
di
o s
za
formed if te
d to
formed if te
if ALT
ed
if ALT ≥
d 
≥3x
3x
ilable, 
se
ilable, reco
e
reco
ect bilirubin
us
ect bilirubin
bilirubin 
be u
bilirubin 
ury
b
ury (possib
be
(possib
r cirrhosis)
ot b
r cirrhosis)
s receiving
not
s receiving
ympt
nn
ymptoms b
nno
oms b
ain or tende
an
ain or tende
atitis A imm
t ca
atitis A imm
ovirus IgM 
nt c
ovirus IgM 
y or monosp
ent
y or monosp
patitis delta
me
patitis delta
hepatitis D
um
hepatitis D
Pharmaco
cu
Pharmaco
interven
doc
interven
prior
do
prior
p
d
p
to
sions or variations thereof.
uscle
of
uscle
ntitative
ere
ntitative
G) or gamm
the
G) or gamm
concentra
ons
concentra
en
t
en adduct
tion
adduct
sessing the
riati
sessing the
n contribu
aria
n contribu
ging (ultra
r va
ging (ultra
nce, or com
or 
nce, or com
or liver bi
s o
or liver bi
isease; co
ons
isease; co
Liver Bi
sio
Liver Bi
application and any extens
esting is av
ens
esting is av
xULN
te
xULN and 
en
and 
ord the ab
exte
ord the ab
n elevation
ex
n elevation
≥
n
≥2xULN (>
ny e
2xULN (>
le ‘Hy’s L
any
le ‘Hy’s L
).
d
). The INR
d an
The INR
g anticoagul
nd 
g anticoagul
believed to 
and
believed to 
erness, or j
n a
erness, or j
munoglobu
on 
munoglobu
antibody; E
tio
antibody; E
pot testing)
cati
pot testing)
a antibody a
lica
a antibody a
D RNA viru
plic
D RNA viru
kinetic sam
app
kinetic sam
tions. Rec
ap
ions. Rec
PK
a
PK
s


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 130 of 202
Table 10-4: Phase 3-4 liver chemistry increased monitoring criteria with 
continued IMP
Liver Chemistry Increased Monitoring Criteria
Criteria
Actions
ALT 5xULN and <8xULN and
bilirubin <2xULN without symptoms 
believed to be related to liver injury or 
hypersensitivity, and who can be 
monitored weekly for 2 weeks.
OR
ALT 3xULN and <5xULN and
bilirubin <2xULN without symptoms 
believed to be related to liver injury or 
hypersensitivity, and who can be 
monitored weekly for 4 weeks.
•
Notify the UCB Medical Monitor within 
24 hours of learning of the abnormality to discuss 
participant safety.
•
Participant can continue IMP
•
Participant must return weekly for repeat liver 
chemistry tests (ALT, AST, alkaline phosphatase, 
bilirubin) until the abnormalities resolve, 
stabilize, or return to Baseline.
•
If at any time, the participant meets liver 
chemistry stopping criteria, proceed as described 
in Section 7.1.1.
•
If ALT decreases from ALT 5xULN and
<8xULN to ≥3xULN but <5xULN, continue to 
monitor liver chemistries weekly.
•
If, after 4 weeks of monitoring, ALT <3xULN 
and bilirubin <2xULN, monitor participants twice 
monthly until liver chemistry tests resolve, 
stabilize, or return to Baseline.
REFERENCES
Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, Dény P, Gault E. Quantification of 
Hepatitis Delta Virus RNA in Serum by Consensus Real-Time PCR Indicates Different Patterns 
of Virological Response to Interferon Therapy in Chronically Infected Patients. J Clin Microbiol. 
2005;43(5):2363–2369.
LIC COPY 
on
Y
on 7
Y
7
LT decr
OPY
LT decr
<8xULN
COP
<8xULN
monit
CO
monit
•
C
•
If,
C C
If,
PUBLI
PU LI
used to support any marketing authorization 
scuss
oriz
scuss
repeat liv
g a
repeat liv
aline phos
ing 
aline phos
ties resolv
eting
ties resolv
eline.
ke
eline.
icipant m
mark
icipant m
criteria, p
ma
criteria, p
ases from
any
ases from
to ≥3xUL
rt a
to ≥3xUL
r liver ch
port
r liver ch
after 4 we
pp
after 4 we
and biliru
sup
and biliru
monthl
o su
monthl
stab
o 
stab
be 
d t
za
i D, Hans
be u
i D, Hans
This document cannot b
A in Serum
t be
A in Serum
e to Interfe
ot b
e to Interfe
69.
n
69.
nsions or variations thereof.
ver 
o
ver 
sphatase,
reo
sphatase,
lve,
he
lve,
meets liver
ns 
meets liver
proceed a
ion
proceed a
m ALT
aria
m ALT 
a
5
LN but <5
var
LN but <5
hemistries
or v
hemistries
eeks of m
s o
eeks of m
ubin <2xU
ons 
ubin <2xU
hly until li
sion
hly until li
bilize, or r
nsio
bilize, or r
ny extensions or variations thereof
n
slik T, All
ny e
slik T, All
application and an
m by Con
any
m by Con
feron The
d a
feron The


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 131 of 202
10.7
Appendix 7: Medical device incidents – definition and 
procedures for recording, evaluating, follow up, and reporting
Not applicable.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 132 of 202
10.8
Appendix 8: Country-specific requirements
Moldova
Specific requirements for study participants in Moldova include a description of vaccination for 
splenectomized study participants who have not received vaccinations according to current 
medical practice and are being considered for the study. Vaccinations in splenectomized patients 
are not routinely performed in Moldova, and the patients likely carry an undeterminable 
increased risk for infections. Hence, study participants who are being considered for the study 
will be administered vaccines accordingly to the schedule as per Table 1-3.
Poland
The Polish Health Authority’s and Clinical Trial Facilitation Group have made recommendations 
related to contraception and pregnancy testing in a clinical study with IMP where the human data 
for exposure at pregnancy and nonclinical reproductive toxicology data are not available. As a 
mitigation measure, pregnancy testing is to be implemented monthly up to 2 months after the 
final dose of IMP. A urine pregnancy test is added at 4 weeks after final IMP administration, at 
Week 27 (Visit 28) for sites located in Poland, thus it meets the above requirement. Based on the 
short half-life of IMP and because genotoxicity is not a class effect of the monoclonal antibodies, 
it is considered safe to reduce the duration of post-IMP administration requirement on 
contraception for female study participants of childbearing potential from 3 months to 2 months, 
with implementation of monthly pregnancy testing during this period.
Romania
Previously, in TP0001, the Romanian authorities introduced the following specific requirement 
for Romania: change in duration for the use of permitted oral corticosteroids (prednisolone) from 
a stable dose of 
 prior to the Baseline Visit (Visit 2). It is recommended for 
sites located in Romania, that oral corticosteroids (prednisone) need to be stable for 
rather than 
 as mentioned in Table 6-2 of this protocol.
PUBLIC COPY
a cla
Y
a cla
IMP adm
PY 
IMP adm
hildbear
OP
hildbear
esting du
CO
esting du
n author
BLI
n author
for the u
UB
for the u
pri
PU
pri
al c
P
al c
PU
This document cannot be used to support any marketing authorization 
udy 
or
udy 
recommen
g a
recommen
here the h
ting
here the h
e not avai
etin
e not avai
p to 2
rke
p to 2 mon
ke
mon
inal IMP 
mark
inal IMP 
bove requ
ma
bove requ
ffect of th
ny m
ffect of th
ministratio
any
ministratio
ng potenti
rt a
ng potenti
uring this p
ort 
uring this p
ties introd
sup
ties introd
e of perm
to s
e of perm
or to the B
d to
or to the B
orticostero
ed 
orticostero
inin Table
se
Table
application and any extensions or variations thereof.
ndations 
eof
ndations
human da
ereo
human da
ilable. As
her
ilable. As
nths after
th
nths after
administ
ns 
administ
uirement. 
ion
uirement. 
he monoc
atio
he monoc
on require
riat
on require
tial from 3
var
tial from 3
period.
r va
period.
duced the
ons
duced the
mitted oral
sio
mitted oral
Baseline V
ens
Baseline V
oids (pred
xten
oids (pred
6
e
6-
e
-2
ex
2 of thi
exte
of thi


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 133 of 202
10.9
Appendix 9: Abbreviations and trademarks
ADA
antidrug antibodies
ADL
activity of daily living
AE
adverse event
AESM
adverse event of special monitoring
ALP
alkaline phosphatase
ALT
alanine aminotransferase
app
application
AST
aspartate aminotransferase
BP
blood pressure
CDC
Centers for Disease Control and Prevention
CI
confidence interval
CIDP
chronic inflammatory demyelinating polyradiculoneuropathy
COVID-19
coronavirus disease 2019
CPM
Clinical Project Manager
CRF
Case Report Form
CRO
contract research organization
DCP
Data Cleaning Plan
DNA
deoxyribonucleic acid
ECG
electrocardiogram
eCRF
electronic Case Report Form
EOS
End of Study
EQ-5D-5L
European Quality of Life Health Status Questionnaire-5 Dimensions, 
5 Levels
eqv
equivalent
EudraCT
European Union Drug Regulating Authorities Clinical Trials
EW
early withdrawal
FAS
Full Analysis Set
FcRn
neonatal Fc receptor
FIH
first-in-human
FSH
follicle stimulating hormone
GCP
Good Clinical Practice
PUBLIC COPY
elinatin
PY 
elinatin
9
O
9
nager
C CO
nager
rm
LIC
rm
earch or
UBL
earch or
leaning P
PUB
leaning P
bon
P
bon
This document cannot be used to support any marketing authorization 
polyradic
ny 
polyradic
ganization
su
ganization
lan
d t
lan
ucleic acid
ed 
ucleic acid
ardiogram
us
ardiogram
tronic Ca
be 
tronic Ca
End of St
ot b
End of St
Europ
nno
Europ
5
n
5
T
FAS
oc
FAS
FcRn
do
FcRn
F
application and any extensions or variations thereof.
culoneuro
iati
culoneuro
n
i
n
d
x
d
m
ase Repor
ny 
ase Repor
tudy
d a
tudy
opean Qua
and
opean Qua
Levels
n an
Levels
equiva
tion
equiva
Eu
t
Eu


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 134 of 202
GI
gastrointestinal
HBsAg
hepatitis B surface antigen
HIV
human immunodeficiency virus
HRQoL
Health-Related Quality of Life
HRT
hormone replacement therapy
IB
Investigator's Brochure
ICF
Informed Consent Form
ICH
International Council for Harmonisation
IDMC
Independent Data Monitoring Committee
IEC
Independent Ethics Committee
Ig
immunoglobulin 
IGRA
interferon-gamma release assay
IMP
investigational medicinal product
INR
International Normalized Ratio
IRB
Institutional Review Board
IRT
interactive response technology
ITP
primary immune thrombocytopenia
ITP-BAT
ITP–Bleeding Assessment Tool
ITP-PAQ
ITP-Patient Assessment Questionnaire
iv
intravenous
IVIg
intravenous immunoglobulin
K-PD
kinetic-pharmacodynamic
LLOQ
lower limit of quantification
LTB
latent tuberculosis
LTBI
latent tuberculosis infection
MG
myasthenia gravis
NTMBI
nontuberculous mycobacterial infection
OLE
open-label extension
OPSI
overwhelming post-splenectomy infection
PD
pharmacodynamic
PDILI
potential drug-induced liver injury
PD-PPS
Pharmacodynamic Per-Protocol Set
PUBLIC COPY 
oduct
PY
oduct
d Ratio
OPY
d Ratio
Board
CO
Board
onse tech
LIC 
onse tech
mune thr
BL
mune thr
eeding A
PUB
eeding A
ent
P
ent
This document cannot be used to support any marketing authorization 
nology
upp
nology
ombocyto
sup
ombocyto
ssessmen
d to 
ssessmen
Assessme
ed 
Assessme
ous
u
ous
venous
be 
venous im
im
kinetic
ot b
kinetic-ph
b
ph
lower
nno
lower
la
n
la
TMBI
um
TMBI
OLE
doc
OLE
OP
d
OP
any extensions or variations thereof.
openia
ions
openia
nt Tool
nsio
nt Tool
ent Quest
xten
ent Quest
mmunogl
ny 
mmunogl
application and a
harmacod
d an
harmacod
er limit of 
and
er limit of 
atent tube
n a
atent tube
latent 
tio
latent 
m


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 135 of 202
PEX
plasma exchange
PGI-C
Patient Global Impression of Change
PGI-S
Patient Global Impression of Severity
PK
pharmacokinetic
PK-PPS
Pharmacokinetic Per-Protocol Set
PPS
Per-Protocol Set
PRO
patient reported outcome
PS
Patient Safety
QMG
Quantitative MG 
QoL
quality of life
QTc
corrected QT interval
QW
once a week
Q2W
twice a week
RNA
ribonucleic acid
RO
receptor occupancy
SAE
serious adverse event
SAP
Statistical Analysis Plan
sc
subcutaneous
SF-36
Short-Form 36-Item Health Survey
SFU
Safety Follow-Up
SMOG
Skin-mucosae-organs tool
SOP
standard operating procedure
SS
Safety Set
TB
tuberculosis
TEAE
treatment-emergent adverse event
TPO-RA
thrombopoietin-receptor agonist
ULN
upper limit of normal
US
United States
VAS
visual analog scale
WHO
World Health Organization
WOCBP
woman of childbearing potential
PUBLIC COPY 
event
IC
event
Analysis 
BL
Analysis 
neous
PUB
neous
orm
P
orm
t be used to support any marketing authorization 
Plan
s
Plan
36
e
36-
ed
-Item H
ed 
Item H
ollow
use
ollow-
s
-Up
se
Up
-
b
-mucosa
be 
mucosa
This document cannot
standard o
ot b
standard o
Safet
nno
Safet
tu
n
tu
RA
m
RA
LN
cu
LN
US
doc
US
VA
d
VA
any extensions or variations thereof.
Health Su
xten
Health Su
p
e-
n
-organs 
ny 
organs 
application and a
operating
d an
operating
ty Set
and
ty Set
uberculos
n a
uberculos
treatm
tio
treatm
thth


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 136 of 202
10.10
Appendix 10: Rapid alert procedures
Not applicable.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 137 of 202
10.11
Appendix 11: Karnofsky Performance Status Scale
Appendix removed.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 138 of 202
10.12
Appendix 12: ITP-BAT
Grading of bleeding symptoms at presentation and at each subsequent evaluation.1
Table 10-5:
ITP-Bleeding Assessment Tool
Type of bleeding
GRADES BASED ON THE WORST INCIDENT EPISODE SINCE LAST VISIT2
0
1
2
3
4
SKIN
Petechiae (does not 
include steroid–induced 
or senile purpura)
No
Less than or equal to 
10 in a patient’s palm-
sized area3 in the most 
affected body area4
Any number if 
reported by the patient
More than 10 in a 
patient’s palm-sized area 
or more than 5 in at least 2 
patient’s palm-sized areas 
located in at least 2 
different body areas4, one 
above and one below the 
belt (in the most affected 
body areas) 4
More than 50, if 
scattered both above 
and below the belt
Ecchymoses
None or up to 2 in 
the same body area4, 
but smaller than a 
patient’s palm-sized 
area, if
a) spontaneous or b) 
disproportionate to 
trauma/constriction5
3 or more in the same
body area4, but all 
smaller than a patient’s 
palm-sized area, if
a) spontaneous or 
b) disproportionate to 
trauma/constriction5
At least 2 in two 
different body areas4, 
smaller than a patient’s 
palm-sized area, if
a) spontaneous or 
b) disproportionate to 
trauma/constriction5
Any number and size 
if reported by the patient
From 1 to 5 larger than 
a patient’s palm-sized area, 
if
a) spontaneous or 
b) disproportionate to 
trauma/constriction5
with or without smaller 
ones
More than 5 
larger than a patient’s 
palm-sized area, if
a) spontaneous or 
b) disproportionate to 
trauma/ constriction5
LIC COPY
C
mor
Y
mor
patient’s
PY 
patient’s
located
OPY
located
diff
OP
diff
O
CO
PUBLI
ore in the
BL
ore in the
rea
U
rea4
UB
4, but 
UB
, but 
ller than 
PU
ller than 
P
sized
P
sized
LIC
ot be used to support any marketing authorization 
06 
n 
06
a
VISIT
g a
VISIT2
a
2
a
3
t
3
ng
et
rk
a
m
a
zed area 
ma
zed area 
 in at least
y m
 in at least
alm
an
alm-
n
-sized a
ny
sized a
n at least 2
an
n at least 2
rent body a
rt a
rent body a
ove and on
ort
ove and on
belt (in the
ppo
belt (in the
body ar
upp
body ar
rk
rk
rk
u
rk
ame
s
ame
t
patient’s
d to
patient’s
area, if
ed
area, if
aneous or 
sed
aneous or 
proportiona
use
proportiona
uma/constr
e u
uma/constr
b
At leas
be
At leas
differen
ot b
differen
smal
ot 
smal
pa
o
pa
sup
up
up
This document cannot
al
T
al
m
ot
su
ns or variations thereof.
of.
re
he
2 
at
2 
reas
ria
reas
areas
v
areas4
va
4, one
va
, one
e below th
r v
e below th
e most 
or
e most affe
or
affe
reas)
s
reas) 4
s o
4
n
More th
ns 
More th
scattered
ion
scattered
and b
tio
and b
s t
ati
ensions
From 1 to
ion
From 1 to
a patient’s 
sio
a patient’s 
if
ns
if
a) sp
en
a) sp
b)
e
b)
ns
on and any exte
ate to 
ex
ate to 
iction
y e
iction5
y e
5
t 2 in two 
any
t 2 in two 
nt body are
d an
nt body are
ller than a p
nd a
ller than a p
alm
an
alm-
n
-sized a
and
sized a
a) spontan
an
a) spontan
b) disp
on a
b) disp
trau
on
trau
application
lic
on
e


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 139 of 202
Type of bleeding
GRADES BASED ON THE WORST INCIDENT EPISODE SINCE LAST VISIT2
0
1
2
3
4
Subcutaneous 
hematomas
No
1 smaller than a 
patient’s palm-sized area
Any number and size 
if reported by the patient
2 smaller than a 
patient’s palm-sized area, 
spontaneous 
2 smaller than a 
patient’s palm-sized area, 
disproportionate to trauma5
More than 2 
smaller or at least 1 
larger than a patient’s 
palm-sized area, 
spontaneous 
More than 2 
smaller or at least 1 
larger than a patient’s 
palm-sized area, 
disproportionate to 
trauma5
Bleeding from minor 
wounds6
No
Lasting <5 min
Any episode if 
reported by the patient
Lasting >5 min or 
interfering with daily 
activities
Requiring 
protracted medical 
observation at the 
time of this visit 
Medical report 
describing patient’s 
evaluation by a 
physician
MUCOSAL
Epistaxis7
No
Lasting <5 min
Any episode if 
reported by the patient
Lasting >5 min or 
interfering with daily 
activities
Packing or 
cauterization or 
in-hospital evaluation 
at the time of this 
visit 
Medical report 
describing packing or 
cauterization or in-
hospital evaluation
RBC transfusion 
or Hb drop >2g/dL
PUBLIC COPY 
patient
C C
patient
OP
L
P
L
in
O
in
OP
CO
P
used to support any marketing authorization 
06 
n 
06
a
za
or
ma
rk
ma5
k
5
than 2 
ut
than 2 
r or 
a
r or at least
au
at least
er than a p
g a
er than a p
palm
tin
palm-
in
-sized 
ng
sized 
spontane
etin
spontane
ke
M
sm
k
sm
th
rk
asting >5 m
rt a
asting >5 m
erfering wi
ort
erfering wi
activities
po
activities
an
su
ed
ot be us
Lasting <5
e us
Lasting <5
b
Any ep
be 
Any ep
reported
t b
reported
This document cannot
al
T
al
us
en
ot
extensions or variations thereof.
1 
of
1 
atient’s 
eof
atient’s 
area, 
ere
area, 
eous 
he
eous 
More than 2
th
More than 2
maller or at 
s t
maller or at 
larger than
ons
larger than
palm
tion
palm-si
n
si
disp
tio
disp
trtr
ati
f
min or 
va
min or 
ith daily 
r v
ith daily 
ar
e
te
on and any ex
min
y e
min
pisode if 
any
pisode if 
d by the pat
an
d by the pat
application
ex
at on


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 140 of 202
Type of bleeding
GRADES BASED ON THE WORST INCIDENT EPISODE SINCE LAST VISIT2
0
1
2
3
4
Oral cavity – gum 
bleeding7
No 
Lasting <5 min
Any episode if 
reported by the patient
Lasting >5 min or 
interfering with daily 
activities
Requiring 
protracted medical 
observation at the 
time of this visit 
Medical report 
describing patient’s 
evaluation by a 
physician
Oral cavity –
hemorrhagic bullae or 
blisters
No
Less than 3
Any number if 
reported by the patient
From 3 to 10 but no 
difficulty with mastication
More than 10 or 
more than 5 if 
difficulty with 
mastication
Oral cavity - bleeding 
from bites to lips & 
tongue or after 
deciduous teeth loss
No
Lasting <5 min
Any episode if 
reported by the patient
Lasting >5 min or 
interfering with daily 
activities
Interventions to 
ensure hemostasis or 
in-hospital evaluation 
at the time of this 
visit
Medical report 
describing 
interventions to 
ensure hemostasis or 
in-hospital evaluation
Subconjunctival 
hemorrhage 
(not due to conjunctival 
disease)
No
Petechiae/ 
hemorrhage partially 
involving one eye
Any episode if 
reported by the patient
Petechiae/ hemorrhage 
partially involving both 
eyes, or diffuse 
hemorrhage in one eye
Diffuse 
hemorrhage in both 
eyes
ORGAN (and internal 
mucosae)
PUBLIC COPY
Fro
Y
Fro
difficulty
PY 
difficulty
CO
C
e if 
IC
e if 
the patien
BLIC
the patien
CO
CO
CO
CO
CO
rt any marketing authorization 
06 
n 
06
a
za
or
ri
a
ring
au
ng
cted medica
au
cted medica
ervation at 
g a
ervation at 
me of this 
ing
me of this 
keti
Med
ti
Med
descr
ke
descr
ev
k
ev
th
rk
10 but no 
y m
10 but no 
with mastica
ny
with mastica
m
be used to support
p
Lasting 
por
Lasting 
interferin
ppo
interferin
activit
upp
activit
ort
su
ot be
t b
Petec
be
Petec
hemor
ot b
hemor
inv
ot
inv
This document cannot
al
T
al
be 
ot
e
cu
variations thereof.
al 
o
al 
the
e
the
visit 
re
visit 
dical report 
ther
dical report 
ribing patie
th
ribing patie
valuation by
ns t
valuation by
physician
ons
physician
f
ation
ria
ation
tio
M
o
M
mo
t
mo
on
ati
ny extensions or v
>5 min or 
or v
>5 min or 
ng with dai
s o
ng with dai
ies
n
ies
v
e
on and any
hiae/ 
an
hiae/ 
rrhage part
d a
rrhage part
volving one
nd 
volving one
a
Any ep
an
Any ep
reporte
n a
reporte
application
ny
on
ca
pp


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 141 of 202
Type of bleeding
GRADES BASED ON THE WORST INCIDENT EPISODE SINCE LAST VISIT2
0
1
2
3
4
Gastrointestinal 
bleeding not explained 
by visible mucosal 
bleeding or lesion:
Hematemesis,
Melena,
Hematochezia,
Rectorrhagia
No
Any episode if 
reported by the patient
Present at the visit
Described in a medical 
report
Requiring 
endoscopy8 or other 
therapeutic 
procedures or in-
hospital evaluation at 
the time of this visit
Medical report 
prescribing 
endoscopy8 or other 
therapeutic 
procedures or in-
hospital evaluation
RBC transfusion 
or Hb drop >2g/dL
Lung bleeding
Hemoptysis
Tracheobronchial 
bleeding
No
Any episode if 
reported by the patient
Present at this visit
Described in a medical 
report
Requiring 
bronchoscopy8 or 
other therapeutic 
procedures or in-
hospital evaluation at 
the time of this visit
An equivalent 
episode if described 
in a medical report
RBC transfusion 
or Hb drop >2g/dL
Hematuria
No
Any episode if 
reported by the patient
Microscopic (lab 
analysis)
Macroscopic 
Described in a medical 
report
Macroscopic, and 
requiring cystoscopy8
or other therapeutic 
procedures or in-
hospital evaluation at 
the time of this visit
RBC transfusion 
or Hb drop >2g/dL
PUBLIC COPY 
O
atient
C C
atient
O
CO
This document cannot be used to support any marketing authorization 
06 
n 
06
a
al
T
al
za
or
ring 
au
ring 
copy
a
copy8
a
8 or
au
or oth
u
oth
apeutic
g a
apeutic
procedures 
ting
procedures 
hospital 
etin
hospital 
the tim
ket
the tim
k
th
rk
Present at
ort
Present at
pp
Descri
ppo
Descri
report
upp
report
rt
ot
su
n
doc
oc
oc
oc
nd any extensions or variations thereof.
her 
of
her 
or in
ere
or in-
re
-
evaluation 
her
evaluation 
me of this v
the
me of this v
Medical r
ns t
Medical r
prescribin
ons
prescribin
endosc
tion
endosc
thera
tio
thera
p
o
ati
f
this visit
r v
this visit
bed in a m
or
bed in a m
va
e
on and
a
Any e
an
Any e
reporte
n a
reporte
n
o
nd
application
ap
on


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 142 of 202
Type of bleeding
GRADES BASED ON THE WORST INCIDENT EPISODE SINCE LAST VISIT2
0
1
2
3
4
An equivalent 
episode if described 
in a medical report
Menorrhagia
(compared to pre-ITP 
or to a phase of disease 
with normal platelet 
count)9
No
Doubling number. of 
pads or tampons in last 
cycle compared to pre-
ITP or to a phase of 
disease with normal 
platelet count
Score >100 using 
PBAC in the last cycle, if 
normal score in pre-ITP 
cycles or in a phase of 
disease with normal 
platelet count
Changing pads more 
frequently than every 
2 hrs. or clot and flooding
Requiring combined 
treatment with 
antifibrinolytics and 
hormonal therapy or 
gynecological 
investigation (either at this 
visit or described in a 
medical report)
Acute 
menorrhagia 
requiring hospital 
admission or 
endometrial ablation 
(either at this visit or 
described in a 
medical report)
RBC transfusion 
or Hb drop >2g/dL
Intramuscular 
hematomas
(only if diagnosed by a 
physician with an 
objective method)
No
Post trauma, 
diagnosed at this visit, if 
judged disproportionate 
to trauma
An equivalent 
episode if described in a 
medical report
Spontaneous, 
diagnosed at this visit 
An equivalent episode 
if described in a medical 
report
Spontaneous or 
post trauma (if 
judged 
disproportionate to 
trauma) diagnosed at 
this visit and 
requiring hospital 
admission or surgical 
intervention
An equivalent 
episode if described 
in a medical report
RBC transfusion 
or Hb drop >2g/dL
Hemarthrosis
No
Post trauma, 
diagnosed at this visit, 
Spontaneous, 
diagnosed at this visit, 
Spontaneous or 
post trauma (if 
Spontaneous or 
post trauma (if 
PUBLIC COPY
0 using
LIC
0 using
e last cyc
BLIC
e last cyc
core in pr
UBL
core in pr
s or in a p
PUB
s or in a p
ase with
PU
ase with
et c
P
et c
Ch
Y
Ch
requentl
PY 
requentl
2
OP
2 hrs. o
OPY
hrs. o
OP
R
P
R
tr
O
tr
CO
sed to support any marketing authorization 
06 
n 
06
a
za
or
uivalent 
uth
uivalent 
e if describe
au
e if describe
medical rep
g a
medical rep
th
rk
e, if 
su
e, if 
ITP
s
ITP
ase of 
to
ase of 
ormal
d to
ormal
unt
e
unt
pads more 
y m
pads more 
han every
ny 
han every
clot and flo
any
clot and flo
equiring co
rt a
equiring co
atment wit
ort
atment wit
antifibrino
ppo
antifibrino
hormon
upp
hormon
gyne
up
gyne
in
u
in
m
su
ot be use
st trauma, 
use
st trauma, 
gnosed at th
e u
gnosed at th
udged disp
be 
udged disp
to traum
t be
to traum
ot 
A
ep
o
ep
This document cannot
al
T
al
cu
se
ot
cum
No
u
No
um
doc
o
on and any extensions or variations thereof.
ed 
of
ed 
port
eo
port
f
ooding
aria
ooding
ombined 
va
ombined 
h
olytics and
or 
olytics and
nal therapy 
s o
nal therapy 
ecological 
ons
ecological 
nvestigation
ion
nvestigation
visit or de
sio
visit or de
medica
ens
medica
tion
Ac
o
Ac
men
ti
men
on
e
ati
his visit, if 
y e
his visit, if 
proportiona
ny 
proportiona
a
An equivale
d a
An equivale
pisode if de
and
pisode if de
medical r
an
medical r
application
xte
on
e
pl
ap


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 143 of 202
Type of bleeding
GRADES BASED ON THE WORST INCIDENT EPISODE SINCE LAST VISIT2
0
1
2
3
4
(only if diagnosed by a 
physician with an 
objective method)
function conserved or 
minimally impaired, if 
judged disproportionate 
to trauma
An equivalent 
episode if described in a 
medical report
function conserved or 
minimally impaired
An equivalent episode 
if described in a medical 
report
judged 
disproportionate to 
trauma), diagnosed at 
this visit and 
requiring 
immobilization or 
joint aspiration
An equivalent 
episode if described 
in a medical report
judged 
disproportionate to 
trauma) diagnosed at 
this visit and 
requiring surgical 
intervention
An equivalent 
episode if described 
in a medical report
Ocular bleeding
(only if diagnosed by a 
physician with an 
objective method)
No
Any post trauma 
vitreous or retinal 
hemorrhage involving one 
or both eyes with or 
without impaired/blurred 
vision present at this visit 
if judged disproportionate 
to trauma
An equivalent episode 
if described in a medical 
report
Spontaneous 
vitreous or retinal 
hemorrhage 
involving one or both 
eyes with 
impaired/blurred 
vision present at this 
visit
An equivalent 
episode if described 
in a medical report
Spontaneous 
vitreous or retinal 
hemorrhage with loss 
of vision in one or 
both eyes present at 
this visit
An equivalent 
episode if described 
in a medical report 
Intracranial 
bleeding10:
intracerebral, 
intraventricular, 
subarachnoidal, subdural, 
extradural
(only if diagnosed with 
an objective method at 
the visit or described in 
a medical report 
provided by the 
patient)
No
Any post trauma event 
requiring hospitalization
Any spontaneous 
event requiring 
hospitalization in 
presence of an 
underlying 
intracranial lesion
Any spontaneous 
event requiring 
hospitalization 
without an 
underlying 
intracranial lesion
COPY 
OPY
Any
PY
Any
vitre
OP
vitre
he
O
he
Y
PUBLIC CO
CO
ny marketing authorization 
06 
n 
06
a
za
or
ortionate to
au
ortionate to
ma), diagno
g a
ma), diagno
is visit and
ng
is visit and
requiring 
eting
requiring 
immob
ket
immob
join
ke
join
th
rk
support any
post trauma
any
post trauma
us or retina
t a
us or retina
morrhage in
ort 
morrhage in
or both eye
po
or both eye
witho
pp
without 
p
ut 
vision
up
vision
if j
u
if j
ny
ot be used to su
su
us
This document cannot
al
T
al
cu
ot
ensions or variations thereof.
o 
o
o 
osed at 
eof
osed at 
d
ilization o
the
ilization o
nt aspiration
s th
nt aspiration
n
An equ
ns
An equ
episode
tion
episode
in a m
tio
in a m
trt
ati
f
a
l l 
nvolving on
r va
nvolving on
s with or 
or 
s with or 
impaired/b
s o
impaired/b
n present at
ns 
n present at
judged disp
ion
judged disp
to trauma
sio
to trauma
ens
An 
s
An 
if de
en
if de
r
e
r
at
iat
at
at
on and any exte
at
ex
application
pp
on


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 144 of 202
Type of bleeding
GRADES BASED ON THE WORST INCIDENT EPISODE SINCE LAST VISIT2
0
1
2
3
4
Other internal 
bleeding:
hemoperitoneum
hemopericardium
hemothorax 
retroperitoneal bleeding
hepatic and splenic 
peliosis with organ 
rupture
retroorbital bleeding
metrorrhagia
etc.
(only if diagnosed with 
an objective method at 
the visit or described in 
a medical report 
provided by the 
patient)
No
Any event 
requiring 
hospitalization 
<48 hrs.
Any event 
requiring 
hospitalization 
>48 hrs. or RBC 
transfusion or Hb 
drop >2g/dL
Hb=hemoglobin; hrs=hours; ITP=immune thrombocytopenia; PBAC=Pictorial Blood Assessment Chart; RBC=red blood cell; SMOG=Skin-Visible Mucosa-
Internal Organs tool
1 In case of study participants examined for the first time, all types of bleeding occurring at the visit and in the 15 days preceding the visit should be considered. 
2 Each type of bleeding should be graded based on the worst bleeding manifestation that occurred during each observation period or in the 15 days preceding the 
first visit.
3 Study participant’s own palm size is commonly considered to be proportional to body surface area. Palm=the inner surface of the hand stretching between the 
distal crease of the wrist and the bases of the fingers (fingers surface excluded).
4 Body areas include: face, neck, right and left upper limbs (considered separately), right and left lower limbs (considered separately), trunk, abdomen, and
recumbent areas (for the ambulatory patient means the area below the knees). 
5 Bleedings considered proportionate to trauma/constriction on a clinical ground should not be reported for skin domain.
6 Minor wound means superficial skin cuts (eg, by shaving razor, knife, or scissors).
7 Epistaxis and gum bleeding are also reported in some normal study participants. Thus, a critical judgment is required in grading these manifestations; they 
should be reported only if judged more severe when compared with pre-ITP bleeding, if any.
PUBLIC COPY 
CO
This document cannot be used to support any marketing authorization 
06 
n 
06
a
al
T
al
za
or
vent 
aut
vent 
ng 
ng 
pitalization
g a
pitalization
48
in
48 hrs.
ing
hrs.
th
su
rk
e u
penia;
be
penia; PBA
e 
PBA
t time, all t
ot b
t time, all t
on the wors
no
on the wors
mmonly con
can
mmonly con
s of the fing
t ca
s of the fing
ht and left u
nt c
ht and left u
atory patien
en
atory patien
ionate to tr
me
ionate to tr
rficial skin 
um
rficial skin 
ding are als
cu
ding are als
nly if judge
doc
nly if judge
application and any extensions or variations thereof.
r
h
e
ati
f
y e
C=Pictoria
ny 
C=Pictoria
types of ble
d a
types of ble
st 
n
st bleeding
nd 
bleeding
nsidered to 
n a
nsidered to 
gers (finger
on 
gers (finger
upper limb
tio
upper limb
nt means th
cati
nt means th
rauma/cons
lica
rauma/cons
cuts (eg, by
plic
cuts (eg, by
so reported
pp
so reported
d more se
ap
more se


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 145 of 202
8 Any endoscopic investigations should be considered for grading only if performed for therapeutic purpose and not solely for diagnostic purpose.
9 In girls at menarche, grade 1 cannot be assigned, lacking comparison with previous cycles.
10 Intracranial bleeding should always be reported, irrespective of its grade. For example, if a woman had S2 (subcutaneous hematoma) M2 (epistaxis) O3 
(menorrhagia) and an intracranial bleeding grade 2 (post trauma, requiring hospitalization), the SMOG index is S2M2O3 (intracranial 2). If the same 
participant also had intracranial bleeding grade 3, the SMOG index is S2M2O3 (intracranial 3) (see text).
Note: Grading is based on physical examination at the time of the visit by the physician or expert nurse or on study participant’s history supplemented by 
available medical reports. Bleeding manifestations reported by the study participant but not visible at the time of data collection are graded 1. Grade 5 is 
assigned to fatal bleeding.
Note: Illustrative examples are available on the website of the Hematology Project Foundation (http://itpbat.fondazioneematologia.it/).
Note: To receive a grade >1, all non-overt skin and non-overt mucosal bleeding (petechiae, ecchymoses, subcutaneous hematomas, vesicles/bullae 
subconjunctival bleeding) should be visible at the time of visit for grading by the physician or expert nurse taking the history. 
Note: For bleeding from minor wounds and overt-mucosal bleeding (epistaxis, gum, bleeding from bites to lips & tongue or after deciduous teeth loss/extraction) 
and all organ bleeding, a medical record describing the symptom or indicating a specific intervention/prescription should be also taken into account for grading.
Note: Requirement for ITP-specific treatments and anti-fibrinolytics (apart from menorrhagia) was not considered for grading, due to their subjective nature and 
their adoption not only to control actual bleeding but also to reduce the “risk” of impendent or future bleeding.
PUBLIC COPY 
Y
orrhagi
Y
orrhagi
mpenden
PY
mpenden
marketing authorization 
06 
n 
06
a
tic purpose
riza
tic purpose
atoma) M2
tho
atoma) M2
ntrac
uth
ntracrani
uth
ranial 
h
al 
icip
g
icipant’s
g a
ant’s hihi
ata coll
ng
ata collectio
g 
ectio
ndazioneem
keti
ndazioneem
cutaneous 
rke
cutaneous 
rse taking t
ark
rse taking t
es to lips &
ma
es to lips &
This document cannot be used to support any m
al
T
al
ion/prescrip
y m
ion/prescrip
as not cons
ny 
as not cons
or future bl
any
or future bl
ons thereof.
istory sup
of.
istory sup
on are grad
reo
on are grad
matologia.it
the
matologia.it
hematoma
th
hematoma
the history
ns t
the history
& tongue or
ons
& tongue or
application and any extensions or variatio
ption shoul
tion
ption shoul
sidered for 
iatio
sidered for 
leeding.
ria
leeding.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
his document cannot be used to support any marketing authorization
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
s document cannot be used to support any marketing authorizatio
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
s document cannot be used to support any marketing authorizatio
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
is document cannot be used to support any marketing authorization
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
This document cannot be used to support any marketing authorizatio
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
PUBLIC COPY 
This document cannot be used to support any marketing authorization
his document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
his document cannot be used to support any marketing authorization
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
his document cannot be used to support any marketing authorizatio
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
is document cannot be used to support any marketing authorization
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
his document cannot be used to support any marketing authorizatio
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
This document cannot be used to support any marketing authorization
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
PUBLIC COPY 
Th
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
his document cannot be used to support any marketing authorization
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
his document cannot be used to support any marketing authorizatio
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
his document cannot be used to support any marketing authorization
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
his document cannot be used to support any marketing authorization
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
his document cannot be used to support any marketing authorization
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
This document cannot be used to support any marketing authorization
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 165 of 202
10.17
Appendix 17: PGI-S
The following question asks you about your current overall symptoms.
Please check the box that best describes your current situation.
How would you describe your ITP symptoms during the past week?
None
Mild
Moderate
Severe
Very severe
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 166 of 202
10.18
Appendix 18: PGI-C
The following question asks you about your overall symptoms now compared to before starting 
treatment within this clinical study. Please check the box that best describes your current
situation.
How would you describe your current ITP symptoms compared to before you started 
treatment in this clinical study?
Very much worse
Much worse
A little bit worse
No change
A little bit improved
Much improved
Very much improved
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
his document cannot be used to support any marketing authorization
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
PUBLIC COPY 
Thihis document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
his document cannot be used to support any marketing authorization
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
This document cannot be used to support any marketing authorization
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
This document cannot be used to support any marketing authoriza
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 172 of 202
10.21
Appendix 21: Sampson Criteria Questionnaire
Anaphylaxis is highly likely when any of the following 3 criteria is fulfilled 
(Sampson et al, 2006):
1. Acute onset of an illness (minutes to several hours) with involvement of the skin, 
mucosal tissue, or both (eg, generalized hives, pruritus or flushing, swollen lips-tongue-
uvula)
AND AT LEAST ONE OF THE FOLLOWING
c.
Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced peak 
expiratory flow [PEF], hypoxemia)
d. Reduced BP or associated symptoms of end-organ dysfunction (eg, hypotonia [collapse], 
syncope, incontinence)
2. Two or more of the following that occur rapidly after exposure to a likely allergen for 
that patient (minutes to several hours):
a.
Involvement of the skin-mucosal tissue (eg, generalized hives, itch-flush, swollen 
lips-tongue-uvula)
b.
Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF, 
hypoxemia)
c.
Reduced BP or associated symptoms (eg, hypotonia [collapse], syncope, 
incontinence)
d.
Persistent GI symptoms (eg, crampy abdominal pain, vomiting)
Reduced blood pressure after exposure to known allergen for that study participant (minutes to 
several hours): Systolic BP of less than 90mmHg or greater than 30% decrease from the study 
participant’s Baseline systolic BP value.
PUBLIC COPY 
a, wheez
OPY
a, wheez
mptoms (
C C
mptoms (
s (eg, cra
UBL
s (eg, cra
xposur
PU
xposur
P
used to support any marketing authorization 
d peak 
uth
d peak 
potonia [c
ng a
potonia [c
o a likely
rket
o a likely
ed hives, 
ma
ed hives, 
broncho
t an
broncho
g, hypoto
ppo
g, hypoto
mpy abdo
o su
mpy abdo
e to know
d to
e to know
than 90mm
sed
than 90mm
This document cannot be u
P value.
use
P value.
application and any extensions or variations thereof.
collapse],
reof
collapse],
y allergen 
the
y allergen 
 itch
tio
 itch-
o
-flush
on
flush
ospasm, st
aria
ospasm, st
onia [colla
or 
onia [colla
ominal pa
ion
ominal pa
wn allerge
tens
wn allerge
mmHg or g
xte
mmHg or g


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 173 of 202
10.22
Appendix 22: Management of headaches
Based on current available clinical data, headache is the most commonly reported adverse drug 
reaction in study participants treated with rozanolixizumab. Study participants should be well 
informed of this potential adverse drug reaction and should be instructed on how to manage it.
Determination of the severity of headache will be consistent with National Cancer Institute 
Terminology Criteria for Adverse Events (CTCAE) version 5.0. Severe headache is defined as 
severe pain limiting self-care activity of daily living (ADL). Self-care ADL refers to bathing, 
dressing and undressing, feeding self, using the toilet, and taking medications. 
In the event of a headache the investigators should take the medical history of previous 
headaches, concomitant medication, and comorbidities (eg, asthma) into consideration.
Study participants experiencing a moderate, severe and/or serious headache will complete the 
Headache Questionnaire (Appendix 20, Section 10.20) daily until resolution (eg, the headache 
becomes nonserious, mild, or is completely resolved, whichever comes first). If the severe and/or 
serious headache is initially reported at a home visit or during a telephone call, the study 
participant should be evaluated by a healthcare professional at the study site as soon as possible 
for further investigations. Study participants should be monitored for signs and symptoms 
suggestive of central nervous system involvement and evaluated immediately if other causes (eg, 
meningitis, intracranial bleeding) are suspected. Further neurological workup may be performed 
(if indicated) at the discretion of the investigator or the treating physician and may include a 
computed tomography scan, magnetic resonance imaging and/or a lumbar puncture for cerebral 
spinal fluid collection. In addition, samples for exploratory safety biomarkers should be collected
for study participants experiencing severe headache or serious headache when possible. These 
investigations will be performed to further understand the mechanism of headaches in the study 
participants.
Treatment must be permanently discontinued if a study participant has a serious headache that is 
considered related to the IMP in the opinion of the investigator. If a study participant experiences 
a severe AE of headache that is considered related to the IMP in the opinion of the investigator, 
the dose of IMP may be reduced or the treatment may be temporarily put on hold. If deemed 
appropriate by the investigator and agreed upon by the study participant and the sponsor, the 
study treatment can resume upon the resolution of the severe headache event, at the previous 
dose or at a lower dose. The benefit and risk of the treatment should be carefully considered prior 
to reinitiating the IMP. If a study participant experiences a second episode of treatment related 
severe headache in the opinion of the investigator, the treatment can only be continued upon 
agreement with the sponsor, investigator, and study participant taking benefit and risk into 
consideration. If the benefit-risk balance is not acceptable, then the participant must discontinue 
the IMP. If a participant experiences >2 severe headaches that are considered related to the IMP 
in the opinion of the investigator, the treatment must be permanently discontinued. 
Dosing modifications are allowed if judged necessary by the investigator from 
 to 
 or from 
 to 
based on specific volume reduction per protocol guidance, 
provided the treatment is effective as evidenced by relevant efficacy measurements (eg, platelet 
count ≥30×109/L). 
Headaches will be treated as clinically indicated according to national guidelines. It is 
recommended that the study participant has an analgesic available in case of headache with the 
PUBLIC COPY 
e
Y
e mo
Y
mo
and eval
PY
and eval
 Further
COP
 Further
ator or th
CO
ator or th
onance i
C C
onance i
mples for
LIC
mples for
severe he
BLI
severe he
to furthe
PUB
to furthe
ent cannot be used to support any marketing authorization 
g,
o
g,
ous
au
ous
ration.
g au
ration.
will comp
ting
will comp
on (eg, th
ketin
on (eg, th
first). If t
rke
first). If t
phone cal
mark
phone cal
e study sit
ma
e study sit
red for sig
ny m
red for sig
uated imm
any
uated imm
neurologi
rt a
neurologi
e treating
ort 
e treating
maging an
ppo
maging an
explorator
upp
explorator
adache or
sup
adache or
r understa
to s
r understa
scontinued
sed
scontinued
n the opini
us
n the opini
is consid
be u
is consid
educed or 
t be
educed or 
stigator an
ot 
stigator an
resume up
nno
resume up
r dose. Th
ann
r dose. Th
the IMP. I
t ca
the IMP. I
dache in th
nt c
dache in th
This docume
nt with th
men
nt with th
deration. I
me
deration. I
e IMP. If a
cum
e IMP. If a
in the opi
doc
in the opi
Dosin
s d
Dosin
s
ation and any extensions or variations thereof.
plete the
ereo
plete the
he headach
ther
he headach
the sever
s th
the sever
ll, the stud
ns 
ll, the stud
te as soon
tion
te as soon
gns and s
atio
gns and s
mediately 
aria
mediately 
ical work
var
ical work
g physicia
r va
g physicia
nd/or a lu
or 
nd/or a lu
ory safety 
ns o
ory safety 
r serious h
ions
r serious h
and the m
sio
and the m
ed if a stud
xte
ed if a stud
nion of the
ex
nion of the
dered rela
ny e
dered rela
r the treatm
any
r the treatm
and agreed
d a
and agreed
upon the re
and
upon the re
he benefit
n an
he benefit
If a study
on 
If a study
he opinio
atio
he opinio
applica
he sponso
cat
he sponso
If the ben
lica
If the ben
a partic
ppl
a particip
pl
ip
nion of t
app
nion of t
f


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 174 of 202
instruction for frequency and dosage provided by a health care professional. The analgesic can 
be started at the early onset of headache. Study participants experiencing any treatment related 
headache will be followed until resolution of the event.
Prophylactic treatment of headaches may be permitted for study participants who have 
experienced previous episodes of treatment related moderate or severe headache after discussion 
with the medical monitor. The benefit risk of continuing treatment with IMP and chronic 
prophylactic treatment with analgesics must be carefully evaluated by the investigator.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 175 of 202
10.23
Appendix 23: Management of diarrhea
Severe (Grade 3) diarrhea is defined as an increase of ≥7 stools per day or hospitalization for 
management of diarrhea or limiting self-care ADL. Determination of the severity of diarrhea will 
be consistent with CTCAE version 5.0 (see Appendix 3, Section 10.3).
Diarrhea will be treated as clinically indicated according to the local guidelines.
Stool samples may be collected for stool analysis to rule out infection for study participants 
reporting severe diarrhea. Stool sampling will be done as clinically indicated in the opinion of 
the investigator and assessed per local guidance. In addition, collection of blood samples for 
assessment of exploratory safety biomarkers is required for study participants with severe GI 
disturbances including diarrhea. 
In study participants experiencing severe treatment related diarrhea, dosing modifications are 
allowed, if judged necessary by the investigator, from 
to 
 or from 
to 
 based on specific volume reduction per protocol guidance, provided the treatment is 
effective as evidenced by relevant efficacy measurements (eg, platelet count ≥30x109/L).
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
n of 
hor
n of 
es for 
tho
es for 
evere GI 
auth
evere GI 
modificatio
ting
modificatio
or from 
etin
or from 
ided the t
rke
ided the t
et count ≥
mark
et count ≥
k
n
hereof.
ions are
ereo
ions are
toto
application and any extensions or variations the
treatment
s th
treatment
≥30x10
ns 
≥30x109
t
9/L
/L
ther


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 176 of 202
10.24
Appendix 24: Management of infusion reactions or 
hypersensitivity reactions
Study participants must be closely monitored for reactions during and after the IMP 
administration period. Standard precautions must be taken for the study participants with regard 
to potential infusion related reactions. Suggested management guidelines for infusion-related 
reactions and anaphylaxis at the study site are provided in Table 10-7. Definitions of the severity 
of the relevant events will be consistent with CTCAE version 5.0 (see Appendix 3, Section 10.3). 
Fully trained healthcare professionals administering the IMP at home should follow their own 
management guidelines, which should be reviewed and endorsed by the investigator prior to first 
home administration.
Table 10-7: Suggested management guidelines at the study site for infusion 
reactions
Type of reaction
Suggested action
Acute – Mild
Grade 1
Monitor vital signs every 10 min.
If the reaction worsens to Grade 2, follow the instructions below.
Acute – Moderate
Grade 2
Interrupt/hold infusion temporarily to further assess and initiate 
treatment if necessary. 
Consider the use of iv fluid and antihistamine iv or im.
Consider administering paracetamol or NSAIDs.
Monitor vital signs initially every 5 min.
If the reaction improves and upon further assessment it is clear that the 
event is not an anaphylaxis, restart the infusion cautiously. Continue to 
monitor vital signs every 5 minutes.
If reaction recurs or worsens to Grade 3, discontinue infusion.
Acute – Severe
Grade 3 or 
anaphylaxis
Discontinue IMP infusion permanently.
Alert crash team.
Maintain airway; ensure oxygen is available.
Administer:
−
Antihistamine iv/im, corticosteroids iv, epinephrine im, and iv 
fluids as appropriate.
−
Monitor vital signs every 2 min.
−
Hospitalize, if condition not improving or worsens.
−
Monitor study participant until symptoms resolve.
CTCAE=Common Terminology Criteria for Adverse Events; im=intramuscular; IMP=investigational medicinal 
product; iv=intravenous(ly); NSAID=nonsteroidal anti-inflammatory drug
Note: Management criteria were adapted from the CTCAE v5.0 (National Cancer Institute, 2017).
In case of suspected anaphylaxis, the Sampson’s Criteria (Sampson et al, 2006) should be 
accessed and Appendix 21 (Section 10.21, Sampson Criteria Questionnaire) should be 
PUBLIC COPY 
e 
Y
e 
n tempor
CO
n tempor
ary.
C C
ary.
e of iv f
LIC 
e of iv f
minister
BLI
minister
vital sig
PUB
vital sig
ea
P
eaction
PU
ction
OP
This document cannot be used to support any marketing authorization 
ty 
z
ty 
0.3
riz
0.3).
riz
).
own
hor
own
rior to firs
utho
rior to firs
or infusio
ng a
or infusio
et
w the inst
y m
w the inst
rk
arily to fu
ort a
arily to fu
uid and an
upp
uid and an
ng parace
sup
ng parace
ns initially
to s
ns initially
improves
ed t
improves
t an anaph
sed
t an anaph
vital sign
us
vital sign
action rec
be u
action rec
t a
Discontinu
ot b
Discontinu
Alert c
not
Alert c
Ma
nn
Ma
be
s d
n
C
s
application and any extensions or variations thereof.
on
e
on
he
structions 
tion
structions 
s t
urther asse
r va
urther asse
ntihistam
s o
ntihistam
etamol or 
ions
etamol or 
y every 5 
nsio
y every 5 
es and upo
tens
es and upo
hylaxis, r
xte
hylaxis, r
ns every 5
ex
ns every 5
curs or wo
ny 
curs or wo
ar
ue IMP in
d an
ue IMP in
rash team
nd 
rash team
aintain air
an
aintain air
Adminis
on 
Adminis
−
o
−
ny
ati


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 177 of 202
completed. The infusion must be discontinued immediately, and emergency resuscitation 
measures implemented.
In study participants experiencing an infusion-related reaction or anaphylaxis, blood samples will 
be collected as soon as possible, while the event is ongoing, to investigate the nature of the 
reaction as per Schedule of Activities (Section 1.3).
Samples for serum complement (C3, C4) and plasma complement (C3a, C5a) should be 
collected as specified in the Schedule of Activities (Section 1.3). Additional tests such as IgE 
levels, tryptase may be performed when there is a suspicion of Type I or III hypersensitivity 
reaction. The results of all monitoring, including laboratory testing, should be made available to 
the study site and Sponsor.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
gE 
o
gE 
vity 
tho
vity 
vailable t
uth
vailable t
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 178 of 202
10.25
Appendix 25: Management of infections and 
hypogammaglobulinemia
Study participants who have the signs or symptoms of any infection should be monitored closely 
and managed according to local guidelines. This may include tests for specific organisms if 
clinically indicated.
If a study participant has a significant infective episode including but not limited 
to bacteremia/sepsis, infectious meningitis, septic arthritis, osteomyelitis, complicated 
pneumonia, or visceral abscess which may or may not result in hospitalization, they MUST 
discontinue IMP, perform the EW Visit, enter the SFU Period and complete the EOS Visit. This 
list is not intended to be all inclusive and the investigator is expected to apply his/her judgment 
on continuing IMP based on the clinical situation at hand.
To maintain the study integrity, study site personnel, the UCB and CRO study teams will remain 
blinded to IgG levels. However, to ensure study participants’ safety, serum IgG level will be 
monitored by unblinded Medical Monitors external to UCB. In case the serum IgG level 
decreases <1g/L, as described below and in Table 10-8, the unblinded Medical Monitors will 
inform the investigator. 
The most recently available IgG value is the trigger for discussions between the unblinded 
Medical Monitors and the investigator and for any decisions on changing the dose of IMP/ 
triggering a mock infusion. All discussions and decisions related to the benefit-risk of dose 
changes/mock infusions are to be based on a holistic approach of the study participant’s status, 
including platelet response (eg, study participant’s ITP history, stability of the current response, 
past and current platelet values), current signs and symptoms of non-serious/serious infection, 
potential risk of acquiring a non-serious/serious infection in the foreseeable future and are at the 
sole discretion of the investigator. 
The investigator must document the respective benefit-risk assessments and decisions in the 
study participant’s source documents. 
BLIC COPY 
er for dis
OPY
er for dis
any decis
COP
any decis
and decis
CO
and decis
n a holis
C C
n a holis
participa
LIC
participa
PUB
rrent sig
BL
rrent sig
serious/
UB
serious/
or.
PU
or.
support any marketing authorization 
ST
h
ST
Visit
uth
Visit. 
t
. Th
h
Th
her judgm
au
her judgm
udy teams
eting
udy teams
um IgG le
ket
um IgG le
he serum 
ark
he serum 
ded Medi
ma
ded Medi
cussions b
any
cussions b
ions on ch
rt a
ions on ch
ions relate
ort
ions relate
tic approa
ppo
tic approa
nt’s ITP hi
upp
nt’s ITP hi
This document cannot be used to s
ns and sym
sup
ns and sym
erious inf
to s
erious inf
e respecti
sed
e respecti
ments.
us
ments.
ns or variations thereof.
ment 
of
ment 
s will rem
here
s will rem
evel will b
the
evel will b
m IgG leve
ns t
m IgG leve
ical Moni
ons
ical Moni
between t
aria
between t
hanging t
var
hanging t
ed to the 
r v
ed to the 
ach of the
or
ach of the
history, sta
ns o
history, sta
application and any extensio
mptoms o
ions
mptoms o
fec
s
fection in
sio
tion in
tive benef
exte
tive benef


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 179 of 202
Table 10-8: Management of infections and hypogammaglobulinemia
IgG value
Actions 
Outcome
IgG <1g/La
Unblinded medical monitor 
informs the investigator
Investigator decides to 
eitherb:
•
maintain the dose
•
reduce the dose
•
request for a mock 
infusion to be triggered
based on the study 
participant’s status regarding 
platelets response, signs and 
symptoms of non-
serious/serious infection, 
potential risk of acquiring a 
non-serious/serious infection
AE=adverse event; eCRF=electronic case report form; IXRS= Interactive Voice/Web Response System
a Events of hypogammaglobulinemia must not be captured as an AE in the eCRF, to protect the blind. 
b In the IXRS, the investigator can only reduce the dose, while the unblinded Medical Monitors can only trigger the 
mock infusion.
Dose adjustments/mock infusions
The dose of IMP can be reduced from 
equivalent (eqv.) to
 eqv., from 
 
eqv. to 
 (approximately 
), or directly from 
 eqv. to 
 (approximately 
), as needed. 
The IgG would be expected to return to values ≥1g/L in up to 3 to 4 weeks (after a dose 
decrease/mock infusion is triggered). The level of IgG recovery will depend on the IgG observed 
value that triggered the intervention and the intra-study participants variability, so that the IgG 
level may not immediately increase, and a delayed effect could be expected. 
The study participant will need to be reassessed on an ongoing basis regarding platelet response 
and risk of infection until the serum IgG returns to values ≥1g/L. The dose may be further 
decreased, or a mock infusion triggered, if needed.
In case a mock infusion is triggered, IMP administration may be restarted at a lower dose 
compared to the previous dose in order to decrease the likelihood of any further repeated 
reduction in the IgG level <1g/L. 
Ad hoc assessments (eg, additional weekly IgG samples) may be performed to monitor recovery 
of IgG levels. 
Splenectomized study participants
Splenectomized study participants are at a higher risk of infections, especially of OPSI. 
Irrespective of the IgG level, in case a splenectomized study participant develops a (persistent or 
recurring) nonserious infection, the dose of IMP can be reduced, or the IMP treatment may be 
temporarily stopped, when appropriate, at the investigator’s discretion. The IMP treatment may 
PUBLIC COPY 
PY
S= Interac
OPY
S= Interac
d as an A
COP
d as an A
e, while t
CO
e, while t
ns
L
ns
rom 
UBL
rom 
)
PUB
)
PUBL
PUB
ent cannot be used to support any marketing authorization 
k 
t
k 
triggered
auth
triggered
tudy 
g a
tudy 
’s status r
ting
’s status r
 response
ketin
 response
toms of n
rke
toms of n
rious/serio
ark
rious/serio
potential
ma
potential
non
y m
non-se
m
se
ny
ny
ny
ny
za
ive Voice/W
any
ive Voice/W
 in the eCR
rt a
 in the eCR
e unblinded
ort 
e unblinded
equiv
o su
equiv
or directl
d to 
or directl
turn to val
use
turn to val
gered). Th
e us
gered). Th
rvention a
be 
rvention a
ly increas
ot b
ly increas
t will nee
nno
t will nee
on
a
on until t
ann
until t
a mock inf
t ca
a mock inf
mock infu
ent 
mock infu
This docume
ed to the p
men
ed to the p
ction in th
um
ction in th
Ad hoc as
docu
Ad hoc as
of IgG 
do
of IgG 
Sp
s 
Sp
o s
cation and any extensions or variations thereof.f
regarding
ereo
regarding
e, signs an
her
e, signs an
non
th
non-
th
-
ious infec
ns t
ious infec
l risk of a
ions
l risk of a
erious/ser
atio
erious/ser
ia
Web Respo
aria
Web Respo
RF, to prote
var
RF, to prote
d d Medical M
r va
Medical M
ivalent (eq
sion
ivalent (eq
ly from 
nsio
ly from 
alues ≥1g/
ext
alues ≥1g/
he level o
y e
he level o
a
a
and the in
ny
nd the in
se, and a 
d an
se, and a 
ed to be re
and
ed to be re
the serum
n an
the serum
nfusion tri
on 
nfusion tri
usion is tri
atio
usion is tri
applic
previous 
lica
previous 
he IgG le
plic
he IgG le
sessment
app
sessment
els.
a
els.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 180 of 202
be resumed at the previous dose after the resolution of the event. The investigator may also reach 
out to the unblinded Medical Monitors, as needed. 
Local guidelines regarding antibiotic prophylaxis in splenectomized study participants should be 
followed. Splenectomized study participants should have a prophylactic antibiotic available, 
unless they are already taking an antibiotic as per local guidance. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 181 of 202
10.26
Appendix 26: Protocol Amendment History
The protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents.
Amendment 2 (08 Dec 2020)
Overall Rationale for the Amendment
The primary reason for protocol amendment 2 was to remove changes which were originally 
incorporated in protocol amendment 1, that are no longer applicable due to a change in the data 
analysis strategy for participants enrolled from Mainland China.
The primary reason for protocol amendment 1 was to incorporate changes in the endpoints, the 
statistical analysis section and to incorporate agency required local protocol amendments into 
one global protocol. As protocol amendment 1 was an internally approved document, which was 
not submitted to the regulatory authorities or implemented at the study sites (see Section 10.26), 
the summary table of changes below reflects the changes made between the original protocol and 
protocol amendment 2.
Additional updates have been incorporated to provide further clarity on the protocol or to correct 
errors.
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of 
Directive 2001/20/EC of the European Parliament and the Council of the European Union.
Section # and Name
Description of Change
Brief Rationale
Global
Minor administrative, consistency, 
formatting, and typographical 
changes have been made.
Updated to provide clarity and be 
consistent with remainder of 
protocol.
Global
Where applicable, rozanolixizumab 
has been replaced with 
investigational medicinal product 
(IMP).
Updated to ensure placebo is 
included in the context of the
applicable section.a
Global
The list of the secondary efficacy 
endpoints has been reordered.
Updated to match the sequence of 
analysis.a
Global 
Where applicable, the wording 
“4-week” was removed from “the 
4-week Screening Period”.
Wording updated for consistency 
reasons.a
Global
“Prednisolone” changed to 
“prednisone”.
Updated to UCB standards.a
Global
All reference to the Fisher’s Exact 
test has been removed from the 
primary analysis and included as a 
separate supplemental estimand. 
For the primary analysis more 
details regarding the 
Cochran-Mantel-Haenszel test 
have been added.
To provide a more accurate 
description of the analysis, and to 
address FDA statistical comments 
on confirmatory analyses.a
PUBLIC COPY 
furt
Y
furt
based o
COP
based o
ament a
C CO
ament a
n of Cha
LIC
n of Cha
C
administr
UBL
administr
matting, a
PUB
matting, a
ange
PU
anges h
PU
s h
LI
P
nnot be used to support any marketing authorization 
y 
o
y 
he data
hor
he data
endpoints,
g au
endpoints,
mendment
ng 
mendment
doc
eti
document,
ting
ument,
tes (see S
ket
tes (see S
en the ori
arke
en the ori
larity on t
y m
larity on t
n the crite
rt a
n the crite
nd the Cou
port
nd the Cou
ge
u
ge
p
ative, cons
o su
ative, cons
d typograp
to s
d typograp
ve been m
d to
ve been m
up
applicable
sed
applicable
been repla
us
been repla
nvestigatio
be u
nvestigatio
(IMP).
be
(IMP).
d
t
The
ot 
The
e
o
e
t b
ot
cument cann
nn
en
s docu
Global
ocu
Global
This d cu
s d
and any extensions or variations thereof.
s, the
of
s, the
ts into 
reo
ts into 
t, which w
here
t, which w
Section
the
Section 10
e
10
iginal pro
s th
iginal pro
the proto
atio
the proto
er
v
eria set fo
var
ia set fo
uncil of th
or v
uncil of th
Br
o
Br
o
s o
sistency,
ion
sistency,
phical 
nsio
phical 
ade.
en
ade.
ns
e, rozanoli
xte
e, rozanoli
aced with
ex
aced with
onal medic
ny e
onal medic
ten
e list of the
d a
e list of the
endpoints h
and
endpoints h
an
on an
Where
n a
Where
“4
n 
“4
4
pplication an
on
at
app
pp


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 182 of 202
Section # and Name
Description of Change
Brief Rationale
1.1 Synopsis, Rationale
1.1 Synopsis, Overall 
design
2.1 Study rationale
The study criteria have been 
modified to include study 
participants who have failed or 
were intolerant to two or more 
prior ITP therapies.
Global implementation of an 
ANSM request and implement 
feedback received from the FDA.a
1.1 Synopsis, Objectives 
and endpoints
3 Objectives and endpoints
The primary efficacy endpoint has 
been updated to delete “as defined 
by proportion of study participants 
who have platelet responses”.
Updated to be consistent with UCB 
writing conventions.a
1.1 Synopsis, Objectives 
and endpoints
3 Objectives and endpoints
The secondary efficacy endpoint 
has been updated from 
“Cumulative number of visits” to 
“Cumulative number of weeks” 
and "over the 24-week treatment 
period" was added.
Updated to provide clarity.a
1.1 Synopsis, Objectives 
and endpoints
3 Objectives and endpoints
The secondary efficacy endpoint 
“Time to first Clinically 
Meaningful Platelet Response of 
≥50x109/L: time from starting 
treatment to achievement of first 
response of ≥50x109/L” was 
updated to include “first”.
Updated for consistency within the 
description of this endpoint.a
1.1 Synopsis, Objectives 
and endpoints
3 Objectives and endpoints
The secondary efficacy endpoint 
“Complete Response defined as 
platelet count ≥100x109/L 
confirmed on at least 2 separate 
occasions at two adjacent nominal 
visits at least 7 days apart, and 
absence of bleeding by visit” has 
been moved to “other efficacy 
endpoints”.
Endpoint did not measure different 
manifestation of the disease and 
did provide redundant information 
with another key secondary 
endpoint.a
1.1 Synopsis, Objectives 
and endpoints
3 Objectives and endpoints
The secondary efficacy endpoint 
related to the ITP Patient 
Assessment Questionnaire 
(ITP-PAQ) Symptoms Score has 
been modified.
Corrected to clarify the variable.a
1.1 Synopsis, Objectives 
and endpoints
3 Objectives and endpoints
The other efficacy endpoint 
relating to “Duration of Clinically 
Meaningful Platelet Response” has 
been updated.
Updated to clarify it is the first 
response.a
1.1 Synopsis, Objectives 
and endpoints
3 Objectives and endpoints
The other efficacy endpoint “Time 
to first Complete Response: time 
from starting treatment to 
achievement of Complete 
Response” has been deleted.
Endpoint did not measure different 
manifestation of the disease and 
provided redundant information 
with another key secondary 
endpoint.a
BLIC COPY 
poin
Y
poin
esponse o
OPY
esponse o
om startin
COP
om startin
evement
CO
evement
50x10
C C
50x109
C C
9/L
C
/L
include “
LIC
include “
PUBL
condary 
UBL
condary 
omplete R
PUB
omplete R
atelet co
PU
atelet co
P BL
support any marketing authorization 
za
UCB
riz
UCB
za
za
e clarity.
g a
e clarity.a
au
f 
t
f 
g
f first
port
f first
was
pp
was
irst”.
up
irst”.
Updated f
y m
Updated f
descrip
ny 
descrip
m
a
t cannot be used to su
fficacy en
o su
fficacy en
esponse de
to 
esponse de
unt ≥100x
d t
unt ≥100x
ed on at 
sed
ed on at lele
sions at tw
use
sions at tw
sits at leas
e u
sits at leas
absence o
be 
absence o
been m
ot b
been m
end
ot 
end
ment 
su
ot
ctives
ann
ctives
s and endp
nt c
s and endp
no
s docum
 Synopsis
cum
 Synopsis
and endpo
ocu
and endpo
3 Obje
do
3 Obje
This do
m
s d
s
nd any extensions or variations thereof.f
for consist
atio
for consist
ption of th
riat
ption of th
on
s o
ndpoint
sion
ndpoint
efined as
nsio
efined as
x10
te
x109
e
9/L 
ens
/L 
east 2 sepa
xte
east 2 sepa
wo adjacen
ext
wo adjacen
st 7 days a
y e
st 7 days a
of bleedin
any
of bleedin
moved to “
d an
moved to “
dpoints”.
nd a
dpoints”.
lication and any extensions
ns
points
tio
points
The seco
an
The seco
relate
n a
relate
As
n
As
nd
on
applic
s, Objectiv
ppli
s, Objectiv
oints
ap
oints
es and
ap
es and
lic


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 183 of 202
Section # and Name
Description of Change
Brief Rationale
1.1 Synopsis, Objectives 
and endpoints
3 Objectives and endpoints
The other efficacy endpoint 
“Duration of first Complete 
Response: measured from 
achievement of Complete 
Response to loss of Complete 
Response (loss of Complete 
Response defined as platelet count 
<100x109/L or bleeding. Platelet 
counts confirmed on at least 2 
separate occasions)” has been 
deleted.
The secondary efficacy endpoint on 
"Complete Response" was deleted 
as it did not measure a different 
manifestation of the disease. For 
consistency, the "Duration of 
Complete Response" was deleted 
too.a
1.1 Synopsis, Objectives 
and endpoints
3 Objectives and endpoints
The following text has been added 
to the other efficacy endpoint 
“Usage of rescue therapy by visit”.
To clarify the timepoint of 
measuring the endpoint.a
1.1 Synopsis, Objectives 
and endpoints
3 Objectives and endpoints
Additional “other” efficacy 
endpoints have been added:
• Cumulative number of weeks 
over the planned 24-week 
treatment period with platelet count 
of ≥100x109/L.
• Cumulative number of weeks 
over the planned 24-week 
treatment period with platelet 
counts ≥30×109/L and at least 
doubling from Baseline.
• Mean change from Baseline in 
platelet count by visit.
• Clinically Meaningful Platelet 
Response of ≥50x109/L, for at least 
4 out of 6 weeks during the last 
6 weeks (Week 19 to 25).
• Clinically Meaningful Platelet 
Response of ≥50x109/L, for at least 
6 out of 8 weeks during the last 
8 weeks (Week 17 to 25).
Updated to include missing 
details.a
1.1 Synopsis, Objectives 
and endpoints
3 Objectives and endpoints
The following text has been added 
to the safety endpoint:
Occurrence of TEAEs leading to 
withdrawal of investigational 
medicinal product (IMP) (ie, study 
discontinuation)
Updated to provide clarity.a
1.1 Synopsis, Objectives 
and endpoints
3 Objectives and endpoints
The exploratory endpoint related to 
ITP bleeding score has been 
changed to “ITP BAT bleeding 
events and severity by visit”.
Updated to specify the bleeding 
assessment tool to be used and 
clarification of the timepoint.a
PUBLIC COPY 
weeks
PY
weeks
eek 
OP
eek 
th platele
COP
th platele
number 
C C
number 
lanned 24
BLIC
lanned 24
nt period
UBL
nt period
ts ≥30×1
PUB
ts ≥30×1
ubling f
PU
ubling f
an
P
an
arketing authorization 
za
timepoint 
ting
timepoint 
the endpoi
keti
the endpoi
g 
ot be used to support any mar
count 
rt a
count 
f weeks
ppo
f weeks
week 
up
week 
with platel
su
with platel
/L and at
to s
/L and at
om Baselin
d to
om Baselin
change fro
sed
change fro
let
u
let count b
use
count b
Clinically
e u
Clinically
Respons
be
Respons
4 out 
ot b
4 out 
6
t
6 w
ent cannot
dated to in
ma
dated to in
details.
y m
details.a
m
a
ar
ot
a
s documen
ynopsis, Ob
me
ynopsis, Ob
d endpoint
um
d endpoint
3 Objectiv
ocu
3 Objectiv
This d
en
s d
s thereof.
of 
e
of 
int.
th
int.a
he
a
eo
on and any extensions or variations 
elet 
io
elet 
t least
sio
t least
ine.
en
ine.
om Baselin
xte
om Baselin
by visit.
ext
by visit.
y Meaningf
y e
y Meaningf
se of ≥50x
any
se of ≥50x
of 6 week
d an
of 6 week
weeks (We
nd 
weeks (We
• Clinica
an
• Clinica
Respo
n a
Respo
6 o
n
6 o
ation
nclude mis
ons
nclude mis
s
on
s o
applicat
bjectives
lica
bjectives
tsts
ves and en
app
ves and en
at


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 184 of 202
Section # and Name
Description of Change
Brief Rationale
1.1 Synopsis, Objectives 
and endpoints
3 Objectives and endpoints
The exploratory endpoints related 
to the effect of rozanolixizumab on 
health-related quality of life 
(HRQoL) have been modified.
Updated to provide clarity and to 
include missing details from 
previous version of the protocol.a
1.1 Synopsis, Objectives 
and endpoints
3 Objectives and endpoints
The exploratory endpoints related 
to the effect of rozanolixizumab on 
patient reported outcomes (PROs) 
have been modified.
Updated to provide clarity and to 
include missing details from 
previous version of the protocol.a
1.1 Synopsis, Objectives 
and endpoints
3 Objectives and endpoints
The exploratory objective has been 
amended from “To assess the 
plasma concentrations of 
rozanolixizumab” to “To assess the 
pharmacokinetics of 
rozanolixizumab”.
Updated to correct an error.a
1.1 Synopsis, Objectives 
and endpoints
3 Objectives and endpoints
Pharmacodynamic (PD) endpoints 
were updated to include “total 
serum IgG” and “serum IgG”.
To include missing details from 
previous version of the protocol.a
1.1 Synopsis, Objectives 
and endpoints
3 Objectives and endpoints
The exploratory endpoint “Percent 
change from Baseline in 
vaccination titers against tetanus in 
study participants” was updated to 
remove reference to all study 
participants.
Updated to provide clarity that 
vaccination titers against tetanus 
are not assessed in all participants.
1.1 Synopsis, Objectives 
and endpoints
3 Objectives and endpoints
1.3 Schedule of Activities, 
Table 1-4
The “Physical Fatigue Instrument” 
has been changed to the 
“FATIGUE-PRO Physical Fatigue 
scale”.
Updated to indicate the correct 
name of the PRO.a
1.1 Synopsis, Overall 
design
“Visit 1” has been added to clarify 
when Screening occurs. 
Updated to provide clarity.a
1.1 Synopsis, Overall 
design
Details have been added to explain 
that a 
 total dose 
corresponds to an average 
 
dose in a participant weighing 
70kg.
Updated to provide clarity.a
1.1 Synopsis, Overall 
design
1.1 Synopsis, Treatment 
groups and duration, Table 
1-2, footer
Additional wording has been 
provided for clarification on the 
action taken for study participants 
with on the lowest dose level with 
a platelet count between 
>200×109/L and <400×109/L.
This update has been included to 
consider that no dose reduction to 
less than 
(fixed dose) is 
set.a,b
PUBLIC COPY 
al
Y
al
gG”.
PY
gG”.
endpoint 
CO
endpoint 
asel
C C
aseline i
C C
ine i
titers ag
LIC
titers ag
rticipants
BLI
rticipants
e referen
UBL
e referen
rticipants
PU
rticipants
O
“Ph
P
“Ph
P
t cannot be used to support any marketing authorization 
ocol.
ho
ocol.a
or
a
za
n error.
aut
n error.a
ut
a
uth
 include m
ma
 include m
previous v
y m
previous v
ar
a
Percent
ort
Percent
inst tetanu
upp
inst tetanu
” was upda
sup
” was upda
e to
o
e to all 
o s
all st
s
st
rt
ysical Fati
ed
ysical Fati
een change
use
een change
ATIGUE
us
ATIGUE
scale”.
be
scale”.
d t
ot
n ot
“
o
“
This document c
ot
ot
ot
ot
sis, Overa
ent 
sis, Overa
t c
d
s do
1.1 S
d
1.1 S
d
do
s d
d any extensions or variations thereof.
missing de
ions
missing de
version of
atio
version of
ns
us in
ns
us in
ated to 
ons
ated to 
tudy 
sio
tudy 
Updated
r v
Updated
vaccin
or 
vaccin
are
o
are
va
s o
igue Instru
xten
igue Instru
ged to the
ext
ged to the
PRO Phys
y ex
PRO Phys
en
application and 
Visit 1” h
and
Visit 1” h
when Sc
an
when Sc
d
on
all
a
all
io
a


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 185 of 202
Section # and Name
Description of Change
Brief Rationale
1.1 Synopsis, Treatment 
groups and duration
Additional wording has been 
provided to explain that placebo 
will be administered at volumes 
matching the rozanolixizumab arm.
Updated to provide clarity.a
1.1 Synopsis, Overall 
design
4.1 Overall design
The study hold criteria was 
amended to remove the following 
wording: “as soon as” and add 
“clearly”.
Updated to provide clarity for the 
stopping rule.a
1.1 Synopsis, Overall 
design
4.1 Overall design
For US and Canada only: The 
stopping rule was updated from 
when 3 study participants 
experience SAEs of the same type 
within the first 15 participants who 
have received 3 doses of IMP 
across TP0003 and TP0006 to 
when 3 study participants 
experience any SAE within the 
first 15 study participants who 
have received at least one dose of 
IMP across TP0003 and TP0006. 
Clarification that the stopping rule 
is applicable unless the SAE is 
clearly unrelated to study drug.
Inclusion of the local US/CAN 
protocol amendment. Updated text 
per FDA request to change the 
study stopping rule.a,c
1.1 Synopsis, Number of 
Participants
The number of additional 
participants that may be recruited 
into the study was changed from 75 
to 60. In addition, the maximum 
total sample size has been changed 
from 105 to 90.
Number of study participants had 
been changed based on revised 
sample size calculation method and 
assumptions.a
1.3 Schedule of Activities, 
Table 1-3
Footnote c has been updated to 
include splenectomized 
participants.
Updated for consistency within the 
protocol.
1.3 Schedule of Activities, 
Table 1-4
Assessment of 12-lead ECG: 
footnote j has been added to 
Baseline (Visit 2).
The following text has been added 
for footnote j “The ECG 
assessment can be done -1 day for 
Baseline (Visit 2) by site’s local 
procedure.”
To enable the site to have ECG 
assessments completed prior to 
randomization, per local site 
procedure.
1.3 Schedule of Activities, 
Table 1-4
Assessment of 12-lead ECG: 
Footnote i has been added to 
Visit 6 and EOS Visit.
Updated to correct an error.a
1.3 Schedule of Activities, 
Table 1-4
Assessment of PGI-C has been 
removed from Visit 2 (Baseline).
Entered in error as “change” cannot 
be assessed at baseline.a
BLIC COPY 
n the
Y
n the
ts who
OPY
ts who
one dos
OP
one dos
3 and TP
CO
3 and TP
at the sto
C C
at the sto
unless th
IC 
unless th
nrelated t
BLIC
nrelated t
PUBL
umber o
UB
umber o
rticipant
PU
rticipant
the 
P
the 
BL
support any marketing authorization 
za
of 
t
of 
0006.
ort
0006.
pping rule
po
pping rule
e SAE is
pp
e SAE is
study dru
sup
study dru
US/CAN
aut
US/CAN
nt. Update
g a
nt. Update
st to chang
ing 
st to chang
ng rule.
eting
ng rule.a,c
n
a,c
uth
a
be used to s
additiona
to s
additiona
that may b
d to
that may b
tudy was c
ed 
tudy was c
In addition
se
In addition
al sample s
us
al sample s
rom 105 t
be u
rom 105 t
nnot be
su
,
Footno
ot b
Footno
incl
ot 
incl
o be
ot
s document can
Activities
can
Activities
This d
n
s d
s 
1
s
ons or variations thereof.
ug.
o
ug.
ed text
eof
ed text
ge the
reo
ge the
s o
ny extension
l
be
en
be recruite
ns
recruite
changed fr
ten
changed fr
n, the max
exte
n, the max
size has be
y ex
size has be
o 90.
ny
o 90.
and any
on
ote c has b
d an
ote c has b
lude
d
lude splen
d a
splen
participan
and
participan
ny
on a
Asses
n a
Asses
foo
n
foo
application
s,s,
an
on


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 186 of 202
Section # and Name
Description of Change
Brief Rationale
1.3 Schedule of Activities, 
Table 1-4
Blood sampling for plasma 
concentration of rozanolixizumab 
has been removed from the EOS 
visit. 
Expected to be below the limit of 
quantification.a
1.3 Schedule of Activities, 
Table 1-4
Footnote g was added to clarify 
that the platelet count assessed by 
the local laboratory can be done -1 
day for the Baseline (Visit 2) and 
for Week 3 (Visit 6). For 
subsequent dosing visits, the last 
two available platelet counts can be 
considered. Subsequent footnotes 
were reordered.
Updated to clarify the platelet 
count assessment. a,d
1.3 Schedule of Activities, 
Table 1-4
Footnote p (previously footnote o): 
has been updated to include EOS 
Visit.
Updated to correct an error.a
1.3 Schedule of Activities, 
Table 1-4
Footnote y (previously footnote x): 
Footnote updated to remove 
reference to all study participants.
Updated to provide clarity that 
exploratory biomarkers are not 
assessed in all participants.
1.3 Schedule of Activities, 
Table 1-4
Footnote z (previously footnote y): 
Footnote changed from “prior to 
the first dose” to “prior to dosing”.
Updated to provide further clarity.a
2.2 Background
“Ongoing” has been removed from 
Study UP0060.
Clinically complete with study 
reporting ongoing.a
4.1 Overall Design
The following sentence 
“Previously, in TP0001, a 15mg/kg 
dose was evaluated. In TP0006, a 
single fixed-unit dose equivalent to 
will be administered at 
the Baseline Visit. Following the 
initial dose, study participants will 
then receive a fixed-unit dose of 
equivalent to 
 
rozanolixizumab or placebo, every 
two weeks until Week 23.” has 
been deleted
To avoid repetition.a
4.1 Overall Design
A new sentence has been added to 
explain that contingency measures 
during a pandemic and other 
exceptional circumstances have 
been included.
Contingency measures have been 
implemented to ensure study 
participant safety in response to the 
COVID-19 pandemic causing the 
inability for sites to adhere to 
protocol visits and assessments.a
4.1 Overall Design
The number of sites has been 
changed from 50 to 70. In addition, 
the maximum number of evaluable 
Increased to reflect the number of 
potential sites.a
PUBLIC COPY
otnote x
PY 
otnote x
move
OPY
move
dy partici
COP
dy partici
Y
viously f
C C
viously f
anged fro
LIC 
anged fro
ose” to “
BLIC
ose” to “
CO
going” ha
UB
going” ha
udy UP0
PU
udy UP0
BL
P
d to support any marketing authorization 
za
ed to corre
arke
ed to corre
ke
ants.
rt
ants.
Update
ny 
Update
expl
an
expl
a
a
a
y m
a
ootnote y):
po
ootnote y):
m “prior to
upp
m “prior to
prior to dos
sup
prior to dos
or
been rem
to s
been rem
60.
d t
60.
s
ot be used 
lowing sen
sed
lowing sen
viously, in
use
viously, in
ose was ev
e u
ose was ev
single fix
be 
single fix
the 
ot 
the 
i
o
i
This document cannot
d
ot
.1 Overall 
cum
.1 Overall 
m
s d
ot b
ensions or variations thereof.
ect an error
s th
ect an error
th
ed to provi
riat
ed to provi
loratory b
aria
loratory b
assessed in
va
assessed in
tio
o o 
sing”.
ons
sing”.
Updat
or 
Updat
r v
s o
moved from
sio
moved from
on
d any exten
ntence
xte
ntence
n TP0001, 
ext
n TP0001, 
valuated. I
y e
valuated. I
xed
an
xed
on and
-
n
-unit do
any
unit do
will be
an
will be
e Baseline 
nd a
e Baseline 
initial dos
and
initial dos
then
an
then rec
n
rec
equi
n 
equi
ro
ro
application
en
on
l Design
pp
l Design
pli
d a


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 187 of 202
Section # and Name
Description of Change
Brief Rationale
study participants has been 
changed from 105 to 90.
Number of study participants had 
been changed based on revised 
sample size calculation method and 
assumptions.a
4.4 End of study definition
Clarified that only study 
participants not rolling over into 
TP0004 will have an EOS Visit 
performed 8 weeks after the final 
dose of IMP, or upon 
discontinuation of the study.
Updated for consistency within the 
protocol.a
5.1 Inclusion criteria
Criterion #4 now 4a, has been 
amended to include documented 
intolerance or insufficient response 
to a minimum of two standard of 
care ITP medications.
Global implementation of an 
ANSM request and implement 
feedback received from the FDA.a
5.1 Inclusion criteria
Criterion #6 now 6a, has been 
amended to remove 
“immunosuppressive”.
Updated to be consistent with 
Table 6-2.a
5.2 Exclusion criteria
Criterion #5 now 5a, has been 
updated to remove reference to 
IMP or comparative drugs (and/or 
an investigational device).
Updated to be consistent across the 
Phase 3 rozanolixizumab clinical 
program.a
5.2 Exclusion criteria
Criterion #7 now 7a, has been 
amended to remove “bacterial or 
viral infection” and “untreated 
H. pylori infection” has been 
added.
Updated for exclusion criteria 
clarification.a
5.2 Exclusion criteria
Criterion #8: now 8a, was updated 
to ensure the criterion was 
applicable to prior to the “first” 
dose.
Updated for exclusion criteria 
clarification.a
5.2 Exclusion criteria
Criterion #11 now 11a, was 
amended to “Study participant has 
any of the following active GI 
disorders: inflammatory bowel 
disease, GI ulceration or 
diverticulitis.”
No scientific reason to exclude 
patients with history of said 
disorders.a
5.2 Exclusion criteria
Criterion #21 now 21a, was 
updated to ensure the criterion was 
applicable to the “final” dose.
Updated for exclusion criteria 
clarification.a
5.2 Exclusion criteria
Criterion #23 now 23a, has been 
updated to clarify that study 
participants with treatment with 
rituximab more than 6 months 
prior to Visit 2 (Baseline Visit) are 
Allowing recovery of B cell 
function is preferable regardless of 
the lapsed time. a,b
BLIC COPY 
n
Y
n
a,
C
a, has be
CO
has be
ove refere
C C
ove refere
parative d
IC 
parative d
gational d
BLIC
gational d
OP
PUBL
ion #7 no
UB
ion #7 no
ended to
PU
ended to
al infe
P
al infe
BL
support any marketing authorization 
za
ntation of 
ng 
ntation of 
st and imp
ting
st and imp
eceived fr
keti
eceived fr
a
Updated to
y m
Updated to
Table 6
ny 
Table 6
ma
a
n
o
n
nce to
po
nce to
ugs (and/o
pp
ugs (and/o
evice).
sup
evice).
U
t a
nnot be used to su
w 7a, has b
to s
w 7a, has b
emove “b
d to
emove “b
tion” and 
ed t
tion” and 
ori
s
ori infectio
sed
infectio
d.
u
d.
su
Criterion 
be 
Criterion 
to ensu
t be
to ensu
appl
ot 
appl
d
o
d
u
ot
cument cann
teria
can
teria
This docu
nn
5.2 Exc
doc
5.2 Exc
cu
s d
ons or variations thereof.
an 
e
an 
plement
here
plement
om the FD
the
om the FD
of
o be consi
tion
o be consi
-2.
ia
2.a
at
a
on
or 
s
or 
Updated t
r va
Updated t
Phase 3
or v
Phase 3
prog
o
prog
ar
s o
and any extension
been
sio
been
ac
n
acterial or
nsi
terial or
“untreate
ten
“untreate
on” has be
xte
on” has be
on
#8: now 8
ny 
#8: now 8
ure the crit
any
ure the crit
licable to 
d a
licable to 
dose.
nd
dose.
y e
on an
Criteri
n a
Criteri
ame
n
ame
application an
on
usion crit
ap
sion crit
pp


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 188 of 202
Section # and Name
Description of Change
Brief Rationale
excluded if B cells have not 
returned to normal, irrespective of 
time.
5.2 Exclusion criteria
Criterion #24 now 24a, has been 
amended to include a 
cross-reference to rescue therapy.
Updated for exclusion criteria 
clarification.a
5.2 Exclusion criteria
Criterion #28 now 28a, has been 
amended to include “at the 
Screening Visit”.
Updated for exclusion criteria 
clarification.a,b
5.2 Exclusion criteria
Criterion #31 now 31a, has been 
amended to include a specific 
timepoint, ie, Baseline.
Updated for exclusion criteria 
clarification.a
5.2 Exclusion criteria
Criterion #33 now 33a, has been 
amended to include a specific 
timepoint, ie, Screening and the 
order of text has been reordered. In 
addition, “understood and” has 
been deleted.
Updated for exclusion criteria 
clarification.a
5.2 Exclusion criteria
Criterion #34 now 34a, has been 
amended to include "at the 
Screening Visit.”
Updated for exclusion criteria 
clarification.a
5.2 Exclusion criteria
Criteria #39 now 39a, was updated 
to replace family history with 
“current or medical history”.
Updated for exclusion criteria 
clarification.a
5.2 Exclusion criteria
Criteria #41 now 41a, was updated 
to specify heart rate using 
Fridericia's formula (QTcF), and to 
correct the visit to “Baseline Visit”.
QTc was not specific enough.a
5.2 Exclusion criteria
Criteria #43 now 43a, has been 
updated to only exclude major 
surgeries, and only whilst 
participants are in the study.
Updated to be consistent across the 
Phase 3 rozanolixizumab clinical 
program.a
5.2 Exclusion criteria, 
Table 5-1
The period relative to the Baseline 
Visit has been updated for 
rituximab in line with Exclusion 
Criterion 23a.
Updated for required treatment-free 
periods.a,b
5.2 Exclusion criteria, 
Table 5-1
Inebulizumab was added to the 
table requiring a 6-month 
treatment-free period prior to 
Baseline, and B-cell counts within 
the normal range.
Updated for clarification of 
prohibited medications and 
required treatment-free periods.a
PUBLIC COPY 
ered
Y
ered
d” has
PY
d” has
w 34a, ha
CO
w 34a, ha
clude "at
C C
clude "at
Visit.”
LIC
Visit.”
CO
a #39 now
UBL
a #39 now
place fam
PUB
place fam
urrent o
PU
urrent o
LI
P
t cannot be used to support any marketing authorization 
za
ria
h
ria
riz
usion criter
g a
usion criter
a
d for exclu
arke
d for exclu
fication.
mar
fication.a
r
a
ke
a
been
ort
been
he
p
he
rt
39a, was 
o su
39a, was 
mily history
to 
mily history
medical
d to
medical h
o
h
up
a #41 now
sed
a #41 now
pecify hea
us
pecify hea
Fridericia's
be u
Fridericia's
correct t
be
correct t
ed
t
Crit
ot 
Crit
u
o
u
t b
ot
cument c
ion criteria
nt 
ion criteria
1
m
1
t c
s docu
5.2 Exc
doc
5.2 Exc
Tabl
do
Tabl
This d cu
s d
pplication and any extensions or variations thereof.
ria
e
ria
f.
usion crite
s th
usion crite
the
Updated
or v
Updated
clarifi
or
clarifi
va
s o
updated 
ion
updated 
y with
nsio
y with
history”.
ens
history”.
ns
w 41a, was
exte
w 41a, was
art rate usin
ex
art rate usin
s formula (
ny e
s formula (
he visit to
any
he visit to
te
teria #43 n
d a
teria #43 n
updated to
and
updated to
surgerie
an
surgerie
parti
n a
parti
a
on
a,
a
a,
T
on
on
on
on
app
usion crit
ap
sion crit
pp


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 189 of 202
Section # and Name
Description of Change
Brief Rationale
5.2 Exclusion criteria, 
Table 5-1
TPO-RAs examples of 
Eltrombopag and Avatrombopag 
were removed. 
Updated for clarification of 
prohibited medications and 
required treatment-free periods.a,c
5.4 Screen failures
New wording has been included 
pertaining to additional 
rescreening.
Updated to provide clarity and be 
consistent with study design and 
remainder of protocol.a
6 Study Treatments, 
Table 6-1
Canada has been added to 
Packaging and label specification. 
Updated to remain consistent 
across the ITP Phase 3 clinical 
program.a
6.2 Measures to minimize 
bias: randomization and 
blinding
The following text has been added 
to: The randomization number will 
be incorporated from the IRT into 
the eCRF by automatic data 
transfer.
Updated to provide further clarity.a
6.2.1.1: Maintenance of 
study treatment blind
Amended to allow disclosure of 
platelet count results to study 
participants.
It is deemed necessary information 
for participants when engaging in 
activities of daily living.a
6.2.1.1: Maintenance of 
study treatment blind
The following sentence was added 
“An independent Quantitative 
Clinical Pharmacologist/Modeling 
and Simulation Scientist may have 
access to the randomization code to 
review unblinded PK, platelet and 
serum IgG data.” 
Added to allow modelling 
activities regarding potential 
pharmacokinetic/pharmacodynamic 
analysis as specified in the 
statistical section to be started by 
and independent scientist.a
6.2.1.1: Maintenance of 
study treatment blind
7.1.4: Temporary IMP 
discontinuation
Clarification that treatment will be 
temporarily discontinued for any 
participant with IgG levels below 
1g/L on any occasion.
Clarification of formal and 
informal unblinding and the role of 
the unblinded Medical Monitor.
Updated to clarify when treatment 
discontinuation is required, 
unblinding, and the role of the 
unblinded Medical Monitor.a,d
6.4.1 Permitted 
concomitant treatments 
(medications and 
therapies), Table 6-2
Clarification of oral corticosteroid 
dose.
Updated to clarify permitted 
concomitant medications.a,d
6.4.1 Permitted 
concomitant treatments 
(medications and 
therapies), Table 6-2
Addition of Eltrombopag, 
Avatrombopag and Fostamatinib at 
any dose as permitted concomitant 
treatments. 
Updated to clarify permitted 
concomitant medications.a,c
6.4.1 Permitted 
concomitant treatments 
(medications and 
therapies), Table 6-2
The following footnote was added 
“a Stable dose is defined as either 
the same dose and frequency of the 
respective medication taken for the 
Added to provide additional clarity 
on the protocol requirements 
related to the stable dose of the 
allowed concomitant treatments.a
PUBLIC COPY 
ure of 
PY
ure of 
study 
OPY
study 
entence w
C C
entence w
dent Qua
IC 
dent Qua
harmaco
BLIC
armaco
mulation 
UBL
mulation 
ss to the 
PUB
ss to the 
view un
PU
view un
m I
P
m I
CO
cument cannot be used to support any marketing authorization 
za
sistent 
uth
sistent 
3 clinical
au
3 clinical
tho
rovide furt
ting
rovide furt
ng
It is dee
ny 
It is dee
for p
any
for p
ac
a
ac
y m
a
was added 
por
was added 
ntitative 
pp
ntitative 
ogist/Mode
sup
ogist/Mode
cientist m
o su
cientist m
andomizat
to s
andomizat
linded PK
d to
linded PK
gG data.”
ed
gG data.”
ort
ification t
us
ification t
emporarily
be u
emporarily
participa
be
participa
1g/L 
t b
1g/L 
C
o
C
se
ot
tted 
nt
tted 
ant treatm
ent
ant treatm
cations an
me
cations an
rapies), Ta
cum
rapies), Ta
c
s docu
6.4.1 Per
doc
6.4.1 Per
conco
do
conco
(m
d
(m
This d cu
s d
pplication and any extensions or variations thereof.
ther clarity
here
ther clarity
eo
emed nece
iati
emed nece
participant
aria
participant
ctivities of
var
ctivities of
tio
eling
ns
eling
may have
ion
may have
tion code 
sio
tion code 
K, platelet a
ens
K, platelet a
Added 
or v
Added 
activ
o
activ
p
v
s o
hat treatm
ex
hat treatm
y discontin
ny e
y discontin
ant with Ig
any
ant with Ig
on any oc
d an
on any oc
larificatio
nd 
larificatio
informal
an
informal
the un
n a
the un
xt
on
ments
cat
ments
nd 
l
nd 
able 6
ppli
able 6-
pl
-2
pli
2
C
on
on
on
on
app
mitted 
app
mitted 
nt tre
a
nt tre
pp


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 190 of 202
Section # and Name
Description of Change
Brief Rationale
period of time defined in 
Table 6-2, or no dose of the 
respective medication taken for the 
period of time as defined in 
Table 6-2.”
6.4.2 Prohibited 
concomitant treatments 
(medications and 
therapies)
Clarification of corticosteroids.
Updated to clarify prohibited 
concomitant medications.a,d
6.4.2 Prohibited 
concomitant treatments 
(medications and 
therapies)
Addition of Romiplostim as 
prohibited treatment.
Updated to clarify prohibited 
concomitant medications.a
6.4.2 Prohibited 
concomitant treatments 
(medications and 
therapies)
Removal of TPO-RA as prohibited 
treatment.
Updated to clarify prohibited 
concomitant medications.a
6.4.2 Prohibited 
concomitant treatments 
(medications and 
therapies)
New wording has been included 
explaining the use of prohibited 
concomitant treatment will lead to 
permanent discontinuation from 
IMP. Subsequently, participants 
should complete the assessments 
outlined for the EW Visit and enter 
the SFU Period.
Updated for clarification of 
prohibited medications.a
6.4.3 Rescue therapy
The following bullet point was 
deleted “Any systemically 
administered corticosteroids (above 
the background doses) for 
management of infusion reaction.”
Updated to correct an error as this 
was duplicated text.
6.4.3 Rescue Therapy
Additional details related to 
platelet transfusion, systemically 
administered corticosteroids, and a 
definition of a high dose of 
corticosteroids have been included.
Updated to clarify rescue 
therapy.a,b
7.1.3 Discontinuation of 
IMP due to other adverse 
events or medical 
condition
New wording has been included on 
the withdrawal of study participant 
during the treatment period and the 
requirement to complete 
assessments outlined in the Early 
Withdrawal Visit. 
Updated to provide further clarity 
on study visits following 
withdrawal.a
7.1.4 Temporary IMP 
discontinuation
Criterion #2, #3, #4, and #5 were 
amended.
In addition, details have been 
added for participants that have 
Updated to provide clarity and 
remain consistent.a
PUBLIC COPY 
n include
OPY
n include
of 
C
of prohib
CO
prohib
atment w
C C
atment w
scontinu
IC 
scontinu
sequently
BLIC
sequently
complete
UBL
complete
ned for t
PUB
ned for t
 SFU P
PU
 SFU P
PY
P
ent cannot be used to support any marketing authorization 
a
za
prohibited
g au
prohibited
dications.
ng 
dications.a
au
ed to clari
ark
ed to clari
comitant m
ma
comitant m
ke
d 
t
d 
ited 
ort
ited 
l lead to
por
l lead to
tion from 
pp
tion from 
participan
sup
participan
the assessm
o su
the assessm
e EW Vis
to 
e EW Vis
riod.
d t
riod.
Up
an
Up
any
a
llowing bu
sed
llowing bu
ted “Any 
us
ted “Any 
dministere
be u
dministere
the back
be
the back
mana
ot b
mana
ed
ot
y
n
y
ot
A
o
A
ot
ot
ot
ot
s docume
Discontin
me
Discontin
MP due to o
cum
MP due to o
events or
ocu
events or
condit
do
condit
This d
e
s d
d any extensions or variations thereof.f
ify prohibi
ns t
ify prohibi
medicatio
ons
medicatio
th
nts
n
nts
sments
ion
sments
it and ente
sio
it and ente
pdated for 
vari
pdated for 
prohibited
r va
prohibited
ria
s o
ullet point 
xte
ullet point 
systemica
ex
systemica
ed corticos
ny e
ed corticos
kground do
any
kground do
agement of
d an
agement of
ten
on and 
Additional
nd
Additional
platelet 
an
platelet 
admi
n a
admi
de
n
de
cation
d
on
applica
nuation of 
lic
nuation of 
other adve
ppl
other adve
me
a
medical
app
dical
ca


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 191 of 202
Section # and Name
Description of Change
Brief Rationale
suspected or confirmed 
COVID-19.
7.2 Participant 
discontinuation/withdrawal 
from the study
This section was updated to reorder 
withdrawal criteria and remove 
repetitive information.
Updated to provide clarity and be 
consistent with study design and 
remainder of protocol.a
7.3 Lost to follow up
This section was updated to 
remove repetitive information.
To avoid repetition.a
8 Study Assessments and 
Procedures
A new paragraph describing 
contingency measures during a 
pandemic and other exceptional 
circumstances has been included.
Contingency measures have been 
implemented to ensure study 
participant safety in response to the 
COVID-19 pandemic causing the 
inability for sites to adhere to 
protocol visits and assessments.a
8.1.1 Platelet counts
Study endpoints related to platelet 
counts were updated to match the 
updates made in Sections 1.1 
and 3.
To be consistent with the rest of the 
protocol.a
8.1.1 Platelet counts
The following sentence was 
modified to clarify that the analysis 
was not for all clinical response 
variables: “The Response and 
Complete Response variables will 
be assessed only for visits for 
which both platelet counts and the 
ITP bleeding score are assessed 
(with the exception of the 
confirmatory platelet assessments 
which may be obtained at any visit 
(scheduled or unscheduled) 
provided that they meet the criteria 
below).”
Updated to provide clarity.a
8.1.2 ITP bleeding score
The following was added ‘with 
grading of severity’ to clarify the 
definition SMOG.
Updated to include missing 
information.a
8.1.3 Patient Reported 
Outcomes
The list of PROs has been updated 
to replace the “Physical Fatigue 
Instrument” by the “FATIGUE-
PRO Physical Fatigue scale”.
To indicate the correct name of the 
PRO.a
8.1.3.1 ITP-PAQ
Details have been added to explain 
the addition of the ITP-PAQ 
Symptoms score as a secondary 
efficacy endpoint.
Corrected to clarify the variable.a
8.1.3.3 FATIGUE-PRO 
Physical Fatigue Scale
The “Physical Fatigue Instrument” 
has been replaced by the 
To indicate the correct name of the 
PRO.a
OPY 
.1 
Y
.1 
PUBLIC COP
ence was
COP
ence was
fy that th
C CO
fy that th
l clinical
C C
l clinical
The
LIC
The Res
IC
Res
ete Respo
BL
ete Respo
sessed on
UB
sessed on
hich both
PU
hich both
blee
P
blee
OP
ot be used to support any marketing authorization 
za
za
za
have been
uth
have been
ure study 
au
ure study 
y in respon
ng a
y in respon
ndemic ca
ting
ndemic ca
r sites to a
keti
r sites to a
visits and
rke
visits and
th
e consiste
mar
e consiste
rotocol.
y m
rotocol.a
m
a
ark
a
e analysis
por
e analysis
response 
ppo
response 
ponse and
upp
ponse and
nse
s
nse variab
su
variab
ly for visit
to s
ly for visit
platelet co
d to
platelet co
ding score 
ed 
ding score 
the except
se
the except
nfirmatory 
us
nfirmatory 
which may
be u
which may
(schedu
t be
(schedu
p
ot
prov
t b
rov
be
o
be
nt cannot be used to support a
U
a
U
a
ot
a
g score
an
g score
nn
This documen
atient Rep
men
atient Rep
omes
um
omes
n
d
s do
8.1.3
d
8.1.3
do
s d
ariations thereof.
n n 
nse to the
eof
nse to the
ausing the
ere
ausing the
adhere to
ther
adhere to
d assessme
s th
d assessme
ent with th
ns
ent with th
s
and any extensions or var
les will 
ons
les will 
ts for 
sio
ts for 
ounts and t
ens
ounts and t
e are assess
ten
e are assess
tion of the
exte
tion of the
y platelet a
y ex
y platelet a
y be obtain
ny e
y be obtain
uled or uns
any
uled or uns
vided that t
d a
vided that t
elow).”
nd
elow).”
on an
Updated to
va
Updated to
ar
s o
The fol
n an
The fol
grad
n 
grad
d
an
application
on
ported 
ica
ported 
at
a
PA
a


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 192 of 202
Section # and Name
Description of Change
Brief Rationale
“FATIGUE-PRO Physical Fatigue 
scale”.
8.2.5.1 Tuberculosis 
assessment
Wording for Monitoring for TB 
during the study has been updated 
to clarify that study participants 
who have withdrawn from the 
study return for the EW visit and 
complete all EOS assessments.
Updated to correct an error.a
8.2.5.1 Tuberculosis 
assessment
TB signs and symptoms 
questionnaire: “and must receive 
prophylactic LTB infection 
therapy” has been deleted.
To provide further clarity.a
8.2.5.2 Tuberculosis 
management
Active TB or nontuberculous 
mycobacterium infection:
New wording has been included 
stating study participants should be 
encouraged to “enter the SFU 
period” and “attend Visit 29”.
Updated to clarify procedures on 
active TB or nontuberculous 
mycobacterium infection.a
8.2.6 Splenectomized 
study participants
Wording specific to 
splenectomized participants 
receiving adequate vaccination 
within 4 years of enrollment or 
prior to enrollment to avoid the 
treatment interruption has been 
included.
Updated to provide further clarity.a
8.3.8 Adverse events of 
special monitoring
A sentence has been added to 
clarify that an AESM is not 
necessarily a serious adverse event 
unless one of the seriousness 
criteria defined in the Appendix 3.
Updated to provide further clarity.a
8.8.2 Immunology
Text updated to specify that serum 
complements (C3, C4), plasma 
complements (C3a, C5a), and 
serum cytokines are collected 
4 hours postdose at Baseline and at 
Week 23.
Updated to provide further clarity 
and be consistent with the rest of 
the protocol.a
8.9 Exploratory 
biomarkers
Text updated to remove reference 
to all study participants.
Updated to provide clarity that 
exploratory biomarkers are not 
assessed in all participants.
8.9 Exploratory 
biomarkers
Duplicate details pertaining to 
sample collection, processing, 
storage, labeling, and shipping 
have been deleted.
To remove repetition.a
PUBLIC COPY 
oul
Y
oul
SFU
PY
SFU
isit 29”.
OPY
isit 29”.
to
C
to
d particip
C C
d particip
equate v
LIC 
equate v
years of e
BLIC
years of e
o enrollm
UBL
o enrollm
tment int
PUB
tment int
luded.
PU
luded.
OP
P
ment cannot be used to support any marketing authorization 
za
rity.
au
rity.a
ut
a
th
to clarify p
rke
to clarify p
TB or non
ark
TB or non
cobacteriu
ma
cobacteriu
et
a
nts
p
nts
ccination
upp
ccination
nrollment o
sup
nrollment o
ent to avoi
o su
ent to avoi
erruption h
to 
erruption h
t a
ence has b
se
ence has b
rify that an
us
rify that an
necessarily
be u
necessarily
unless o
t be
unless o
criter
ot b
criter
ed
ot
T
o
T
no
s docum
.9 Explora
cum
.9 Explora
biomarke
doc
biomarke
This d
m
s d
s 
8
s
plication and any extensions or variations thereof.
procedure
the
procedure
ntuberculo
s t
ntuberculo
um infectio
ons
um infectio
he
or 
o
or 
id the
sion
id the
has been
nsio
has been
Updated 
r va
Updated 
va
s o
been adde
exte
been adde
n AESM i
y ex
n AESM i
y a serious
ny e
y a serious
one of the 
any
one of the 
eria defined
d a
eria defined
te
Text upda
and
Text upda
comple
n an
comple
com
n 
com
se
se
d 
on
appli
atory 
pp
atory 
rs
a
rs
pli


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 193 of 202
Section # and Name
Description of Change
Brief Rationale
9.1 Definition of analysis 
sets
Text around the analysis of the PD, 
efficacy and immunologic 
variables has been updated and 
moved to be under the definition of 
the Safety Set (SS).
To clarify that all efficacy will be 
analyzed on the Randomized 
Set (RS) and the PD and 
immunology will be analyzed on 
the SS analysis set, unless 
otherwise specified.a
9.1 Definition of analysis 
sets
The definition of the Full Analysis 
Set (FAS) has been updated.
Updated to be consistent with the 
SAP.a
9.1 Definition of analysis 
sets
Updated the analysis set for the 
“Pharmacodynamic data” and the 
“Pharmacodynamic Per Protocol 
Set” analysis to the SS.
Updated to clarify that the 
pharmacodynamics will be 
analyzed in the safety set (all 
randomized study participants who 
received at least one dose of IMP).a
9.2 General statistical 
considerations
A sentence was added to explain 
that data handling conventions for 
data affected by COVID-19 will be 
detailed fully in the SAP.
Added to confirm that the potential 
effects of COVID-19 on the data 
analysis will be addressed.a
9.3.1 Analysis of the 
primary efficacy/primary 
endpoint
The primary efficacy endpoint was 
updated to match the updates made 
in Sections 1.1 and 3.
To be consistent with the rest of the 
protocol.a
9.3.1: Analysis of the 
primary efficacy/primary 
endpoint
The description of the primary 
analysis was updated. In addition, 
the test statistic for the 
combination test(s) was updated 
from t-test to Mantel-Haenszel
chi-square. 
Updated to correct an error in the 
previous version.a,d
9.3.1 Analysis of the 
primary efficacy/primary 
endpoint
Table 9-1: The primary efficacy 
endpoint was updated to match the 
updates made in Sections 1.1 and 
3. In addition, the intercurrent 
event strategy for the sensitivity 
analysis was amended.
To be consistent with the rest of the 
protocol.a
9.3.1 Analysis of the 
primary efficacy/primary 
endpoint
Table 9-1: Updated the analysis of 
the primary endpoint.
To provide further clarity.a
9.3.1 Analysis of the 
primary efficacy/primary 
endpoint
Table 9-1: Added a sensitivity 
analysis for the same endpoint, 
using the same analysis set (RS), 
but different methods for imputing 
missing values.
To confirm the robustness of the 
primary result.a
9.3.1 Analysis of the 
primary efficacy/primary 
endpoint
Table 9-1: Included a 
‘supplemental analysis’ for the 
difference in the proportion of 
To confirm the result should the 
placebo rate be low.a
C COPY 
wi
Y
wi
endpoin
OP
endpoin
the updat
CO
the updat
and 3.
C C
and 3.
PY
PUBLIC 
ption of t
LIC
ption of t
was upd
BL
was upd
st statist
UB
st statist
mbinatio
PU
mbinatio
m t
P
m t-
P
-t
P
t
C
pport any marketing authorization 
za
h the 
hor
h the 
riz
at the
au
at the
s will be
g a
s will be
safety set 
ing 
safety set 
study parti
eting
study parti
at least one
ket
at least one
uth
d to confir
ark
d to confir
ects of CO
ma
ects of CO
analysis w
y m
analysis w
rk
a
was 
rt a
was 
es made
ort
es made
To
a
To
an
a
used to supp
he primary
upp
he primary
ated. In add
su
ated. In add
for the 
to s
for the 
n test(s) wa
d to
n test(s) wa
t to Mant
ed 
t to Mant
uare.
se
uare.
ment cannot be us
pp
able 9
e u
able 9-
u
-1: T
u
1: T
endpoint 
be 
endpoint 
update
ot b
update
3. I
t 
3. I
o
us
ot
is of the
t c
is of the
fficacy/pri
ent 
fficacy/pri
nt
m
nt
ca
This docum
.1 Analys
cum
.1 Analys
primary ef
ocu
primary ef
endpoin
doc
endpoin
m
s d
extensions or variations thereof.
(all
re
(all
icipants w
here
icipants w
e dose of I
the
e dose of I
rm that the
ns t
rm that the
OVID
on
OVID-
n
-19 o
ns
19 o
will be add
atio
will be add
th
o be
va
o be consis
var
consis
protocol.
r va
protocol.
ria
o
y
ddition,
ions
ddition,
was updated
ens
was updated
el
t
el-
te
-Haensz
ten
Haensz
lication and any extensions o
Up
Up
o
s o
The primar
y e
The primar
t was upda
any
t was upda
es made in
d an
es made in
In addition
nd a
In addition
event strat
and
event strat
analysi
n an
analysi
ex
n
imary 
atio
imary 
Ta
n
Ta
n
applic
on
sis of the
ppli
sis of the
fficacy/pri
app
fficacy/pri
lic


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 194 of 202
Section # and Name
Description of Change
Brief Rationale
responders using Fisher’s Exact 
test.
9.3.2 Analysis of the 
secondary efficacy 
endpoints
The secondary efficacy endpoints 
were updated to match the updates 
made in Sections 1.1 and 3.
To be consistent with the rest of the 
protocol.a
9.3.2 Analysis of the 
secondary efficacy 
endpoints
Table 9-2: Estimands for secondary 
endpoints: Details for the “patient 
reported outcomes” have been 
updated.
To provide further clarity.a
9.3.2 Analysis of the 
secondary efficacy 
endpoints
Table 9-2: Updated the analysis of 
the secondary endpoint 
“Cumulative number of weeks with 
Clinically Meaningful Platelet 
Response of ≥50x109/L over the 
24-week treatment period” to 
include the geographical region.
To provide further clarity.a
9.3.2 Analysis of the 
secondary efficacy 
endpoints
Table 9-2: Updated the analysis of 
the secondary endpoint “Time to 
first Clinically Meaningful Platelet 
Response of ≥50x109/L: time from 
starting treatment to achievement 
of first response of ≥50x109/L” to 
include the geographical region.
To provide further clarity.a
9.3.2 Analysis of the 
secondary efficacy 
endpoints
Table 9-2: Updated the analysis of 
the secondary endpoint “Clinically 
Meaningful Platelet Response of 
≥50x109/L by Day 8”
To provide further clarity.a
9.3.2 Analysis of the 
secondary efficacy 
endpoints
Table 9-2: Updated the analysis of 
the secondary endpoint “Response 
defined as platelet count ≥30x109/L 
and at least a 2 fold increase of the 
Baseline count confirmed on at 
least 2 separate occasions at two 
adjacent nominal visits at least 7 
days apart, and absence of 
bleeding”
To provide further clarity.a
9.3.2 Analysis of the 
secondary efficacy 
endpoints
Table 9-2: Updated the sensitivity 
analysis of the secondary endpoint 
“Response defined as platelet count 
≥30x109/L and at least a 2 fold 
increase of the Baseline count 
confirmed on at least 2 separate 
occasions at two adjacent nominal 
visits at least 7 days apart, and 
To provide further clarity.a
PUBLIC COPY
o
Y
o
analysis o
PY 
analysis o
nt “Time
OPY
nt “Time
aningful 
CO
aningful 
0x10
C C
0x109
C
9/L: 
C
/L: 
ment to a
IC 
ment to a
ponse of
BLIC
ponse of
the geog
UBL
the geog
Y
ble 9
PU
ble 9-
PU
-2: U
U
2: U
secon
P
secon
UB
used to support any marketing authorization 
za
za
za
r clarity.
g a
r clarity.a
a
a
a
a
o
t
o
Platelet
ort
Platelet
me from 
por
me from 
chievemen
pp
chievemen
≥50x10
sup
≥50x109/
pp
9/L
p
L
raphical re
o su
raphical re
To pro
any
To pro
y
a
pdated the
d to
pdated the
dary endpo
ed t
dary endpo
ngful Plate
sed
ngful Plate
x10
u
x109
us
9/L by 
us
/L by 
o
ot be u
Table 9
be 
Table 9-2
the sec
t be
the sec
defi
ot 
defi
a
o
a
ment cannot
u
ot
s docum
3.2 Analys
cum
3.2 Analys
secondary
docu
secondary
endpoi
do
endpoi
This d
m
s d
y extensions or variations thereof.f.
nt 
s
nt 
” to
ns
” to
egion.
ion
egion.
ovide furth
riat
ovide furth
ati
s o
e analysis 
nsi
e analysis 
oint “Clin
ten
oint “Clin
elet Respo
xte
elet Respo
y Day
ex
y Day 8”
ex
8”
sio
on and any e
2: Updated
ny 
2: Updated
ondary en
any
ndary en
ined as pla
d a
ined as pla
nd at leas
nd
nd at leas
Baseline
an
Baseline
least 
n a
least 
ad
n
ad
lication
y e
on
applic
sis of the
ppl
sis of the
y efficacy
app
y efficacy
lic


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 195 of 202
Section # and Name
Description of Change
Brief Rationale
absence of bleeding” to include the 
geographical region.
9.3.2 Analysis of the 
secondary efficacy 
endpoints
Table 9-2: The following 
secondary endpoints were deleted: 
“Complete Response defined as: 
platelet count ≥100x109/L 
confirmed at two adjacent nominal 
visits at least 7 days apart, and 
absence of bleeding.”, “Clinically 
meaningful Response defined as: 
platelet count ≥50x109/L.” and 
“Duration of Clinically Meaningful 
Response: measured from 
achievement of first Response to 
loss of Response (loss of Response 
defined as platelet count 
<50x109/L).”
To be consistent with the rest of the 
protocol as these are no longer 
secondary endpoints.a
9.3.2 Analysis of the 
secondary efficacy 
endpoints
The study endpoint related to 
ITP-PAQ Symptoms Score has 
been updated.
To provide further clarity.a
9.3.2 Analysis of the 
secondary efficacy 
endpoints
Updated the analysis of the 
secondary endpoint “Change from
Baseline to Week 25, including all 
intermediate timepoints, in ITP 
PAQ Symptom score” to include 
the geographical region.
To provide further clarity.a
9.3.3.1: Analysis of 
pharmacokinetic endpoint
Language was updated to be in 
agreement with the SAP, and state 
that individual plasma 
concentration data will be 
summarized up to Week 4 where 
most subjects will have not 
followed down titration yet, if any.
Updated for clarification. Further 
details will be described in the 
SAP.a
9.3.3.1 Analysis of 
pharmacokinetic endpoint
The following sentence was added. 
“Summaries by geographical 
region may be performed.”
To provide further clarity.a
9.7 Planned interim 
analysis and data 
monitoring
Details were added to explain that 
the interim analysis will be 
conducted on combined data from 
TP0003 and TP0006. The text for 
the sample size re-estimation 
procedure was modified to allow 
for the option of maintaining the 
minimum sample size or increasing 
it. An additional sentence was 
To provide information for the 
proposal to potentially combine 
information from TP0003 and 
TP0006 for the estimand of the 
observed treatment effect in the 
assessment of futility and sample 
size re-estimation for Stage 2. 
Also, to update the decision criteria 
for futility to the stricter 5% level.a
PUBLIC COPY 
ed to
PY
ed to
Score ha
OPY
Score ha
Y
nalysis of
C C
nalysis of
endpoint 
LIC
endpoint 
to Week
BLI
to Week
mediate ti
UB
mediate ti
Q Symp
PU
Q Symp
geog
P
geog
C
ed to support any marketing authorization 
za
To pro
any
To pro
y
a
the
pp
the
Change fr
upp
Change fr
25, includi
sup
25, includi
mepoints, i
to s
mepoints, i
om score” 
d to
om score” 
aphical reg
ed t
aphical reg
or
ot be used
uage was u
use
uage was u
reement w
e us
reement w
that indivi
be 
that indivi
concen
t be
concen
sum
t 
sum
m
o
m
ment cannot
ed
ot
sis of 
t ca
sis of 
inetic end
nt 
inetic end
ca
s docume
Planned in
um
Planned in
analysis an
ocu
analysis an
monitor
doc
monitor
This d
me
s d
tensions or variations thereof.
ovide furth
riat
ovide furth
ati
rom
ns
rom
ding all
ons
ding all
in ITP 
sion
in ITP 
to include
nsi
to include
gion.
ten
gion.
To pr
or 
To pr
r v
s o
ication and any exte
updated to
ext
updated to
with the SA
y ex
with the SA
vidual plasm
ny 
vidual plasm
ntration da
any
ntration da
mmarized u
d a
mmarized u
most subje
and
most subje
followe
an
followe
te
n
dpoint
atio
dpoint
The
n 
The
“
n a
on
applic
nterim 
plic
nterim 
nd data 
app
nd data 
ng
a
g
ic


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 196 of 202
Section # and Name
Description of Change
Brief Rationale
added to state that no decrease in 
sample size will be permitted.
The futility stopping rule was 
amended to “The study may stop 
for futility if the difference in 
response rates of the combined 
data from TP0003 and TP0006 is 
<5%, ie, the rate in the 
experimental arm is no less than 
5% greater than the placebo arm.”
9.7.2 Early stopping for 
futility
The futility stopping rule was 
amended to “The futility stopping 
rule (non-binding) utilized for the 
study requires that at stage 1 the 
response in the rozanolixizumab 
arm is less than 5% greater than the 
placebo arm.”
Updated due to an amendment to 
the futility decision rule.a
9.8 Determination of 
sample size
Response rates were added from a 
publication (Kuter et al, 2008)
Updated owing to an amendment to 
the futility decision rule.a
9.8 Determination of 
sample size
The alpha level has been changed 
from 0.05 (2-sided) to 0.025 
(1-sided).
The 1-sided test is more correct 
owing to the nature of the adaptive 
design.a
9.8 Determination of 
sample size
Details about the interim analysis 
were modified to describe the 
combination of studies TP0003 and 
TP0006. In addition, it was 
clarified that the Stage 1 and 
Stage 2 p-values for the 
combination test will be obtained 
solely on an analysis of the primary 
endpoint for TP0006.
To increase the precision of the 
estimate of the observed treatment 
effect for assessment of futility and 
sizing of Stage 2, data from 
TP0003 and TP0006 will be 
combined at the interim analysis 
provided the studies recruit to a 
similar timeline.a
9.8 Determination of 
sample size
Table 9-3: The expected sample 
size for TP0006 has been updated.
Number of study participants had 
been changed based on revised 
sample size calculation method and 
assumptions.a
9.8 Determination of 
sample size
Details of the simulation results 
were updated.
Updated following the reduction in 
the sample size cap of 
90 participants and the change in 
the futility stopping rule of more 
than 5% better than placebo.a
10.2, Appendix 2: Clinical 
laboratory tests
Table 10-1: Footnotes b, c, d, e, 
and g added to clarify collection 
timepoints and requirements for 
protocol-required safety laboratory 
assessments.
Updated for clarification.a,d
BLIC COPY 
ded from
OPY
ded from
al, 2008
OP
al, 2008
Y
has been 
C CO
has been 
sided) to 
C C
sided) to 
CO
PUBL
abou
UBL
about th
BL
t th
e modifi
PUB
e modifi
mbinat
PU
mbinat
0
P
0
BL
support any marketing authorization 
za
n amendm
ng a
n amendm
cision rule
ting
cision rule
a
Upda
any
Upda
the
a
the
y 
a
hanged 
port
hanged 
0.025
pp
0.025
rt
ot be used to su
e interim a
o su
e interim a
d to descri
to 
d to descri
n of studi
d t
n of studi
. In additi
sed
. In additi
fied that t
use
fied that th
e
h
age
e
age 2 p
e u
2 p-
u
-va
va
combinat
be 
combinat
solely 
t b
solely 
end
ot 
end
ent cannot b
su
ot
of 
a
of 
no
s documen
eterminati
me
eterminati
mple size
cum
mple size
This do
en
s d
s
nd any extensions or variations thereof.
ment to
eof
ment to
e.e.a
of.
ated owing
aria
ated owing
e
v
e futility d
var
futility d
at
The 1
or v
The 1-si
v
si
owin
or
owin
de
de
va
s o
analysis 
sion
analysis 
be the
nsio
be the
es TP000
ens
es TP000
ion, it was
xte
ion, it was
he Stage 1
ext
he Stage 1
alues for th
y e
alues for th
tion test w
ny
tion test w
y on an ana
d an
y on an ana
dpoint for 
nd a
dpoint for 
ation and any extensions
ns
Table 9
an
Table 9
size fo
n a
size fo
nd
on
applica
on of 
lica
on of 
ca


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 197 of 202
Section # and Name
Description of Change
Brief Rationale
10.2, Appendix 2: Clinical 
laboratory tests
Table 10-1: Footnote h updated to 
include post baseline results for 
vaccination specific titers
To ensure blinding is consistent 
throughout all studies in the 
rozanolixizumab clinical program.a
10.6 Appendix 6: Liver 
safety – suggested actions 
and follow-up assessments
Table 10-3: The following wording 
has been removed: These criteria 
are not directly applicable to 
TP0006 because it is a single dose 
study; however, these criteria are 
indirectly applicable because upon 
completion of study TP0006, the 
study participants are to be 
provided a chance to enroll in the 
OLE study TP0004.
Clarification of language related to 
acetaminophen contribution to 
liver injury and removal of 
wording pertaining to requirements 
in China. 
To remove wording that was left 
from a previous version and to 
clarify the language for suggested 
actions.a
10.6 Appendix 6: Liver 
safety – suggested actions 
and follow-up 
assessments, References
The following reference was 
removed:
James LP, Letzig L, Simpson PM, 
Capparelli E, Roberts DW, Hinson 
JA, et al. Pharmacokinetics of 
acetaminophen-protein adducts in 
adults with acetaminophen 
overdose and acute liver failure. 
Drug Metab Dispos. 2009; 
37:1779-84
Updated to maintain consistency 
within the protocol.a
10.13, Appendix 13: 
ITP-PAQ
Removed an additional version of 
the ITP-PAQ questionnaire.
Updated to remove an additional 
version of the questionnaire that 
was accidentally included.a,d
10.15, Appendix 15: 
FATIGUE-PRO Physical 
Fatigue scale
The “Physical Fatigue Instrument” 
has been replaced by the 
“FATIGUE-PRO Physical Fatigue 
scale”.
Updated questionnaire.a,d
10.15, Appendix 15: 
Physical Fatigue 
Instrument
The Physical Fatigue PRO was 
updated to a new version.
Updated questionnaire.a,b
10.15, Appendix 15: 
Physical Fatigue 
Instrument
Mental fatigue and fatigability 
were removed.
Updated questionnaire.a
10.22, Appendix 22: 
Management of headaches
Text added to clarify that treatment 
may be temporarily put on hold if a 
study participant experiences an 
AE of a severe headache that is 
To add clarity.a
PUBLIC COPY 
reme
Y
reme
ence was
COP
ence was
tzig L, Si
C C
tzig L, Si
E, Rober
LIC
E, Rober
. Pharma
BLI
. Pharma
minophe
UB
minophe
ults with
PU
ults with
rdos
P
rdos
OPY
ent cannot be used to support any marketing authorization 
ed 
ri
ed 
a
za
mpson PM
ppo
mpson PM
s DW, Hin
upp
s DW, Hin
okinetics 
sup
okinetics 
protein ad
to s
protein ad
acetaminop
d to
acetaminop
and acute
ed 
and acute
Metab Disp
sed
Metab Disp
779
u
779-
us
-84
us
84
Up
a
Up
an
a
Removed
be 
Removed
the ITP
t b
the ITP
e u
ot
5:
a
5:
O Physical
can
O Physical
o
no
ocumen
, Appendix
me
, Appendix
ysical Fati
um
ysical Fati
nstrumen
ocu
nstrumen
en
s doc
10.15
do
10.15
Phy
d
Phy
This doc
s d
nd any extensions or variations thereof.
M,
s
M,
nson 
ns
nson 
of 
o
of 
adducts in 
sio
adducts in 
ophen
ens
ophen
liver failu
ten
liver failu
spos. 2009
exte
spos. 2009
Updated to 
var
Updated to 
within th
r v
within th
ari
s o
d an additi
ny
d an additi
P-PAQ qu
d an
PAQ qu
y e
ation and
The “Phy
an
The “Phy
has be
n a
has be
“FA
n
“FA
nd
on
applica
x 15:
lic
x 15:
igue 
ppl
igue 
t
a
t
at
ap
endi
a
endi
ap


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 198 of 202
Section # and Name
Description of Change
Brief Rationale
considered related to the IMP in 
the opinion of the investigator, and 
is not resolved prior to the next 
scheduled IMP.
10.23, Appendix 23: 
Management of diarrhea
Definition of severe (grade 3) 
diarrhea has been updated.
To add clarity.a
10.23, Appendix 23: 
Management of diarrhea
Modification of language regarding 
stool sample collection for 
participants reporting severe 
diarrhea.
To clarify when stool samples may 
be collected.a,d
10.24 Appendix 24: 
Management of infusion 
reactions or 
hypersensitivity reactions
Modification of language regarding 
potential infusion related reactions.
Updated to provide further clarity.a
10.25 Appendix 25: 
Management of Infections 
and 
Hypogammaglobulinemia
The following sentence was 
modified to state that study 
participants who discontinue must 
perform the EW Visit, enter the 
SFU Period and complete the EOS 
Visit. Study participants MUST 
discontinue IMP, perform the EW 
Visit, enter the SFU Period and 
complete the EOS Visit if any of 
the following events occur:
To add clarity.a
10.25 Appendix 25: 
Management of Infections 
and 
Hypogammaglobulinemia
Modification of language regarding 
the Medical Monitor to clarify they 
are unblinded.
The following sentence was 
modified to include “must”: 
Treatment must be temporarily 
discontinued for a study participant 
who develops an event of 
hypogammaglobulinemia with a 
serum total IgG of <1g/L 
irrespective of infection.
The following sentence was added 
“Mock infusions will be
administered to maintain the blind 
in case of low IgG levels (see 
Section 7.1.4).”
Updated to be consistent across the 
Phase 3 rozanolixizumab clinical 
program.a
10.26 Appendix 26: 
Protocol Amendment 
History
Details of the changes between 
Protocol Amendment 1 and 
Protocol Amendment 2 have been 
added.
General update.
PUBLIC COPY
inue mu
PY 
inue mu
, enter th
OPY
, enter th
mplete th
CO
mplete th
ticipants 
C C
ticipants 
MP, 
IC
MP, per
C 
per
er the SF
BLIC
er the SF
et
U
ete the E
BL
e the E
following
PUB
following
PU
difica
P
difica
PU
to support any marketing authorization 
za
les may 
hor
les may 
riz
vide furth
ting
vide furth
g
e EOS 
ort
e EOS 
MUST 
por
MUST 
orm the E
pp
orm the E
U Period a
sup
U Period a
OS Visit
su
OS Visit if
u
if
events occ
to 
events occ
o add clari
ma
o add clari
ma
a
ot be used to
ion of lang
ed t
ion of lang
dical Mon
sed
dical Mon
unblinded.
us
unblinded.
The follow
be u
The follow
m
t b
modifie
be
odifie
Trea
ot b
Trea
di
o
di
This document cannot
d to
s d
ot
1
s
nsions or variations thereof.
her clarity.
ereo
her clarity.
eo
EW 
s
EW 
and
ns
and
f any of 
ion
f any of 
cur:
ns
cur:
ity.
tio
ity.a
o
a
ns
s o
on and any extens
guage reg
ten
guage reg
nitor to cla
xte
nitor to cla
wing sente
ny e
wing sente
d to inclu
any
d to inclu
atment mus
d a
atment mus
iscontinue
nd 
iscontinue
who dev
an
who dev
hypog
n a
hypog
ser
n
ser
application
ns
on


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 199 of 202
Section # and Name
Description of Change
Brief Rationale
11 References
An additional reference has been 
added, as cited in Section 9.8.
General update.
a This update was previously incorporated to protocol amendment 1.
b This update was previously incorporated to local protocol amendment 0.2.
c This update was previously incorporated to local protocol amendment 0.1.
d This update was previously incorporated to local protocol amendments 0.1 and 0.2.
Amendment 1 (29 Sep 2020)
The following changes were implemented in protocol amendment 1 (an internally approved 
document, which was not submitted to the regulatory authorities or implemented at the study 
sites) but are no longer applicable due to a change in the data analysis strategy for participants 
enrolled from Mainland China and have been removed in protocol amendment 2.
Section # and Name
Description of Change
Brief Rationale
1.1 Synopsis, Number of 
Participants
The following sentence has been 
added “It is also planned to 
randomize an additional group of 
up to 24 study participants in 
Mainland China.”
This additional text and proposal to 
include additional study 
participants has been incorporated 
to meet local regulatory 
requirements.
9.2 General statistical 
considerations
A new paragraph describing data 
analysis in China.
Added to outline details of the 
stepwise statistical analysis for the 
Chinese cohort of participants.
LIC COPY
has been
PY 
has been
ned to
OP
ned to
tional gro
CO
tional gro
articipan
C C
articipan
ina.”
IC
ina.”
Y
PUBLIC
aragraph
BLI
aragraph
sis in Ch
UB
sis in Ch
LIC
P
upport any marketing authorization 
ho za
nally appr
ting
nally appr
mented at 
ketin
mented at 
trategy fo
rke
trategy fo
mendmen
mark
mendmen
Brief Rati
y m
Brief Rati
ma
up of 
ort
up of 
s in 
po
s in 
This a
any
This a
inc
an
inc
y
a
d to sup
describing 
sup
describing 
na.
to
na.
up
This document cannot be used 
d
ensions or variations thereof.
roved 
ereo
roved 
the study
her
the study
or parti
th
or particip
h
cip
nt 2.
ns
nt 2.
ionale
tion
ionale
on
additional 
riat
additional 
clude addit
vari
clude addit
participan
r va
participan
to meet
or v
to meet
requ
o
requ
ati
s o
g data
on
g data
s
application and any extensions s
en
s


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 200 of 202
11
REFERENCES
Arnold DM, Nazi I, Toltl LJ, Ross C, Ivetic N, Smith JW, et al. Antibody binding to 
megakaryocytes in vivo in patients with immune thrombocytopenia. Eur J Haematol. 
2015;95(6):532-7.
Anderson CL, Chaudhury C, Kim J, Bronson CL, Wani MA, Mohanty S. Perspective - FcRn 
transports albumin: relevance to immunology and medicine. Trends Immunol. 2006;27(7):343-8.
CPMP/ICH/135/95 Note for guidance on Good Clinical Practice (EMEA) Jul 2002.
EMA/CHMP/153191/2013 Guideline on the clinical development of medicinal products 
intended for the treatment of chronic primary immune thrombocytopenia, Mar 2014.
EMA/CHMP/BPWP/94033/2007 rev.3 Guideline on the clinical investigation of human normal 
immunoglobulin for intravenous administration (IVIg), Jun 2018.
Food and Drug Administration. Guidance for Industry. Drug-induced liver injury: premarketing 
clinical evaluation. US Dept of Health and Human Services, Center for Drug Evaluation and 
Research, Center for Biologics Evaluation and Research, 07/2009.
Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB. Thrombopoietin receptor agonists: 
ten years later. Haematologica. 2018;104(6):1112-23.
Ghanima W, Godeau B, Cines DB, Bussel JB. How I treat immune thrombocytopenia: the choice 
between splenectomy or a medical therapy as a second-line treatment. Blood. 2012;120(5):960-9.
Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of 
romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind 
randomised controlled trial. Lancet. 2008;371(9610):395-403.
Lehmacher W and Wassmer G. Adaptive Sample Size Calculations in Group Sequential Trials. 
Biometrics. 1999;55:1286-90.
McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte 
production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 
2004;103:1364–1369.
Mathias SD, Bussel JB, George JN, McMillan R, Okano GJ, Nichol JL. A disease-specific 
measure of health-related quality of life for use in adults with immune thrombocytopenic 
purpura: its development and validation. Health Qual Life Outcomes. 2007 Feb 22;5:11.
Mathias SD, Gao SK, Rutstein M, Snyder CF, Wu AW, Cella D. Evaluating clinically 
meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences. 
Curr Med Res Opin. 2009 Feb;25(2):375-83.
Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA. The American Society 
of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 
2011;117(16):4190-207.
Oxford Textbook of Palliative Medicine, Oxford University Press. 1993;109.
Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International 
consensus report on the investigation and management of primary immune thrombocytopenia. 
Blood. 2010;115(2):168-86.
PUBLIC COPY
ussel J
PY 
ussel J
23.
OPY
23.
B. How I
CO
B. How I
y as a sec
C C
y as a sec
arkat V, 
LIC
arkat V, 
c immun
UBL
c immun
cet. 200
PUB
cet. 200
Ada
P
Ada
used to support any marketing authorization 
-8.
iz
8.
ucts
ut
ucts
4.4.
of human
ng 
of human
ver injury
rke
ver injury
for Drug E
mark
for Drug E
9.9.
Thrombo
ny 
Thrombo
treat imm
ort 
treat imm
ond
p
ond-
po
-line t
po
line t
Gernsheim
supp
Gernsheim
e thrombo
o su
e thrombo
;371(9610
to 
;371(9610
ptive Samp
ed 
ptive Samp
This document cannot be 
A, Nicho
e u
A, Nicho
autoantibo
be
autoantibo
JB, Geor
nno
JB, Geor
-related q
an
related q
evelopmen
t ca
evelopmen
D, G
ent
D, Gao S
nt 
ao S
ngful chan
me
ngful chan
r Med Res
um
r Med Res
Neunert C
docu
Neunert C
of Hem
do
of Hem
201
s d
201
extensions or variations thereof.
n normal
reo
n normal
y: premar
s th
y: premar
Evaluatio
ns t
Evaluatio
opoietin r
iati
opoietin r
mune throm
r va
mune throm
treatment
or 
treatment
mer T
ns
mer TB, S
s 
B, S
ocytopen
ion
ocytopen
0):395
nsio
0):395-40
o
40
mple Size C
ten
mple Size C
application and any 
ol J, Pistil
y e
ol J, Pistil
odies from
any
odies from
rge JN, M
and
rge JN, M
quality of
n an
quality of
nt and va
on 
nt and va
SK, Rutste
atio
SK, Rutste
nge on the
lica
nge on the
es Opin. 2
plic
es Opin. 2
C, Lim W
app
, Lim W
ogy 
a
ogy


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 201 of 202
Rodeghiero F, Michel M, Gernsheimer T, Ruggeri M, Blanchette V, Bussel JB, et al.
Standardization of bleeding assessment in immune thrombocytopenia: report from the 
International Working Group. Blood. 2013;121(14):2596-606.
Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization 
of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults 
and children: report from an international working group. Blood. 2009;113(11):2386-93.
Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 
2007;7(9):715-25.
Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, et al. 
Second symposium on the definition and management of anaphylaxis: summary report – Second 
National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network 
symposium. J Allergy Clin Immunol. 2006;117(2):391-7.
Sandler SG. The spleen and splenectomy in immune (idiopathic) thrombocytopenic purpura. 
Semin Hematol. 2000;37(1):10-2.
World Health Organization. Global Tuberculosis Report. Sep 2018;ANNEX 4.
PUBLIC COPY 
Y
g authorization 
o
m A, et al.
auth
m A, et al.
report 
g au
report –
a
– S
u
S
This document cannot be used to support any marketing
laxis Netw
ng 
laxis Netw
bocytopen
rke
bocytopen
018;A
y m
018;ANNE
m
NNE
thereof.
econd 
of.
econd 
application and any extensions or variations t
twork 
reo
twork 
enic purpu
s th
enic purpu
EX 4.
tion
EX 4.


UCB
06 Dec 2021
Clinical Study Protocol Amendment 3
Rozanolixizumab
TP0006
Confidential
Page 202 of 202
SPONSOR DECLARATION
I confirm that I have carefully read and understand this protocol and agree to conduct this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


Approval Signatures
Name:
tp0006-protocol-amendment-3
Version:
1. 0
Document Number:
CLIN-000180818
Title:
tp0006-protocol-amendment-3
Approved Date:
06 Dec 2021
Document Approvals
Approval
Verdict: Approved
Name:
Capacity: Clinical
Date of Signature: 06-Dec-2021 09:14:09 GMT+0000
Approval
Verdict: Approved
Name: 
Capacity: Clinical
Date of Signature: 06-Dec-2021 09:14:14 GMT+0000
Approval
Verdict: Approved
Name: 
Capacity: Subject Matter Expert
Date of Signature: 06-Dec-2021 10:25:53 GMT+0000
COPY 
OP
ent Ap
COP
ent Ap
UBLIC CO
CO
PUB
UB
This document cannot be used to support any marketing authorization 
a
provals
ort a
provals
suppor
ort
u
Name:
po
Name:
Capac
upp
Capac
Da
p
Da
used to s
ot be us
us
ot
o
or variations thereof.
ar
s
or v
r v
application and any extensioions o
city: Clinica
s o
city: Clinica
te of Signa
ons
te of Signa
extensioio
en
Name:
nsi
Name:
Cap
ns
Cap
D
d any ex
ex
d
or 
o

SAP_001.pdf: 
UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 1 of 85
TP0006
STATISTICAL ANALYSIS PLAN
AMENDMENT 1
Study: TP0006
Product: Rozanolixizumab
A PHASE 3 MULTICENTER, DOUBLE-BLIND, RANDOMIZED,
PLACEBO-CONTROLLED STUDY TO EVALUATE THE
EFFICACY, SAFETY, AND TOLERABILITY OF
ROZANOLIXIZUMAB IN ADULT STUDY PARTICIPANTS WITH
PERSISTENT OR CHRONIC PRIMARY IMMUNE
THROMBOCYTOPENIA (ITP) 
SAP/Amendment Number
Date
Final SAP
23 Feb 2021
SAP Amendment 1
16 Aug 2022
Confidentiality Statement 
Confidential
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.
PUBLIC COPY 
TUD
Y
TUD
IC PRI
OPY
IC PRI
YTOPE
COP
YTOPE
te
UB
te
23 Feb 2
PUB
23 Feb 2
16
P
16 A
P
A
ment cannot be used to support any marketing authorization 
ANDOM
ket
ANDOM
LUATE 
ark
LUATE 
BILITY 
ma
BILITY 
PARTIC
y m
PARTIC
MARY I
any
MARY I
ENIA (IT
rt a
ENIA (IT
021
t
021
ug
e
ug 2022
ed t
2022
This docume
This
cu
This
me
do
ication and any extensions or variations thereof.
MIZED,
the
MIZED,
THE
ns t
THE
Y OF
ion
Y OF
CIPANT
atio
CIPANT
IMMUN
aria
IMMUN
TP) 
v
TP) 
applica
s docume
app
s docume
eprodu
ap
eprodu
ica
a


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 2 of 85
TABLE OF CONTENTS
1
INTRODUCTION ...........................................................................................................10
2
PROTOCOL SUMMARY...............................................................................................10
2.1
Study objectives...........................................................................................................10
2.1.1
Primary objective.................................................................................................10
2.1.2
Secondary objective.............................................................................................10
2.1.3
Exploratory objectives.........................................................................................10
2.2
Study endpoints............................................................................................................11
2.2.1
Efficacy endpoints ...............................................................................................11
2.2.1.1
Primary efficacy endpoint .........................................................................11
2.2.1.2
Secondary efficacy endpoints....................................................................11
2.2.1.3
Other efficacy endpoints ...........................................................................11
2.2.1.4
Exploratory endpoints ...............................................................................12
2.2.2
Safety endpoints...................................................................................................12
2.2.2.1
Other safety endpoints...............................................................................13
2.3
Study design and conduct ............................................................................................13
2.4
Determination of sample size.......................................................................................15
3
DATA ANALYSIS CONSIDERATIONS......................................................................16
3.1
General presentation of summaries and analyses ........................................................16
3.2
General study level definitions ....................................................................................17
3.2.1
Analysis time points ............................................................................................17
3.2.1.1
Relative day...............................................................................................18
3.2.2
Study periods .......................................................................................................18
3.2.3
Mapping of assessments performed at Early Withdrawal Visit ..........................19
3.2.4
Dosing Regimen ..................................................................................................19
3.3
Definition of Baseline values.......................................................................................19
3.4
Protocol deviations.......................................................................................................19
3.5
Analysis sets.................................................................................................................19
3.5.1
Enrolled Set (ES) .................................................................................................19
3.5.2
Randomized Set (RS) ..........................................................................................19
3.5.3
Safety Set (SS).....................................................................................................20
3.5.4
Full Analysis Set (FAS).......................................................................................20
3.5.5
Pharmacodynamic Per-Protocol Set (PD-PPS) ...................................................20
3.5.6
Pharmacokinetic Per-Protocol Set (PK-PPS) ......................................................20
3.6
Treatment assignment and treatment groups ...............................................................20
3.7
Center pooling strategy................................................................................................21
3.8
Coding dictionaries ......................................................................................................21
PUBLIC COPY 
....
Y
....
..........
PY
..........
.........
CO
.........
..........
C C
..........
TIONS
LIC 
TIONS
maries a
BLI
maries a
itions
PUB
itions .
nts
P
nts ...
P
...
to support any marketing authorization 
10
or
10
......
th
......10
ho
10
...........
au
...........1
............
g a
............
............
ting
............
............
ke
............
............
ark
............
...........
ma
...........
..........
y
..............
....
a
............
an
........
............
rt
............
.......
po
............
po
.....
...........
pp
...........
nd analyse
sup
nd analyse
nnot be used to
............
to
............
............
d
............
............
se
............
...........
u
...........
sessments
be 
sessments
gimen
ot b
gimen ......
Baseline 
no
Baseline 
This document can
deviations
ann
deviations
sis sets
t ca
sis sets.
Enrolle
ent 
Enrolle
2
Ran
e
Ran
.5.3
cu
.5.3
3.5.4
doc
3.5.4
3.5
do
3.5
sions or variations thereof.
1
f
1
...
e
...11
of
11
.........
ere
.........11
e
11
..........
the
............
e
..
.........
s
...............
..........
on
..............
............
ati
............
............
ria
............
............
va
............
............
or 
............
............
s
............
es
o
es .........
on
.........
on and any extensi
............
si
............
..........
en
..............
............
xt
............
..........
y e
............
e
..
s perform
any 
s perform
............
d a
............
values
nd
values.
plication
s...........
a
...........
............
on
............
ed Set (ES
atio
ed Set (ES
ndomized
lica
ndomized
app
Safety Se
ppl
Safety Se
Full A
app
Full A
Ph
a
Ph


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 3 of 85
3.9
Changes to protocol-defined analyses .........................................................................21
4
STATISTICAL/ANALYTICAL ISSUES.......................................................................23
4.1
Adjustments for covariates/factors ..............................................................................23
4.2
Handling of dropouts or missing data..........................................................................23
4.2.1
Handling missing data for the primary and secondary efficacy endpoints..........23
4.2.2
Missing Data due to COVID-19..........................................................................23
4.2.3
Dates and times....................................................................................................23
4.3
Handling of repeated and unscheduled measurements ................................................26
4.4
Handling and definition of the Corticosteroid (CS) prednisone equivalent dose ........26
4.5
Interim analysis and data monitoring...........................................................................27
4.5.1
Data Monitoring...................................................................................................27
4.6
Multicenter studies.......................................................................................................28
4.7
Multiple comparisons/multiplicity...............................................................................28
4.8
Use of an efficacy subset of participants .....................................................................28
4.9
Active-control studies intended to show equivalence..................................................28
4.10
Examination of subgroups ...........................................................................................28
5
STUDY POPULATION CHARACTERISTICS.............................................................28
5.1
Subject disposition.......................................................................................................28
5.2
Protocol deviations.......................................................................................................29
6
DEMOGRAPHICS AND OTHER BASELINE CHARACTERISTICS ........................30
6.1
Demographics ..............................................................................................................30
6.2
Other Baseline characteristics......................................................................................31
6.2.1
Baseline disease characteristics ...........................................................................31
6.2.2
Lifestyle ...............................................................................................................32
6.3
Previous and ongoing medical history.........................................................................32
6.4
Procedure history and concomitant medical procedures .............................................32
6.5
Concomitant medications.............................................................................................32
6.5.1
Assignment of medications to treatment period ..................................................34
6.6
Prohibited concomitant medications and rescue medication.......................................34
6.6.1
Prohibited concomitant medication .....................................................................34
6.6.2
Rescue Therapy ...................................................................................................35
7
MEASUREMENTS OF TREATMENT COMPLIANCE...............................................35
8
EFFICACY ANALYSES ................................................................................................35
8.1
Statistical analysis of the primary efficacy endpoint ...................................................35
8.1.1
Primary analysis of the primary efficacy endpoint..............................................35
8.2
Statistical analysis of the secondary efficacy endpoints..............................................36
8.2.1
Cumulative number of weeks with Clinically Meaningful Platelet Response of 
≥50x109/L over the 24-Week treatment period (Week 1 to Week 25)................36
BLIC COPY
.
Y
.
uivalenc
PY 
uivalenc
..........
OP
..........
RISTICS
CO
RISTICS
PUBL
.........
C
..........
.........
BLI
.........
TH
U
THER B
UBL
ER B
.........
PU
.........
sti
P
sti
pport any marketing authorization 
23
r
23
....
h
....23
hor
23
..........
ut
..........26
h
26
dose
g a
dose .....
a
.....
..........
ng
............
g
..
...........
et
...........
............
rk
............
............
ma
............
......
y m
............
y m
......
............
ny
............
...........
t a
...........
............
or
............
nnot be used to supp
............
pp
............
............
sup
............
ASELINE
o s
ASELINE
....
d t
...........
d t
.......
s..........
ed
..........
aracteristi
use
aracteristi
............
be 
............
oing medi
t be
oing medi
ory and c
not
ory and c
This document can
nt medica
ann
nt medica
ssignment
t ca
ssignment
hibited co
nt c
hibited co
Proh
en
Proh
6.2
u
6.2
R
MEA
ocu
MEA
8
d
8
E
o
E
8.1
s 
8.1
or variations thereof.
.26
of
26
.......
re
.......27
eo
27
.........
he
...........
e
.. 2
...........
s t
............
.........
ns
............
s
...
............
tio
............
............
ria
............
...........
va
...........
............
r v
............
n and any extensions o
............
s o
............
............
ns
............
E CHARA
sion
E CHARA
...........
ns
...........
............
xte
............
ics
e
ics .......
ex
.......
......
ny
............
y
......
dical histo
d any
dical histo
concomita
nd 
concomita
application
ations
an
ations......
nt of medi
on a
nt of medi
oncomitan
tio
oncomitan
hibited co
icat
hibited co
Rescue Th
plic
Rescue Th
ASUR
app
ASUREM
pp
EM
CACY
a
CACY


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 4 of 85
8.2.2
Time to first Clinically Meaningful Platelet Response of ≥50x109/L: time from 
starting treatment to achievement of first response of ≥50x109/L.......................37
8.2.2.1
Definition...................................................................................................37
8.2.2.2
Estimand’s attributes .................................................................................37
8.2.3
Clinically Meaningful Platelet Response by Day 8, defined as platelet count 
≥50x109/L ............................................................................................................38
8.2.4
Response defined as platelet count ≥30x109/L and at least a 2-fold increase of 
the Baseline count confirmed on at least 2 separate occasions at two adjacent 
nominal visits at least 7 days apart, and absence of bleeding..............................38
8.2.4.1
Estimand’s attributes .................................................................................39
8.2.4.2
Sensitivity analysis....................................................................................39
8.2.5
Time to first rescue therapy .................................................................................39
8.2.5.1
Estimand’s attributes .................................................................................39
8.2.6
Change from Baseline to Week 25 in ITP-PAQ Symptom score........................39
8.3
Statistical analysis of other efficacy endpoints............................................................40
8.3.1
Cumulative number of weeks over the planned 24-Week treatment period with 
platelet counts ≥30×109/L and at least doubling from Baseline..........................40
8.3.2
Mean change from Baseline in platelet count by visit.........................................40
8.4
Statistical analysis of exploratory endpoints................................................................40
8.4.1
ITP Bleeding Score..............................................................................................40
8.4.1.1
ITP-specific Bleeding Assessment Tool (ITP-BAT) bleeding events and 
severity by visit .........................................................................................40
8.4.1.2
ITP bleeding at Screening .........................................................................41
8.4.1.3
Presence/Absence of ITP bleeding............................................................41
8.4.2
Effect of Rozanolixizumab on Health-Related Quality of Life (HRQoL) ..........41
8.4.2.1
European Quality of Life-5 Dimensions, 5 Levels (EQ-5D-5L) item 
responses ...................................................................................................41
8.4.2.2
Short form 36-item (SF-36) domain and composite scores.......................42
8.4.2.3
ITP-PAQ Domain Scores ..........................................................................42
8.4.3
Hospitalization due to ITP / Number and length of hospitalizations...................43
8.4.4
Effect of Rozanolixizumab on Patient Reported Outcomes (PRO).....................43
8.4.4.1
FATIGUE-PRO physical fatigue score.....................................................43
8.4.4.2
Patient Global Impression of Severity (PGI-S).........................................43
8.4.4.3
Patient Global Impression of Change (PGI-C)..........................................43
9
PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) ........................43
9.1
Pharmacokinetics .........................................................................................................43
9.2
Antidrug antibodies (ADA) .........................................................................................44
9.3
Pharmacodynamic endpoints (PD) ..............................................................................48
PUBLIC COPY 
....
Y
....
e planned
OPY
e planned
ast doub
COP
ast doub
platelet 
CO
platelet 
y endpoin
IC C
y endpoin
..........
BL
..........
leeding 
UB
leeding 
visit
PU
visit ..
PU
..
at
P
at
This document cannot be used to support any marketing authorization 
8
f 
h
f 
ent 
th
ent 
...........
au
...........3
............
g a
............
..
ti
...........
ting
.........
...........
ket
............
............
ark
............
tom score
ma
tom score
............
y
............
24
a
24-
an
-Week
any
Week
ling from
rt a
ling from
ount by v
port
ount by v
ts
p
ts..........
pp
..........
..........
su
..............
Assessmen
to s
Assessmen
............
d t
............
Screening
sed
Screening
ence of IT
use
ence of IT
lixizuma
be u
lixizuma
ean Quali
t be
ean Quali
ponses
not
ponses ..
t
..
Short form
nno
Short form
ITP
can
ITP-P
n
P
Hospitali
nt c
Hospitali
Effec
en
Effec
8.4.4.1
ume
8.4.4.1
8.4.4
cu
8.4.4
8
c
8
9
s d
9
9
s
9
application and any extensions or variations thereof.
8
f
8
......39
of
39
........
ere
........39
eo
39
............
the
............
...
s
............
s
.........
e
o
e...........
on
...........
...
at
............
ati
.........
k treatmen
aria
k treatmen
Baseline
var
Baseline
visit
or
visit......
r
......
............
s o
............
............
on
............
ent Tool (I
sio
ent Tool (I
...........
ns
............
s
.
g ...........
xte
...........
TP bleedi
ex
TP bleedi
ab on Hea
ny e
ab on Hea
ity of Life
any
ity of Life
............
d
............
m 36
and
m 36-
n
-item
nd
item
PAQ Dom
n a
PAQ Dom
lization du
tion
lization du
ct of Roza
cat
ct of Roza
FAT
plic
FAT
4.2
p
4.2
P
p
P
4.3
ap
4.3


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 5 of 85
9.3.1
Total serum IgG (absolute value) and change from Baseline (absolute value and 
percentage) in serum IgG and in serum IgG subclass concentration at each 
scheduled assessment...........................................................................................48
9.3.2
Serum immunoglobulin concentrations (IgA, IgE, IgM) at each scheduled 
assessment............................................................................................................48
9.4
Influence of Rozanolixizumab on vaccination titers ...................................................49
9.4.1
Vaccination titers against Streptococcus pneumoniae, Neisseria meningitidis, 
and Haemophilus influenzae in splenectomized study participants ....................49
9.4.2
Percent change from Baseline in vaccination titers against tetanus in all study 
participants...........................................................................................................49
10
SAFETY ANALYSES.....................................................................................................49
10.1
Extent of exposure .......................................................................................................49
10.2
Adverse events.............................................................................................................50
10.2.1
Data considerations..............................................................................................50
10.2.2
Adverse Event Summaries...................................................................................52
10.3
Vital Signs, Physical Findings, and Other Observations Related to Safety.................53
10.3.1
Vital Signs and Physical Findings .......................................................................53
10.4
12-lead Electrocardiograms (ECG)..............................................................................54
10.5
Clinical Safety Laboratory Assessments .....................................................................54
10.5.1
Potential Drug-Induced Liver Injury ...................................................................55
10.6
Concentrations of Total Protein and Albumin.............................................................55
10.7
Serum and Plasma Complement Levels ......................................................................56
10.8
Other Safety Variables.................................................................................................56
10.8.1
Physical examination...........................................................................................56
10.8.2
Pregnancy testing.................................................................................................56
10.8.3
Childbearing potential .........................................................................................56
10.8.4
Assessment and management of Tuberculosis ....................................................56
11
OTHER ANALYSES ......................................................................................................56
11.1
Headache questionnaire ...............................................................................................56
12
REFERENCES ................................................................................................................56
13
APPENDICES .................................................................................................................58
13.1
AE of focus (AEOF) for the Rozimab Program ..........................................................58
13.2
Laboratory assessments – Marked abnormality criteria ..............................................63
13.2.1
Hematology..........................................................................................................63
13.2.2
Chemistry.............................................................................................................64
13.3
Vital sign assessments - abnormal ...............................................................................66
13.4
Electrocardiogram (ECG) – Abnormal........................................................................66
13.5
ITP-PAQ Scoring.........................................................................................................67
13.5.1
ITP-PAQ Scales...................................................................................................67
PUBLIC COPY
..
Y
..
Observat
PY 
Observat
.........
OP
.........
..........
C
..........
sments
IC C
sments
Liver Inj
BLIC
Liver Inj
otein an
UB
otein an
mplemen
PU
mplemen
This document cannot be used to support any marketing authorization 
......
th
......49
ho
49
 study 
aut
 study 
.....
g
............
g a
.......
...........
ing
...........
............
ket
............
............
rk
............
........
ma
............
a
....
............
y m
............
ons Relate
any
ons Relate
............
t a
............
............
o
............
............
pp
............
ury
s
ury .......
su
.......
d Albumin
to s
d Albumin
t Levels
d to
t Levels
............
se
............
on
on.........
us
.........
ng
b
ng.........
be
.........
g potentia
ot b
g potentia
ent and m
not
ent and m
ALYSES
ann
ALYSES
che questi
t ca
che questi
RENCES
nt 
RENCES
PPENDIC
men
PPENDIC
AE of
um
AE of
3.2
oc
3.2
La
u
La
13.2
do
13.2
pplication and any extensions or variations thereof.
....49
of
49
.........
re
.....49
eo
49
......
he
............
he
...... 4
......
s t
............
s t
......
............
on
............
...........
tio
............
o
.
ed to Safe
riat
ed to Safe
..
v
............
va
..........
............
r
...........
............
s o
............
............
on
............
n
s
n.........
sio
.........
............
en
............
..........
xte
............
e
..
............
e
............
............
ny
............
al
d
al .........
a
.........
manageme
nd 
manageme
...........
a
...........
ionnaire
on 
ionnaire
S
a
S ..........
ati
..........
CES
ic
CES .....
ca
.....
f foc
pli
f focus (A
plic
us (A
ap
aboratory
app
boratory
He
a
He


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 6 of 85
13.6
ITP bleeding score .......................................................................................................69
13.7
Classification of the SF-36v2 questionnaire................................................................80
14
AMENDMENT(S) TO THE STATISTICAL ANALYSIS PLAN (SAP)......................81
14.1
AMENDMENT 1.........................................................................................................81
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 7 of 85
LIST OF TABLES
Table 2-1: 
Expected sample size.......................................................................................16
Table 4-1:
Calculation rules for duration of AEs ..............................................................24
Table 4-2:
Prednisone equivalent doses of systemic corticosteroids/steroids...................27
Table 6-1:
Concomitant Medications Classification.........................................................34
Table 8-1:
Intercurrent Events (ICE), Intercurrent Events Strategies (ICES) and 
Missing data Strategies for the analysis of the primary endpoint....................36
Table 8-2:
Intercurrent Events (ICE), Intercurrent Events Strategies (ICES) and 
Missing data Strategies for the analysis of the Cumulative number of 
weeks with Clinically Meaningful Platelet Response of ≥50x109/L over 
the 24-Week treatment period..........................................................................36
Table 8-3:
Intercurrent Events (ICE), Intercurrent Events Strategies (ICES) and 
Missing data Strategies for the analysis of Time to first Clinically 
Meaningful Response of ≥50x109/L................................................................37
Table 8-4:
Intercurrent Events (ICE), Intercurrent Events Strategies (ICES) and 
Missing data Strategies for the analysis of Clinically Meaningful 
Response by Day 8...........................................................................................38
Table 8-5:
Intercurrent Events (ICE), Intercurrent Events Strategies (ICES) and 
Missing data Strategies for the analysis of Time to first rescue therapy .........39
Table 8-6:
Intercurrent Events (ICE), Intercurrent Events Strategies (ICES) and 
Missing data Strategies for the analysis of cumulative number of weeks 
over the planned 24-Week treatment period with platelet counts 
≥30×109/L and at least doubling from Baseline..............................................40
Table 8-7:
ITP-specific Bleeding Assessment Tool (ITP-BAT) Domains and 
categories .........................................................................................................41
Table 9-1:
Terms and Definitions for ADA Status Evaluation in Study Participants.......45
Table 10-1:
TP0006 dose levels and weight tiers of rozanolixizumab ...............................50
Table 10-2:
Laboratory criteria for PDILI...........................................................................55
Table 13-1:
ITP-BAT scoring .............................................................................................70
PUBLIC COPY 
......
Y
......
rrent Ev
OPY
rrent Ev
analysis
COP
analysis
..........
C C
..........
E), Interc
LIC
E), Interc
es for th
BLI
es for th
nts (ICE)
PUB
nts (ICE)
rategie
PU
rategie
t be used to support any marketing authorization 
4
r
4
.........
ut
.........36
h
36
nd 
g
nd 
ber of 
ing
ber of 
x10
eti
x109
ti
9/L ov
ting
/L ov
............
ke
............
gies (ICES
mar
gies (ICES
o first Clin
ma
o first Clin
............
y 
............
nts Strate
t any
nts Strate
of Clinica
ort a
of Clinica
...
p
............
po
.........
urrent Eve
upp
urrent Eve
e analysis 
sup
e analysis 
, Intercurr
to 
, Intercurr
s for the a
ed t
s for the a
Week tre
sed
Week tre
t least dou
us
t least dou
Bleeding 
be 
Bleeding 
This document cannot b
............
t b
............
s and Defi
nno
s and Defi
P0006 do
can
P0006 do
Labora
nt c
Labora
-1:
e
1:
ITP
n
ITP
any extensions or variations thereof.
ver 
he
ver 
......
th
............
th
......
ES) and 
ns
ES) and 
nically 
tion
nically 
............
at
............
egies (ICE
aria
egies (ICE
ally Mean
va
ally Mean
............
or 
............
vents Strat
ns o
vents Strat
s of Time
ons
s of Time
rent Even
nsio
rent Even
analysis o
tens
analysis o
eatment p
xte
eatment p
oubling fro
ex
oubling fro
g Assessm
ny 
g Assessm
application and a
............
a
............
finitions f
nd 
finitions f
ose levels 
n a
ose levels 
atory crite
tion
atory crite
P
c
P-
c
-BAT sc
icat
BAT sc


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 8 of 85
List of Abbreviations
ADAs
Antidrug antibodies
AEOF
Adverse event of focus
BLQ
Below the limit of quantification
BP
Blood pressure
CP
Confirmed positive
CSR              
Clinical Study Report
CV                  
Coefficient of variation
DEM
Data Evaluation Meeting
DNA
Deoxyribonucleic acid 
ECG             
Electrocardiogram
eCRF
Electronic Case Report Form
EOS
End of Study 
EQ-5D-5L
European Quality of Life-5 Dimension 5 Level Assessment
ES                  
Enrolled Set
EudraCT       
European Union Drug Regulating Authorities Clinical Trials
EW
Early withdrawal 
FAS              
Full Analysis Set
FDA
Food and Drug Administration
geoCV         
Geometric coefficient of variation
geoMean       
Geometric mean
hCG           
Human chorionic gonadotropin
HLT            
High level term
HRQoL
Health-related quality of life
ICH             
International Council for Harmonisation 
IDMC             
Independent Data Monitoring Committee
IgA
Immunoglobulin A
IgG
Immunoglobulin G
IgM
Immunoglobulin M
IMP            
Investigational medicinal product
IPD
Important protocol deviations 
ITP             
Primary immune thrombocytopenia
ITP-BAT      
ITP- Bleeding Assessment Tool
ITP-PAQ
ITP-Patient Assessment Questionnaire
LLOQ         
Lower limit of quantification
MCS
Mental Component Summary
MedDRA        
Medical Dictionary for Regulatory Activities
PUBLIC COPY 
Dimensi
COP
Dimensi
g Regula
IC 
g Regula
Set
U
Set
rug Adm
PU
rug Adm
effi
P
effi
not be used to support any marketing authorization 
on 5 Leve
rt a
on 5 Leve
ting Autho
pp
ting Autho
inistration
d to
inistration
ient of va
ed 
ient of va
an
u
an
orionic go
be u
orionic go
vel term
t be
vel term
th
o
th-
ot
-related
ot b
related
This document cann
nternation
nno
nternation
Indepen
can
Indepen
Imm
ca
Imm
I
P
um
P
IPD
oc
IPD
ITP
do
ITP
IT
d
IT
nd any extensions or variations thereof.
el Assessm
var
el Assessm
horities Cl
s o
horities Cl
on
e
on
ariation
ten
ariation
onadotrop
ny e
onadotrop
d quality 
d a
d quality 
application an
nal Counc
and
nal Counc
ndent Dat
n a
ndent Dat
munoglob
ion 
munoglob
Immunog
atio
Immunog
Immun
lica
Immun
Inv
pli
Inv
a


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 9 of 85
n                   
Number of participants
NCP             
Not confirmed positive
OLE
Open Label Extension
PCS
Physical Component Summary
PD              
Pharmacodynamic
PDILI
Potential drug-induced liver injury
PGI-C
Patient Global Impression of Change
PGI-S
Patient Global Impression of Severity
PK              
Pharmacokinetic
PK-PPS        
Pharmacokinetic Per Protocol Set
PROs
Patient reported outcomes
PT               
Preferred term
RNA
Ribonucleic acid 
RLZ
Rozanolixizumab
SAP            
Statistical Analysis Plan
SC               
Subcutaneous
SD              
Standard deviation
SF-36 
Short-Form 36-Item Health Survey
SFU
Safety Follow-up 
SOC          
System organ class
SS              
Safety Set
TEAE          
Treatment-emergent adverse event
TEMA         
Treatment-emergent markedly abnormal
TFLs         
Tables, figures and listings
TPO
Thrombopoietin
TPO-RAs
Thrombopoietin-receptor agonists 
ULN           
Upper limit of normal
PUBLIC COPY 
h Survey
CO
h Survey
mergent a
PUB
mergent a
merge
PU
merge
be used to support any marketing authorization 
dverse ev
to 
dverse ev
nt marked
ed t
nt marked
and listing
sed
and listing
etin
u
etin
poietin
be 
poietin-rere
This document cannot 
r limit of n
ot b
r limit of n
d any extensions or variations thereof.
vent
ns
vent
dly abnorm
tens
dly abnorm
ngs
ex
ngs
eceptor ag
ny 
eceptor ag
application and a
normal
d an
normal


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 10 of 85
1
INTRODUCTION
The purpose of this statistical analysis plan (SAP) is to provide all information that is necessary 
to perform the statistical analyses of the study TP0006, including the final analyses. It also 
defines the summary tables, figures and listings (TFLs) to be included in the final Clinical Study 
Report (CSR) according to the protocol. 
This SAP is based upon, and assumes familiarity with, the following documents:
Protocol Amendment 3: 06 Dec 2021 and all previous protocol versions
DMC Charter 2: 14 Jun 2021
At the time this SAP, that is based on Protocol Amendment 3, was written, the sponsor had 
decided to terminate this study. No study participant was randomized under Protocol 
Amendment 3 and hence all analyses that are described in this SAP will be run on data from 
study participants that were randomized according to previous versions of the protocol. These 
study participants did all receive a starting dose of 
equivalent rozanolixizumab and 
continued dosing on a bi-weekly basis. None of the study participants were switched to weekly 
dosing prior to termination of the study.
If a future protocol amendment necessitates a substantial change to the statistical analysis of the 
study data, this SAP may be amended accordingly. The content of this SAP is compatible with 
the International Council for Harmonisation (ICH)/Food and Drug Administration (FDA) E9 
Guidance documents.
UCB is the Sponsor and Parexel is the Contract Research Organization (CRO) for this study.
Note: The terms Investigational Medical Product (IMP) and study medication are used 
interchangeably in this document.
2
PROTOCOL SUMMARY
2.1
Study objectives
2.1.1
Primary objective
To demonstrate the clinical efficacy of rozanolixizumab in maintenance treatment in study 
participants with primary ITP.
2.1.2
Secondary objective
To assess the safety and tolerability of rozanolixizumab    
2.1.3
Exploratory objectives
•
To evaluate the clinical efficacy as measured by the ITP bleeding score
•
To assess the effect of rozanolixizumab on health-related quality of life (HRQoL) 
•
To assess hospitalizations due to ITP
•
To assess the effect of rozanolixizumab on patient reported outcomes (PROs)
•
To assess the pharmacokinetics of rozanolixizumab administered by subcutaneous (sc) 
infusion
PUBLIC COPY 
stantial c
OPY
stantial c
gly. The
COP
gly. The
(ICH)/F
CO
(ICH)/F
he Contra
BLIC
he Contra
Medical 
PUB
Medical 
nt.
P
nt.
ot be used to support any marketing authorization 
ponsor ha
g a
ponsor ha
rotocol
ing
rotocol
e run on d
etin
e run on d
of the pro
rket
of the pro
nt rozano
ark
nt rozano
ants
m
ants were
ma
were
hange to t
any
hange to t
content o
rt a
content o
ood and D
port
ood and D
ct Researc
sup
ct Researc
Product (I
to s
Product (I
UMMA
sed
UMMA
ives
be
ives
bjective
t be
bjective
This document canno
inical effi
not
inical effi
rimary IT
ann
rimary IT
Seconda
t ca
Seconda
the safety
ent 
the safety
E
To eval
ocu
To eval
•
d
•
To 
o
To 
•
s
•
d any extensions or variations thereof.
ad 
e
ad 
data f
her
data from
er
rom
frf
er
frf
otocol. Th
the
otocol. Th
olixizuma
ns t
olixizuma
switched
ions
switched
the statist
aria
the statist
of this SA
var
of this SA
Drug Adm
or v
Drug Adm
rch Organ
ons
rch Organ
IMP) and
sio
MP) and
ARY
ext
ARY
application and
ficacy of r
nd 
ficacy of r
TP.
a
TP.
ary
o
ary objec
on 
objec
y and tole
atio
y and tole
Explorat
plica
Explorat
luate the c
app
luate the c
ess th
ap
ess th


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 11 of 85
•
To evaluate the incidence and emergence of antidrug antibodies (ADAs) of rozanolixizumab   
•
To assess the pharmacodynamic (PD) effects of rozanolixizumab   
•
To assess the influence of rozanolixizumab treatment on vaccination titers
•
To assess the effect of rozanolixizumab on response to vaccination in study participants who 
received COVID-19 vaccine
2.2
Study endpoints
2.2.1
Efficacy endpoints
2.2.1.1
Primary efficacy endpoint
Durable Clinically Meaningful Platelet Response of ≥50x109/L for at least 8 out of 12 weeks 
during the last 12 weeks (Week 13 to 25)
2.2.1.2
Secondary efficacy endpoints
•
Cumulative number of weeks with Clinically Meaningful Platelet Response of ≥50x109/L 
over the 24-week treatment period 
•
Time to first Clinically Meaningful Platelet Response of ≥50x109/L: time from starting 
treatment to achievement of first response of ≥50x109/L
•
Clinically Meaningful Platelet Response of ≥50x109/L by Day 8
•
Response defined as platelet count ≥30x109/L and at least a 2-fold increase of the Baseline 
count confirmed on at least 2 separate occasions at two adjacent nominal visits at least 7 days 
apart, and absence of bleeding by visita,b
•
Time to first rescue therapy
•
Change from Baseline to Week 25 in ITP Patient Assessment Questionnaire (ITP-PAQ) 
Symptoms Score
Notes:
a Absence of bleeding indicated by Grade 0 for all domains of the skin, mucosae, and organs 
(SMOG), or a Skin Grade of 0 or 1.
b Nominal visits are on-site visits where ITP bleeding scale assessment is performed.
2.2.1.3
Other efficacy endpoints
•
Duration of first Clinically Meaningful Platelet Response of ≥50x109/L: measured from 
achievement of first Response to loss of Response (loss of Response defined as platelet count 
<50x109/L)
•
Time to first Response: time from starting treatment to achievement of Response
•
Usage of rescue therapy (Yes/No) by visit
•
Complete Response (platelet count): defined as platelet count ≥100x109/L confirmed on at 
least 2 separate occasions at two adjacent nominal visits at least 7 days apart, and absence of 
bleeding by visit 
PUBLIC COPY 
Response
OPY
Response
of ≥50x
COP
of ≥50x
nse of ≥5
C C
nse of ≥5
t ≥30x1
BLIC
t ≥30x1
eparate o
UBL
eparate o
ng by vi
PUB
ng by vi
ment cannot be used to support any marketing authorization 
out of 12
ting
out of 12
telet Resp
ma
telet Resp
of ≥50x1
t any
of ≥50x1
10
o
109
r
9/L
rt
/L
0x10
ppo
0x109
po
9/L b
po
/L b
/L and at
sup
/L and at
ccasions a
o su
ccasions a
it
d
ita,b
to
a,b
eek 25 in 
us
eek 25 in 
g indicate
nno
g indicate
n Grade o
ann
n Grade o
its are on
t ca
its are on
This docum
Oth
nt
Oth
Duration o
ume
Duration o
achievem
cum
achievem
<50x
oc
<50x
•
s d
•
T
tion and any extensions or variations thereof.
 weeks
ere
 weeks
ponse of ≥
tion
ponse of ≥
0
a
09
a
9/L: tim
aria
/L: tim
by Day 8
or 
by Day 8
t least a 2
ns 
t least a 2
at two ad
sion
at two ad
ITP Patie
ex
ITP Patie
ed by Gra
nd 
ed by Gra
of 0 or 1.
an
of 0 or 1.
-site visit
ion 
site visit
applica
her effica
cati
her effica
of first Cli
plic
of first Cli
ement of f
pp
ement of f
0
a
09
a
9/L)
ap
/L)


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 12 of 85
•
Cumulative number of weeks over the planned 24-Week treatment period with platelet 
counts of ≥100x109/L
•
Cumulative number of weeks over the planned 24-Week treatment period with platelet 
counts ≥30×109/L and at least doubling from Baseline
•
Mean change from Baseline in platelet count by visit
•
Clinically Meaningful Platelet Response of ≥50x109/L, for at least 4 out of 6 weeks during 
the last 6 weeks (Week 19 to 25)
•
Clinically Meaningful Platelet Response of ≥50x109/L, for at least 6 out of 8 weeks during 
the last 8 weeks (Week 17 to 25)
2.2.1.4
Exploratory endpoints
•
ITP-specific Bleeding Assessment Tool (ITP-BAT) bleeding events and severity by visit
•
Change from Baseline in European Quality of Life-5 Dimension 5 Levels (EQ-5D-5L) item 
responses 
•
Change from Baseline in Short form 36-item (SF-36) domain and composite scores
•
Change from Baseline in the ITP-PAQ V1 domain Scores 
•
Number and length of hospitalizations
•
Change from Baseline in FATIGUE-PRO Physical Fatigue Score by visit 
•
Change from Baseline in Patient Global Impression of Severity (PGI-S) 
•
Patient Global Impression of Change (PGI-C) at all available post-baseline assessments 
•
Plasma concentration of rozanolixizumab 
•
ADAs at each scheduled assessment
2.2.1.4.1
Exploratory pharmacodynamic endpoint:
•
Total serum IgG (absolute value) and change from Baseline (absolute values and percentage) 
in serum IgG and in serum IgG subclass concentration at each scheduled assessment 
•
Absolute values and change from Baseline (absolute values and percentage) in serum 
immunoglobulin concentrations (IgA, IgE, IgM) at each scheduled assessment
2.2.1.4.2
Other exploratory endpoints
•
Percent change from Baseline in vaccination titers against Streptococcus pneumoniae, 
Neisseria meningitidis, and Haemophilus influenzae in splenectomized study participants
•
Percent change from Baseline in vaccination titers against tetanus in all study participants
•
Change in biomarkers of COVID-19 vaccine response over time
2.2.2
Safety endpoints
Secondary Safety Endpoints:
BLIC COPY
F
P
F-
PY
-36) d
PY 
36) d
domain 
COP
domain 
E
L
E-
L
-
PUB
PRO 
LIC
PRO 
nt Globa
UBL
nt Globa
of Chan
PU
of Chan
pport any marketing authorization 
ring 
hori
ring 
eeks durin
aut
eeks durin
and sever
rket
and sever
n 5 Levels
mar
n 5 Levels
main and 
any
main and 
Scores
rt a
Scores
not be used to sup
Physical F
upp
Physical F
l Impress
o s
l Impress
ge (PGI
d to
ge (PGI-C
o
C
olixizuma
sed
olixizuma
ssessmen
e u
ssessmen
ry pharm
t be
ry pharm
absolute v
not
absolute v
ument can
nd in seru
ann
nd in seru
values and
t ca
values and
oglobulin 
nt c
oglobulin 
2
m
2
O
n
O
This docu
Percent c
cum
Percent c
Neisse
ocu
Neisse
•
s d
•
P
•
s or variations thereof.
ng 
f
ng 
erity by vi
the
erity by vi
s (EQ
ns
s (EQ-
s
-5D
s 
5D
d composi
riat
d composi
nd any extensions
Fatigue Sc
ns o
Fatigue Sc
sion of Se
sion
sion of Se
C) at all a
ens
C) at all a
ab
x
ab
t
macodyna
any
macodyna
value) an
nd 
value) an
plication a
um IgG su
and
um IgG su
d change f
on 
d change f
 concentr
atio
 concentr
Other exp
lica
Other exp
app
change fr
ppl
change fr
eria
ap
ria meni
app
meni
h


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 13 of 85
•
Occurrence of treatment-emergent adverse events (TEAEs)
•
Occurrence of TEAEs leading to withdrawal of investigational medicinal product (IMP) (ie, 
study discontinuation)
2.2.2.1
Other safety endpoints
•
Occurrence of serious TEAEs
•
Occurrence of treatment related TEAEs
•
Occurrence of adverse events of special monitoring (AESM)
2.3
Study design and conduct
This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study with 
rozanolixizumab in study participants with persistent or chronic primary ITP defined as more 
than 3 months, or 12 months of duration, respectively, since diagnosis.
The study participants will be male and female adults with persistent or chronic primary ITP, a 
platelet count measurement at Screening and at Baseline with an average of the two <30x109/L 
(no single count may be >35x109/L) and a documented history of low platelet count prior to 
Screening.
The primary objective of TP0006 is to evaluate the clinical efficacy of rozanolixizumab as a 
maintenance treatment in participants with persistent or chronic primary ITP.
The study will assess whether multiple sc infusions of rozanolixizumab will result in a durable 
Clinically Meaningful Platelet count increase of ≥50x109/L, for at least 8 out of 12 weeks during 
the last 12 weeks of the Treatment Period (Week 13 to 25). On Day 1 (Baseline Visit), study 
participants will be randomized 2:1 to receive a fixed-unit dose of rozanolixizumab equivalent to 
 or placebo QW until Week 24, with randomization stratified by the degree of 
thrombocytopenia (platelet count < or ≥15x109/L) and history of splenectomy (yes or no). The 
last assessments prior to the SFU Visit will be done at Week 25. Study participants will be 
observed during the 8-week SFU Period after the final administered dose. 
Note: As all study participants for the analysis were enrolled under previous protocol versions, 
they were randomized to receive a fixed-unit starting dose of rozanolixizumab equivalent to 
or placebo. Following the initial dose, study participants were receiving a fixed unit 
dose equivalent to
 rozanolixizumab or placebo Q2W until Week 23. 
The total maximum study duration per study participant is up to 35 weeks, including a Screening 
Period (up to 4 weeks), a Dose Adaptation Period (12 weeks), a Maintenance Period (12 weeks) 
and an SFU Period (8 weeks after final dose administered). Splenectomized participants will be 
required to attend a Prolonged Screening Period prior to the Screening Visit in order to receive, 
if applicable, the required vaccinations, which will extend the total study duration by up to 20 
weeks.
The eligibility of study participants to participate in the study will be determined during the 
Screening Period. Once eligibility is confirmed, the study participants will come to the site on 
Day 1 (Baseline Visit) and receive a single fixed-unit dose of rozanolixizumab or placebo 
administered sc (based on randomization).
PUBLIC COPY
ne 
Y
ne 
nted his
PY 
nted his
ate the c
CO
ate the c
h persist
C C
h persist
le sc infu
BLIC
le sc infu
nt increa
UBL
nt increa
ent Perio
PUB
ent Perio
d 2:1 t
PU
d 2:1 t
used to support any marketing authorization 
d study wi
ting
d study wi
ITP define
keti
ITP define
ent or chro
ma
ent or chro
n average
y m
n average
ry of low 
any 
ry of low 
inical effi
ort
inical effi
ent or chro
ppo
ent or chro
sions of r
sup
sions of r
se of ≥50x
o su
se of ≥50x
d (Week 
d to 
d (Week 
o re
ed
o receive a
ed t
ceive a
ek 24, wit
sed
ek 24, wit
nt cannot be u
nt < or ≥1
us
nt < or ≥1
SFU Visit
be u
SFU Visit
ek SFU P
t be
ek SFU P
rticipants 
not
rticipants 
zed to rec
nn
zed to rec
cebo. Foll
can
cebo. Foll
ent to
t ca
ent to
This documen
maximum
men
maximum
d (up to 4 
me
d (up to 4 
d an SFU 
cum
d an SFU 
required t
docu
required t
if appl
do
if appl
wee
s d
wee
c
y extensions or variations thereof.
ith 
e
ith 
ned as mor
the
ned as mor
ronic prim
ons
ronic prim
e of the tw
atio
e of the tw
w platelet c
riat
w platelet c
ficacy of r
r v
ficacy of r
ronic prim
or
ronic prim
rozanolixi
ons 
rozanolixi
0x10
sio
0x109
io
9/L, f
on
/L, f
13 to 25)
nsio
13 to 25)
a fixed
ten
a fixed-
n
-un
un
th random
exte
th random
ation and any
15x10
y ex
15x109
ex
9/L)
ex
/L)
it will be d
ny e
it will be d
eriod afte
any
eriod afte
 for the an
nd 
 for the an
ceive a fix
and
ceive a fix
lowing th
n a
lowing th
 roz
tion
 roz
applica
um study d
cat
um study d
4 weeks), 
plica
4 weeks), 
Period (8
ppl
Period (8
o attend 
app
o attend 
e, th
a
e th
tion


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 14 of 85
Rozanolixizumab or placebo will be administered as a sc infusion with an infusion pump at a 
 (based on the syringe driver used) for up to 
 
(depending on the dose). A fixed-unit dose across different body weight tiers, as 
presented in Table 1-2 in the study protocol will be applied.
If the participant is unable to tolerate a
 a slower rate may be used at the discretion 
of the clinical personnel administering the infusion.
The placebo arm will use 0.9% sodium chloride aqueous solution (physiological saline, 
preservative-free) for sc administration, matching the volumes of the rozanolixizumab arm. 
Dosing will be followed by a series of postdose study assessments on Day 1 through Day 169, 
with a subsequent SFU Period through Day 218. On dosing days, for the first 2 weeks, a 4-hour 
post-dose observation will be in place. Assuming the first 2 doses were well tolerated, on dosing 
days in Week 3, 4, and 5, a 1-hour post dose observation will be in place. Assuming the first 5 
doses were well tolerated, on subsequent weeks, a 15-minute post-dose observation will be in 
place. However, if the dose needs to be decreased due to a TEAE(s) or dose needs to be 
increased, post dose observation will be extended to 1 hour after the end of infusion for the next 
2 infusions. The post-dose observation time frame may be extended at the discretion of the 
investigator. These recommendations are applicable for dosing at site and at home. Approval 
from the investigator and sponsor is required prior to the start of home dosing.
Note: All study participants for the analysis described in this SAP were enrolled under previous 
protocol versions and randomized to bi-weekly dosing. SFU Period was until Day 211. For the 
first three infusions, they were expected to stay at the study site for 4 hours after the end of 
infusion, and 2 hours after the IMP infusion for the remaining visits until W23. If needed, 
observation time at site could be extended for each study participant.
In exceptional circumstances (eg, pandemic, hurricanes, etc) where study-specific investigations 
may not be conducted according to study protocol, contingency measures will be in place (see 
Section 8 in the study protocol for details).
Approximately 150 study participants were planned to be screened at approximately 70 sites 
from North America, Europe and Asia to achieve the targeted number of approximately 60
evaluable study participants randomized to weekly dosing.
Note: Due to a strategic decision, the study was stopped early after 30 participants were 
randomized to bi-weekly dosing per previous protocol versions. Thus, no participants were 
randomized to weekly dosing in the study per Protocol Amendment 3.
All study participants completing the Treatment Period (with or without the need for rescue 
therapy) and fulfilling the OLE study (TP0004) eligibility criteria will be allowed to enroll into 
TP0004.
If study participants require rescue therapy during the Treatment Period (Week 1 to Week 25), 
they were allowed to receive commercially available rescue therapy (Section 6.4.3 in the study 
protocol).
An external IDMC was established to review the safety data at predefined intervals and ad hoc as 
needed, should emerging safety concerns arise during the study. The first IDMC meeting for the 
review of safety data was planned to occur after approximately 15 participants had received 3 
PUBLIC COPY
y be
Y
y be
e for do
PY 
e for do
or to the
OPY
or to the
describe
CO
describe
weekly do
C C
weekly do
ed to stay
LIC
ed to stay
infusion
UBL
infusion
extende
PUB
extende
g, pa
P
g, pa
t cannot be used to support any marketing authorization 
arm.
uth
arm.
h Day 169
aut
h Day 169
weeks, a 4
g a
weeks, a 4
olerated, o
ing 
olerated, o
Assuming
etin
Assuming
observati
ket
observati
or dose ne
ark
or dose ne
he end of 
ma
he end of 
nded at th
y m
nded at th
ng at site 
any
ng at site 
start of ho
t an
start of ho
d in this S
port
d in this S
sing. SFU
ppo
sing. SFU
at the stu
upp
at the stu
for the re
su
for the re
d for each
to s
d for each
ndemic, hu
ed t
ndemic, hu
o study pr
sed
o study pr
for details
us
for details
articipant
be 
articipant
urope and 
ot b
urope and 
cipants
not
cipants ran
ot
ran
ment
rategic
ann
rategic d
n
d
n
bi
t c
bi-
c
-weekl
ca
weekl
d to weekl
nt c
d to weekl
dy particip
men
dy particip
This docu
apy) and f
um
apy) and f
P0004.
ocu
P0004.
If stud
do
If stud
they
s d
they
p
s
p
and any extensions or variations thereof.
9, 
f
9, 
4
e
4-hour 
of
hour 
on dosing
reo
on dosing
g the first 
here
g the first 
on will b
the
on will b
eeds to be
ns t
eeds to be
infusion 
ons
infusion 
he discret
atio
he discret
e and at ho
riat
e and at ho
ome dosin
vari
ome dosin
SAP were
or v
SAP were
U Period w
s or
U Period w
udy site fo
ns 
udy site fo
emaining 
ion
emaining 
h study 
nsio
h study pa
o
pa
hurricanes
ten
hurricanes
rotocol, c
exte
rotocol, c
ls).
y
ls).
nts were pl
any
nts were pl
d Asia to a
d an
d Asia to a
andomized
nd 
andomized
lication a
ecision, th
n an
ecision, th
ly dosing 
on 
ly dosing 
kly dosing
atio
kly dosing
ipants com
lica
ipants com
app
fulfilling 
plic
fulfilling 
rticip
a
rticip


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 15 of 85
doses of IMP in TP0003 or TP0006. The study was to be put on hold if any of the following 
occurred:
•
The IDMC judges it necessary for medical or safety reasons and
•
The sponsor or its designee judges it necessary for medical, safety, regulatory, or any other 
reasons consistent with applicable laws, regulations and Good Clinical Practice.
•
Three study participants experience any SAE of same type within the first 15 study 
participants who have received 3 doses of IMP across TP0003 and TP0006, unless the SAE 
is clearly unrelated to the study drug.  After Protocol Amendment 3, this rule no longer 
applied.
−  For US and Canada only: Three study participants experience any SAE within the first 15 
study participants who have received at least one dose of IMP across TP0003 and TP0006, 
unless the SAE is clearly unrelated to the study drug.
The IDMC has the possibility to unblind the data. Details of the IDMC composition, processes, 
and responsibilities will be documented in the IDMC charter. It is intended to have one IDMC 
for both of the pivotal studies (TP0003 and TP0006), where the data will be presented unpooled, 
ie, data from each study will be reviewed separately. Key safety data may be pooled at the 
discretion of the IDMC for protection of all study participants if warranted.
Based on feedback from the IDMC, weekly dosing was suggested and it was implemented in 
protocol amendment 3. Study participants being treated with the bi-weekly dosing regimen 
would switch to the weekly dosing regimen once protocol amendment 3 was approved at the 
respective study site.
Note: No study participants were actually switched to weekly dosing or started on weekly dosing 
prior to the termination of the study.
Additionally, a Safety Signal Detection Team performed rozanolixizumab program-wide 
aggregated safety data reviews at predefined intervals.
2.4
Determination of sample size
Following Protocol Amendment 3, the sample size calculation was amended to reflect the 
primary objective of assessing the treatment effect on participants who were randomized to 
weekly infusions. To achieve the study objectives within the sample size cap of the original 2-
stage adaptive design, the futility assessment and option for a sample size re-assessment were no 
longer considered and the sample size calculation was amended as appropriate for a fixed 
parallel group design.
The observed durable platelet response rates (platelet count ≥50×10⁹/L during 6 or more of the 
last 8 weeks of treatment), from Kuter et al (2008) in splenectomized participants were 38% 
(16/42) on active and 0% (0/21) on placebo. In non-splenectomized participants the rates were 
61% (25/41) and 5% (1/21), respectively.
Using the true response rate of 0.45 versus 0.05, a sample size of 60 participants randomized in a 
2:1 ratio (ie, n=40 on rozanolixizumab and n=20 on placebo) receiving weekly infusions would 
provide >90% power to detect a statistically significant difference between treatment groups 
using Fisher’s Exact Test at an alpha level of 0.025 (1-sided). 
PUBLIC COPY 
, wher
PY 
, wher
ly. Key 
OPY
ly. Key 
dy partic
COP
dy partic
y dosing
C C
y dosing
nts being
LIC 
nts being
gimen o
BLIC
gimen o
ere actu
PU
ere actu
udy
P
udy
ument cannot be used to support any marketing authorization 
he SAE
tho
he SAE
longer 
auth
longer 
within th
ing 
within th
P0003 an
etin
P0003 an
MC comp
mar
MC comp
s intended
ma
s intended
he data wi
ny m
he data wi
afety data
any
afety data
ipants if w
rt a
ipants if w
was sugge
por
was sugge
treated wi
upp
treated wi
nce protoc
sup
nce protoc
ally switch
d to
ally switch
etection T
us
etection T
ws at pred
be u
ws at pred
nation o
ot b
nation o
Amendme
nno
Amendme
 of assess
ann
 of assess
ns. To ac
t ca
ns. To ac
ve design
nt c
ve design
onsidered 
men
onsidered 
el group d
me
el group d
This docu
e observe
cum
e observe
last 8 wee
docu
last 8 wee
(16/42
do
(16/42
61%
s d
61%
plication and any extensions or variations thereof.
he first 15
reo
he first 15
nd TP000
her
nd TP000
position, p
ns 
position, p
ed to have
tion
ed to have
will be pres
iatio
will be pres
a may be 
aria
a may be 
warranted
var
warranted
gested 
or
gested and
r v
and
with the bi
s o
with the bi
col amend
ons
col amend
hed to we
ens
hed to we
Team perf
ex
Team perf
defined in
ny e
defined in
of sample
d an
of sample
ent 3, the
and
ent 3, the
sing the tr
an
sing the tr
chieve the
on 
chieve the
n, the futi
tio
n, the futi
d and the s
cat
d and the s
design.
plica
design.
app
ed durable
ppl
ed durable
ks of tre
app
ks of tre
activ
a
activ


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 16 of 85
By definition participants who dropout of the study are determined as nonresponders and are 
incorporated in the overall response rate. If the number of dropouts is greater than anticipated by 
10%, the impact on the rozanalixizumab response rate would mean that it would drop to a 
response rate of 0.4. In such cases, the study would still achieve >80% power if the overall 
response rate on placebo remains at 0.05.
If the response rate on placebo was 0.1 rather than the anticipated 0.05, the rozanolixizumab rate 
would need to be >0.45 to achieve 80% and >0.5 to achieve 90% power. Table 2-1 provides 
power estimates for a fixed study design of n=60 participants in a 2:1 randomization ratio.
Table 2-1: 
Expected sample size
Scenario
Placebo Response Rate of 0.05
Placebo Response Rate of 0.1
RLZ
Placebo
Powera
RLZ
Placebo
Powera
1
0.30
0.05
56%
0.30
0.10
32%
2
0.35
0.05
73%
0.35
0.10
48%
3
0.40
0.05
85%
0.40
0.10
63%
4
0.45
0.05
93%
0.45
0.10
77%
5
0.50
0.05
97%
0.50
0.10
87%
6
0.55
0.05
98%
0.55
0.10
93%
a Power for a Parallel Group Design with N=60 in a 2:1 randomization test computed with 
Fisher’s exact test using NQuery Advisor 7.0.
Note: Due to sponsor decision, the study was stopped early after 30 study participants were 
randomized to bi-weekly dosing per previous protocol versions. Thus, no study participants were 
randomized to weekly dosing in the study per Protocol Amendment 3 and all analyses will be 
conducted on the first 30 study participants who had bi-weekly dosing.
3
DATA ANALYSIS CONSIDERATIONS
3.1
General presentation of summaries and analyses
Statistical analysis and generation of tables, figures, participant data listings, and statistical 
output will be performed using SAS® Version 9.4 or higher (SAS Institute, Cary, NC, USA). 
All tables and listings will use Courier New font size 9.
Descriptive statistics will be displayed to provide an overview of the study results. For 
continuous variables, descriptive statistics will include number of participants with available 
measurements (n), mean, standard deviation (SD), the median, minimum, and maximum. 
For categorical variables, the number and percentage of participants in each category will be 
presented. Unless otherwise noted, the denominator for percentages will be based on the number 
of participants included in the respective analysis set. Participants with missing data can 
generally be accounted for using the following approaches:
LIC COPY 
0.4
Y
0.4
0.
PY
0.
PY
OP
CO
98%
C
98%
C
LIC C
PUBL
n with N
BLI
n with N
Advisor
UB
Advisor
the st
PU
the st
upport any marketing authorization 
rate
iz
rate
s
o
s
io.
th
io.
Rate of 0.1
ng 
Rate of 0.1
a
bo
et
bo
ing
ng
ng
ng
0.10
rke
0.10
ke
0.10
ma
0.10
ar
m
ny
5
ny
ny
ny
ny
0.50
ort
0.50
t a
0.55
ppo
0.55
o
pp
ument cannot be used to s
=60 in a 2
sup
=60 in a 2
7.0.
to
7.0.
udy was st
ed t
udy was st
r previou
sed
r previou
the study
use
the study
dy particip
be u
dy particip
ANALY
t b
ANALY
eral pres
nno
eral pres
sis and ge
can
sis and ge
e perform
t ca
e perform
s and listin
ent
s and listin
riptive sta
um
riptive sta
This doc
ontinuous 
cu
ontinuous 
measurem
doc
measurem
For c
s d
For c
p
s
p
ns or variations thereof.
of
P
her
Powe
er
owe
re
the
s
0.10
ati
0.10
io
0.10
aria
0.10
ia
0
a
0
va
r
or
or
or
s or
plication and any extension
2:1 random
ons
2:1 random
stopped ea
tens
stopped ea
us protoco
xte
us protoco
y per Prot
ex
y per Prot
pants
ny
pants who
y e
who
YSIS CO
d an
YSIS CO
sentation
and
sentation
eneration 
n a
eneration 
med using 
tion
med using 
ings will u
cati
ings will u
atistics w
plic
atistics w
app
 variables
app
 variables
ments (n)
ap
ents (n)


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 17 of 85
•
For summaries of demographics and Baseline characteristics: summarize percentages based 
on all participants in the analysis set and include a “Missing” category (corresponding to 
participants with missing data for the variable being summarized) as the last row in the list of 
categories being summarized. 
•
For summaries of efficacy and safety variables, unless otherwise specified: summarize 
percentages based only on those participants with observed data for the variable being 
summarized. As the denominator may be different from the number of participants in the 
analysis set being considered, the denominator should be displayed in the table. The general 
format for displaying this will be “n/Nsub (%).”
Unless otherwise noted, all percentages will be displayed to one decimal place. No percentage 
will be displayed for zero counts, and no decimal will be presented when the percentage is 100%. 
For the purpose of the tabulations the lower and upper confidence limits for the percentages will 
be truncated at 0 and 100% respectively.
For PK concentrations, summary statistics will include geometric mean, geometric coefficient of 
variation (CV), 95% confidence intervals (CIs) for geometric mean, arithmetic mean, SD, 
median, minimum, and maximum. All summaries of PK variables will be based on the observed 
values. No imputation will be used.
Decimal places for descriptive statistics will always apply the following rules:
•
“n” will be an integer
•
Mean, SD, and median will use one additional decimal place compared to the original data
•
CV [%] will be presented with one decimal place
•
Minimum and maximum will have the same number of decimal places as the original value.
If no participants have data at a given time point, for example, then only n=0 will be presented. 
However, if n<3, present the n, minimum and maximum only. If n=3, n, mean, median, 
minimum and maximum will be presented only. The other descriptive statistics will be left blank.
Derived variables in general will display the mean, SD and median to 1 more decimal place than 
the variables used in the derivation. If the number of decimal places reported in the raw data is 
varied, then use either the maximum raw number of reported decimal places or 3, whichever is 
the lowest, as a guide for the descriptive statistics. 
3.2
General study level definitions
3.2.1
Analysis time points
All data will be analyzed based on the visits identified per the Schedule of Activities in the 
protocol.
Note: As no study participants were randomized under Protocol Amendment 3 the visit schedule 
and associated activities relate to those of earlier protocol versions.
Mapping to visit windows will not be applied.  For Early Withdrawal visits refer to Section 3.2.3.
PUBLIC COPY
ome
Y
ome
of PK va
PY 
of PK va
always 
CO
always 
one add
UBL
one add
with one 
PU
with one 
l h
P
l h
be used to support any marketing authorization 
the
ho
the
e general
tho
e general
No percen
g a
No percen
percentag
ting
percentag
for the per
keti
for the per
mean, geo
ma
mean, geo
mean, arith
y m
mean, arith
iables wil
any
iables wil
apply the 
port
apply the 
tional dec
su
tional dec
decimal pl
d to
decimal pl
ave the sam
sed
ave the sam
given tim
us
given tim
n, minim
be u
n, minim
cument cannot b
will be pre
t be
will be pre
general wi
not
general wi
in the deri
ann
in the deri
either the
can
either the
s a guide f
t ca
s a guide f
Ge
n
Ge
This do
All data w
docu
All data w
protoco
do
protoco
Not
s d
Not
a
s
a
ny extensions or variations thereof.
ntage
eof
ntage
ge is 100%
ereo
ge is 100%
ercentages
the
ercentages
eometric c
ons
eometric c
hmetic m
atio
hmetic m
ll be base
riat
ll be base
following
or v
following
cimal plac
ions
cimal plac
lace
ns
lace
ame numb
xten
ame numb
me point, f
y ex
me point, f
mum and m
ny e
mum and m
lication and a
resented o
any
resented o
will display
nd 
will display
rivation. I
and
rivation. I
e maximu
n a
e maximu
for the de
tion
for the de
eneral st
cat
eneral st
applic
Analysi
plic
Analysi
will be an
app
ill be an


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 18 of 85
3.2.1.1
Relative day
Relative day for an event will be derived with the date of the first sc infusion of study drug as 
reference.
Relative days for an event of measurement occurring before the date of first sc infusion will be 
prefixed with '-' and are calculated as follows:
Relative Day = [(Event Date – Date of First Infusion)]
The relative day for an event or measurement occurring on or after the reference date to the date 
of the last infusion is calculated as follows:
Relative Day = [(Event Date - Date of First Infusion) + 1]
For events or measurements occurring after the date of the last sc infusion, relative day will be 
prefixed with ‘+’ in the data listings and will be calculated as follows:
Relative Day = [(Event Date – Date of Last Infusion)]
There is no relative Day 0. Relative day is not calculated for partial dates in cases where relative 
day is shown in a participant data listing. In such cases, relative day should be presented as ‘- -’ 
in the participant data listings.
3.2.2
Study periods
The following study periods are defined for this trial:
•
Prolonged Screening Period: splenectomized participants will be required to attend a 
Prolonged Period prior to the Screening Visit for the assessment of vaccination titers and to 
receive, if applicable, the required vaccinations, which will extend the total study duration by 
up to 20 weeks.
•
Screening Period (up to 4 weeks): Starts at the time of the informed consent date and ends 
the day before the first dose administration of study drug (i.e. generally the day before Day 1 
visit date). 
Note: after signing the ICF splenectomized participants will go first through the Prolonged 
Screening Period and then to the Screening Period, while the non-splenectomized will go 
directly to the Screening Period.
•
Dose Adaptation Period (12 weeks): Starts on the day of the first dose administration of 
study drug (Day 1) and ends after the Week 13 visit assessments. 
•
Maintenance Period (12 weeks): Starts on the day after the 12-week Dose Adaptation Period 
(Week 13) and ends after the Week 25 visit assessments (or at the Early Withdrawal (EW) 
Visit for study participants withdrawn from the study before Week 25 visit). 
•
Treatment Period: Starts on the day of the first dose administration of study drug (Day 1) and 
ends after the Week 25 visit assessments (or at the EW Visit for study participants withdrawn 
from the study before Week 25 visit). It is the combination of the Dose Adaptation Period 
and the Maintenance Period.
•
Safety Follow-up Period (SFU): Starts with last dose administered and ends 8 weeks after 
final dose administered.
PUBLIC COPY
es, r
PY
es, rel
Y 
el
for this t
C C
for this t
nectomi
BLIC
nectomi
Screenin
UBL
Screenin
equired v
PU
equired v
nnot be used to support any marketing authorization 
o the date
tho
o the date
relative da
eting
relative da
tial dates 
y m
tial dates 
ve day sh
ny 
ve day sh
ial:
p
ial:
zed partici
sup
zed partici
g Visit for
to s
g Visit for
accination
d to
accination
eks): Star
use
eks): Star
se admini
e u
se admini
the ICF s
not 
the ICF s
d and then
nno
d and then
This document ca
e Screenin
can
e Screenin
aptation P
nt c
aptation P
drug (Day
ent
drug (Day
aintenanc
me
aintenanc
(Week 1
cum
(Week 1
Visit 
oc
Visit 
•
s d
•
T
and any extensions or variations thereof.
day will be
here
day will be
in cases w
tion
in cases w
hould be p
iati
hould be p
cipants wi
ons
cipants wi
r the asse
sion
r the asse
ns, which
nsi
ns, which
rts at the t
ext
rts at the t
istration o
y e
istration o
splenectom
d a
splenectom
n to the S
and
n to the S
application a
ng Period
n an
ng Period
Period (12
tion
Period (12
ay 1) and e
catio
ay 1) and e
ce Perio
plic
ce Period
13) and en
ppl
13) and en
for study
ap
or study


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 19 of 85
A study participant is considered to have completed the study if he/she has completed all phases 
of the study including the SFU Period or has successfully been enrolled (completed Visit 1 in 
TP0004) into TP0004 at Week 25.
A study participant will be said to have completed the SFU period if she/he had completed the 
last scheduled visit in the SFU period.
Study participants will have an EOS Visit performed 8 weeks after the final dose of IMP (unless 
they are enrolling in TP0004 at Week 25), or upon discontinuation of the study.
3.2.3
Mapping of assessments performed at Early Withdrawal Visit
Early Withdrawal assessments will be assigned to the next scheduled site visit (following the last 
scheduled visit that the participant completed prior to EW) where each assessment is evaluated 
as per protocol. This approach means that there is a chance that EW data will be mapped to 
different visits according to the schedule of assessments.  
3.2.4
Dosing Regimen
Because no participants in TP0006 were randomized or treated under Protocol Amendment 3.0, 
analysis by dosing regimen will not be performed.
3.3
Definition of Baseline values
Baseline will be the last available pre-dose value prior to the first infusion of study drug in the 
Treatment Period, or if missing, the Screening value. Scheduled or unscheduled measurements 
can be used as the Baseline value. If an unscheduled measurement occurs after the planned 
baseline measurement time point but before dosing, then the unscheduled measurement will be 
used.
3.4
Protocol deviations
Important protocol deviations are deviations from the protocol which potentially could have a 
meaningful impact on study conduct or on the primary efficacy, key safety, or PK/PD outcomes 
(if applicable) for an individual participant. The criteria for identifying important protocol 
deviations will be defined within the appropriate protocol-specific document. Important protocol 
deviations will be reviewed as part of the ongoing data cleaning process and data evaluation. All 
important protocol deviations will be identified and documented prior to unblinding to confirm 
exclusion from the Pharmacokinetic Per-Protocol Set analysis set. 
3.5
Analysis sets
3.5.1
Enrolled Set (ES)
All study participants who have signed the informed consent.
3.5.2
Randomized Set (RS)
The RS will include all enrolled study participants who were randomized. This is equivalent to 
the Intent-to-Treat Set.
PUBLIC COPY 
Y
value pr
C CO
value pr
ening va
IC C
ening va
n uns
LIC
n unsch
IC
ch
ut before
UBL
ut before
tion
P
tion
ument cannot be used to support any marketing authorization 
nless
riz
nless
ollowing t
g au
ollowing t
ment is ev
ng 
ment is ev
ill be map
eting
ill be map
under Pro
y m
under Pro
or to the f
port
or to the f
lue. Sched
ppo
lue. Sched
duled me
supp
duled me
dosing, th
o su
dosing, th
e deviatio
use
e deviatio
conduct or
be u
conduct or
idual part
t be
idual part
ed within
ot b
ed within
viewed as
nno
viewed as
l deviatio
ann
l deviatio
the Pharm
ca
the Pharm
This doc
Ana
nt 
Ana
E
ll study pa
cum
ll study pa
3.5.2
do
3.5.2
The
s 
The
tion and any extensions or variations thereof.
the last 
of.
the last 
valuated 
reo
valuated 
pped to
here
pped to
otocol Am
tion
otocol Am
first infus
or v
first infus
duled or u
s or
duled or u
easuremen
ns 
easuremen
then the u
ion
then the u
ons from t
ex
ons from t
r on the p
ny e
r on the p
ticipant. T
any
ticipant. T
n the appr
d a
n the appr
s part of t
nd 
s part of t
ons will b
an
ons will b
macokine
on a
macokine
applicat
alysis set
atio
alysis set
Enrolled 
lica
Enrolled 
articipant
pp
articipant
R
p
R


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 20 of 85
3.5.3
Safety Set (SS)
The SS will include all randomized study participants who received at least one dose of IMP 
(partial or full). Analysis of this set will be according to the treatment the participants received 
and will be used for the demographic and safety analyses.
3.5.4
Full Analysis Set (FAS)
The FAS consists of all randomized study participants who have received at least one sufficient 
sc infusion of IMP, have a valid Baseline, and at least 1 valid post-Baseline platelet count 
measurement during Weeks 13-25.
Note: Due to the early termination of the study and changes to the analysis, the Full Analysis Set 
will not be included in the analysis and the clinical study report.
3.5.5
Pharmacodynamic Per-Protocol Set (PD-PPS)
The PD-PPS is a subset of the SS, consisting of those study participants who had no important 
protocol deviations potentially affecting the serum concentration of total IgG, as confirmed 
during a pre-analysis review of the data prior to database lock. Protocol deviations may not 
necessarily lead to total exclusion of a participant from the PD-PPS but may lead to exclusion of 
specific data.
Note: Due to the early termination of the study and changes to the analysis, the PD-PPS will not 
be included in the analysis and the clinical study report.
3.5.6
Pharmacokinetic Per-Protocol Set (PK-PPS)
The PK-PPS is a subset of the SS, consisting of those study participants who received at least 
1 dose (as described above), had at least 1 valid PK measurement and no important protocol 
deviations affecting the PK variable, as confirmed during a pre-analysis review of the data prior 
to database lock.
3.6
Treatment assignment and treatment groups
If after unblinding it is determined that participants at any time received incorrect treatment from 
their randomized assignment, then for safety analyses these participants will be reallocated to the 
appropriate treatment group. For example, if participants randomized to placebo received 
rozanolixizumab, then for the safety analyses, these participants will be reallocated to 
rozanolixizumab. 
Participants randomized to rozanolixizumab will only be reallocated to the placebo treatment 
group if they never received rozanolixizumab. 
Efficacy data will be summarized by randomized treatment group as shown below: 
•
Placebo 
•
RLZ
Safety data will also be summarized based on the two groups and dose will not be shown in the 
header. Dose will be captured in the listings.
PUBLIC COPY
se
Y
se
om the
PY 
om the
dy and ch
CO
dy and ch
l stu
C C
l study r
C C
dy r
Protoco
BLIC
Protoco
 consist
UBL
 consist
d at leas
PU
d at leas
able
P
able
d to support any marketing authorization 
cient 
ori
cient 
nt 
th
nt 
ull Analy
g au
ull Analy
nts who ha
arke
nts who ha
f total IgG
mar
f total IgG
Protocol d
y m
Protocol d
D-
n
-PPS bu
ny 
PPS bu
anges to t
ort 
anges to t
port.
ppo
port.
l Set (PK
supp
l Set (PK
ng of thos
to s
ng of thos
t 1
d
t 1 valid P
d to
valid P
This document cannot be used
as confirm
ed 
as confirm
ssignmen
be u
ssignmen
termined 
t be
termined 
nment, th
not 
nment, th
nt group. 
nno
nt group. 
, then for 
can
, then for 
mab.
t c
mab.
nts random
ent
nts random
if they ne
me
if they ne
ficacy dat
cum
ficacy dat
•
d
•
Plac
oc
Plac
•
s 
•
ensions or variations thereof.
ysis Set 
of.
ysis Set 
ad no imp
s th
ad no imp
G, as conf
ons
G, as conf
deviations
tion
deviations
ut may lea
iati
ut may lea
the analy
r va
the analy
K-PPS)
ns
PPS)
se study p
sion
se study p
PK measu
nsi
PK measu
application and any exte
rmed durin
ten
rmed durin
ent and tr
ny e
ent and tr
d that parti
any
d that parti
hen for sa
nd a
hen for sa
 For exam
and
 For exam
r the safet
n a
r the safet
mized to r
catio
mized to r
ever receiv
lica
ever receiv
ata will be
ppl
ata will be
o
a
o


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 21 of 85
3.7
Center pooling strategy
It is planned to recruit participants in North America, Europe, and Asia in this study, with 
possible extension to other regions and countries. The data from all sites will be pooled for 
analysis purposes.
3.8
Coding dictionaries
Adverse events (AEs) will be coded using version 24.0 or later of the Medical Dictionary for 
Regulatory Activities (MedDRA®). 
Medications will be coded according to version Mar 2021 or later of the World Health 
Organization Drug Dictionary (WHODD). Medical procedures will not be coded.
3.9
Changes to protocol-defined analyses
(1) Analysis sets
   (1.2) The FAS was removed from analysis
   (1.3) The PD-PPS was removed from analysis
(2) Added COVID-19 as an intercurrent event to all endpoints
(3) Note: The study was terminated early after 30 participants were randomized to bi-weekly 
infusions per Protocol Amendment 2; no participants were randomized to weekly infusions in the 
study per Protocol Amendment 3. 
(4) No formal statistical analyses of efficacy endpoints were conducted. Only the primary and 
secondary efficacy endpoints were summarized descriptively and listed. Protocol-defined 
analyses for efficacy endpoints are described below.
The primary efficacy analysis of the study was planned to conduct a Stratified Cochran-Mantel-
Haenszel test statistic. Sensitivity, supplemental and subgroup analyzes were planned to test the 
robustness of the assumption. The secondary efficacy analyses were planned to conduct a 
sequential hierarchical test procedure to protect the overall significance level for the multiplicity 
of endpoints.
Primary and secondary efficacy endpoints listed below will be listed and summarized 
descriptively for study participants randomized to bi-weekly dosing according to previous 
protocol versions.
•
Durable Clinically Meaningful Platelet Response of ≥50x109/L for at least 8 out of 12 weeks 
during the last 12 weeks (Week 13 to 25)
•
Cumulative number of weeks with Clinically Meaningful Platelet Response of ≥50x109/L 
over the 24-week treatment period (Week 1 to Week 25)
•
Time to first Clinically Meaningful Platelet Response of ≥50x109/L: time from starting 
treatment to achievement of first response of ≥50x109/L
•
Clinically Meaningful Platelet Response of ≥50x109/L by Day 8
PUBLIC COPY
endpo
PY 
endpo
0
O
0 partic
OP
partic
ticipants
CO
ticipants
fficacy e
BLIC
fficacy e
summar
UBL
summar
are desc
PUB
are desc
f the
P
f the
This document cannot be used to support any marketing authorization 
for 
o
for 
alth
a
alth
d.
g
d.
tsts
pants wer
rt a
pants wer
were rand
ort 
were rand
ndpoints
sup
ndpoints
ized descr
o su
ized descr
ibed below
d to 
ibed below
study wa
ed 
study wa
, supplem
use
, supplem
The secon
e us
The secon
procedure
be 
procedure
ary efficac
nno
ary efficac
tudy part
ann
tudy part
ns.
c
ns.
e Clinical
ent 
e Clinical
ng the las
men
ng the las
Cumulati
cum
Cumulati
over th
ocu
over th
•
d
•
Ti
o
Ti
application and any extensions or variations thereof.
re random
var
re random
domized t
r va
domized t
were
ns
were cond
s 
cond
riptively
ion
riptively
ow.
n
ow.
as planned
xten
as planned
mental and
exte
mental and
ndary effi
y ex
ndary effi
e to protec
ny 
e to protec
cy endpoi
nd 
cy endpoi
ticipants r
an
ticipants r
ally Meani
atio
ally Meani
st
i
st 12 wee
icat
12 wee
tive numb
ppli
tive numb
he 24
app
he 24-
p
-we
pp
we
fir
a
fi


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 22 of 85
•
Response defined as platelet count ≥30x109/L and at least a 2-fold increase of the Baseline 
count confirmed on at least 2 separate occasions at two adjacent nominal visits at least 7 days 
apart, and absence of bleeding by visit
•
Time to first rescue therapy
•
Change from Baseline to Week 25 in ITP Patient Assessment Questionnaire (ITP-PAQ) 
Symptoms Score
Other efficacy endpoints listed below will be listed and summarized descriptively as well.
•
Cumulative number of weeks over the planned 24-Week treatment period with platelet 
counts ≥30×109/L and at least doubling from Baseline
•
Mean change from Baseline in platelet count by visit
The data collected for all other efficacy endpoints will be listed only.
(5) All sensitivity and supplemental analysis to the primary endpoint and to the secondary 
efficacy endpoints will not be performed
(6) Subgroup analyses to the primary efficacy analysis will not be performed
(7) Change from baseline will not be calculated for the following endpoints. Only item responses 
will be listed.
•
Change from Baseline in European Quality of Life-5 Dimension 5 Levels (EQ-5D-5L) item 
responses 
•
Change from Baseline in Short form 36-item (SF-36) domain and composite scores
•
Change from Baseline in the ITP-PAQ V1 domain Scores
•
Change from Baseline in FATIGUE-PRO Physical Fatigue Score by visit 
•
Change from Baseline in Patient Global Impression of Severity (PGI-S)
(8) Percent change from Baseline will not be calculated for the following endpoint. Titers will be 
listed.
•
Percent change from Baseline in vaccination titers against Streptococcus pneumoniae, 
Neisseria meningitidis, and Haemophilus influenzae in splenectomized study participants
(9) The following endpoint will not be analyzed because no samples were collected:
•
Change in biomarkers of COVID-19 vaccine response over time
(10) Change from Baseline will not be calculated for the following safety endpoints. Only raw 
data will be listed.
•
Vital signs change from Baseline (blood pressure [BP], pulse rate, body temperature) at each 
scheduled assessment during Treatment and SFU Periods
•
12-lead echocardiogram (ECG) change from Baseline at each scheduled ECG visit
•
Laboratory change from Baseline (hematology including coagulation parameters, clinical 
chemistry, and urinalysis) at each scheduled assessment during Treatment and SFU Periods 
•
Change from Baseline in concentrations of total protein and albumin
PUBLIC COPY 
s wil
Y
s wil
r the
OPY
r the fol
PY
fol
ality of L
C C
ality of L
form 36
UBL
form 36
e ITP
PUB
e ITP-
U
-PA
UB
PA
TI
P
TI
used to support any marketing authorization 
ell.
th
ell.
platelet 
aut
platelet 
and to the
ark
and to the
t be perf
ny m
t be perfo
m
o
fo
f
m
fo
f
owing
any
owing en
ny
en
ife
p
ife-
po
-5 Dim
por
5 Dim
item (SF
su
item (SF
AQ V1 dom
d to
AQ V1 dom
GUE
sed
GUE-
ed
-
This document cannot be u
PRO
ed
PRO
atient Glob
us
atient Glob
seline wil
be 
seline wil
om Baseli
not
om Baseli
ngitidis
ann
ngitidis a
n
a
ing endpo
ca
ing endpo
e in bioma
ent 
e in bioma
hange fro
me
hange fro
will be 
um
will be l
•
d
•
Vital
oc
Vital
sc
o
sc
•
s
•
tensions or variations thereof.
he seconda
ns t
he seconda
rmed
atio
rmed
ndpoints
aria
ndpoints O
mension 5
or v
mension 5
36) doma
ions
36) doma
omain Sco
nsi
omain Sco
application and any ext
O Physica
xten
O Physica
obal Impre
y ex
obal Impre
ll not be c
ny 
ll not be c
line in vac
nd 
line in vac
and 
a
and Haem
an
Haem
oint will n
on a
oint will n
markers of 
atio
markers of 
om Baseli
lica
om Baseli
isted
ppli
isted
a
.
p
.
signs ch
ap
igns ch
ed
a
d


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 23 of 85
•
Change from Baseline in serum complement levels (C3 and C4) and plasma complement 
levels (C3a and C5a) at each scheduled assessment during the study (for study participants 
experiencing infusion reactions or hypersensitivity reactions)
•
Absolute values and change from Baseline (absolute values and percentage) in serum 
immunoglobulin concentrations (IgA, IgE, IgM) at each scheduled assessment
4
STATISTICAL/ANALYTICAL ISSUES
4.1
Adjustments for covariates/factors
No statistical analysis will be performed adjusting for covariates/factors.
4.2
Handling of dropouts or missing data
4.2.1
Handling missing data for the primary and secondary efficacy endpoints
Study participants who have not met the threshold for clinically meaningful response will be 
imputed as non-responders for the analysis. Missing platelet data at any visit will be considered 
"worst case" and set to zero ("no response") for that specific visit.
Missing data for ITP Patient Assessment Questionnaire (ITP PAQ) instrument will not be 
imputed. 
Missing efficacy data encountered due to permanent treatment discontinuation due to TEAEs, or 
the receipt of rescue therapy will be considered as intercurrent events. For the primary efficacy 
analysis, patients with intercurrent events will be considered as non-responders.
Missing data strategy for PRO related endpoints will follow instructions indicated in each 
instrument.
4.2.2
Missing Data due to COVID-19 
Unless specified otherwise, study participants who have visits impacted by COVID-19 for any 
reason will be considered non-responders at the corresponding visit, and missing platelet count 
data due to COVID-19 will be considered worst case and set to zero (“no response”) for that 
particular visit.
4.2.3
Dates and times
Partially and completely missing dates may be imputed for the following reasons:
•
Classification of Adverse events (AEs) as treatment-emergent
•
Classification of medications as past, prior, or concomitant
•
Durations of AEs.
Imputed dates will not be shown in listings.  All dates will be displayed as reported in the 
database.
The following rules will be applied for partial start dates:
•
If only start month and year are specified and are not the same as month and year of first 
dosing, then use the 1st of the month 
PUBLIC COPY
naire (IT
PY 
naire (IT
rmanent
CO
rmanent
idered as
C C
idered as
nts will 
LIC
nts will 
ated e
UBL
ated endp
BL
ndp
e t
P
e t
ment cannot be used to support any marketing authorization 
fficacy en
ketin
fficacy en
ngful resp
arke
ngful resp
any visit 
mar
any visit 
t.
y
t.
P PAQ) in
any
P PAQ) in
treatm
port
treatment
rt
ent
intercurre
ppo
intercurre
be conside
upp
be conside
oints will
o s
oints will
 COVID
ed
 COVID
dy particip
us
dy particip
n
b
n-respond
be u
respond
ll be cons
t be
ll be cons
es and tim
nn
es and tim
ompletely
ca
ompletely
ication of
nt 
ication of
This docum
assificatio
me
assificatio
Duratio
cu
Duratio
Impute
do
Impute
data
s d
data
cation and any extensions or variations thereof.
ndpoints
her
ndpoints
ponse wil
s th
ponse wil
t will be c
ons 
t will be c
nstrument
riat
nstrument
t discontin
or v
t discontin
rent event
s or
rent event
ered as no
ns o
ered as no
l follow i
sion
l follow i
-19
xte
19
pants who
ex
pants who
ders at the
ny e
ders at the
sidered w
any
sidered w
mes
an
mes
y missing 
on a
y missing 
f Adver
atio
f Adverse
o
se
applic
on of med
lica
on of med
ns of AE
pp
ns of AE
ates w
ap
ates w


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 24 of 85
•
If only the month and year are specified and the month and year of first dosing is the same as 
the month and year of the start date, then use the date of first dosing. If this results in an 
imputed start date that is after the specified end date, then use the 1st of the start month, or 
the date of screening if this is later (if the latter imputation results in an end date that is 
earlier than the start date, then use the 1st of the month). 
•
If only the year is specified, and the year of dosing is not the same as the year of the start date 
then use January 01 of the year of the start date. 
•
If only the year is specified, and the year of dosing is the same as the year of the start date, 
then use the date of first dosing. If this results in an imputed start date that is after the 
specified end date, then use January 01 of the year of the start date, or the date of screening if 
this is later (if the latter imputation results in an end date that is earlier than the start date, 
then use January 01). 
•
If the start date is completely unknown, then use the date of first dosing. If this results in an 
imputed start date that is after the specified end date, then use January 01 of the year of the 
end date, or the date of screening if this is later (if the latter imputation results in an end date 
that is earlier than the start date, then use January 01). 
Any medication with a start date on the first dosing date, will be assumed to be concomitant.
The following rules will be applied for partial stop dates:
•
If only the month and year are specified, then use the last day of the month
•
If only the year is specified, then use December 31 of the known year
If the stop date is completely unknown, do not impute the stop date, except for ITP medications 
where end date is missing and ongoing is ticked as “no”, which will be imputed as “Past” 
medications.
Imputed AE dates will be used for the calculation of duration of AEs as described in Table 4-1.
Table 4-1:
Calculation rules for duration of AEs
Data 
availability
Onset date
Outcome 
date
Calculation rules
Complete data
Analysis 
Start Date 
(D1)
Analysis 
End Date 
(D2)
Duration = D2 – D1 + 1 day               
Start date 
partially or 
completely 
missing
--
D2
Duration = < D2 – D0 + 1 day             
Notes: D0 = imputed dose start date per partial stop dates. 
PUBLIC COPY 
Y
y 01).
PY
y 01).
ing date
OP
ing date
tial stop
C CO
tial stop
fied, the
LIC 
fied, the
n use D
UBL
n use D
L
nknown,
PU
nknown,
ngoi
P
ngoi
ment cannot be used to support any marketing authorization 
date
riz
date
tart date, 
utho
tart date, 
ter the
aut
ter the
te of scre
g a
e of scre
an the star
ting
an the star
osing. If t
arke
osing. If t
anuary 01
mar
anuary 01
imputation
y m
imputation
will be as
t an
will be as
dates
port
dates:
or
:
n use the l
upp
n use the l
cember 3
o su
cember 3
do not im
d to
do not im
ng is ticke
ed 
ng is ticke
d for the c
e u
for the c
n rules fo
t be
n rules fo
set date
no
set date
ot
Analy
ca
Analy
Star
c
Star
(
an
t c
This docume
date
m
date
rtially or 
cum
rtially or 
completely
doc
completely
missing
do
missing
me
s d
cation and any extensions or variations thereof.
eening if 
eof.
eening if
rt date,
ereo
rt date,
this resul
s th
this resul
1 of the y
ons
1 of the y
on results 
tion
on results 
assumed to
vari
assumed to
last day o
s o
last day o
31 of the k
ion
31 of the k
mpute the 
nsi
mpute the 
ed as “no”
ten
ed as “no”
calculatio
y e
calculatio
or durati
any
or durati
Outcom
nd 
Outcom
date
an
date
d a
a
ysis 
o
ysis 
rt Date 
tion
rt Date 
(D1)
cat
(D1)
A
a
 a
pplica
--
lic
--
ca
appl
y
ppl


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 25 of 85
Data 
availability
Onset date
Outcome 
date
Calculation rules
End date 
partially or 
completely 
missing
D1
--
If end date is completely missing, then:
For ongoing AE 
Duration ≥ (Discharge day – D1) + 1 day or
Duration ≥ (Data cut-off day – D1) + 1 day
For resolved AE:
Duration ≤ (Discharge day – D1) + 1 day  or
Duration ≤ (Data cut-off day – D1) + 1 day 
Note: Where discharge refers to the date when the 
participant rolls over TP0004, or the date of EOS visit  
for study completers, or date of discontinuation for 
participants that were withdrawn from the study.
If end date is partially missing, then:
Duration = D3  - D1 + 1 day, where D3 is imputed end 
date using partial stop dates (see above).
For any AEs with known start date, if the end date is 
missing, the date of last contact will be used as the 
discharge day.
For participants still ongoing in the study at the time of 
the data cut-off, and for whom no discharge date is 
available, the date of the data cut-off will be used instead 
of the discharge date.
IC COPY 
e is p
Y
e is p
on = D3 
PY
on = D3 
e using
OP
e using pa
P
pa
For a
C C
For a
mi
C
mi
PUBLIC
LIC
d to support any marketing authorization 
or
u
or
day 
a
day 
he date wh
ting
he date wh
or the date
ketin
or the date
te of disco
rke
te of disco
thdrawn fr
ark
thdrawn fr
ally missin
y m
ally missin
D1 + 1 da
any
D1 + 1 da
rtial stop d
rt a
rtial stop d
y AEs wit
ppo
y AEs wit
sing, the d
upp
sing, the d
discharge d
sup
discharge d
For par
to s
For par
the d
to
the d
av
av
This document cannot be used t
us d t
za
application and any extensions or variations thereof.
hen the
ereo
hen the
te of EOS 
her
te of EOS 
ontinuation
the
ontinuation
from the st
ns t
from the st
ng
at
ng, then:
atio
, then:
day, where 
aria
day, where 
dates
va
dates (see 
ar
(see 
s
h known s
or
h known s
date of last
ns o
date of last
day.
ion
day.
rticipants s
sio
rticipants s
data cut
ens
data cut-
s
-of
s
of
vailable, t
xten
vailable, t
of the di
ext
of the di
ex


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 26 of 85
Data 
availability
Onset date
Outcome 
date
Calculation rules
Start and end 
date partially or 
completely 
missing
--
--
For ongoing AE:
Duration ≥ (Discharge day – D0) + 1 day  or
Duration ≥ (Data cut-off day – D0) + 1 day  
For resolved AE:
Duration ≤ (Discharge day – D0) + 1 day  or
Duration ≤ (Data cut-off day – D0) + 1 day  
For a participant in the SS, D0 is the date of first 
administration of IMP, and for screen failures, D0 is the 
date of the screening visit.
Note: Discharge refers to the date of the end of study 
visit or the date of discontinuation from the study for 
participants that withdraw.
For any AEs with known start date if the end date is 
missing, the date of last contact will be used as the 
discharge day.
For participants still ongoing in the study at the time of 
the data cut-off, and for whom no discharge date is 
available, the date of the data cut-off will be used instead 
of the discharge date. 
4.3
Handling of repeated and unscheduled measurements
All repeated and unscheduled measurements will be presented in the listings, where applicable. 
The following general rules will apply to all repeated and unscheduled measurements:
•
For repeated or unscheduled measurements obtained prior to the first dose of IMP the latest 
reliable value (which may be scheduled or unscheduled) will be used in the calculation of 
descriptive statistics (ie, Screening and/or Baseline)
•
For repeated or unscheduled measurements obtained at the designated Baseline visit, the 
latest reliable value (which may be scheduled or unscheduled) will be defined as the Baseline 
record if occurred prior to the first dose of IMP
•
If any scheduled measurement obtained at any time point after the first dose of IMP is 
missing, unscheduled measurements will not be used for any missing assessment.
•
See Section 10.4 for the rules applied to ECG triplicate measurements.
4.4
Handling and definition of the Corticosteroid (CS) prednisone 
equivalent dose
For the purposes of further analysis and tabulations, all corticosteroid doses (including both prior 
and concomitant corticosteroids taken for any indication) will be converted to prednisone 
equivalent doses. The conversion table for systemic corticosteroids is presented in Table 4-2.
PUBLIC COPY 
pants t
Y
pants t
y AEs w
OPY
y AEs w
sing, the
COP
sing, the
discharge
CO
discharge
For p
C C
For p
the
C
the
PU LIC
epeat
PU
epeat
This document cannot be used to support any marketing authorization 
or
u
or
day 
au
day 
he date of 
ting
he date of 
screen failu
keti
screen failu
to the date
mar
to the date
iscontinua
ma
iscontinua
withdraw.
ny m
withdraw.
th known s
any
th known s
date of last
rt a
date of last
day.
or
day.
rticipants s
ppo
rticipants s
data cut
upp
data cut-
pp
-of
p
of
vailable, t
sup
vailable, t
of the di
to s
of the di
to
za
ed and u
ed t
ed and u
asuremen
use
asuremen
ill apply t
e us
ill apply t
eduled me
t be
eduled me
ch may be
ot 
ch may be
tics (ie, S
nno
tics (ie, S
d or unsch
can
d or unsch
able value
t ca
able value
if occurr
ent 
if occurr
any sched
me
any sched
missing,
cum
missing,
•
d
•
See
oc
See
4.4
s d
4.4
application and any extensions or variations thereof.
first 
er
first 
ures, D0 i
the
ures, D0 i
te of the en
ns 
te of the en
ation from
tion
ation from
start date i
aria
start date i
st contact w
var
st contact w
still ongoi
or
still ongoi
ff, and for
ns o
ff, and for
the date of
ons
the date of
ischarge d
sio
ischarge d
s
unschedu
ten
unschedu
nts will be
ext
nts will be
to all repe
y e
to all repe
easureme
any
easureme
e schedul
d a
e schedul
Screening
and
Screening
heduled m
n a
heduled m
ue (which 
tion
ue (which 
red prior t
atio
red prior t
duled me
plica
duled me
, unsched
ppl
, unsched
ection
ap
ction 1
p
1


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 27 of 85
Systemic corticosteroids are those with a route of administration of oral, intravenous, or 
intramuscular. All others (including topical, ocular, nasal, subcutaneous, intraarticular, etc.) will 
be considered non-systemic steroids which will have a prednisone equivalent dose = 0mg/day.
Budenoside is considered non-systemic even if taken orally and will always be assigned a 
prednisone equivalent dose = 0mg/day. 
The prednisone equivalent dose will be included in the listing. 
For example, if the total daily dose of triamcinolone is 8mg, the equivalent total daily dose of 
prednisone will be 10mg. If a new corticosteroid is reported that is not in Table 4-2, the 
appropriate prednisone equivalent conversion will be determined and the prednisone equivalent 
dose will be included in a separate systemic corticosteroids concomitant medication listing.
If medications are available in 
 which are not in table below, then the dose 
equivalent to 5mg/day Prednisone will be provided by the physician for this new system CS and 
the TFL footnote will be updated with this information for the newly identified CS
Table 4-2:
Prednisone equivalent doses of systemic corticosteroids/steroids  
Corticosteroids /Steroids
Dose equivalent to 
5mg/day Prednisone
Cortisone 
25
Hydrocortisone 
20
Deflazacort 
6.5
Prednisone 
5
Prednisolone
Methylprednisolone 
5
4
Triamcinolone 
4
Dexamethasone 
0.75
Betamethasone 
0.6
Notes: 
−
All non-systemic corticosteroids (including topical, ocular, nasal, subcutaneous, intra articular, etc.) will be 
assigned a prednisone equivalent dose = 0 mg/day. 
−
 "CORTICOSTEROIDS FOR SYSTEMIC USE, 
4.5
Interim analysis and data monitoring
4.5.1
Data Monitoring 
An external IDMC will be established to review the safety data at predefined intervals and ad 
hoc as needed, should emerging safety concerns arise during the study. The IDMC will consist of 
members independent from UCB. Study enrollment will not be halted during planned IDMC 
review of the safety and efficacy data. The IDMC will have the possibility to unblind the data. 
Details of the IDMC composition, processes, and responsibilities will be documented in the 
IDMC charter. One IDMC is planned for both pivotal studies (TP0006 and TP0003), where the 
safety data will be initially presented unpooled, ie, data from each study will be reviewed 
separately. Key safety data may be pooled at the discretion of the IDMC for protection of all 
study participants if warranted. The first IDMC meeting for the review of safety data is planned 
to occur after approximately 15 participants have received 3 doses of IMP in TP0003. The 
PUBLIC COPY 
D
Y
CO
ment cannot be used to support any marketing authorization 
ose of 
tho
ose of 
he
u
he
ne eq
au
ne equiva
au
uiva
at
n
ation listin
ng a
ion listin
low, then 
eting
low, then 
this new 
ket
this new 
identified
ark
identified
osteroids/
ma
osteroids/
ose equiv
any
ose equiv
5m
t a
5mg/day
t a
g/day
y
rt
e
osteroids (i
ot 
osteroids (i
ne equivalen
nno
ne equivalen
ORTICOS
ann
ORTICOS
Interim
t ca
Interim
This docum
Data
nt
Data
xternal ID
ume
xternal ID
c as neede
cum
c as neede
members
doc
members
review
do
review
Det
s d
Det
I
s
I
tion and any extensions or variations thereof.
alent 
of
alent 
ing.
e
ing.
the dose
here
the dose
system C
the
system C
d CS
ns t
d CS
/steroids 
tion
/steroids 
valent to
riat
valent to
y Prednis
var
y Prednis
tio
25
r v
25
va
2
r
2
y
including t
d a
including t
nt dose = 0
nd
nt dose = 0
TEROIDS
an
TEROIDS
m analysi
ion 
m analysi
applica
ta Monito
atio
ta Monito
DMC will 
plica
DMC will 
ded, should
ppl
ded, should
independ
app
ndepend
he sa
a
he sa


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 28 of 85
intervals for planned IDMC meetings are included in the section 4.1.2.1 in the TP0003/TP0006 
Independent Data Monitoring Committee Charter. The study will be put on hold if any of the 
following occurs:
•
The IDMC judges it necessary for medical or safety reasons and
•
The sponsor or its designee judges it necessary for medical, safety, regulatory, or any other 
reasons consistent with applicable laws, regulations and Good Clinical Practice.
•
An ad hoc IDMC meeting for the review of safety data is planned to occur if one of the 
stopping rules is met:
−
US & Canada Rule: Three participants experience any serious adverse event (SAE) 
within the first 15 study participants who have received at least one dose of IMP across 
TP0003 and TP0006, unless the SAE is clearly unrelated to the study drug.
−
Rest of World Rule: Three participants experience an SAE of the same type within the 
first 15 study participants who have received 3 doses of IMP across TP0003 and TP0006, 
unless the SAE is clearly unrelated to the study drug.
4.5.2 
Interim analyses:
The interim analysis planned for this study under previous protocol versions was removed from 
Protocol Amendment #3.
4.6
Multicenter studies
This is a multicenter study however individual center’s results will not be presented. 
4.7
Multiple comparisons/multiplicity
As inferential statistical analyses will no longer be performed this section is not applicable.
4.8
Use of an efficacy subset of participants
Subset analyses will no longer be performed.
4.9
Active-control studies intended to show equivalence
Not applicable
4.10
Examination of subgroups
Subgroups will no longer be examined.
5
STUDY POPULATION CHARACTERISTICS
5.1
Subject disposition
The following outputs will be created.
Summaries:
−
Reasons for screen failures (as collected on the Study Termination Screen Failure CRF 
page) will be summarized using the ES for overall for all screened study participants who 
failed to be randomized.
PUBLIC COPY 
Y
der previ
COP
der previ
r individ
UBL
r individ
parison
PU
parison
w
P
w
This document cannot be used to support any marketing authorization 
the 
th
the 
event
g a
event (SA
a
(SA
se
in
se of IMP
ing
of IMP
dy drug.
etin
dy drug.
the same
arke
the same
P across T
mar
P across T
ous protoc
rt a
ous protoc
ual center’
su
ual center’
/multipl
d to
/multipl
ll no long
sed
ll no long
acy subs
us
acy subs
ger be per
be 
ger be per
control 
not 
control 
Exa
ca
Examin
ca
min
s will no l
ent 
s will no l
S
1
o
1
The fo
do
The fo
Su
s 
Su
application and any extensions or variations thereof.
AE)
eo
AE)
P across
reo
P across
e type
s th
e type wit
th
wit
TP0003 a
ons
TP0003 a
col versio
var
col versio
r’s results 
ion
r’s results 
lici
n
licity
nsi
ty
ger be per
xten
ger be per
set of pa
y ex
set of pa
erformed.
any
erformed.
studies i
d a
studies i
nation of
on 
nation of
longer be
atio
longer be
STUDY
lica
STUDY
Sub
pp
Sub
ing o
a
ing o


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 29 of 85
−
Disposition of study participants screened will be summarized using the ES for overall, 
by region and by site. In this summary, the site number, principal investigator name, first 
subject in date, last subject out date, will be captured by randomized treatment, and by 
each analysis set (ES, RS, SS, PK-PPS).
−
Disposition of Analysis Sets: summary of disposition of study participants by treatments 
group, by analysis sets (ES, RS, SS, and PK-PPS) using the RS.
−
Disposition and Discontinuation Reasons, using the RS, will contain the number and 
percentage of study participants who:
o
Started study and started each study period (Dose Adaptation Period, 
Maintenance Period and SFU Period)
o
Completed the study and completed each study period study period (Dose 
Adaptation Period, Maintenance Period and SFU Period)
o
Discontinued study and discontinued in each study period (Dose Adaptation 
Period, Maintenance Period and SFU Period)
o
Primary Reason for discontinuation (premature study termination as collected in 
the Study Termination CRF)
−
Discontinuation due to AEs, using the RS to tabulate the total number of study 
participants who discontinued the study due to AEs by treatment group, and the 
categories: AE serious, fatal, AE non-fatal and other (AE non-serious, fatal).
-
COVID-19 Disposition:  Disposition and discontinuation reasons using the RS will 
contain the number and percentage of study participants who started, completed and 
permanently discontinued Treatment Period / Observation Period overall and by pre- and
during the COVID-19 pandemic based on the start, completed and discontinuation date 
relative to the pandemic cut-off date. The pandemic start date is March 20, 2020. The 
discontinuation reason in each period will also be summarized. Discontinuation due to 
COVID-19 pandemic will be listed as sub-category under “Other” reason. 
5.2
Protocol deviations
Important Protocol deviations will be summarized by treatment group, using the RS to include 
the number and percentage of participants with:
a.
No important protocol deviations
b. At least one important protocol deviation and the 
−
Inclusion criteria deviation 
−
Exclusion criteria deviation
−
Withdrawal criteria deviation 
−
Prohibited concomitant medication use 
−
Incorrect treatment or dose
−
Treatment non-compliance 
PUBLIC COPY
(premat
PY 
(premat
the RS to
CO
the RS to
study du
C C
study du
AE non
LIC
AE non-
C
-f
C
f
Disposit
UBL
Disposit
percenta
PUB
percenta
ed Tr
P
ed Tr
ot be used to support any marketing authorization 
s
r and 
hor
r and 
od,
od,
y period 
etin
y period (
eriod 
mar
eriod (
ar
(Do
r
Do
re study te
any 
re study te
tabulate 
ort
tabulate 
e to AEs b
ppo
e to AEs b
tal 
u
tal and ot
upp
and ot
on and dis
o s
on and dis
ge of stud
d to 
ge of stud
atment Pe
ed t
atment Pe
dem
se
demic
sed
ic bas
ed
bas
cut
u
cut-
u
-off d
us
off d
n in each 
be u
n in each 
mic will b
t be
mic will b
This document canno
col devia
not
col devia
ol deviati
ann
ol deviati
d percent
t ca
d percent
portant pr
ent 
portant pr
least one
me
least one
−
c
−
Incl
u
Incl
−
o
−
and any extensions or variations thereof.
(
h
(Dose
her
Dose
ose Adapt
ns 
ose Adapt
terminatio
riat
terminatio
the total n
or v
the total n
by treatm
or
by treatm
her 
ns
her (AE n
s o
(AE n
scontinua
sion
scontinua
dy particip
nsi
dy particip
eriod / Ob
ten
eriod / Ob
sed on the
exte
sed on the
ate.
e
ate. The p
ex
The p
h period w
ny 
h period w
be
a
be
pplication a
listed a
any
listed a
ations
nd
ations
ions will b
n an
ions will b
tage of pa
on 
tage of pa
rotocol de
atio
rotocol de
e im
lic
e importa
plica
porta
app
lusion cri
pp
lusion cri
clusio
a
clusio


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 30 of 85
−
Procedural non-compliance
c.
Number of Participants excluded from the PK-PPS (and all categories in item b above).
d. A summary of number and percentage of participants with an important protocol deviation 
by relationship to COVID-19 and treatment group will be provided for the RS. Additionally, 
the summary will be repeated by pre- and during the COVID-19 pandemic based on the 
deviations start date relative to the pandemic cut-off date. The pandemic start date is March 
20, 2020.  
A by-study participant listing of important protocol deviations will be provided using the RS.
Note:  The criteria for exclusion of study participants and/or study data from the PK-PPS will be 
defined in the Protocol Deviation Specification document.
6
DEMOGRAPHICS AND OTHER BASELINE 
CHARACTERISTICS
Unless otherwise specified, all summaries will be based on the RS. 
6.1
Demographics
Demographic variables will be summarized on the RS, by categories mentioned below using 
descriptive statistics, by treatment group and overall.  
Categories for continuous variables (including n, mean, SD, Median, Min and Max):
•
Age (years) - at the time of study entry.
•
Weight (kg)
•
Height (cm)
•
BMI (kg/m2) calculated as: 𝐵𝑀𝐼=
Weight (kg)
(Height (m))2
Categorical variables (using frequency counts and percentages):
•
Age (18 - <65, 65 - <85, ≥85 years)
•
Age (≤18, 19 - <65, ≥65 years) 
•
BMI (<25, 25 to <30, ≥30 kg/m2)
•
Weight (<50kg, 50kg-<70 kg, 70-<100kg, ≥100kg)
•
Gender (Male, Female)
•
Race (American Indian or Alaska native, Asian, Black, Native Hawaiian or Other Pacific 
Islander, White, Other/Mixed)
•
Ethnicity (Hispanic or Latino, Not Hispanic or Latino)
•
Region (North America, Europe, Asia)
•
Country
By-study participant listings of demographics will be provided. 
PUBLIC COPY 
he RS, b
OPY
he RS, b
overall. 
CO
overall. 
cluding
C C
cluding
entry.
BLIC
entry.
cannot be used to support any marketing authorization 
rch
ri
rch
the RS.
uth
the RS.
PK
g
PK-
a
-PPS w
g au
PPS w
.
y categorie
t an
y categorie
n,
p
n, mean, 
ppo
mean, 
𝑀𝐼
us
𝑀𝐼=
us
=
We
e
We
ng freque
be 
ng freque
<85, ≥85
ot 
<85, ≥85
<65, ≥65
ann
<65, ≥65
This document c
25 to <30
t ca
25 to <30
ht (<50kg,
ent 
ht (<50kg,
ender (Ma
me
ender (Ma
Race (A
ocu
Race (A
Islan
oc
Islan
•
s 
•
n and any extensions or variations thereof.
will be
of.
will be
ies mentio
vari
ies mentio
SD, Med
or
SD, Med
eight (kg)
ext
eight (kg)
(
y
(Height (m)
y ex
Height (m))
x
)
ex
uency cou
any
uency cou
5 years)
d a
5 years)
5 years)
an
5 years)
application
0, ≥30 kg
on 
0, ≥30 kg
, 50kg
atio
, 50kg-
i
-<7
o
<7
Male, Fema
plica
Male, Fema
American
app
American
a
er, Wh
ap
er, Wh


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 31 of 85
Childbearing potential will be listed for the RS.
6.2
Other Baseline characteristics
6.2.1
Baseline disease characteristics 
Baseline disease variables will be summarized using the RS, using descriptive statistics by 
treatment group and overall:
•
Age at first ITP diagnosis (years)
•
Time since first confirmed diagnosis of ITP (as collected in the eCRF)
•
Splenectomy (Yes/No)
•
IgG level (g/L) for
−
Non-splenectomized participants
−
Splenectomized participants
•
Platelet count (x109/L) (as collected in the eCRF)
•
Degree of thrombocytopenia (platelet count < or ≥15x109/L) (using data collected in the 
eCRF) 
•
ITP Duration (persistent or chronic primary ITP as defined in Section 2.3)
•
Total number of prior unique ITP medications (continuous)
•
Total number of prior ITP medications (continuous)
•
Number of prior unique ITP medications (1, 2 and ≥3) 
•
Concomitant use of TPO-RAs (eg,  Eltrombopag and/or Avatrombopag) (Yes/No)
Notes:
−
Persistent or chronic primary ITP as defined in Section 2.3
−
In addition, the number and percentages of study participants in each stratum for each 
stratification factor (splenectomy (yes/no), degree of thrombocytopenia (platelet count < 
or ≥15x109/L) will be presented. 
−
Data will be summarized using data captured or derived from eCRF.
−
The duration of ITP for chronic ITP participants will be computed in years and it will be 
calculated as follows:
Date of Screening – Date of Diagnosis
365.25
, where the date of diagnosis will be obtained from the ITP 
history eCRF page.
−
The duration of ITP – for persistent ITP participants will be computed in months and it 
will be calculated as:
Date of Screening – Date of Diagnosis
30.5
, where the date of diagnosis will be obtained from the ITP 
history eCRF page.
PUBLIC COPY 
or ≥15x
OPY
or ≥15x
mary ITP
C CO
mary ITP
medicatio
LIC
medicatio
dications
UBL
dications
P
P
P medic
PU
medic
t cannot be used to support any marketing authorization 
0
a
09/L)
an
/L) (usi
ny
(usi
as define
por
as define
ns (contin
upp
ns (contin
(continuo
o su
(continuo
ations
d to
ations (1, 
to
(1, 
(eg,  Eltro
sed
(eg,  Eltro
ic primary
t be
ic primary
e number 
not
e number 
n factor (s
nno
n factor (s
0
c
09/L) w
can
/L) w
This document
il
n
il
a will be s
nt c
a will be s
The durat
men
The durat
calcula
um
calcula
Dat
u
Dat
and any extensions or variations thereof.
ing data c
aria
ing data c
ed in
or
ed in Sect
r v
Sect
nuous)
ns o
nuous)
ous)
sio
ous)
 2 and ≥3
ens
 2 and ≥3
ombopag 
exte
ombopag 
ry ITP as 
any
ry ITP as 
r and perc
nd a
r and perc
(splenecto
and
(splenecto
application 
ll be prese
n a
ll be prese
summariz
tion
summariz
ation of IT
lica
ation of IT
ated as fo
plic
ated as fo
e
a
e of
ap
of Screen
app
Screen
ap
ap
ry
a


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 32 of 85
−
Age at diagnosis (years) will be calculated as:
Date of first diagnosis −Date of birth
365.25
−
If the date of diagnosis is missing, the duration of disease and age at first diagnosis will 
not be calculated. In the case of the day (of the date of first diagnosis) being missing, then 
the day will be imputed with the last of the month. In the case day and month being 
missing (for the date of first diagnosis), the date will be imputed with 31st December.
Note: if the imputation results in an imputed diagnosis date that is after screening date, 
then the diagnosis date will be imputed to the screening date.
−
The duration of ITP will be presented in the listings as follows:
◦
In years to 1 decimal place for chronic primary ITP participants
◦
In months (3-12) for persistent primary ITP participants
−
Unique Prior ITP is derived as follows:
◦
To derive prior ITP medications, see Section 6.5
◦
To derive unique: count all medications with 
 as one, count all 
medication with 
 as one, for remaining prior ITP medications count all 
unique standardized medication names (CMDECOD)
6.2.2
Lifestyle
A listing for DILI CRFs (DILI patients only) data (alcohol use and illicit drug use in the past six 
months (yes/no)) will be created using the RS.
6.3
Previous and ongoing medical history 
Previous and ongoing medical history will be summarized by treatment group and overall system 
organ class (SOC), high level group term (HGLT), high level term (HLT) and preferred term 
(PT). Medical procedures are not coded. 
Previous and ongoing medical history will be listed (separated) for the RS by treatment group 
and will include the MedDRA SOC, high level group term (HGLT), high level term (HLT) and 
PT. 
6.4
Procedure history and concomitant medical procedures
Procedure history and concomitant medical procedures will be listed using the RS.
6.5
Concomitant medications 
Definitions: 
Past Medications: defined as any medications that started and stopped before first 
administration of IMP.
This includes medications reported in the following eCRF pages:
-
“ITP Treatment history” 
-
“Prior and Concomitant Medications”, if end date before first IMP date
PUBLIC COPY 
ith 
Y
ith 
for rema
PY
for rema
mes (CMD
COP
mes (CMD
only) da
LIC 
only) da
ng the R
BLI
ng the R
ngoing 
PUB
ngoing 
isto
P
isto
Y
y marketing authorization 
date,
ori
date,
nnot be used to support any
ining prio
any
ining prio
DECOD)
rt a
DECOD)
ta (alcoho
upp
ta (alcoho
S.
S.
medical 
to 
medical 
y will be 
ed 
y will be 
up term (H
use
up term (H
not coded.
e us
not coded.
ical hi
t be
ical histor
e
stor
dDRA SO
ot b
dDRA SO
This document ca
rocedure
can
rocedure
istory and
nt c
istory and
Co
n
Co
nitions:
um
nitions:
Past Med
doc
Past Med
ad
o
ad
ny m
and any extensions or variations thereof.
as one, c
atio
as one, c
or ITP me
aria
or ITP me
ol use and
ns o
ol use and
history 
nsio
history 
summariz
ten
summariz
HGLT),
exte
HGLT), h
e
h
.
ory will be
any
ory will be
OC, 
d a
OC, high 
a
high 
application 
re history
n a
re history
d concom
tion
d concom
oncomit
cat
oncomit
dications
app
ications
trat
a
trat


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 33 of 85
-
“Prior and Concomitant Medications ITP Treatment”, if end date before first IMP 
date.
Prior Medications: defined as any medications that started before the first administration of 
IMP. 
This includes medications reported in the following eCRF pages:
-
“ITP Treatment History”, 
-
“Prior and Concomitant Medications”, if start date before first IMP date.
-
“Prior and Concomitant Medications ITP Treatment”, if start date before first IMP 
date.
Baseline Medications: defined as any medications that started prior to first administration of 
IMP and stopped after the first administration of IMP (classified as prior and concomitant 
medications). This includes medications reported in the following eCRF pages:
-
“Prior and Concomitant Medications”, if start date before first IMP date and end date 
after first IMP date or ongoing
-
“Prior and Concomitant Medications ITP Treatment”, if start date before first IMP 
date and end date after first IMP date or ongoing
Concomitant medications: defined as any medication that has been taken at least once after the 
first administration of IMP.
This includes medications reported in the following eCRF pages:
-
“Prior and Concomitant Medications”, if end date after first IMP date or ongoing 
-
“Prior and Concomitant Medications ITP Treatment”, if end date after first IMP date 
or ongoing
Concomitant only medication: defined as any medication that started after first administration 
of IMP
This includes any medication reported in the following eCRF pages:
-
“Prior and Concomitant Medications”, if start date after first IMP date
-
“Prior and Concomitant Medications ITP Treatment”, if start date after first IMP date
Table 6-1 below summarizes concomitant medication classification with details around 
medication start and finish.
UBLIC COPY 
TP Trea
OPY
TP Trea
te or ong
COP
te or ong
y medica
C C
y medica
in the fo
UBL
in the fo
PU
tant Med
PUB
tant Med
ant
P
ant
to support any marketing authorization 
e first IM
au
e first IM
administr
eting
administr
and conc
ket
and conc
RF pages:
arke
RF pages:
ore first IM
ma
ore first IM
ment”, 
any
ment”, if 
ny
if 
oing
rt
oing
tion that h
por
tion that h
lowing
su
lowing
cannot be used t
eC
u
eC
ications”,
d to 
ications”,
Medicatio
ed 
Medicatio
on:
be
on: define
e u
define
medicatio
not 
medicatio
and Conc
ann
and Conc
ent c
rior and C
t ca
rior and C
bel
en
below su
ent
ow su
This docum
tion start
me
tion start
ns or variations thereof.
MP 
f
MP 
tration of 
here
tration of 
omitant 
the
omitant 
IMP date 
ions
IMP date 
start date
aria
start date
has been t
or 
has been t
n and any extensio
CRF page
ions
CRF page
, if end da
nsi
, if end da
ons ITP T
xten
ons ITP T
ned as any
ny e
ned as any
on reporte
nd a
on reporte
comitant M
an
comitant M
catio
Concomit
ion 
Concomit
ummarize
atio
ummarize
applic
and finis
lica
and finis


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 34 of 85
Table 6-1:
Concomitant Medications Classification
Medication Started
Medication finished
Classification
Before 1st Dose IMP    
Before 1st Dose IMP    
Past Medications
Before 1st Dose IMP    
Any time
Prior Medications
Before 1st Dose IMP    
After 1st Dose IMP       
Baseline Medications (= prior and 
concomitant) 
Any time
After 1st Dose IMP       
Concomitant
After 1st Dose IMP       
After 1st Dose IMP       
Concomitant Only Medications
All the categories mentioned above will be summarized separately for ITP medications; Non-ITP 
medications will be listed only (using the RS) to display the number and percentage of 
participants in each category by treatment group, overall and by Anatomical Therapeutic 
Chemical classification (ATC) class, presenting Anatomical Main Group (ATC Level 1), 
Pharmacological Subgroup (ATC level 3), and preferred term.  
Any medications with missing dates will be handled as described in Section 4.2.2 in order to 
classify them as prior and/or concomitant.
Listings for ITP medications will be also produced using the RS.
Notes: 
•
WHODD Mar2021 will be used for ATC terms.
6.5.1
Assignment of medications to treatment period
•
Treatment Period: The treatment period will include medications taken at least once 
between the first administration of IMP on Day 1, up to the earliest of:
−
Week 25 (for participants who roll over to TP0004)
−
 after the last dose of IMP
−
The early withdrawal visit.
•
Safety Follow-Up Period: A medication will be assigned to the Safety Follow Up Period if 
it has been taken at least once from the day after the end of the Treatment Period up until the 
EOS visit.
6.6
Prohibited concomitant medications and rescue medication
6.6.1
Prohibited concomitant medication
All prohibited concomitant medication listed in section 6.4.2 in the protocol will be summarized 
on the RS using the number and percentage of study participants who received prohibited 
concomitant medication by ATC class, presenting ATC Level 1, ATC level 3, and PT, ordered 
LIC COPY 
erall an
Y
erall an
Anatomic
OPY
Anatomic
preferre
COP
preferre
e handle
C C
e handle
PUB
nt.
LIC
nt.
e also pro
BLI
e also pro
sed
P
sed
support any marketing authorization 
a
za
nd 
t
nd 
or
a
Medicati
keti
Medicati
ting
rk
for ITP m
mar
for ITP m
ber and p
ma
ber and p
by Anatom
ny m
by Anatom
al Main G
any
al Main G
d term. 
rt a
d term. 
d as descri
por
d as descri
ment cannot be used to s
duced usi
sup
duced usi
for ATC 
ed 
for ATC 
medication
use
medication
treatmen
be 
treatmen
ministratio
ot b
ministratio
participa
nno
participa
fter th
can
fter the la
n
e la
early with
nt c
early with
ety Follow
men
ety Follow
This docum
t has been
um
t has been
EOS vi
cu
EOS vi
6.6
do
6.6
6.6
s 
6.6
ns or variations thereof.f.
ions
th
ions
ere
th
medication
ns 
medication
percentage
tion
percentage
mical The
iatio
mical The
Group (AT
aria
Group (AT
ribed in Se
or v
ribed in Se
lication and any extensio
ing the R
ions
ing the R
terms.
ten
terms.
ons to trea
ex
ons to trea
nt period w
ny 
nt period w
on of IMP
d an
on of IMP
ants who r
nd 
ants who r
ast dose o
n a
ast dose o
hdrawal v
tion
hdrawal v
w
i
w-
c
-
appl
Up Per
icat
Up Per
n taken at 
plic
n taken at 
sit.
p
sit.
P
p
P


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 35 of 85
alphabetically for the ATC class and in terms of decreasing frequency for PT within ATC class 
by treatment group. In the event of ties, PT will be ordered alphabetically.
6.6.2
Rescue Therapy
All rescue therapies mentioned in section 6.4.3 in the protocol, identified if Rescue Medication is 
ticked as yes on CRF will be summarized using the RS. 
The number and percentage of study participants who received rescue medication will be 
displayed by ATC class, presenting ATC Level 1, ATC level 3, and PT (ordered alphabetically 
for the ATC class and in terms of decreasing frequency for PT within ATC class by treatment 
group. In the event of ties, PT will be ordered alphabetically). 
7
MEASUREMENTS OF TREATMENT COMPLIANCE
Not applicable. The number of infusions will be recorded as detailed in Section 10.1.
8
EFFICACY ANALYSES
All efficacy variables will be listed for all participants by treatment group and visit, and analyses 
performed using the RS unless specified otherwise.  
8.1
Statistical analysis of the primary efficacy endpoint
8.1.1
Primary analysis of the primary efficacy endpoint
The primary efficacy endpoint will be analyzed according to the following estimands’ attributes:
(1) Treatment conditions:  Placebo and rozanolixizumab (please refer to section 6 Study 
treatments in the protocol for details)
(2) Population: Adult Study Participants with Persistent or Chronic Primary Immune 
Thrombocytopenia (ITP) who fulfill the inclusion / exclusion criteria according to the 
protocol.
(3) Endpoint:  Durable Clinically Meaningful Platelet Response of ≥50x109/L, for at least 8 
out of 12 weeks during the last 12 weeks (Week 13 to Week 25)
This endpoint includes the platelet count recorded at Week 14 to Week 25 corresponding 
to the response achieved following dosing at Week 13 to Week 24)
(4) Intercurrent Events: see below.
PUBLIC COPY 
mary ef
OPY
mary ef
mary eff
CO
mary eff
nalyzed 
LIC 
nalyzed 
bo and ro
BLI
bo and ro
for detai
UB
for detai
Partic
PU
Partic
ot be used to support any marketing authorization 
etically 
thor
etically 
reatment 
uth
reatment 
ANCE
ng
ANCE
ection 10
keti
ection 10
ent group
ma
ent group
ficacy en
t an
ficacy en
icacy end
port
icacy end
ccording 
pp
ccording 
zanolixizu
sup
zanolixizu
s)
t
s)
pants with
ed t
pants with
ho fulfill th
sed
ho fulfill th
linically M
be 
linically M
uring the l
t be
uring the l
cann
includes t
not
includes t
nse achie
ann
nse achie
This document c
rent Even
t ca
rent Even
d any extensions or variations thereof.
0.1.
th
0.1.
p and visi
tion
p and visi
ndpoint
vari
ndpoint
dpoint
or v
dpoint
to the fol
s o
to the fol
umab (ple
ions
umab (ple
th Persiste
tens
th Persiste
the inclus
xte
the inclus
Meaningf
ny 
Meaningf
last 12 we
d any
last 12 we
n and
the platel
nd 
the platel
eved follo
an
eved follo
application
nts: see b
on 
nts: see b


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 36 of 85
Table 8-1:
Intercurrent Events (ICE), Intercurrent Events Strategies (ICES) and 
Missing data Strategies for the analysis of the primary endpoint
Intercurrent Events (ICE)
ICE Strategy
Missing data strategy
a) Use of Rescue therapy from 
Baseline prior Week 25
A composite strategy  
Participants impacted by any 
ICE (a, b, c and d) will be 
considered as non-responders 
after the time of event.
Not applicable
Section 4.2.2
b) Participants who experience any 
TEAEs leading to permanent 
treatment discontinuation
c) Participants who discontinue 
prior to receiving IMP 
d) Participants who do not have 
any post-treatment assessment
e) COVID-19*
A composite strategy  
Participants impacted by ICE 
(e) will be considered as non-
responders at the time of event.
* COVID-19 Impact category: Temporary discontinuation of study drug, Permanent discontinuation of study drug, 
Termination of study participation and Relationship to COVID-19: confirmed, suspected, general or other as 
recorded in the COVID-19 impact eCRF form.
(5) Population-level summary: Owing to early termination of the study, the population-level 
summary will be provided using descriptive statistics.
8.2
Statistical analysis of the secondary efficacy endpoints
8.2.1
Cumulative number of weeks with Clinically Meaningful Platelet Response 
of ≥50x109/L over the 24-Week treatment period (Week 1 to Week 25)
The secondary efficacy endpoint: Cumulative number of weeks with Clinically Meaningful 
Platelet Response of ≥50x109/L over the 24-week treatment period will be analyzed on the RS, 
under the same treatment conditions and population of interest as for the primary endpoint. Note: 
if platelet count was assessed multiple times in a given week, Clinically Meaningful Platelet 
Response only needed to be observed at one timepoint during the week. ICE, ICES and 
population level summary will be handled as described below:
Table 8-2:
Intercurrent Events (ICE), Intercurrent Events Strategies (ICES) and 
Missing data Strategies for the analysis of the Cumulative number of weeks 
with Clinically Meaningful Platelet Response of ≥50x109/L over the 24-Week 
treatment period
Intercurrent Events (ICE)
ICE Strategy
Missing data strategy
a) Use of rescue therapy 
A while on-treatment 
strategy:
Participants impacted by 
Participants impacted by 
any of the ICE will be 
considered as having a loss 
b) Withdrawal from the study 
due to treatment emergent AE
PUBLIC COPY
mpact
Y
mpact
onsidere
PY 
onsidere
rs at the 
OP
rs at the 
O
tion of st
CO
tion of st
p to COVI
C C
p to COVI
wing to 
BLI
wing to 
using de
UB
using de
lysis 
PU
lysis 
This document cannot be used to support any marketing authorization 
za
z
a
y ICE
ny m
y ICE
d as non
any
d as non-
y
-
time of ev
rt a
time of ev
a
rt
ma
dy drug, Pe
ort 
dy drug, Pe
-19: confi
po
19: confi
early term
sup
early term
scriptive s
to s
scriptive s
of the sec
ed t
of the sec
ber of wee
use
ber of wee
ver the 24
us
ver the 24
dpoint: Cu
t be
dpoint: Cu
0x10
ot b
0x109
t b
9/L o
t b
/L o
ment cond
not
ment cond
as assesse
ann
as assesse
needed to
can
needed to
evel summ
nt c
evel summ
2
m
2:
m
:
Int
n
Int
s d
Inte
d
Inte
d
s d
a)a)
s
application and any extensions or variations thereof.
vent.
va
vent.
vari
a
ermanent di
r va
ermanent di
rmed, susp
or 
rmed, susp
mination o
ons
mination o
statistics.
sio
statistics.
condary 
tens
condary 
eeks with 
exte
eeks with 
4
y
4-Week t
y ex
Week t
umulative
any
umulative
over the 2
d a
over the 2
ditions an
nd 
ditions an
ed multip
an
ed multip
o be obser
on a
o be obser
mary will
tion
mary will
ntercurre
icat
ntercurre
Missing 
plic
Missing 
with 
ppl
with 
tre
p
tre


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 37 of 85
Intercurrent Events (ICE)
ICE Strategy
Missing data strategy
c) Permanent treatment 
discontinuation
any of the ICE will be 
considered as having a loss 
of durable platelet response 
at the time of the ICE 
occurring.  
of durable platelet response 
at the time of the ICE 
occurring. Platelet data up 
to the start date of this ICE 
will be utilized in statistical 
analysis.
d) COVID-19* 
A composite strategy: data 
impacted by COVID-19 will 
be considered as having a 
loss of durable platelet 
response at the time of the 
ICE occuring.
Section 4.2.2
* COVID-19 Impact category: Temporary discontinuation of study drug, Permanent discontinuation of study drug, 
Termination of study participation and Relationship to COVID-19: confirmed, suspected, general or other as 
recorded in the COVID-19 impact eCRF form.
Population-level summary: Owing to early termination of the study, the population-level 
summary will be provided using descriptive statistics.
8.2.2
Time to first Clinically Meaningful Platelet Response of ≥50x109/L: time 
from starting treatment to achievement of first response of ≥50x109/L.
8.2.2.1
Definition
Time to first Clinically Meaningful Response of ≥50x109/L: time from starting treatment to 
achievement of first response of ≥50x109/L (computed as time from starting treatment to 
achievement of first response of ≥50x109/L: Date of first clinically meaningful response - Date 
of first treatment + 1)  
The visit date when the first clinically meaningful response was recorded will be considered as 
the date of first clinically meaningful response.
8.2.2.2
Estimand’s attributes 
This secondary efficacy endpoint will be analyzed using the RS, under the same treatment 
conditions and population as for the primary endpoint while using the ICE, ICES described in 
Table 8-3 and the population level summary described below:
Table 8-3:
Intercurrent Events (ICE), Intercurrent Events Strategies (ICES) and 
Missing data Strategies for the analysis of Time to first Clinically Meaningful 
Response of ≥50x109/L
Intercurrent Events (ICE)
ICE Strategy
Missing data strategy
a) Use of rescue therapy prior 
to Week 25
A while on-treatment 
strategy:  For participants 
impacted by any of the ICE 
(a, b and c). 
Impacted data will be 
excluded from the time at 
risk. 
Available platelet data up to 
the start date of this ICE will 
be utilized in statistical 
analysis. 
b) Withdrawal from the study 
due to treatment emergent
AE
c) Permanent treatment 
discontinuation
d) COVID-19* 
Composite Strategy: data 
impacted by COVID-19 will 
Section 4.2.2
PUBLIC COPY
l Platel
PY 
l Platel
evement
OPY
evement
onse of 
IC C
onse of 
10
BL
109
LI
9/L (c
LIC
/L (c
0x10
UBL
0x109
BL
9/L
L
/L
nical
P
nical
d to support any marketing authorization 
za
iza
ng
za
inuation of
ting
inuation of
 general or
ketin
 general or
y, the pop
mar
y, the pop
Respons
ny 
Respons
of first re
t any
of first re
≥50x10
ppo
≥50x109
po
9/L
po
/L
omputed a
supp
omputed a
Date of f
o su
Date of f
ment cannot be used
y meaning
ed 
y meaning
gful respon
use
gful respon
tributes 
e u
tributes 
ndpoint w
t be
ndpoint w
ion as for
not 
ion as for
opulation 
nno
opulation 
ntercurr
can
ntercurr
Missin
nt c
Missin
Resp
nt
Resp
rcurrent 
me
rcurrent 
me
ocum
Use of re
cum
Use of re
to Wee
ocu
to Wee
This doc m
b)
do
b) With
oc
With
du
du
oc
s d
s
ensions or variations thereof.
eo
f study drug
ere
f study drug
r other as
her
r other as
pulation
ns 
pulation l
se of ≥50x
riati
se of ≥50x
esponse o
aria
esponse o
L: time fro
s or
L: time fro
as time fro
ns 
as time fro
first clinic
ion
first clinic
ication and any exte
ngful respo
ten
ngful respo
onse.
ext
onse.
will be an
any
will be an
r the prim
d a
r the prim
n level sum
and
n level sum
rent Even
n a
rent Even
ng data St
tion
ng data St
ponse of 
atio
ponse of 
Events (I
plica
Events (I
ca
appli
escue ther
ppli
escue ther
ek 25
app
ek 25
applic
rawal f
ap
rawal f
ap


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 38 of 85
Intercurrent Events (ICE)
ICE Strategy
Missing data strategy
be excluded from the time at 
risk.
* COVID-19 Impact category: Temporary discontinuation of study drug, Permanent discontinuation of study drug, 
Termination of study participation and Relationship to COVID-19: confirmed, suspected, general or other as 
recorded in the COVID-19 impact eCRF form.
Population-level summary: Owing to early termination of the study, the population-level 
summary will be provided using descriptive statistics.  Median time to event will be estimated as 
median of observed values and also using the Kaplan-Meier estimate.
8.2.3
Clinically Meaningful Platelet Response by Day 8, defined as platelet count 
≥50x109/L
This secondary efficacy endpoint will be analyzed using the RS, under the same treatment 
conditions and population as for the primary endpoint while using the ICE, ICES described in 
Table 8-4 and the population level summary described below:
Table 8-4:
Intercurrent Events (ICE), Intercurrent Events Strategies (ICES) and 
Missing data Strategies for the analysis of Clinically Meaningful Response by 
Day 8
Intercurrent Events (ICE)
ICE Strategy
Missing data strategy
a) Use of rescue therapy up to 
Day 8
Composite strategy:
Participants impacted by 
any of these ICE will be 
considered as non-
responders.   
Participants with missing data 
due to any of these ICE will 
be considered as non-
responders.
b) TEAEs leading to permanent 
treatment discontinuation
c) Discontinue prior to receiving 
IMP
d) Study participant do not have a 
post-treatment assessment up 
to day 8 
e) COVID-19* 
Composite Strategy: 
Participants impacted by 
ICE (e) will be 
considered as non-
responders at the time of 
event.
Section 4.2.2
* COVID-19 Impact category: Temporary discontinuation of study drug, Permanent discontinuation of study drug, 
Termination of study participation and Relationship to COVID-19: confirmed, suspected, general or other as 
recorded in the COVID-19 impact eCRF form.
Population-level summary: Owing to early termination of the study, the population-level 
summary will be provided using descriptive statistics.
8.2.4
Response defined as platelet count ≥30x109/L and at least a 2-fold increase of 
the Baseline count confirmed on at least 2 separate occasions at two adjacent 
nominal visits at least 7 days apart, and absence of bleeding
Definitions:
a) Two adjacent nominal visits are defined as on-site visits where ITP bleeding scale 
assessment is performed
PUBLIC COPY 
sis 
Y
sis 
tegy
COP
tegy
OP
osite stra
CO
osite stra
cipants 
C C
cipants 
ny of the
LIC 
ny of the
conside
BLIC
conside
respo
UBL
respo
CO
UB
ve a 
PU
ve a 
PU
This document cannot be used to support any marketing authorization 
ated
or
ated as
ori
as
atelet cou
aut
atelet cou
ame treatm
ting
ame treatm
E, ICES d
keti
E, ICES d
Strategie
ma
Strategie
nically M
y m
nically M
a
egy:
or
egy:
mpacted b
ppo
mpacted b
e ICE wil
upp
e ICE wil
ed as non
sup
ed as non
nders.   
o su
nders.   
rt
us
Co
s
Co
us
us
us
an
us
ct category
can
ct category
study 
t c
study partic
c
partic
he COVID
nt 
he COVID
ation
me
ation-
me
-leve
e
leve
mmary wil
cum
mmary wil
8.2.4
doc
8.2.4
application and any extensions or variations thereof.
unt
f
unt
tment 
here
tment 
described
the
described
es (ICES
ons
es (ICES
Meaningf
atio
Meaningf
Missing 
var
Missing 
ar
by 
o
by 
ll be
s
ll be
-
Partic
r va
Partic
due
r 
due
b
va
or
o
omposite
y e
omposite
Participa
ny 
Participa
ICE (e
any
ICE (e
con
a
con
rere
ex
a d a
y: Tempora
n a
y: Tempora
cipation an
tion
cipation an
19 impact
atio
19 impact
el summa
lica
el summa
ll be prov
ppli
ll be prov
Re
pp
Re


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 39 of 85
b) Absence of bleeding indicated by Grade 0 for all domains of the SMOG, or a Skin Grade 
of 0 or 1 by visit
8.2.4.1
Estimand’s attributes 
Estimated on the RS. The same considerations mentioned in Section 8.2.3, except the endpoint 
which in this case is considered:  Response defined as platelet count ≥30x109/L and at least a 
2-fold increase of the Baseline count confirmed on at least 2 separate occasions at two adjacent 
nominal visits at least 7 days apart, and absence of bleeding. Endpoint will be descriptively 
summarized.
8.2.4.2
Sensitivity analysis
Sensitivity analysis will no longer be performed.
8.2.5
Time to first rescue therapy 
Definitions:
Time to first rescue therapy (in days) is defined as: Date of first rescue therapy use - Date of first 
treatment + 1. 
Participants who are withdrawn due to TEAEs will be censored at the start date of the TEAE, 
and participants who do not take rescue therapy will be censored at the date of withdrawal/study 
completion.  Where there are several AEs which led to drop out, consider the earliest starting 
AE.
8.2.5.1
Estimand’s attributes 
The same considerations for treatment conditions and population of interest as mentioned in 
items 1 and 2 in Section 8.1.1, except the endpoint which is described above and the following 
approach for ICE (see Table 8-5) and the population level summary:
Table 8-5:
Intercurrent Events (ICE), Intercurrent Events Strategies (ICES) and 
Missing data Strategies for the analysis of Time to first rescue therapy
Intercurrent Events (ICE)
ICE Strategy
Missing data strategy
a) Withdrawal from the study 
due to TEAE
A composite strategy:
Participants will be 
considered censored at the 
time of the ICE.
Not applicable
b) COVID-19* 
A composite strategy:
Section 4.2.2
* COVID-19 Impact category: Temporary discontinuation of study drug, Permanent 
discontinuation of study drug, Termination of study participation and Relationship to COVID-
19: confirmed, suspected, general or other as recorded in the COVID-19 impact eCRF form.
Population level summary: Endpoint will be descriptively summarized.  Median time to event 
will be estimated using the Kaplan-Meier estimate.
8.2.6
Change from Baseline to Week 25 in ITP-PAQ Symptom score 
Change in ITP-Patient Assessment Questionnaire (ITP-PAQ, see section 8.1.3.1 in the protocol 
for details) Symptom score will be calculated at week 25 relative to the Baseline and will be 
PUBLIC COPY 
ll be cen
OPY
ll be cen
y will be
COP
y will be
which led
C CO
which led
s 
B
s 
tment co
PUB
tment co
except 
PU
except 
a
P
a
ot be used to support any marketing authorization 
ent 
ri
ent 
ly 
h
ly 
escue ther
ma
escue ther
sored at th
any
sored at th
censored 
rt a
censored 
to drop ou
port
to drop ou
nditions a
to s
nditions a
the endpo
d to
the endpo
nd the pop
sed
nd the pop
vents (ICE
us
vents (ICE
Strategi
be u
Strategi
CE)
ot b
CE)
b
t cannot 
the study 
not 
the study 
ument c
ot
19*
nt
19*
t c
e
VID
m
VID-
m
-19 Im
me
19 Im
This docu
continuati
cum
continuati
19: confir
docu
19: confir
Popu
s do
Popu
wi
s 
wi
d any extensions or variations thereof.
rapy use
ions
rapy use
he
a
he start da
aria
start da
d at the da
var
d at the da
out, consid
or v
out, consid
and popul
nsio
and popul
oint which
ens
oint which
pulation l
xte
pulation l
E), Inter
y ex
E), Inter
ies for the
ny 
ies for the
ICE Stra
d an
ICE Stra
any
and a
A com
nd a
A com
Part
nd
Part
co
n
co
plication and a
and
ion
ca
mpact cat
plica
mpact cat
app
tion of stu
ppli
tion of stu
med,
ap
med, sus
pp
sus
lev
a
l


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 40 of 85
limited to the participants with a Baseline ITP-PAQ score available. Endpoint will be 
descriptively summarized. Please see Section 13.5 for details about ITP-PAQ scoring and ITP-
PAQ scales.
8.3
Statistical analysis of other efficacy endpoints
8.3.1
Cumulative number of weeks over the planned 24-Week treatment period 
with platelet counts ≥30×109/L and at least doubling from Baseline.
Cumulative number of weeks over the planned 24-Week treatment period with platelet counts 
≥30×109/L and at least doubling from Baseline will be summarized descriptively using the RS
and listed.  
The same considerations for treatment conditions and population of interest as mentioned in 
items 1 and 2 in Section 8.1.1, except the endpoint which is described above and the following 
approach for ICE (see Table 8-6) and the population level summary:
Table 8-6:
Intercurrent Events (ICE), Intercurrent Events Strategies (ICES) and 
Missing data Strategies for the analysis of cumulative number of weeks over 
the planned 24-Week treatment period with platelet counts ≥30×109/L and at 
least doubling from Baseline..
Intercurrent Events (ICE)
ICE Strategy
Missing data strategy
a) Use of rescue therapy prior to 
Week 25
Composite strategy:
Participants impacted 
by any of these ICE of 
interest will be 
considered as non-
responders.   
Participants with missing values 
due to any of these ICE of 
interest will be considered as 
non-responders.
b) TEAEs leading to permanent 
treatment discontinuation
c) Discontinue prior to receiving 
IMP
d) Study participant do not have 
a valid Baseline assessment
e) COVID-19* 
Composite Strategy: 
Participants impacted 
by ICE (e) will be 
considered as non-
responders at the time 
of event.
Section 4.2.2
8.3.2
Mean change from Baseline in platelet count by visit
Mean change from Baseline in platelet count will be summarized descriptively using the RS at 
each timepoint. 
8.4
Statistical analysis of exploratory endpoints
All exploratory variables will be listed only by treatment group and visit. No inferential 
assessments / testing will be performed. 
8.4.1
ITP Bleeding Score
8.4.1.1
ITP-specific Bleeding Assessment Tool (ITP-BAT) bleeding events and 
severity by visit
ITP-BAT bleeding events by visit, will be listed using the RS.    
PUBLIC COPY 
iod w
Y
iod w
tegy
CO
tegy
OP
osite stra
C CO
osite stra
icipants 
IC C
icipants 
y any of 
LIC
y any of 
interest
BLI
interest
consi
UB
consi
res
U
res
CO
PU
g
PU
g
U
PU
P
used to support any marketing authorization 
counts
tho
counts
ng the RS
uth
ng the RS
s mention
ing 
s mention
ve and the
eting
ve and the
trategies 
mar
trategies 
ulati
m
ulative nu
ma
ve nu
platelet c
ny m
platelet c
M
a
M
t a
egy:
po
egy:
mpacted 
ppo
mpacted 
hese ICE 
upp
hese ICE 
will be
sup
will be
dered as n
o s
dered as n
ponders.  
d to
ponders.  
ort
annot be us
Co
u
Co
P
ment can
us
an
u
Mean c
t ca
Mean c
ange from
ent
ange from
This docum
mepoint.
me
mepoint.
4
All exp
do
All exp
asse
s d
asse
extensions or variations thereof.
ned in
reo
ned in
e followin
here
e followin
 (ICES) a
ns 
 (ICES) a
umber of
ion
umber of
counts ≥3
iatio
counts ≥3
Missing d
va
Missing d
a
E of 
ns
E of 
non
si
non-
sio
-
 
Particip
or v
Particip
due to
or
due to
int
o
int
v
s o
s
d any e
omposite
y e
omposite
Participan
any 
Participan
by ICE
d any
by ICE
cons
d a
cons
re
d
re
application and
e
a d
change fr
tion
change fr
m Baseline
cati
m Baseline
Stati
pp
Stati
atory 
ap
atory 


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 41 of 85
Table 8-7:
ITP-specific Bleeding Assessment Tool (ITP-BAT) Domains and categories
Skin
Mucosal
Organ
- Petechiae
- Ecchymoses
- Subcutaneous 
Hematomas
- Bleeding from Minor 
Wounds
- Epistaxis
- Oral cavity [a]
- Subconjunctival 
Hemorrhage
- Gastrointestinal Bleeding Not 
Explained by Visible Mucosal Bleeding 
or Lesion
- Lung Bleeding
- Hematuria
- Menorrhagia
- Intramuscular Hematomas
- Hemarthrosis
- Ocular Bleeding
- Intracranial Bleeding
- Other Internal Bleedings
[a] Includes gum bleeding, hemorrhagic bullae or blisters, bleeding after bites to lip & tongue or 
after deciduous teeth loss
Notes: 
−
Presence of bleeding will be indicated by a Mucosae or Organs Grade ≥1, or Skin Grade 
≥2. 
−
Bleeding reported by the participant without medical documentation will be graded 1.
−
Within each domain, the same grade is assigned to bleeding manifestations of similar 
clinical impact. 
−
The “worst” bleeding manifestation since the last visit will be graded, and the highest 
grade within each domain will be recorded.
Please see Section 13.6  ITP bleeding score for more details.
8.4.1.2
ITP bleeding at Screening
Data collected in the Bleeding Assessment Tool – Screening eCRF will be listed using the RS.
8.4.1.3
Presence/Absence of ITP bleeding 
The number and percentage of participants with absence/presence of bleeding (see definitions 
below) will be summarized, and individual participants will be listed at each visit.
•
Presence of bleeding is indicated by a Grade of 1 or above, for at least one domain of the 
SMOG (except for Skin, where it is Grade 2 or above).
•
Absence of bleeding is indicated by Grade 0 for all domains of the SMOG, or a Skin Grade 
of 0 or 1
8.4.2
Effect of Rozanolixizumab on Health-Related Quality of Life (HRQoL)
8.4.2.1
European Quality of Life-5 Dimensions, 5 Levels (EQ-5D-5L) item responses
As described in section 8.1.3.4 in the protocol, the EQ-5D-5L health questionnaire consists of 2 
pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).
PUBLIC COPY 
Mucosa
OPY
Mucosa
t withou
C C
t withou
grade is 
LIC
grade is 
manifesta
PU
manifesta
in
P
in wi
P
wi
This document cannot be used to support any marketing authorization 
g
t
g
eedings
keti
eedings
ke
ter bites to
arke
ter bites to
e or Organ
any
e or Organ
medical 
por
medical 
assigned t
upp
assigned t
ion since 
d to
ion since 
be 
ed
be record
ed t
record
ding scor
use
ding scor
at Screen
be u
at Screen
eding Ass
ot b
eding Ass
nce/Abse
nno
nce/Abse
percentag
can
percentag
e summar
t ca
e summar
nce of ble
ent
nce of ble
MOG (exc
me
MOG (exc
Absenc
ocu
Absenc
of 0 
oc
of 0 
8.4.2
s d
8.4.2
application and any extensions or variations thereof.
th
to lip & to
s th
to lip & to
ans Grade 
aria
ans Grade 
documen
or v
documen
to bleedin
ns o
to bleedin
the last v
nsi
the last v
ded.
te
ded.
re for mor
ext
re for mor
ening
ny
ening
sessment
d an
sessment
ence of IT
and
ence of IT
age of 
n a
age of part
a
part
rized, and
ion 
rized, and
eeding is 
cati
eeding is 
cept for S
lica
cept for S
ce of bleed
app
ce of bleed
r 1
a
1


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 42 of 85
The descriptive system comprises five dimensions: mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight 
problems, moderate problems, severe problems and extreme problems. The patient is asked to 
indicate his/her health state by ticking the box next to the most appropriate statement in each of 
the five dimensions. This decision results in a 1-digit number that expresses the level selected for 
that dimension. The digits for the five dimensions can be combined into a 5-digit number that 
describes the patient’s health state.
The EQ VAS records the patient’s self-rated health on a vertical visual analogue scale, where the 
endpoints are labelled ‘The best health you can imagine’ and ‘The worst health you can 
imagine’. The VAS can be used as a quantitative measure of health outcome that reflect the 
patient’s own judgement.
The EQ-5D-5L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual 
analogue scale (EQ VAS).
Observed values in the European Quality of Life 5 Dimension 5 Levels (EQ 5D 5L) item 
responses and VAS scores will be listed only.
8.4.2.2
Short form 36-item (SF-36) domain and composite scores 
The SF-36v2, standard recall, measures the following eight health domains as rated by the 
subjects over the past four weeks: Physical Functioning, Role Physical, Bodily Pain, General 
Health, Vitality, Social Functioning, Role Emotional, and Mental Health. The classification of 
the questionnaire items to the health domains is shown in Section 13.7.
The SF-36 PCS and MCS scores are used to measure the two broad components, or aspects, of 
health-physical and mental. PCS and MCS are based on the aggregate of the eight health 
concepts described above and all of the eight health domain scales are used to score both 
components summary measures.
One additional item asks responders about health change over the past year.
The SF-36 will be used using QualityMetric’s Health Outcomes™Scoring Software. The 
software uses updated 2009 U.S. population norms and applies a Full Missing Score Estimation 
(Full MSE) method as follows:
•
A health domain score (except the PF domain) will be estimated provided that at least 
one non-missing response is available within that domain
•
For the PF domain item, response theory will be used to develop a model for estimates of 
the missing score
•
Regression methods are then applied to estimate the PCS and the MCS on the basis of the 
available domains.
A by-participant listings of SF-36 item responses will be provided. Missing data will not be 
imputed.
8.4.2.3
ITP-PAQ Domain Scores
The ITP-PAQ V1 consists of 44 items that comprise 10 scales. Each of the 10 scales is scored 0 
to 100 according to formula shown in section 13.5, with higher scores indicating better quality of 
PUBLIC COPY
n and c
PY 
n and c
owing e
COP
owing e
Function
CO
Function
Emotio
C C
Emotio
omains i
LIC
omains i
re used t
UBL
re used t
S and M
PUB
S and M
all of t
PU
all of t
This document cannot be used to support any marketing authorization 
where the
tho
where the
can
au
can
reflect the
au
reflect the
em and th
etin
em and th
vels (EQ 
mar
vels (EQ 
mposite s
any 
mposite s
ght health
rt a
ght health
ng, Role P
ort
ng, Role P
nal, and M
ppo
nal, and M
shown in
upp
shown in
o measure
o su
o measure
CS are bas
d to 
CS are bas
he eight h
ed t
he eight h
onders abo
e us
onders abo
ing Qualit
t be
ing Qualit
2009 U.S.
ot b
2009 U.S.
as follows
nno
as follows
domain s
can
domain s
on
t
on-
t
-missin
t ca
missin
or the PF 
en
or the PF 
the miss
me
the miss
•
c
•
Reg
u
Reg
A b
d
A b
im
s
im
application and any extensions or variations thereof.
e
o
e
he EQ vis
her
he EQ vis
5D 5L) it
ns 
5D 5L) it
scores
riat
scores
h domains
var
h domains
Physical, 
r v
Physical, 
Mental He
or 
Mental He
n Section
ns o
n Section
e the two 
sion
e the two 
ased on the
nsio
ased on the
health dom
ten
health dom
out health
y e
out health
ityMetric’
any
ityMetric’
. populati
d a
. populati
ws:
a
ws:
score (exc
n a
score (exc
ng respon
tion
ng respon
F domain i
cati
F domain i
sing score
plica
sing score
gres
ap
gres
a
sion m
pp
sion m
ailable 
ap
ailable 


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 43 of 85
life. Four of the scales measure physical health: Symptoms, Bother, Fatigue, and Activity. Two 
of the scales measure emotional health: Fear and Psychological Health. The remaining four 
scales measure other aspects of QOL: Work QOL, Social QOL, Women’s Reproductive QOL, 
and Overall QOL.
A by-subject listing of the ITP-PAQ V1 questionnaire, ITP-PAQ V1 item responses will be 
provided by treatment group. 
8.4.3
Hospitalization due to ITP / Number and length of hospitalizations
Hospitalizations will be listed.
8.4.4
Effect of Rozanolixizumab on Patient Reported Outcomes (PRO)
8.4.4.1
FATIGUE-PRO physical fatigue score 
The Fatigue Patient Reported Outcome (PRO) physical fatigue scale consists of 9 items. The 
scale is 1 out of the 3 scales composing the broader Fatigue instrument developed by UCB. Items 
are rated within a 7-day recall period on a 5-point Likert frequency scale ranging from “none of 
the time” to “all of the time.”
A by-subject listing of the FATIGUE-PRO items will be provided by treatment group.
8.4.4.2
Patient Global Impression of Severity (PGI-S)
The PGI-S consists of a single-state, self-report measure that rates a study participant's severity 
of specific condition, depicting a study participant's rating of overall symptoms (“none”, “mild”, 
“moderate”, “severe”, or “very severe”). 
A by-subject listing of PGI-S will be provided by treatment group. 
8.4.4.3
Patient Global Impression of Change (PGI-C)
The PGI-C is a single-state, self-report measure that reflects a study participant's belief about the 
efficacy of treatment for a specific condition. The PGI-C is a 7-point scale depicting a study 
participant's rating of overall improvement (“very much improved,” “much improved,” 
“minimally improved,” “no change,” “minimally worse,” “much worse,” or “very much worse”), 
was planned to be summarized at all available post-baseline visits using descriptive statistics by 
treatment groupon the RS. 
A by-subject listing of PGI-C will be provided by treatment group. 
The PGI-C sample questionnaire is available in the protocol, Appendix 18, Section 10.18.
9
PHARMACOKINETICS (PK) AND PHARMACODYNAMICS 
(PD)
9.1
Pharmacokinetics 
Individual plasma concentration of rozanolixizumab will be summarized by scheduled sampling 
day for the PK-PPS using n, arithmetic mean, median, SD, minimum, maximum, geometric 
mean (geomean), geometric coefficient of variation (geoCV) and 95% CI (assuming log-
normally distributed data) up to week 4.
The following rules will apply for PK data listings and summaries:
PUBLIC COPY
will be p
PY 
will be p
Severity
COP
Severity
eport me
C C
eport me
participa
LIC 
participa
e”).
BL
e”).
ll be pro
PUB
ll be pro
Impr
P
Impr
cannot be used to support any marketing authorization 
RO)
g
RO)
sists of 9
ket
sists of 9
nt develop
arke
nt develop
y sc
m
y scale ran
mar
ale ran
ovided by
any
ovided by
(PGI
rt a
(PGI-
t a
-S)
a
S)
asure that
por
asure that
nt's rating
upp
nt's rating
vided by t
to s
vided by t
ession of C
ed t
ession of C
report me
use
report me
cific cond
e us
cific cond
ll improv
be 
ll improv
“no chang
ot b
“no chang
mmarized
not
mmarized
the RS
ann
the RS.
This document c
isting of P
t ca
isting of P
C sample q
ent 
C sample q
P
9.1
do
9.1
Ind
s 
Ind
tion and any extensions or variations thereof.
items. Th
the
items. Th
ped by UC
s th
ped by UC
nging from
ons
nging from
y treatmen
riat
y treatmen
t rates a st
or 
t rates a st
g of overa
s o
g of overa
treatment 
nsio
treatment 
Change (
ten
Change (
easure tha
ext
easure tha
di
y
dition. Th
y e
tion. Th
vement (“v
any
vement (“v
ge,” “min
d an
ge,” “min
at all ava
nd 
at all ava
applicat
PGI
on
PGI-
on
-C wi
n 
C wi
questionn
atio
questionn
P
l
PHARM
plica
HARM
(PD)
ppl
(PD)
P
p
P


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 44 of 85
•
Values below the LLOQ will be reported as below the limit of quantification (BLQ)
•
Descriptive statistics of concentrations will be calculated if at most 1/3 of the individual data 
points at a timepoint are missing or are not quantifiable (<LLOQ). Values that are BLQ will 
be replaced by the numerical value of the LLOQ/2 in this instance. 
•
The 95% CI lower and 95% CI upper should be left blank if the SD (or equivalently, the 
geoCV) is 0
•
The geoCV will be calculated using the following formula where SD is the standard 
deviation from the log-transformed data
geoCV (%) = sqrt[(exp (SD^2) – 1)] x 100
Individual concentrations of rozanolixizumab will be listed for the RS for each individual with 
the actual time and will include the equivalent dose and actual dose being administered previous 
to the pk sample, the sampling time in days relative to the previous dose, the IgG observed at the 
same visit, the ADA titer observed for the binding assay and the NAb titer for the same visit and 
platelet count for the corresponding visit.  
9.2
Antidrug antibodies (ADA)
The immunogenicity analysis should be done on the safety set SS. Samples from study 
participants on placebo will not be tested for anti-drug antibodies.
Anti-rozanolixizumab antibodies will be measured using a three-tiered assay approach: screening 
assay, confirmatory assay and titration assay. Samples will first be evaluated in the screening 
assay (reported as ‘negative screen’ or ‘positive screen’), followed by analysis of screened 
positive samples in the confirmatory assay to confirm the true positivity of the samples (reported 
as ‘negative immuno-depletion’ or ‘positive immuno-depletion’). Samples that are confirmed as 
positive in the confirmatory assay will be evaluated in a titration assay to quantify the ADA level 
and will be reported as titer (reciprocal dilution factor including minimum required dilution 
(MRD)). Any sample confirmed positive for ADA within the confirmatory assay will be further 
evaluated for the presence of neutralizing anti-rozanolixizumab antibodies. 
Screening, confirmatory, and titer cut points of the respective assays will be determined by the 
bioanalytical laboratory. The relevant statistical reports will be provided as part of the 
bioanalytical reports. Rozanolixizumab has the potential to interfere with the antibody assay at 
concentrations above the drug tolerance limit (DTL); therefore, an integrated evaluation of anti-
rozanolixizumab antibody results and rozanolixizumab plasma concentration will be used to 
enable the interpretation of immunogenicity results.The ADA sample status will be determined 
for each visit where samples were taken for ADA analysis: 
•
Sample values that are either ‘negative screen’ or the combination of ‘positive screen’ 
and ‘negative immunodepletion’, will be defined as ADA negative if corresponding 
rozanolixizumab concentrations are equal or below the validated drug tolerance limit of 
the ADA assay (
 rozanolixizumab) allowing detection of 100ng/mL ADA
•
Sample values that are either ‘negative screen’ or the combination of ‘positive screen’ 
and ‘negative immuno-depletion’, but with corresponding rozanolixizumab 
PUBLIC COPY 
n the sa
COP
n the sa
r anti
CO
r anti-
CO
-dru
CO
dru
e measur
LIC 
e measur
n assay
BLIC
n assay
C
n’ or ‘po
UBL
n’ or ‘po
atory as
PU
atory as
 or ‘p
P
 or ‘p
not be used to support any marketing authorization 
ch individ
ting
ch individ
g administ
keti
g administ
se, the IgG
arke
se, the IgG
Ab titer fo
mar
Ab titer fo
ety set SS
rt a
ety set SS
g antibod
port
g antibod
ed using a
upp
ed using a
Samples w
sup
Samples w
sitive scre
o s
sitive scre
ay to con
d to
ay to con
ositive im
ed t
ositive im
will be ev
sed
will be ev
ciprocal d
us
ciprocal d
med posit
be u
med posit
e of neutra
t be
e of neutra
ry, and tit
not 
ry, and tit
This document cann
tory. The 
nno
tory. The 
orts. Roza
can
orts. Roza
s above th
t ca
s above th
zumab ant
ent 
zumab ant
he interpr
men
he interpr
ch visit 
ume
ch visit w
e
w
•
oc
•
Sam
u
Sam
nd any extensions or variations thereof.
dual with
ere
dual with
tered prev
the
tered prev
G observ
s th
G observ
or the sam
ons 
or the sam
S. Sample
var
S. Sample
dies.
or
dies.
a three
s o
a three-
o
-tie
o
tie
will first 
ons
will first 
een’), foll
sion
een’), foll
nfirm the t
nsi
nfirm the t
mmuno
ten
mmuno-
n
-de
de
valuated i
exte
valuated i
dilution fa
y ex
dilution fa
tive for A
ny 
tive for A
ralizing an
any
ralizing an
ter cut poi
d a
ter cut poi
lication an
e relevant 
and
e relevant 
zanolixizu
n a
zanolixizu
he drug to
ion 
he drug to
tibody res
atio
tibody res
retation o
icat
retation o
appl
where sam
plic
where sam
ample valu
app
mple valu
d ‘neg
ap
d ‘neg


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 45 of 85
concentrations above the validated drug tolerance limit of the ADA assay, will be defined 
as ADA inconclusive 
•
Sample values that are ‘positive screen’ and ‘positive immunodepletion’ will be defined 
as ADA positive
•
Samples that could not be tested for ADA status due to inadequate sample volume, 
mishandling, or errors in sample collection, processing, storage, etc., will be defined as 
Missing 
•
Neutralizing antibody (NAb) sample status (positive/negative/missing) will be 
determined for ADA positive samples. Samples that are NAb positive will be evaluated 
in a titration assay to quantify the NAb level and will be reported as titer.
The ADA participant status will be classified on individual and group level as outlined below 
(Shankar et al. 2014; Rup et al, 2015). A description of how study participants will be 
categorized for the immunogenicity assessment is provided in Table 9-1. 
Individual study participants will be assessed for ADA participant status, composed of 6 
categories: ADA negative, inconclusive, and ADA positive, whereby a positive participant’s 
status is determined as originating from a treatment-induced, boosted, reduced or unaffected 
ADA response.
Study participants who are identified as being treatment-induced or treatment-boosted ADA-
positive will be grouped as treatment emergent (TE)-ADA positive participants. Study 
participants who are identified as being treatment-reduced or treatment-unaffected ADA-positive 
will be grouped as non-TE-ADA positive participants. Both TE-ADA positive and non-TE–ADA 
positive participants will be further classified as NAb negative or NAb positive.
The individual and combined ADA participant categories will be summarized overall through the 
SFU sample if applicable (timepoint of interest). The ADA categories are defined in Table 9-1
below.
Notes:
−
The ADA sample status should be determined for each visit where samples were taken 
for ADA analysis.
ADA Baseline
By default, the Day 1 will be the Baseline value if the ADA status at screening is ADA negative 
or missing. If the ADA status at screening is ADA positive and ADA status at Day 1 is ADA 
negative or missing, the screening will be the Baseline value. If the ADA status at screening and 
Day 1 are same, Day 1 will be the Baseline value.  
Table 9-1:
Terms and Definitions for ADA Status Evaluation in Study Participants
Term
Definition
Category
Individual participant categories
BLIC COPY 
ositiv
Y
ositiv
nt
OP
nt-
P
-induce
OPY
induce
ng treatm
C CO
ng treatm
mergent (
IC 
mergent (
PUB
ng
BL
ng treatm
BLIC
treatm
ositive p
UBL
ositive p
ther clas
PUB
ther clas
D
P
DA
P
A
support any marketing authorization 
as
ri
as
e 
a
e 
be evalua
au
be evalua
er.
n
er.
l as outlin
etin
l as outlin
cipants wi
rket
cipants wi
9-
a
-1
a
1.
ar
.
nt status, c
ma
nt status, c
whereby a 
ny m
whereby a 
d, boosted
any
d, boosted
ment
po
ment-
po
-induc
por
induc
TE)
p
TE)-
p
-ADA
pp
ADA
ment cannot be used to 
ent
su
ent-
u
-reduc
sup
reduc
articipant
o su
articipant
ified as N
d to 
ified as N
participan
ed 
participan
int of inte
use
int of inte
ple status
not 
ple status
alysis.
nno
alysis.
the Day 
ent 
the Day 
ng. If the 
men
ng. If the 
This docum
tive or mi
ume
tive or mi
ay 1 are sa
cum
ay 1 are sa
Tabl
do
Tabl
s
s or variations thereof.
uated 
of
uated 
ned below
here
ned below
will be 
th
will be 
composed
tion
composed
a positive 
iatio
a positive 
d, reduce
aria
d, reduce
ced or tre
or v
ced or tre
A positive 
s o
A positive 
lication and any extensions
ced or trea
ns 
ced or trea
ts. Both T
sion
ts. Both T
NAb nega
nsio
NAb nega
nt categor
xten
nt categor
erest). Th
ext
erest). Th
s should b
nd a
s should b
1 will be 
atio
1 will be 
e ADA sta
icat
e ADA sta
appl
issing, the
plic
issing, the
same, Day
pp
same, Day


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 46 of 85
Table 9-1:
Terms and Definitions for ADA Status Evaluation in Study Participants
Term
Definition
Category
Pre-ADA negative – treatment induced 
ADA negative (ADA-NEG)
Study participants who have an ADA negative sample 
at Baseline and at all sampling points post-Baseline up 
to the timepoint of interest. 
1
Inconclusive
Study participants who have an ADA positive or 
negative Baseline sample and some post-Baseline 
samples are missing or inconclusive, while other post-
Baseline samples are ADA negative up to the 
timepoint of interest.
2
Pre-ADA negative – treatment induced 
ADA positive (TI-POS)
Study participants who have an ADA negative sample 
at Baseline and at least one ADA positive sample at 
any sampling point post-Baseline up to the timepoint 
of interest 
3
Pre-ADA positive – treatment boosted 
ADA positive (TB-POS)
Study participants who have an ADA positive sample 
at Baseline and at least one ADA positive sample at 
any sampling point post-Baseline up to the timepoint 
of interest, with increased titer values compared to 
Baseline (greater than a predefined fold difference 
increase from Baseline value which will be defined 
within the validation of the assay ie MSR of the 
assay1) 
4
Pre-ADA positive – treatment reduced 
ADA positive (TR-POS)
Study participants with an ADA positive sample at 
Baseline, and ADA negative samples at all sampling 
points post-Baseline up to the timepoint of interest 
5
Pre-ADA positive – treatment unaffected 
ADA positive (TU-POS)
Study participants with an ADA positive sample at 
Baseline and an ADA positive sample at any sampling 
point post-Baseline up to the timepoint of interest, 
with titer values of the same magnitude as Baseline 
(less than a predefined fold difference from the 
Baseline value which will be defined within the 
validation of the assay, ie MSR of the assay1)
6
Combined participant categories
Treatment emergent ADA positive (TE-
POS)
Includes study participants who are treatment induced 
ADA positive (category 3) or treatment boosted ADA 
positive (category 4).
7
Non-treatment emergent ADA positive 
(Non-TE-POS)
Includes study participants who are treatment reduced 
ADA positive (category 5) or treatment unaffected 
ADA positive (category 6).
8
Treatment emergent ADA positive –
NAb positive (TE-POS, NAb-POS)
Includes study participants who are treatment 
emergent positive (category 7) and have at least one 
NAb positive sample
9
PUBLIC COPY
pan
Y
pan
and at 
PY 
and at 
pling po
OPY
pling po
erest, wi
COP
erest, wi
aseline (g
CO
aseline (g
increase
C C
increase
withi
LIC
withi
as
L
as
BL
uced 
PUB
uced 
UB
This document cannot be used to support any marketing authorization 
y
n
y
n
on
er post
uth
er post-
t
-
he 
he 
2
ori
2
riz
o
A negative
eting
A negative
positive sa
ket
positive sa
ne up to th
arke
ne up to th
ng
ha
y
have an A
y m
ve an A
ast one AD
ny 
ast one AD
nt post
t an
nt post-
an
-Bas
ny
Bas
h increased
rt a
h increased
eater than 
port
eater than 
from Base
ppo
from Base
the valida
upp
the valida
ay
ay1
s
1)
s
)
m
Study par
to 
Study par
Baseli
d t
Baseli
poi
d
poi
o s
ed
affected 
us
affected 
se
participa
nt c
participa
c
ent
m
ent emerg
men
emerg
S)
u
S)
en
Non
doc
Non-
o
-tre
c
tre
(Non
d
(Non
oc
s d
application and any extensions or variations thereof.
of
e sample
here
e sample
ample at 
the
ample at 
he timepo
s th
he timepo
re
ADA positi
atio
ADA positi
DA positiv
riat
DA positiv
aseline up t
aria
aseline up t
d titer valu
va
d titer valu
n a predefin
or v
n a predefin
liline value
or
ne value
ation of th
ns o
ation of th
on
articipants 
nsio
articipants 
ine, and A
tens
ine, and A
in
x
ints post
xte
ts post-
e
-B
io
Study pa
y ex
Study pa
Basel
ny e
Basel
poi
ny
poi
xt
ny
ant catego
tio
ant catego
on
gent ADA 
ica
gent ADA 
at
ment em
ap
ment em
S
ap


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 47 of 85
Table 9-1:
Terms and Definitions for ADA Status Evaluation in Study Participants
Term
Definition
Category
Treatment emergent ADA positive –
NAb negative (TE-POS, NAb-NEG)
Includes study participants who are treatment 
emergent positive (category 7) and have no NAb 
positive samples
10
Non-treatment emergent ADA positive -
NAb positive (Non-TE-POS, NAb-POS)
Includes study participants who are non-treatment 
emergent positive (category 8) and have at least one 
NAb positive sample
11
Non-treatment emergent ADA positive -
NAb negative (Non-TE-POS, NAb-
NEG)
Includes study participants who are non-treatment 
emergent positive (category 8) and have no NAb 
positive samples
12
1 The fold difference increase from baseline value, ie the minimum significant ratio (MSR) determined during assay 
validation, will be reported in the relevant tables, listings and figures. It reflects the fold difference in titer level that 
considered higher than the assay variation in titer determination.
The following outputs will be created:
Summaries on the SS:
Tables:
•
Number and percentage of participants in the RLZ arm with positive, negative, inconclusive 
or missing sample ADA status at the time of each visit will be summarized overall. 
Denominator is the number of study participants having a non-missing result at that visit. 
•
Number and percentage of participants in the RLZ arm in each of the ADA individual 
categories (1 to 6) and combined (7-12) presented above will be summarized overall. 
Denominator will be the total number of study participants having an individual ADA 
participant category defined
•
Summary tables displaying the total prevalence of pre-existing ADA and NAb, and persistent 
ADA positivity in the RLZ arm, as defined below:
-
Total prevalence of pre-existing ADA and NAb: number and percentage of participants 
having an ADA positive sample status at baseline, with the denominator being the total 
number of study participants having a non-missing sample result at baseline. The same 
will be repeated for NAb.
-
Persistent ADA positivity: Number and percentage of study participants with treatment-
induced ADA positive samples detected at 2 or more sequential sampling time points 
during the treatment (including observation and off-treatment periods), where the first 
and last ADA positive samples are separated by at least 16 weeks (equal to 5 half-lives of 
human IgG [22 days], as per Rup et al., 2015).
PUBLIC COPY 
s
C
s in the R
C C
in the R
he time o
LIC
he time o
tudy par
BL
tudy par
participa
PUB
participa
bined
PU
bined
be used to support any marketing authorization 
y
n
y
n
on
ne
th
ne
11
ori
11
riz
o
eatment
g a
eatment
e no NAb
ing 
e no NAb
au
et
SR) determ
ket
SR) determ
fold differe
ark
fold differe
LZ
pp
LZ ar
ppo
arm
po
m
f each vis
upp
f each vis
icipants h
sup
icipants h
nts
d t
nts in the R
to 
in the R
(7
e
(7-
d
-12) pre
ed t
12) pre
number of
sed
number of
This document cannot b
ying the to
be 
ying the to
e RLZ arm
ot b
e RLZ arm
ence of pr
nno
ence of pr
ADA pos
ann
ADA pos
r of study
t ca
r of study
be repeat
nt c
be repeat
Persistent
men
Persistent
induce
um
induce
dur
u
dur
ny extensions or variations thereof.f
12
of.
12
f
he
of
mined durin
the
mined durin
ence in titer
s t
ence in titer
with posit
or 
with posit
sit will be
ns o
sit will be
having a n
ions
having a n
RLZ arm
nsio
RLZ arm
esented ab
ten
esented ab
f study pa
exte
f study pa
pplication and any
otal preva
any
otal preva
m
d
m, as def
d an
, as def
re
a
re-
n
-existing
and
existing
ositive sam
n an
ositive sam
y participa
on 
y participa
ted for NA
atio
ted for NA
nt ADA po
lica
nt ADA po
ed ADA 
plic
ed ADA 
c
ap
ring the tr
app
ring the tr
d last A
ap
d last A


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 48 of 85
Listings:
Listings by timepoint using the SS will be created. The following datapoints will be included:
-
Rozanolixizumab concentration
-
Total IgG, and absolute platelet counts 
-
ADA screening results (with the confirmatory result, the ADA titer result if applicable 
and the ADA sample status) 
-
NAb result titer (when performed)
-
Time since administration of IMP (in days)
-
Individual ADA participant classification that apply (as defined above)
-
Previous visit actual dose (mg/kg equivalent) and actual dose (mg) 
-
By-subject listing of immune-Related TEAEs, TEAEs of hypersensitivity reaction, 
anaphylactic reaction, injection site reaction, or autoimmune disorder anti-drug 
antibodies, the time of onset, the ADA and NAb sample status and ADA and NAb titers 
at the closest sampling time point prior to and subsequent to the TEAE, and time since 
last administration of IMP (in days).
-
Notes:  Study physician/safety physician/safety lead will mark the Preferred Term of 
immune related AEs based on an excel output of all TEAEs (blinded) after database lock. 
The marked AEs will be used for the summary.
9.3
Pharmacodynamic endpoints (PD) 
The following pharmacodynamic endpoints will be based on the SS.
9.3.1
Total serum IgG (absolute value) and change from Baseline (absolute value 
and percentage) in serum IgG and in serum IgG subclass concentration at 
each scheduled assessment
Total serum IgG concentrations will be summarized and listed on the SS by time point for 
absolute values, change from Baseline, and percentage change from Baseline overall and 
stratified by body weight tier. 
IgG subclasses will be listed on the SS by treatment group, and time point for absolute values, 
change from Baseline, and percentage change from Baseline overall 
9.3.2
Serum immunoglobulin concentrations (IgA, IgE, IgM) at each scheduled 
assessment
Immunoglobulins (IgE, IgA and IgM) will no longer be summarized; IgE, IgA and IgM 
concentrations will be listed only.
PUBLIC COPY
Ab s
Y
Ab s
PY
nd subs
PY 
nd subs
cian/safe
CO
cian/safe
excel ou
C C
excel ou
for the su
LIC
for the su
mic endp
UBL
mic endp
mic endp
PU
mic endp
cument cannot be used to support any marketing authorization 
le
r
le
e)
ti
e)
g)
k
g)
ersensitiv
ark
ersensitiv
ne disorde
ma
ne disorde
e status an
y m
e status an
any 
quent to th
any
quent to th
ty lead wi
port
ty lead wi
put of all 
ppo
put of all 
mmary.
supp
mmary.
points (PD
to s
points (PD
oints will
d to
oints will
absolute 
sed
absolute 
) in serum
us
) in serum
ed assess
be u
ed assess
trations w
ot b
trations w
ge from B
not
ge from B
weight tie
ann
weight tie
s will be l
t ca
s will be l
m Baseline
nt c
m Baseline
S
n
S
This doc
Immunog
docu
Immunog
concen
do
concen
cation and any extensions or variations thereof.
vity reacti
ns t
vity reacti
der anti
ions
der anti-
n
-dr
s
dr
nd ADA a
atio
nd ADA a
ri
the
ri
the TEAE
riat
TEAE
will mark t
or v
will mark t
l TEAEs (
s or
l TEAEs (
PD) 
si
PD) 
l be based
ens
l be based
value) an
exte
value) an
m IgG an
y ex
m IgG an
ment
ny
ment
will be sum
d an
will be sum
Baseline, 
nd 
Baseline, 
er.
a
er.
listed on t
on 
listed on t
ne, and per
atio
ne, and per
pplic
erum im
lica
erum im
assessm
plic
assessm
ap
lobulins (
app
obulins (
ons w
ap
ons w


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 49 of 85
9.4
Influence of Rozanolixizumab on vaccination titers
9.4.1
Vaccination titers against Streptococcus pneumoniae, Neisseria meningitidis, 
and Haemophilus influenzae in splenectomized study participants
Vaccine specific antibodies concentrations will be listed to capture absolute in vaccination titers 
against Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae in 
splenectomized study participants by visit using the SS.
9.4.2
Percent change from Baseline in vaccination titers against tetanus in all 
study participants
Anti-tetanus toxoid serum titers will be listed to capture absolute values and the percent change 
from baseline in vaccination titers against tetanus in all study participants by visit using the SS.
10
SAFETY ANALYSES
All safety analyses will be presented using the SS. Listings will be presented by period, 
treatment group and participant; tabulations will be presented by period (treatment and safety FU 
Period) and treatment group. 
Unless otherwise specified, safety analyses will be presented by safety treatment group as 
defined in Section 3.6.
For results disclosure on public registries (eg. ClinicalTrials.gov), treatment-emergent adverse 
events and treatment-emergent serious adverse events will be published.
10.1
Extent of exposure
The following summary will be created using the SS by treatment group:
a) Study IMP duration and Subject-Years of Time at Risk will be summarized using 
descriptive statistics. 
-
The number of days on IMP (extent of exposure), will be summarized using 
descriptive statistics for the overall treatment period.  
The number of days on IMP will be calculated as follows:  
Number of days on IMP = [(Date of Last Dose Received) - (Date of First Dose 
Received)] + 1
In all calculations, if a patient dies and the date of death is missing, the date of 
death can be imputed as the date of last infusion of the treatment the participant 
was taking.
-
Subject-Years of Time at Risk: 
o
For study participants who complete the study as planned and continue 
into an open label study (and, therefore, do not have the SFU visit in the 
parent study)
Date of last visit – Date of first dose + 1
o
For study participants who die prior to the final visit
PUBLIC COPY 
e present
OPY
e present
eg. Clini
C CO
eg. Clini
dverse e
LIC 
dverse e
e
B
e
created 
PUB
created 
Sub
P
Sub
This document cannot be used to support any marketing authorization 
in
za
in
all 
th
all 
e percent 
g au
e percent 
visit using
ing 
visit using
esented b
ark
esented b
eriod (tre
ma
eriod (tre
ed by safe
any
ed by safe
calTrials.g
por
calTrials.g
vents will 
pp
vents will 
using the 
d to 
using the 
ect
ed
ect-
ed
-Y
ed
Years
d 
ears
f days on 
be u
f days on 
statistics 
t be
statistics 
umber of d
not 
umber of d
umber of d
ann
umber of d
Received)
can
Received)
In a
nt
In a
d
cation and any extensions or variations thereof.
change
of.
change
g t
r
g the SS.
reo
he SS.
by period,
ns t
by period,
eatment an
ons
eatment an
ety treatm
aria
ety treatm
gov), trea
or v
gov), trea
l be publis
s o
l be publis
SS by tre
nsio
SS by tre
rs of Time
xten
rs of Time
IMP (ext
ny e
IMP (ext
for the ov
any
for the ov
days on I
nd a
days on I
days on IM
an
days on IM
d)] + 1
on a
d)] + 1
all calcul
atio
all calcul
applic
death can
lica
death can
was ta
pplic
was ta
-
ap
-
Su
pp
Su


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 50 of 85
Date of death – Date of first dose + 1
o
For all other study participants, use the minimum of the following:
Date of last dose – Date of first dose + 56
Date of last clinical contact – Date of first dose + 1
o
This last group could include study participants who discontinue early, 
study participants who complete the study as scheduled but choose not to 
continue into an open label study, or study participants who are ongoing in 
the SFU period at the time of the data snapshot.
-
The total time at risk is calculated as the sum of the person-time at risk (days) 
across all participants in the population divided by 365.25.
As described in the protocol, a fixed-unit doses across body weight tiers and treatment arms will 
be employed in this study according to the following scheme, as presented in Table 10-1 below
Table 10-1:
TP0006 dose levels and weight tiers of rozanolixizumab
Bodyweight
Starting dose
Maintenance dose
level 1
Maintenance 
dose
level 2
Maintenance 
dose level 3
>35 to <50kg
No weight
adjustment
≥50 to <70kg
≥70 to <100kg
≥100kg
Note: the starting dose of
 is not applicable in Protocol Amendment 3, but is applicable 
in earlier protocol versions.
If a study participant is in the lowest body weight tier (below 50kg) and is on the lowest dose 
level with a platelet count between >150×109/L and <400×109/L, the investigator might decide to 
temporarily stop treatment according to medical judgement based on the observation of platelet 
variability. If the platelet count increases above 400×109/L then treatment must be stopped 
anyway.
The placebo arm will use 0.9% sodium chloride aqueous solution (physiological saline, 
preservative free) for sc administration, matching the volumes of the rozanolixizumab arm.
A listing with all drug administration details including date, start and stop time of infusion, 
interruptions, discontinuations, dose, volume delivered, percent of planned dose and reasons for 
any interruptions or discontinuations will be created using the SS. 
10.2
Adverse events
10.2.1
Data considerations
Adverse events will be recorded from the time of informed consent until study completion. All 
AEs will be coded (Section 3.8).
In addition, AEs will be classified according to the Common Terminology Criteria for Adverse 
Events (CTCAE) Version 5 or later for severity. For any AEs where it is not possible to provide 
COPY 
ance dos
PY
ance dos
evel 1
OP
evel 1
PY
PU
 is
PU
 is
PUBLIC C
PU
ort any marketing authorization 
,
not to 
horiz
not to 
ongoing in
tho
ongoing in
at risk (da
g a
at risk (da
and treatm
keti
and treatm
nted in
arke
nted in Ta
e
Ta
izumab
ma
izumab
Mai
ny
Mai
m
a y 
This document cannot be used to
to
not applic
ed t
not applic
owest bod
e us
owest bod
etween >1
be 
etween >1
nt accordi
ot b
nt accordi
elet count 
not 
elet count 
m will us
ca
m will us
 free) for 
nt c
 free) for 
g with all 
men
g with all 
ruptions, d
um
ruptions, d
ny interrup
cu
ny interrup
10.2
do
10.2
10.
s 
10.
to suppor
r variations thereof.
ays)
eof
ays)
ment ar
the
ment arms
e
ms
able
s t
able 10
th
10-1
h
1
ntenance 
ria
ntenance 
dose
var
dose
level
va
level
tio
iat
application and any extensisi
cable in P
tens
cable in P
dy weight
y ex
dy weight
150×10
ny 
150×109
y
9/
ing to me
d an
ing to me
t increases
nd a
t increases
se 0.9% so
on a
se 0.9% so
r sc admin
tion
r sc admin
l drug adm
icat
l drug adm
discontin
plic
discontin
ptions or 
app
ptions or 
A
p
A
sions or v


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 51 of 85
a CTCAE grading, the events will be assessed using a standard intensity classification (mild, 
moderate and severe). For the purpose of the tabulations all CTCAE severity classifications will 
be mapped to a mild/moderate/severe grade as described below: 
CTCAE Toxicity Grade: Severity 
−
Grade 1: Mild
−
Grade 2: Moderate
−
Grade 3, 4, 5: Severe
−
Not gradable
In summaries including intensity, the categories will be summarized according to the following:
Grade: Intensity 
−
Grade 1: Mild
−
Grade 2: Moderate
−
Grade 3: Severe 
For AEs that were not classified according to the CTCAE Toxicity (Severity) criteria, the 
standard intensity Grade will be applied. In case there are mismatches between Severity and 
Intensity Grade, the worst case (i.e., the most severe grade) will be applied.
Treatment-emergent AEs are defined as AEs starting after the time of first IMP administration up 
to and including 8 weeks (56 days) after the final dose.
AEs before first dosing and AEs after 8 (56 days) weeks following the final dose will be 
combined in one category and listed.
Where dates are missing or partially missing, AEs will be assumed to be treatment-emergent 
unless evidence exists that does not allow the AE to be treatment-emergent. Handling of missing 
dates for classification of AEs as TEAEs is described in Section 4.2.2 .
The following rules will be used to assign a TEAE to a study period: 
TEAE-Treatment Period: a TEAE will be assigned to the Treatment Period for the tabulations 
if the start date of the event is on or after the date of the first administration of IMP on Day 1, up 
to 7 days following the final dose of IMP. 
TEAE-Safety Follow up Period: a TEAE will be assigned to the Safety Follow up Period for 
the tabulations if the start date of the event is greater than 7 days after the date of the final dose 
of IMP until 8 weeks following the final dose; events starting later than 8 weeks following the 
final dose of IMP are not considered TEAEs.
In the case of early withdrawal in the Treatment Period, a TEAE will be assigned to the 
Treatment Period based on the last received infusion plus 7 days. Subsequent TEAEs (up to 8 
weeks post-last dose) will be assigned to the Safety Follow up Period.
A TEAE will be counted as a TEAE related to IMP if the response to the question “Relationship
to Study Medication” is “Related”. 
AEs will be presented as “number of participants (percentage of participants) [number of 
events]”.  In this style of output, “[number of events]” will include all cases of an AE including 
repeat occurrences in individual participants, while “number of participants” will count each 
participant only once. AE analysis will be summarized by Treatment and follow up periods.
PUBLIC COPY 
rad
Y
rad
ng after 
OPY
ng after 
al dose.
COP
al dose.
days) w
C CO
days) w
missing
BLI
missing
ot allow
UB
ot allow
as TEA
PU
as TEA
P
document cannot be used to support any marketing authorization 
e followin
auth
e followin
Severity) c
ark
Severity) c
hes betwe
ma
hes betwe
 be applie
y m
 be applie
he time o
any
he time o
eeks follo
por
eeks follo
AEs will
sup
AEs will
the AE to
to s
the AE to
s is descr
d to
s is descr
assign a T
sed
assign a T
TEAE will
e us
TEAE will
is on or af
be 
is on or af
nal dose o
t b
nal dose o
w up Peri
no
w up Peri
he start d
ann
he start d
weeks fol
can
weeks fol
IMP are 
nt c
IMP are 
se of
men
se of earl
en
earl
ment Peri
ume
ment Peri
eeks post
cum
eeks post
This do
A TEA
doc
A TEA
to St
s d
to St
A
plication and any extensions or variations thereof.
ng
f
ng
criteria, th
ns t
criteria, th
ween Sever
ons
ween Sever
ed.
ati
ed.
of first IM
aria
of first IM
owing the
or v
owing the
l be assum
ons
l be assum
o be treatm
sio
o be treatm
ribed in
ns
ribed in S
TEAE to 
xte
TEAE to 
ll be assig
y ex
ll be assig
after the d
ny 
after the d
of IMP.
d any
of IMP.
iod
nd
iod: a TE
nd 
: a TE
date of the
an
date of the
llowing th
on a
llowing th
not cons
tion
not cons
rly withdr
icat
rly withdr
riod based
plic
riod based
app
last dose
pp
last dose
will be
ap
will be


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 52 of 85
10.2.2
Adverse Event Summaries 
The number and percentage of participants who experience AEs will be summarized by 
treatment group. The following outputs will be created:
(1) Incidence of TEAEs (defined as the number and percentage of participants with at least 
one TEAE (incidence proportion)) – Overview. The following categories will be included 
by treatment arm: 
-
Any TEAEs
-
AESMs
-
AESIs
-
Serious TEAEs 
-
TEAEs leading to Study Discontinuation
-
Permanent withdrawal from IMP due to TEAEs
-
Drug-related TEAEs
-
TEAEs with CTCAE Grade 3 and above [or rated as ‘severe’ for events with no 
CTCAE classification] 
-
All Deaths (AEs leading to death)
-
All Deaths (TEAEs leading to death)
-
TEAEs leading to dose modification (defined as TEAEs with an action taken with 
study medication of “dose increased” or “dose decreased”)
-
TEAEs resulting in temporary treatment interruption
The following summaries will be created by SOC, HLT and PT
(2)
Incidence of fatal TEAEs by relationship 
(3)
Incidence of Serious TEAEs by Relationship 
(4)
Incidence of TEAEs leading to permanent discontinuation of IMP 
(5)
Incidence of Non-Serious TEAEs Above Reporting Threshold of 5% of participants by 
System Organ Class and Preferred Term
−
AESIs are Potential Hy’s Law, defined as ≥3xULN ALT or AST with coexisting 
≥2xULN total bilirubin in the absence of ≥2xULN ALP, with no alternative explanation 
for the biochemical abnormality.
−
AESMs are severe headache, severe GI disturbance (ie, diarrhea, abdominal pain, 
vomiting), opportunistic infections, arterial and venous thrombotic and thromboembolic 
events.
−
AESMs and AESIs will be identified based on the assessment by the Investigator as 
recorded in the CRF. An AE will be counted as an AESM if there is a ‘yes’ response to 
the question “Is this an event of Special Monitoring?” and not otherwise. An AE will be 
counted as an AESI if there is a ‘yes’ response to the question “Adverse Event of Special 
Interest?” and not otherwise.
Listing will be presented by treatment group, most recent dose and participant for all 
AEs. This will include the onset date/time and outcome date/time of the event (including 
relative days), the AE duration, days since first dose of IMP, days since most recent dose 
of IMP, most recent dose, pattern of event, severity/intensity, relationship, action taken 
PUBLIC COPY 
(defined 
OPY
(defined 
d” or “d
COP
d” or “d
reatment
C CO
reatment
ated by S
BLIC
ated by S
AEs by re
PUB
AEs by re
TEAE
PU
TEAE
ot be used to support any marketing authorization 
ed 
z
ed 
re’ for ev
ark
re’ for ev
as TEAEs
t an
as TEAEs
ose decrea
ort a
ose decrea
interrupti
por
interrupti
OC, HLT
sup
OC, HLT
lationship
d to 
lationship
 by Relat
ed t
 by Relat
ing to per
sed
ing to per
ous TEAE
us
ous TEAE
s and Pref
be u
s and Pref
ial Hy’s L
ot b
ial Hy’s L
This document canno
bilirubin 
not
bilirubin 
hemical a
ann
hemical a
Ms are seve
t ca
Ms are seve
miting), op
nt c
miting), op
vents.
en
vents.
AESM
um
AESM
reco
u
reco
t
d any extensions or variations thereof.
vents with
s t
vents with
s with an 
aria
s with an 
as
ased”)
va
ed”)
ion
o
ion
T and PT
ons 
T and PT
p p 
tionship 
ten
tionship 
rmanent d
xte
rmanent d
Es Above
ex
Es Above
ferred Ter
ny e
ferred Ter
Law, defi
d an
Law, defi
application and
n in the ab
nd a
n in the ab
abnormal
and
abnormal
vere heada
on 
vere heada
pportunist
tio
pportunist
Ms and AE
plic
Ms and AE
corded in t
app
corded in t
a
e questi
ap
e questi
t


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 53 of 85
and outcome. In addition, the listing will flag AEs that led to discontinuation, TEAEs, 
serious adverse events (SAEs), AESMs, and AESIs.
AEs of Focus:
AEs of Focus (AEOF) will be defined using Version 3.0 or later of “Adverse Events of 
Focus for the Rozanolixizumab program”. In addition, worsening thrombocytopenia and 
haemorrhagic events will be included as AEOF as described in AEOF Version 1.4. The 
following AEs are defined in the rozanolixizumab program as AEs of focus (please see 
Section 13.1￼for more details)
−
Headaches
−
Gastrointestinal Disturbances
−
Hypersensitivity Reactions
−
Anaphylactic Reactions
−
Injection Site Reactions
−
Infusion Reactions
−
Opportunistic Infections
−
Reductions in Albumin and Plasma Proteins
−
Effects on the Kidney
−
Drug Related Hepatic Disorders
−
Thromboembolic Events
−
Hemorrhagic Events
−
Worsening of Thrombocytopenia
AEOFs will be listed only.
10.3
Vital Signs, Physical Findings, and Other Observations Related to 
Safety
10.3.1
Vital Signs and Physical Findings
The following vital signs measurements will be obtained:
−
Pulse rate
−
Systolic and diastolic blood pressure
−
Temperature (oral, tympanic, or axillary)
A summary of participants who meet each of the Marked Abnormality (MA) Criteria (Appendix 
13.3) will be summarized by treatment group at each timepoint.
A by-participant listing of all vital sign measurements and change from Baseline will be 
presented by treatment group and timepoint. The listing will include a flag for values identified 
as MA criteria (Appendix 13.3).
PUBLIC COPY 
roteins
CO
roteins
ders
BL
ders
This document cannot be used to support any marketing authorization 
he 
i
he 
see
ori
see
cytopenia
us
cytopenia
igns, Phy
ot b
igns, Phy
ty
n
ty
Vital Sign
can
Vital Sign
ng vital si
nt c
ng vital si
Pulse rate
men
Pulse rate
−
Systo
um
Systo
−
o
−
T
A su
s d
A su
1
s
1
plication and any extensions or variations thereof.
ysical Fi
d a
ysical Fi
ns and Ph
n a
ns and Ph
signs mea
tion
signs mea
e
i
e
app
olic and d
ppli
olic and d
emperat
ap
mperat


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 54 of 85
Repeated and unscheduled measurements will be handled as described in Section 4.3.
10.4
12-lead Electrocardiograms (ECG)
12-Lead ECG data (measured values and changes from Baseline) will be listed only. The 
following variables will be reported:
−
Heart rate
−
PR interval
−
RR interval
−
QRS duration
−
QT interval
−
QT corrected for heart rate using Bazett’s formula (QTcB = QT/RR1/2)
−
QT corrected for heart rate using Fridericia’s formula (QTcF = QT/RR1/3)
A summary of participants who meet each of the Market Abnormally (MA) criteria outlined in 
Appendix 13.4 will be summarized by treatment group at each timepoint and overall.
All calculations of changes from Baseline will be based on the mean of triplicate assessments at 
each timepoint. If there are not 3 available measurements at a given timepoint, the mean will be 
calculated based on the number of measurements for which data are provided. 
Electrocardiogram findings for the individual triplicate measurements will be listed separately.
Repeated and unscheduled measurements will be handled as described in Section 4.3.
10.5
Clinical Safety Laboratory Assessments 
Laboratory data (as specified in Table 10-1 Protocol-required safety laboratory assessments in 
the protocol) and changes from Baseline (if applicable) for numeric variables will be listed by 
treatment group and timepoint. Values outside the reference range for the numeric variables will 
be flagged in the listings. The reference ranges will also be reported in the listings. In addition, 
the listings will include a flag for values identified as Laboratory assessments – MA Criteria 
(Appendix 13.2 ).
Measurements BLQ will be imputed with half of the LLOQ for the purpose of calculating 
change from Baseline. Measurements ALQ, if applicable, will be imputed to the upper 
quantification limit. These rules will be applied to all safety laboratory data including clinical 
chemistry and urinalysis.
Descriptive statistics will be calculated if at most 1/3 of the individual data points at a time point 
are missing or are either not quantifiable (<LLOQ) or ALQ. Values that are BLQ will be 
replaced by the numerical value of the LLOQ/2 in this instance and values that are ALQ will be 
imputed to the value of the upper quantification limit. If more than two-thirds of the individual 
data points at a timepoint are missing or not quantifiable (BLQ and/or ALQ), no descriptive 
statistics will be calculated.
The following summaries/tables will be created:
PUBLIC COPY
ket 
Y
ket 
oup at e
PY 
oup at e
be based
COP
be based
measurem
CO
measurem
rements 
C C
rements 
dividual
BLIC
dividual
rements
UB
rements
y Lab
PU
y Lab
annot be used to support any marketing authorization 
RR1/2)
rket
RR1/2)
F = QT/RR
mar
F = QT/RR
mally (M
y m
mally (M
ch timepo
any 
ch timepo
on the me
rt a
on the me
ents at a g
ort
ents at a g
for which 
ppo
for which 
triplicate m
sup
triplicate m
will be ha
to s
will be ha
oratory A
ed t
oratory A
able
us
able 10
se
10-
e
-1
m Baseline
e us
m Baseline
int. Value
be 
int. Value
 The refe
ot b
 The refe
de a flag fo
not
de a flag fo
ument c
BLQ will
ca
BLQ will
m Baseline
nt c
m Baseline
ation lim
ent
ation limi
stry and u
me
stry and u
This doc
escriptive
ocu
escriptive
are missi
doc
are missi
replac
s do
replac
im
s 
im
n and any extensions or variations thereof.
RR1/3)
ns
RR1/3)
MA) criter
atio
MA) criter
oint and o
riat
oint and o
ean of trip
var
ean of trip
given tim
r va
given tim
data are p
or 
data are p
measurem
ons 
measurem
andled as
sio
andled as
Assessm
tens
Assessm
 Protocol
exte
 Protocol
e (if appli
y ex
e (if appli
es outside
ny 
es outside
erence ran
d an
erence ran
for values
nd a
for values
plication
ll be impu
on a
ll be impu
e. Measur
tion
e. Measur
it. These r
cati
it. These r
urinalysis
plica
urinalysis
app
e statistics
app
e statistics
ng or are
ap
g or are
th
a
th


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 55 of 85
−
A summary of participants who meet each of the Laboratory assessments – MA criteria 
(Appendix 13.2) will be summarized by treatment group at each timepoint.
A listing for laboratory assessments will be also created using the SS.
10.5.1
Potential Drug-Induced Liver Injury
Data from subjects with any of the laboratory results meeting the criteria for potential drug-
induced liver injury (PDILI) (below) was planned to be summarized by treatment arm and visit 
using the SS to include:
−
Subjects with at least one post-Baseline liver laboratory assessment
−
Incidence of potential hepatotoxicity with symptoms potentially associated with hepatitis 
or hypersensitivity, which will account for the number and percentage of subjects 
meeting laboratory criteria for PDILI for at least 1 visit and reporting at least 1 symptom 
potentially associated with hepatitis or hypersensitivity according to the Investigator on 
the PDILI CRF)
−
Incidence of potential hepatotoxicity with no symptoms potentially associated with 
hepatitis or hypersensitivity, which will account for the number and percentage of 
subjects meeting laboratory criteria for PDILI for at least 1 visit and not reporting any 
symptom potentially related to hepatitis or hypersensitivity according to the Investigator 
on the PDILI CRF
−
Number and percentage of study participants who meet the Laboratory criteria for PDILI 
(see table below)
Table 10-2:
Laboratory criteria for PDILI
Laboratory Criteria
Comments
(AST or ALT > 3 x ULN) and TBL > 1.5 x ULN
- All values must be met at the same sample 
taken from the same visit
(AST or ALT > 3 x ULN) and TBL > 2 x ULN
(AST or ALT > 3 x ULN) and TBL > 2 x ULN 
and ALP < 2 x ULN 
- All values must be met at the same visit
- Subjects who potentially meet Hy’s law 
criteria at least 1 time during exposure. To 
be counted as potential Hy’s Law, all 
criteria must be met at the same sample 
taken at the same visit.
ALP = Alkaline phosphatase; ALT = Alanine aminotransferase; AST = Aspartate aminotransferase; TBL = total 
bilirubin; ULN = upper limit of normal range.
A listing will be created only for visits for which at least one of the above criteria was fulfilled 
for a given participant and will display all results obtained at that visit for the specified 
parameters.  The listing will specify AST, ALT, TBL, and ALP.
10.6
Concentrations of Total Protein and Albumin 
Concentrations of total protein and albumin for each visit (as described in the schedule of events 
in the protocol) will be listed using the SS.
PUBLIC COPY
ym
Y
ym
ount for
PY 
ount for
DILI for
OPY
DILI for
is or hyp
CO
is or hyp
dy partic
LIC
dy partic
teria for
PUB
teria for
P
e used to support any marketing authorization 
visit 
ori
visit 
ted with h
ng a
ted with h
e of subje
ting
e of subje
ing at lea
keti
ing at lea
ng to the 
arke
ng to the 
potential
y m
potential
he numbe
any
he numbe
at least 1 
t an
at least 1 
ersensitiv
ort 
ersensitiv
pants who
upp
pants who
PDILI
to
DILI
d
TBL > 1.
use
TBL > 1.
se
nd TBL >
e u
nd TBL >
us
nt cannot be 
N) and TBL
be
N) and TBL
This document 
e
nt
line phosph
ent
line phosph
ULN = up
men
ULN = up
sting will
cum
sting will
for a given
ocu
for a given
parame
do
parame
10
s 
10
y extensions or variations thereof.
hepatitis
eof
hepatitis
ects 
er
ects 
ast 1 symp
the
ast 1 symp
Investiga
s th
Investiga
lly associ
atio
lly associ
er and per
riat
er and per
 visit and
vari
 visit and
vity accor
r va
vity accor
o meet th
ns o
o meet th
en
.5 x ULN
ext
.5 x ULN
xte
> 2 x ULN
y e
> 2 x ULN
ex
tion and any 
BL > 2 x U
any
BL > 2 x U
applicatio
y
tio
hatase; AL
atio
hatase; AL
pper limit o
ica
pper limit o
l be creat
ppli
l be creat
n particip
app
n particip
a
The
ap
The


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 56 of 85
10.7
Serum and Plasma Complement Levels
Serum (C3 and C4) and plasma (C3a and C5a) complement variables will be listed by treatment 
group and time point.
Measurements below the limit of quantification (BLQ) will be imputed with half of the lower 
limit of quantification (LLOQ). Measurements above the limit of quantification (ALQ), if 
applicable, will be imputed to the upper limit of quantification.
All analyses described in this section will be performed on the SS.
10.8
Other Safety Variables
10.8.1
Physical examination
Results of physical examination abnormalities will be listed.
10.8.2
Pregnancy testing
Pregnancy testing will consist of serum testing at the Screening. The pregnancy test will be urine
at all other visits.
A by-participant listing of the pregnancy test data will be provided by treatment group.
10.8.3
Childbearing potential 
Childbearing potential will be collected at Screening. A by participant listing will be provided 
using the RS.
10.8.4
Assessment and management of Tuberculosis
Results of the interferon-gamma release assay tuberculosis (TB) test will be listed.
Results of the chest X-ray for TB will be listed.
Results of TB signs and symptoms questionnaire will be listed.
11
OTHER ANALYSES 
11.1
Headache questionnaire
The results of the headache questionnaire will be listed for each participant. No summary 
tabulations will be provided for these assessments.
12
REFERENCES
Chow SC, Lin M. Analysis of two-stage adaptive seamless trial design. Pharm Anal Acta. 
2015;6(341):2.
Hedges, Larry V., and Ingram Olkin. "Statistical methods for meta-analysis." (1985).
Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of 
romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind 
randomised controlled trial. Lancet. 2008;371(9610):395-403.
Lehmacher W and Wassmer G. Adaptive Sample Size Calculations in Group Sequential Trials. 
Biometrics. 1999;55:1286-90.
PUBLIC COPY 
will be 
OPY
will be 
t Screen
C C
t Screen
managem
UBL
managem
a relea
PU
a relea
ument cannot be used to support any marketing authorization 
he pregnan
mar
he pregnan
provided b
any
provided b
ng. A by p
ppo
ng. A by p
ent of Tu
o s
ent of Tu
e assay tu
d to
e assay tu
will be list
sed
will be list
oms ques
e us
oms ques
ANALY
t be
ANALY
ache que
not
ache que
headache
ann
headache
ll be provi
t ca
ll be provi
REF
nt 
REF
 SC, Lin M
me
 SC, Lin M
This docu
2015;6(3
cum
2015;6(3
Hedges,
doc
Hedges,
Kut
s d
Kut
application and any extensions or variations thereof.
ancy test w
ons
ancy test w
by treatm
aria
by treatm
participan
s or
participan
uberculos
sion
uberculos
uberculos
ens
uberculos
sted.
xt
sted.
stionnaire
y e
stionnaire
YSES 
any
YSES 
estionnai
nd 
estionnai
e question
an
e question
vided for t
on 
vided for t
FEREN
atio
FEREN
M. Analy
plica
M. Analy
341):2.
ppl
341):2.
Larry 
ap
arry V
p
V


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 57 of 85
Levey et al. A New Equation to Estimate Glomerular Filtration Rate. Ann Intern Med. 2009; 
150: 604-612.
Mantel, N., Fleiss, J.L. (1980). Minimum expected cell size requirements for the Mantel-
Haenszel one-degree-of-freedom chi-square test and a related rapid procedure. American 
Journal of Epidemiology 112, 129-134
Nehring, S.M.; Goyal, A.; Patel, B.C. (2020). StatPearls Publishing, web link: 
https://www.ncbi.nlm.nih.gov/books/NBK441843/.
United States Department of Health and Human Services, National Cancer Institute. Common 
Terminology for Adverse Events (CTCAE), Version 5.0, November 17, 2017.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
Common
uth
Common
application and any extensions or variations thereof.


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 58 of 85
13
APPENDICES
13.1
AE of focus (AEOF) for the Rozimab Program
AEOF Version: 3.0 or later, Date: 13Dec2021 will be used in this SAP as described 
below.  In addition, worsening thrombocytopenia and haemorrhagic events will be included as 
AEOF as described in AEOF Version 1.4:
ARTICLE I. MedDRA 22.0 and 22.1 and 23.0 and 23.1 AND 24.0
The purpose of this document is to detail the approach to identifying TEAEs meeting criteria for 
AEs of focus (AEOF) for the Rozanolixizumab (also called Rozimab) program. 
The document is organized by MedDRA version. At the time of writing this document, 
MedDRA version 22.0 was planned to be used for all indications under investigation (MG, ITP, 
CIDP, HV). As there is no change between 22.0 and 22.1 and 23.0 and 23.1 and 24.0 regarding 
terms used in below selection criteria, all below specified algorithms apply to these Meddra 
versions.  If future studies are planned which use a different (more recent) version of MedDRA, 
this document will be updated.
The MedDRA SMQ files version 22.0, 22.1, 23.0 and 23.1 are attached in the original document.
MedDRA SMQ file 24.0:
SMQ_spreadsheet_
24_0_English.xlsx
Following Events are Adverse Event of focus For Rozanolixizumab for all indications:
No
Event (also included in 
Title of TFL output)
Selection criteria
Purpose
CSR/ 
SSD/ IB
1
Headache
(Note: also included in 
AESM if severe)
TEAE with HLGT=’Headaches’
CSR/ 
SSD/ IB
2
Gastrointestinal 
disturbances
(Note: also included in 
AESM if severe)
TEAE with 
HLT=‘Gastrointestinal and abdominal pains 
(excl oral and throat)’ or 
HLT=‘Gastrointestinal signs and symptoms 
NEC’ or  
HLT=‘Nausea and vomiting symptoms’ or
HLT=‘Diarrhoea (excl infective)‘ or
HLT=‘Gastritis (excl infective)’
CSR/ 
SSD/ IB
3
Hypersensitivity reactions 
SMQ=’Hypersensitivity’
CSR/ 
SSD/ IB
4
Anaphylactic reactions
SMQ=‘Anaphylactic reaction’ and
TEAEs that either emerged on the same day
as when a study medication injection 
CSR/ 
SSD/ IB
PUBLIC COPY 
ifferen
PY 
ifferen
23.0 and
CO
23.0 and
e Eve
P
e Eve
annot be used to support any marketing authorization 
ing criteri
au
ing criteri
m.
n
m.
his docum
keti
his docum
r investig
arke
r investig
and 23.1 a
mar
and 23.1 a
hms apply
ma
hms apply
more rece
ny m
more rece
23.1 are a
ort a
23.1 are a
nt of focu
ed t
nt of focu
n 
n 
t)
b
t)
Sele
s
Sele
se
us
included i
nno
included i
f severe)
ann
f severe)
t b
cument can
intestinal
ca
intestinal
urbances
nt c
urbances
(Note: als
men
(Note: als
AESM
me
AESM
This docu
an
s d cu
s
n and any extensions or variations thereof.
ria for 
of.
ria for 
ment,
the
ment,
gation (M
s th
gation (M
and 24.0 
ns 
and 24.0 
ly to these
tion
ly to these
ent) versio
iatio
ent) versio
attached i
r va
attached i
us For Ro
ten
us For Ro
ection cr
ex
ection cr
xt
a
in
a
in
a
d a
TEA
a
TEA
a
d a
application a
l
o
l
so include
cat
so include
M 
M if severe
plica
if severe
n a


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 59 of 85
reaction was received, or that emerged one
day after a study medication injection was 
received, and which fulfill any of the 
following 3 criteria should be included in the 
summary table:
1. If a subject reports any TEAE which 
codes to a PT included in Category A, 
then the event will be flagged as an
anaphylactic reaction.
2. If a subject reports any TEAE which 
codes to a PT included in Category B 
AND reports any TEAE which codes to a 
PT included in Category C, and both 
TEAEs have the same start date, then 
both events will be flagged as 
anaphylactic reactions. 
3. If a subject reports any TEAE which 
codes to a PT included in Category D 
AND reports (either a TEAE which 
codes to a PT included in Category B 
OR a TEAE which codes to a PT 
included in Category C), and both 
TEAEs have the same start date, then 
both events will be flagged as 
anaphylactic reactions.
5
Injection site reactions
TEAE with
HLT=’Injection site reactions’ or
HLT=’Infusion site reactions’ or
HLT=’Administration site reactions NEC’
CSR/ 
SSD/ IB
6
Infusion Reactions
Infusion reaction marked on AE CRF page
CSR/ 
SSD/ IB
7
Infections
TEAE with SOC =”Infections and 
infestations” 
Note: This was added as a reminder for 
safety that infections are considered as AE of 
focus and require assessment. No 
programming of this topic is required as 
TEAEs can be found in general AE Tables. 
8
Opportunistic infections
(Note: also included in 
AESM)
Opportunistic infections (including 
tuberculosis) will be summarized in a stand-
alone table using UCB-defined search 
criteria. Opportunistic infections are 
CSR/ 
SSD/ IB
UBLIC COPY
will
Y
will
tic rea
PY
tic reac
Y 
c
subject r
CO
subject r
odes to a
C C
odes to a
AND
IC
AND
cod
LIC
cod
O
L
O
PUB
UB
used to support any marketing authorization 
i
ry B 
eti
ry B 
h codes to
rket
h codes to
and both
ark
and both
tart date
ma
tart date
agged as
y m
agged as
ons.
n
ons.
eports any
ort 
eports any
PT includ
por
PT includ
eports (eit
upp
eports (eit
es to a PT 
sup
es to a PT 
R
o
R a TEA
o s
a TEA
included
d to
included
TEA
ed t
TEA
bo
ed
bo
nt cannot be us
us
g
za
ctions
t b
ctions
be
on Reacti
t ca
on Reacti
ca
cumen
Infection
men
Infection
This docu
n
s d cu
ny extensions or variations thereof.
o a
t
o a
h
e, then
ons
, then
y TEAE w
r va
y TEAE w
uded in Ca
or v
uded in Ca
ther a TE
s o
ther a TE
T included
ons
T included
E which 
sion
E which 
d in Categ
nsi
d in Categ
Es have 
ten
Es have 
oth events
exte
th events
anaphyla
y ex
anaphyla
ation and any
th
TEAE
any
TEAE
HL
a
HL
H
ny
d a
ions
on
ions
n a
applicat
s
ati


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 60 of 85
identified in two steps using the attached 
spreadsheet
for MedDRA v24.0:
OI_MedDRA24_0.xls
x
Step 1: Refer to column B of the spreadsheet 
which identifies the Preferred Terms (PTs) to 
be classified as opportunistic infections using 
either a single ‘x’ or a double ‘xx’.
•
TEAEs which code to a PT flagged 
with a single ‘x’ need to also be 
serious in order to be considered an 
opportunistic infection. 
•
All TEAEs which code to a PT 
flagged with a double ‘xx’ are 
considered to be an opportunistic 
infection, regardless of seriousness. 
All serious TEAEs in the study database 
which code to a PT flagged with a single ‘x’ 
and all TEAEs in the study database which 
code to a PT flagged with a double ‘xx’ will 
be summarized as an opportunistic infection 
in the stand-alone table. [CQ97NAM= 
’Opportunistic Infection - Automatic’]
Step 2: Refer to column C of the spreadsheet 
which identifies the PTs that need to be 
evaluated on a case-by-case basis by the 
study physician and safety physician in order 
to determine whether it is a true 
opportunistic infection or not. The process 
for physician review is as follows:
1. Study programming team creates a 
spreadsheet which lists all of the 
subjects with a TEAE present in the 
database which codes to a PT 
identified as case-by-case. 
[CQ98NAM= Opportunistic 
Infection - Manual Review 
Candidate] 
Information from the AE dataset to 
be included in the spreadsheet: 
Subject ID, AE verbatim term, 
PUBLIC COPY
d with 
PY 
d with 
sidered t
OPY
sidered t
nfection,
COP
nfection,
rious TE
C CO
rious TE
ich code
IC C
ich code
and all T
BLIC
and all T
code 
UBL
code 
be
UB
be
UB
This document cannot be used to support any marketing authorization 
ng
ng
gged 
etin
gged 
o be
ket
o be
sidered a
arke
sidered a
n.
m
n.
code to a 
y m
code to a 
double ‘xx
ny 
double ‘xx
o be an op
t any
o be an op
regardless
rt a
regardless
AEs in th
port
AEs in th
to a PT fl
ppo
to a PT fl
EAEs in t
supp
EAEs in t
o a PT fla
o su
o a PT fla
summariz
to 
summariz
n the stan
d t
n the stan
’Oppor
sed
’Oppor
S
s d cu
us
g
za
application and any extensions or variations thereof.
an
s
an
PT
tio
PT
x’ are
iati
x’ are
pportunist
aria
pportunist
ss of serio
va
ss of serio
he study d
or v
he study d
flagged wi
s or
flagged wi
the study 
ns 
the study 
agged wit
ion
agged wit
zed as an 
nsio
zed as an 
nd
e
nd-
e
-alone t
ens
alone t
rtunistic I
xte
rtunistic I
Step 2: Re
ny e
Step 2: Re
which i
any
which i
eval
a
eval
stst
d a
th


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 61 of 85
System Organ Class (SOC), High 
Level Term (HLT), Lower Level 
Term (LLT), PT, AE start date, AE 
end date, seriousness, severity, 
relationship to study medication, 
action taken. Additionally, a column 
will be included where the study 
physician/safety physician can 
document their decision on the case.
2. Study physician/safety physician 
(SPs) reviews the cases in the 
spreadsheet separately and reconciles 
final decision, and indicates in the 
additional column which AEs are 
confirmed to be opportunistic 
infections via a single ‘x’.
3. Study programming team 
incorporates these decisions into the 
AE dataset by merging the SPs  
decisions for individual subjects / 
PTs and flagging both the automatic 
and the confirmed opportunistic 
infections as such in the dataset.
[CQ99NAM= ‘Opportunistic 
Infection – Adjudicated’]
The SPs reviews the context of all of a 
subject’s data (AEs and possibly other) and 
concludes individually.  
Indicators of relevant cases may be e.g. 
repetitive occurrences, conjunction of other 
events or findings considered relevant. 
All subjects with a case-by-case PT reported 
that has been confirmed by the SPs to be an 
OI will be summarized as such in the stand-
alone table, along with all of the events 
identified in Step 1 of this process. 
[CQ99NAM= ‘Opportunistic Infection –
Adjudicated’] 
The timing and frequency of Step 2 should 
be outlined and agreed to by the study team 
at the beginning of the study. It is suggested 
that this process be executed multiple times 
throughout the course of the study, more 
frequently in the weeks leading up to 
UBLIC COPY
ogr
Y
ogr
orates t
PY 
orates t
dataset 
OPY
dataset 
decision
CO
decision
PTs a
C C
PTs a
and
C 
and
PUB
UB
used to support any marketing authorization 
nciles
ing
nciles
n the
eti
n the
Es are 
ket
Es are 
unistic
ark
unistic
e ‘x’.
ma
e ‘x’.
ng team
y m
ng team
ese decisi
any
ese decisi
by mergin
t an
by mergin
for indiv
ort 
for indiv
nd flaggin
por
nd flaggin
the conf
pp
the confififif
nfections 
sup
nfections 
[CQ99
o s
[CQ99
Infec
to
Infec
The SP
sed
The SP
sub
s
sub
This document cannot be us
s d cu
us
g
za
d any extensions or variations thereof.
ions into 
riat
ions into 
ng the SPs
vari
ng the SPs
vidual sub
r va
vidual sub
ng both th
or v
ng both th
irmed opp
s o
irmed opp
as such i
ns
as such i
9NAM= ‘
sion
9NAM= ‘
ction
nsi
ction –
s
– A
Ps review
xte
Ps review
bject’s dat
y ex
bject’s dat
conclude
ny 
conclude
Indica
any
Indica
repe
a
repe
application and a
d a
th


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 62 of 85
database lock, and one final time 
immediately prior to database lock.  
Following the initial physician review of 
case-by-case events, subsequent reviews will 
be based on the cumulative set of case-by-
case events present in the database at each 
time point of spreadsheet creation.  
Physician decisions from previous runs 
should be retained in each subsequent run. 
The final run of the spreadsheet, with all SP
decisions on the full set of case-by-case 
events, will be archived at the conclusion of 
the study analysis prepared for agency 
submission.
9
Reductions in albumin and 
plasma proteins
TEAEs with
PT=’Blood albumin decreased’ or
PT=’Protein albumin ratio’ or
LLT=’Plasma protein abnormal’ or
LLT=’Proteins serum plasma low’
CSR/ 
SSD/ IB
10
Effects on the kidney
TEAEs in 
SMQ= ‘Acute renal failure’
CSR/ 
SSD/ IB
11
Drug related hepatic 
disorders 
TEAEs in 
SMQ=’Drug related hepatic disorders -
comprehensive search’
CSR/ 
SSD/ IB
12
Effect on lipids
TEAEs with 
PT= ‘Blood cholesterol increased’ or 
PT= ‘Low density lipoprotein increased’ or 
PT= ‘Blood triglycerides increased’ or 
PT= ‘Hypercholesterolaemia’ or 
PT= ‘Hypertriglyceridaemia’ or 
PT= ‘Hyperlipidaemia’ or 
PT= ‘Dyslipidaemia’ or 
PT= ‘Lipids increased’
CSR/ 
SSD/IB 
ITP specific output
13
Thromboembolic events
Embolic and thrombotic events (SMQ)
CSR/ 
SSD/ IB
14
Worsening 
thrombocytopenia *
Haematopoietic thrombocytopenia (SMQ)
15
Haemorrhagic events *
Haemorrhages (SMQ)
* Data will be summarized by period and listed after adjudication of those events have been properly investigated
PUBLIC COPY
min
Y
min
lbumin
PY 
lbumin
sma prot
OPY
sma prot
Proteins 
CO
Proteins 
Es in 
C C
Es in 
MQ=
LIC
MQ= ‘A
C 
‘A
CO
TEAEs
BLIC
TEAEs
SMQ
UBL
SMQ
c
U
c
LIC
UB
PU
d to support any marketing authorization 
P
g
P
sion of 
etin
sion of 
ency 
rke
ency 
g
za
eased’ or
y m
eased’ or
atio’ or
ny
atio’ or
in abnorm
t an
in abnorm
erum plas
ort 
erum plas
a
ute renal 
pp
ute renal 
or
in 
s
in 
Q=’
to
Q=’Drug r
to s
Drug r
mprehens
d to
mprehens
up
used t
TEAEs w
ed 
TEAEs w
PT=
se
PT= ‘B
‘B
PT
s
PT
ocument cannot be us d t
us
men
ent c
ific outpu
ent 
ific outpu
t c
Thro
um
Thro
m
cu
s doc
14
do
14
oc
This d
s d c
s s
nsions or variations thereof.
th
mal’ or
vari
mal’ or
sma low’
r va
sma low’
ns
failure’
s o
failure’
r v
related he
sion
related he
nsive searc
nsi
nsive searc
s 
d any exten
with 
te
with 
Blood cho
exte
Blood cho
=
y
= ‘Low d
y ex
‘Low d
PT=
ny
PT= ‘Blo
y 
‘Blo
PT=
an
PT= ‘H
y
‘H
PT
a
PT
application and a
n
d a
licat
atio
ut
a
ut
io
mboemb
plic
mboemb
lic
ap
Worsen
ap
Worsen
ap


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 63 of 85
13.2
Laboratory assessments – Marked abnormality criteria
The following criteria will be applied in the determination of marked abnormalities for 
laboratory assessment values. They are based on Version 5 of the Common Terminology Criteria 
for Adverse Events (CTCAE) grade 3 or higher criteria unless otherwise noted. If both high and 
low criteria are shown for a parameter, the criteria should be summarized separately in tabular or 
graphical data summaries. 
13.2.1
Hematology
PARAMETER
UNIT 
(conventional)
UNIT
(standard)
MARKED 
ABNORMALITY 
CRITERIA
Hemoglobin 
g/dL
g/L
<8.0 g/dL; <80 g/L 
WBC (Leukocytes)1
109/L
109/L
Low: <2.0 x 109/L 
High:  >30 x 109/L 
Lymphocytes 
Absolute
109/L
109/L
Low:  <0.5 x 109/L 
High: >20 x 109/L
Neutrophils Absolute 
109/L
109/L
<1.0 x 109/L  
Platelets2
109/L
109/L
<50.0 x 109/L 
1WBC (Leukocytes) markedly abnormal high criterion is not based on Version 5 CTCAE Grade 3 or higher criteria. 
Due to the mechanism of action of RLZ, the safety alert is related to infection risk which would be identified by a 
lower cut-point than the standard which is related to acute leukemias. A markedly abnormal high cut-point >30 x 
109/L is applied to flag leukocytosis (George 2012).
2For blinded ITP protocols, Platelets will not be assessed for TEMA because this parameter will be blinded and is 
expected to be abnormally low due to the participant population and entry criteria. 
OPY 
10
OPY
109
PY
9/L
Y
/L
C COPY
1
O
1
OP
C
BLIC
iterion is 
LIC 
iterion is 
e safety a
BLIC
e safety a
PUB
is related 
UBL
is related 
George 2
PUB
George 2
will not b
PU
will not b
o the
P
o the
t any marketing authorization 
ED
ut
ED
MALITY
au
MALITY
ITERIA
g a
ITERIA
th
0 g/dL; <
ting
0 g/dL; <
ng
Low: <
rke
Low: <
ke
Hig
ar
Hig
ark
L
ma
y m
y m
y m
y m
pport any
ny
0 /L
ort
/L
t a
p
supp
ot based on
upp
ot based on
rt is related
sup
rt is related
This document cannot be used to s
o acute leuk
o su
o acute leuk
12).
to
12).
e assessed f
d to
e assessed f
participant p
ed 
participant p
riations thereof.
Y
o
Y
A
<80 g/L 
ere
<80 g/L 
eo
<2.0 x 10
s th
<2.0 x 109
th
gh:  >30 x
ns 
gh:  >30 x
s
Low:  <0.
tion
Low:  <0.
on
High: 
iati
High: 
tio
or varia
ria
va
o
ons 
v
n Version 5
s o
n Version 5
d to infectio
ns 
d to infectio
application and any extensio
kemias. A m
ion
kemias. A m
for TEMA 
ens
for TEMA 
population
ten
population


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 64 of 85
13.2.2
Chemistry
PARAMETER
UNIT 
(conventional)
UNIT
(standard)
MARKED ABNORMALITY 
CRITERIA
AST (SGOT)
U/L
U/L
>5.0 x ULN 
ALT (SGPT)
U/L
U/L
>5.0 x ULN 
ALP (Alkaline 
Phosphatase)
U/L
U/L
>5.0 x ULN 
GGT (Gamma 
Glutamyl 
Transferase)1
U/L
U/L
>5.0 x ULN 
Bilirubin (Total)
mg/dL
umol/L
>3.0 x ULN if Baseline value is normal;
>3.0 x Baseline value if Baseline is 
abnormal 
Albumin
g/dL
g/L
<2 g/dL; <20 g/L 
Creatinine
mg/dL
umol/L
>3.0 x ULN
Estimate 
glomerular filtrate 
rate (eGFR)2
mL/min/1.73 
m
mL/min/1.73 
m
eGFR <29 mL/min/1.73 m
C reactive protein 
(CRP)3
mg/L
mg/L
>10mg/L
Corrected 
Calcium4
mg/dL
mmol/L
Low: Corrected serum calcium of <7.0 
mg/dL; <1.75 mmol/L
High: Corrected serum calcium of >12.5 
mg/dL; >3.1 mmol/L
Immunoglobulin 
G5
(g/L)
(g/L)
≤1 g/L
Potassium
mmol/L
mmol/L
Low: <2.5 mmol/L
High: >6.0 mmol/L
Sodium
mmol/L
mmol/L
Low: <125 mmol/L 
High: >155 mmol/L
Glucose6
mg/dL
mmol/L
Low: <40 mg/dL; <2.2 mmol/L 
High: > 250 mg/dL; >13.9 mmol/L
Total Cholesterol1
mg/dL
mmol/L
>400 mg/dL; >10.34 mmol/L 
Triglycerides1
mg/dL
mmol/L
>500 mg/dL; >5.7 mmol/L
Abbreviations: ALT= alanine aminotransferase; AST = aspartate aminotransferase; dL = deciliter; GGT: gamma-
glutamyltransferase; L = liter; mg = milligram; mmol = millimoles; μg = microgram; U = unit; ULN = upper limit 
of normal
Note: Marked abnormality criteria are defined by Grade 3 or higher events according to the CTCAE, Version 5.0  
unless otherwise noted. 
1GGT, Total Cholesterol and Triglycerides were to be collected under Protocol Amendment 3 but were not collected 
under Protocol Amendment 2. Since no participants were enrolled under Protocol Amendment 3, these laboratory 
assessments will not summarized or listed.
PUBLIC COPY 
Y
1.73 
PY
1.73 
m
O
m
Y
mg/L
C C
mg/L
C
LI
BL
cannot be used to support any marketing authorization 
tititi
ati
thoriza
riza
za
g aut
utho
tho
seline valu
ting
seline valu
ne value 
ketin
ne value 
abnorm
rke
abnorm
g
<2 g/dL
mark
<2 g/dL
rk
m
eGF
ny
eGF
ny
or
or
or
po
mmol/L
su
mmol/L
up
sed
)
se
se
se
se
mmol/L
be
mmol/L
be
mm
o
mm
ot
n
ment can
e
t
e6
t
6
ca
Choleste
me
Choleste
en
cum
Triglycer
cum
Triglycer
m
cu
This doc
Abbreviation
ocu
Abbreviation
glutamy
doc
glutamy
of no
do
of no
Not
s 
Not
n and any extensions or variations thereo
eof.
lue is norm
ereo
lue is norm
if Baselin
her
if Baselin
mal
th
mal
eo
L; <20 g/L
ns 
L; <20 g/L
s t
>3.0 x U
tio
>3.0 x U
on
FR <29
riat
FR <29 m
t
m
at
r
n
Low
n
Low
ns
on
(g/L)
ext
(g/L)
xt
ny
ny
an
an
an
mol/L
nd
mol/L
d
lication
mg/
on
mg/
on
t
cat
erol
lic
erol1
ic
1
ca
ca
pplica
ca
rides
ppl
rides1
pli
1
lic
pp
ap
c
ns: ALT= a
app
ns: ALT= a
ansferas
ap
ansferas


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 65 of 85
2eGFR is calculated using the Chronic Kidney Disease Epidemiology Collaboration or CKD-EPI formula 
(https://qxmd.com/calculate/calculator_251/egfr-using-ckd-epi) which is eGFR = 141 * min(Scr/κ,1)α * 
max(Scr/κ, 1)-1.209 * 0.993Age * 1.018 [if female] * 1.159 [if black];  where Scr is serum creatinine (mg/dL), κ is 0.7 
for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or 
1, and max indicates the maximum of Scr/κ or 1. For derivation from values in standard units (umol/L) the κ 
values are 61.9 for females and 79.6 for males.
3Includes CRP and High Sensitivity (HS) CRP. Reference for marked abnormality criteria: Nehring, S.M.; Goyal, 
A.; Patel, B.C. (2020). StatPearls Publishing, web link: https://www.ncbi.nlm.nih.gov/books/NBK441843/. A 
moderate elevation of CRP level per referred reference is used for the marked abnormality criteria for RLZ to 
ensure a change suggestive of inflammatory process is captured.
4Corrected Calcium = 0.02 * (40 – albumin (g/L)) + calcium (mmol/L)
5Immunoglobulin G criterion based on immunodeficiency literature and noted in RLZ study protocols.
6Glucose high criterion defined by Grade 3 and higher events according to CTCAE, Version 4.03, June 14, 2010.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
3/
ri
3/. A 
riz
. A 
ri
Z to 
ho
Z to 
cols.
a
cols.
03, June 14
g a
03, June 14
application and any extensions or variations thereof.
4, 2010.
eof
4, 2010.


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 66 of 85
13.3
Vital sign assessments - abnormal
Abnormality criteria to be applied in the assessment of vital signs parameter values are given 
below.
PARAMETER
ABNORMALITY CRITERIA
Pulse Rate (beats/minute)
<50 and a decrease from Baseline of ≥15
>120 and an increase from Baseline of ≥15
Systolic Blood Pressure (mmHg)
≤90 and a decrease from Baseline of ≥20
≥ 180 and an increase from Baseline of ≥20
Diastolic Blood Pressure (mmHg)
<50 and a decrease from Baseline of ≥15
>105 and an increase from Baseline of ≥ 15
Temperature
>101 0F (38.3 0C)
Body Weight
≥ 10% decrease from Baseline
≥ 10% increase from Baseline
13.4
Electrocardiogram (ECG) – Abnormal
Abnormality criteria to be applied in the assessment of ECG parameter values are given below:
Parameter
Abnormality Criteria
QT interval (ms)
≥500ms
≥60ms increase from Baseline
QTc(F) (ms)
≥500ms
≥60ms increase from Baseline
PR interval (ms)
Treatment-emergent value >200ms
QRS interval (ms)
Treatment-emergent value >100ms
Heart rate (bpm)
<50bpm
>120bpm
Abbreviations: BL= Baseline, bpm = beats per minute; ms = milliseconds; QTc(F) = Fridericia corrected 
QT interval; 
Note: Treatment-emergent is defined as meeting the criteria at any post-Baseline visit during the 
Treatment Period (including unscheduled visits) and not meeting the same criteria during Baseline
PUBLIC COPY
norma
PY 
norma
ment of 
COP
ment of 
Ab
C C
Ab
CO
C 
BL
PU
P
nnot be used to support any marketing authorization 
a
za
15
h
15
of ≥15
uth
of ≥15
or
e of ≥20
au
e of ≥20
eline of ≥
g a
eline of ≥
ut
aseline of
ting
aseline of
m Baselin
ketin
m Baselin
g
38.3
rk
38.3 0
ke
0C)
ke
C)
ke
ease from
mar
ease from
crease fro
m
crease fro
ark
y m
ECG para
rt a
ECG para
normality
ppo
normality
or
≥
p
≥
pp
≥
to
≥60ms
to s
60ms in
s
in
su
to
≥
d
≥6
d
T
se
u
be
b
no
t can
Baseline,
ann
Baseline,
nt
t
nt-
t
-emerge
t ca
emerge
This documen
Period (inc
ent 
Period (inc
nd any extensions or variations thereof.
≥20
eo
≥20
f ≥15
ere
f ≥15
ne of ≥ 15
her
ne of ≥ 15
eo
the
m Baseline
ns 
m Baseline
om Basel
tion
om Basel
s
tio
ameter va
var
ameter va
y Criteria
or
y Criteria
r v
500ms
ns
500ms
s o
ncrease fr
sio
ncrease fr
on
≥
s
≥50
s
50
s
0ms incr
xten
0ms incr
en
Treatmen
ex
Treatmen
xte
Treat
ny
Treat
y e
any
d a
nd
tion and
bpm = be
an
bpm = be
ent is defin
ion
ent is defin
applicat
cluding un
atio
cluding un


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 67 of 85
13.5
ITP-PAQ Scoring
13.5.1 ITP-PAQ Scales
Please see below for the items associated for each scale and the number of points in the 
Likert Scale that will be used per scale where higher numbers mean better health status.
Question
Scale
Response Categories
1
Physical Health: symptoms 
0-4
2
3
4
5
6
7
Physical Health: fatigue
0-4
8
9
10
11
Physical Health: bother
0-4
12
0-6
13
0-6
14
Physical Health: activity
0-4
15
0-4
16
Emotional Health: psychological
0-4
17
0-4
18
0-4
19
0-4
20
0-4
21
Emotional Health: fear
0-4
22
0-4
23
0-4
24
0-4
25
0-4
26
Overall QoL
0-6
27
0-6
28
0-3
29
0-3
30
0-3
31
Social Activity
0-4
32
0-4
33
0-4
34
0-4
35
Women’s reproductive health
0-4
36
0-4
37
0-4
38
0-4
39
0-4
40
0-4
41
Work
0-5
42
0-5
43
0-5
44
0-5
PUBLIC COPY 
Y
OP
LI
ument cannot be used to support any marketing authorization 
a
za
za
za
riz
ho
th
ut
a
0
n
0-
n
-4
ng
4
g
ing
eti
ke
rk
a
m
y m
ny
ny
ny
ny
an
up
se
Activity
no
Activity
ot
Women
nt c
Women
t c
nt
nt
ent
7
m
7
en
en
en
38
um
38
me
This docum
39
cu
39
um
40
c
40
cu
4
do
d
s d
s d
s
application and any extensions or variations thereof.f.
eo
re
her
th
0
ns
0-
s
-4
ns
4
s t
0
ns
0-
n
-6
ns
6
ns
0 6
on
tio
ia
ari
va
r v
or
or
or
or
o
ns
xt
d
n’s reproduc
tio
n’s reproduc
on
app
p
ap
W
ap
ap
ap
ap


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 68 of 85
The ITP-PAQ domain scores will be obtained by transforming the raw sum of the item 
responses to a 0-100 scale. This can be obtained using the following formula:
ITP-PAQ score = Sum of item scores within the scale
raw sum range
∗100
ITP-PAQ domain
Raw sum range
Symptoms
24
Fatigue
16
Bother
16
Activity
8
Psychological health
20
Fear
20
Work
20
Social activity
16
Women’s reproductive health
24
Overall Quality of Life
21
Missing data:
A domain score is not calculated if there is more than half of the items of this domain are 
missing.
If 50% or more of the items are available, missing items are imputed using the mean of non-
missing items. For domains that include items with a different number of categories, the imputed 
response for missing items has to be transformed on the range of the response scale of the 
missing item.
PUBLIC COPY 
PY 
Y
s more t
C C
s more t
ailable, 
UBL
ailable, 
t include
PUB
t include
P
to be 
P
to be 
d to support any marketing authorization 
han half o
ppo
han half o
missing ite
o su
missing ite
items wit
d to 
items wit
This document cannot be used
ransforme
ed t
ransforme
nsions or variations thereof.
f the item
or
f the item
ems are im
sion
ems are im
th a differ
nsio
th a differ
application and any exte
med on the
ten
med on the


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 69 of 85
13.6
ITP bleeding score
The ITP-BAT tool version 1.0 consists of the following domains:
−
Skin (S)
−
Visible mucosae (M)
−
Organs (O)
The domain for skin comprises the following bleeding types:
−
Petechiae
−
Ecchymoses
−
Subcutaneous hematomas
−
Bleeding from minor wounds
The domain for visible mucosae comprises the following bleeding types:
−
Epistaxis
−
Oral cavity- gum bleeding
−
Oral cavity – hemorrhagic bullae or blisters
−
Oral cavity – bleeding from bites to lips and tongue or after deciduous teeth loss
−
Subconjunctival hemorrhage (not due to conjunctival disease)
The domain for organs comprises the following bleeding types:
−
Gastrointestinal bleeding not explained by visible mucosal bleeding or lesion
−
Lung bleeding
−
Hematuria
−
Menorrhagia
−
Intramuscular hematomas
−
Hemarthrosis
−
Ocular bleeding
−
Intracranial bleeding
−
Other internal bleeding
The grading for each bleeding type within each domain is presented in Table 13-1. Each bleeding 
type is graded based on the worst manifestation that occurred during the most recent observation 
period (since the previous visit). The grade for each domain is then taken as the worst (most 
severe) grade across all bleeding types within that domain.
Missing data will not be imputed. In the case that data for one or more bleeding types are 
missing within a given domain, the grade for that domain will be evaluated based on the 
PUBLIC COPY 
blisters
CO
blisters
s to lips 
LIC 
s to lips 
e (not du
BLI
e (not du
es the fo
PUB
es the fo
no
P
no
This document cannot be used to support any marketing authorization 
ty
m
types:
ma
pes:
yp
y
m
yp
y
nd tongue
pp
nd tongue
e to conjun
sup
e to conjun
lowing bl
d to 
lowing bl
explained
ed 
explained
ar hemato
nno
ar hemato
hrosis
ca
hrosis
ular bleed
ent 
ular bleed
Intracran
me
Intracran
−
c
−
Oth
u
Oth
The
do
The gra
o
gra
type
s d
type
p
s
p
application and any extensions or variations thereof.
e or after 
s o
e or after 
unctival di
ions
unctival di
leeding ty
nsio
leeding ty
ed by visib
xten
ed by visib
omas
and
omas
ding
ati
ding
anial bleed
lica
anial bleed
her interna
app
her interna
g for 
ap
g for 


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 70 of 85
available data. In the case that no data are available within a given domain, the score for that 
domain will not be evaluated at the specific visit.
Table 13-1:
ITP-BAT scoring 
Type of 
bleeding
GRADES BASED ON THE WORST INCIDENT EPISODE SINCE 
LAST VISIT2
0
1
2
3
4
SKIN
Petechiae 
(does not 
include 
steroid–
induced or 
senile 
purpura) 
No
Less than 
or equal to 10 
in a patient’s 
palm-sized 
area3 in the 
most affected 
body area4
Any 
number if 
reported by 
the patient
More than 
10 in a 
patient’s palm-
sized area or 
more than 5 in 
at least 2 
patient’s palm-
sized areas 
located in at 
least 2 different 
body areas4, 
one above and 
one below the 
belt (in the 
most affected 
body areas) 4
More 
than 50, if 
scattered 
both above 
and below 
the belt 
Ecchymoses 
None or 
up to 2 in the 
same body 
area4, but 
smaller than 
a patient’s 
palm-sized 
area, if
a) 
spontaneous 
or b) 
disproportio
nate to 
trauma/const
riction5
3 or more 
in the same 
body area4, 
but all smaller 
than a 
patient’s 
palm-sized 
area, if
a) 
spontaneous 
or
b) 
disproportiona
te to 
trauma/constri
ction5
At least 2 
in two 
From 1 to 5 
larger than a 
patient’s 
palm-sized 
area, if
a) spontaneous 
or
b) 
disproportionat
e to 
trauma/constric
tion5
with or without 
smaller ones
More 
than 5 larger 
than a 
patient’s 
palm-sized 
area, if
a) 
spontaneous 
or
b) 
disproportio
nate to 
trauma/ 
constriction5
PUBLIC COPY 
nt
C
nt
Y
zed ar
Y
zed ar
located
OPY
located
leas
OP
leas
b
O
b
P
CO
sed to support any marketing authorization 
za
iz
ho
m
y
m-
in at 
an
in at 
2 differen
rt a
2 differen
ody areas
port
ody areas4
one abov
ppo
one abov
one b
upp
one b
be
u
be
f 
n
f 
ed 
t
ed 
above
ket
above
nd below
arke
nd below
the belt
mar
the belt
ut
su
y m
ng
e us
e us
3 o
us
3 o
in t
e 
in t
b
us
t cannot be
the
be
the
body 
ot b
body 
, but 
not
, but 
maller tha
nno
maller tha
a patien
can
a patien
palm
ca
palm
arar
This document c
s d
t c
e
y extensions or variations thereof.
nt 
v
nt 
, 
o
, 
ve and 
or
ve and 
elow the 
ns 
elow the 
elt (in the 
ion
elt (in the 
most affe
sio
most affe
body 
ens
body 
te
v
s t
and any e
or more
y e
or more
the same 
ny 
the same 
body area
d an
body area
but all
nd a
but all
than
nd
than
ex
plication and
an
a
an
nt’s
n
nt’s
m
ti
m-sized 
ion
sized 
rea, if
atio
rea, if
a)
ic
a)
spon
plic
spon
o
p
o
appli
ppli
and


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 71 of 85
Type of 
bleeding
GRADES BASED ON THE WORST INCIDENT EPISODE SINCE 
LAST VISIT2
0
1
2
3
4
different body 
areas4, smaller 
than a 
patient’s 
palm-sized 
area, if
a) 
spontaneous 
or
b) 
disproportiona
te to 
trauma/constri
ction5
Any 
number and 
size if 
reported by 
the patient 
Subcutaneou
s hematomas
No
1 smaller 
than a 
patient’s 
palm-sized 
area
Any 
number and 
size if 
reported by 
the patient
2 smaller 
than a patient’s 
palm-sized 
area, 
spontaneous 
2 smaller 
than a patient’s 
palm-sized 
area, 
disproportionat
e to trauma5
More 
than 2 
smaller or at 
least 1 
larger than a 
patient’s 
palm-sized 
area, 
spontaneous 
More 
than 2 
smaller or at 
least 1 
larger than a 
patient’s 
palm-sized 
area, 
disproportio
nate to 
trauma5
BLIC COPY 
d 
C
d 
ted by 
LIC
ted by 
e patient
BLI
e patient
CO
PUB
PUB
1
UB
1
B
than
PU
than
PUB
P
e used to support any marketing authorization 
su
y m
ng
za
maller 
to
maller 
a 
d
a 
atient’s 
sed
atient’s 
palm
use
palm-
s
-siz
e
siz
area
e u
area
e
This document cannot be used to s
s d
t c
e
s
ions or variations thereof.
v
s t
and any extensio
zed 
e
zed 
a
Any 
any
Any 
number
d a
number
size 
nd
size 
re
n
re
application and
nsi
2 sm
sio
2 sm
than a
ens
than a
pa
e
pa
io
ppli
and
te


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 72 of 85
Type of 
bleeding
GRADES BASED ON THE WORST INCIDENT EPISODE SINCE 
LAST VISIT2
0
1
2
3
4
Bleeding 
from minor 
wounds6
No
Lasting 
<=5 min
Any 
episode if 
reported by 
the patient 
Lasting >5 
min or 
interfering with 
daily activities 
Requiring 
protracted 
medical 
observation 
at the time 
of this visit 
Medical 
report 
describing 
patient’s 
evaluation 
by a 
physician 
MUCOSAL
Epistaxis7
No
Lasting 
<=5 min
Any 
episode if 
reported by 
the patient 
Lasting >5 
min or 
interfering with 
daily activities 
Packing 
or 
cauterizatio
n or 
in-hospital 
evaluation 
at the time 
of this visit 
Medical 
report 
describing 
packing or 
cauterizatio
n or in-
hospital 
evaluation
RBC 
transfusion 
or Hb drop 
>2g/dL
Oral cavity –
gum 
bleeding7
No 
Lasting 
<=5 min
Any 
episode if 
reported by 
the patient
Lasting >5 
min or 
interfering with 
daily activities 
Requiring 
protracted 
medical 
observation 
at the time 
of this visit 
PUBLIC COPY 
OP
CO
ing
C
ing
min
LIC
min
UB
Any 
UBL
Any 
epi
PUB
episod
UB
sod
repo
PU
repo
t
P
t
C
P
C
ment cannot be used to support any marketing authorization 
dical
tin
dical
rt 
k
rt 
escribing
arke
escribing
patient’s
mar
patient’s
e
m
evalu
ma
valu
by
m
by
y m
ng
za
t a
if 
t
if 
rted by 
d to
rted by 
he patient 
sed
he patient 
pp
Lastin
ppo
Lastin
min or
upp
min or
inte
up
inte
d
or
t c
e
su
s docum
Oral cavit
cum
Oral cavit
gum
doc
gum
bleed
do
bleed
This d
m
s d
plication and any extensions or variations thereof.
s s 
uation
tion
uation
y a 
ia
y a 
physicia
aria
physicia
s t
ar
v
ng >5 
or
ng >5 
r 
n
r 
erfering w
ions
erfering w
daily acti
sio
daily acti
r v
pli
and
te
v
appli
ty
p
ty –
pp
–
plplpli
pli
pli
ppli


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 73 of 85
Type of 
bleeding
GRADES BASED ON THE WORST INCIDENT EPISODE SINCE 
LAST VISIT2
0
1
2
3
4
Medical 
report 
describing 
patient’s 
evaluation 
by a 
physician
Oral cavity –
hemorrhagic 
bullae or 
blisters 
No
Less than 
3
Any 
number if 
reported by 
the patient
From 3 to 
10 but no 
difficulty with 
mastication 
More 
than 10 or 
more than 5 
if difficulty 
with 
mastication
Oral cavity -
bleeding 
from bites to 
lips & tongue 
or after 
deciduous 
teeth loss
No
Lasting 
<=5 min
Any 
episode if 
reported by 
the patient 
Lasting >5 
min or 
interfering with 
daily activities
Intervention
s to ensure 
hemostasis 
or in-
hospital 
evaluation 
at the time 
of this visit
Medical 
report 
describing 
intervention
s to ensure 
hemostasis 
or in-
hospital 
evaluation
Subconjuncti
val 
hemorrhage 
(not due to 
conjunctival 
disease)
No
Petechiae/ 
hemorrhage 
partially 
involving one 
eye
Any 
episode if 
Petechiae/ 
hemorrhage 
partially 
involving both 
eyes, or diffuse 
hemorrhage in 
one eye 
Diffuse 
hemorrhage 
in both eyes
PUBLIC COPY 
O
g
n
C
n
Any 
BLI
Any 
pi
UB
pisode if
BL
sode if
reporte
PUB
reporte
the 
PU
the 
O
P
CO
This document cannot be used to support any marketing authorization 
g
za
re
t
re
10 or 
keti
10 or 
ore than 
rke
ore than 
if difficu
mar
if difficu
with
ma
with
m
m
m
g
y m
ng
d by 
to
d by 
patient 
d to
patient 
Lasting 
ort
Lasting 
min or 
ppo
min or 
interfe
upp
interfe
dai
up
dai
t a
t c
e
su
Subcon
doc
Subcon
val 
do
val 
he
he
cu
s d
application and any extensions or variations thereof.
5
s
5
culty 
ns
culty 
astication
atio
astication
eo
v
s t
>5 
r
>5 
fering with
ns o
fering with
ily activit
ions
ily activit
va
va
ppli
and
te
v
uncti
ap
uncti
pp
pp
pp


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 74 of 85
Type of 
bleeding
GRADES BASED ON THE WORST INCIDENT EPISODE SINCE 
LAST VISIT2
0
1
2
3
4
reported by 
the patient 
ORGAN (and 
internal 
mucosae)
Gastrointesti
nal bleeding 
not explained 
by visible 
mucosal 
bleeding or 
lesion:
Hematemesis,
Melena,
Hematochezia
,
Rectorrhagia
No
Any 
episode if 
reported by 
the patient
Present at 
the visit 
Described 
in a medical 
report 
Requiring 
endoscopy8
or other 
therapeutic 
procedures 
or in-
hospital 
evaluation 
at the time 
of this visit
Medical 
report 
prescribing 
endoscopy8
or other 
therapeutic 
procedures 
or in-
hospital 
evaluation
RBC 
transfusion 
or Hb drop 
>2g/dL
Lung 
bleeding
Hemoptysis
Tracheobronc
hial bleeding
No
Any 
episode if 
reported by 
the patient
Present at 
this visit
Described 
in a medical 
report 
Requiring 
bronchosco
py8 or other 
therapeutic 
procedures 
or in-
hospital 
evaluation 
RBC 
transfusion 
or Hb drop 
>2g/dL
PUBLIC COPY 
P
CO
cument cannot be used to support any marketing authorization 
za
or
g
uiring
keti
uiring
doscopy
rke
doscopy8
or other 
ark
or other 
therap
ma
therap
pro
m
pro
g
t c
e
su
y m
ng
s doc
eding
um
eding
Hemopty
ocu
Hemopty
Trach
do
Trach
hia
d
hia
This d
n
s d
ation and any extensions or variations thereof.
peutic
ions
peutic
ocedures
atio
ocedures
or in
riat
or in-
a
-
hospit
vari
hospit
eva
va
eva
e
RBC
reo
RBC
transfusi
her
transfusi
or Hb
th
or Hb
>2
t
>2
eo
and
te
v
s t
plicat
ica
No
ca
No
ati
appli
ysis
ap
ysis
ronc
ap
ronc
ppli


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 75 of 85
Type of 
bleeding
GRADES BASED ON THE WORST INCIDENT EPISODE SINCE 
LAST VISIT2
0
1
2
3
4
at the time 
of this visit 
An 
equivalent 
episode if 
described in 
a medical 
report 
Hematuria 
No
Any 
episode if 
reported by 
the patient
Microscopic 
(lab analysis 
exhibited)
Macroscopic 
(lab analysis 
exhibited)
Described 
in a medical 
report 
Macroscopi
c, and 
requiring 
cystoscopy8
or other 
therapeutic 
procedures 
or in-
hospital 
evaluation 
at the time 
of this visit
An 
equivalent 
episode if 
described in 
a medical 
report 
RBC 
transfusion 
or Hb drop 
>2g/dL
Menorrhagia
(compared to 
pre-ITP or to 
a phase of 
disease with 
normal 
platelet 
count)9
No
Doubling 
nr. of pads or 
tampons in 
last cycle 
compared to 
pre-ITP or to 
a phase of 
disease with 
normal 
platelet count
Score 
>100 using 
Changing 
pads more 
frequently than 
every 2 hrs. or 
clot and 
flooding
Requiring 
combined 
treatment with 
antifibrinolytic
s and hormonal 
Acute 
menorrhagia 
requiring 
hospital 
admission 
or 
endometrial 
ablation 
(either at 
this visit or 
described in 
RBC 
transfusion 
or Hb drop 
>2g/dL 
PUBLIC COPY
c 
C
c 
lysis
C C
lysis
it
L
ited)
LIC
ed)
b an
Y
b an
exhibite
PY 
exhibite
O
P
CO
ment cannot be used to support any marketing authorization 
ng
za
)
a
)
Describe
ort 
Describe
in a medi
ppo
in a medi
report
upp
report
a
Macro
ma
Macro
c, an
m
c, an
r
ke
c
e
su
y m
This document c
gia
nt
gia
red to
en
red to
TP or to
me
TP or to
phase of 
cum
phase of 
disease w
ocu
disease w
norm
do
norm
pla
d
pla
ca
s d
t c
n and any extensions or variations thereof.
t
ed 
r
ed 
ical
o
ical
oscopi
ons
oscopi
and 
ati
and 
requiring
riat
requiring
cystosc
ari
cystosc
or o
va
or o
th
v
th
th
t
th
and
te
v
s t
plication 
No
tio
No
n
appli
with 
ap
with 
ppli


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 76 of 85
Type of 
bleeding
GRADES BASED ON THE WORST INCIDENT EPISODE SINCE 
LAST VISIT2
0
1
2
3
4
PBAC in the 
last cycle, if 
normal score 
in pre-ITP 
cycles or in a 
phase of 
disease with 
normal 
platelet count
therapy or 
gynecological 
investigation 
(either at this 
visit or 
described in a 
medical report) 
a medical 
report) 
Intramuscula
r hematomas
(only if 
diagnosed by 
a physician 
with an 
objective 
method) 
No
Post 
trauma, 
diagnosed at 
this visit, if 
judged 
disproportiona
te to trauma
An 
equivalent 
episode if 
described in a 
medical report 
Spontaneous, 
diagnosed at 
this visit 
An 
equivalent 
episode if 
described in a 
medical report 
Spontaneou
s or post 
trauma (if 
judged 
disproportio
nate to 
trauma) 
diagnosed at 
this visit 
and 
requiring 
hospital 
admission 
or surgical 
intervention
An 
equivalent 
episode if 
described in 
a medical 
report 
RBC 
transfusion 
or Hb drop 
>2g/dL
Hemarthrosis 
(only if 
diagnosed by 
a physician 
with an 
objective 
method)
No 
Post 
trauma, 
diagnosed at
this visit, 
function 
conserved or 
minimally 
impaired, if 
judged 
Spontaneous, 
diagnosed at 
this visit, 
function 
conserved or 
minimally 
impaired
Spontaneou
s or post 
trauma (if 
judged 
disproportio
nate to 
trauma), 
diagnosed at 
Spontaneou
s or post 
trauma (if 
judged 
disproportio
nate to 
trauma) 
diagnosed 
PUBLIC COPY 
na
CO
na
a
C
a
ivalent 
BLIC
ivalent 
pisode i
UBL
pisode i
describ
PUB
describ
me
PU
me
is vis
Y
is vis
OP
P
CO
ment cannot be used to support any marketing authorization 
ng
za
ed in a
to
ed in a
ical repor
ed t
ical repor
An
o
An
quivalent
por
quivalent
episode
pp
episode
desc
up
desc
m
u
m
a
Spontan
mar
Spontan
s or p
m
s or p
tra
m
tra
ket
t c
e
su
y m
s docume
marthrosi
ume
marthrosi
(only if 
ocu
(only if 
diagno
doc
diagno
a ph
d
a ph
w
This d
me
s d
cation and any extensions or variations thereof.
rt 
te
rt 
t t 
e if 
s
e if 
ribed in a
ns
ribed in a
medical re
sion
medical re
neou
ns
neou
post 
tio
post 
auma (if 
iatio
auma (if 
judged 
aria
judged 
dispr
var
dispr
na
v
na
th
R
h
R
trtr
the
and
te
v
s t
plica
plic
N
c
N
ca
appli
is
p
is
ed by 
ap
ed by 
ppli


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 77 of 85
Type of 
bleeding
GRADES BASED ON THE WORST INCIDENT EPISODE SINCE 
LAST VISIT2
0
1
2
3
4
disproportiona
te to trauma
An 
equivalent 
episode if 
described in a 
medical report
An 
equivalent 
episode if 
described in a 
medical report 
this visit 
and 
requiring 
immobilizat
ion or joint 
aspiration
An 
equivalent 
episode if 
described in 
a medical 
report
at this visit 
and 
requiring 
surgical 
intervention
An 
equivalent 
episode if 
described in 
a medical 
report 
Ocular 
bleeding
(only if 
diagnosed by 
a physician 
with an 
objective 
method)
No
Any post 
trauma vitreous 
or retinal 
hemorrhage 
involving one 
or both eyes 
with or without 
impaired/blurre
d vision present 
at this visit if 
judged 
disproportionat
e to trauma
An 
equivalent 
episode if 
described in a 
medical report 
Spontaneou
s vitreous or 
retinal 
hemorrhage 
involving 
one or both 
eyes with 
impaired/bl
urred vision 
present at 
this visit
An 
equivalent 
episode if 
described in 
a medical 
report 
Spontaneou
s vitreous or 
retinal 
hemorrhage 
with loss of 
vision in 
one or both 
eyes present 
at this visit
An 
equivalent 
episode if 
described in 
a medical 
report 
Intracranial 
bleeding10:
intracerebral, 
intraventricula
r, 
subarachnoida
l, subdural, 
extradural 
No
Any post 
trauma event 
requiring 
hospitalization 
Any 
spontaneous 
event 
requiring 
hospitalizati
on in 
presence of 
an 
underlying 
Any 
spontaneous 
event 
requiring 
hospitalizati
on without 
an 
underlying 
COPY
PY
Any
PY 
Any
trauma
OPY
trauma
or r
OP
or r
h
O
h
PUBLIC CO
P
CO
marketing authorization 
ent 
ti
ent 
ode if 
keti
ode if 
scribed in
rke
scribed in
a medica
ark
a medica
report
ma
report
g
cal
ho
cal
ervention
tho
ervention
au
An
au
An
equiv
g a
equiv
ep
g
ep
m
ng
za
support any m
ost
n
ost
vitreous
any
vitreous
tinal
rt
tinal
emorrhag
port
emorrhag
involvin
ppo
involvin
or bo
upp
or bo
wi
u
wi
ment cannot be used to support any m
t c
e
su
y m
s docume
racrania
um
racrania
bleeding
ocu
bleeding1
intrac
do
intrac
int
d
int
This d
me
s d
tions thereof.
n
al
n
al
rt
i
rt
valent 
eof
valent 
pisode if 
ereo
pisode if 
describe
her
describe
a med
th
a med
rep
rep
s t
tensions or variatio
ge
o
ge
ng one 
s or
ng one 
oth eyes
ns 
oth eyes
ith or wit
ion
ith or wit
impaired
nsio
impaired
d visi
ens
d visi
at 
e
at 
lication and any exte
i
Spontan
aria
Spontan
s vitr
va
s vitr
re
v
re
tio
li
and
te
v
plic
plic
N
appli
alal
g 0:
a
:
ral,
a
ral,
lililic
ppli


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 78 of 85
Type of 
bleeding
GRADES BASED ON THE WORST INCIDENT EPISODE SINCE 
LAST VISIT2
0
1
2
3
4
(only if 
diagnosed 
with an 
objective 
method at the 
visit or 
described in 
a medical 
report 
provided by 
the patient) 
intracranial 
lesion
intracranial 
lesion
Other 
internal 
bleeding:
hemoperitone
um
hemopericardi
um
hemothorax 
retroperitoneal 
bleeding
hepatic and 
splenic 
peliosis with 
organ rupture
retroorbital 
bleeding
metrorrhagia
etc.
(only if 
diagnosed 
with an 
objective 
method at the 
visit or 
described in 
a medical 
report 
No
Any 
event 
requiring 
hospitalizati
on <48 hrs.
Any 
event 
requiring 
hospitalizati
on >48 hrs. 
or RBC 
transfusion 
or Hb drop 
>2g/dL 
PUBLIC COPY 
P
CO
marketing authorization 
ng
za
y ma
ma
A
a
A
ev
ev
ma
s document cannot be used to support any m
m
nosed
ume
nosed
ith an
cum
ith an
objectiv
doc
objectiv
meth
do
meth
vis
d
vis
This d
s d
t c
e
su
y m
variations thereof.
s t
Any 
tio
Any 
vent 
at
vent 
requirin
aria
requirin
hospi
var
hospi
on
v
on
s
ns
application and any extensions or v
e
a
e
t the
a
t the
ppli
and
te
v
s


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 79 of 85
Type of 
bleeding
GRADES BASED ON THE WORST INCIDENT EPISODE SINCE 
LAST VISIT2
0
1
2
3
4
provided by 
the patient) 
Grading is based on physical examination at the time of the visit by the physician or expert nurse or on patient’s 
history supplemented by available medical reports. Bleeding manifestations reported by the patient but not visible at 
the time of data collection are graded 1. Grade 5 is assigned to fatal bleeding.
To receive a grade >1, all non-overt skin and non-overt mucosal bleeding (petechiae, ecchymoses, subcutaneous 
hematomas, vesicles/bullae subconjunctival bleeding) should be visible at the time of visit for grading by the 
physician or expert nurse taking the history. 
For bleeding from minor wounds and overt-mucosal bleeding (epistaxis, gum, bleeding from bites to lips & tongue 
or after deciduous teeth loss/extraction) and all organ bleeding, a medical record describing the symptom or 
indicating a specific intervention/prescription should be also taken into account for grading. 
Requirement for ITP-specific treatments and anti-fibrinolytics (apart from menorrhagia) was not considered for 
grading, due to their subjective nature and their adoption not only to control actual bleeding but also to reduce the 
“risk” of impendent or future bleeding. 
1 In case of patients examined for the first time, all types of bleeding occurring at the visit and in the 15 days 
preceding the visit should be considered. 
2 Each type of bleeding should be graded based on the worst bleeding manifestation that occurred during each 
observation period or in the 15 days preceding the first visit.
3 Patient’s own palm size is commonly considered to be proportional to body surface area. Palm = the inner 
surface of the hand stretching between the distal crease of the wrist and the bases of the fingers (fingers surface 
excluded).
4 Body areas include: face, neck, right and left upper limbs (considered separately), right and left lower limbs 
(considered separately), trunk, abdomen, and recumbent areas (for the ambulatory patient means the area below 
the knees). 
5 Bleedings considered proportionate to trauma/constriction on a clinical ground should not be reported for skin 
domain.
6 Minor wound means superficial skin cuts (eg, by shaving razor, knife, or scissors).
7 Epistaxis and gum bleeding are also reported in some normal subjects. Thus, a critical judgment is required in 
grading these manifestations; they should be reported only if judged more severe when compared with pre-ITP 
bleeding, if any.
8 Any endoscopic investigations should be considered for grading only if performed for therapeutic purpose and 
not solely for diagnostic purpose.
9 In girls at menarche grade 1 cannot be assigned, lacking comparison with previous cycles.
10 Intracranial bleeding should always be reported, irrespective of its grade. For example, if a woman had S2 
(subcutaneous hematoma) M2 (epistaxis) O3 (menorrhagia) and an intracranial bleeding grade 2 (post trauma, 
requiring hospitalization), the SMOG index is S2M2O3 (intracranial 2). If the same patient also had intracranial 
bleeding grade 3, the SMOG index is S2M2O3 (intracranial 3).
PUBLIC COPY 
edin
Y
edin
orst bleed
OPY
orst bleed
t visit.
COP
t visit.
o be prop
CO
o be prop
crease of
C C
crease of
left upper
BLIC
left upper
n, and recu
UBL
n, and recu
P
te to tra
PU
te to tra
U
to support any marketing authorization 
iza
za
t’s
o
t’s
visible at 
hor
visible at 
bcutaneous
auth
bcutaneous
ding by the 
au
ding by the 
bites to lip
ting
bites to lip
ng the symp
etin
ng the symp
ding. 
ke
ding. 
agia) was no
ark
agia) was no
al bleeding 
mar
al bleeding 
rring at the
y m
rring at the
ng manifest
t an
ng manifest
rtional to b
ort
rtional to b
he wrist an
ppo
he wrist an
limbs (cons
sup
limbs (cons
mbent areas
o su
mbent areas
nnot be used 
ma/constric
d to
ma/constric
cuts (eg, by
use
cuts (eg, by
o reported 
us
o reported 
y should be
be u
y should be
tions should
ot b
tions should
purpose.
not
purpose.
grade 1 can
nno
grade 1 can
This document ca
ding should
an
ding should
em
c
ematoma) 
ca
atoma) 
pitalization
nt c
pitalization
rade 3, the 
ent
rade 3, the 
nsions or variations thereof.f
ps & tongu
ereo
ps & tongu
ptom or 
her
ptom or 
ot consider
s th
ot consider
but also to
ns 
but also to
e visit and i
atio
e visit and i
tation that o
aria
tation that o
body surfac
or v
body surfac
nd the bases
or 
nd the bases
sidered sep
ons
sidered sep
s (for the am
ion
s (for the am
and any exten
ction on a c
ens
ction on a c
y shaving ra
exte
y shaving ra
in some no
y ex
in some no
e reported o
ny e
e reported o
d be consid
d an
d be consid
nnot be ass
and
nnot be ass
application a
d always be
n an
d always be
M2 (epista
on 
M2 (epista
n), the SMO
tion
n), the SMO
SMOG ind
atio
SMOG ind


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 80 of 85
13.7
Classification of the SF-36v2 questionnaire
Items
Scales
3a. Vigorous activities
3b. Moderate activities
3c. Lifting or carrying groceries
3d. Climbing several flights
3e. Climbing one flight
3f. Bending, kneeling
3g. Walking more than a mile
3h. Walking several hundred yards
3i. Walking one hundred yards
3j. Bathing, dressing
Physical Functioning
4a. Cut down time
4b. Accomplished less
4c. Limited in the kind of work
4d. Had difficulty performing the work
Role-Physical
7. Pain magnitude
8. Pain interfere
Bodily Pain
1 Global health condition rating
11a. Sick easier
11b. As healthy
11c. Health to get worse
11d. Health excellent
General Health
9a. Full of life
9e. Energy
9g. Worn out
9i. Tired
Vitality
6. Social extent
10. Social time
Social Functioning
5a. Cut down time
5b. Accomplished less
5c. Not careful
Role-Emotional
9b. Nervous
9c. Down in dumps
9d. Peaceful
9f. Blue/sad
9h. Happy
Mental Health
PUBLIC COPY
dily P
PY 
dily P
Y
Gene
COP
Gene
OP
CO
UB
used to support any marketing authorization 
za
ti
y m
al Health
rt a
al Health
a
s
V
o s
annot be u
ess
nn
ess
t b
cument can
in dumps
nt c
in dumps
eful
en
eful
ue/sad
me
ue/sad
h. Happy
cum
h. Happy
an
This docu
cu
extensions or variations thereof.
her
tio
h
ar
Vitality
nsio
Vitality
io
xte
and any e
an
pplication a
app
pp


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 81 of 85
14
AMENDMENT(S) TO THE STATISTICAL ANALYSIS PLAN 
(SAP)
14.1
AMENDMENT 1
Rationale for the amendment
The primary reason for this SAP amendment is to incorporate the changes from Protocol 
Amendment 3 and the reduced scope of analyses following sponsor’s decision to terminate the 
study early.
Modifications and changes
Section # and Name
Description of Change
Brief Rationale
2.1.3
Removed objective “To evaluate the 
effects of rozanolixizumab on exploratory 
biomarkers”
Updated to align with 
Protocol Amendment 3
2.1.3
Added objective “To assess the effect of 
rozanolixizumab on response to 
vaccination in study participants who 
received COVID-19 vaccine”
2.2.1.2
Removed “Including all intermediate 
timepoints” from ITP-PAQ endpoint
2.2.1.4.1
Changed text of IgG, IgA, IgE and IgM 
endpoints
2.2.1.4.1
Removed ITP-specific autoantibodies 
endpoint
2.2.1.4.2
Removed several exploratory endpoints
2.2.1.4.2
Added COVID-19 vaccination endpoint
2.2.2.1
Removed α-globulin, and β-globulin 
endpoints
2.2.2.1
Removed Cytokines endpoint
2.3
Starting dose of 
instead of 
 
2.3
Dosing is QW instead of Q2W
2.3
Study size reduced to 60 from a maximum 
of 90 participants
2.3
Various other changes to study design that 
do not have a direct impact on analysis
2.4
Changed derivation of sample size and 
power calculation table
To reflect the requirement 
to randomize a fixed 
number of participants on 
weekly sc infusions and 
removal of option to 
PUBLIC COPY 
se to 
Y
se to 
ticipants 
PY
ticipants 
vaccine
OP
vaccine”
P
”
ding all i
CO
ding all i
om ITP
C C
om ITP
CO
text of Ig
BLIC
text of Ig
nts
UB
nts
IC
moved I
PU
moved I
poin
P
poin
UB
annot be used to support any marketing authorization 
e the
hori
e the
ationale
ng 
ationale
g a
dated to al
ketin
dated to al
rotocol A
rke
rotocol A
ting
m
f f 
who
an
who
m
termediate
port
termediate
AQ endpo
ppo
AQ endpo
rt
G, IgA, IgE
sup
G, IgA, IgE
pp
P
d
P-
d
-specific
d to
specific
o
oved sever
use
oved sever
ed
Added CO
be u
Added CO
u
Remov
t b
Remov
end
ot 
end
be
ot
no
This document can
an
n
me
2.3
do
2.3
doc
s d
s
ation and any extensions or variations thereof.
of
lign with
her
lign with
Amendmen
th
Amendmen
ere
va
e
o
e
oint
o
oint
va
va
va
E and IgM
ons
E and IgM
s o
c autoantib
ns
c autoantib
sio
ral explora
ext
ral explora
xte
VID
ny
VID-
y
-19 v
y e
19 v
e
ved 
a
ved α
an
α-
a
-glob
an
glob
dpoints
nd a
dpoints
ny
Removed
an
Removed
nd
application a
Start
n 
Start
a
on
ati
lic
ap


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 82 of 85
Section # and Name
Description of Change
Brief Rationale
increase sample size based 
on an interim analysis
3.2.4
Definition of dosing regimen groups 
(weekly and biweekly)
Need to define subsets of 
protocol-defined analysis 
sets which will be used for 
analysis
3.5.4
Change complete infusion to sufficient 
infusion
Requested by FDA
3.5.4
The FAS will no longer appear in any 
analysis
Owing to the sponsor’s 
decision to terminate this 
study the set is no longer 
required.
3.5.5
The PD-PPS will no longer appear in any 
analysis
Owing to the sponsor’s 
decision to terminate this 
study the set is no longer 
required.
3.8
Updated to MedDRA version 24 dictionary
New version available
3.8
Updated to WHODD, Mar 2021 version 
New version available
3.9
Text added to describe analysis omitted 
because of early termination of study. 
Sponsor decision to 
terminate study early.
4.2.1
Text referring to sensitivity analysis and 
MI MAR analysis removed.
Analysis no longer 
required.
4.2.2
Changed intercurrent event strategy for 
COVID-19 to composite strategy and 
platelet data set to 0
Requested by FDA
4.5.2 and throughout
Remove all references to interim analysis 
and to Stage 1 and Stage 2 analysis
Interim analysis removed 
in Protocol Amendment 3
4.7
Analysis described in this section removed.
Analysis is no longer 
required.
4.8
Analysis removed
Analysis is no longer 
required.
6.5.1
Modification to assignment of medications 
to treatment period
Be consistent with the 
definition of treatment 
period
8.1.2
Sensitivity and supplemental analysis has 
been removed.
Owing to the sponsor’s 
decision to terminate this 
study the analysis is no 
longer required. 
8.1.3
Analysis has been removed.
Owing to the sponsor’s 
decision to terminate this 
PUBLIC COPY 
A version
COP
A version
PY
ODD, M
C CO
ODD, M
CO
to describ
LIC 
to describ
of early t
BLIC
of early t
C C
referring
PUB
referring
MAR a
PU
MAR a
BL
P
cannot be used to support any marketing authorization 
or 
i
or 
za
A
t
A
ho
the sponso
g a
the sponso
n to termin
ing
n to termin
y the set 
etin
y the set is
n
is
equired.
ket
equired.
au
Owing 
mark
Owing 
decis
ma
decis
st
m
st
rk
m
24 dictiona
rt a
24 dictiona
an
r 2021 ver
por
r 2021 ver
rt 
e analysis 
upp
e analysis 
rmination 
sup
rmination 
po
to sensitiv
to s
to sensitiv
nalysis rem
d to
nalysis rem
s
ed intercur
sed
ed intercur
VID
u
VID-
us
-19 to 
use
19 to 
latelet data
e u
latelet data
d
Remov
t be
Remov
and 
ot 
and 
be
ot
document canno
no
ca
en
s do
8.1.2
do
8.1.2
do
This d
s d
d any extensions or variations thereof.
or’s
eo
or’s
nate this
reo
nate this
s no longe
here
s no longe
f
to the spo
ns 
to the spo
sion to ter
ons
sion to ter
tudy the se
atio
tudy the se
required
riat
required
t
nary
va
nary
New
ar
New
ria
va
rsion 
or
rsion 
va
va
va
va
omitted 
s o
omitted 
of study.
ons
of study.
or
vity analys
sio
vity analys
mo
e
moved.
ns
ved.
on
rrent event
xte
rrent event
composite
ex
composite
a set to 0
y e
a set to 0
en
ve all refer
any
ve all refer
to Stage 1
d a
to Stage 1
ny
n and
Analysis 
and
Analysis 
application and
n
An
n
An
n
on
ca
ap
ap


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 83 of 85
Section # and Name
Description of Change
Brief Rationale
8.1.4
Analysis has been removed.
study the analysis is no 
longer required.
8.1.5
Analysis has been removed.
8.2
All formal statistical analysis has been 
removed 
8.3
Subsections 8.3.1 – 8.3.5 and 8.3.8 – 8.3.9
have been removed. Statistical analysis has 
been removed from section 8.3.6.
8.42
Text modified to reflect that item responses 
will be listed only, no derived scores will 
be calculated, and no change from baseline 
will be computed.
8.4.4
Text added to reflect that item responses 
will be listed only, no derived scores will 
be calculated, and no change from baseline 
will be computed.
9.2
Updated the analysis for antidrug 
antibodies
Owing to the sponsor’s 
decision to terminate this 
study the majority of the
analysis is no longer 
required.
9.3.1 – 9.3.4
Changed text of IgG, IgA, IgE and IgM 
endpoints
Updated to align with 
Protocol Amendment 3
9.3.5
Removed ITP-specific autoantibodies 
endpoint
9.4
Removed several exploratory endpoints
10.1
Clarified definition for time at risk
Account for participants 
who roll over to TP0004
10.2
Clarified definitions of severity and 
intensity for adverse events
Clarify how severe adverse 
events will be summarized
10.2.2
Add AESIs and TEAEs leading to study 
discontinuation to overview
Categories in overview 
should match categories in 
adverse event tables
10.2.2
Removed some adverse event tables
No longer needed
10.2.2
Added AEs of focus: hemorrhagic events, 
worsening thrombocytopenia and effect on 
lipids
These were added to the 
AE of Focus document 3.0, 
or they were removed from 
the document but were still 
considered relevant for ITP
PUBLIC COPY
em re
Y
em re
rived sc
PY 
rived sc
change f
OP
change f
nalysis fo
C C
nalysis fo
C
nge
P
nge
P
This document cannot be used to support any marketing authorization 
a
za
m
nses
ny
nses
res will
any
res will
om baselin
t an
om baselin
m
r antidrug
ppo
r antidrug
or
d text of Ig
sed
d text of Ig
oints
us
oints
d
emoved I
e u
emoved I
endpoin
t be
endpoin
us
t
Rem
ot 
Rem
t b
ot
no
ca
.2
u
.2
me
d
10.2
d
10.2
do
s d
s
application and any extensions or variations thereof.
ne 
va
ne 
va
r v
gG, IgA, I
xten
gG, IgA, I
en
TP
y
TP-
y
-specif
y e
specif
nt
a
nt
e
moved sev
d a
moved sev
a
Clarified
an
Clarified
nd
on
C
n
C
on
on
on
on
ica
a


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 84 of 85
Section # and Name
Description of Change
Brief Rationale
10.5.1
Added “All values must be met at the same 
sample taken from the same visit”
Clarified how PDILI is 
defined
10.5.1
Added the components of the Hy’s law 
definition presented separately in a 
stepwise fashion to the table
Provide more information 
about the components of 
PDILI
10.6
Removed α-globulin, and β-globulin 
endpoints
Updated to align with 
Protocol Amendment 3
10.7
Removed change from baseline for 
Complement endpoint
Owing to the sponsor’s 
decision to terminate this 
study the analysis is no 
longer required.
10.8
Removed Cytokines endpoint
Updated to align with 
Protocol Amendment 3
13.2.2
Removed several labs from MA table
Labs not collected or 
calculated in TP0006
Throughout
Minor editorial and formatting changes 
have been made.
Minor, therefore have not 
been summarized.
PY 
M
Y
M
PUBLIC COPY
ormatting
OP
ormatting
PY
C
any marketing authorization 
za
th
h
th
ment 3
tho
ment 3
riz
e sponsor’
au
e sponsor’
o terminat
g a
o terminat
he analysi
ting
he analysi
ger require
ketin
ger require
ut
Updated t
arke
Updated t
Protoc
mar
Protoc
ke
ma
La
m
La
This document cannot be used to support any ma
m
changes 
t an
changes 
any
or
ons thereof.
s
o
s
te this
eof
te this
is is no 
ereo
is is no 
ed.
h
ed.
to align w
s th
to align w
ol Amend
ns 
ol Amend
the
riation
abs not col
tio
abs not col
calculate
iati
calculate
application and any extensions or varia on
Mino
aria
Mino
be
a
be
ria
r va


UCB
16Aug2022
Statistical Analysis Plan
Rozanolixizumab
TP0006
Confidential
Page 85 of 85
STATISTICAL ANALYSIS PLAN SIGNATURE PAGE
This document has been reviewed and approved per the Review and Approval of Clinical 
Documents Standard Operating Procedures. Signatures indicate that the final version of the 
Statistical Analysis Plan (SAP) or amended SAP is released for execution.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


Approval Signatures
Name:
tp0006-sap-amend-1
Version:
1. 0
Document Number:
CLIN-000194313
Title:
TP0006 Statistical Analysis Plan
Approved Date:
16 Aug 2022
Document Approvals
Approval
Verdict: Approved
Name: 
Capacity: Clinical
Date of Signature: 16-Aug-2022 14:35:40 GMT+0000
Approval
Verdict: Approved
Name: 
Capacity: Clinical
Date of Signature: 16-Aug-2022 20:18:53 GMT+0000
COPY 
OP
ent Ap
COP
ent Ap
UBLIC CO
CO
PUB
UB
This document cannot be used to support any marketing authorization 
a
provals
ort a
provals
suppor
ort
u
Name:
po
Name:
Capac
upp
Capac
Da
p
Da
used to s
us
o
or variations thereof.
ar
s
or v
r v
application and any extensioions o
city: Clinica
s o
city: Clinica
te of Signa
ons
te of Signa
extensio
ex
io
en
Name:
nsi
Name:
Cap
ns
Cap
D
or 
o